,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,olabel,orig_index,label,prob_0,prob_1
0,22-oxacalcitriol,0,1,0,16,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,0,-1,0.99714345,0.0028565559
1,secondary hyperparathyroidism,2,4,28,57,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,1,-1,0.0009927166,0.9990073
2,low bone turnover,6,9,75,92,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,2,-1,0.0014262939,0.99857366
3,renal failure,12,14,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,3,-1,0.0009008809,0.99909914
4,Calcitriol,2,3,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,4,-1,0.9982546,0.0017454097
5,parathyroid hormone,8,10,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,5,-1,0.98906064,0.010939402
6,PTH,11,12,79,82,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,6,-1,0.9884899,0.011510069
7,renal failure,16,18,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,7,-1,0.00096429675,0.9990357
9,suppression of bone turnover,27,31,180,208,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,9,-1,0.0040504048,0.9959496
10,lead,34,35,220,224,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,10,-1,0.014728849,0.9852711
11,adynamic bone disease,36,39,228,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,11,-1,0.0011515454,0.99884844
12,vitamin D,2,4,6,15,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,12,-1,0.9952136,0.004786373
13,22-oxacalcitriol,6,7,26,42,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,13,-1,0.997022,0.0029780623
14,OCT,8,9,44,47,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,14,-1,0.9965126,0.0034874205
15,OCT,9,10,54,57,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,15,-1,0.99393684,0.0060631656
16,turnover,16,17,87,95,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,16,-1,0.0017511118,0.99824893
17,impaired renal function,22,25,119,142,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,17,-1,0.0020085596,0.99799144
18,N,10,11,52,53,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,18,-1,0.11622827,0.8837717
19,N,19,20,84,85,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,19,-1,0.12475469,0.8752453
22,OCT,19,20,108,111,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,-1,-1,-1,22,-1,0.9966878,0.0033122434
24,OCT,26,27,156,159,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,-1,24,-1,0.99542075,0.0045791706
25,OCT,6,7,21,24,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,25,-1,0.9497158,0.050284166
26,renal insufficiency,17,19,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,26,-1,0.00087039935,0.9991296
27,secondary hyperparathyroidism,2,4,17,46,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,27,-1,0.00097195903,0.9990281
28,OCT,5,6,48,51,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,28,-1,0.98961467,0.010385399
30,hyperphosphatemia,9,10,64,81,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,-1,-1,30,-1,0.0010282677,0.9989717
31,OCT,7,8,39,42,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,-1,-1,-1,31,-1,0.49515513,0.5048449
32,OCT,4,5,12,15,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,32,-1,0.95438564,0.0456144
33,abnormal bone formation,6,9,25,48,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,33,-1,0.0022095365,0.99779046
34,osteoid,13,14,64,71,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,34,-1,0.0021019562,0.997898
36,bone turnover,25,27,131,144,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,36,-1,0.002443294,0.9975567
37,OCT,3,4,13,16,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,-1,-1,-1,37,-1,0.96928495,0.030715074
38,OCT,8,9,53,56,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,38,-1,0.99123436,0.008765674
40,renal insufficiency,21,23,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,40,-1,0.0009026733,0.99909735
41,secondary hyperparathyroidism,33,35,202,231,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,41,-1,0.0011613829,0.9988386
42,low bone turnover,40,43,259,276,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,42,-1,0.0027735163,0.9972264
43,adynamic bone disease,53,56,323,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,43,-1,0.0012149881,0.9987851
52,ischemic cardiac disease,5,8,23,47,There was a history of ischemic cardiac disease 9 years earlier.,10074612_2,-1,-1,-1,52,-1,0.0010373788,0.99896264
53,hemoptysis,9,10,62,72,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,53,-1,0.000917839,0.9990822
54,rapidly progressive renal failure,11,15,74,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,54,-1,0.0013812562,0.9986187
55,hypoxemia,17,18,113,122,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,55,-1,0.0010902418,0.9989097
56,ventricular arrhythmia,7,9,43,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,-1,-1,56,-1,0.0011159419,0.998884
57,sudden death,8,10,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,57,-1,0.0011640531,0.998836
59,IVMP,18,19,120,124,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,59,-1,0.9821056,0.017894378
60,cardiac disease,4,6,30,45,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,60,-1,0.0010883242,0.99891174
61,ventricular arrhythmia,20,22,126,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,61,-1,0.0011650814,0.9988349
63,Parkinson's disease,4,7,21,40,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,-1,-1,63,-1,0.0009888295,0.99901116
68,p<0.05,25,26,142,148,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,68,-1,0.086300276,0.91369975
69,p<0.05,34,35,182,188,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,69,-1,0.11403341,0.8859666
70,p<0.05,41,42,211,217,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,70,-1,0.10213938,0.89786065
71,p<0.05,52,53,262,268,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,71,-1,0.102780916,0.89721906
73,postural hypotension,1,3,19,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,73,-1,0.0008546639,0.99914527
74,Parkinson's disease,4,7,43,62,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,74,-1,0.001065568,0.99893445
75,Parkinson's Disease,5,8,31,50,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,75,-1,0.0025327897,0.99746716
76,Parkinson's disease,21,24,127,146,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,76,-1,0.0014782434,0.99852175
77,PD,25,26,148,150,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,77,-1,0.001340879,0.99865913
78,mg selegiline,31,33,177,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,78,-1,0.9954401,0.004559798
80,systolic orthostatic hypotension,14,17,89,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,-1,-1,80,-1,0.00087160023,0.9991284
84,PD,14,15,94,96,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,-1,-1,-1,84,-1,0.0023175683,0.99768245
86,systolic orthostatic hypotension,5,8,29,61,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,86,-1,0.00094598404,0.999054
87,PD,15,16,92,94,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,87,-1,0.0017071702,0.99829286
93,systolic and diastolic blood pressures,7,12,58,96,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,-1,93,-1,0.002556727,0.9974433
96,monoamine oxidase,14,16,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,96,-1,0.9768375,0.023162441
98,metamphetamine,20,21,144,158,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,98,-1,0.9988391,0.001160942
101,Picloxydine,0,1,0,11,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,-1,-1,101,-1,0.9986442,0.0013558774
103,tetrandrine,2,3,11,22,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,103,-1,0.9982316,0.0017683996
104,fangchinoline,4,5,27,40,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,104,-1,0.99832386,0.001676122
107,Tetrandrine,0,1,0,11,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,107,-1,0.9970727,0.0029273066
108,TET,2,3,13,16,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,108,-1,0.96400106,0.035998974
109,fangchinoline,5,6,22,35,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,109,-1,0.9970024,0.0029976177
110,FAN,7,8,37,40,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,110,-1,0.97940904,0.02059097
111,bisbenzylisoquinoline,16,17,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,111,-1,0.9898441,0.010155882
112,TET,10,11,63,66,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,112,-1,0.30018088,0.69981915
113,FAN,12,13,71,74,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,113,-1,0.4358644,0.5641357
116,EP,23,24,144,146,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,116,-1,0.98164374,0.018356299
119,TET,16,17,61,64,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,119,-1,0.008372706,0.99162734
120,FAN,18,19,69,72,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,120,-1,0.008619859,0.99138016
123,ASA,39,40,175,178,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,123,-1,0.99585295,0.004147071
124,platelet aggregations,4,6,19,40,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,124,-1,0.00327187,0.99672806
125,TET,14,15,80,83,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,125,-1,0.8989544,0.101045676
126,FAN,16,17,88,91,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,126,-1,0.94496316,0.0550369
127,TET,4,5,21,24,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,127,-1,0.03332492,0.96667504
128,FAN,6,7,29,32,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,128,-1,0.028793978,0.97120595
129,TET,6,7,45,48,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,129,-1,0.0037200386,0.99628
130,FAN,8,9,53,56,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,130,-1,0.006223463,0.99377656
131,tubular damage?BACKGROUND,6,8,51,76,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,131,-1,0.014461059,0.98553896
132,renal tubular dysfunction,13,16,103,128,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,132,-1,0.0014482575,0.9985518
133,Puromycin aminonucleoside,2,4,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,133,-1,0.99736124,0.0026387752
134,PAN,5,6,36,39,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,134,-1,0.9927267,0.0072732987
136,PAN,4,5,31,34,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,136,-1,0.8366516,0.16334836
138,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,138,-1,0.0018427891,0.9981572
140,cauda equina syndrome,18,21,103,124,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,140,-1,0.0020661259,0.99793386
141,cauda equina syndrome,32,35,197,218,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,141,-1,0.0019666015,0.99803334
144,mg,13,14,72,74,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,-1,-1,-1,144,-1,0.1982899,0.8017101
148,neurological deficits,4,6,30,51,All cases sustained permanent neurological deficits.,10225068_6,-1,-1,-1,148,-1,0.0012569269,0.9987431
150,mg,24,25,149,151,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,-1,-1,-1,150,-1,0.6557351,0.34426495
155,capillary leak syndrome,15,18,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,-1,-1,155,-1,0.0012799301,0.99872005
159,capillary leak syndrome,7,10,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,-1,-1,159,-1,0.001342716,0.9986572
161,capillary leak syndrome,11,14,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,-1,-1,161,-1,0.0013540308,0.99864596
168,capillary leak syndrome,13,16,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,-1,-1,168,-1,0.0015818111,0.9984182
170,capillary leak,7,9,51,65,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,170,-1,0.0012992183,0.99870074
171,inflammatory diseases,21,23,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,171,-1,0.0011715709,0.9988285
173,ACE inhibitors,3,5,18,32,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,-1,-1,173,-1,0.9967002,0.0032997709
178,thyroid disease,30,32,160,175,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,-1,-1,-1,178,-1,0.0015319999,0.998468
179,Affective Disorders,2,4,9,28,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,-1,-1,-1,179,-1,0.00254412,0.9974559
180,bipolar disorder,15,17,66,82,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,-1,-1,-1,180,-1,0.0018425955,0.99815744
188,thyroid illness,7,9,55,70,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,-1,-1,188,-1,0.0012033988,0.9987966
199,thyroid illness,3,5,22,37,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,-1,-1,199,-1,0.0009829075,0.9990171
203,mood disorder,1,3,16,29,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,203,-1,0.0010453361,0.99895465
204,psychiatric symptoms,7,9,52,72,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,204,-1,0.001216447,0.9987835
205,mood disorders,17,19,116,130,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,-1,205,-1,0.0014410327,0.99855894
206,mood disorder,5,7,55,68,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,206,-1,0.0012040948,0.99879587
207,CIMD,8,9,70,74,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,207,-1,0.008989654,0.9910103
208,mood disorders,12,14,83,97,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,208,-1,0.0011115225,0.99888843
209,mood disorder,17,19,105,118,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,209,-1,0.0010802015,0.99891984
210,psychiatric symptoms,24,26,148,168,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,210,-1,0.0011641951,0.99883586
211,CIMD,4,5,24,28,The prevalence rate for CIMD was 12% at baseline.,10365197_3,-1,-1,-1,211,-1,0.0031195977,0.9968804
212,CIMD,6,7,40,44,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,212,-1,0.0056312024,0.99436885
213,depressive disorders,15,17,93,113,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,213,-1,0.0014068453,0.99859315
214,CIMD,2,3,14,18,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,214,-1,0.00264402,0.99735606
215,mood disorder,15,17,92,105,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,215,-1,0.0012479787,0.998752
216,CIMD,11,12,69,73,"These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.",10365197_6,-1,-1,-1,216,-1,0.009270079,0.99072987
217,fucoidan,2,3,10,18,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,217,-1,0.99695045,0.0030495871
218,intracerebral hemorrhage,6,8,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,218,-1,0.0010230341,0.99897695
221,Intracerebral hemorrhage,0,2,0,24,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,-1,-1,221,-1,0.001130072,0.99886996
224,fucoidan,5,6,38,46,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,224,-1,0.9918773,0.00812273
226,intracerebral hemorrhage,22,24,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,226,-1,0.0010047944,0.99899524
227,fucoidan,9,10,57,65,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,-1,227,-1,0.9963468,0.0036532243
229,impaired blood clotting,5,8,44,67,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,229,-1,0.001763343,0.99823666
230,hemodilution,9,10,72,84,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,230,-1,0.000815124,0.9991849
231,hematomas,13,14,97,106,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,231,-1,0.0018850997,0.99811494
235,white matter edema,1,4,6,24,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,235,-1,0.0016069189,0.998393
236,neuronal loss,6,8,38,51,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,236,-1,0.0014429422,0.99855703
238,intracerebral hemorrhage,12,14,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,-1,238,-1,0.00097623555,0.9990238
240,cefotetan,9,10,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,-1,240,-1,0.9986854,0.001314563
242,cefotetan,6,7,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,-1,-1,242,-1,0.9983981,0.0016018228
244,hemolytic anemias,10,12,56,73,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,244,-1,0.00076565775,0.9992343
245,cefotetan,18,19,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,245,-1,0.9986796,0.0013204154
247,aneurysmal subarachnoid hemorrhage,10,13,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,-1,-1,247,-1,0.0009910511,0.9990089
248,NSAIDs,9,10,71,77,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,-1,-1,-1,248,-1,0.99262345,0.0073765996
249,aneurysmal subarachnoid hemorrhage,2,5,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,249,-1,0.0013557412,0.9986443
250,SAH,6,7,50,53,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,250,-1,0.0011753377,0.99882466
251,ketoprofen,13,14,89,99,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,251,-1,0.9988242,0.0011757755
252,mg,16,17,105,107,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,252,-1,0.97750026,0.0224998
253,ketoprofen,23,24,128,138,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,253,-1,0.9987109,0.001289138
254,n,26,27,146,147,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,254,-1,0.1340021,0.8659979
255,NSAID,33,34,163,168,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,255,-1,0.9948507,0.0051492946
258,n,48,49,230,231,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,258,-1,0.18760148,0.81239855
259,aneurysmal SAH,58,60,281,295,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,259,-1,0.0014388476,0.9985612
261,adenosine diphosphate,8,10,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,261,-1,0.9979601,0.0020399166
262,ketoprofen,14,15,108,118,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,262,-1,0.99886084,0.0011392328
263,P,4,5,23,24,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,263,-1,0.17808592,0.8219141
264,ketoprofen,10,11,39,49,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,264,-1,0.99880445,0.0011955292
266,contrast,1,2,3,11,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,266,-1,0.031030867,0.9689691
270,P,25,26,174,175,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,270,-1,0.13719927,0.8628008
271,ketoprofen,4,5,19,29,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,-1,-1,271,-1,0.9988147,0.0011853222
273,Coagulation,0,1,0,11,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,273,-1,0.0029677064,0.9970323
274,antithrombin III,20,22,112,128,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,274,-1,0.7899774,0.21002261
275,AT III,23,25,130,136,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,275,-1,0.60223854,0.39776143
276,Ketoprofen,0,1,0,10,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,276,-1,0.9988306,0.0011693465
277,acetaminophen impaired platelet function,3,7,19,59,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,277,-1,0.54062766,0.45937237
278,SAH,10,11,77,80,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,278,-1,0.0013792107,0.99862075
279,ketoprofen,1,2,3,13,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,279,-1,0.9987897,0.0012103274
280,cerebral artery aneurysms,7,10,40,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,280,-1,0.0014725751,0.9985274
282,atracurium,2,3,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,282,-1,0.99830997,0.0016899848
283,flushing,11,12,79,87,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,283,-1,0.01640131,0.9835987
284,respiratory arrest,1,3,2,20,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,284,-1,0.001230911,0.9987691
285,desaturation,5,6,33,45,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,285,-1,0.0011679523,0.99883205
287,neuromuscular blockade,10,12,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,-1,-1,-1,287,-1,0.0019606617,0.9980393
290,ASA,13,14,88,91,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,-1,290,-1,0.2651936,0.7348064
295,mg,10,11,48,50,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,295,-1,0.9030127,0.09698727
297,mg,15,16,71,73,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,297,-1,0.7923521,0.20764785
299,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,299,-1,0.075237714,0.92476237
308,myocardial ischemia,8,10,45,64,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,-1,-1,308,-1,0.0010621996,0.9989378
309,Nitric oxide,0,2,0,12,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,-1,-1,309,-1,0.99334997,0.0066500935
311,reactive oxygen species,4,7,28,51,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,311,-1,0.6858303,0.3141697
312,nitrotyrosine,26,27,144,157,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,312,-1,0.9968976,0.0031024788
317,drinking water,19,21,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,317,-1,0.9029945,0.09700544
318,lead,30,31,157,161,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,318,-1,0.99696785,0.0030321507
320,MDA,11,12,68,71,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,-1,-1,-1,320,-1,0.9933275,0.0066725556
321,MDA,11,12,69,72,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,321,-1,0.9955922,0.0044077625
322,Vitamin E,0,2,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,322,-1,0.997459,0.0025410422
324,MDA,8,9,67,70,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,324,-1,0.99107975,0.008920283
325,Vitamin E,0,2,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,325,-1,0.9977385,0.002261508
326,MDA,12,13,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,326,-1,0.80761147,0.1923885
327,lead,11,12,76,80,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,-1,327,-1,0.9963259,0.0036741097
330,Glyceryl trinitrate,0,2,0,19,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,330,-1,0.9980494,0.0019506272
331,migraine without aura,5,8,39,60,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,331,-1,0.00112046,0.9988795
332,migraine with aura,11,14,77,95,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,332,-1,0.0012827716,0.9987173
333,Migraine with aura,0,3,0,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,333,-1,0.0020837844,0.99791616
334,migraine without aura,4,7,23,44,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,334,-1,0.0018920503,0.9981079
336,migraine with aura,16,19,92,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,336,-1,0.0019497974,0.9980502
337,migraine without aura,20,23,115,136,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,337,-1,0.0018080256,0.998192
338,nitric oxide,12,14,79,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,338,-1,0.99628747,0.0037125065
340,migraine without aura,23,26,131,152,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,340,-1,0.0011754597,0.99882454
341,migraine with aura,10,13,49,67,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,341,-1,0.0013411938,0.9986588
343,glyceryl trinitrate,27,29,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,343,-1,0.99783945,0.0021604707
344,GTN,30,31,172,175,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,344,-1,0.9951637,0.0048363134
345,migraine with aura,43,46,227,245,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,345,-1,0.001334627,0.99866533
346,migraine without aura,13,16,70,91,The specific aim was to elucidate whether an aura and/or an attack of migraine without aura could be induced.,10524660_4,-1,-1,-1,346,-1,0.0012284226,0.9987716
348,migraineurs,5,6,28,39,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,348,-1,0.0011070236,0.99889296
349,GTN,14,15,90,93,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,349,-1,0.99652606,0.003473885
350,p=0.037,17,18,104,111,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,350,-1,0.08974498,0.910255
351,h,26,27,148,149,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,351,-1,0.03907526,0.96092474
352,p,28,29,151,152,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,352,-1,0.0805147,0.91948533
354,migraineurs,12,13,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,-1,-1,354,-1,0.0018598975,0.9981401
357,migraineurs,10,11,45,56,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,357,-1,0.0014428762,0.99855715
358,migraine without aura,16,19,95,116,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,358,-1,0.0011730092,0.99882704
361,migraine with aura,13,16,76,94,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,-1,-1,361,-1,0.0013284531,0.99867153
365,migraine with aura,29,32,188,206,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,-1,-1,365,-1,0.0011909436,0.9988091
368,nonsmall cell lung carcinoma,4,8,32,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,-1,-1,-1,368,-1,0.0024136547,0.99758637
370,nonsmall cell lung carcinoma,6,10,39,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,370,-1,0.0039974847,0.9960025
371,NSCLC,11,12,69,74,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,371,-1,0.0015637754,0.9984363
374,VNB,10,11,68,71,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,374,-1,0.9941155,0.005884493
376,GEM,15,16,89,92,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,376,-1,0.9959875,0.004012457
379,GEM,12,13,69,72,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,379,-1,0.9968202,0.0031798163
380,VNB,14,15,77,80,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,380,-1,0.99401075,0.0059892433
381,NSCLC,20,21,115,120,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,381,-1,0.0013234125,0.9986766
383,NSCLC,6,7,43,48,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,-1,-1,-1,383,-1,0.0012032121,0.9987968
386,VNB,4,5,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,386,-1,0.9946831,0.0053169318
387,GEM,11,12,49,52,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,387,-1,0.99659485,0.0034051698
395,P,28,29,151,152,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,-1,-1,395,-1,0.08471381,0.9152862
396,GEM,5,6,32,35,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,396,-1,0.9958055,0.0041944874
397,VNB,7,8,40,43,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,397,-1,0.994121,0.0058789137
400,NSCLC,16,17,116,121,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,-1,-1,400,-1,0.0014749217,0.9985251
402,calcium chloride,7,9,65,81,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,-1,-1,-1,402,-1,0.99828976,0.0017102046
404,respiratory arrest,9,11,55,73,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,-1,-1,-1,404,-1,0.0010388735,0.9989611
406,calcium chloride,3,5,22,38,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,-1,-1,406,-1,0.99791294,0.0020870524
410,calcium chloride,18,20,136,152,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,-1,-1,-1,410,-1,0.99780124,0.0021987287
411,decreased renal function,2,5,14,38,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,411,-1,0.0019509725,0.998049
412,heart failure,8,10,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,412,-1,0.0010400316,0.9989599
413,left ventricular dysfunction,21,24,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,413,-1,0.0015129816,0.998487
414,congestive heart failure,37,40,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,414,-1,0.0010703468,0.9989297
415,CHF,41,42,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,415,-1,0.0010437573,0.9989562
416,decreased renal function,48,51,350,374,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,416,-1,0.0021728603,0.9978271
417,reduction in renal function,8,12,55,82,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,417,-1,0.0016378736,0.9983621
418,CHF,15,16,100,103,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,418,-1,0.0009776653,0.99902236
419,Left Ventricular Dysfunction,9,12,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,419,-1,0.0020061552,0.9979938
421,CHF,29,30,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,421,-1,0.0010831392,0.99891686
423,Decreased renal function,0,3,0,24,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,-1,-1,-1,423,-1,0.0016704322,0.9983296
425,in renal function,10,13,76,93,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,425,-1,0.0035146063,0.99648535
427,low systolic blood pressure,23,27,158,185,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,427,-1,0.006598186,0.9934018
428,mm Hg,30,32,192,197,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,428,-1,0.013273912,0.98672605
431,diuretic,45,46,260,268,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,431,-1,0.99613154,0.0038684243
433,decreased renal function,14,17,81,105,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,433,-1,0.0017466663,0.9982533
434,P,20,21,121,122,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,434,-1,0.11980318,0.88019675
436,diuretic,14,15,78,86,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,436,-1,0.9937226,0.006277337
438,decreased renal function,22,25,130,154,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,438,-1,0.0016092538,0.9983908
439,decreased renal function,10,13,59,83,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,-1,439,-1,0.0018804381,0.99811953
443,Diuretic,0,1,0,8,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,443,-1,0.9939366,0.006063442
444,decreased renal function,10,13,64,88,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,444,-1,0.0016101161,0.99838996
448,renal impairment,4,6,16,32,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,-1,448,-1,0.0010075684,0.9989924
450,decreased renal function,13,16,64,88,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,450,-1,0.001388173,0.9986118
451,CHF,19,20,106,109,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,451,-1,0.0009878568,0.9990121
452,Diuretic,0,1,0,8,Diuretic use and advanced age increased this risk.,10539815_14,-1,-1,-1,452,-1,0.99669206,0.0033078964
454,renal impairment,8,10,50,66,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,454,-1,0.0008615998,0.99913836
455,CHF,14,15,88,91,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,455,-1,0.0008656007,0.9991345
458,psychotic disorder,13,15,73,91,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,458,-1,0.0011689523,0.9988311
459,hypomania,20,21,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,459,-1,0.001166903,0.9988331
462,NRA0160,7,8,45,52,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,-1,-1,-1,462,-1,0.97691524,0.023084769
463,NRA0160,0,1,0,7,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,-1,463,-1,0.9184485,0.08155154
466,NRA0160,0,1,0,7,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,-1,-1,-1,466,-1,0.96010154,0.039898396
469,NRA0160,0,1,0,7,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,469,-1,0.9715067,0.028493293
472,(5-HT)2A,18,19,100,108,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,472,-1,0.9677963,0.03220366
473,NRA0160,0,1,0,7,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,473,-1,0.98948085,0.010519194
477,MAP,10,11,86,89,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,477,-1,0.76664364,0.23335633
478,NRA0160,0,1,0,7,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,-1,478,-1,0.9927205,0.007279491
480,NRA0160,0,1,0,7,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,-1,-1,-1,480,-1,0.9895252,0.010474798
483,NRA0160,0,1,0,7,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,-1,483,-1,0.9903008,0.009699243
486,NRA0160,0,1,0,7,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,486,-1,0.98448074,0.015519276
488,phencyclidine,6,7,50,63,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,488,-1,0.9987985,0.0012015393
489,NRA0160,4,5,28,35,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,489,-1,0.9909601,0.009039864
490,antipsychotics,20,21,142,156,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,490,-1,0.7535502,0.24644978
492,vitamin D.The,8,10,67,80,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,-1,492,-1,0.9061557,0.09384431
493,vitamin D,16,18,125,134,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,-1,493,-1,0.9978054,0.0021946318
499,calcification of the artery media,9,14,57,90,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,-1,-1,499,-1,0.0028041867,0.99719584
501,contrast,1,2,3,11,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,-1,-1,501,-1,0.016981257,0.98301876
506,calcification of the artery media,11,16,81,114,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,506,-1,0.0026510921,0.9973489
515,vitamin D,10,12,68,77,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,-1,-1,515,-1,0.99836904,0.0016310131
518,vitamin D,3,5,14,23,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,518,-1,0.99736965,0.0026302976
519,calcification of the artery media,9,14,43,76,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,519,-1,0.0023372953,0.99766266
520,vitamin K,4,6,18,27,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,520,-1,0.9967265,0.0032734976
522,calcification of the artery media,13,18,72,105,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,522,-1,0.002542383,0.9974577
525,vitamin D,9,11,49,58,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,525,-1,0.9983987,0.0016012967
527,vitamin D,19,21,106,115,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,527,-1,0.9982346,0.0017653459
529,vitamin D,32,34,176,185,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,529,-1,0.99825996,0.0017400874
534,vitamin D,14,16,87,96,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,534,-1,0.99816763,0.0018322841
536,vitamin D,22,24,131,140,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,536,-1,0.9981536,0.0018463404
540,vitamin D,17,19,98,107,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,-1,-1,540,-1,0.9979917,0.0020083524
552,contrast,1,2,3,11,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,-1,552,-1,0.06513533,0.9348647
554,DOPAC,4,5,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,554,-1,0.9972746,0.0027253893
555,DA,6,7,32,34,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,555,-1,0.995684,0.0043160096
556,HVA,8,9,39,42,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,556,-1,0.9957936,0.00420641
557,DA,10,11,43,45,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,557,-1,0.99574345,0.0042565204
559,Gerstmann syndrome,1,3,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,-1,-1,-1,559,-1,0.0015795566,0.9984205
561,acetazolamide,4,5,27,40,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,561,-1,0.9987956,0.0012043081
562,adverse drug reaction,9,12,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,562,-1,0.0016557745,0.9983442
563,renal impairment,15,17,96,112,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,563,-1,0.0010696551,0.9989303
564,Gerstmann syndrome,6,8,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,-1,-1,564,-1,0.0013773915,0.99862266
568,TAM,2,3,11,14,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,-1,-1,568,-1,0.9967168,0.0032831295
571,TAM,6,7,35,38,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,-1,-1,571,-1,0.99740535,0.002594689
573,TAM,0,1,0,3,TAM induces hemolysis of erythrocytes as a function of concentration.,10704919_3,-1,-1,-1,573,-1,0.99637043,0.0036296025
576,TAM,13,14,81,84,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,-1,-1,576,-1,0.9958118,0.0041882657
578,TAM,6,7,46,49,"Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.",10704919_5,-1,-1,-1,578,-1,0.99609154,0.0039084866
579,hemolytic,1,2,4,13,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,579,-1,0.0010955209,0.99890447
580,TAM,4,5,24,27,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,580,-1,0.99781764,0.0021823344
581,hydroxyl,24,25,158,166,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,581,-1,0.63570017,0.36429983
585,TAM,6,7,34,37,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,585,-1,0.99733716,0.0026627698
586,AAPH,15,16,97,101,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,586,-1,0.9493459,0.05065416
588,TAM,3,4,20,23,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,-1,588,-1,0.9961492,0.0038508172
590,TAM,2,3,9,12,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,-1,-1,-1,590,-1,0.99648947,0.0035105525
591,TAM,9,10,68,71,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,-1,-1,-1,591,-1,0.9368623,0.06313767
593,tocopherols,9,10,60,71,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,593,-1,0.99848974,0.0015102086
594,TAM,15,16,98,101,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,594,-1,0.99492115,0.0050788224
596,TAM,13,14,100,103,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,-1,-1,596,-1,0.9958449,0.004155091
598,cytotoxicity,10,11,57,69,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,598,-1,0.0015743185,0.9984257
599,TAM,21,22,139,142,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,599,-1,0.99572057,0.004279511
601,ATP,4,5,22,25,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,601,-1,0.996716,0.0032839535
602,nitric oxide,15,17,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,602,-1,0.9967362,0.0032637913
608,ATP,9,10,53,56,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,-1,608,-1,0.9947343,0.0052656825
610,ATP,30,31,165,168,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,-1,610,-1,0.99489355,0.0051065097
629,domperidone,0,1,0,11,domperidone (0.5 mg/kg).,10721819_6,-1,-1,-1,629,-1,0.9986582,0.0013418391
640,heart failure,9,11,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,-1,-1,640,-1,0.0009225299,0.99907744
641,phosphodiesterase,3,4,11,28,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,641,-1,0.97160596,0.028393978
642,inhibitors,4,5,29,39,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,642,-1,0.9662402,0.033759803
643,milrinone,7,8,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,643,-1,0.99859625,0.0014037526
644,heart failure,13,15,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,644,-1,0.0008893556,0.99911064
646,heart failure,4,6,31,44,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,646,-1,0.0008958418,0.9991041
648,milrinone,11,12,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,648,-1,0.9987919,0.0012081227
650,milrinone,26,27,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,650,-1,0.9987645,0.0012354909
661,venous thromboembolism,10,12,59,81,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,-1,661,-1,0.0010054561,0.9989945
662,venous thromboembolism,8,10,54,76,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,662,-1,0.0010621996,0.9989378
663,VTE,11,12,78,81,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,663,-1,0.001221553,0.9987784
665,OC,19,20,126,128,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,665,-1,0.9903308,0.009669157
666,OC,27,28,170,172,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,666,-1,0.98977065,0.01022936
667,VTE,13,14,77,80,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,-1,667,-1,0.0013185311,0.9986815
668,VTE,10,11,40,43,"Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls.",10739826_3,-1,-1,-1,668,-1,0.0015821914,0.99841785
669,VTE,5,6,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,669,-1,0.001870448,0.99812955
670,OC,12,13,68,70,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,670,-1,0.9537602,0.046239782
671,VTE,14,15,92,95,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,-1,671,-1,0.0013080675,0.998692
672,OC,11,12,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,-1,-1,-1,672,-1,0.98545015,0.014549827
684,mg,6,7,32,34,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,684,-1,0.954868,0.04513203
686,mg,23,24,114,116,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,686,-1,0.9704653,0.029534698
704,CyA,14,15,113,116,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,-1,-1,-1,704,-1,0.048844952,0.951155
707,CyA.,15,16,104,108,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,-1,-1,-1,707,-1,0.6837298,0.3162702
710,diabetes mellitus,13,15,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,710,-1,0.0012033072,0.9987967
711,IDDM,16,17,97,101,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,711,-1,0.0021694822,0.99783045
713,gastrointestinal (GI) toxicity,27,32,128,158,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,713,-1,0.001597418,0.99840254
716,IDDM,52,53,237,241,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,716,-1,0.0013966478,0.9986034
718,GI toxicity,62,64,268,279,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,718,-1,0.0015569453,0.99844307
720,PTLD,77,78,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,720,-1,0.0025240278,0.9974759
725,CyA,12,13,79,82,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,-1,-1,-1,725,-1,0.9487619,0.051238175
733,juvenile rheumatoid arthritis,3,6,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,-1,-1,733,-1,0.0014958612,0.99850416
734,juvenile rheumatoid arthritis,5,8,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,-1,-1,734,-1,0.0012136012,0.9987864
735,iridocyclitis,10,11,49,62,Thirty-six of the 210 patients (17.2%) developed iridocyclitis.,1079693_2,-1,-1,-1,735,-1,0.00334008,0.9966599
736,Iridocyclitis,0,1,0,13,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,-1,-1,736,-1,0.0035867642,0.9964133
738,uveitis,8,9,39,46,"However, 30% of the patients developed uveitis after 16 years of age.",1079693_4,-1,-1,-1,738,-1,0.0009443172,0.9990557
739,uveitis,17,18,87,94,"Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.",1079693_5,-1,-1,-1,739,-1,0.0009631876,0.9990368
740,uveitis,6,7,40,47,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,740,-1,0.00095407333,0.9990459
741,uveitis,13,14,82,89,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,741,-1,0.0009815797,0.99901843
742,uveitis,5,6,36,43,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,742,-1,0.00086459424,0.99913543
743,ocular pain,20,22,109,120,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,743,-1,0.0013726804,0.9986273
744,decreased visual acuity,23,26,122,145,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,744,-1,0.002264764,0.99773526
745,photophobia,28,29,150,161,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,745,-1,0.0012403647,0.9987596
746,uveitis,13,14,65,72,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,-1,-1,-1,746,-1,0.00090774725,0.9990922
748,uveitis,17,18,94,101,"Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies.",1079693_9,-1,-1,-1,748,-1,0.0008827767,0.9991172
750,band keratopathy,2,4,13,29,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,-1,-1,-1,750,-1,0.0021277354,0.99787223
752,hydroxychloroquine,4,5,23,41,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,752,-1,0.9987166,0.0012834651
753,chorioretinopathy,16,17,89,106,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,753,-1,0.0010996289,0.9989003
756,keratoconjunctivitis sicca,1,3,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,756,-1,0.0014103693,0.9985896
757,uveitis,8,9,61,68,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,757,-1,0.0011441818,0.9988558
758,uveitis,3,4,22,29,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,758,-1,0.000923236,0.9990767
759,JRA,5,6,34,37,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,759,-1,0.0010340987,0.99896586
761,band keratopathy,5,7,33,49,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,-1,-1,761,-1,0.002389502,0.99761045
763,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,-1,-1,763,-1,0.0015241846,0.99847585
765,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,-1,-1,765,-1,0.0011570851,0.99884284
768,ruptured aneurysms,12,14,66,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,-1,768,-1,0.0015658971,0.9984341
770,subarachnoid hemorrhage,15,17,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,-1,-1,770,-1,0.0013878392,0.99861217
773,P,19,20,108,109,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,-1,773,-1,0.121309794,0.87869024
776,mm,18,19,89,91,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,776,-1,0.005398199,0.99460185
777,mm,24,25,110,112,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,777,-1,0.0060374844,0.99396247
778,P,26,27,114,115,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,778,-1,0.082425416,0.9175746
779,P,5,6,21,22,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,779,-1,0.09786493,0.902135
780,P,12,13,41,42,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,780,-1,0.11615503,0.883845
783,aneurysmal rupture,5,7,36,54,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,-1,-1,-1,783,-1,0.0013260306,0.99867404
786,acute stroke,10,12,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,-1,-1,786,-1,0.0012339943,0.99876606
789,reduction in blood pressure,19,23,134,161,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,789,-1,0.0032997113,0.9967002
790,BP,24,25,163,165,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,790,-1,0.003360746,0.99663925
791,acute stroke,31,33,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,791,-1,0.0012007892,0.9987992
792,BP reduction,23,25,157,169,We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction.,10835440_2,-1,-1,-1,792,-1,0.008592493,0.99140745
794,n=100,22,23,130,135,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,794,-1,0.15362945,0.8463706
796,n=101,32,33,168,173,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,796,-1,0.1755861,0.82441384
798,n=94,43,44,210,214,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,798,-1,0.1556281,0.8443719
799,n=92,12,13,73,77,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,-1,-1,-1,799,-1,0.082684465,0.9173155
801,reduction,7,8,61,70,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,801,-1,0.0079870615,0.9920129
802,systolic,9,10,74,82,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,802,-1,0.0039915578,0.9960084
803,diastolic BP,15,17,96,108,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,803,-1,0.0023626473,0.9976374
804,DBP reduction,8,10,60,73,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,804,-1,0.04809428,0.95190567
805,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,805,-1,0.28579646,0.7142036
808,neurological worsening,12,14,61,83,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,808,-1,0.00096054235,0.9990395
810,acute stroke,22,24,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,810,-1,0.0011910804,0.998809
814,visceral pain,14,16,105,118,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,-1,814,-1,0.001207384,0.9987925
815,visceral pain,7,9,31,44,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,-1,-1,-1,815,-1,0.0013279673,0.998672
817,CP,2,3,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,817,-1,0.98969716,0.01030277
818,acrolein,22,23,129,137,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,818,-1,0.99753225,0.002467705
820,CP,4,5,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,-1,-1,-1,820,-1,0.9883385,0.011661493
823,CP,6,7,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,-1,-1,-1,823,-1,0.9843195,0.015680553
825,CP,19,20,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,-1,-1,-1,825,-1,0.9945279,0.0054721492
826,mg,5,6,15,17,i.p. and of 20 mg.,10840460_10,-1,-1,-1,826,-1,0.5292506,0.47074938
827,acrolein,6,7,31,39,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,827,-1,0.99768376,0.0023162179
828,mg,11,12,56,58,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,828,-1,0.8111532,0.1888468
829,CP,4,5,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,-1,829,-1,0.9943234,0.0056766677
831,behavioral disorders,4,6,41,61,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,-1,831,-1,0.0012603339,0.99873966
832,CP,19,20,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,-1,-1,-1,832,-1,0.99307114,0.0069288933
836,CP,4,5,16,18,"In female rats, CP 200 mg./kg.",10840460_18,-1,-1,-1,836,-1,0.99366957,0.0063305087
837,mg,6,7,31,33,Administered at the dose of 20 mg.,10840460_20,-1,-1,-1,837,-1,0.56591153,0.43408847
838,CP,2,3,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,838,-1,0.9745837,0.025416298
839,acrolein,11,12,67,75,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,839,-1,0.997601,0.0023989868
840,mg,14,15,83,85,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,840,-1,0.8148436,0.18515639
841,CP,8,9,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,-1,-1,-1,841,-1,0.9960295,0.0039705387
842,acrolein,2,3,12,20,"Conversely, acrolein 5 mg./kg.",10840460_24,-1,-1,-1,842,-1,0.99740297,0.002597032
844,visceral pain,23,25,156,169,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,844,-1,0.0012641159,0.99873585
845,painful syndromes,32,34,212,229,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,845,-1,0.0016999664,0.9983
851,clonic fits,21,23,129,140,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,-1,-1,851,-1,0.0015027111,0.99849725
852,fits,1,2,4,8,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,-1,-1,-1,852,-1,0.001518916,0.9984811
858,emergency department,11,13,67,87,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,-1,-1,858,-1,0.0036853063,0.9963147
862,emergency department,26,28,145,165,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,-1,-1,862,-1,0.003670374,0.9963296
863,fracture,32,33,164,172,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,863,-1,0.0025362726,0.9974637
864,dislocation,34,35,176,187,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,864,-1,0.0019940806,0.9980059
865,emergency department,37,39,195,215,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,865,-1,0.008570878,0.99142915
866,trauma,42,43,229,235,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,866,-1,0.0068664276,0.99313354
867,Ketamine hydrochloride,0,2,0,22,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,867,-1,0.9966689,0.0033311616
868,body weight,15,17,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,868,-1,0.016555002,0.983445
869,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,869,-1,0.014826159,0.98517376
873,fracture,14,15,93,101,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,873,-1,0.0017872151,0.9982128
874,dislocation,16,17,105,116,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,874,-1,0.0015989792,0.998401
877,fracture,32,33,162,170,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,-1,877,-1,0.0049929186,0.99500704
878,fracture,1,2,9,17,Adequate fracture reduction was obtained in 111 of the children.,10901305_9,-1,-1,-1,878,-1,0.003913188,0.99608684
880,emesis,10,11,56,62,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,880,-1,0.000897726,0.99910235
882,clumsiness,21,22,109,119,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,882,-1,0.001293857,0.9987061
883,ataxic movements,25,27,132,148,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,883,-1,0.001669893,0.99833006
884,dysphoric reaction,33,35,171,189,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,884,-1,0.0009980492,0.9990019
886,nightmares,12,13,72,82,"No long-term sequelae were noted, and no patients had hallucinations or nightmares.",10901305_14,-1,-1,-1,886,-1,0.0012762126,0.9987238
889,emergency department,23,25,150,170,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,-1,-1,889,-1,0.0038826135,0.99611735
891,emergency department,11,13,59,79,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,-1,-1,-1,891,-1,0.010177148,0.98982286
892,muscle dysfunction,1,3,21,39,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,-1,-1,892,-1,0.0011796397,0.99882036
895,glucocorticoids,3,4,15,30,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,-1,-1,-1,895,-1,0.997412,0.0025879445
900,twitch,7,8,32,38,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,900,-1,0.0019314905,0.9980685
901,tetanic,10,11,49,56,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,901,-1,0.0022314356,0.9977685
902,body weight gain,2,5,8,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,-1,-1,902,-1,0.0021356854,0.9978643
904,twitch,3,4,16,22,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,904,-1,0.0016650613,0.99833494
905,tetanic,5,6,27,34,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,905,-1,0.0029293338,0.99707067
906,P,13,14,62,63,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,-1,-1,-1,906,-1,0.17369631,0.8263037
907,neuromuscular dysfunction,5,7,29,54,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,907,-1,0.0011980074,0.99880195
909,muscle atrophy,16,18,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,909,-1,0.0016763373,0.9983236
910,muscle atrophy,12,14,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,-1,-1,910,-1,0.0017591236,0.9982408
915,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,-1,915,-1,0.0018068658,0.9981931
918,immunoglobulin G,23,25,169,185,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,-1,918,-1,0.99664885,0.003351172
922,TMA,21,22,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,-1,-1,-1,922,-1,0.004005476,0.99599457
924,TMA,12,13,99,102,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,-1,-1,-1,924,-1,0.006223799,0.9937762
925,TMA,10,11,65,68,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,-1,-1,-1,925,-1,0.002630932,0.99736905
928,TMA,14,15,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,-1,-1,-1,928,-1,0.004909234,0.9950907
931,TMA,13,14,99,102,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,-1,-1,-1,931,-1,0.0040369905,0.99596304
934,signs and symptoms,17,20,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,934,-1,0.0020187122,0.99798137
935,TMA,22,23,140,143,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,935,-1,0.0026740031,0.997326
937,Parkinson's disease,6,9,42,61,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,-1,-1,-1,937,-1,0.0013383803,0.99866164
939,Parkinson's disease,12,15,75,94,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,-1,-1,-1,939,-1,0.0014838559,0.99851614
940,Parkinson's disease,17,20,114,133,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,-1,-1,-1,940,-1,0.0010875926,0.99891245
951,psychiatric complications,18,20,129,154,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,-1,-1,-1,951,-1,0.0013815601,0.9986185
953,Parkinson's disease,12,15,89,108,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,-1,-1,-1,953,-1,0.0011227776,0.9988772
954,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,-1,954,-1,0.0019218717,0.9980781
957,tropicamide,4,5,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,-1,-1,-1,957,-1,0.99851066,0.0014892961
958,tropicamide,4,5,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,-1,-1,-1,958,-1,0.99869114,0.0013088268
961,mg,12,13,58,60,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,-1,961,-1,0.9409307,0.059069317
962,tropicamide,11,12,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,962,-1,0.99879766,0.0012023648
964,impairment in word recall,16,20,117,142,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,964,-1,0.0058584777,0.9941415
965,tropicamide,16,17,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,965,-1,0.9986273,0.0013727321
966,p,22,23,138,139,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,966,-1,0.14557515,0.85442483
967,p,30,31,175,176,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,-1,967,-1,0.14796658,0.85203344
968,impairment in word recall,12,16,81,106,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,968,-1,0.006426705,0.99357325
969,p,25,26,152,153,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,969,-1,0.120213285,0.87978673
971,tropicamide,15,16,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,971,-1,0.9987055,0.0012944987
977,opioid,15,16,89,95,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,977,-1,0.71897626,0.2810238
978,MM,21,22,141,143,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,978,-1,0.86210656,0.13789341
979,n,25,26,156,157,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,979,-1,0.09897535,0.90102464
980,n,37,38,220,221,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,980,-1,0.090709366,0.9092906
981,CP,13,14,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,981,-1,0.008364167,0.9916358
983,hydromorphone,32,33,188,201,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,983,-1,0.9985858,0.0014142254
984,mg,34,35,204,206,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,984,-1,0.92458594,0.07541412
985,ketorolac,40,41,244,253,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,985,-1,0.9986634,0.0013366262
986,mg,42,43,257,259,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,986,-1,0.9242747,0.0757253
987,MM,3,4,20,22,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,987,-1,0.007034048,0.99296594
988,CP pain,10,12,71,78,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,988,-1,0.0019901616,0.99800986
995,NMDA,9,10,70,74,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,995,-1,0.9970054,0.0029946237
997,analgesia,23,24,144,153,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,997,-1,0.0017910883,0.9982089
1005,nausea and vomiting,10,13,45,64,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,1005,-1,0.0018824601,0.99811757
1006,drowsiness,14,15,66,76,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,1006,-1,0.0016708998,0.9983291
1013,mg,9,10,63,65,These episodes reversed after the administration of diazepam 1 mg intravenously.,11027905_8,-1,-1,-1,1013,-1,0.95736593,0.042634103
1014,drowsiness,3,4,25,35,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,-1,-1,-1,1014,-1,0.00085921655,0.99914074
1019,morphine analgesia,3,5,21,39,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,-1,-1,1019,-1,0.3441527,0.65584725
1024,spinal cord injury,7,10,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,-1,-1,-1,1024,-1,0.0012183326,0.9987816
1025,Spinal Cord Injury,5,8,30,48,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1025,-1,0.0020704877,0.99792945
1027,spinal cord injury,23,26,138,156,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1027,-1,0.0014423446,0.9985576
1028,corticosteroid myopathy,13,15,71,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,-1,-1,-1,1028,-1,0.06983914,0.9301608
1032,damage to the muscle,7,11,38,58,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1032,-1,0.0028925526,0.99710745
1033,spinal cord injury,12,15,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1033,-1,0.0014315206,0.9985684
1034,steroid myopathy,2,4,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1034,-1,0.055211373,0.94478863
1035,steroid myopathy,26,28,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1035,-1,0.044770427,0.9552295
1037,spinal cord injury,38,41,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1037,-1,0.0017305829,0.99826944
1039,corticosteroid myopathy,21,23,141,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,-1,-1,-1,1039,-1,0.0385503,0.9614497
1041,RAPA,13,14,64,68,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1041,-1,0.98573387,0.014266183
1043,CsA,20,21,117,120,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1043,-1,0.9973334,0.0026666706
1045,Tac,25,26,137,140,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1045,-1,0.99643505,0.003564964
1048,RAPA,13,14,83,87,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,-1,-1,-1,1048,-1,0.9967334,0.0032666435
1049,CsA,6,7,40,43,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1049,-1,0.9959072,0.0040927646
1050,Tac nephrotoxicity,8,10,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1050,-1,0.045998257,0.9540017
1051,CsA,15,16,78,81,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1051,-1,0.99573994,0.004260093
1052,Tac toxicity,17,19,85,97,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1052,-1,0.15370171,0.84629834
1053,facial dysmorphism,24,26,110,128,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1053,-1,0.0011504292,0.9988495
1054,posttransplant lymphoproliferative disorder,30,33,134,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1054,-1,0.0019786563,0.99802136
1055,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1055,-1,0.0013018077,0.9986981
1059,P<0.05,25,26,162,168,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,-1,-1,1059,-1,0.10601264,0.89398736
1060,Facial dysmorphism,0,2,0,18,Facial dysmorphism improved in two patients.,11063349_7,-1,-1,-1,1060,-1,0.0012182107,0.99878174
1061,PTLD,3,4,14,18,No relapse of PTLD was observed.,11063349_8,-1,-1,-1,1061,-1,0.0012273097,0.9987727
1062,pneumonia,3,4,24,33,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1062,-1,0.0009922201,0.99900776
1063,Pneumocystis,6,7,39,51,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1063,-1,0.011720714,0.9882792
1064,pneumonia,8,9,60,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1064,-1,0.001205194,0.9987948
1065,infectious mononucleosis,11,13,75,99,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1065,-1,0.0014260726,0.9985739
1066,PTLD,15,16,116,120,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1066,-1,0.001804311,0.9981957
1067,bronchiolitis obliterans,22,24,150,174,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1067,-1,0.0014741835,0.9985258
1069,RAPA,0,1,0,4,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1069,-1,0.005314786,0.9946852
1070,pneumonia,9,10,51,60,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1070,-1,0.000976654,0.9990233
1071,PTLD,13,14,69,73,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1071,-1,0.0010546383,0.9989454
1072,aphtous ulcers,19,21,91,105,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1072,-1,0.0009692476,0.9990307
1073,RAPA,0,1,0,4,RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.,11063349_12,-1,-1,-1,1073,-1,0.8887043,0.11129572
1074,RAPA,2,3,13,17,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1074,-1,0.19074738,0.8092527
1075,CsA,9,10,75,78,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1075,-1,0.9962574,0.0037425715
1076,RAPA,6,7,37,41,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1076,-1,0.93663156,0.063368455
1077,Pneumocystis,19,20,133,145,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1077,-1,0.017931025,0.98206896
1078,pneumonia,21,22,154,163,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1078,-1,0.0018413996,0.99815863
1079,visual field constriction,15,18,142,167,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,-1,-1,-1,1079,-1,0.0017045382,0.9982955
1080,visual field constriction,3,6,21,46,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,-1,-1,-1,1080,-1,0.0017872677,0.9982127
1082,visual field loss,16,19,129,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,-1,-1,-1,1082,-1,0.0019675042,0.9980325
1084,visual field constriction,6,9,38,63,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,-1,-1,-1,1084,-1,0.0017213138,0.99827874
1085,visual field constriction,3,6,19,44,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,-1,-1,-1,1085,-1,0.001648982,0.998351
1088,Myocardial ischemia,0,2,0,19,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1088,-1,0.0010808099,0.99891925
1089,coronary artery spasm,4,7,27,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1089,-1,0.0010639112,0.9989361
1092,myocardial ischemia,14,16,83,102,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,-1,1092,-1,0.0012166487,0.9987834
1093,coronary artery,15,17,71,86,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1093,-1,0.003747535,0.9962525
1094,coronary artery stenosis,28,31,153,177,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1094,-1,0.0018396631,0.9981603
1095,myocardial ischemia,10,12,51,70,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,-1,-1,1095,-1,0.0012280348,0.99877197
1098,coronary spastic angina,7,10,37,60,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1098,-1,0.0010343185,0.99896574
1099,coronary artery stenosis,14,17,91,115,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1099,-1,0.0014001917,0.9985998
1100,anginal attacks,3,5,17,32,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,-1,-1,1100,-1,0.001134718,0.99886525
1104,coronary artery stenosis,13,16,85,109,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,-1,1104,-1,0.0014038319,0.99859613
1106,chest pain,8,10,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1106,-1,0.0013091001,0.9986909
1107,chest pain,15,17,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1107,-1,0.0013140286,0.998686
1110,coronary spastic angina,13,16,89,112,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,-1,-1,1110,-1,0.0010485472,0.99895144
1111,coronary artery disease,6,9,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1111,-1,0.0020171623,0.99798286
1112,coronary stenosis,13,15,74,91,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1112,-1,0.0018137868,0.9981862
1116,myocardial ischemia,11,13,95,114,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,-1,-1,-1,1116,-1,0.0010326968,0.9989673
1119,technetium-99m sestamibi,14,17,89,113,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,-1,-1,-1,1119,-1,0.99690944,0.0030905853
1125,mg,29,30,176,178,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,-1,-1,-1,1125,-1,0.9342839,0.065716125
1127,predobutamine,7,8,42,55,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1127,-1,0.9901952,0.009804769
1128,mg,20,21,123,125,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1128,-1,0.77362496,0.22637507
1134,myocardial ischemia,13,15,94,113,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,-1,-1,-1,1134,-1,0.0012310744,0.99876887
1135,mg,2,3,11,13,"Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.",11079278_13,-1,-1,-1,1135,-1,0.9521625,0.047837473
1138,LID,36,37,216,219,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,-1,1138,-1,0.0013175865,0.99868244
1141,LID,52,53,360,363,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,-1,1141,-1,0.001890627,0.99810934
1142,P,8,9,48,49,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1142,-1,0.25431746,0.74568254
1143,LID,31,32,145,148,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1143,-1,0.0015709044,0.9984291
1149,LID,17,18,109,112,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,-1,-1,1149,-1,0.001227888,0.9987721
1155,LID,26,27,137,140,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,-1,-1,-1,1155,-1,0.0013077211,0.99869233
1161,nonsmall cell lung carcinoma,15,19,126,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,-1,-1,-1,1161,-1,0.0029156695,0.9970843
1162,nonsmall cell lung carcinoma,13,17,103,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1162,-1,0.0030950017,0.996905
1163,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1163,-1,0.0017400756,0.99825996
1168,NSCLC,30,31,175,180,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,-1,1168,-1,0.0016572112,0.99834275
1169,NSCLC,7,8,66,71,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,-1,1169,-1,0.0016244985,0.99837554
1173,disease progression,17,19,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,-1,-1,1173,-1,0.0016461695,0.99835384
1186,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,-1,1186,-1,0.001801082,0.9981989
1187,Serotonergic antidepressants,0,2,0,28,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1187,-1,0.9870821,0.012917865
1188,urinary incontinence,3,5,33,53,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1188,-1,0.0011113198,0.9988887
1189,serotonergic antidepressants,2,4,9,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,-1,-1,-1,1189,-1,0.9240777,0.07592228
1190,urinary incontinence,1,3,9,29,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,-1,-1,-1,1190,-1,0.001143814,0.9988562
1195,reuptake,18,19,124,132,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,-1,-1,1195,-1,0.98308843,0.016911576
1199,lithium carbonate,11,13,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,-1,-1,-1,1199,-1,0.99812657,0.0018733926
1202,serotonergic antidepressants,7,9,54,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,-1,1202,-1,0.9945581,0.0054419274
1212,emergency department seizure,6,9,37,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,-1,-1,-1,1212,-1,0.0019039406,0.99809605
1215,emergency department seizure,23,26,141,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,-1,-1,-1,1215,-1,0.002292905,0.9977071
1222,seizure disorder,9,11,68,84,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1222,-1,0.0010915768,0.9989084
1229,amphetamine abuse,19,21,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1229,-1,0.70496476,0.29503524
1230,p,22,23,129,130,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1230,-1,0.13670687,0.8632931
1232,amphetamines,13,14,80,92,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,-1,-1,-1,1232,-1,0.98870414,0.011295793
1235,sodium valproate,2,4,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1235,-1,0.99840564,0.00159442
1236,syndrome of inappropriate secretion of antidiuretic hormone,6,13,40,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1236,-1,0.07954101,0.9204589
1237,sodium valproate,11,13,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1237,-1,0.9984397,0.0015602711
1238,VPA,14,15,79,82,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1238,-1,0.994158,0.0058419793
1239,syndrome of inappropriate secretion of antidiuretic hormone,21,28,119,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1239,-1,0.058140606,0.9418594
1240,SIADH,29,30,180,185,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1240,-1,0.0036719893,0.99632806
1241,VPA,4,5,19,22,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,-1,-1,-1,1241,-1,0.9972542,0.0027458603
1243,VPA,2,3,19,22,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,-1,-1,-1,1243,-1,0.9968821,0.003117915
1246,SIADH,5,6,28,33,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1246,-1,0.002106031,0.997894
1247,weakness of the central nervous system,17,23,91,129,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1247,-1,0.0026504102,0.9973496
1248,VPA,28,29,166,169,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1248,-1,0.99646795,0.0035319973
1250,tizanidine,5,6,40,50,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,-1,-1,1250,-1,0.998591,0.0014089409
1252,adrenergic agonists,3,5,25,44,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1252,-1,0.9603778,0.039622195
1253,spasticity,16,17,110,120,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1253,-1,0.00075894344,0.9992411
1254,disorders of the central nervous system,19,25,132,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1254,-1,0.002545485,0.99745446
1255,spasticity,6,7,32,42,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,-1,-1,-1,1255,-1,0.0007397284,0.99926025
1256,angiotensin converting enzyme inhibitors,4,8,32,72,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,-1,-1,1256,-1,0.99471384,0.005286186
1258,lisinopril,9,10,63,73,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1258,-1,0.99852765,0.0014723844
1261,tizanidine,27,28,195,205,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1261,-1,0.9985909,0.0014090964
1262,spasticity,37,38,248,258,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1262,-1,0.000732637,0.9992674
1263,tizanidine,4,5,28,38,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1263,-1,0.99858284,0.0014172306
1264,antihypertensive agents,7,9,49,72,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1264,-1,0.28534332,0.7146567
1266,spasticity,22,23,153,163,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1266,-1,0.0007913333,0.99920875
1273,pentylenetetrazol,24,25,140,157,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,-1,1273,-1,0.99874735,0.0012526447
1274,nitric oxide,2,4,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,-1,-1,-1,1274,-1,0.99559855,0.004401469
1276,nitric oxide,8,10,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,-1,-1,-1,1276,-1,0.9967062,0.0032938088
1277,nephrotic syndrome,17,19,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1277,-1,0.0008660907,0.9991339
1279,ADR,27,28,158,161,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1279,-1,0.8903209,0.10967909
1280,nitrite,12,13,68,75,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,-1,1280,-1,0.9954945,0.0045054858
1282,aminoguanidine,21,22,107,121,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1282,-1,0.99860126,0.0013986989
1283,AG,23,24,123,125,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1283,-1,0.99528027,0.0047197985
1284,ADR,11,12,75,78,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1284,-1,0.47816816,0.5218318
1285,mesangial proliferation,16,18,103,126,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1285,-1,0.0012520865,0.99874794
1286,tubulointerstitial inflammation,20,22,136,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1286,-1,0.0010913418,0.99890864
1288,P,15,16,101,102,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,-1,-1,1288,-1,0.1377495,0.86225057
1289,nitrite,1,2,6,13,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1289,-1,0.9911794,0.008820583
1290,P,11,12,80,81,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1290,-1,0.14575061,0.8542494
1293,AG,2,3,15,17,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1293,-1,0.9943896,0.0056104194
1294,nitrite,15,16,98,105,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1294,-1,0.9932886,0.006711453
1296,melatonin,3,4,16,25,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1296,-1,0.99807006,0.0019300075
1297,narcosis,6,7,49,57,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1297,-1,0.0018234998,0.99817646
1298,Melatonin,0,1,0,9,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1298,-1,0.99737215,0.0026277818
1299,narcosis,17,18,108,116,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1299,-1,0.0039184345,0.99608153
1300,Sodium thiopenthal,0,2,0,18,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1300,-1,0.99794227,0.0020577202
1301,melatonin,10,11,86,95,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1301,-1,0.99820375,0.0017962423
1302,Melatonin,0,1,0,9,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1302,-1,0.9977901,0.0022098506
1303,barbiturate narcosis,7,9,50,70,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1303,-1,0.4251337,0.5748663
1304,barbiturate narcosis,14,16,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,-1,-1,-1,1304,-1,0.49251375,0.5074863
1305,contrast,1,2,3,11,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1305,-1,0.08813468,0.9118653
1306,melatonin,7,8,33,42,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1306,-1,0.99770576,0.002294327
1307,narcosis,28,29,153,161,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1307,-1,0.0020611235,0.9979388
1308,Melatonin,0,1,0,9,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1308,-1,0.99799985,0.0020000925
1309,narcosis,16,17,103,111,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1309,-1,0.0021189717,0.997881
1310,melatonin,6,7,25,34,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1310,-1,0.99804187,0.0019581153
1311,narcosis,9,10,54,62,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1311,-1,0.0047722235,0.9952278
1312,barbiturate,16,17,92,103,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1312,-1,0.9982231,0.0017769295
1319,Myocet,5,6,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1319,-1,0.98110974,0.018890265
1322,doxorubicin cardiotoxicity,27,29,187,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1322,-1,0.08307747,0.91692257
1324,MBC,42,43,313,316,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1324,-1,0.003816872,0.9961831
1325,MBC,9,10,61,64,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1325,-1,0.0025279915,0.997472
1326,Myocet,26,27,162,168,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1326,-1,0.020294026,0.979706
1329,disease progression,53,55,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1329,-1,0.0014212495,0.9985788
1332,congestive heart failure,19,22,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1332,-1,0.000919399,0.99908054
1333,CHF,23,24,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1333,-1,0.00090650056,0.99909353
1335,CHF,15,16,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1335,-1,0.0010183806,0.99898154
1337,P,23,24,118,119,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1337,-1,0.045345247,0.9546548
1339,P,21,22,106,107,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1339,-1,0.11175888,0.8882412
1341,Myocet,2,3,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1341,-1,0.004171993,0.995828
1346,MBC,33,34,247,250,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1346,-1,0.0032100072,0.99679
1348,nitric oxide,9,11,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,-1,-1,1348,-1,0.9918616,0.008138415
1356,contrast,1,2,3,11,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,-1,-1,-1,1356,-1,0.060752824,0.93924713
1360,cyclophosphamide cytotoxicity,6,8,56,85,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,-1,-1,1360,-1,0.68207955,0.31792045
1363,cytotoxicity,23,24,131,143,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,-1,-1,1363,-1,0.0016157159,0.99838424
1374,se,10,11,74,76,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,-1,-1,1374,-1,0.02106395,0.9789361
1381,cytotoxicity,7,8,63,75,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,-1,-1,1381,-1,0.0016037304,0.9983962
1396,Graves' disease,6,9,34,49,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1396,-1,0.0023593095,0.9976407
1397,febrile illness,11,13,56,71,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1397,-1,0.0010263098,0.9989737
1409,solitary kidney,11,13,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,-1,-1,1409,-1,0.0018030839,0.9981969
1411,solitary kidney,11,13,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1411,-1,0.0017627076,0.99823725
1412,chronic renal insufficiency,14,17,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1412,-1,0.0011122355,0.99888784
1415,myocardial infarction,5,7,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1415,-1,0.0009489549,0.99905103
1416,pulmonary edema,8,10,53,68,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1416,-1,0.00094229315,0.9990577
1417,systolic dysfunction losartan,3,6,14,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,-1,-1,-1,1417,-1,0.57902545,0.42097452
1418,mg,7,8,35,37,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1418,-1,0.8636964,0.1363036
1422,amine,24,25,137,142,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1422,-1,0.9976113,0.0023886804
1424,mg,18,19,90,92,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,-1,-1,-1,1424,-1,0.9693242,0.030675815
1427,renal artery stenosis,10,13,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,-1,-1,-1,1427,-1,0.0017085888,0.99829143
1428,renal artery stenosis,4,7,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1428,-1,0.0011882805,0.9988117
1429,heart failure,9,11,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1429,-1,0.00097603915,0.9990239
1430,diuretic,12,13,71,79,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1430,-1,0.9961908,0.003809243
1434,renovascular disease,21,23,150,170,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1434,-1,0.0010884124,0.9989116
1435,pain syndrome,2,4,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1435,-1,0.0012027916,0.9987972
1436,CIPS,5,6,45,49,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1436,-1,0.0020063042,0.9979937
1437,Bone pain,0,2,0,9,Bone pain after transplantation is a frequent complication that can be caused by several diseases.,11263551_1,-1,-1,-1,1437,-1,0.0016863003,0.99831367
1440,oedema,6,7,52,58,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1440,-1,0.0013802556,0.9986198
1441,painful,9,10,66,73,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1441,-1,0.0026829625,0.997317
1443,foot pain,8,10,49,58,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1443,-1,0.0011581994,0.9988418
1444,reflex sympathetic dystrophy,12,15,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1444,-1,0.0018253546,0.99817467
1446,Morton's neuralgia,18,21,111,129,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1446,-1,0.005771057,0.99422896
1447,gout,22,23,131,135,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1447,-1,0.0011013246,0.9988986
1449,avascular necrosis,26,28,151,169,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1449,-1,0.0014812562,0.99851876
1450,intermittent claudication,29,31,171,196,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1450,-1,0.0012370051,0.99876297
1451,foot deformities,33,35,210,226,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1451,-1,0.001257728,0.9987423
1452,stress fractures,36,38,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1452,-1,0.0021093667,0.99789065
1453,hyperparathyroidism,40,41,250,269,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1453,-1,0.0013007636,0.9986992
1455,calcium channel blockers,12,15,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,-1,-1,-1,1455,-1,0.9960729,0.003927111
1457,Pain Syndrome,3,5,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1457,-1,0.0012545259,0.99874544
1458,CIPS,6,7,49,53,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1458,-1,0.0019314868,0.9980685
1461,lead,6,7,41,45,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1461,-1,0.022385554,0.9776144
1462,CIPS,18,19,116,120,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1462,-1,0.0011423465,0.9988576
1463,haemorrhagic myocarditis,1,3,6,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,-1,1463,-1,0.0009301841,0.99906987
1465,Haemorrhagic myocarditis,0,2,0,24,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,-1,-1,-1,1465,-1,0.000920337,0.9990797
1468,Anthracyclines,0,1,0,14,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1468,-1,0.9916407,0.008359248
1474,acute leukemia,29,31,191,205,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,-1,-1,1474,-1,0.00091891474,0.999081
1476,acute leukemia,3,5,23,37,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,-1,1476,-1,0.0009215495,0.9990784
1477,atrial natriuretic peptide,4,7,21,47,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1477,-1,0.9144991,0.08550093
1478,ANP,8,9,49,52,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1478,-1,0.9645242,0.03547579
1479,BNP,11,12,58,61,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1479,-1,0.9743516,0.02564839
1480,congestive heart failure,3,6,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,-1,-1,-1,1480,-1,0.00094238564,0.9990576
1481,heart failure,7,9,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,-1,-1,-1,1481,-1,0.0009299532,0.9990701
1482,heart failure,13,15,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1482,-1,0.0009976061,0.9990024
1483,heart failure,31,33,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1483,-1,0.0010201222,0.99897987
1484,heart failure,13,15,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1484,-1,0.0011276971,0.99887234
1485,DNR,16,17,84,87,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1485,-1,0.9815394,0.018460548
1486,ANP,4,5,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1486,-1,0.9755781,0.024421828
1487,heart failure,17,19,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1487,-1,0.0009815736,0.99901843
1490,atrial fibrillation,4,6,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,-1,1490,-1,0.0011231396,0.99887687
1491,atrial fibrillation,11,13,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1491,-1,0.0017134234,0.99828655
1492,AF,14,15,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1492,-1,0.001535627,0.99846435
1493,AF,15,16,89,91,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1493,-1,0.0014614736,0.9985385
1494,AF,20,21,112,114,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1494,-1,0.0033413153,0.9966587
1495,AF,8,9,49,51,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1495,-1,0.0036042281,0.99639577
1496,blockers,15,16,80,88,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1496,-1,0.9790502,0.020949764
1500,nadolol,13,14,81,88,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,-1,-1,-1,1500,-1,0.9986418,0.0013581914
1501,AF,12,13,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,-1,1501,-1,0.0020496305,0.9979504
1503,AF,4,5,26,28,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1503,-1,0.0023118397,0.9976882
1504,AF,14,15,80,82,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1504,-1,0.0020555407,0.9979444
1505,P<0.01,30,31,149,155,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1505,-1,0.19874181,0.8012582
1506,P<0.0005,45,46,217,225,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1506,-1,0.22644252,0.77355754
1509,ms,17,18,105,107,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1509,-1,0.03284494,0.9671551
1510,P<0.02,19,20,109,115,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1510,-1,0.12422325,0.8757767
1511,ms,27,28,142,144,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1511,-1,0.11315096,0.886849
1512,P<0.05,39,40,199,205,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1512,-1,0.12813897,0.871861
1513,AF,52,53,288,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1513,-1,0.0029915886,0.9970084
1514,ms,57,58,309,311,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1514,-1,0.030741012,0.96925896
1515,P<0.005,59,60,313,320,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1515,-1,0.14400077,0.8559993
1517,AF,6,7,30,32,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1517,-1,0.0053491388,0.9946509
1518,AF,10,11,49,51,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1518,-1,0.0039093685,0.9960906
1520,n=5,24,25,136,139,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1520,-1,0.12888196,0.87111807
1522,AF,11,12,67,69,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,-1,-1,-1,1522,-1,0.0012402018,0.99875987
1526,AF,6,7,53,55,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,-1,-1,-1,1526,-1,0.0014214924,0.99857855
1528,AF,4,5,32,34,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,-1,-1,-1,1528,-1,0.0015914632,0.9984086
1533,nitric oxide,5,7,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1533,-1,0.99696475,0.0030352687
1535,primary headaches,13,15,64,81,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1535,-1,0.0013483558,0.9986517
1537,CGRP,25,26,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1537,-1,0.9782681,0.021731874
1538,CGRP,11,12,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1538,-1,0.97898304,0.021016989
1540,glyceryl trinitrate,19,21,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1540,-1,0.9979631,0.0020369503
1541,GTN,22,23,128,131,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1541,-1,0.99586606,0.0041338895
1543,GTN,9,10,66,69,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,-1,-1,-1,1543,-1,0.9949056,0.0050944407
1545,GTN,11,12,86,89,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,-1,-1,1545,-1,0.99437237,0.0056276284
1547,CGRP,9,10,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1547,-1,0.99644727,0.0035527518
1548,GTN,15,16,75,78,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1548,-1,0.9928148,0.007185156
1549,P=0.65,23,24,115,121,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1549,-1,0.043367244,0.95663273
1550,P=0.48,28,29,136,142,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1550,-1,0.062340263,0.93765974
1551,GTN,5,6,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1551,-1,0.5364689,0.46353105
1552,P=0.36,15,16,82,88,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1552,-1,0.08018279,0.9198172
1553,CGRP,6,7,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1553,-1,0.9901564,0.00984365
1554,GTN,16,17,88,91,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1554,-1,0.9942439,0.00575613
1555,P,21,22,110,111,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1555,-1,0.13983946,0.8601605
1557,CGRP,14,15,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,-1,1557,-1,0.9955487,0.0044513247
1558,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,-1,1558,-1,0.0042890348,0.99571097
1559,torsade de pointes,8,11,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1559,-1,0.0044442527,0.9955557
1560,TDP,12,13,75,78,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1560,-1,0.005098084,0.9949019
1561,fluconazole,16,17,92,103,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1561,-1,0.9987055,0.001294516
1562,TDP,21,22,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1562,-1,0.0040616826,0.9959383
1563,TDP,16,17,106,109,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1563,-1,0.00389868,0.9961014
1564,fluconazole,22,23,143,154,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1564,-1,0.9986504,0.0013496586
1565,TDP,31,32,197,200,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1565,-1,0.0039538518,0.9960461
1566,coronary artery disease,34,37,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1566,-1,0.002485826,0.9975141
1568,congestive heart failure,40,43,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1568,-1,0.0012427913,0.99875724
1569,fluconazole,56,57,368,379,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1569,-1,0.9985998,0.0014001703
1570,TDP,58,59,384,387,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1570,-1,0.0075841937,0.9924158
1571,TDP,1,2,4,7,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1571,-1,0.002040035,0.99796
1572,fluconazole,4,5,22,33,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1572,-1,0.9987105,0.0012894364
1573,premature ventricular contractions,15,18,91,125,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1573,-1,0.0012003353,0.9987997
1575,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1575,-1,0.0017882618,0.99821174
1576,fluconazole,47,48,312,323,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1576,-1,0.99872226,0.0012776623
1577,TDP,52,53,347,350,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1577,-1,0.002864409,0.99713564
1580,QT prolongation,13,15,74,89,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1580,-1,0.0030128215,0.99698716
1581,TDP,16,17,93,96,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1581,-1,0.0030467615,0.99695325
1582,NSVT,21,22,127,131,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1582,-1,0.0015657898,0.99843425
1583,premature ventricular contractions,23,26,136,170,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1583,-1,0.0014099261,0.99859005
1584,fluconazole,39,40,257,268,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1584,-1,0.998439,0.0015609666
1585,fluconazole,7,8,45,56,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1585,-1,0.9985983,0.0014017113
1586,prolongation of the QT interval,16,21,87,118,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1586,-1,0.0038044797,0.99619555
1587,TDP,24,25,131,134,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1587,-1,0.0025838825,0.99741614
1588,fluconazole,7,8,62,73,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,-1,-1,1588,-1,0.99856454,0.001435444
1592,renal failure,12,14,90,103,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1592,-1,0.0009038773,0.99909616
1593,cephalothin sodium,22,24,148,166,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1593,-1,0.99848133,0.0015186238
1594,gentamicin sulfate,25,27,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1594,-1,0.9977367,0.002263299
1596,renal insufficiency,2,4,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,-1,-1,-1,1596,-1,0.0011379519,0.998862
1599,lung toxicity,17,19,143,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1599,-1,0.0010962302,0.99890375
1601,grape seed proanthocyanidin,26,29,213,240,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1601,-1,0.98166084,0.018339107
1602,Grape seed extract,0,3,0,18,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1602,-1,0.9680311,0.03196895
1603,proanthocyanidins,8,9,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1603,-1,0.9612905,0.038709555
1604,IH636 grape seed proanthocyanidin extract,6,11,35,76,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1604,-1,0.93212503,0.06787495
1605,GSPE,12,13,78,82,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1605,-1,0.9706081,0.029391909
1609,lung toxicity,22,24,164,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1609,-1,0.0010822265,0.9989178
1612,GSPE,11,12,68,72,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,-1,-1,-1,1612,-1,0.99536884,0.004631147
1613,AAP,7,8,42,45,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1613,-1,0.98869073,0.011309233
1614,h,13,14,64,65,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1614,-1,0.052441154,0.9475589
1615,AMI,15,16,67,70,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1615,-1,0.98967606,0.0103239175
1616,DOX,23,24,100,103,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1616,-1,0.9954137,0.0045863213
1617,h,29,30,121,122,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1617,-1,0.06199639,0.93800366
1618,PAS,39,40,247,250,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1618,-1,0.85204726,0.14795269
1619,GSPE,3,4,22,26,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1619,-1,0.993961,0.006038995
1620,AAP,7,8,48,51,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1620,-1,0.99080276,0.009197201
1621,AMI,9,10,53,56,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1621,-1,0.994729,0.0052710082
1622,DOX,11,12,61,64,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1622,-1,0.99668026,0.0033197491
1623,tissue damage,13,15,94,107,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1623,-1,0.0020418232,0.9979582
1624,GSPE,30,31,193,197,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1624,-1,0.99568224,0.0043177865
1625,AAP,9,10,39,42,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1625,-1,0.9921665,0.007833552
1626,AMI,11,12,44,47,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1626,-1,0.9830688,0.016931161
1627,DOX,13,14,52,55,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1627,-1,0.9808905,0.01910946
1630,GSPE,31,32,167,171,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1630,-1,0.99633944,0.0036605278
1631,AAP,1,2,6,9,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1631,-1,0.994522,0.0054780487
1632,AMI,3,4,11,14,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1632,-1,0.9941537,0.0058463593
1633,DOX,5,6,19,22,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1633,-1,0.99482924,0.005170774
1634,GSPE,21,22,119,123,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1634,-1,0.9938313,0.0061687375
1636,GSPE,7,8,51,55,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,-1,1636,-1,0.98695034,0.013049716
1637,leucocytoclastic vasculitis,1,3,10,37,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1637,-1,0.0009598694,0.99904007
1638,oxacillin,5,6,54,63,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1638,-1,0.9988834,0.001116563
1639,oxacillin,7,8,39,48,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1639,-1,0.9988506,0.0011494319
1640,bacteremia,15,16,95,105,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1640,-1,0.00090019533,0.99909985
1641,renal failure,18,20,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1641,-1,0.00094852055,0.9990515
1642,purpuric lesions,26,28,164,180,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1642,-1,0.0014638925,0.9985361
1643,blisters,1,2,9,17,Necrotic blisters were noted on his fingers.,11337188_2,-1,-1,-1,1643,-1,0.0017888476,0.99821115
1644,leucocytoclastic vasculitis,6,8,44,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,-1,-1,-1,1644,-1,0.0011738066,0.9988262
1645,Oxacillin,0,1,0,9,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,-1,-1,-1,1645,-1,0.9984894,0.0015106517
1648,Leucocytoclastic vasculitis,0,2,0,27,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1648,-1,0.0012601886,0.9987398
1649,purpura,5,6,49,56,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1649,-1,0.0011758964,0.99882406
1650,abdominal pain,13,15,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1650,-1,0.0011863348,0.9988136
1651,arthralgia,16,17,119,129,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1651,-1,0.0012282735,0.9987717
1652,renal involvement,19,21,135,152,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1652,-1,0.0015189608,0.9984811
1654,collagen vascular disease,10,13,75,100,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1654,-1,0.0029860383,0.9970139
1655,neoplasia,14,15,105,114,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1655,-1,0.0015959988,0.99840397
1656,corticosteroid,8,9,43,57,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,-1,-1,-1,1656,-1,0.99764144,0.0023586147
1658,Oxacillin,0,1,0,9,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1658,-1,0.99878126,0.0012186911
1659,leucocytoclastic vasculitis,10,12,60,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1659,-1,0.000982314,0.9990177
1660,mania,1,2,23,28,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,-1,-1,1660,-1,0.0009977563,0.9990023
1662,mania,9,10,58,63,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1662,-1,0.0011822714,0.99881774
1664,bipolar depression,25,27,178,196,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1664,-1,0.0014285347,0.9985714
1665,bipolar disorder,11,13,64,80,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1665,-1,0.001555103,0.998445
1667,Mania,32,33,216,221,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1667,-1,0.0018619,0.99813807
1669,hypomanic,6,7,36,45,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1669,-1,0.0022876326,0.9977124
1670,bipolar I,26,28,149,158,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1670,-1,0.024695152,0.9753049
1671,bipolar II,29,31,163,173,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1671,-1,0.016079782,0.9839203
1675,serotonin reuptake inhibitors,56,59,333,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1675,-1,0.99535465,0.0046453946
1676,SSRIs,60,61,364,369,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1676,-1,0.99485934,0.0051406496
1678,hypomania,4,5,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1678,-1,0.0012226712,0.99877733
1679,mania,6,7,34,39,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1679,-1,0.0010171565,0.99898285
1680,N,15,16,73,74,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1680,-1,0.05622144,0.9437786
1681,SSRIs,31,32,134,139,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1681,-1,0.9952602,0.0047397795
1682,N,40,41,154,155,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1682,-1,0.06128348,0.9387165
1684,N,52,53,198,199,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1684,-1,0.06579257,0.9342074
1685,hypomanic,57,58,217,226,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1685,-1,0.0016833262,0.99831665
1686,bipolar I,6,8,21,30,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1686,-1,0.022649543,0.9773505
1687,bipolar II,9,11,35,45,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1687,-1,0.017777145,0.9822229
1688,contrast,1,2,3,11,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1688,-1,0.026389854,0.9736101
1691,p,31,32,142,143,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1691,-1,0.10669719,0.8933028
1693,p,37,38,236,237,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,-1,1693,-1,0.1585731,0.8414269
1696,kidney disease,9,11,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,-1,-1,-1,1696,-1,0.0014481581,0.9985518
1697,transplant glomerulopathy,8,10,50,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1697,-1,0.001895384,0.9981046
1698,TG,11,12,77,79,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1698,-1,0.0067140157,0.99328595
1699,TG,6,7,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1699,-1,0.0060935756,0.99390644
1701,chronic allograft nephropathy,19,22,117,146,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1701,-1,0.001236951,0.9987631
1702,glomerulopathies,8,9,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1702,-1,0.0009069329,0.99909306
1704,malignant hypertension,17,19,114,136,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1704,-1,0.0011002047,0.9988998
1707,TG,11,12,44,46,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1707,-1,0.0032090186,0.99679095
1708,TG,19,20,89,91,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1708,-1,0.0027870357,0.99721295
1709,malignant hypertension,5,7,27,49,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1709,-1,0.0009980254,0.99900204
1711,lupus nephritis,11,13,79,94,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1711,-1,0.0010899792,0.99891007
1712,nephritis,15,16,113,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1712,-1,0.00095719093,0.9990428
1714,acute renal failure,22,25,175,194,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1714,-1,0.0008759575,0.999124
1715,TG,5,6,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1715,-1,0.0032599198,0.99674004
1716,renal failure,9,11,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1716,-1,0.00091757625,0.99908245
1718,TG,17,18,108,110,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1718,-1,0.0045302534,0.9954698
1719,TG,33,34,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1719,-1,0.0026476902,0.99735236
1720,kidney diseases,6,8,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1720,-1,0.001456613,0.9985434
1721,TG,19,20,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1721,-1,0.4397102,0.56028974
1722,endothelial injury,4,6,25,43,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1722,-1,0.003327459,0.9966725
1723,immunologic injury,8,10,55,73,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1723,-1,0.0021155656,0.99788445
1724,renal,1,2,4,9,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1724,-1,0.0015976144,0.9984024
1725,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1725,-1,0.0010008609,0.9989992
1726,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,-1,-1,1726,-1,0.0010190848,0.99898094
1728,cardiac arrhythmia,1,3,17,35,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,-1,-1,-1,1728,-1,0.00094536185,0.9990546
1729,mitral valve prolapse,7,10,50,71,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1729,-1,0.0017081423,0.9982919
1730,ventricular fibrillation,13,15,98,122,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1730,-1,0.0010434857,0.99895644
1732,BD1008,4,5,39,45,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1732,-1,0.9959453,0.004054684
1733,oligodeoxynucleotide,8,9,63,83,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1733,-1,0.9640915,0.03590855
1735,BD1018,17,18,109,115,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1735,-1,0.9914341,0.008565884
1736,"3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",19,20,117,181,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1736,-1,0.9832796,0.016720429
1737,BD1063,22,23,184,190,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1737,-1,0.9906351,0.009364924
1739,LR132,28,29,249,254,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1739,-1,0.99487114,0.005128841
1740,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1740,-1,0.9767685,0.023231508
1742,NMDA,22,23,134,138,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,-1,-1,-1,1742,-1,0.99438995,0.0056100097
1743,BD1018,8,9,50,56,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1743,-1,0.99316746,0.006832504
1744,BD1063,10,11,58,64,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1744,-1,0.9936381,0.006361867
1745,LR132,13,14,69,74,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1745,-1,0.9973642,0.0026358226
1747,LR132,4,5,30,35,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,-1,1747,-1,0.99731714,0.0026828938
1748,contrast,1,2,3,11,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1748,-1,0.23731562,0.76268435
1749,DTG,18,19,135,138,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1749,-1,0.99648345,0.0035165895
1750,BD1031,26,27,177,183,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1750,-1,0.99547654,0.0045234067
1751,"3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",28,29,185,249,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1751,-1,0.98376274,0.016237225
1752,behavioral toxicity,33,35,269,288,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1752,-1,0.0017975466,0.99820244
1754,BD1018,13,14,74,80,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1754,-1,0.9949634,0.005036558
1755,BD1063,15,16,82,88,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1755,-1,0.9938816,0.0061183893
1756,LR132,17,18,93,98,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1756,-1,0.99723864,0.002761337
1758,oligodeoxynucleotide,21,22,139,159,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,-1,-1,1758,-1,0.9673266,0.032673422
1765,allograft dysfunction,20,22,136,157,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,-1,-1,1765,-1,0.0010405817,0.9989594
1766,eosinophilic,8,9,61,73,"The biopsy specimen showed pathognomonic features, including eosinophilic infiltration of the interstitial compartment.",11431197_5,-1,-1,-1,1766,-1,0.0040450296,0.995955
1767,Cholestatic jaundice,0,2,0,20,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1767,-1,0.0009899295,0.9990101
1768,metformin,7,8,48,57,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1768,-1,0.997801,0.002198944
1769,cholestatic jaundice,6,8,34,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1769,-1,0.000985427,0.9990145
1770,metformin hydrochloride,14,16,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1770,-1,0.9980702,0.0019298603
1774,Metformin hydrochloride,0,2,0,23,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,-1,-1,-1,1774,-1,0.9969007,0.003099333
1777,metformin,12,13,61,70,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,-1,-1,1777,-1,0.9980332,0.0019668038
1783,chronic liver disease,17,20,86,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,-1,-1,-1,1783,-1,0.0012690042,0.99873096
1787,levobupivacaine,8,9,50,65,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1787,-1,0.9986325,0.0013674338
1788,ropivacaine,11,12,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1788,-1,0.99866533,0.0013346889
1790,levobupivacaine,2,3,13,28,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1790,-1,0.9986426,0.0013573295
1791,ropivacaine,5,6,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1791,-1,0.9987123,0.0012877611
1792,mg,13,14,72,74,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1792,-1,0.8624542,0.13754582
1795,mm Hg,13,15,84,89,Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min.,11524350_8,-1,-1,-1,1795,-1,0.009706162,0.99029386
1796,levobupivacaine,4,5,24,39,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1796,-1,0.99864405,0.0013559744
1797,ropivacaine,6,7,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1797,-1,0.9986835,0.0013164537
1800,levobupivacaine,4,5,24,39,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1800,-1,0.9986903,0.001309683
1801,dysrhythmias,7,8,54,66,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1801,-1,0.00086108036,0.99913895
1803,ropivacaine,17,18,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1803,-1,0.9986603,0.0013396644
1806,Ropivacaine,11,12,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,-1,-1,-1,1806,-1,0.9987041,0.0012958592
1808,levobupivacaine,7,8,42,57,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1808,-1,0.99866796,0.0013320919
1809,ropivacaine,13,14,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1809,-1,0.99870896,0.0012910684
1813,levobupivacaine,40,41,277,292,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1813,-1,0.9987336,0.0012663852
1814,rabbit syndrome,1,3,20,35,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,-1,-1,-1,1814,-1,0.0018575257,0.9981425
1816,Rabbit syndrome,0,2,0,15,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1816,-1,0.0029648747,0.99703515
1817,RS,3,4,17,19,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1817,-1,0.0022034745,0.99779654
1818,neuroleptic,14,15,78,89,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1818,-1,0.9962685,0.0037314652
1819,RS,7,8,46,48,"Here we present a case of withdrawal-emergent RS, which is the first of its kind to be reported.",11532387_2,-1,-1,-1,1819,-1,0.0017929382,0.9982071
1820,RS,3,4,22,24,The patient developed RS during dose reduction of risperidone.,11532387_3,-1,-1,-1,1820,-1,0.0017042794,0.9982957
1823,RS,5,6,48,50,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1823,-1,0.0016237431,0.99837625
1826,RS,37,38,261,263,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1826,-1,0.0018580704,0.9981419
1827,E4031,6,7,61,66,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,-1,1827,-1,0.99420965,0.005790328
1831,Torsades de pointes,0,3,0,19,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1831,-1,0.0033271792,0.99667275
1832,TDP,4,5,21,24,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1832,-1,0.0035806561,0.9964193
1834,TDP,0,1,0,3,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,-1,-1,-1,1834,-1,0.006486689,0.9935133
1837,TDP,6,7,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,-1,1837,-1,0.0023481268,0.9976519
1838,TDP,9,10,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1838,-1,0.0018279125,0.99817204
1842,E4031,19,20,117,122,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1842,-1,0.993196,0.0068039345
1846,E4031,28,29,117,122,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,-1,-1,-1,1846,-1,0.9956831,0.004316872
1847,TDP,5,6,30,33,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,-1,-1,-1,1847,-1,0.00840916,0.99159086
1851,TDP,13,14,80,83,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,-1,1851,-1,0.98960567,0.010394296
1853,AIDS.OBJECTIVE,7,8,50,64,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1853,-1,0.0072801537,0.9927199
1855,AIDS,21,22,130,134,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1855,-1,0.002224789,0.99777526
1856,amphotericin B,24,26,152,166,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1856,-1,0.99831736,0.0016826615
1857,grand mal seizures,9,12,71,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1857,-1,0.0018053649,0.99819463
1858,amphotericin B,16,18,121,135,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1858,-1,0.99793184,0.0020681561
1859,petit mal seizures,20,23,142,160,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1859,-1,0.0022624505,0.9977375
1861,hydroxyzine,7,8,57,68,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1861,-1,0.9985512,0.0014488479
1862,promethazine,9,10,70,82,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1862,-1,0.99871504,0.0012849389
1866,lorazepam,5,6,40,49,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1866,-1,0.99854785,0.001452066
1868,amphotercin B,14,16,99,112,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1868,-1,0.99830997,0.0016900501
1869,AIDS,2,3,12,16,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1869,-1,0.0016569928,0.998343
1870,cryptococcal meningitis,4,6,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1870,-1,0.0013423439,0.9986576
1872,alcohol abuse,6,8,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,-1,-1,1872,-1,0.13986732,0.86013263
1878,amphotericin B,7,9,41,55,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1878,-1,0.99775213,0.0022479265
1880,AIDS,17,18,94,98,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1880,-1,0.0016214595,0.9983785
1881,Amphotericin B,2,4,13,27,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,-1,-1,1881,-1,0.9973603,0.0026397237
1884,amphotericin B,10,12,54,68,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,-1,1884,-1,0.9982615,0.0017384578
1885,retention of urine,1,4,8,26,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,-1,-1,-1,1885,-1,0.0016309912,0.99836904
1890,chest wall rigidity,8,11,65,84,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1890,-1,0.0019222705,0.99807775
1892,respiratory depression,14,16,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1892,-1,0.0013520045,0.998648
1894,urinary bladder retention,5,8,17,42,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1894,-1,0.0012235706,0.9987764
1895,hydronephrosis,14,15,95,109,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1895,-1,0.0009308765,0.99906915
1898,mycophenolate mofetil,2,4,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,-1,-1,-1,1898,-1,0.9984042,0.0015958325
1899,Calcineurin inhibitors,0,2,0,22,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,-1,-1,-1,1899,-1,0.9861477,0.013852296
1906,mycophenolate mofetil,6,8,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1906,-1,0.99853814,0.0014618894
1910,myeloencephalopathy,1,2,6,25,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1910,-1,0.0008082397,0.9991918
1911,vincristin,6,7,56,66,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1911,-1,0.9986424,0.0013575577
1913,acute lymphoblastic leucemia,18,21,116,144,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1913,-1,0.000859237,0.99914074
1914,lymphoblastic lymphoma,27,29,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1914,-1,0.0010585049,0.9989415
1916,sensory and motor dysfunction,12,16,70,99,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,-1,-1,-1,1916,-1,0.0012789604,0.99872106
1920,Palpebral twitching,0,2,0,19,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,-1,-1,-1,1920,-1,0.0017713113,0.9982287
1926,palpebral twitching,18,20,117,136,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,-1,-1,1926,-1,0.0020856902,0.99791425
1935,lymphadenitis,12,13,84,97,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1935,-1,0.00092789234,0.9990721
1936,eosinophilic,19,20,149,161,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1936,-1,0.0034429352,0.9965571
1937,adverse drug reaction,30,33,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1937,-1,0.0024366793,0.99756336
1939,autoimmunity,22,23,139,151,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1939,-1,0.0012721093,0.99872786
1940,multi-organ,28,29,173,184,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1940,-1,0.0026066839,0.99739325
1941,failure,29,30,185,192,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1941,-1,0.001070767,0.9989292
1943,massive hepatocellular necrosis,5,8,43,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1943,-1,0.0014363874,0.9985636
1944,hypersensitivity myocarditis,10,12,82,110,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1944,-1,0.0012264784,0.9987735
1945,nephritis,16,17,144,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1945,-1,0.0010072778,0.99899274
1946,bone marrow necrosis,19,22,168,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1946,-1,0.0017669281,0.9982331
1951,akathisia,16,17,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,-1,1951,-1,0.0011754776,0.99882454
1952,akathisia,10,11,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,-1,-1,1952,-1,0.0011465619,0.99885345
1954,emergency department,13,15,75,95,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,-1,1954,-1,0.008607997,0.991392
1959,mg,7,8,49,51,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1959,-1,0.9187348,0.08126524
1961,mg,23,24,145,147,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1961,-1,0.9165883,0.08341164
1962,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,-1,-1,1962,-1,0.0011485491,0.9988514
1963,Akathisia,0,1,0,9,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1963,-1,0.0010749528,0.99892503
1964,restlessness,9,10,56,68,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1964,-1,0.0010354765,0.99896455
1966,akathisia,22,23,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1966,-1,0.0013762907,0.9986237
1967,akathisia,35,36,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1967,-1,0.0013215371,0.9986784
1972,akathisia,11,12,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,-1,1972,-1,0.001235771,0.9987643
1975,akathisia,10,11,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,-1,-1,-1,1975,-1,0.0011718037,0.99882823
1980,nimesulide,2,3,16,26,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,-1,-1,-1,1980,-1,0.99822086,0.0017791833
1982,nimesulide,6,7,44,54,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1982,-1,0.9983992,0.0016008103
1984,NSAIDs,24,25,188,194,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1984,-1,0.9908828,0.009117186
1985,nimesulide,9,10,62,72,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,-1,-1,-1,1985,-1,0.9982048,0.0017952158
1988,nimesulide,19,20,118,128,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,-1,-1,-1,1988,-1,0.99845386,0.0015461633
1989,nimesulide,6,7,58,68,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1989,-1,0.99839056,0.0016094852
1991,nimesulide,12,13,59,69,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,-1,-1,-1,1991,-1,0.99833703,0.0016629304
1993,nimesulide,6,7,32,42,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,-1,-1,-1,1993,-1,0.99826115,0.0017388702
1998,nimesulide,10,11,61,71,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,1998,-1,0.99822253,0.0017774402
2000,NSAIDs,20,21,147,153,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,2000,-1,0.996498,0.0035020022
2012,ocular hypertension,10,12,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2012,-1,0.0011421264,0.99885786
2013,/-SD,17,18,110,114,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2013,-1,0.07349369,0.9265063
2018,P,18,19,109,110,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,-1,-1,-1,2018,-1,0.166128,0.833872
2023,P,34,35,216,217,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,-1,2023,-1,0.15476628,0.8452337
2029,hepatitis C,10,12,81,92,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,-1,-1,2029,-1,0.001339991,0.99865997
2030,interferon,15,16,127,137,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2030,-1,0.99812275,0.0018772628
2031,chronic hepatitis C,26,29,224,243,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2031,-1,0.0018760381,0.99812394
2032,CHC,30,31,245,248,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2032,-1,0.0018093857,0.9981906
2034,RIHA,15,16,114,118,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,-1,2034,-1,0.002661676,0.99733835
2035,RIHA,15,16,91,95,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2035,-1,0.05293918,0.94706076
2036,CHC,19,20,116,119,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2036,-1,0.0020505327,0.99794954
2037,RIHA,17,18,115,119,METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.,11705128_4,-1,-1,-1,2037,-1,0.012730126,0.9872699
2038,RIHA,10,11,72,76,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,-1,2038,-1,0.008566269,0.99143374
2039,RIHA,2,3,9,13,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,-1,2039,-1,0.0038034949,0.9961965
2040,RIHA,7,8,39,43,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,-1,-1,-1,2040,-1,0.0050962963,0.9949037
2042,RIHA,9,10,64,68,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,-1,2042,-1,0.004360579,0.99563944
2043,RIHA,24,25,135,139,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,-1,2043,-1,0.006133698,0.99386626
2045,RIHA,12,13,74,78,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,-1,-1,-1,2045,-1,0.003321092,0.99667895
2046,RIHA,13,14,84,88,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,-1,-1,-1,2046,-1,0.0150276655,0.9849723
2048,lactate,8,9,74,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2048,-1,0.92133546,0.0786646
2049,AIDS,11,12,96,100,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2049,-1,0.0021239836,0.99787605
2051,CM,12,13,78,80,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2051,-1,0.0024200273,0.99757993
2052,lactate,18,19,105,112,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2052,-1,0.9759645,0.024035562
2053,LA,20,21,114,116,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2053,-1,0.6321931,0.3678069
2054,AIDS,23,24,121,125,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2054,-1,0.0013358385,0.99866414
2056,AIDS,12,13,87,91,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2056,-1,0.0032050158,0.996795
2060,atrial natriuretic factor,22,25,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2060,-1,0.9299945,0.070005536
2061,ANF,26,27,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2061,-1,0.9884299,0.011570048
2063,LA,41,42,251,253,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2063,-1,0.907033,0.092966974
2064,TG,5,6,21,23,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,-1,-1,-1,2064,-1,0.15382302,0.84617704
2065,ANF,2,3,13,16,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,-1,2065,-1,0.9756245,0.024375474
2066,LA,2,3,15,17,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2066,-1,0.17598146,0.8240186
2067,mM,10,11,44,46,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2067,-1,0.013663672,0.98633635
2068,ANF,5,6,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2068,-1,0.6928626,0.30713737
2069,TG,13,14,54,56,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2069,-1,0.47659287,0.5234071
2070,CM,7,8,56,58,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2070,-1,0.0028865328,0.99711347
2071,LA,10,11,73,75,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2071,-1,0.43739614,0.56260383
2072,AIDS,12,13,79,83,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2072,-1,0.0024407362,0.9975593
2074,WR-2721,7,8,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,-1,2074,-1,0.99529254,0.0047075413
2087,WR-2721,0,1,0,7,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,-1,-1,-1,2087,-1,0.98891324,0.0110867005
2090,alkylating agents,13,15,86,103,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,-1,-1,-1,2090,-1,0.97541136,0.024588684
2105,disease progression,7,9,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,-1,-1,-1,2105,-1,0.0014848482,0.9985152
2106,disease progression,10,12,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,-1,2106,-1,0.0014540525,0.998546
2107,Neurologic toxicity,0,2,0,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,-1,-1,-1,2107,-1,0.0011757341,0.9988243
2115,myocardial infarction,6,8,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,-1,-1,-1,2115,-1,0.0011282117,0.99887174
2117,myocardial infarction,14,16,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,-1,-1,-1,2117,-1,0.0011308447,0.9988691
2118,progestagen,10,11,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2118,-1,0.99683374,0.0031662409
2120,gestodene,19,20,122,131,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2120,-1,0.9986254,0.0013746126
2121,levonorgestrel,26,27,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2121,-1,0.9987213,0.0012786923
2124,myocardial infarction,72,74,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2124,-1,0.0015876362,0.9984124
2125,myocardial infarction,87,89,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2125,-1,0.0015713712,0.99842864
2126,factor V Leiden,3,6,16,31,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2126,-1,0.009542181,0.9904578
2127,myocardial infarction,28,30,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2127,-1,0.0012634246,0.99873656
2128,combined oral contraceptive,37,40,211,238,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2128,-1,0.99265516,0.007344909
2132,myocardial infarction,50,52,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,-1,2132,-1,0.0012054214,0.99879456
2136,myocardial infarction,3,5,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,-1,-1,-1,2136,-1,0.0009372048,0.99906284
2146,mg,38,39,242,244,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2146,-1,0.9507524,0.04924766
2148,mg,49,50,306,308,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2148,-1,0.9332719,0.0667281
2150,mechanical hyperalgesia,20,22,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2150,-1,0.0011785867,0.99882144
2151,allodynia,23,24,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2151,-1,0.0009607976,0.9990392
2156,allodynia,21,22,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2156,-1,0.0009994803,0.9990005
2158,h.,30,31,205,207,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2158,-1,0.06628523,0.93371475
2159,contrast,32,33,211,219,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2159,-1,0.1090667,0.8909333
2161,h,46,47,287,288,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2161,-1,0.09964868,0.9003513
2167,renal disease,1,3,10,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2167,-1,0.0011486751,0.9988513
2168,ESRD,4,5,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2168,-1,0.001346826,0.9986532
2169,calcineurin inhibitors cyclosporine,3,6,16,51,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,-1,-1,2169,-1,0.99751556,0.0024844315
2172,renal disease,18,20,100,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2172,-1,0.0009770216,0.99902296
2173,ESRD,21,22,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2173,-1,0.0010228676,0.9989772
2174,ESRD,9,10,65,69,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2174,-1,0.0008839424,0.999116
2176,CRF,15,16,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2176,-1,0.0010505549,0.99894947
2177,n=834,22,23,133,138,METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).,11773892_5,-1,-1,-1,2177,-1,0.1352793,0.8647207
2178,CRF,10,11,54,57,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2178,-1,0.0013922043,0.9986078
2179,ESRD,12,13,61,65,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2179,-1,0.0012204023,0.9987796
2180,n=748,14,15,67,72,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2180,-1,0.062398177,0.9376018
2181,CRF,16,17,74,77,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2181,-1,0.001652446,0.9983475
2183,n=41,25,26,118,122,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2183,-1,0.027164897,0.97283506
2184,ESRD,28,29,128,132,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2184,-1,0.0014182391,0.99858177
2185,n=45,30,31,134,138,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2185,-1,0.028088754,0.97191125
2186,ESRD,17,18,114,118,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2186,-1,0.0013954672,0.9986046
2187,ESRD,25,26,155,159,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2187,-1,0.0010547619,0.9989453
2189,CRF,18,19,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2189,-1,0.0014558377,0.9985442
2190,ESRD,22,23,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2190,-1,0.0012960827,0.99870396
2191,CRF,5,6,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2191,-1,0.0012322747,0.99876773
2192,ESRD,7,8,40,44,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2192,-1,0.0012918236,0.9987081
2194,hepatorenal syndrome,22,24,141,161,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2194,-1,0.0009764011,0.99902356
2197,CRF,39,40,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2197,-1,0.0013908778,0.9986091
2198,ESRD,41,42,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2198,-1,0.0012420049,0.99875796
2199,ESRD,26,27,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,-1,2199,-1,0.0012175426,0.99878246
2200,ESRD,2,3,20,24,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2200,-1,0.0010642132,0.99893576
2201,ESRD,10,11,62,66,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2201,-1,0.001072738,0.9989273
2202,ESRD,26,27,155,159,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2202,-1,0.0011135162,0.9988865
2203,CRF,11,12,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2203,-1,0.0011925084,0.99880755
2204,ESRD,13,14,72,76,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2204,-1,0.0011891497,0.9988109
2205,ESRD,3,4,19,23,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,-1,-1,-1,2205,-1,0.0009947304,0.99900526
2206,ESRD,3,4,21,25,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2206,-1,0.0009515932,0.9990484
2208,hepatorenal syndrome,18,20,109,129,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2208,-1,0.0009366112,0.99906343
2210,CRF,18,19,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2210,-1,0.0010716507,0.99892837
2211,ESRD,20,21,122,126,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2211,-1,0.0010835293,0.9989165
2212,Epileptic seizures,0,2,0,18,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2212,-1,0.0010926155,0.9989073
2213,tranexamic acid,9,11,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2213,-1,0.99867934,0.0013206437
2214,fibrinolysis inhibitors,3,5,20,43,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2214,-1,0.05040401,0.94959605
2215,tranexamic acid,7,9,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2215,-1,0.99860567,0.001394302
2216,tAMCA,10,11,69,74,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2216,-1,0.99706227,0.0029377497
2217,tAMCA,2,3,9,14,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2217,-1,0.7876043,0.21239565
2218,epileptic seizures,8,10,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2218,-1,0.001000677,0.9989993
2219,tAMCA,5,6,27,32,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,-1,-1,2219,-1,0.9961777,0.0038223641
2221,tAMCA,9,10,63,68,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,-1,-1,-1,2221,-1,0.9975963,0.002403612
2222,tAMCA,4,5,24,29,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,-1,-1,2222,-1,0.99562764,0.0043723364
2225,tAMCA,10,11,72,77,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,-1,-1,2225,-1,0.9970099,0.0029900568
2226,tAMCA,6,7,31,36,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2226,-1,0.9973763,0.0026237236
2227,generalized seizures,8,10,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2227,-1,0.0011451859,0.99885476
2228,n=6,15,16,85,88,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2228,-1,0.0537131,0.94628686
2229,tAMCA,22,23,124,129,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2229,-1,0.9975274,0.0024725713
2231,contrast,1,2,3,11,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,-1,-1,-1,2231,-1,0.09956441,0.90043557
2232,Tranexamic acid,2,4,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,-1,-1,2232,-1,0.99849856,0.001501398
2234,tAMCA,6,7,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,-1,2234,-1,0.99584585,0.0041542095
2238,thromboemboli,19,20,126,139,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,-1,-1,2238,-1,0.0009514336,0.99904853
2242,thromboembolic complications,19,21,134,162,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,-1,-1,2242,-1,0.00094388454,0.99905616
2243,thromboembolism,9,10,63,78,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2243,-1,0.0008466771,0.9991534
2244,platelet factor 4,14,17,107,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2244,-1,0.89781183,0.10218815
2247,thromboembolic complications,35,37,192,220,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,-1,-1,2247,-1,0.0009942515,0.99900573
2248,Thromboemboli,0,1,0,13,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2248,-1,0.0012684369,0.99873155
2249,pulmonary emboli,9,11,47,63,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2249,-1,0.0013952373,0.99860483
2255,thromboembolism,17,18,142,157,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,-1,-1,2255,-1,0.0009007114,0.99909925
2258,dopamine agonist,6,8,59,75,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,-1,-1,2258,-1,0.9975629,0.0024371606
2261,prolactinomas,7,8,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2261,-1,0.0026394476,0.9973605
2262,arrested,12,13,92,100,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2262,-1,0.0025991038,0.9974009
2263,delayed puberty,19,21,144,159,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2263,-1,0.0013426509,0.99865735
2264,short stature,22,24,163,176,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2264,-1,0.0010516555,0.9989484
2267,cabergoline,9,10,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,-1,-1,2267,-1,0.9988808,0.0011191522
2269,cabergoline,16,17,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,-1,-1,2269,-1,0.99884474,0.0011552393
2270,Mental Disorders,17,19,79,95,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2270,-1,0.003537306,0.99646276
2271,bipolar disorder,23,25,113,129,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2271,-1,0.0012302188,0.9987697
2272,psychoses,26,27,133,142,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2272,-1,0.0013942941,0.99860567
2273,cabergoline,51,52,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2273,-1,0.9987734,0.0012266092
2274,cabergoline,19,20,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,-1,2274,-1,0.99874073,0.001259246
2275,cabergoline,6,7,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,-1,2275,-1,0.9987992,0.0012008386
2277,Cabergoline,0,1,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,-1,-1,-1,2277,-1,0.99868876,0.0013112081
2278,Cabergoline,2,3,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,-1,-1,2278,-1,0.9987733,0.001226664
2280,cholestatic hepatitis,1,3,6,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,-1,-1,2280,-1,0.0010235782,0.99897647
2282,cholestatic hepatitis,8,10,37,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,-1,2282,-1,0.00094205985,0.99905795
2284,cholestatic hepatitis,11,13,68,89,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,-1,-1,2284,-1,0.0012333598,0.99876666
2286,dipyrone,7,8,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2286,-1,0.99874747,0.0012524895
2287,analgesia,9,10,59,68,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2287,-1,0.0019305733,0.99806947
2290,dipyrone,6,7,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,-1,-1,-1,2290,-1,0.99864477,0.0013551853
2291,halothane hepatitis,11,13,71,90,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,-1,2291,-1,0.66095084,0.3390492
2293,cholestatic hepatitis,12,14,69,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,-1,-1,2293,-1,0.0011003703,0.9988996
2294,Torsade de pointes,0,3,0,18,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2294,-1,0.0026852374,0.99731475
2296,left bundle branch block,13,17,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2296,-1,0.0044250726,0.99557495
2297,long QT syndrome,10,13,56,72,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2297,-1,0.001677637,0.9983223
2298,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2298,-1,0.0025587343,0.9974413
2301,left bundle branch block,9,13,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2301,-1,0.004690919,0.99530905
2302,torsade de pointes,15,18,98,116,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2302,-1,0.001995438,0.9980046
2304,torsade de pointes,4,7,28,46,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2304,-1,0.0016444933,0.99835545
2306,erythromycin,10,11,66,78,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2306,-1,0.9985876,0.0014123841
2308,torsade de pointes,8,11,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,-1,-1,-1,2308,-1,0.005513163,0.99448687
2310,torsade de pointes,11,14,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,-1,-1,-1,2310,-1,0.0025966081,0.9974033
2312,cell death,6,8,49,59,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,-1,-1,-1,2312,-1,0.0017802329,0.9982198
2314,DA,2,3,10,12,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2314,-1,0.99548495,0.004515062
2315,epileptic seizures,18,20,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2315,-1,0.0008955538,0.99910444
2316,Excitotoxicity,0,1,0,14,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,-1,2316,-1,0.0010222119,0.9989778
2319,DA,11,12,51,53,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2319,-1,0.99555236,0.004447573
2320,cell death,19,21,111,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2320,-1,0.0014041641,0.9985958
2324,kainic acid,9,11,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2324,-1,0.9984628,0.0015372188
2325,KA,12,13,75,77,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2325,-1,0.9967321,0.0032679138
2330,neuronal death,9,11,66,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2330,-1,0.001340404,0.9986596
2331,KA,21,22,128,130,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2331,-1,0.003427261,0.99657273
2335,neurodegeneration,7,8,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,-1,-1,2335,-1,0.00090352783,0.9990965
2337,pregnenolone sulphate,10,12,87,108,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,-1,-1,-1,2337,-1,0.99780995,0.00219004
2338,Pregnenolone sulphate,0,2,0,21,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2338,-1,0.99569196,0.004308101
2339,PREGS,3,4,23,28,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2339,-1,0.9837683,0.016231697
2341,PREGS,6,7,41,46,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,-1,2341,-1,0.8787961,0.12120389
2342,PREGS,2,3,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2342,-1,0.95650816,0.043491833
2343,PREGS,18,19,122,127,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,-1,2343,-1,0.9365479,0.063452125
2344,11-ketopregnenolone sulphate,5,7,25,53,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2344,-1,0.99443734,0.005562624
2345,epipregnanolone,19,20,107,122,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2345,-1,0.99757344,0.0024265365
2346,PREGS,42,43,243,248,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2346,-1,0.9704892,0.029510774
2347,PREGS,49,50,283,288,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2347,-1,0.9819771,0.018022878
2348,PREGS,4,5,32,37,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,-1,-1,2348,-1,0.9793001,0.020699924
2350,PREGS,1,2,5,10,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,-1,-1,-1,2350,-1,0.9629408,0.037059218
2352,PREGS,6,7,30,35,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2352,-1,0.90949667,0.09050329
2353,11-ketopregnenolone sulphate,8,10,37,65,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2353,-1,0.99574006,0.0042599235
2354,epipregnanolone sulphate,11,13,70,94,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2354,-1,0.9973653,0.0026347623
2356,NMDA,27,28,181,185,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2356,-1,0.99141407,0.008585973
2357,PREGS,34,35,239,244,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2357,-1,0.9747206,0.025279457
2358,PREGS,10,11,72,77,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,-1,-1,-1,2358,-1,0.8297544,0.17024562
2361,heart failure,10,12,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,-1,-1,-1,2361,-1,0.0008937717,0.9991062
2362,DNA damage,13,15,88,98,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2362,-1,0.037304297,0.9626957
2363,dysfunction,21,22,131,142,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2363,-1,0.0014147015,0.99858534
2364,tissue injury,23,25,147,160,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2364,-1,0.0019463337,0.99805367
2367,DOX,14,15,94,97,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,-1,-1,2367,-1,0.99639195,0.0036080764
2370,PJ34,19,20,136,140,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2370,-1,0.99328107,0.0067189527
2372,DOX,36,37,231,234,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2372,-1,0.99614954,0.0038504552
2373,DOX,9,10,60,63,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,-1,2373,-1,0.99635977,0.0036402545
2374,DOX,3,4,16,19,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,-1,2374,-1,0.9964503,0.0035497015
2376,PJ34,9,10,63,67,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,-1,2376,-1,0.9920889,0.007911108
2377,PJ34,3,4,17,21,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,-1,-1,2377,-1,0.8722368,0.12776318
2379,PJ34,2,3,12,16,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2379,-1,0.98730123,0.012698701
2380,lactate,11,12,77,84,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2380,-1,0.9925184,0.007481601
2381,creatine kinase,14,16,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2381,-1,0.9865051,0.013494899
2383,DOX,9,10,59,62,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,-1,-1,2383,-1,0.99465746,0.0053425184
2384,cardiac complications,11,13,79,100,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2384,-1,0.00092986855,0.9990701
2385,DOX,16,17,121,124,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2385,-1,0.9942925,0.0057075443
2387,hypokalemia,13,14,80,91,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2387,-1,0.00083564105,0.99916434
2390,amphotericin B,25,27,168,182,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2390,-1,0.9981502,0.0018498502
2391,AmB,28,29,184,187,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2391,-1,0.99538875,0.004611209
2392,epithelial toxicity,3,5,25,44,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2392,-1,0.0015674111,0.9984326
2393,potassium wasting,12,14,86,103,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2393,-1,0.12366889,0.87633115
2394,AmB.,24,25,159,163,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2394,-1,0.84808236,0.15191767
2396,tubular toxicity,30,32,205,221,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2396,-1,0.0013025263,0.99869746
2397,AmB.,33,34,225,229,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2397,-1,0.8230524,0.17694752
2400,hypokalemia,51,52,342,353,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2400,-1,0.0009968973,0.9990031
2401,neutropenic,53,54,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2401,-1,0.00096219155,0.99903786
2402,AmB,56,57,381,384,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2402,-1,0.99722207,0.0027779592
2403,hematological disorders,9,11,48,71,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2403,-1,0.0010174895,0.9989825
2404,AmB,17,18,118,121,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2404,-1,0.9970079,0.0029921376
2405,AmB,20,21,131,134,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2405,-1,0.9973436,0.0026564153
2407,mg,25,26,163,165,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2407,-1,0.9882188,0.011781173
2408,fungal infection,34,36,216,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2408,-1,0.001977181,0.9980228
2409,AmB,5,6,40,43,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2409,-1,0.99754286,0.0024571104
2412,AmB,17,18,133,136,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2412,-1,0.9975496,0.0024504566
2413,P,20,21,144,145,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2413,-1,0.13709827,0.86290175
2414,AmB,3,4,25,28,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2414,-1,0.9975165,0.0024835367
2418,P,21,22,162,163,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2418,-1,0.18219326,0.8178067
2420,AmB,11,12,81,84,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2420,-1,0.99753726,0.0024627799
2422,AmB,17,18,125,128,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2422,-1,0.997546,0.0024539323
2423,P,20,21,136,137,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2423,-1,0.12435182,0.8756482
2426,hypokalemia,13,14,96,107,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2426,-1,0.0009585233,0.9990415
2428,neutropenic,20,21,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2428,-1,0.0011598245,0.99884015
2429,AmB,23,24,170,173,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2429,-1,0.99617356,0.003826457
2446,hemorrhaging,11,12,83,95,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,-1,2446,-1,0.0012373192,0.9987627
2451,peripheral circulatory failure,19,22,137,167,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2451,-1,0.0018168318,0.9981832
2452,hemorrhaging,23,24,175,187,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2452,-1,0.0011496493,0.99885035
2456,Erectile dysfunction,0,2,0,20,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2456,-1,0.00096657424,0.99903345
2457,nigra,5,6,49,54,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2457,-1,0.011959024,0.9880409
2459,penile erections,2,4,31,47,Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.,11890511_2,-1,-1,-1,2459,-1,0.0009883653,0.99901164
2461,erectile dysfunction,9,11,62,82,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2461,-1,0.0009046553,0.9990953
2462,erectile dysfunction,21,23,125,145,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2462,-1,0.000884769,0.99911517
2463,Parkinson's disease,24,27,149,168,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2463,-1,0.0013587652,0.9986412
2464,myocardial infarction,5,7,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,-1,-1,-1,2464,-1,0.0009468929,0.99905306
2468,glucaric acid,6,8,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,-1,-1,-1,2468,-1,0.99483913,0.0051608738
2469,h,9,10,51,52,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,-1,-1,2469,-1,0.046137985,0.953862
2471,infarct,8,9,61,68,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2471,-1,0.0013288897,0.9986712
2472,h,10,11,72,73,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2472,-1,0.025541939,0.9744581
2474,contrast,7,8,42,50,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2474,-1,0.1077747,0.8922253
2475,h,17,18,95,96,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2475,-1,0.17353426,0.8264657
2476,cardiac infarction,31,33,161,179,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2476,-1,0.0010523942,0.9989477
2489,mecamylamine,7,8,54,66,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,-1,-1,2489,-1,0.99889284,0.001107147
2503,morphine catalepsy,4,6,22,40,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,-1,-1,-1,2503,-1,0.109307274,0.8906927
2507,Parkinson's disease,6,9,51,70,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,-1,-1,2507,-1,0.0015117783,0.9984882
2508,Parkinson's disease,8,11,46,65,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2508,-1,0.0010547721,0.9989453
2511,LID,26,27,177,180,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2511,-1,0.0012201599,0.99877983
2512,Parkinson's disease,5,8,25,44,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2512,-1,0.0014876222,0.9985123
2513,Parkinson's disease,11,14,60,79,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2513,-1,0.0017245993,0.9982754
2514,LID,15,16,82,85,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2514,-1,0.0013438981,0.99865603
2515,n,17,18,87,88,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2515,-1,0.018981429,0.98101854
2517,Parkinson's disease,26,29,137,156,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2517,-1,0.0019069159,0.99809307
2518,LID,30,31,159,162,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2518,-1,0.0014678696,0.9985322
2519,n,32,33,164,165,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2519,-1,0.016044348,0.9839557
2520,Parkinson's Disease,6,9,31,50,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,-1,2520,-1,0.0017859192,0.9982141
2523,Parkinson's disease,10,13,58,77,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2523,-1,0.0015714894,0.9984285
2524,LID,14,15,80,83,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2524,-1,0.001531248,0.9984687
2525,Parkinson's disease,1,4,3,22,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2525,-1,0.0017704202,0.99822956
2526,LID,5,6,25,28,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2526,-1,0.0015611628,0.9984389
2528,P,27,28,141,142,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2528,-1,0.18099432,0.8190057
2529,P,10,11,43,44,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2529,-1,0.09816637,0.9018336
2530,P,23,24,86,87,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2530,-1,0.10021074,0.89978933
2531,contrast,1,2,3,11,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2531,-1,0.044088412,0.9559116
2532,Parkinson's disease,9,12,45,64,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2532,-1,0.0015726292,0.9984274
2533,LID,13,14,67,70,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2533,-1,0.0016294748,0.9983706
2534,P,9,10,38,39,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2534,-1,0.1540201,0.84597987
2535,Parkinson's disease,15,18,58,77,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2535,-1,0.0022353302,0.9977647
2536,LID,19,20,80,83,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2536,-1,0.0016860033,0.998314
2537,Parkinson's disease,22,25,92,111,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2537,-1,0.002219564,0.9977805
2538,LID,26,27,114,117,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2538,-1,0.0019863558,0.9980136
2539,P,38,39,166,167,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2539,-1,0.14887497,0.851125
2541,P,20,21,113,114,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,-1,2541,-1,0.21243021,0.78756976
2542,LID,8,9,48,51,Force excess was only observed in patients with LID and motor fluctuations.,11912119_11,-1,-1,-1,2542,-1,0.001032957,0.99896705
2544,LID,4,5,23,26,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,-1,-1,-1,2544,-1,0.0017884591,0.9982115
2546,Zyban,2,3,11,16,Bupropion (Zyban) toxicity.,11928786_0,-1,-1,-1,2546,-1,0.9957885,0.0042114584
2551,Zyban,0,1,0,5,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2551,-1,0.9955888,0.004411225
2552,bupropion hydrochloride,6,8,42,65,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2552,-1,0.9984022,0.0015978394
2557,drowsiness,5,6,38,48,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,-1,-1,2557,-1,0.0012144755,0.99878556
2567,Zyban,0,1,0,5,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2567,-1,0.9954562,0.004543816
2568,cardiovascular toxicity,5,7,42,65,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2568,-1,0.0010550594,0.99894494
2571,PAN nephrosis,9,11,52,65,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,-1,-1,-1,2571,-1,0.0014014409,0.9985985
2572,tyrosine phosphatase,13,15,81,101,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,-1,-1,-1,2572,-1,0.7356714,0.2643286
2573,glomerular injury,11,13,58,75,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,-1,2573,-1,0.0012070436,0.9987929
2574,Puromycin aminonucleoside nephrosis,0,3,0,35,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2574,-1,0.5250228,0.4749772
2575,puromycin aminonucleoside,10,12,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2575,-1,0.9977597,0.0022402229
2576,PAN,13,14,114,117,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2576,-1,0.99296606,0.007033888
2577,PAN,21,22,68,71,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,-1,2577,-1,0.93628836,0.06371162
2581,p,42,43,177,178,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,-1,2581,-1,0.1571752,0.84282476
2582,p,23,24,111,112,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,-1,2582,-1,0.1433144,0.8566856
2583,contrast,1,2,3,11,"In contrast, podocalyxin did not change significantly at this time.",11961407_9,-1,-1,-1,2583,-1,0.16497469,0.83502525
2584,PAN,14,15,92,95,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,-1,-1,-1,2584,-1,0.9634935,0.036506444
2585,MK-801,3,4,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,-1,2585,-1,0.9969886,0.00301143
2586,dizocilpine,3,4,15,26,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2586,-1,0.9985648,0.0014352122
2587,MK-801,5,6,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2587,-1,0.9964858,0.0035141574
2588,NMDA,12,13,76,80,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2588,-1,0.99716765,0.0028323329
2590,Parkinson's disease,12,15,71,90,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2590,-1,0.001162302,0.99883777
2591,tardive dyskinesia,17,19,95,113,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2591,-1,0.0009227159,0.9990773
2593,orofacial dyskinesia,18,20,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2593,-1,0.001454272,0.99854577
2594,tardive dyskinesia,34,36,188,206,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2594,-1,0.0009735077,0.99902654
2598,Parkinson's disease,12,15,76,95,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,-1,-1,2598,-1,0.0014952508,0.99850476
2599,MK-801,0,1,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,-1,-1,2599,-1,0.99708074,0.0029192537
2602,MK-801,2,3,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,-1,2602,-1,0.9968137,0.0031862385
2605,apomophine,15,16,73,83,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,-1,-1,2605,-1,0.99828964,0.0017103333
2610,MK-801,0,1,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,-1,-1,2610,-1,0.9969522,0.0030478335
2615,h,8,9,41,42,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2615,-1,0.40004396,0.59995604
2618,MK-801,33,34,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2618,-1,0.9974733,0.00252672
2621,abnormal movements,8,10,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2621,-1,0.0020353447,0.9979646
2622,tardive dsykinesia,26,28,172,190,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2622,-1,0.002384649,0.99761534
2623,NMDA,5,6,39,43,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,-1,-1,2623,-1,0.9972748,0.0027251418
2626,visual disturbances,4,6,41,60,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2626,-1,0.0011370591,0.998863
2628,LSD,14,15,110,113,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2628,-1,0.9332723,0.0667277
2630,LSD,10,11,55,58,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2630,-1,0.84265804,0.1573419
2631,EPS,17,18,98,101,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2631,-1,0.0013680058,0.998632
2632,antipsychotics,20,21,115,129,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2632,-1,0.9829804,0.01701966
2634,visual disturbances,7,9,47,66,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,-1,-1,-1,2634,-1,0.0012703636,0.99872965
2636,visual disturbances,3,5,23,42,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2636,-1,0.0020488081,0.9979512
2637,LSD,14,15,99,102,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2637,-1,0.99631906,0.0036808967
2639,visual disturbances,6,8,49,68,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,-1,-1,-1,2639,-1,0.0017749092,0.99822515
2640,visual disturbances,11,13,64,83,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,-1,-1,-1,2640,-1,0.0015091082,0.9984909
2642,Antithymocyte globulin,0,2,0,22,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,-1,-1,2642,-1,0.00274202,0.99725795
2644,antithymocyte globulin,4,6,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,-1,-1,2644,-1,0.087827526,0.91217244
2646,antithymocyte globulin,2,4,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,-1,-1,2646,-1,0.007822578,0.9921774
2649,Topiramate,0,1,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2649,-1,0.9985164,0.0014836625
2652,lead,23,24,138,142,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2652,-1,0.03322062,0.96677935
2653,calcium phosphate nephrolithiasis,28,31,165,198,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2653,-1,0.14381365,0.85618633
2655,Metamizol,0,1,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,-1,-1,2655,-1,0.99841094,0.0015890404
2658,constipating,6,7,44,56,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,-1,-1,-1,2658,-1,0.0021524203,0.99784756
2660,metamizol,0,1,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,-1,-1,-1,2660,-1,0.99821645,0.0017835303
2661,functional impairment,17,19,111,132,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2661,-1,0.0014507116,0.9985493
2662,charcoal,23,24,148,156,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2662,-1,0.98055786,0.01944208
2664,metamizol,5,6,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2664,-1,0.9987387,0.0012612765
2665,P<0.001,33,34,205,212,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2665,-1,0.20574354,0.79425645
2666,P<0.001,44,45,269,276,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2666,-1,0.19197685,0.80802315
2669,P<0.05,16,17,102,108,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,-1,-1,-1,2669,-1,0.15697967,0.8430203
2671,constipating,31,32,186,198,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,-1,-1,-1,2671,-1,0.0021715,0.9978284
2673,metamizol,20,21,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,-1,-1,2673,-1,0.99873644,0.0012635647
2676,metamizol,9,10,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2676,-1,0.99876237,0.0012375973
2677,chronic pain,26,28,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2677,-1,0.001256061,0.99874395
2678,Ifosfamide encephalopathy,0,2,0,25,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,-1,-1,-1,2678,-1,0.6421605,0.35783955
2681,IFX,9,10,58,61,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2681,-1,0.97614676,0.023853276
2682,neurological symptoms,18,20,101,122,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2682,-1,0.0011731092,0.9988269
2685,plasmacytoma,27,28,161,173,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,-1,-1,2685,-1,0.0020331407,0.9979668
2686,structural lesions of the brain,11,16,85,116,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2686,-1,0.0024567577,0.9975432
2687,metabolic abnormalities,17,19,121,144,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2687,-1,0.0022068648,0.9977932
2690,h,9,10,64,65,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,-1,-1,2690,-1,0.0142179,0.985782
2695,IFX,41,42,265,268,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,-1,2695,-1,0.99609286,0.003907148
2699,thymidine,6,7,37,46,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,-1,2699,-1,0.99410605,0.0058939625
2700,thymidine,18,19,150,159,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,-1,2700,-1,0.994317,0.0056829904
2710,postoperative analgesia,10,12,71,94,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,-1,2710,-1,0.0032958712,0.99670416
2711,h,11,12,70,71,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,-1,2711,-1,0.022201456,0.9777985
2714,adenovirus disease,5,7,43,61,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,-1,-1,-1,2714,-1,0.0016263726,0.9983736
2715,adenovirus disease,4,6,24,42,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,-1,2715,-1,0.0029460045,0.997054
2716,adenovirus disease,14,16,88,106,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2716,-1,0.001969252,0.9980307
2717,adenovirus disease,8,10,53,71,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,-1,2717,-1,0.0020330206,0.99796695
2719,cidofovir,7,8,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,-1,-1,-1,2719,-1,0.99855894,0.0014410733
2721,guanosine,3,4,13,22,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,-1,2721,-1,0.99770147,0.0022985614
2723,respiratory syncytial virus infection,10,14,59,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2723,-1,0.001674687,0.9983253
2724,interferon,20,21,129,139,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2724,-1,0.9978794,0.0021206613
2725,hepatitis C.,23,25,149,161,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2725,-1,0.0132225985,0.9867775
2728,hemorrhagic fever,35,37,230,247,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2728,-1,0.0012697175,0.99873024
2731,cidofovir,3,4,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2731,-1,0.9986119,0.0013880553
2732,adenovirus infection,6,8,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2732,-1,0.0034120055,0.996588
2735,adenovirus disease,12,14,82,100,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,-1,-1,-1,2735,-1,0.0015823481,0.9984176
2737,adenovirus disease,18,20,135,153,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,-1,2737,-1,0.0017942454,0.9982058
2738,hemorrhagic cystitis,4,6,34,54,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,-1,-1,-1,2738,-1,0.00094280054,0.99905723
2739,cidofovir,8,9,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2739,-1,0.99846786,0.0015320736
2740,disseminated disease,11,13,87,107,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2740,-1,0.0011840229,0.998816
2741,pneumonia,6,7,46,55,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2741,-1,0.0010888957,0.99891114
2742,DiGeorge syndrome,17,19,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2742,-1,0.0010979646,0.99890196
2744,hemorrhagic cystitis,22,24,147,167,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2744,-1,0.00093037327,0.99906963
2745,pneumonia,30,31,216,225,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2745,-1,0.0010346244,0.9989654
2746,adenovirus disease,6,8,33,51,The remaining 3 children died of adenovirus disease.,12093990_18,-1,-1,-1,2746,-1,0.0035238222,0.99647623
2748,cidofovir,2,3,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2748,-1,0.9985267,0.0014732651
2749,progressive renal failure,9,12,48,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2749,-1,0.0009358364,0.99906415
2751,adenovirus disease,19,21,127,145,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2751,-1,0.0036580039,0.996342
2752,immunodeficiency,35,36,233,249,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2752,-1,0.001077977,0.9989221
2754,adenovirus disease,11,13,78,96,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,-1,-1,-1,2754,-1,0.0017059686,0.99829406
2756,adenovirus disease,15,17,96,114,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,-1,2756,-1,0.0022301672,0.99776983
2757,adenovirus disease,8,10,43,61,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,-1,2757,-1,0.0014618065,0.99853826
2759,adenovirus infection,22,24,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,-1,2759,-1,0.016237386,0.9837626
2760,adenovirus disease,7,9,51,69,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,-1,2760,-1,0.0036198604,0.99638015
2762,asystolic cardiac arrest,1,4,8,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2762,-1,0.0011601931,0.9988398
2763,diltiazem overdose,5,7,39,57,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2763,-1,0.5790705,0.42092943
2769,isosorbide nitrate,21,23,96,114,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,-1,-1,-1,2769,-1,0.99830973,0.0016902738
2772,charcoal,16,17,104,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,-1,2772,-1,0.9915167,0.0084832655
2776,asystolic,15,16,108,117,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,-1,-1,2776,-1,0.002180736,0.9978193
2781,diltiazem overdose,16,18,98,116,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,-1,2781,-1,0.44015598,0.559844
2784,diltiazem overdose,11,13,63,81,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,-1,-1,2784,-1,0.6304345,0.36956552
2787,Unfractionated heparin,0,2,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2787,-1,0.9831131,0.01688689
2788,UH,3,4,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2788,-1,0.96558094,0.034419015
2790,LMWH,3,4,30,34,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2790,-1,0.9934395,0.0065605626
2791,UH,9,10,71,73,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2791,-1,0.10340597,0.896594
2792,UH,23,24,151,153,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2792,-1,0.060745668,0.9392543
2793,LMWH,20,21,97,101,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,-1,-1,-1,2793,-1,0.99509466,0.0049053733
2794,LMWH,11,12,59,63,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,-1,-1,-1,2794,-1,0.9949104,0.0050895945
2796,n,21,22,123,124,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2796,-1,0.09719102,0.902809
2797,n,34,35,192,193,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2797,-1,0.049822476,0.9501775
2798,n,50,51,244,245,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2798,-1,0.039060216,0.96093976
2799,n,63,64,282,283,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2799,-1,0.06442943,0.93557054
2800,thromboembolism,4,5,22,37,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2800,-1,0.0012341589,0.9987658
2802,LMWH,10,11,66,70,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2802,-1,0.9971353,0.0028646826
2803,LMWH,5,6,27,31,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,-1,2803,-1,0.9973973,0.002602715
2804,LMWH,16,17,99,103,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,-1,-1,-1,2804,-1,0.9971648,0.0028352165
2812,mg,5,6,39,41,The patient received metoclopramide 10 mg i.v.,12139551_2,-1,-1,-1,2812,-1,0.971046,0.028953984
2813,h.,4,5,21,23,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,-1,-1,-1,2813,-1,0.072247215,0.9277528
2818,mg,7,8,36,38,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,-1,-1,-1,2818,-1,0.9696465,0.030353434
2822,adverse drug reaction,21,24,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,-1,-1,-1,2822,-1,0.0016073334,0.99839264
2823,nitric oxide,6,8,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2823,-1,0.984382,0.0156180505
2824,arteritis,27,28,151,160,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2824,-1,0.0011922489,0.9988078
2825,fenoldopam,32,33,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2825,-1,0.9986518,0.0013482769
2827,Arteritis,0,1,0,9,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2827,-1,0.0011089372,0.99889106
2828,vasodilators,5,6,29,41,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2828,-1,0.25628316,0.74371684
2829,fenoldopam,7,8,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2829,-1,0.998686,0.0013139773
2831,nitric oxide,20,22,144,156,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2831,-1,0.9785388,0.021461232
2832,fenoldopam,3,4,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,-1,2832,-1,0.9986528,0.0013471184
2835,arteritis,31,32,172,181,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,-1,2835,-1,0.0011207286,0.99887925
2842,neostigmine,8,9,50,61,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,-1,-1,2842,-1,0.99868184,0.0013181015
2845,ACh,11,12,84,87,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,-1,-1,-1,2845,-1,0.9945643,0.0054356367
2847,ACh,1,2,12,15,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,-1,-1,2847,-1,0.954818,0.045181964
2852,neostigmine,14,15,89,100,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,-1,2852,-1,0.9985514,0.0014486065
2853,ACh,13,14,75,78,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2853,-1,0.99262047,0.007379491
2854,mM KCl,17,19,87,93,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2854,-1,0.9899503,0.01004977
2855,ACh,20,21,104,107,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2855,-1,0.9941093,0.0058907163
2856,ACh,7,8,36,39,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2856,-1,0.9831214,0.016878637
2857,KCl,14,15,77,80,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2857,-1,0.9969644,0.003035586
2858,ACh,2,3,17,20,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2858,-1,0.990568,0.009432057
2860,ACh,12,13,97,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2860,-1,0.99004596,0.009954054
2861,convulsants,15,16,120,131,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,-1,-1,2861,-1,0.07524636,0.92475367
2864,convulsants,10,11,65,76,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,-1,2864,-1,0.021903569,0.9780964
2865,muscle pain,1,3,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,-1,-1,2865,-1,0.0014078143,0.9985922
2866,painful temporomandibular disorders,3,6,23,58,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2866,-1,0.0015376646,0.9984623
2867,muscle pain,15,17,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2867,-1,0.0022033784,0.99779665
2872,painful,17,18,106,113,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,-1,-1,2872,-1,0.0030390588,0.99696094
2873,muscle pain,8,10,59,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,-1,-1,-1,2873,-1,0.0013137808,0.99868625
2876,muscle rigidity,8,10,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,-1,-1,2876,-1,0.0011667262,0.99883324
2877,AIDA,3,4,41,45,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,-1,2877,-1,0.99492294,0.0050771316
2878,AIDA,0,1,0,4,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2878,-1,0.9855123,0.014487723
2879,muscle rigidity,12,14,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2879,-1,0.0012037795,0.9987962
2880,contrast,1,2,3,11,"In contrast, 2R,4R-APDC injections were ineffective.",12231232_5,-1,-1,-1,2880,-1,0.1435256,0.85647434
2881,parkinsonian muscle rigidity,23,26,129,157,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,-1,-1,-1,2881,-1,0.0008948638,0.99910516
2885,GR 55562,21,23,128,136,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2885,-1,0.99653256,0.0034674252
2886,CP 93129,31,33,176,184,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2886,-1,0.99671495,0.0032850585
2887,GR 55562,7,9,39,47,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2887,-1,0.99550146,0.004498525
2888,CP 93129,16,18,72,80,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2888,-1,0.9966395,0.0033604696
2890,GR 55562,0,2,0,8,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,-1,-1,2890,-1,0.9965056,0.0034943759
2893,GR 55562,12,14,71,79,Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core.,12369736_6,-1,-1,-1,2893,-1,0.996741,0.0032590511
2895,CP 93129,15,17,74,82,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,-1,-1,-1,2895,-1,0.9969944,0.00300564
2897,GR 55562,10,12,80,88,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,-1,-1,-1,2897,-1,0.9961408,0.0038592773
2899,hyperlocomotion,6,7,43,58,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2899,-1,0.0010359071,0.9989641
2900,GR 55562,37,39,255,263,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2900,-1,0.9941204,0.005879569
2901,CP 93129,43,45,278,286,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2901,-1,0.9959786,0.004021368
2903,chest pain,2,4,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,-1,2903,-1,0.0016675591,0.99833244
2907,chest pain,9,11,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2907,-1,0.0013199175,0.99868006
2908,chest pain,28,30,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2908,-1,0.0012824233,0.99871755
2909,chest pain,3,5,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,-1,-1,2909,-1,0.0012448457,0.9987551
2913,renal cell carcinoma,9,12,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,-1,-1,2913,-1,0.0014051561,0.9985948
2916,renal cell cancer,15,18,102,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,-1,2916,-1,0.0014198553,0.9985801
2919,metastases,23,24,137,147,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,-1,-1,-1,2919,-1,0.0015130976,0.9984869
2924,renal cell carcinoma,15,18,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,-1,2924,-1,0.0020202096,0.9979798
2926,renal cell carcinoma,10,13,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,-1,-1,2926,-1,0.0016127864,0.9983872
2929,postoperative myalgia?This,5,7,45,71,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,-1,-1,-1,2929,-1,0.007365108,0.99263495
2933,mg,13,14,76,78,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2933,-1,0.9453744,0.054625534
2935,mg,23,24,113,115,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2935,-1,0.95651555,0.043484427
2937,mg,30,31,149,151,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2937,-1,0.9340792,0.06592085
2938,rocuronium,41,42,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2938,-1,0.9986181,0.001381864
2939,mg,43,44,205,207,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2939,-1,0.94715583,0.052844156
2941,mg,2,3,13,15,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,-1,-1,-1,2941,-1,0.946347,0.05365305
2942,thiopental,7,8,40,50,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2942,-1,0.9985342,0.0014658022
2944,rocuronium,20,21,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2944,-1,0.9986609,0.0013390471
2947,muscle fasciculation,4,6,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2947,-1,0.0022919124,0.9977081
2948,muscle fasciculation,23,25,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2948,-1,0.0023505231,0.9976495
2949,p,31,32,174,175,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2949,-1,0.12769967,0.8723003
2950,h,2,3,6,7,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2950,-1,0.023561029,0.976439
2952,PS,12,13,54,56,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2952,-1,0.03223457,0.9677654
2953,p,20,21,82,83,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2953,-1,0.1364014,0.8635986
2955,muscle fasciculation,14,16,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,-1,-1,2955,-1,0.0017465185,0.9982535
2958,postoperative myalgia,21,23,123,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,-1,-1,-1,2958,-1,0.0012504191,0.9987496
2960,mg,9,10,67,69,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,-1,-1,2960,-1,0.9643305,0.035669465
2965,mg,14,15,102,104,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2965,-1,0.93892115,0.061078876
2967,mg,22,23,146,148,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2967,-1,0.9364178,0.063582204
2970,p,25,26,131,132,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,-1,-1,-1,2970,-1,0.17799737,0.82200265
2974,h,9,10,48,49,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,-1,-1,2974,-1,0.019221572,0.98077846
2977,h,8,9,48,49,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2977,-1,0.017740935,0.98225904
2979,p,20,21,123,124,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2979,-1,0.1117157,0.8882843
2981,h,32,33,176,177,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2981,-1,0.045657642,0.9543423
2983,h,4,5,21,22,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2983,-1,0.009178509,0.9908215
2985,p,16,17,84,85,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2985,-1,0.11556569,0.8844343
2989,h,12,13,62,63,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2989,-1,0.022286912,0.97771305
2990,h,24,25,130,131,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2990,-1,0.021111514,0.97888845
2991,p,35,36,185,186,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2991,-1,0.0932804,0.9067196
2995,phonophobia,17,18,110,121,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2995,-1,0.0010170751,0.99898285
2996,photophobia,19,20,125,136,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2996,-1,0.0011356616,0.9988644
2997,h,27,28,177,178,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2997,-1,0.0649646,0.93503535
2998,p,32,33,198,199,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2998,-1,0.14742038,0.85257965
2999,h,12,13,62,63,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,2999,-1,0.1281834,0.8718166
3001,h,24,25,115,116,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3001,-1,0.12068026,0.8793197
3002,p,33,34,166,167,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3002,-1,0.118561834,0.88143814
3016,contrast,1,2,3,11,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,-1,-1,3016,-1,0.062071215,0.9379288
3022,glioblastomas,12,13,93,106,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,-1,-1,-1,3022,-1,0.0012907818,0.9987092
3024,malignant tumor,5,7,30,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,-1,-1,3024,-1,0.0017418151,0.9982582
3032,glioblastomas,13,14,88,101,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,-1,-1,3032,-1,0.0013931314,0.99860686
3034,visual disturbance,5,7,26,44,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3034,-1,0.0013226621,0.9986773
3035,h,12,13,71,72,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3035,-1,0.024154918,0.97584504
3036,carboplatin toxicity,7,9,47,67,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,-1,-1,-1,3036,-1,0.68635976,0.3136402
3038,glycerin,11,12,79,87,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,-1,3038,-1,0.9981869,0.0018130738
3040,ocular pain,13,15,107,118,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3040,-1,0.0015541665,0.9984458
3041,papilledema,18,19,142,153,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3041,-1,0.0011490142,0.99885094
3042,retinal detachment,21,23,168,186,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3042,-1,0.0012576334,0.9987424
3043,chorioretinal atrophy,7,9,32,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3043,-1,0.0018684204,0.9981316
3044,optic atrophy,10,12,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3044,-1,0.0016752436,0.9983247
3046,ocular toxicity,17,19,112,127,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,-1,-1,-1,3046,-1,0.0013165303,0.9986835
3059,absence seizures,4,6,37,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,-1,-1,3059,-1,0.0012524478,0.9987476
3060,absence epilepsy,8,10,48,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,-1,-1,-1,3060,-1,0.0010182327,0.9989818
3063,absence seizure,11,13,72,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,-1,-1,3063,-1,0.0011745079,0.9988255
3064,absence epilepsy,16,18,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,-1,-1,3064,-1,0.0014114658,0.9985885
3065,absence seizure,4,6,29,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,-1,3065,-1,0.0010928842,0.9989071
3066,absence seizure,21,23,136,151,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,-1,-1,-1,3066,-1,0.0011848893,0.9988152
3069,absence epilepsy,6,8,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3069,-1,0.0010271036,0.9989729
3071,absence seizures,24,26,168,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3071,-1,0.0010231243,0.99897695
3075,liver failure,8,10,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,-1,3075,-1,0.0010492236,0.9989507
3084,deterioration of renal function,7,11,44,75,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,-1,-1,3084,-1,0.001444365,0.9985556
3085,acute liver injury,7,10,57,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,-1,-1,3085,-1,0.0010198393,0.9989801
3096,acute liver insult,10,13,62,80,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,-1,-1,3096,-1,0.0011165588,0.9988834
3099,pyeloureteritis cystica,3,5,16,39,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,-1,-1,3099,-1,0.001547162,0.9984528
3104,pelvic thrombophlebitis,12,14,83,106,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,-1,-1,-1,3104,-1,0.0008905755,0.99910945
3105,pyeloureteritis cystica,15,17,98,121,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3105,-1,0.0016168887,0.99838316
3106,submucosal hemorrhage,18,20,126,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3106,-1,0.0025711248,0.99742883
3108,contrast medium,6,8,33,48,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,-1,-1,3108,-1,0.94172454,0.058275513
3110,contrast medium,2,4,20,35,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3110,-1,0.8641733,0.13582666
3112,contrast medium,9,11,73,88,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3112,-1,0.8734582,0.12654182
3114,contrast medium,24,26,152,167,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3114,-1,0.75280106,0.24719897
3116,contrast medium,38,40,229,244,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3116,-1,0.78202873,0.21797122
3117,iohexol,41,42,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3117,-1,0.998329,0.0016710599
3120,mg,15,16,97,99,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,-1,-1,3120,-1,0.47583103,0.52416897
3123,mg,12,13,73,75,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3123,-1,0.61280674,0.38719326
3124,mg,22,23,118,120,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3124,-1,0.5647724,0.43522757
3129,mg,15,16,67,69,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3129,-1,0.27692926,0.7230708
3131,mg,24,25,116,118,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3131,-1,0.3129863,0.6870137
3132,iohexol,29,30,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3132,-1,0.9986411,0.0013588778
3133,P=0.001,32,33,155,162,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3133,-1,0.26135138,0.73864865
3135,iohexol,42,43,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3135,-1,0.998492,0.0015079281
3136,mg,45,46,231,233,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3136,-1,0.2755219,0.7244781
3139,mg,22,23,113,115,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3139,-1,0.3401204,0.6598796
3140,iohexol,38,39,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3140,-1,0.99842995,0.0015700266
3141,P=0.002,45,46,213,220,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3141,-1,0.14148073,0.85851926
3144,mg,9,10,54,56,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3144,-1,0.34201005,0.65799
3145,iohexol,20,21,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3145,-1,0.99847025,0.0015297879
3147,mg,15,16,77,79,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3147,-1,0.23508878,0.76491123
3149,mg,24,25,126,128,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3149,-1,0.2748589,0.7251411
3150,iohexol,29,30,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3150,-1,0.99855965,0.0014402994
3151,P=0.003,32,33,165,172,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3151,-1,0.20356242,0.7964376
3153,iohexol,44,45,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3153,-1,0.99838614,0.0016138124
3154,mg,48,49,247,249,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3154,-1,0.21087036,0.7891297
3156,contrast medium,5,7,36,51,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3156,-1,0.98644614,0.013553834
3158,contrast medium,26,28,163,178,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3158,-1,0.9387483,0.061251644
3164,increase in blood pressure,15,19,101,127,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,-1,-1,3164,-1,0.0017497753,0.9982502
3167,body weight,16,18,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,-1,3167,-1,0.12089599,0.87910396
3169,in,16,17,93,95,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3169,-1,0.026613083,0.97338694
3170,P<0.05,36,37,195,201,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3170,-1,0.119416885,0.8805831
3171,glomeruli,47,48,253,262,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3171,-1,0.0032497055,0.99675035
3173,P<0.05,31,32,165,171,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3173,-1,0.11608366,0.8839163
3175,elevated blood pressures,23,26,108,132,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,-1,-1,-1,3175,-1,0.0025612267,0.9974388
3180,reduction in,11,13,66,78,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,-1,-1,-1,3180,-1,0.008411825,0.9915882
3185,cyclosporine A,9,11,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,-1,-1,-1,3185,-1,0.99831057,0.0016893952
3189,SRL,4,5,23,26,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3189,-1,0.9956814,0.004318557
3190,calcineurin inhibitors,8,10,43,65,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3190,-1,0.99269414,0.0073058656
3192,SRL,5,6,27,30,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,-1,-1,3192,-1,0.99629253,0.00370745
3194,SRL,7,8,41,44,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,-1,3194,-1,0.99114484,0.008855174
3196,cyclosporine A,26,28,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3196,-1,0.9980921,0.0019079209
3197,CsA,29,30,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3197,-1,0.9980077,0.0019922792
3199,FK506,34,35,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3199,-1,0.99844116,0.0015588516
3200,SRL,37,38,205,208,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3200,-1,0.99664634,0.0033536272
3201,CsA,9,10,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3201,-1,0.99767476,0.0023252824
3202,FK506,17,18,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3202,-1,0.99856925,0.0014307437
3203,SRL,25,26,105,108,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3203,-1,0.9969199,0.0030801748
3204,Cr(EDTA,22,23,113,120,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,-1,-1,-1,3204,-1,0.99108386,0.008916187
3208,CsA,2,3,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3208,-1,0.9979867,0.00201333
3209,FK506,4,5,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3209,-1,0.9987073,0.0012927393
3210,SRL,6,7,24,27,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3210,-1,0.9965945,0.0034054709
3211,CsA,6,7,38,41,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3211,-1,0.99784434,0.0021556385
3212,FK506,11,12,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3212,-1,0.9987205,0.0012794975
3213,SRL,13,14,76,79,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3213,-1,0.9978969,0.0021030607
3214,FK506,25,26,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3214,-1,0.9986118,0.0013881247
3215,SRL,27,28,153,156,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3215,-1,0.99766576,0.0023342473
3216,CsA,11,12,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3216,-1,0.9975795,0.002420564
3217,SRL,13,14,89,92,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3217,-1,0.99603146,0.0039685494
3218,P<0.001,15,16,94,101,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3218,-1,0.14814962,0.85185033
3220,P<0.02,45,46,274,280,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3220,-1,0.113064885,0.88693506
3221,FK506,1,2,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3221,-1,0.9984226,0.0015773975
3222,SRL,3,4,15,18,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3222,-1,0.99514896,0.0048510875
3224,P=0.05,18,19,109,115,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3224,-1,0.089965545,0.9100344
3226,CsA,11,12,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3226,-1,0.9980585,0.0019414583
3227,SRL,13,14,85,88,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3227,-1,0.99742573,0.0025742352
3228,FK506,16,17,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3228,-1,0.99861884,0.0013811759
3229,SRL,18,19,109,112,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3229,-1,0.9972838,0.0027162097
3232,myocardial cell injury,24,27,115,137,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,-1,3232,-1,0.0026988238,0.99730116
3236,cardiac disorders,38,40,239,256,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,-1,3236,-1,0.0010650003,0.99893504
3237,DOX,9,10,54,57,"METHODS: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW.",12589964_3,-1,-1,-1,3237,-1,0.9963025,0.003697484
3238,DOX,26,27,160,163,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3238,-1,0.99584347,0.0041565616
3239,DOX,13,14,68,71,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,-1,-1,-1,3239,-1,0.9966234,0.0033766541
3240,DOX,5,6,25,28,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,-1,3240,-1,0.44424483,0.5557552
3242,DOX,24,25,131,134,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3242,-1,0.99470204,0.0052979533
3243,p<0.001,27,28,142,149,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3243,-1,0.16578367,0.8342163
3244,DOX,8,9,54,57,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,-1,-1,3244,-1,0.995606,0.0043940027
3247,DOX,8,9,40,43,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3247,-1,0.9518802,0.048119843
3248,p<0.05,23,24,121,127,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3248,-1,0.09633828,0.9036617
3249,DOX,16,17,93,96,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,-1,-1,-1,3249,-1,0.9952166,0.0047834166
3250,DOX,12,13,69,72,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3250,-1,0.9583971,0.04160291
3251,p=0.006,18,19,102,109,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3251,-1,0.30154765,0.69845235
3252,DOX,12,13,54,57,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,-1,-1,-1,3252,-1,0.9384034,0.061596572
3253,p<0.0001,21,22,121,129,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,-1,3253,-1,0.24546647,0.7545335
3254,ischemic injury,5,7,30,45,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3254,-1,0.001345608,0.99865437
3255,DOX,8,9,52,55,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3255,-1,0.99451536,0.005484651
3257,DOX,13,14,75,78,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3257,-1,0.9910755,0.008924512
3258,DOX,38,39,209,212,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3258,-1,0.9864145,0.01358551
3260,hypoxemia,1,2,19,28,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,-1,-1,3260,-1,0.0008830307,0.99911696
3262,fistula,11,12,73,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3262,-1,0.0010031264,0.9989969
3263,necrotizing enterocolitis,13,15,94,119,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3263,-1,0.00088791957,0.99911207
3266,fistula,17,18,123,130,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,-1,-1,3266,-1,0.0014846136,0.9985154
3267,edaravone,3,4,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3267,-1,0.9985781,0.0014219079
3268,vestibulotoxicity,6,7,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3268,-1,0.0010353724,0.99896467
3269,vestibulotoxicity,6,7,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3269,-1,0.0009985208,0.99900144
3270,edaravone,8,9,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3270,-1,0.99856937,0.0014305679
3271,Edaravone,0,1,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3271,-1,0.99818194,0.001818138
3272,cerebral infarction,21,23,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3272,-1,0.0009455331,0.9990545
3274,h,12,13,70,71,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3274,-1,0.08000733,0.9199926
3275,edaravone,15,16,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3275,-1,0.998408,0.0015919775
3276,n=8,17,18,88,91,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3276,-1,0.3670518,0.6329482
3277,n=6,22,23,104,107,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3277,-1,0.3564447,0.6435553
3278,edaravone,12,13,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,-1,-1,-1,3278,-1,0.99846554,0.0015345213
3279,edaravone,4,5,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3279,-1,0.9982863,0.0017136509
3280,vestibulotoxicity,7,8,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3280,-1,0.0012705777,0.9987294
3281,venous thromboembolism,3,5,12,34,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3281,-1,0.0010265992,0.99897337
3282,cyproterone acetate,8,10,55,74,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3282,-1,0.99856734,0.0014326416
3283,ethinyl estradiol,13,15,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3283,-1,0.99856263,0.0014373781
3284,Cyproterone acetate,2,4,12,31,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3284,-1,0.9985177,0.0014823081
3285,ethinyl estradiol,6,8,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3285,-1,0.99865663,0.0013434036
3287,hirsutism,24,25,136,145,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3287,-1,0.0011446178,0.99885535
3288,polycystic ovary syndrome,32,35,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3288,-1,0.0015436332,0.99845636
3289,PCOS,36,37,208,212,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3289,-1,0.0011611549,0.99883884
3290,venous thromboembolism,8,10,56,78,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3290,-1,0.0010321169,0.9989679
3291,VTE,11,12,80,83,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3291,-1,0.001103448,0.9988965
3292,combined oral contraceptives,19,22,135,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3292,-1,0.9932382,0.006761808
3293,COCs,23,24,165,169,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3293,-1,0.9890626,0.010937353
3295,hirsutism,31,32,184,193,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3295,-1,0.001256381,0.9987436
3296,PCOS,33,34,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3296,-1,0.0011907348,0.9988092
3297,VTE,39,40,226,229,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3297,-1,0.0013251588,0.99867487
3298,COCs,11,12,78,82,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,-1,3298,-1,0.36498696,0.63501304
3299,oral contraception,10,12,54,72,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3299,-1,0.9820411,0.017958857
3300,menopausal symptoms,18,20,101,120,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3300,-1,0.0016713508,0.9983286
3301,COCs,65,66,305,309,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3301,-1,0.9821177,0.017882297
3302,VTE,9,10,55,58,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3302,-1,0.0011168226,0.9988832
3304,hirsutism,21,22,113,122,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3304,-1,0.0010219447,0.99897814
3305,PCOS,23,24,126,130,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3305,-1,0.0010588504,0.9989411
3306,gum Arabic,5,7,29,39,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3306,-1,0.99670285,0.0032971278
3307,gentamicin nephrotoxicity,8,10,43,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3307,-1,0.057783123,0.94221693
3308,gum Arabic,13,15,69,79,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3308,-1,0.9962843,0.0037156949
3309,acute renal failure,16,19,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3309,-1,0.0009183467,0.9990816
3311,GM,23,24,126,128,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3311,-1,0.6448936,0.3551064
3313,gum Arabic,22,24,95,105,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3313,-1,0.9972173,0.002782703
3314,gum Arabic,35,37,150,160,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3314,-1,0.9954922,0.0045078024
3315,gum Arabic,46,48,193,203,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3315,-1,0.9968471,0.0031528627
3316,GM,50,51,223,225,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3316,-1,0.99400264,0.005997347
3320,reduced glutathione,15,17,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3320,-1,0.99650013,0.0034998495
3321,GSH,18,19,122,125,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3321,-1,0.9959919,0.0040081358
3322,gum Arabic,7,9,54,64,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3322,-1,0.99647456,0.0035253775
3323,GM,10,11,69,71,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3323,-1,0.9967411,0.0032589552
3326,cellulose,38,39,214,223,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3326,-1,0.9964881,0.0035119103
3327,GM,40,41,228,230,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3327,-1,0.9967068,0.0032932127
3328,GSH,48,49,264,267,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3328,-1,0.98544866,0.014551332
3329,cellulose,59,60,299,308,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3329,-1,0.9948455,0.0051545105
3330,GM,61,62,314,316,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3330,-1,0.99451536,0.005484617
3331,proximal tubular necrosis,66,69,339,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3331,-1,0.0015310805,0.99846894
3332,GM,78,79,415,417,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3332,-1,0.9954526,0.004547465
3333,gum Arabic,81,83,432,442,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3333,-1,0.9966016,0.0033983558
3334,GM,87,88,463,465,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3334,-1,0.9964065,0.003593514
3335,cellulose,89,90,470,479,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3335,-1,0.99690706,0.003092931
3336,gum Arabic,5,7,26,36,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3336,-1,0.99688417,0.0031158275
3337,GM nephrotoxicity,22,24,136,153,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3337,-1,0.0030496945,0.9969503
3339,venous thromboembolism,3,5,23,45,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,-1,-1,3339,-1,0.0009102183,0.99908984
3343,venous thromboembolism,8,10,46,68,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3343,-1,0.0009927768,0.9990073
3344,VTE,11,12,70,73,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3344,-1,0.0010433685,0.99895656
3351,mg,29,30,182,184,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,-1,-1,-1,3351,-1,0.97921157,0.02078846
3354,disease progression,13,15,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,-1,3354,-1,0.0012640994,0.99873596
3356,VTE,14,15,90,93,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3356,-1,0.0013189223,0.998681
3359,VTE,31,32,176,179,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3359,-1,0.0013380654,0.9986619
3360,p=0.025,33,34,181,188,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3360,-1,0.12745146,0.8725485
3364,VTE,19,20,130,133,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,-1,-1,3364,-1,0.0011738285,0.9988262
3366,cholestatic hepatitis,1,3,20,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,-1,-1,-1,3366,-1,0.0010884969,0.9989115
3367,cholestatic hepatitis,8,10,52,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,-1,3367,-1,0.0010919091,0.99890804
3368,cholestatic hepatitis,7,9,49,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,-1,-1,-1,3368,-1,0.0010645078,0.9989355
3371,Cholestatic hepatitis,2,4,12,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,-1,3371,-1,0.0011190984,0.9988809
3375,cholestatic hepatitis,16,18,127,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,-1,-1,3375,-1,0.00094437035,0.9990557
3377,adverse drug,7,9,52,64,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,-1,-1,-1,3377,-1,0.004785109,0.99521494
3381,Cholestatic hepatitis,2,4,13,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,-1,-1,3381,-1,0.0010315754,0.9989685
3386,nephrotic syndrome,16,18,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,-1,-1,3386,-1,0.00094411883,0.9990559
3387,nephrotic syndrome,2,4,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,-1,-1,3387,-1,0.0009389755,0.99906105
3392,puromycin aminonucleoside,11,13,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3392,-1,0.9980386,0.0019614366
3393,nephrotic syndrome,14,16,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3393,-1,0.00092648726,0.9990735
3397,PAN,26,27,173,176,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,-1,3397,-1,0.9954596,0.0045403624
3401,PAN,11,12,51,54,"Sodium retention occurred on days 2, 3 and 6 after PAN injection.",12653683_8,-1,-1,-1,3401,-1,0.9937716,0.006228425
3406,nephrotic syndrome,23,25,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,-1,-1,3406,-1,0.0010172446,0.9989827
3408,GABA,4,5,33,37,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,-1,3408,-1,0.99802965,0.0019703724
3411,GABA,3,4,23,27,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3411,-1,0.99771297,0.0022870395
3412,GVG,5,6,29,32,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3412,-1,0.99529666,0.0047033383
3413,GABA,12,13,95,99,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,-1,3413,-1,0.995484,0.0045160116
3414,substance abuse,8,10,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3414,-1,0.021934194,0.9780658
3416,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3416,-1,0.0015037089,0.9984963
3417,GVG,35,36,218,221,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3417,-1,0.9332074,0.06679262
3419,DA,47,48,289,291,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3419,-1,0.99614346,0.0038565286
3420,GVG,3,4,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,-1,3420,-1,0.72673804,0.273262
3422,GVG,5,6,34,37,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3422,-1,0.9753361,0.024663892
3424,VFDS,25,26,178,182,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3424,-1,0.0013321723,0.99866784
3425,oromandibular dystonia,1,3,17,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3425,-1,0.0019261847,0.9980738
3426,progressive supranuclear palsy,4,7,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3426,-1,0.0014867244,0.9985133
3428,Parkinson's disease,6,9,51,70,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3428,-1,0.0012347263,0.99876535
3429,multiple system atrophy,10,13,75,98,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3429,-1,0.0020943754,0.9979056
3430,Cranial dystonias,0,2,0,17,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3430,-1,0.0011206474,0.9988794
3431,progressive supranuclear palsy,7,10,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3431,-1,0.0013769534,0.998623
3432,PSP,11,12,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3432,-1,0.0012469818,0.99875295
3433,Oromandibular dystonia,11,13,74,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3433,-1,0.0026329635,0.9973671
3434,OMD,14,15,98,101,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3434,-1,0.002411738,0.9975883
3435,PSP,18,19,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3435,-1,0.0019255218,0.9980744
3436,PSP,34,35,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3436,-1,0.0013094984,0.99869055
3438,MR,6,7,39,41,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3438,-1,0.030193236,0.96980673
3439,neurologic symptoms,24,26,153,172,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3439,-1,0.0010886072,0.9989114
3441,MR,1,2,6,8,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3441,-1,0.013750395,0.98624957
3443,neurologic complications,20,22,136,160,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3443,-1,0.0010892977,0.99891067
3444,MR,9,10,53,55,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3444,-1,0.0186922,0.98130786
3445,MR,14,15,75,77,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3445,-1,0.017660653,0.9823393
3446,MR,10,11,59,61,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,-1,3446,-1,0.16560028,0.83439976
3447,white matter abnormalities,11,14,34,60,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3447,-1,0.0036565827,0.99634343
3448,putaminal hemorrhage,21,23,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3448,-1,0.0030379063,0.99696213
3449,MR,35,36,142,144,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3449,-1,0.16267323,0.8373267
3450,white matter abnormalities,5,8,26,52,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3450,-1,0.0027369082,0.9972631
3451,MR,23,24,121,123,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3451,-1,0.12308082,0.87691915
3452,laminar necrosis,20,22,114,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,-1,-1,3452,-1,0.00205241,0.99794763
3457,mg,4,5,27,29,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,-1,-1,-1,3457,-1,0.9068743,0.09312568
3459,P<0.05,16,17,113,119,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,-1,-1,-1,3459,-1,0.15842313,0.84157693
3460,mm Hg,10,12,56,61,Systolic blood pressure was elevated by an average of 7 mm Hg.,12707296_10,-1,-1,-1,3460,-1,0.005600904,0.99439913
3463,increases in blood pressure,4,8,34,61,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,-1,3463,-1,0.0018155539,0.9981844
3466,intracerebral hemorrhage,9,11,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,-1,3466,-1,0.0011522212,0.9988477
3467,intracerebral hemorrhage,4,6,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3467,-1,0.0011401349,0.9988599
3468,ICH,7,8,49,52,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3468,-1,0.0012429382,0.9987571
3470,ICH,10,11,77,80,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3470,-1,0.0016497863,0.99835026
3471,ICH deterioration,15,17,104,121,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3471,-1,0.0014071695,0.9985928
3472,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,-1,3472,-1,0.0028716144,0.9971284
3477,ICH deterioration,21,23,144,161,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,-1,-1,3477,-1,0.0012497606,0.9987502
3478,ICH,1,2,3,6,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3478,-1,0.0015183615,0.9984817
3481,ICH,18,19,119,122,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3481,-1,0.0016789504,0.998321
3483,ICH,10,11,64,67,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3483,-1,0.0013559342,0.99864405
3484,ICH,20,21,109,112,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3484,-1,0.0014661966,0.99853384
3485,ICH,36,37,204,207,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3485,-1,0.0012021019,0.9987979
3486,Dexatrim,3,4,13,21,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3486,-1,0.99846494,0.0015350942
3487,Phenylpropanolamine,5,6,23,42,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3487,-1,0.9984409,0.0015590881
3488,myocardial infarction,11,13,58,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3488,-1,0.0010757836,0.9989242
3489,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3489,-1,0.9980684,0.0019316808
3490,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3490,-1,0.9936208,0.0063791987
3491,amine,7,8,43,48,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3491,-1,0.9664816,0.033518363
3493,hemorrhagic strokes,9,11,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,-1,-1,3493,-1,0.0008530917,0.99914694
3494,PPA,7,8,41,44,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,-1,3494,-1,0.1679324,0.83206755
3497,Dexatrim,7,8,33,41,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,-1,-1,3497,-1,0.9985299,0.0014700735
3499,PPA,10,11,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,-1,-1,3499,-1,0.039097905,0.9609021
3501,PPA,16,17,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,-1,3501,-1,0.99176323,0.008236776
3502,creatine kinase,5,7,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3502,-1,0.9957755,0.0042245532
3503,systemic lupus erythematosus,9,12,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3503,-1,0.0014746616,0.9985253
3505,systemic lupus erythematosus,8,11,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3505,-1,0.001234548,0.99876547
3506,SLE,12,13,70,73,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3506,-1,0.0013126014,0.99868745
3507,renal involvement,15,17,80,97,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3507,-1,0.0012384098,0.99876165
3511,CQ,5,6,37,39,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3511,-1,0.99728787,0.0027121475
3512,arthralgia,11,12,64,74,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3512,-1,0.00089946314,0.99910057
3513,creatine kinase,7,9,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,-1,-1,-1,3513,-1,0.99069536,0.009304685
3514,Myositis,0,1,0,8,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,-1,-1,-1,3514,-1,0.001013447,0.99898654
3516,muscular weakness,11,13,66,83,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3516,-1,0.0011293053,0.9988707
3517,muscular atrophy,14,16,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3517,-1,0.0011577389,0.9988423
3518,myositis,9,10,71,79,The neurological and electrophysiological findings were not typical of myositis.,12739036_8,-1,-1,-1,3518,-1,0.0011525803,0.99884737
3519,polymyositis,14,15,76,88,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,-1,-1,3519,-1,0.0009911055,0.9990089
3522,affection of the musculoskeletal system,4,9,43,82,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3522,-1,0.0018522086,0.99814785
3523,SLE,19,20,155,158,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3523,-1,0.0014166603,0.9985833
3525,sleep deprivation,3,5,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,-1,-1,3525,-1,0.004241847,0.9957581
3529,sleep deprivation,13,15,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,-1,-1,3529,-1,0.004673783,0.99532616
3533,tonic clonic seizure,12,15,70,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,-1,-1,3533,-1,0.0010940243,0.998906
3535,sleep deprivation,3,5,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,-1,-1,3535,-1,0.07438976,0.9256102
3538,hippocampal injury,3,5,34,52,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,-1,-1,-1,3538,-1,0.0013499267,0.99865013
3539,Estrogens,0,1,0,9,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3539,-1,0.99513525,0.004864725
3540,hippocampal injury,5,7,43,61,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3540,-1,0.0012386868,0.9987613
3541,status epilepticus,11,13,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3541,-1,0.0013162575,0.99868375
3542,SE,14,15,113,115,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3542,-1,0.0017924936,0.99820745
3543,SE,16,17,130,132,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,-1,3543,-1,0.0026132853,0.99738675
3544,oil,11,12,76,79,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,-1,-1,-1,3544,-1,0.99483794,0.005162037
3545,SE,0,1,0,2,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3545,-1,0.005591097,0.9944089
3546,h,4,5,18,19,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3546,-1,0.049961988,0.9500381
3547,h,12,13,68,69,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3547,-1,0.037202913,0.96279705
3548,SE,14,15,88,90,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,-1,3548,-1,0.035715092,0.96428496
3552,Postoperative myalgia,0,2,0,21,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,-1,-1,-1,3552,-1,0.0013305519,0.9986695
3555,postoperative myalgia,8,10,56,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,-1,3555,-1,0.001078432,0.99892163
3562,n,20,21,159,160,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,-1,-1,-1,3562,-1,0.08390868,0.9160913
3567,h,2,3,6,7,"At 48 h after surgery, 12 patients in both groups still suffered from myalgia (not significant).",12760988_6,-1,-1,-1,3567,-1,0.025752911,0.97424704
3575,postoperative myalgia,19,21,158,179,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,-1,-1,-1,3575,-1,0.0010685542,0.99893147
3576,postoperative myalgia,8,10,59,80,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,-1,-1,-1,3576,-1,0.0012683711,0.9987317
3579,postoperative myalgia,8,10,60,81,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,-1,-1,-1,3579,-1,0.001075842,0.9989241
3581,Pseudoacromegaly,0,1,0,16,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3581,-1,0.0011613397,0.9988387
3582,minoxidil,7,8,49,58,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3582,-1,0.99870837,0.0012916063
3583,Acromegaly,0,1,0,10,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3583,-1,0.0010942548,0.9989058
3584,endocrine disorder,3,5,17,35,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3584,-1,0.0011974279,0.99880254
3585,growth hormone,9,11,64,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3585,-1,0.928169,0.071831
3587,cutis verticis gyrata,30,33,172,193,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,-1,-1,3587,-1,0.0034401075,0.9965599
3588,Pseudoacromegaly,0,1,0,16,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3588,-1,0.0012745679,0.9987255
3589,growth hormone,19,21,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3589,-1,0.9852309,0.014769088
3590,pseudoacromegaly,5,6,26,42,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3590,-1,0.0010299353,0.99897003
3591,minoxidil,13,14,83,92,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3591,-1,0.9986313,0.0013686357
3592,pseudoacromegaly,7,8,33,49,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3592,-1,0.0010181211,0.9989819
3593,minoxidil,13,14,70,79,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3593,-1,0.9986249,0.0013750768
3596,androgen,10,11,58,66,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3596,-1,0.9943105,0.005689526
3599,prostatic adenocarcinoma,8,10,60,84,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3599,-1,0.0023044103,0.9976956
3600,leuprolide acetate,5,7,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3600,-1,0.99829,0.0017099946
3601,mg,11,12,60,62,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3601,-1,0.9529764,0.04702364
3602,mg flutamide,20,22,104,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3602,-1,0.99488246,0.0051175123
3608,SE,24,25,100,102,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3608,-1,0.102799304,0.89720076
3610,SE,47,48,191,193,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3610,-1,0.11735832,0.8826417
3612,p,29,30,153,154,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,-1,-1,3612,-1,0.09827619,0.90172386
3622,body weight,14,16,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,-1,3622,-1,0.056077283,0.9439227
3624,3-methylcholanthrene,9,10,64,84,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3624,-1,0.9973845,0.0026155256
3625,MC,11,12,86,88,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3625,-1,0.99651814,0.0034818589
3629,PB,37,38,239,241,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3629,-1,0.9947178,0.0052822055
3634,cobalt chloride,11,13,71,86,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3634,-1,0.9971806,0.002819446
3638,se,27,28,186,188,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3638,-1,0.8721274,0.12787254
3639,PB,33,34,218,220,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3639,-1,0.9964611,0.0035389722
3641,neurobehavioral,43,44,278,293,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3641,-1,0.0016399903,0.99836
3642,neurobehavioral toxicity,43,45,278,302,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3642,-1,0.0011219196,0.99887806
3643,venous thromboembolism,5,7,34,56,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3643,-1,0.0009566784,0.9990433
3644,cyproterone acetate,11,13,78,97,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3644,-1,0.9987025,0.0012974784
3645,ethinylestradiol,14,15,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3645,-1,0.99886644,0.0011335366
3646,venous thromboembolism,8,10,49,71,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3646,-1,0.0011173881,0.9988826
3647,VTE,11,12,73,76,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3647,-1,0.0011860953,0.99881387
3648,cyproterone acetate,16,18,93,112,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3648,-1,0.9985832,0.001416796
3649,ethinylestradiol,19,20,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3649,-1,0.9987489,0.0012511269
3650,combined oral contraceptives,28,31,164,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3650,-1,0.9962101,0.0037899488
3651,COCs,32,33,194,198,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3651,-1,0.99129725,0.008702758
3652,VTE,36,37,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,-1,3652,-1,0.0017154702,0.9982845
3653,COC,0,1,0,3,COC use was ascertained through mailed questionnaires.,12851669_3,-1,-1,-1,3653,-1,0.9919579,0.00804205
3654,COCs,3,4,20,24,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,-1,3654,-1,0.9924144,0.007585557
3655,VTE,17,18,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3655,-1,0.0014180877,0.9985819
3656,COCs,20,21,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3656,-1,0.93378216,0.06621776
3657,COCs,8,9,53,57,"Of these women, 67 were on levonorgestrel-containing COCs.",12851669_6,-1,-1,-1,3657,-1,0.9585261,0.041473962
3658,VTE,5,6,35,38,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3658,-1,0.0014448108,0.99855524
3659,COCs,24,25,106,110,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3659,-1,0.98103493,0.018965052
3660,COCs,43,44,197,201,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3660,-1,0.9600295,0.03997057
3661,VTE,9,10,53,56,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3661,-1,0.0014617697,0.99853826
3662,COCs,14,15,79,83,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3662,-1,0.98256415,0.0174359
3665,NSAIDs,11,12,81,87,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3665,-1,0.99283844,0.0071615577
3666,developmental anomalies,19,21,122,145,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3666,-1,0.0018130989,0.9981869
3667,NSAIDs,25,26,167,173,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3667,-1,0.99620557,0.003794407
3670,ASA,5,6,31,34,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3670,-1,0.996911,0.0030889867
3671,developmental anomalies,18,20,96,119,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3671,-1,0.0019775706,0.99802244
3672,Teratology,0,1,0,10,"Teratology 4:15-24, 1971).",12852481_3,-1,-1,-1,3672,-1,0.0045705563,0.9954294
3673,ASA,4,5,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,-1,-1,-1,3673,-1,0.22533888,0.7746611
3674,SD,12,13,80,82,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3674,-1,0.022125645,0.97787434
3675,ASA,18,19,108,111,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3675,-1,0.9973974,0.0026025428
3676,malformation,33,34,163,175,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3676,-1,0.0013346882,0.99866533
3677,SD,43,44,247,249,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3677,-1,0.010383531,0.9896165
3678,gastrointestinal toxicity,53,55,297,322,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3678,-1,0.0012435107,0.9987565
3679,malformations,61,62,364,377,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3679,-1,0.0014162874,0.9985837
3680,ASA,63,64,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3680,-1,0.9964007,0.0035992379
3681,ASA,2,3,9,12,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3681,-1,0.99684024,0.0031597323
3682,SD,76,77,237,239,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3682,-1,0.017092174,0.98290783
3683,NSAIDs,7,8,50,56,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3683,-1,0.99748117,0.0025188087
3684,ventricular septal defects,9,12,64,90,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3684,-1,0.0031245605,0.9968754
3685,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3685,-1,0.0029174027,0.99708253
3686,midline defects,16,18,102,117,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3686,-1,0.0021774014,0.99782264
3687,MDs,19,20,119,122,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3687,-1,0.0018703172,0.99812967
3688,diaphragmatic hernia,24,26,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3688,-1,0.0022381577,0.99776185
3689,DH,27,28,158,160,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3689,-1,0.0033356529,0.99666435
3690,MDs,30,31,163,166,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3690,-1,0.001678976,0.998321
3691,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3691,-1,0.0020675529,0.99793243
3692,malformations,53,54,254,267,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3692,-1,0.0019312716,0.99806875
3693,ASA,57,58,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3693,-1,0.99725705,0.0027429853
3694,malformations,62,63,321,334,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3694,-1,0.001712462,0.9982875
3695,DH,5,6,24,26,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3695,-1,0.024667563,0.97533244
3696,MD,7,8,28,30,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3696,-1,0.025671571,0.9743284
3697,VSD,10,11,36,39,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3697,-1,0.005708262,0.9942918
3698,VSD,0,1,0,3,VSD also was noted following treatment on GD 11.,12852481_10,-1,-1,-1,3698,-1,0.0016986706,0.99830127
3699,contrast,1,2,3,11,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3699,-1,0.025629604,0.97437036
3700,DH,3,4,13,15,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3700,-1,0.002034699,0.99796534
3701,MD,5,6,20,22,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3701,-1,0.0017155927,0.9982844
3702,VSD,21,22,101,104,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3702,-1,0.0026441866,0.9973558
3703,developmental anomalies,6,8,39,62,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3703,-1,0.0014786603,0.9985214
3704,SD,11,12,82,84,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3704,-1,0.0076660123,0.992334
3705,VSD,19,20,123,126,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3705,-1,0.001650817,0.9983492
3706,SD,22,23,134,136,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3706,-1,0.005161782,0.9948382
3707,hydrocephalus,25,26,146,159,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3707,-1,0.00092023815,0.9990797
3708,malformations,2,3,15,28,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3708,-1,0.0011581513,0.9988418
3709,ASA,6,7,47,50,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3709,-1,0.99740195,0.0025981192
3710,malformations,17,18,85,98,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3710,-1,0.0016789096,0.9983211
3711,ASA,38,39,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3711,-1,0.9970048,0.0029951418
3713,flumazenil,6,7,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,-1,3713,-1,0.99875474,0.0012452881
3715,Flumazenil,1,2,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3715,-1,0.99830997,0.0016900405
3718,flumazenil,21,22,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3718,-1,0.9985802,0.001419827
3719,Flumazenil,0,1,0,10,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3719,-1,0.99864763,0.0013524025
3720,mg,6,7,28,30,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3720,-1,0.69930583,0.30069414
3723,meperidine,41,42,201,211,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3723,-1,0.99876595,0.0012340925
3725,flumazenil,10,11,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,-1,-1,-1,3725,-1,0.9985587,0.0014412715
3726,Flumazenil,0,1,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,-1,-1,-1,3726,-1,0.9984621,0.0015379011
3727,nausea and vomiting,6,9,37,56,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3727,-1,0.0012540688,0.9987459
3728,flumazenil,11,12,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3728,-1,0.9985777,0.0014223388
3731,Flumazenil,0,1,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,-1,-1,-1,3731,-1,0.99864393,0.001356088
3740,n,4,5,19,20,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3740,-1,0.11647676,0.8835232
3742,mg,46,47,198,200,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3742,-1,0.8984179,0.10158212
3747,MPEP,3,4,26,30,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,-1,3747,-1,0.9951114,0.0048885923
3755,h,25,26,143,144,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,-1,-1,-1,3755,-1,0.09061673,0.9093833
3757,MPEP,8,9,70,74,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,-1,-1,-1,3757,-1,0.9958263,0.0041737095
3760,MPEP,2,3,9,13,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3760,-1,0.9945109,0.0054890374
3764,veratridine,37,38,215,226,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3764,-1,0.9987723,0.0012277049
3767,MPEP,0,1,0,4,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,-1,-1,-1,3767,-1,0.9964257,0.003574289
3769,MPEP,12,13,65,69,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,-1,-1,3769,-1,0.99729234,0.0027076246
3771,MPEP,3,4,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,-1,3771,-1,0.9972715,0.0027284927
3775,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,-1,-1,3775,-1,0.0012608969,0.99873906
3778,fluvoxamine,14,15,120,131,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,-1,-1,-1,3778,-1,0.99889934,0.0011005925
3791,renal disease,12,14,97,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,-1,-1,3791,-1,0.0010880517,0.998912
3795,psychiatric disorders,14,16,108,129,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,-1,-1,-1,3795,-1,0.0011003782,0.9988996
3797,drug dependence,17,19,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,-1,-1,3797,-1,0.030801216,0.96919876
3802,Allopregnanolone,0,1,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3802,-1,0.9982488,0.0017512367
3803,pregnanolone,5,6,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3803,-1,0.9982153,0.0017847465
3804,ganaxolone,10,11,112,122,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3804,-1,0.9985744,0.0014256572
3805,allopregnanolone,16,17,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3805,-1,0.99749243,0.0025075818
3810,allopregnanolone,16,17,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3810,-1,0.9986077,0.0013923476
3811,ganaxolone,18,19,122,132,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3811,-1,0.99862075,0.0013792515
3812,Allopregnanolone,0,1,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3812,-1,0.99848974,0.0015102784
3813,pregnanolone,2,3,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3813,-1,0.9984902,0.0015097535
3814,ganaxolone,6,7,43,53,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3814,-1,0.99870276,0.0012972772
3821,renal insufficiency,15,17,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,-1,3821,-1,0.0009814949,0.99901855
3823,mg,14,15,78,80,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3823,-1,0.92474717,0.075252816
3824,contrast material,24,26,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3824,-1,0.81725055,0.1827494
3825,contrast material,11,13,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,-1,-1,-1,3825,-1,0.8710211,0.12897897
3826,Renal function significantly deteriorated,0,4,0,41,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3826,-1,0.0018424551,0.99815756
3828,p,11,12,83,84,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3828,-1,0.11430689,0.8856931
3830,h,37,38,180,181,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3830,-1,0.030195283,0.9698047
3831,Renal failure,0,2,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3831,-1,0.00092247996,0.99907756
3832,weight loss,5,7,34,45,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3832,-1,0.0016304076,0.99836963
3838,blood coagulation factors,14,17,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,-1,3838,-1,0.022345372,0.97765464
3842,hypercoagulability,11,12,64,82,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,-1,-1,-1,3842,-1,0.0010538854,0.99894613
3843,myocardial infarction,6,8,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,-1,3843,-1,0.0009715089,0.99902844
3844,retinopathy,3,4,22,33,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3844,-1,0.0010203809,0.9989796
3845,thrombophlebitis,14,15,91,107,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3845,-1,0.0008660989,0.9991339
3846,thrombophlebitis,4,5,29,45,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3846,-1,0.0007956841,0.99920434
3847,contraceptive,10,11,74,87,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3847,-1,0.9966898,0.0033101721
3848,thromboembolic episodes,9,11,72,95,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,-1,-1,-1,3848,-1,0.0009850176,0.999015
3855,mg,28,29,134,136,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3855,-1,0.899299,0.100701004
3856,rauwolscine,34,35,151,162,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3856,-1,0.99832624,0.0016737091
3857,mg,37,38,166,168,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3857,-1,0.90571696,0.09428302
3859,MAP,16,17,94,97,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,-1,-1,3859,-1,0.035327658,0.9646723
3860,MAP,2,3,10,13,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3860,-1,0.010434303,0.98956573
3862,MAP,17,18,88,91,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3862,-1,0.012588612,0.98741144
3863,rauwolscine,20,21,97,108,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3863,-1,0.99823356,0.0017664706
3864,MAP,24,25,122,125,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3864,-1,0.014564563,0.9854354
3867,MAP,17,18,97,100,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3867,-1,0.003393952,0.9966061
3868,n,19,20,102,103,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3868,-1,0.069407925,0.93059206
3869,rauwolscine,31,32,142,153,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3869,-1,0.99798596,0.0020140111
3870,MAP,38,39,169,172,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3870,-1,0.00299221,0.9970078
3871,n,40,41,174,175,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3871,-1,0.08311708,0.91688293
3873,mg,13,14,60,62,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,-1,3873,-1,0.8765818,0.123418204
3874,MAP,0,1,0,3,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3874,-1,0.011485762,0.98851424
3876,n,18,19,95,96,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3876,-1,0.12777287,0.87222713
3879,mg,23,24,138,140,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,-1,-1,3879,-1,0.88034457,0.11965544
3880,rauwolscine,4,5,30,41,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3880,-1,0.9983473,0.0016527679
3881,mg,7,8,45,47,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3881,-1,0.8773353,0.1226647
3883,MAP,20,21,111,114,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3883,-1,0.0152280005,0.984772
3884,n,27,28,126,127,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3884,-1,0.14359778,0.8564022
3885,MAP,39,40,180,183,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3885,-1,0.01503791,0.9849621
3887,cirazoline,11,12,64,74,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3887,-1,0.998752,0.0012480167
3888,Abbott-53693,25,26,129,141,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3888,-1,0.99527377,0.0047262493
3892,cirazoline,7,8,44,54,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3892,-1,0.9986975,0.0013024495
3894,n,16,17,103,104,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3894,-1,0.052456424,0.94754356
3895,n,27,28,144,145,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3895,-1,0.04689411,0.95310587
3896,Abbott-53693,9,10,42,54,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,-1,3896,-1,0.9972293,0.0027707587
3901,increase in locomotor activity,6,10,49,79,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,-1,3901,-1,0.0021912805,0.99780875
3902,increase in locomotor activity,8,12,57,87,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,-1,3902,-1,0.002228222,0.9977718
3905,physostigmine,10,11,84,97,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,-1,-1,3905,-1,0.9985734,0.0014266255
3906,contrast,1,2,3,11,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3906,-1,0.16690493,0.83309513
3907,methscopolamine,4,5,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3907,-1,0.99843043,0.0015694981
3908,neostigmine,6,7,38,49,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3908,-1,0.9985794,0.0014206296
3923,renal failure,35,37,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,-1,-1,3923,-1,0.0009450895,0.99905497
3928,Li,15,16,102,104,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,-1,-1,-1,3928,-1,0.99354386,0.0064561944
3931,systolic hypertension,5,7,36,57,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,-1,-1,3931,-1,0.0010767524,0.99892324
3933,renal failure,6,8,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,-1,-1,3933,-1,0.0008068791,0.99919313
3936,rise in blood pressure,4,8,23,45,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,-1,-1,-1,3936,-1,0.0016558005,0.9983442
3939,arterial systolic hypertension,21,24,129,159,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,-1,-1,3939,-1,0.0014420431,0.998558
3948,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3948,-1,0.0014009678,0.998599
3949,fusidic acid,6,8,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3949,-1,0.99839157,0.0016084083
3950,cyclosporin,16,17,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3950,-1,0.99822086,0.001779074
3951,Fusidic acid,0,2,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3951,-1,0.99820054,0.0017994231
3952,cyclosporin,14,15,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3952,-1,0.99833006,0.0016699528
3953,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3953,-1,0.0016882714,0.99831176
3954,fusidic acid,27,29,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3954,-1,0.99847287,0.0015270821
3955,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,-1,-1,3955,-1,0.0018299399,0.99817
3956,Fusidic acid,0,2,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3956,-1,0.9978947,0.0021053685
3957,mg,10,11,54,56,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3957,-1,0.91030747,0.08969255
3958,fusidic acid,10,12,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,-1,-1,-1,3958,-1,0.9983113,0.0016887666
3960,alkaline phosphatases,5,7,30,51,"Biochemically, an increase in alkaline phosphatases was noted in 5 of 8 cases (63%), and the greatest increases were seen in those who had elevated levels prior to treatment.",1420741_8,-1,-1,-1,3960,-1,0.14782459,0.85217535
3961,fusidic acid,8,10,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3961,-1,0.9981248,0.0018752473
3962,Crohn's disease,18,21,103,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3962,-1,0.0017423575,0.9982577
3963,fusidic acid,12,14,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3963,-1,0.9982603,0.001739655
3964,inflammatory bowel disease,19,22,105,131,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3964,-1,0.0014594189,0.99854064
3965,Amnestic syndrome,0,2,0,17,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3965,-1,0.0012528904,0.9987471
3966,propranolol toxicity,4,6,34,54,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3966,-1,0.76382154,0.23617847
3968,propranolol toxicity,12,14,78,98,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,-1,-1,3968,-1,0.7408656,0.25913438
3969,impairment of memory,7,10,50,70,Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.,1423339_2,-1,-1,-1,3969,-1,0.0018393752,0.99816066
3970,drug toxicity,7,9,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,-1,-1,3970,-1,0.037188686,0.9628113
3975,betaxolol,24,25,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,-1,-1,3975,-1,0.9982186,0.0017813396
3976,glaucomatous,1,2,6,18,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,-1,3976,-1,0.0014416703,0.99855834
3982,p,28,29,180,181,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3982,-1,0.11354273,0.88645726
3983,betaxolol,4,5,27,36,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,-1,-1,-1,3983,-1,0.9981592,0.0018407634
3987,LY274614,11,12,100,108,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,-1,-1,3987,-1,0.99717665,0.0028233053
3989,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid",0,6,0,88,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,3989,-1,0.9825973,0.017402673
3990,NMDA,18,19,161,165,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,3990,-1,0.99278426,0.007215708
3994,iprindole,18,19,96,105,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,-1,-1,-1,3994,-1,0.99859864,0.0014013348
3997,dizocilpine,11,12,72,83,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3997,-1,0.9986431,0.0013569561
3998,MK-801,13,14,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3998,-1,0.9961139,0.0038860894
3999,NMDA,19,20,125,129,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3999,-1,0.9969029,0.003097121
4000,LY274614,24,25,147,155,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4000,-1,0.997517,0.0024830631
4001,NMDA,30,31,185,189,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4001,-1,0.9966497,0.0033503536
4002,LY274614,4,5,25,33,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,-1,4002,-1,0.9971981,0.0028018313
4003,LY274614,5,6,19,27,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,-1,-1,-1,4003,-1,0.9975504,0.002449559
4008,LY274614,10,11,64,72,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4008,-1,0.9976841,0.0023159017
4010,LY274614,19,20,119,127,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4010,-1,0.997563,0.002436991
4014,LY274614,24,25,163,171,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,-1,4014,-1,0.9967025,0.0032975415
4018,NMDA,19,20,144,148,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4018,-1,0.9907478,0.009252194
4019,LY274614,23,24,168,176,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4019,-1,0.9973506,0.0026494786
4020,NMDA,26,27,183,187,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4020,-1,0.9905338,0.009466172
4023,penicillins,15,16,110,121,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,-1,4023,-1,0.99683267,0.0031673445
4026,cefotetan,10,11,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,-1,-1,-1,4026,-1,0.9986474,0.0013525814
4027,cefotetan,13,14,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,-1,4027,-1,0.9984285,0.0015715021
4030,hemolytic,9,10,57,66,This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins.,1445986_6,-1,-1,-1,4030,-1,0.0011016236,0.9988984
4032,neurologic sequelae,1,3,21,40,Ketoconazole-induced neurologic sequelae.,14513889_0,-1,-1,-1,4032,-1,0.0012056723,0.9987943
4033,weakness of extremities,4,7,29,52,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4033,-1,0.0014988455,0.9985012
4034,legs paralysis,8,10,54,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4034,-1,0.0013384072,0.99866164
4035,dysarthria,11,12,70,80,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4035,-1,0.0010310812,0.99896896
4037,h,15,16,94,95,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4037,-1,0.0375732,0.9624268
4038,mg ketoconazole,20,22,119,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4038,-1,0.99313956,0.0068604206
4039,h.,6,7,36,38,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,4039,-1,0.041911695,0.9580883
4040,mg ketoconazole,16,18,84,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,4040,-1,0.9934957,0.006504304
4041,adverse drug reactions,9,12,54,76,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,-1,-1,-1,4041,-1,0.0019634578,0.99803656
4045,LIDs,3,4,30,34,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4045,-1,0.0014906697,0.99850935
4046,Parkinson's disease,14,17,92,111,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4046,-1,0.0014416565,0.99855834
4047,PD,18,19,113,115,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4047,-1,0.0014560798,0.998544
4048,LIDs,24,25,155,159,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,-1,4048,-1,0.0014893889,0.99851054
4051,LIDs,41,42,255,259,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,-1,4051,-1,0.0011715507,0.9988285
4052,MPTP,6,7,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,-1,-1,4052,-1,0.99554306,0.0044569764
4056,contrast,1,2,3,11,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4056,-1,0.049753062,0.95024693
4057,MPTP,6,7,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4057,-1,0.99649435,0.0035056097
4059,LIDs,27,28,179,183,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4059,-1,0.0012619591,0.9987381
4063,LIDs,10,11,69,73,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4063,-1,0.0012786996,0.9987213
4065,LIDs,38,39,254,258,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4065,-1,0.0012482896,0.99875176
4066,sugar dependency,3,5,17,33,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,-1,-1,-1,4066,-1,0.11899876,0.8810012
4068,sugar,13,14,85,90,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4068,-1,0.9948925,0.0051075397
4069,drug dependency,24,26,170,185,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4069,-1,0.019214496,0.9807854
4071,sucrose,30,31,155,162,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4071,-1,0.995926,0.004074001
4072,h,37,38,193,194,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4072,-1,0.3308147,0.66918534
4073,h,41,42,213,214,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4073,-1,0.12452961,0.87547046
4075,sucrose,6,7,40,47,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4075,-1,0.9958385,0.004161435
4076,hyperactive,10,11,62,73,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4076,-1,0.0026188616,0.99738115
4078,sucrose,25,26,151,158,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4078,-1,0.9972525,0.0027475203
4082,sucrose,50,51,298,305,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4082,-1,0.99685127,0.0031487995
4087,hemorrhagic cystitis,10,12,73,93,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,-1,-1,-1,4087,-1,0.000871259,0.99912876
4088,Hemorrhagic cystitis,2,4,5,25,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4088,-1,0.0009849422,0.9990151
4089,HC,5,6,27,29,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4089,-1,0.002081124,0.9979189
4091,IFS,16,17,90,93,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4091,-1,0.18216318,0.8178368
4094,HC,21,22,130,132,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,-1,4094,-1,0.004198576,0.9958014
4096,h,33,34,122,123,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4096,-1,0.30054408,0.6994559
4097,IFS,41,42,155,158,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4097,-1,0.9468185,0.05318158
4103,h,4,5,26,27,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,-1,-1,4103,-1,0.04684392,0.9531561
4106,IFS,26,27,146,149,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,-1,-1,-1,4106,-1,0.17394435,0.82605565
4107,IFS,13,14,88,91,"In addition, it almost abolished the macroscopic and microscopic alterations induced by IFS.",14633084_7,-1,-1,-1,4107,-1,0.9314925,0.06850746
4113,HC,12,13,90,92,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,-1,4113,-1,0.006002631,0.99399734
4117,HC,23,24,125,127,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,-1,-1,-1,4117,-1,0.022424443,0.97757554
4118,erythema nodosum,3,5,33,49,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4118,-1,0.0012039618,0.998796
4119,acute promyelocytic leukemia,8,11,67,95,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4119,-1,0.0011720741,0.9988279
4120,Erythema nodosum,0,2,0,16,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4120,-1,0.001313019,0.99868697
4121,ATRA,8,9,59,63,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4121,-1,0.10690743,0.8930926
4122,acute promyelocytic leukemia,11,14,69,97,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4122,-1,0.0013291884,0.9986708
4123,APL,15,16,99,102,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4123,-1,0.0013395904,0.99866045
4124,APL,6,7,39,42,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4124,-1,0.0014393582,0.9985606
4125,erythema nodosum,9,11,57,73,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4125,-1,0.0013586333,0.9986413
4126,ATRA,12,13,81,85,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4126,-1,0.9893885,0.0106114205
4128,painful erythematous nodules,4,7,30,58,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4128,-1,0.001831756,0.99816823
4129,ATRA,23,24,133,137,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4129,-1,0.99639314,0.0036068128
4130,erythema nodosum,10,12,60,76,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,-1,-1,-1,4130,-1,0.0016547533,0.99834526
4133,skin lesions,5,7,31,43,Fever subsided rapidly and the skin lesions regressed completely.,14648024_6,-1,-1,-1,4133,-1,0.0019228919,0.99807715
4134,ATRA,8,9,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,-1,-1,-1,4134,-1,0.9841232,0.015876831
4135,ATRA,0,1,0,4,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4135,-1,0.0023343584,0.99766564
4136,erythema nodosum,9,11,48,64,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4136,-1,0.0016342696,0.9983657
4138,erythema nodosum,9,11,60,76,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,-1,-1,-1,4138,-1,0.0012254051,0.9987746
4140,amphotericin B,5,7,45,59,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,-1,-1,4140,-1,0.99814546,0.0018546071
4142,congestive heart failure,10,13,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4142,-1,0.0008934031,0.9991066
4143,amphotericin B,19,21,128,142,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4143,-1,0.9981958,0.0018042466
4144,AmB,22,23,144,147,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4144,-1,0.9962878,0.003712129
4145,coccidioidomycosis,26,27,166,184,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4145,-1,0.0060502375,0.9939498
4146,heart failure,4,6,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4146,-1,0.0010129387,0.998987
4147,posaconazole,8,9,69,81,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4147,-1,0.9984681,0.0015318999
4148,AmB.,12,13,102,106,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4148,-1,0.85174483,0.1482552
4150,AmB.,25,26,184,188,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4150,-1,0.8335065,0.16649343
4153,CGRP,12,13,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,-1,-1,-1,4153,-1,0.993234,0.006765972
4156,CGRP,17,18,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4156,-1,0.9931143,0.006885664
4159,5-HT,26,27,168,172,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4159,-1,0.9961909,0.003809033
4163,migraineurs,2,3,15,26,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4163,-1,0.0015004519,0.9984995
4164,without aura,4,6,28,40,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4164,-1,0.001608857,0.9983911
4166,mg,4,5,30,32,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,-1,-1,-1,4166,-1,0.85244536,0.14755468
4170,CGRP,1,2,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4170,-1,0.9962573,0.003742651
4171,P<0.01,6,7,51,57,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4171,-1,0.18934321,0.8106567
4174,migraine headache,13,15,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4174,-1,0.0015439317,0.9984561
4175,P<0.001,17,18,110,117,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4175,-1,0.19411175,0.80588824
4176,CGRP,3,4,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,-1,-1,4176,-1,0.99613935,0.003860682
4179,CGRP,1,2,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4179,-1,0.99641126,0.0035887365
4180,5-HT,8,9,63,67,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4180,-1,0.9887686,0.011231416
4183,P<0.01,6,7,52,58,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,-1,-1,4183,-1,0.11251911,0.8874809
4187,CGRP,7,8,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4187,-1,0.99714226,0.0028577475
4188,migraine headache,17,19,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4188,-1,0.0010920624,0.9989079
4189,CGRP,24,25,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4189,-1,0.9956529,0.0043470976
4191,contrast,1,2,3,11,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4191,-1,0.104470454,0.89552957
4195,CGRP,21,22,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4195,-1,0.99419785,0.0058021224
4197,hemorrhagic cystitis,8,10,78,98,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,-1,-1,-1,4197,-1,0.00089203566,0.9991079
4198,hemorrhagic cystitis,6,8,32,52,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4198,-1,0.0009187375,0.99908125
4200,Wegener's granulomatosis,13,16,89,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4200,-1,0.0034076173,0.99659234
4201,prostaglandin F2 alpha,12,15,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,-1,-1,4201,-1,0.9963403,0.0036596968
4206,hemorrhagic cystitis,17,19,106,126,"In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.",1468485_6,-1,-1,-1,4206,-1,0.0009037331,0.9990963
4207,psychosis,1,2,6,15,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,-1,-1,-1,4207,-1,0.0009768979,0.9990231
4209,psychosis,3,4,19,28,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,-1,-1,-1,4209,-1,0.0009082344,0.99909174
4211,psychosis,8,9,49,58,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4211,-1,0.00095960737,0.9990403
4213,trigeminal neuralgia,13,15,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4213,-1,0.0009485237,0.9990515
4218,convulsants,3,4,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4218,-1,0.0024995727,0.9975005
4219,loreclezole,9,10,57,68,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4219,-1,0.9984567,0.0015432804
4220,valproate,14,15,95,104,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4220,-1,0.9987924,0.0012075118
4221,clonazepam,16,17,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4221,-1,0.9985347,0.0014653514
4222,Loreclezole,0,1,0,11,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,-1,-1,-1,4222,-1,0.99792224,0.002077744
4224,loreclezole,3,4,20,31,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4224,-1,0.99862945,0.0013706257
4225,valproate,9,10,49,58,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4225,-1,0.9988637,0.0011363107
4226,clonazepam,11,12,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4226,-1,0.998629,0.0013710539
4229,BAY k-8644,9,11,74,84,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4229,-1,0.9971591,0.0028408815
4231,loreclezole,24,25,161,172,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4231,-1,0.9984366,0.0015633121
4232,valproate,30,31,204,213,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4232,-1,0.9986676,0.0013323798
4235,BAY k-8644,9,11,50,60,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4235,-1,0.9965544,0.0034456388
4236,loreclezole,16,17,100,111,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4236,-1,0.99848336,0.0015166585
4237,clonazepam,19,20,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4237,-1,0.9986443,0.0013557599
4238,loreclezole,10,11,67,78,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4238,-1,0.99843055,0.0015694258
4240,doxorubicin nephrosis,10,12,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,-1,4240,-1,0.04812454,0.95187545
4243,tubular lesions,13,15,113,128,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,-1,-1,-1,4243,-1,0.0011896085,0.9988104
4244,mitochondrial injury,6,8,38,58,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,-1,-1,-1,4244,-1,0.007239762,0.9927603
4246,mg,10,11,59,61,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,-1,-1,-1,4246,-1,0.8869389,0.11306104
4247,h,11,12,58,59,Additional rats received a single dose either 6 days or 2 h prior to euthanasia.,14736955_4,-1,-1,-1,4247,-1,0.13810445,0.86189556
4248,Glomerular and tubular injury,0,4,0,29,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,-1,-1,4248,-1,0.0012047397,0.9987953
4250,glomerular and tubular lesions,9,13,47,77,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4250,-1,0.0011963403,0.9988036
4252,NADH,18,19,117,121,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4252,-1,0.9926267,0.007373322
4253,citrate,28,29,181,188,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4253,-1,0.9941719,0.0058280383
4254,tubular lesions,9,11,39,54,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4254,-1,0.0014221314,0.99857783
4255,glomerular lesions,16,18,79,97,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4255,-1,0.0019009989,0.998099
4256,tubular injury,6,8,34,48,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4256,-1,0.0014726494,0.9985273
4259,renal lesions,28,30,221,234,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,-1,-1,4259,-1,0.0012940352,0.998706
4264,sexually dysfunctional,1,3,9,31,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4264,-1,0.0015590043,0.99844104
4269,mg,30,31,207,209,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4269,-1,0.9103278,0.089672215
4270,mg ephedrine,16,18,119,131,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,-1,-1,-1,4270,-1,0.9937431,0.00625693
4273,anastrozole,7,8,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4273,-1,0.99882513,0.0011748945
4275,n=94,17,18,97,101,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4275,-1,0.06536284,0.9346372
4277,n=35,28,29,147,151,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4277,-1,0.03742356,0.9625764
4278,p=0.032,16,17,88,95,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4278,-1,0.13953467,0.86046535
4279,p=0.026,27,28,142,149,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4279,-1,0.17394504,0.826055
4281,oestrogen,9,10,56,65,"Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women.",14745746_7,-1,-1,-1,4281,-1,0.99741507,0.0025848767
4283,leg cramps,13,15,85,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,-1,4283,-1,0.0014242646,0.9985757
4286,neurological complications,10,12,80,106,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,-1,-1,4286,-1,0.0009989538,0.9990011
4294,heart failure,19,21,148,161,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,-1,4294,-1,0.00091411977,0.9990859
4295,propafenone overdose,5,7,57,77,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4295,-1,0.62634486,0.37365517
4296,Ebstein's anomaly,12,15,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4296,-1,0.0067895725,0.9932105
4297,Ebstein's anomaly,13,16,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4297,-1,0.009791446,0.9902085
4299,cyanosis,36,37,245,253,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4299,-1,0.0011014788,0.9988985
4300,propafenone overdose,26,28,146,166,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,-1,-1,4300,-1,0.56090665,0.43909335
4301,biventricular dysfunction,3,5,17,42,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,-1,-1,4301,-1,0.00092244294,0.99907756
4303,contrast,12,13,74,82,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,-1,-1,-1,4303,-1,0.75925577,0.24074419
4304,cholestatic jaundice,1,3,20,40,Methimazole-induced cholestatic jaundice.,14982270_0,-1,-1,-1,4304,-1,0.001004353,0.9989956
4305,Methimazole,0,1,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,-1,-1,-1,4305,-1,0.99836403,0.0016360258
4307,itching,7,8,44,51,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4307,-1,0.0012592382,0.99874073
4308,methimazole,12,13,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4308,-1,0.9988575,0.0011424647
4309,mg,15,16,92,94,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4309,-1,0.9436255,0.05637452
4311,mg,22,23,120,122,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4311,-1,0.9299871,0.07001299
4314,emergency department,4,6,17,37,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4314,-1,0.0074026883,0.99259734
4315,icterus,14,15,74,81,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4315,-1,0.001127202,0.9988728
4317,hyperbilirubinemia,19,20,97,115,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4317,-1,0.0010481467,0.9989518
4321,methimazole,19,20,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,-1,-1,-1,4321,-1,0.9987418,0.0012582662
4322,cholestatic jaundice,18,20,95,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,-1,-1,-1,4322,-1,0.0009355017,0.9990645
4323,methimazole,19,20,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,-1,-1,-1,4323,-1,0.9986767,0.0013232064
4324,vascular dysfunctions,20,22,154,175,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4324,-1,0.0015743678,0.9984256
4325,cluster headache,23,25,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4325,-1,0.0014494143,0.9985506
4326,Cluster headache,0,2,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4326,-1,0.0013869982,0.998613
4327,dysfunctions,7,8,55,67,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4327,-1,0.0014484292,0.99855155
4328,vascular disturbances,12,14,102,123,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4328,-1,0.0013820666,0.9986179
4330,mm,5,6,18,20,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4330,-1,0.87699044,0.12300964
4331,hexamethonium chloride,8,10,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,-1,-1,-1,4331,-1,0.99843496,0.0015650146
4332,increases in,2,4,11,23,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4332,-1,0.01026662,0.9897334
4334,mm,17,18,106,108,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4334,-1,0.9157962,0.08420385
4335,mm,30,31,152,154,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4335,-1,0.898784,0.10121605
4337,cluster headache,9,11,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,-1,-1,-1,4337,-1,0.001349917,0.99865013
4339,neuropathological damages,5,7,54,79,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,-1,-1,4339,-1,0.0010803692,0.9989196
4340,organophosphorus,1,2,5,21,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4340,-1,0.82986534,0.17013471
4341,OP,3,4,23,25,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4341,-1,0.97063816,0.02936182
4342,diisopropylfluorophosphate,7,8,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4342,-1,0.9963955,0.0036044263
4343,DFP,9,10,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4343,-1,0.9967673,0.003232709
4344,sarin,12,13,74,79,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4344,-1,0.9968016,0.0031983245
4345,soman,14,15,84,89,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4345,-1,0.9977397,0.0022603634
4347,OPs,4,5,22,25,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4347,-1,0.9287796,0.07122038
4349,ACh,27,28,148,151,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4349,-1,0.9947184,0.0052815997
4350,DFP,14,15,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,-1,4350,-1,0.9922483,0.0077517033
4351,pralidoxime-2-chloride,5,6,35,57,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4351,-1,0.99676216,0.0032377678
4352,2PAM,7,8,59,63,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4352,-1,0.9920283,0.007971756
4354,N(6)-cyclopentyl adenosine,26,28,154,180,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4354,-1,0.99607015,0.003929871
4355,CPA,29,30,182,185,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4355,-1,0.99750346,0.002496533
4356,dizocilpine maleate,39,41,228,247,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4356,-1,0.9980142,0.0019857867
4357,hydrogen maleate,44,46,257,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4357,-1,0.99502784,0.004972122
4358,atropine sulfate,58,60,335,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4358,-1,0.9984024,0.0015976037
4359,DFP,75,76,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4359,-1,0.9948049,0.0051950896
4360,atropine sulfate,4,6,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4360,-1,0.9983381,0.001661908
4361,olive oil,11,13,64,73,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4361,-1,0.9950117,0.0049883965
4362,DFP,18,19,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4362,-1,0.16088438,0.8391156
4363,h,6,7,35,36,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4363,-1,0.03872273,0.96127725
4364,DFP,12,13,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4364,-1,0.99693835,0.0030616128
4366,CPA,1,2,5,8,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4366,-1,0.9951479,0.0048520956
4368,2PAM,5,6,22,26,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4368,-1,0.9970644,0.0029355935
4370,DFP toxicity,8,10,63,75,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,-1,-1,-1,4370,-1,0.087216556,0.9127835
4371,CPA,3,4,15,18,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4371,-1,0.9866151,0.013384958
4373,2PAM,7,8,33,37,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4373,-1,0.9967615,0.003238559
4377,DFP,26,27,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4377,-1,0.9829091,0.017090924
4378,Atrial fibrillation,0,2,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4378,-1,0.0013429475,0.998657
4379,gastric lymphoma,10,12,79,95,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4379,-1,0.0021401981,0.9978598
4380,myotonic dystrophy,16,18,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4380,-1,0.0013246387,0.9986753
4381,Steinert's disease).The,19,22,134,157,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4381,-1,0.02605922,0.97394073
4382,gastric lymphoma,30,32,222,238,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4382,-1,0.0019946727,0.99800533
4383,myotonic dystrophy,33,35,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4383,-1,0.0013043315,0.9986957
4384,muscular dystrophy,42,44,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4384,-1,0.0013712752,0.99862874
4385,atrial fibrillation,47,49,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4385,-1,0.0012988755,0.9987011
4386,Atrial fibrillation,0,2,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,-1,-1,4386,-1,0.0011017706,0.99889815
4392,dilevalol,7,8,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4392,-1,0.9982901,0.0017098857
4393,dilevalol,15,16,97,106,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4393,-1,0.9979722,0.0020278369
4396,dilevalol,19,20,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4396,-1,0.9984769,0.0015230391
4397,dilevalol,31,32,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4397,-1,0.9984269,0.0015730979
4398,dilevalol,20,21,119,128,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,-1,-1,-1,4398,-1,0.99822575,0.0017742857
4399,dilevalol,8,9,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,-1,-1,4399,-1,0.99835974,0.0016402557
4400,dilevalol,16,17,120,129,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,-1,4400,-1,0.99792224,0.0020777676
4402,nephrotic syndrome,12,14,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,-1,-1,-1,4402,-1,0.00092071394,0.9990792
4403,Nephrotic syndrome,0,2,0,18,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,-1,-1,4403,-1,0.00096282235,0.99903715
4407,Na,4,5,32,34,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,-1,-1,-1,4407,-1,0.994389,0.0056109643
4409,puromycin aminonucleoside,8,10,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4409,-1,0.9977939,0.0022061267
4410,PAN,11,12,74,77,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4410,-1,0.9949019,0.0050981203
4411,PAN,4,5,14,17,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4411,-1,0.90595245,0.09404756
4413,hypoalbuminemia,10,11,61,76,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4413,-1,0.0010245172,0.9989755
4416,contrast,1,2,3,11,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,-1,4416,-1,0.09512892,0.90487105
4418,nephrotic syndrome,39,41,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,-1,4418,-1,0.0010577475,0.9989423
4420,behavioral disorder,2,4,23,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,-1,-1,-1,4420,-1,0.0010958674,0.9989041
4422,behavioral deterioration,4,6,22,46,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4422,-1,0.0010020498,0.998998
4423,hyperkinesis,8,9,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4423,-1,0.00091220386,0.9990878
4425,sleeping difficulties,13,15,85,106,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4425,-1,0.0015453846,0.9984546
4427,pyridoxine hydrochloride,6,8,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,-1,-1,-1,4427,-1,0.9982141,0.0017859022
4430,niacinamide,7,8,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,-1,-1,-1,4430,-1,0.9984383,0.0015616444
4433,hyperkinesis,10,11,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,-1,-1,4433,-1,0.0009147427,0.9990853
4434,pyridoxal,3,4,13,22,The level of pyridoxal in the blood was normal during the periods of relapse.,150790_6,-1,-1,-1,4434,-1,0.9978618,0.0021382582
4435,kynurenine,7,8,43,53,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4435,-1,0.99847883,0.0015211914
4436,tryptophan,10,11,65,75,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4436,-1,0.9975204,0.0024796454
4438,Parkinson's disease,15,18,106,125,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4438,-1,0.0014661596,0.99853384
4439,PD,19,20,127,129,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4439,-1,0.0013094486,0.99869055
4440,PD,8,9,62,64,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,-1,-1,-1,4440,-1,0.0012390758,0.99876094
4441,PD,12,13,70,72,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4441,-1,0.0013017147,0.99869823
4444,bradykinesia,31,32,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4444,-1,0.00094153034,0.9990584
4445,bradykinesia,3,4,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,-1,-1,4445,-1,0.0007724248,0.9992275
4448,dyskinetic,9,10,59,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,-1,-1,4448,-1,0.0014946281,0.99850535
4451,status epilepticus,8,10,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4451,-1,0.0011281677,0.99887186
4452,SE,11,12,75,77,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4452,-1,0.0012430276,0.998757
4455,SE,40,41,276,278,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,-1,4455,-1,0.003824095,0.9961759
4456,SE,1,2,3,5,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4456,-1,0.013132747,0.9868672
4459,SE,28,29,170,172,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,-1,4459,-1,0.037186127,0.96281385
4462,Urinary bladder cancer,0,3,0,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4462,-1,0.0016396631,0.99836034
4463,Wegener's granulomatosis,4,7,26,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4463,-1,0.0030700413,0.99692994
4467,Wegener's granulomatosis,21,24,121,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,-1,-1,4467,-1,0.0035322336,0.9964677
4468,Wegener's granulomatosis,17,20,103,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,-1,-1,-1,4468,-1,0.0048181885,0.99518174
4474,Wegener's granulomatosis,10,13,58,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4474,-1,0.007951946,0.9920481
4476,Wegener's granulomatosis,30,33,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4476,-1,0.00727872,0.99272126
4478,n,11,12,70,71,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4478,-1,0.075388186,0.9246118
4479,n,18,19,92,93,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4479,-1,0.08399866,0.9160013
4483,Wegener's granulomatosis,17,20,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4483,-1,0.0052324818,0.99476755
4485,Wegener's granulomatosis,42,45,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4485,-1,0.005896181,0.99410385
4488,Wegener's granulomatosis,35,38,226,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,-1,4488,-1,0.0041020485,0.99589795
4495,rilmenidine,8,9,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,-1,4495,-1,0.9987644,0.0012356738
4497,rilmenidine,4,5,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4497,-1,0.9986368,0.0013632085
4499,h,15,16,107,108,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4499,-1,0.012996994,0.987003
4501,contrast,10,11,76,84,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4501,-1,0.08265695,0.9173431
4502,rilmenidine hypotension,15,17,101,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4502,-1,0.6874318,0.31256822
4504,reduced locomotor activity,16,19,106,132,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,-1,4504,-1,0.0028579033,0.997142
4508,left ventricular systolic and diastolic dysfunction,2,8,18,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4508,-1,0.001435377,0.99856466
4509,epinephrine overdose,12,14,99,119,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4509,-1,0.13174532,0.8682547
4512,contrast,1,2,3,11,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4512,-1,0.051210064,0.94878995
4513,myocardial dysfunction,5,7,24,46,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4513,-1,0.0010391626,0.99896085
4515,mg,11,12,73,75,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4515,-1,0.88698524,0.113014765
4517,myocardial stunning,15,17,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4517,-1,0.0012202233,0.99877983
4518,left ventricular systolic and diastolic dysfunction,30,36,206,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4518,-1,0.0028590153,0.997141
4519,myocardial necrosis,44,46,309,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4519,-1,0.0016381356,0.9983619
4520,tincture of Crataegus,3,6,27,48,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4520,-1,0.017951727,0.9820483
4521,myocardial infarction,8,10,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4521,-1,0.0010240122,0.998976
4522,Tincture of Crataegus,0,3,0,21,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4522,-1,0.1187297,0.88127035
4523,TCR,4,5,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4523,-1,0.3000832,0.69991684
4524,berries of hawthorn,12,15,57,76,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4524,-1,0.9413021,0.058697835
4525,TCR,11,12,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4525,-1,0.9771388,0.022861127
4526,myocardial infarction,15,17,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4526,-1,0.0010264522,0.9989736
4527,TCR,2,3,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4527,-1,0.8818653,0.11813467
4528,bodyweight,11,12,47,57,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4528,-1,0.15378171,0.8462182
4529,mg,37,38,206,208,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4529,-1,0.7483526,0.25164744
4530,h,50,51,254,255,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4530,-1,0.06498198,0.93501806
4531,TCR,0,1,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,-1,4531,-1,0.9725816,0.02741833
4534,TCR,6,7,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,-1,-1,-1,4534,-1,0.9816108,0.018389279
4536,valdecoxib,6,7,51,61,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4536,-1,0.9979225,0.0020775096
4539,thrombotic events,9,11,57,74,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4539,-1,0.001079862,0.9989202
4540,NSAIDs,24,25,192,198,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4540,-1,0.99198955,0.008010489
4541,valdecoxib,6,7,43,53,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4541,-1,0.99797267,0.002027314
4542,osteoarthritis,17,18,122,136,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4542,-1,0.0010237801,0.99897623
4546,valdecoxib,23,24,160,170,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4546,-1,0.9981604,0.0018396204
4547,mg,28,29,178,180,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4547,-1,0.9138149,0.0861851
4548,NSAID,33,34,202,207,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4548,-1,0.9956905,0.0043094587
4550,mg,37,38,223,225,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4550,-1,0.9441963,0.055803727
4552,mg,42,43,245,247,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4552,-1,0.94801986,0.051980082
4553,naproxen,46,47,256,264,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4553,-1,0.9987412,0.0012588662
4554,mg,48,49,269,271,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4554,-1,0.92136055,0.078639425
4555,osteoarthritis,57,58,313,327,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4555,-1,0.0019464338,0.99805355
4557,n,11,12,63,64,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4557,-1,0.058040965,0.9419591
4558,mg,25,26,109,111,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4558,-1,0.9810378,0.018962188
4560,n,30,31,128,129,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4560,-1,0.08421498,0.915785
4562,n,39,40,163,164,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4562,-1,0.07063268,0.9293673
4563,thrombotic events,5,7,42,59,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4563,-1,0.0010796572,0.9989203
4564,valdecoxib,10,11,77,87,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4564,-1,0.99816614,0.0018338969
4565,NSAIDs,12,13,89,95,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4565,-1,0.9971746,0.002825414
4566,thrombotic events,4,6,20,37,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4566,-1,0.0010258128,0.9989742
4567,valdecoxib,11,12,64,74,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4567,-1,0.9981768,0.0018231987
4571,valdecoxib,23,24,115,125,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4571,-1,0.9981719,0.001828105
4572,NSAIDs,31,32,142,148,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4572,-1,0.9973417,0.0026582717
4574,valdecoxib,17,18,91,101,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,-1,4574,-1,0.9984097,0.0015902877
4575,mg,10,11,66,68,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4575,-1,0.96140087,0.038599145
4576,mg,19,20,107,109,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4576,-1,0.933372,0.06662806
4577,valdecoxib,22,23,117,127,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4577,-1,0.99838114,0.0016189166
4578,thrombotic events,32,34,184,201,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4578,-1,0.00097266585,0.9990274
4579,NSAIDs,37,38,227,233,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4579,-1,0.9972385,0.002761446
4580,osteoarthritis,41,42,248,262,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4580,-1,0.0011855604,0.99881446
4582,Hypersensitivity myocarditis,0,2,0,28,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4582,-1,0.0011447858,0.99885523
4583,hypertrophic cardiomyopathy,3,5,42,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4583,-1,0.0011720307,0.998828
4584,eosinophilic myocarditis,7,9,39,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4584,-1,0.0010235576,0.99897647
4585,hypertrophic cardiomyopathy,10,12,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4585,-1,0.001070184,0.9989298
4586,hypertrophic cardiomyopathy,8,10,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4586,-1,0.00090751075,0.99909246
4587,biventricular failure,14,16,93,114,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4587,-1,0.0011450959,0.9988549
4589,left ventricular dysfunction,7,10,50,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,-1,-1,4589,-1,0.0015203819,0.99847966
4591,hypertrophic cardiomyopathy,9,11,52,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,-1,-1,4591,-1,0.0010192917,0.9989807
4594,eosinophilic myocarditis,4,6,24,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,-1,-1,4594,-1,0.0015057436,0.99849427
4596,eosinophilic,7,8,40,52,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,-1,-1,4596,-1,0.0013818541,0.9986181
4599,Eosinophilic myocarditis,0,2,0,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,-1,-1,-1,4599,-1,0.0010451031,0.9989549
4603,Idiopathic subjective tinnitus,0,3,0,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4603,-1,0.0017720239,0.998228
4604,IST,4,5,32,35,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4604,-1,0.0027309875,0.997269
4605,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,-1,4605,-1,0.0058011515,0.9941988
4611,vertigo,9,10,52,59,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4611,-1,0.0012534084,0.9987465
4614,lead,43,44,247,251,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4614,-1,0.12340445,0.8765955
4617,hypolocomotion,14,15,111,125,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,-1,-1,4617,-1,0.0010576285,0.99894243
4624,hypolocomotion,12,13,76,90,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,-1,-1,-1,4624,-1,0.0011179349,0.9988821
4629,hypolocomotion,18,19,118,132,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,-1,-1,-1,4629,-1,0.0011503898,0.99884963
4632,intracranial bleeding,7,9,42,63,"The proportion of patients with major and intracranial bleeding increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.",15276120_2,-1,-1,-1,4632,-1,0.0014088094,0.9985911
4638,SD,7,8,35,37,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4638,-1,0.050376557,0.94962347
4639,mg,14,15,56,58,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4639,-1,0.6034976,0.39650238
4641,mg,34,35,155,157,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4641,-1,0.5537228,0.44627723
4643,mg,9,10,37,39,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,-1,4643,-1,0.30390915,0.6960908
4655,Apamin,0,1,0,6,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4655,-1,0.9983291,0.0016709485
4658,Apamin,0,1,0,6,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4658,-1,0.99778444,0.0022156117
4659,ng,3,4,11,13,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4659,-1,0.8421517,0.1578483
4661,mg,23,24,97,99,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4661,-1,0.4661649,0.5338351
4664,lidocaine toxicity,10,12,66,84,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4664,-1,0.26839006,0.73160994
4665,circulatory depression,18,20,114,136,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4665,-1,0.0008702352,0.99912983
4674,thiotepa,12,13,80,88,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,-1,-1,4674,-1,0.99846447,0.0015355833
4679,congestive heart failure,30,33,238,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4679,-1,0.00094893225,0.99905103
4680,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4680,-1,0.0010145435,0.99898547
4683,diabetes mellitus,60,62,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4683,-1,0.0024167807,0.99758315
4684,anthracyclines,66,67,451,465,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4684,-1,0.9954087,0.0045912433
4685,CHF,15,16,71,74,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,-1,4685,-1,0.0009856604,0.9990144
4688,CHF,7,8,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4688,-1,0.0013892058,0.99861073
4689,CHF,21,22,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4689,-1,0.0012949771,0.998705
4691,CHF,9,10,74,77,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,-1,-1,-1,4691,-1,0.0011330512,0.9988669
4698,obstructive lung disease,10,13,64,88,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,-1,-1,4698,-1,0.0011663479,0.9988337
4707,P,14,15,75,76,Within healthy adults no age-dependency could be found (b = 0.262 mm/year; P = 0.72).,15338796_13,-1,-1,-1,4707,-1,0.13585179,0.8641482
4709,P,15,16,81,82,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,-1,-1,-1,4709,-1,0.1084051,0.8915949
4710,Postural tremor,0,2,0,15,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4710,-1,0.0013925119,0.99860746
4711,P,13,14,86,87,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4711,-1,0.09437777,0.9056223
4716,sexual side effects,3,6,23,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,-1,-1,4716,-1,0.0011661003,0.99883395
4719,male impotence,20,22,135,149,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,-1,-1,-1,4719,-1,0.0016676425,0.9983323
4721,sexual side effects,13,16,70,89,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,-1,-1,-1,4721,-1,0.0025539144,0.99744606
4724,sexual side effects,9,12,54,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,-1,-1,4724,-1,0.0016540249,0.998346
4726,obsessive compulsive disorder,6,9,33,62,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4726,-1,0.001077009,0.998923
4727,trichotillomania,10,11,64,80,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4727,-1,0.002073294,0.9979267
4728,anxiety,12,13,82,89,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4728,-1,0.0011857857,0.9988142
4729,affective disorders,15,17,94,113,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4729,-1,0.0009781041,0.9990219
4730,sexual side effects,19,22,127,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4730,-1,0.0020205614,0.99797946
4737,excessive sweating,5,7,35,53,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4737,-1,0.0013062559,0.99869376
4738,anxiety,9,10,65,72,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4738,-1,0.0017297264,0.9982703
4740,sexual side effects,17,20,100,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,-1,-1,4740,-1,0.0017882669,0.99821174
4743,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,-1,-1,-1,4743,-1,0.0010923586,0.9989077
4744,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,-1,-1,-1,4744,-1,0.0009553464,0.9990446
4748,hemorrhagic cystitis,30,32,202,222,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,-1,4748,-1,0.00079798937,0.9992021
4749,hemorrhagic cystitis,11,13,68,88,"Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.",1545575_4,-1,-1,-1,4749,-1,0.00080794154,0.99919206
4750,contrast,1,2,3,11,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4750,-1,0.015758965,0.98424107
4752,hemorrhagic cystitis,19,21,137,157,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4752,-1,0.00081923004,0.99918073
4753,hemorrhagic cystitis,21,23,121,141,"Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis.",1545575_6,-1,-1,-1,4753,-1,0.0009622538,0.99903774
4754,raloxifene,6,7,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4754,-1,0.99873,0.0012699509
4755,raloxifene,11,12,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4755,-1,0.99855345,0.0014465799
4756,raloxifene,7,8,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,-1,-1,-1,4756,-1,0.9986846,0.0013154047
4759,Raloxifene,6,7,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,-1,4759,-1,0.9985989,0.0014011727
4761,raloxifene,5,6,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,-1,-1,-1,4761,-1,0.99846256,0.0015374128
4762,venous thromboembolism,2,4,18,40,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4762,-1,0.0013518776,0.9986481
4765,endometrial hyperplasia,11,13,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4765,-1,0.0023083736,0.99769163
4767,raloxifene,10,11,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4767,-1,0.99849737,0.0015026138
4768,venous thromboembolism,18,20,100,122,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4768,-1,0.0012666428,0.99873334
4769,raloxifene,3,4,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,-1,-1,-1,4769,-1,0.99851865,0.0014814078
4770,Raloxifene,0,1,0,10,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4770,-1,0.99821633,0.0017836833
4773,endometrial hyperplasia,33,35,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4773,-1,0.002093886,0.9979061
4775,Raloxifene,2,3,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4775,-1,0.9983852,0.0016147962
4776,venous thromboembolism,10,12,65,87,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4776,-1,0.0011170385,0.99888295
4779,endometrial hyperplasia,25,27,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4779,-1,0.00176462,0.99823534
4783,lead,45,46,264,268,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,-1,4783,-1,0.02220393,0.977796
4785,dopamine agonist,24,26,160,176,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,-1,-1,-1,4785,-1,0.99648845,0.0035115264
4786,gastrointestinal disorders,7,9,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4786,-1,0.0010357942,0.9989642
4788,psychosis,14,15,110,119,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4788,-1,0.0010006446,0.9989994
4789,sleep disturbances,16,18,121,139,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4789,-1,0.0012480095,0.998752
4790,parasomnias,19,20,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4790,-1,0.0011276396,0.99887234
4791,Parkinson's disease,5,8,39,58,"Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.",1549199_5,-1,-1,-1,4791,-1,0.0020153672,0.99798465
4792,hearing loss,18,20,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,-1,4792,-1,0.0015879098,0.998412
4794,DFO,5,6,41,44,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,-1,-1,-1,4794,-1,0.99626356,0.0037364764
4796,SNHL,21,22,107,111,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,-1,-1,4796,-1,0.0020816254,0.9979184
4797,ototoxic,1,2,3,11,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4797,-1,0.0016393111,0.9983607
4798,DFO,6,7,31,34,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4798,-1,0.9862368,0.013763114
4799,SNHL,2,3,14,18,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,-1,4799,-1,0.0019253598,0.99807465
4800,SNHL,2,3,14,18,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4800,-1,0.0013616431,0.99863833
4801,DFO,6,7,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4801,-1,0.9953904,0.0046096295
4802,DFO,7,8,43,46,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4802,-1,0.01656442,0.9834356
4803,hearing impairment,15,17,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4803,-1,0.0015434547,0.9984566
4804,thalassemic,7,8,51,62,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4804,-1,0.0017114279,0.9982886
4805,hearing impairment,28,30,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4805,-1,0.0013986271,0.9986014
4807,autoimmune diseases,14,16,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4807,-1,0.0010222401,0.9989778
4808,systemic sclerosis,21,23,171,189,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4808,-1,0.001038933,0.9989611
4809,multiple sclerosis,24,26,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4809,-1,0.0012237547,0.99877626
4810,autoimmune diseases,17,19,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,-1,-1,-1,4810,-1,0.0010070422,0.998993
4815,anthracyclines,8,9,54,68,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4815,-1,0.9943234,0.005676597
4817,heart damage,20,22,138,150,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4817,-1,0.0012270889,0.9987729
4818,systemic sclerosis,26,28,165,183,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4818,-1,0.0012305914,0.99876934
4819,autoimmune disease,25,27,144,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,-1,4819,-1,0.0021026044,0.9978974
4820,vitamin C,2,4,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4820,-1,0.99701583,0.0029842162
4821,cardiovascular disease,5,7,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4821,-1,0.00125944,0.9987406
4822,diabetes?BACKGROUND,11,12,79,98,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4822,-1,0.010687267,0.9893127
4823,Vitamin C,13,15,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4823,-1,0.9964696,0.0035304115
4824,vitamin C,11,13,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,-1,-1,4824,-1,0.9957682,0.0042318525
4827,vitamin C,10,12,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4827,-1,0.9971963,0.002803715
4828,cardiovascular disease,16,18,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4828,-1,0.0014099912,0.99858993
4829,vitamin C,7,9,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4829,-1,0.996757,0.0032430275
4830,cardiovascular disease,14,16,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4830,-1,0.0013639823,0.99863595
4831,n,17,18,106,107,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4831,-1,0.019676387,0.9803237
4832,coronary artery disease,22,25,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4832,-1,0.001627969,0.998372
4833,n,26,27,141,142,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4833,-1,0.0142923575,0.9857077
4835,n,34,35,163,164,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4835,-1,0.012519039,0.98748094
4837,coronary artery disease,15,18,98,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4837,-1,0.0013372985,0.9986627
4838,cardiovascular disease,29,31,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4838,-1,0.0020273044,0.99797267
4841,folate,47,48,298,304,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4841,-1,0.9973073,0.002692695
4842,vitamin E,49,51,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4842,-1,0.9969932,0.003006792
4843,cardiovascular disease,61,63,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4843,-1,0.0017559931,0.99824405
4844,P,76,77,444,445,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4844,-1,0.17736147,0.8226385
4845,vitamin C,86,88,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4845,-1,0.9955811,0.0044189487
4846,coronary artery disease,4,7,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4846,-1,0.0021802585,0.9978198
4847,P,19,20,89,90,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4847,-1,0.2171585,0.7828415
4849,P,40,41,161,162,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4849,-1,0.19200902,0.807991
4850,vitamin C,4,6,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4850,-1,0.9966126,0.003387426
4851,vitamin C,12,14,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4851,-1,0.9963702,0.003629849
4852,Vitamin C,0,2,0,9,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4852,-1,0.99683726,0.003162682
4853,cardiovascular disease,8,10,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4853,-1,0.0009848928,0.9990151
4854,vitamin C,4,6,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4854,-1,0.9962101,0.0037899448
4855,cardiovascular disease,16,18,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4855,-1,0.0013937431,0.99860626
4857,optic neuropathy,11,13,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,-1,-1,4857,-1,0.0011847223,0.9988153
4858,map,3,4,12,15,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4858,-1,0.030939898,0.9690601
4859,axonal degeneration,13,15,54,73,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4859,-1,0.0014270032,0.99857295
4860,optic neuropathy,17,19,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4860,-1,0.0013548938,0.9986451
4861,OCT,24,25,149,152,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4861,-1,0.15336011,0.8466399
4862,Ethambutol,0,1,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,-1,-1,4862,-1,0.99837935,0.0016205906
4864,ethambutol,4,5,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4864,-1,0.9985567,0.0014433545
4865,optic neuropathy,7,9,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4865,-1,0.0011276859,0.99887234
4866,contrast,14,15,88,96,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4866,-1,0.9144005,0.085599504
4867,toxic optic neuropathy,7,10,28,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,-1,-1,4867,-1,0.0013891911,0.99861073
4868,ethambutol,8,9,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4868,-1,0.99856335,0.001436646
4869,optic neuropathy,10,12,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4869,-1,0.0012232233,0.99877673
4870,visual deficits,19,21,124,139,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4870,-1,0.0016969637,0.99830306
4871,contrast,34,35,237,245,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4871,-1,0.9562794,0.04372066
4872,OCT,3,4,13,16,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4872,-1,0.1801622,0.81983775
4873,OCT,5,6,18,21,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4873,-1,0.43767828,0.5623217
4874,OCT,0,1,0,3,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4874,-1,0.40912908,0.59087086
4875,OCT,20,21,123,126,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4875,-1,0.36604694,0.6339531
4876,n=661,22,23,128,133,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4876,-1,0.14118758,0.8588124
4877,optic neuropathy,7,9,44,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4877,-1,0.00123714,0.99876285
4878,visual deficits,48,50,247,262,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4878,-1,0.0021865384,0.99781346
4879,visual deficits,60,62,298,313,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4879,-1,0.0019431871,0.9980568
4880,visual deficits,13,15,60,75,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4880,-1,0.0014033108,0.9985967
4881,OCT,3,4,17,20,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4881,-1,0.38134605,0.6186539
4882,optic neuropathy,10,12,64,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4882,-1,0.0013888903,0.9986111
4883,optic neuropathies,27,29,189,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,-1,4883,-1,0.0015365777,0.9984634
4884,OCT,0,1,0,3,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4884,-1,0.20895125,0.7910487
4885,optic neuropathies,11,13,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4885,-1,0.0017438625,0.99825615
4886,optic neuropathy,8,10,52,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4886,-1,0.0010327041,0.9989673
4887,ethambutol,17,18,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4887,-1,0.9985661,0.0014339883
4888,renal impairment,22,24,140,156,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4888,-1,0.0012105545,0.9987895
4894,n,19,20,96,97,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,-1,-1,4894,-1,0.25076148,0.74923855
4895,n,0,1,0,1,n = 9].,15572383_6,-1,-1,-1,4895,-1,0.108619526,0.8913805
4900,renal interstitial damage,11,14,74,99,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4900,-1,0.0012024076,0.99879754
4901,focal glomerulosclerosis,16,18,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4901,-1,0.0009843432,0.9990157
4904,focal glomerulosclerosis,7,9,42,66,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4904,-1,0.0010107018,0.9989893
4905,NS,14,15,78,80,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4905,-1,0.03726668,0.96273327
4909,renal disease,2,4,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4909,-1,0.001152363,0.9988476
4911,glomerular hypertension,7,9,49,72,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4911,-1,0.0010461315,0.9989538
4913,diseased kidney,14,16,88,103,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,-1,-1,4913,-1,0.0016976746,0.99830234
4915,nephrotic syndrome,16,18,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,-1,-1,4915,-1,0.0009350107,0.999065
4917,puromycin aminonucleoside,18,20,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,-1,4917,-1,0.99787724,0.0021227286
4919,tubulointerstitial injury,10,12,69,94,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,-1,-1,4919,-1,0.000953212,0.99904674
4920,dUTP,16,17,116,120,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4920,-1,0.98153883,0.018461134
4921,hypoxic,22,23,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4921,-1,0.003398411,0.9966016
4923,progressive glomerular diseases,12,15,91,122,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,-1,-1,-1,4923,-1,0.0013164312,0.9986835
4926,interferon,13,14,96,106,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4926,-1,0.9978788,0.0021212678
4928,chronic hepatitis C.BACKGROUND,17,20,125,155,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4928,-1,0.0070193894,0.9929806
4930,interferon,35,36,239,249,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4930,-1,0.997724,0.0022759822
4937,mg,14,15,72,74,"After that, these 37 patients were reduced one tablet of ribavirin (200 mg) per day.",15580403_4,-1,-1,-1,4937,-1,0.91342264,0.086577296
4941,P,26,27,96,97,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,-1,-1,-1,4941,-1,0.10614735,0.89385265
4943,P,38,39,194,195,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,-1,-1,-1,4943,-1,0.13980652,0.86019343
4948,corticosteroid,17,18,97,111,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4948,-1,0.99744225,0.0025576937
4949,renal function,20,22,121,135,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4949,-1,0.0013963272,0.99860364
4950,impaired,23,24,145,153,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4950,-1,0.0018217901,0.99817824
4953,renal insufficiency,1,3,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4953,-1,0.0008463206,0.99915373
4955,heart failure,8,10,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4955,-1,0.00094289583,0.9990571
4957,heart failure,13,15,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4957,-1,0.0011032742,0.9988967
4959,renal insufficiency,27,29,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4959,-1,0.0009054685,0.9990945
4960,heart failure,3,5,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,-1,-1,-1,4960,-1,0.0010382882,0.9989617
4963,renal insufficiency,13,15,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4963,-1,0.000879724,0.9991203
4964,heart failure,16,18,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4964,-1,0.0010418936,0.9989581
4966,heart failure,9,11,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,-1,-1,4966,-1,0.0012071966,0.99879277
4969,renal insufficiency,14,16,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4969,-1,0.0010165293,0.99898344
4970,Cr,17,18,89,91,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4970,-1,0.006149363,0.9938506
4973,n,18,19,108,109,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4973,-1,0.013595112,0.9864049
4974,renal failure,23,25,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4974,-1,0.0009233178,0.9990766
4975,n,26,27,134,135,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4975,-1,0.017215285,0.9827847
4980,n,38,39,240,241,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,-1,4980,-1,0.15102789,0.84897214
4981,renal insufficiency,3,5,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4981,-1,0.0008670131,0.99913305
4982,body weight,8,10,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4982,-1,0.009099343,0.99090064
4984,thiazide,31,32,193,201,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4984,-1,0.9984452,0.0015547585
4986,renal insufficiency,5,7,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,-1,-1,4986,-1,0.00090922316,0.9990908
4991,HAL,17,18,97,100,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,-1,-1,4991,-1,0.99702924,0.0029707341
4992,PRL,5,6,35,38,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,-1,-1,-1,4992,-1,0.8993197,0.10068028
4994,PRL,12,13,62,65,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,-1,4994,-1,0.9763183,0.02368172
4996,hyperplasia,9,10,70,81,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,4996,-1,0.0021571878,0.9978428
4997,contrast,7,8,55,63,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,4997,-1,0.8214783,0.17852168
4998,coronary stenosis,13,15,100,117,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,4998,-1,0.0015405818,0.99845946
4999,contrast,7,8,45,53,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,4999,-1,0.6561624,0.34383768
5000,coronary occlusion,21,23,161,179,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5000,-1,0.0017986883,0.99820125
5001,coronary stenoses,26,28,196,213,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5001,-1,0.0015280494,0.9984719
5002,hyperemic,32,33,233,242,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5002,-1,0.004971781,0.9950282
5003,contrast,10,11,58,66,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5003,-1,0.027774481,0.97222555
5004,coronary stenosis,31,33,222,239,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5004,-1,0.0016255898,0.99837434
5005,coronary occlusion,6,8,26,44,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5005,-1,0.0014309414,0.998569
5006,contrast,15,16,83,91,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5006,-1,0.9024555,0.097544506
5007,p,16,17,88,89,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,-1,-1,-1,5007,-1,0.15574673,0.84425324
5009,coronary stenosis,12,14,72,89,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5009,-1,0.0013803007,0.9986197
5010,contrast,21,22,129,137,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5010,-1,0.8148815,0.18511847
5011,stenosis,9,10,47,55,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,-1,-1,5011,-1,0.0012973308,0.99870265
5013,stenosis,7,8,40,48,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,5013,-1,0.002133244,0.9978668
5014,p,21,22,116,117,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,5014,-1,0.24513252,0.75486743
5016,p,33,34,200,201,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5016,-1,0.13998926,0.8600107
5017,contrast,44,45,251,259,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5017,-1,0.8610757,0.13892426
5018,p,51,52,288,289,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5018,-1,0.14182054,0.85817945
5019,contrast,3,4,17,25,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5019,-1,0.31091842,0.6890816
5020,coronary stenosis,23,25,157,174,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5020,-1,0.0018695617,0.9981305
5024,orofacial dyskinesia,13,15,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,-1,-1,5024,-1,0.0012670477,0.998733
5025,orofacial dyskinesia,3,5,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5025,-1,0.0011942248,0.99880576
5026,tardive dyskinesia,10,12,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5026,-1,0.0009612422,0.9990388
5027,TD,13,14,106,108,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5027,-1,0.001480515,0.9985195
5028,orofacial dyskinesia,8,10,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,-1,-1,5028,-1,0.0011068328,0.9988932
5038,orofacial diskinesia,16,18,103,123,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,-1,-1,-1,5038,-1,0.0020312704,0.99796873
5041,spinal cord ischemia,23,26,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,5041,-1,0.0012133619,0.9987866
5042,NMDA,16,17,122,126,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5042,-1,0.9954716,0.0045284815
5044,aortic occlusion,27,29,200,216,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5044,-1,0.0020714584,0.9979285
5045,Spinal cord ischemia,0,3,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5045,-1,0.0012673584,0.9987326
5046,aortic occlusion,6,8,36,52,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5046,-1,0.0024243998,0.9975756
5047,n,13,14,53,54,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5047,-1,0.2792599,0.7207401
5049,n,25,26,92,93,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5049,-1,0.27495998,0.72504
5050,h,35,36,135,136,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5050,-1,0.08906883,0.9109312
5052,n,48,49,185,186,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5052,-1,0.27218798,0.72781205
5053,n,60,61,223,224,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5053,-1,0.28856194,0.7114381
5054,h,67,68,250,251,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5054,-1,0.11360989,0.8863901
5055,h,22,23,98,99,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,-1,-1,-1,5055,-1,0.0355928,0.96440727
5056,MK-801,8,9,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5056,-1,0.99533504,0.004664983
5057,spastic paraparesis,23,25,130,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5057,-1,0.0007417182,0.9992582
5060,P,25,26,137,138,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,5060,-1,0.20530193,0.79469806
5061,MK-801,1,2,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5061,-1,0.99469584,0.0053042164
5062,spastic paraparesis,11,13,100,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5062,-1,0.0007550638,0.9992449
5064,spastic paraparesis,7,9,45,64,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5064,-1,0.00074920116,0.9992508
5066,NMDA,21,22,132,136,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5066,-1,0.99500567,0.0049943165
5068,spinal cord ischemia,11,14,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5068,-1,0.001146101,0.9988539
5069,NMDA,15,16,85,89,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5069,-1,0.994898,0.0051019867
5070,low back pain,1,4,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,-1,-1,5070,-1,0.0012095091,0.99879056
5073,atrial fibrillation,10,12,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5073,-1,0.0011505039,0.9988495
5074,AF,13,14,110,112,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5074,-1,0.0010691488,0.9989309
5075,atrial fibrillation,8,10,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5075,-1,0.001173303,0.9988267
5076,low back pain,16,19,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5076,-1,0.0013438968,0.99865603
5078,biliary pseudolithiasis,1,3,23,46,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,-1,-1,-1,5078,-1,0.0013146828,0.9986853
5081,gallbladder dysfunction,9,11,71,94,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,-1,-1,5081,-1,0.001337492,0.9986625
5089,psychosis,5,6,38,47,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5089,-1,0.0010178302,0.99898213
5091,hyperkinesia,14,15,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5091,-1,0.00080520305,0.9991948
5094,psychiatric emergency,20,22,135,156,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5094,-1,0.002232335,0.9977677
5095,psychosis,30,31,217,226,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5095,-1,0.0010621591,0.9989378
5099,psychopathology,8,9,62,77,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5099,-1,0.0013071974,0.9986928
5100,hyperkinesia,13,14,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5100,-1,0.0008556495,0.9991443
5101,HVA,0,1,0,3,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5101,-1,0.9416274,0.05837259
5102,hyperkinesia,6,7,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5102,-1,0.00076844345,0.9992316
5103,psychopathology,10,11,58,73,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5103,-1,0.001400547,0.99859947
5105,Coronary aneurysm,0,2,0,17,Coronary aneurysm after implantation of a paclitaxel-eluting stent.,15804801_0,-1,-1,-1,5105,-1,0.0018710571,0.99812895
5106,coronary aneurysm,2,4,13,30,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5106,-1,0.0016860097,0.998314
5109,vessel rupture,45,47,287,301,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5109,-1,0.0021310342,0.9978689
5110,coronary aneurysm,8,10,45,62,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,-1,-1,-1,5110,-1,0.0017217087,0.99827826
5113,mm,24,25,162,164,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,-1,-1,5113,-1,0.012509617,0.98749036
5114,Pheochromocytoma,0,1,0,16,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5114,-1,0.001182374,0.9988176
5115,amisulpride,3,4,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5115,-1,0.99860436,0.001395685
5116,tiapride,5,6,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5116,-1,0.9988311,0.0011688637
5117,pheochromocytoma,7,8,40,56,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5117,-1,0.0011312336,0.99886876
5118,amisulpride,13,14,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5118,-1,0.99869835,0.0013016199
5119,tiapride,15,16,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5119,-1,0.99882895,0.0011710475
5123,amisulpride,22,23,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5123,-1,0.9985954,0.0014045306
5124,mg,24,25,150,152,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5124,-1,0.86980766,0.13019235
5125,tiapride,26,27,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5125,-1,0.9987386,0.0012613926
5126,mg,28,29,170,172,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5126,-1,0.85108405,0.14891596
5127,nicardipine,12,13,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,-1,-1,-1,5127,-1,0.9987684,0.0012315519
5129,pheochromocytoma,15,16,113,129,"Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.",15811908_4,-1,-1,-1,5129,-1,0.0018109315,0.99818903
5130,pheochromocytoma,5,6,37,53,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5130,-1,0.0011244414,0.99887556
5131,benzamide,14,15,103,112,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5131,-1,0.9982121,0.0017879317
5133,amisulpride,19,20,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5133,-1,0.9986388,0.0013612347
5134,tiapride,21,22,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5134,-1,0.9987785,0.0012214663
5136,pheochromocytoma,25,26,142,158,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,-1,-1,-1,5136,-1,0.0012346338,0.99876535
5137,tiapride,14,15,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5137,-1,0.99877435,0.0012255802
5138,amisulpride,16,17,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5138,-1,0.99867874,0.0013211777
5139,neurological dysfunction,1,3,6,30,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,-1,-1,-1,5139,-1,0.0010525015,0.99894756
5141,neurological dysfunction,9,11,48,72,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,-1,-1,-1,5141,-1,0.0010130637,0.9989869
5146,asphyxia,3,4,24,32,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5146,-1,0.00096960133,0.99903035
5147,malformations,5,6,34,47,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5147,-1,0.001282741,0.9987173
5148,haemorrhage,17,18,123,134,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5148,-1,0.0013973402,0.9986027
5149,periventricular leukomalacia,23,25,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5149,-1,0.0010094603,0.9989905
5150,psychomotor retardation,28,30,195,218,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5150,-1,0.00096102065,0.99903905
5151,neurological dysfunctions,9,11,57,82,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,-1,5151,-1,0.0012460474,0.9987539
5152,p<0.01,15,16,91,97,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,-1,5152,-1,0.14126816,0.85873187
5153,p<0.001,12,13,65,72,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,-1,5153,-1,0.1798683,0.8201317
5155,neurological dysfunctions,11,13,70,95,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,-1,-1,-1,5155,-1,0.0010671666,0.9989328
5157,Valproic acid,0,2,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5157,-1,0.99791104,0.0020889002
5158,liver toxicity,11,13,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5158,-1,0.0016724955,0.99832755
5159,valproic acid,15,17,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5159,-1,0.9980191,0.0019809278
5160,valproic acid,4,6,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5160,-1,0.9985216,0.0014783497
5161,VPA,7,8,32,35,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5161,-1,0.9976199,0.0023800884
5162,15-F(2t)-isoprostane,33,34,173,193,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5162,-1,0.9947807,0.005219274
5163,15-F(2t)-IsoP,35,36,195,208,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5163,-1,0.9886389,0.011361126
5165,VPA,23,24,167,170,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,-1,5165,-1,0.9978694,0.00213064
5166,15-F(2t)-IsoP,11,12,72,85,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5166,-1,0.9874707,0.012529296
5167,lipid hydroperoxides,13,15,87,107,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5167,-1,0.4357783,0.5642217
5168,LPO,16,17,109,112,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5168,-1,0.21956784,0.78043216
5169,thiobarbituric acid reactive substances,20,24,119,158,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5169,-1,0.93170285,0.068297155
5170,TBARs,25,26,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5170,-1,0.9709203,0.029079704
5171,15-F(2t)-IsoP,3,4,17,30,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5171,-1,0.96695745,0.033042535
5172,VPA,14,15,82,85,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5172,-1,0.99714285,0.002857129
5173,LPO,1,2,6,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5173,-1,0.27987945,0.72012055
5174,p,16,17,86,87,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5174,-1,0.148668,0.85133195
5175,TBARs,3,4,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5175,-1,0.8236972,0.1763028
5176,p,15,16,77,78,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5176,-1,0.15022652,0.8497735
5177,Liver toxicity,0,2,0,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,-1,-1,5177,-1,0.001409004,0.998591
5181,steatosis,30,31,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,-1,-1,5181,-1,0.001095717,0.9989042
5182,VPA,7,8,50,53,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,-1,5182,-1,0.9959164,0.004083597
5183,VPA,6,7,38,41,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5183,-1,0.99701846,0.0029815773
5184,15-F(2t)-IsoP,18,19,106,119,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5184,-1,0.9776897,0.022310294
5186,steatosis,27,28,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5186,-1,0.0012066874,0.99879324
5193,n=25,45,46,252,256,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,-1,-1,5193,-1,0.084097914,0.9159021
5199,antiphospholipid syndrome,11,13,72,97,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5199,-1,0.0076746717,0.9923253
5200,systemic lupus erythematosus,17,20,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5200,-1,0.0010675946,0.9989324
5210,DFU,15,16,125,128,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,-1,-1,5210,-1,0.9870227,0.012977348
5215,DFU,20,21,117,120,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5215,-1,0.99569607,0.004303946
5216,"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon",22,25,122,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5216,-1,0.9881809,0.011819174
5217,COX-2 inhibitors,26,28,198,214,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5217,-1,0.84096307,0.15903692
5219,DFU,18,19,86,89,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,-1,-1,-1,5219,-1,0.99703026,0.0029696752
5220,MD,13,14,74,76,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5220,-1,0.0029092275,0.9970907
5223,intrauterine growth retardation,5,8,28,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5223,-1,0.0013086643,0.9986914
5224,increase of external and skeletal variations,10,16,65,109,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5224,-1,0.0019943935,0.99800557
5226,DFU,10,11,51,54,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,-1,-1,-1,5226,-1,0.7390982,0.26090184
5228,teratogenicity,2,3,8,22,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,-1,-1,-1,5228,-1,0.0009705644,0.9990294
5230,COX inhibitors,4,6,35,49,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5230,-1,0.9901557,0.009844347
5231,VSD,10,11,72,75,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5231,-1,0.002160331,0.9978397
5232,MD,12,13,80,82,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5232,-1,0.0018385604,0.9981615
5233,COX-2 inhibitors,22,24,140,156,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5233,-1,0.9796199,0.020380031
5234,COX-2 inhibitors,6,8,45,61,CONCLUSION: Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose.,15863244_13,-1,-1,-1,5234,-1,0.931669,0.068331
5235,DFU,1,2,7,10,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,-1,-1,-1,5235,-1,0.9930869,0.0069131455
5237,COX-2 inhibitors,4,6,31,47,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,-1,5237,-1,0.98400927,0.015990777
5238,midline defects,15,17,101,116,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,-1,5238,-1,0.0014156091,0.9985844
5239,hepatitis B,3,5,24,35,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5239,-1,0.003110497,0.99688953
5240,rubella,6,7,40,47,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5240,-1,0.009583126,0.9904169
5241,hepatitis B,9,11,68,79,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5241,-1,0.0065944497,0.9934056
5242,rubella,12,13,84,91,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5242,-1,0.026679711,0.9733203
5243,hepatitis B,10,12,61,72,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5243,-1,0.01335158,0.9866484
5244,rubella,13,14,77,84,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5244,-1,0.035726905,0.9642731
5245,hepatitis B vaccine,18,21,108,127,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5245,-1,0.5076452,0.49235484
5246,hepatitis B,29,31,173,184,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5246,-1,0.15734011,0.84265983
5247,hepatitis B,39,41,229,240,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5247,-1,0.21596983,0.78403014
5248,rubella,45,46,275,282,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5248,-1,0.14404197,0.85595804
5249,rubella vaccine,53,55,338,353,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5249,-1,0.7409634,0.25903657
5250,rubella,56,57,357,364,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5250,-1,0.1228088,0.8771912
5251,hepatitis B,6,8,38,49,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5251,-1,0.0027637975,0.9972362
5252,rubella,13,14,62,69,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5252,-1,0.0039585084,0.99604154
5253,Hepatitis B vaccine,0,3,0,19,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,-1,-1,-1,5253,-1,0.027871028,0.972129
5254,hepatitis B,6,8,29,40,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5254,-1,0.027683437,0.9723166
5255,hepatitis B,13,15,88,99,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5255,-1,0.033256486,0.9667436
5256,birth weight,11,13,78,90,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5256,-1,0.0037871986,0.99621284
5257,hepatitis B,17,19,122,133,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5257,-1,0.048391968,0.951608
5258,rubella,13,14,66,73,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,-1,-1,-1,5258,-1,0.038789585,0.96121037
5259,rubella vaccine,2,4,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,-1,-1,-1,5259,-1,0.26643077,0.73356926
5260,hepatitis B,18,20,126,137,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5260,-1,0.0047893994,0.9952106
5261,rubella,21,22,142,149,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5261,-1,0.008794138,0.9912059
5262,masseter muscle rigidity,1,4,24,48,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,-1,-1,-1,5262,-1,0.0019393085,0.99806064
5263,Masseter muscle rigidity,0,3,0,24,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5263,-1,0.0035262622,0.9964737
5264,malignant hyperthermia,17,19,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5264,-1,0.00095131213,0.99904865
5265,masseter muscle rigidity,19,22,116,140,The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.,15893386_2,-1,-1,-1,5265,-1,0.0041637383,0.99583626
5266,masseter muscle rigidity,8,11,35,59,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5266,-1,0.0033515126,0.9966485
5267,jaw of steel,12,15,61,73,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5267,-1,0.008974311,0.9910256
5269,Sch,19,20,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5269,-1,0.9953548,0.0046452708
5271,malignant hyperthermia,16,18,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,-1,-1,-1,5271,-1,0.0010971663,0.9989028
5272,Dexrazoxane,0,1,0,11,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,-1,-1,5272,-1,0.9982406,0.0017593798
5277,anthracyclines daunorubicin,3,5,13,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5277,-1,0.99719316,0.0028069136
5279,epipodophyllotoxin etoposide,9,11,65,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5279,-1,0.99742633,0.0025735863
5282,Dexrazoxane,0,1,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5282,-1,0.9984023,0.0015976827
5283,ICRF-187,2,3,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5283,-1,0.97719157,0.022808477
5285,hematologic toxicity,10,12,58,78,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5285,-1,0.0012868587,0.99871314
5286,dexrazoxane,15,16,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5286,-1,0.9985654,0.0014346855
5290,dexrazoxane,44,45,304,315,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5290,-1,0.9984705,0.0015294543
5294,dexrazoxane,20,21,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,-1,5294,-1,0.99846315,0.0015368515
5295,dexrazoxane,5,6,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5295,-1,0.9983492,0.0016508547
5297,weight loss,9,11,68,79,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5297,-1,0.001889767,0.9981102
5300,dexrazoxane,29,30,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5300,-1,0.99833244,0.0016676316
5302,weight loss,34,36,244,255,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5302,-1,0.0019075578,0.9980925
5303,cytotoxicity,41,42,274,286,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5303,-1,0.0018632467,0.99813676
5305,dexrazoxane,9,10,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,-1,5305,-1,0.99846137,0.0015385924
5309,dexrazoxane,16,17,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,-1,-1,-1,5309,-1,0.99867046,0.0013295428
5310,brain metastases,5,7,33,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5310,-1,0.0011785434,0.99882144
5311,dexrazoxane,8,9,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5311,-1,0.9985782,0.0014218363
5313,hematologic toxicity,24,26,166,186,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5313,-1,0.00095083914,0.9990491
5314,atrial fibrillation,1,3,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,-1,5314,-1,0.0010822002,0.9989178
5316,Atrial fibrillation,0,2,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5316,-1,0.001160298,0.9988397
5317,structural heart disease,6,9,46,70,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5317,-1,0.0013961544,0.9986039
5319,Thyroid disorders,0,2,0,17,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,-1,5319,-1,0.0020179786,0.997982
5321,emergency department,13,15,66,86,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5321,-1,0.004706159,0.9952938
5322,atrial fibrillation,16,18,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5322,-1,0.0011475037,0.9988525
5328,unfractionated heparin,10,12,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,-1,-1,-1,5328,-1,0.9923987,0.007601343
5365,inability to repeat words,8,12,48,73,The mean highest BIS score corresponding to the inability to repeat words was 81.5 (95% CI = 78.1 to 84.8).,15930398_13,-1,-1,-1,5365,-1,0.07220348,0.9277965
5366,retrograde amnesia,25,27,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,-1,5366,-1,0.0018031355,0.9981969
5367,Ro4368554,5,6,40,49,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5367,-1,0.99589074,0.0041092206
5368,memory deficiency,15,17,120,137,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5368,-1,0.0013801444,0.9986199
5370,5-HT(6,6,7,33,39,Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory.,15957009_1,-1,-1,-1,5370,-1,0.9899304,0.0100695705
5372,ACh,19,20,118,121,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,-1,5372,-1,0.99545324,0.0045467503
5373,5-HT(6,11,12,80,86,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5373,-1,0.9913741,0.008625956
5374,Ro4368554,14,15,99,108,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5374,-1,0.99612325,0.0038767073
5375,3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole,16,17,110,164,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5375,-1,0.9894804,0.010519561
5377,tryptophan,35,36,271,281,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5377,-1,0.9963386,0.0036614502
5378,TRP,37,38,283,286,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5378,-1,0.9953707,0.004629354
5379,metrifonate,56,57,399,410,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5379,-1,0.9984787,0.001521297
5380,metrifonate,17,18,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5380,-1,0.99843055,0.0015693838
5381,Ro4368554,33,34,192,201,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5381,-1,0.99568045,0.0043195724
5382,Ro4368554,2,3,6,15,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5382,-1,0.9956357,0.0043642567
5383,metrifonate,16,17,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5383,-1,0.99873716,0.0012628152
5384,memory deficits,27,29,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5384,-1,0.002250667,0.99774927
5386,TRP,33,34,158,161,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5386,-1,0.99436307,0.0056369244
5387,Ro4368554,4,5,24,33,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5387,-1,0.99705386,0.0029461922
5388,retention deficit,10,12,65,82,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5388,-1,0.002266373,0.9977336
5389,memory deficit,20,22,129,143,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5389,-1,0.0024311303,0.9975688
5390,Ro4368554,37,38,233,242,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5390,-1,0.99730814,0.0026918794
5391,5-HT(6,43,44,264,270,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5391,-1,0.9882117,0.01178832
5392,Amiodarone pulmonary toxicity,0,3,0,29,Amiodarone pulmonary toxicity.,1595783_0,-1,-1,-1,5392,-1,0.59269637,0.40730363
5394,pneumonitis,18,19,122,133,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,-1,-1,5394,-1,0.0009096577,0.9990903
5395,pulmonary toxicity,1,3,4,22,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5395,-1,0.0010127574,0.99898726
5397,hypersensitivity pneumonitis,22,24,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5397,-1,0.0009190212,0.999081
5398,pulmonary toxicity,7,9,61,79,The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.,1595783_3,-1,-1,-1,5398,-1,0.0010641109,0.9989359
5399,heart failure,11,13,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,-1,-1,5399,-1,0.0013884816,0.99861145
5404,kainate,7,8,43,50,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,-1,-1,5404,-1,0.99305737,0.006942661
5406,Amino acids,0,2,0,11,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5406,-1,0.98552346,0.014476561
5409,thermal hyperalgesia,22,24,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5409,-1,0.0014975438,0.9985025
5410,mechanical hyperalgesia,27,29,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5410,-1,0.0015192385,0.99848074
5416,pharyngitis,17,18,116,127,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,-1,-1,5416,-1,0.0013810943,0.99861896
5419,baclofen,6,7,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,-1,-1,-1,5419,-1,0.9987669,0.0012330872
5430,macrolide,10,11,64,73,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,-1,-1,5430,-1,0.9972445,0.0027555618
5431,macrolides,36,37,213,223,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,-1,5431,-1,0.9936353,0.0063646496
5436,macrolide,2,3,9,18,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,-1,5436,-1,0.99452233,0.005477648
5438,GNC92H2,6,7,50,57,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5438,-1,0.8059635,0.19403644
5439,cocaine overdose,11,13,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5439,-1,0.09048471,0.9095153
5441,cocaine overdose,12,14,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,-1,5441,-1,0.08770416,0.9122959
5442,GNC92H2,7,8,54,61,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5442,-1,0.58663136,0.41336858
5443,cocaine overdose,14,16,92,108,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5443,-1,0.093196385,0.9068036
5445,GNC92H2,23,24,141,148,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,-1,5445,-1,0.98005164,0.019948341
5446,GNC92H2,0,1,0,7,"GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.",16005948_5,-1,-1,-1,5446,-1,0.94186896,0.05813099
5448,cocaine toxicity,3,5,24,40,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5448,-1,0.16228348,0.8377166
5449,GNC92H2,12,13,78,85,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5449,-1,0.9874839,0.012516064
5452,GNC92H2,2,3,13,20,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5452,-1,0.8891184,0.11088164
5454,post-cocaine,6,7,42,54,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5454,-1,0.7930112,0.20698878
5455,GNC92H2,7,8,47,54,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5455,-1,0.91799873,0.082001284
5456,cocaine overdose,13,15,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5456,-1,0.09862604,0.901374
5457,Calcium carbonate toxicity,0,3,0,26,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,-1,5457,-1,0.48100224,0.5189977
5462,acute renal insufficiency,6,9,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5462,-1,0.0010766868,0.99892324
5463,metabolic alkalosis,11,13,64,83,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5463,-1,0.0011053354,0.99889475
5464,low parathyroid hormone,15,18,89,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5464,-1,0.7601756,0.23982441
5465,PTH,19,20,114,117,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5465,-1,0.99224985,0.007750148
5466,"1,25-dihydroxyvitamin D",26,28,145,168,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5466,-1,0.9955403,0.0044596237
5469,pamidronate,10,11,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5469,-1,0.99858034,0.0014196443
5470,mg,16,17,106,108,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5470,-1,0.8842946,0.11570538
5473,calcium carbonate,27,29,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,-1,-1,-1,5473,-1,0.99697924,0.0030208162
5475,calcium carbonate,22,24,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,-1,-1,5475,-1,0.99717784,0.0028222064
5478,vitamin D,12,14,77,86,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,-1,-1,-1,5478,-1,0.9976714,0.00232851
5479,Pamidronate,0,1,0,11,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,-1,-1,5479,-1,0.99836797,0.0016321045
5487,myocardial infarction,19,21,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5487,-1,0.0011663063,0.9988337
5489,bundle branch block,25,28,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5489,-1,0.002013243,0.9979868
5490,leukocytoclastic vasculitis,1,3,17,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,-1,-1,5490,-1,0.0008350135,0.99916506
5491,Skin reactions,0,2,0,14,Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence.,16047871_1,-1,-1,-1,5491,-1,0.0015420187,0.998458
5492,Leukocytoclastic vasculitis,0,2,0,27,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5492,-1,0.0011220376,0.99887794
5493,LV,3,4,29,31,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5493,-1,0.0023558147,0.9976441
5494,small vessel vasculitis,9,12,58,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5494,-1,0.0026036906,0.99739635
5495,LV,6,7,37,39,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,-1,-1,5495,-1,0.0014156225,0.9985844
5497,skin eruptions,5,7,30,44,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,-1,-1,-1,5497,-1,0.001434448,0.9985656
5499,skin lesion,3,5,15,26,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5499,-1,0.0023524698,0.9976476
5500,LV Cutaneous lesions,13,16,77,97,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5500,-1,0.0063760174,0.993624
5503,LV,0,1,0,2,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,-1,5503,-1,0.0023304294,0.9976695
5514,Parkinson disease,9,11,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,-1,5514,-1,0.0010500876,0.99894994
5516,Parkinson disease,23,25,135,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5516,-1,0.00093264494,0.99906737
5517,dyskinetic,41,42,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5517,-1,0.0010780251,0.998922
5521,brain tumors,2,4,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,-1,5521,-1,0.0013425461,0.99865746
5522,lipid,6,7,45,50,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,-1,5522,-1,0.674133,0.32586697
5526,glioblastoma multiforme,10,12,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,-1,5526,-1,0.0015364183,0.99846363
5529,mg paclitaxel,8,10,42,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5529,-1,0.98221165,0.017788302
5530,brain edema,16,18,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5530,-1,0.0010598137,0.99894017
5531,mg paclitaxel,29,31,163,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5531,-1,0.97843826,0.021561764
5532,brain edema,5,7,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,-1,-1,-1,5532,-1,0.0011310058,0.998869
5534,Lamotrigine,0,1,0,11,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5534,-1,0.9982547,0.0017453008
5536,idiopathic generalized epilepsies,9,12,65,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5536,-1,0.0010532156,0.99894685
5537,idiopathic generalized epilepsies,3,6,19,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5537,-1,0.0009797618,0.9990202
5538,IGE,7,8,54,57,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5538,-1,0.0022817315,0.99771833
5539,lamotrigine,11,12,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5539,-1,0.9987205,0.0012795579
5540,LTG,13,14,85,88,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5540,-1,0.2801389,0.7198611
5542,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5542,-1,0.0018873044,0.9981127
5543,LTG,4,5,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5543,-1,0.01953621,0.9804638
5544,MJ,6,7,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5544,-1,0.0034836628,0.99651635
5545,MJ,0,1,0,2,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5545,-1,0.009409336,0.99059063
5546,LTG,3,4,20,23,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5546,-1,0.9967918,0.0032081844
5547,LTG,4,5,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5547,-1,0.055574283,0.9444257
5548,MJ,6,7,33,35,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5548,-1,0.0019915842,0.99800843
5549,myoclonic status,16,18,78,94,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5549,-1,0.0011371565,0.99886286
5550,LTG,22,23,118,121,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5550,-1,0.9731814,0.026818609
5553,thyrotropin,16,17,116,127,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,-1,5553,-1,0.99036485,0.009635163
5554,penile erection,20,22,126,141,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,-1,5554,-1,0.0010619073,0.99893814
5556,psychiatric disorders,12,14,64,85,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,-1,-1,-1,5556,-1,0.0010892929,0.99891067
5562,memory dissociation,4,6,18,37,It was shown that memory dissociation occurred in both groups.,1616457_5,-1,-1,-1,5562,-1,0.0022948615,0.99770516
5565,raloxifene,4,5,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5565,-1,0.998613,0.0013870155
5566,raloxifene,52,53,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5566,-1,0.9985928,0.0014071629
5567,osteopenia,6,7,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,-1,5567,-1,0.0008221756,0.99917775
5569,raloxifene hydrochloride,4,6,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,-1,-1,-1,5569,-1,0.99845207,0.0015479244
5571,n,3,4,22,23,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,-1,5571,-1,0.15812457,0.8418754
5573,raloxifene,5,6,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5573,-1,0.99861145,0.0013884943
5574,P,24,25,144,145,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5574,-1,0.20874085,0.7912591
5575,P,42,43,225,226,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5575,-1,0.21645784,0.78354216
5576,amenorrhea,14,15,101,111,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5576,-1,0.0007934183,0.9992066
5577,P,16,17,113,114,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5577,-1,0.14561622,0.85438377
5578,venous thromboembolism,9,11,50,72,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5578,-1,0.0010688188,0.9989312
5579,raloxifene,13,14,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5579,-1,0.99866927,0.0013306931
5580,subarachnoid hemorrhage,7,9,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,-1,-1,-1,5580,-1,0.0010169641,0.99898297
5582,neurovascular complications,8,10,51,78,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,-1,-1,5582,-1,0.0010609375,0.9989391
5585,subarachnoid hemorrhage,13,15,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5585,-1,0.0011856086,0.99881446
5586,SAH,16,17,124,127,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5586,-1,0.0009917468,0.99900824
5588,SAH,6,7,35,38,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,-1,-1,-1,5588,-1,0.0013193055,0.99868065
5590,SAH,17,18,135,138,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,-1,-1,-1,5590,-1,0.0011931362,0.99880683
5592,p,35,36,226,227,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,-1,5592,-1,0.17322618,0.82677376
5593,p,48,49,316,317,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,-1,5593,-1,0.17468975,0.8253102
5595,aneurysmal SAH,29,31,209,223,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,-1,5595,-1,0.001198528,0.99880147
5604,Aggressive behaviors,0,2,0,20,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5604,-1,0.001341365,0.99865866
5605,psychiatric disorders,11,13,73,94,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5605,-1,0.0009993212,0.9990007
5607,METH,20,21,131,135,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5607,-1,0.98767126,0.012328772
5608,METH,13,14,63,67,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,-1,-1,5608,-1,0.9956726,0.0043274323
5612,MAP,14,15,112,115,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5612,-1,0.85888046,0.14111951
5613,METH,21,22,166,170,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5613,-1,0.9941724,0.005827638
5614,p<0.05,5,6,38,44,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5614,-1,0.13628541,0.86371464
5615,METH,32,33,153,157,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5615,-1,0.9935509,0.0064491145
5616,METH,10,11,66,70,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5616,-1,0.99666303,0.0033369898
5617,METH,23,24,134,138,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5617,-1,0.99636143,0.003638532
5618,METH,22,23,129,133,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,-1,5618,-1,0.9944823,0.005517698
5619,MAP,6,7,43,46,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5619,-1,0.9408119,0.05918807
5620,aggressive behaviors,20,22,151,171,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5620,-1,0.001513305,0.99848664
5621,Amisulpride,0,1,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,-1,-1,5621,-1,0.9978333,0.0021666863
5623,Tic disorders,0,2,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5623,-1,0.0013818983,0.9986181
5624,antipsychotics,8,9,53,67,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5624,-1,0.98731405,0.012685968
5627,ziprasidone,15,16,104,115,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5627,-1,0.9986204,0.001379624
5628,quetiapine,22,23,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,-1,-1,-1,5628,-1,0.99874866,0.0012513377
5631,amisulpride,16,17,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5631,-1,0.9985524,0.0014475859
5632,mg,20,21,148,150,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5632,-1,0.9388744,0.061125584
5633,amisulpride,11,12,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5633,-1,0.99852234,0.0014776404
5634,mg,15,16,95,97,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5634,-1,0.9440714,0.05592863
5635,psychosis,3,4,13,22,"However, her psychosis recurred after the dose reduction.",16225977_5,-1,-1,-1,5635,-1,0.0011027913,0.9988972
5636,mg,8,9,40,42,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5636,-1,0.8743068,0.12569328
5637,quetiapine,12,13,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5637,-1,0.9987582,0.0012417713
5638,antipsychotics,22,23,162,176,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5638,-1,0.98413557,0.015864432
5639,quetiapine,25,26,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5639,-1,0.9987759,0.0012240403
5641,amisulpride,30,31,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5641,-1,0.9985085,0.0014915045
5642,dysphonia,1,2,10,19,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5642,-1,0.00096678006,0.9990332
5643,acitretin,3,4,24,33,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5643,-1,0.90474087,0.09525916
5644,dysphonia,9,10,45,54,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5644,-1,0.0008727462,0.9991272
5645,acitretin,15,16,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5645,-1,0.998304,0.0016959469
5646,acitretin,10,11,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,-1,-1,5646,-1,0.99818206,0.0018180134
5647,dysphonia,11,12,62,71,"To our knowledge, this is the first case of acitretin-induced dysphonia.",16274958_3,-1,-1,-1,5647,-1,0.00093974953,0.9990602
5649,heart block,3,5,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5649,-1,0.0011698824,0.99883014
5650,blindness,6,7,46,55,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5650,-1,0.0010820429,0.99891794
5652,deterioration of vision,14,17,101,124,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5652,-1,0.0026321034,0.9973679
5653,fatiguability,19,20,131,144,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5653,-1,0.0012363732,0.9987637
5654,dyspnoea,21,22,146,154,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5654,-1,0.0010521561,0.9989479
5656,syncopal attacks,26,28,181,197,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5656,-1,0.0012298445,0.9987702
5657,chloroquine retinopathy,5,7,49,72,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5657,-1,0.69320005,0.30679995
5658,heart failure,13,15,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5658,-1,0.0011447627,0.99885523
5659,heart block,18,20,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5659,-1,0.0014404559,0.99855953
5660,right bundle branch block,21,25,160,185,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5660,-1,0.0032648863,0.99673504
5661,heart block,1,3,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5661,-1,0.0011447121,0.99885523
5662,heart failure,10,12,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5662,-1,0.0010966146,0.9989034
5664,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,-1,5664,-1,0.09868658,0.9013134
5665,nitric oxide,1,3,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5665,-1,0.99357563,0.0064243856
5666,hearing loss,20,22,122,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5666,-1,0.0014215397,0.9985784
5670,ototoxic,11,12,60,68,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,-1,-1,5670,-1,0.0017547279,0.99824524
5673,hearing loss,9,11,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,-1,-1,-1,5673,-1,0.0014343482,0.99856573
5674,hearing loss,3,5,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,-1,5674,-1,0.0014612301,0.99853873
5683,heart disease,15,17,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5683,-1,0.0015827294,0.99841726
5685,diabetes mellitus,25,27,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5685,-1,0.0011263174,0.99887365
5698,tissue injury,27,29,184,197,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,-1,-1,5698,-1,0.0030634082,0.99693656
5701,neurogenic hyperalgesia,6,8,60,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,-1,-1,5701,-1,0.00094833656,0.99905163
5708,mg,6,7,33,35,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,-1,-1,-1,5708,-1,0.8834622,0.116537824
5716,Mitochondrial abnormalities,0,2,0,27,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,-1,5716,-1,0.0043415325,0.9956585
5718,status epilepticus,12,14,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5718,-1,0.001417484,0.9985825
5719,c,30,31,195,196,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5719,-1,0.9641933,0.03580669
5722,mitochondrial abnormalities,3,5,22,49,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,-1,5722,-1,0.0038967286,0.9961033
5723,suprofen,2,3,11,19,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,-1,-1,-1,5723,-1,0.9983797,0.0016202265
5724,suprofen,1,2,9,17,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5724,-1,0.9981584,0.001841622
5725,acute renal failure,9,12,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5725,-1,0.00084452453,0.9991555
5727,mg,10,11,54,56,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5727,-1,0.69092846,0.30907157
5728,suprofen,12,13,60,68,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5728,-1,0.9982791,0.0017209108
5729,uric acid,34,36,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5729,-1,0.9964227,0.0035773236
5732,suprofen,21,22,132,140,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,-1,5732,-1,0.9982693,0.0017306869
5733,contrast,1,2,3,11,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5733,-1,0.026891759,0.9731083
5734,suprofen,16,17,101,109,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5734,-1,0.9985013,0.0014987299
5735,uric acid,22,24,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5735,-1,0.9950488,0.0049512153
5736,suprofen,30,31,176,184,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5736,-1,0.9983883,0.0016116872
5737,uric acid,35,37,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5737,-1,0.9946226,0.0053774687
5738,uric acid,9,11,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5738,-1,0.9808507,0.01914934
5739,suprofen,16,17,91,99,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5739,-1,0.9983803,0.0016196719
5740,uric acid,6,8,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,-1,-1,-1,5740,-1,0.97743374,0.022566304
5741,suprofen,3,4,12,20,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5741,-1,0.99809283,0.0019071709
5742,declines in renal function,6,10,34,60,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5742,-1,0.0017063925,0.9982936
5743,uric acid,20,22,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5743,-1,0.9937285,0.0062714266
5744,ritanserin,2,3,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,-1,5744,-1,0.99872357,0.001276404
5746,ritanserin,3,4,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,-1,5746,-1,0.99877614,0.0012238328
5749,DMSO,11,12,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5749,-1,0.9951841,0.004815883
5750,saline+DMSO,13,14,65,76,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5750,-1,0.9910755,0.008924414
5752,ritanserin,29,30,150,160,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5752,-1,0.99887115,0.0011288574
5754,ritanserin,55,56,278,288,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5754,-1,0.9987679,0.0012320165
5755,injection)+ritanserin,56,57,289,310,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5755,-1,0.97632444,0.023675513
5756,DMSO,61,62,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5756,-1,0.98854095,0.011459098
5758,ritanserin,4,5,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,-1,5758,-1,0.99875426,0.0012457627
5759,ritanserin,6,7,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,-1,5759,-1,0.9986791,0.0013208368
5763,nephrosclerosis,9,10,62,77,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5763,-1,0.0008136011,0.99918634
5764,renovascular hypertension,13,15,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5764,-1,0.001049437,0.9989505
5770,renovascular hypertension,43,45,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5770,-1,0.0011740933,0.99882585
5772,mm Hg,16,18,75,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5772,-1,0.0069931615,0.9930068
5774,n,30,31,155,156,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5774,-1,0.078241356,0.9217586
5775,n,36,37,182,183,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5775,-1,0.083235525,0.9167645
5776,n,43,44,215,216,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5776,-1,0.110119455,0.8898805
5777,mm Hg,11,13,62,67,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5777,-1,0.0068648215,0.9931352
5778,n,14,15,69,70,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5778,-1,0.12263666,0.8773634
5779,sclerosis,10,11,67,76,Renal tissue was obtained for determination of glomerular size and sclerosis.,1639466_5,-1,-1,-1,5779,-1,0.001177293,0.99882275
5784,contrast,1,2,3,11,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,-1,5784,-1,0.024211327,0.97578865
5791,torsades de pointes,2,5,21,40,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,-1,-1,-1,5791,-1,0.0017712894,0.9982287
5793,coronary artery disease,5,8,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5793,-1,0.0018344485,0.99816555
5794,prolonged QT interval,12,15,72,93,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5794,-1,0.0057779914,0.994222
5795,torsades de pointes,16,19,98,117,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5795,-1,0.003540289,0.99645966
5796,TdP,20,21,119,122,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5796,-1,0.004064038,0.9959359
5798,fungal infection,28,30,167,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5798,-1,0.0018200929,0.9981799
5802,long QT syndrome,37,40,227,243,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,-1,5802,-1,0.0020763187,0.9979236
5804,Turner Syndrome,6,8,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5804,-1,0.0014698397,0.99853015
5805,Graves' disease,9,12,61,76,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5805,-1,0.0027980253,0.99720204
5806,purpura,1,2,9,16,"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes.",16418614_1,-1,-1,-1,5806,-1,0.001108596,0.9988914
5808,Turner syndrome,5,7,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5808,-1,0.0014302002,0.9985697
5809,Graves' disease,8,11,42,57,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5809,-1,0.0025353816,0.99746466
5810,purpuric lesions,15,17,86,102,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5810,-1,0.0013179567,0.9986821
5813,PTU,36,37,245,248,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,-1,-1,5813,-1,0.88386005,0.11613999
5816,Cerebral vasculitis,0,2,0,19,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,-1,-1,-1,5816,-1,0.0010753102,0.9989247
5820,Cerebral vasculitis,0,2,0,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5820,-1,0.0009156452,0.99908435
5821,amphetamine abuse,4,6,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5821,-1,0.70542794,0.29457206
5822,ischaemic stroke,14,16,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5822,-1,0.0011354657,0.99886453
5826,ischaemic strokes,20,22,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,-1,-1,5826,-1,0.001122515,0.99887747
5827,cerebral vasculitis,3,5,25,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5827,-1,0.00083392893,0.99916613
5828,ischaemic strokes,12,14,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5828,-1,0.0009946096,0.9990054
5831,neurological symptoms,12,14,91,112,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,-1,-1,5831,-1,0.0011047192,0.9988953
5834,Daidzein,0,1,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,-1,-1,5834,-1,0.9982449,0.001755144
5839,ACh,22,23,154,157,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5839,-1,0.99612767,0.0038723622
5840,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5840,-1,0.0022262384,0.9977737
5841,AD,37,38,224,226,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5841,-1,0.0017254798,0.99827456
5842,daidzein,15,16,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,-1,5842,-1,0.99735034,0.0026496877
5843,daidzein,7,8,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,-1,5843,-1,0.99811447,0.001885523
5844,daidzein,2,3,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5844,-1,0.9982589,0.0017411229
5845,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5845,-1,0.12931503,0.8706849
5848,contrast,3,4,10,18,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5848,-1,0.21375802,0.78624195
5849,daidzein,8,9,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5849,-1,0.99834216,0.0016578181
5851,daidzein,4,5,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,-1,-1,-1,5851,-1,0.9982496,0.0017503852
5854,overactive bladder,11,13,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5854,-1,0.0012020676,0.9987979
5855,tolterodine,14,15,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5855,-1,0.99867994,0.0013200842
5856,overactive bladder,16,18,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5856,-1,0.0017301826,0.9982698
5857,OAB,19,20,109,112,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5857,-1,0.0042259735,0.9957741
5858,tolterodine,22,23,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5858,-1,0.99865144,0.0013486333
5859,OAB,16,17,73,76,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,-1,5859,-1,0.005867463,0.9941326
5860,Tolterodine,0,1,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5860,-1,0.9985096,0.0014904084
5861,mg,2,3,14,16,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5861,-1,0.9504806,0.049519405
5862,nocturia,3,4,14,22,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,-1,5862,-1,0.0012954546,0.99870455
5863,dry month,6,8,32,41,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,-1,-1,-1,5863,-1,0.0031197933,0.9968802
5865,Tolterodine,2,3,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5865,-1,0.99846363,0.0015364464
5866,OAB,18,19,107,110,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5866,-1,0.008398682,0.9916013
5867,Remifentanil,0,1,0,12,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5867,-1,0.9986243,0.0013757437
5869,etomidate,5,6,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5869,-1,0.99847883,0.0015212275
5870,remifentanil,16,17,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5870,-1,0.9986432,0.0013567454
5872,etomidate,33,34,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5872,-1,0.99871707,0.0012829223
5873,remifentanil,12,13,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,-1,5873,-1,0.99851876,0.0014812922
5874,remifentanil,3,4,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5874,-1,0.99871564,0.0012844035
5875,etomidate,8,9,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5875,-1,0.9985952,0.0014048659
5881,remifentanil,12,13,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5881,-1,0.9985958,0.0014042567
5882,P,28,29,131,132,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5882,-1,0.11021445,0.8897855
5887,etomidate,16,17,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,-1,-1,5887,-1,0.99871254,0.0012874189
5888,remifentanil,4,5,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5888,-1,0.9986559,0.0013441223
5890,etomidate,10,11,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5890,-1,0.99872106,0.0012788664
5895,etomidate,9,10,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,-1,-1,-1,5895,-1,0.99877936,0.001220693
5896,MDMA,0,1,0,4,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5896,-1,0.99405825,0.0059417114
5897,central executive impairments,5,8,42,71,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5897,-1,0.0031450342,0.9968549
5898,impaired social and emotional judgement processes,10,16,85,134,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5898,-1,0.008706787,0.99129325
5899,working memory deficits,3,6,16,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5899,-1,0.004733131,0.9952669
5900,MDMA,12,13,71,75,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5900,-1,0.9981711,0.0018289161
5903,MDMA,9,10,48,52,"The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on ""prefrontal"" mediated social and emotional judgement processes.",16574712_2,-1,-1,-1,5903,-1,0.99778014,0.0022198819
5905,MDMA,6,7,43,47,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,-1,-1,-1,5905,-1,0.9949884,0.005011604
5909,MDMA,11,12,81,85,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,-1,-1,-1,5909,-1,0.99771845,0.0022815818
5911,MDMA,3,4,44,48,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5911,-1,0.9980129,0.001987135
5914,5-HT,15,16,103,107,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5914,-1,0.99454594,0.005454071
5915,5-HT neurotoxic lesions,33,36,214,237,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5915,-1,0.34941393,0.6505861
5916,5-HT,40,41,260,264,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5916,-1,0.9931584,0.006841668
5917,5-HT,1,2,8,12,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5917,-1,0.99215007,0.007849892
5918,5-HT,12,13,75,79,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5918,-1,0.99373996,0.0062600016
5919,5-HT,30,31,185,189,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5919,-1,0.99197054,0.008029426
5920,MDMA,43,44,263,267,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5920,-1,0.99719894,0.0028010241
5921,MDMA,14,15,74,78,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5921,-1,0.99730814,0.0026918948
5922,MDMA,29,30,158,162,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5922,-1,0.99695194,0.0030480043
5923,MDMA,2,3,17,21,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,-1,5923,-1,0.99576074,0.0042392416
5924,p,12,13,71,72,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5924,-1,0.13859569,0.86140424
5925,p,22,23,108,109,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5925,-1,0.041037403,0.9589626
5926,p,30,31,154,155,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5926,-1,0.050570987,0.94942904
5927,contrast,1,2,3,11,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5927,-1,0.026879156,0.9731208
5929,MDMA,12,13,71,75,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5929,-1,0.99649256,0.0035073909
5930,MDMA,4,5,17,21,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5930,-1,0.9972904,0.0027096104
5931,impaired memory functioning,18,21,93,120,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5931,-1,0.0015815437,0.99841845
5932,MDMA,25,26,135,139,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5932,-1,0.99690324,0.0030967263
5933,lead,28,29,148,152,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5933,-1,0.007999883,0.9920001
5934,memory impairments,32,34,169,187,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5934,-1,0.0014088213,0.9985911
5935,MDMA,10,11,54,58,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,-1,5935,-1,0.99560744,0.0043925345
5936,mangiferin,2,3,8,18,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5936,-1,0.99768174,0.002318296
5937,myocardial infarction,11,13,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5937,-1,0.0009248049,0.9990752
5938,mangiferin,9,10,52,62,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5938,-1,0.9969139,0.0030860917
5939,polyphenol,12,13,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5939,-1,0.9692137,0.03078629
5941,myocardial infarction,25,27,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5941,-1,0.0011708188,0.9988292
5942,MI,28,29,177,179,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5942,-1,0.001427759,0.99857223
5943,ISPH,3,4,26,30,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5943,-1,0.9001381,0.099861935
5944,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5944,-1,0.08614129,0.9138587
5946,lactate,36,37,196,203,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5946,-1,0.98377174,0.016228193
5948,uric acid,50,52,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5948,-1,0.99417675,0.0058232048
5950,mangiferin,4,5,23,33,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5950,-1,0.9979644,0.0020356588
5951,triphenyl tetrazolium chloride,8,11,50,80,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5951,-1,0.9969097,0.0030903546
5952,TTC,12,13,82,85,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5952,-1,0.9388542,0.06114576
5953,ischemic myocardium,23,25,141,160,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5953,-1,0.0018325478,0.9981674
5954,superoxide dismutase,7,9,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5954,-1,0.986161,0.013839002
5955,glutathione peroxidase,12,14,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5955,-1,0.985987,0.014012938
5956,glutathione transferase,15,17,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5956,-1,0.986811,0.013188994
5957,glutathione reductase,18,20,129,150,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5957,-1,0.9852448,0.014755224
5958,Vitamin C,28,30,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5958,-1,0.9970758,0.0029241962
5959,Vitamin E,31,33,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5959,-1,0.9970879,0.002912084
5961,MI,39,40,272,274,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5961,-1,0.0033923844,0.99660766
5962,mangiferin,3,4,23,33,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5962,-1,0.99803585,0.0019641474
5963,body weight,7,9,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5963,-1,0.22141266,0.7785874
5964,dimethyl sulphoxide,14,16,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5964,-1,0.9967013,0.0032986873
5965,MI,23,24,138,140,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5965,-1,0.0032777586,0.9967223
5966,mangiferin,14,15,114,124,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5966,-1,0.99780864,0.0021913887
5967,MI,20,21,168,170,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5967,-1,0.0019825045,0.99801755
5968,mangiferin,8,9,44,54,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5968,-1,0.99733186,0.0026681125
5969,MI,15,16,103,105,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5969,-1,0.0011837245,0.99881625
5970,cardiac damage,29,31,191,205,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5970,-1,0.0015523968,0.99844754
5971,cyclooxygenase inhibitors,3,5,25,50,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5971,-1,0.99489564,0.0051043252
5972,myocardial infarction,23,25,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5972,-1,0.0010553268,0.9989447
5975,heart failure,30,32,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5975,-1,0.0010983449,0.9989016
5976,cyclooxygenase inhibitors,35,37,273,298,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5976,-1,0.9947864,0.005213583
5977,Cyclooxygenase inhibitors,0,2,0,25,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5977,-1,0.9917394,0.008260625
5978,cyclooxygenase inhibitors,7,9,53,78,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,-1,5978,-1,0.919771,0.08022894
5979,cardiovascular toxicity,33,35,217,240,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,-1,-1,-1,5979,-1,0.0010303408,0.9989697
5980,Pilocarpine seizures,0,2,0,20,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,5980,-1,0.6758686,0.32413137
5981,impairment in auditory location discrimination,4,9,41,87,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,5981,-1,0.0075215646,0.9924784
5982,status epilepticus,3,5,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,-1,-1,5982,-1,0.0012098133,0.9987902
5984,status epilepticus,4,6,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,5984,-1,0.0014074792,0.99859256
5985,deficits in auditory discrimination,7,11,46,81,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,5985,-1,0.005544304,0.99445575
5986,status epilepticus,17,19,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,-1,-1,5986,-1,0.0012221565,0.9987778
5989,status epilepticus,5,7,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,5989,-1,0.0011941623,0.9988059
5990,status epilepticus,8,10,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,5990,-1,0.0012933447,0.9987067
5993,status epilepticus,1,3,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,-1,5993,-1,0.0015587469,0.9984413
5994,Status epilepticus,0,2,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,-1,5994,-1,0.0018422997,0.9981577
5995,Status epilepticus,0,2,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,5995,-1,0.0012595839,0.9987405
5996,impairment in auditory discrimination,9,13,61,98,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,5996,-1,0.0067498917,0.99325013
5997,impaired auditory location discrimination,7,11,41,82,This impairment may explain one cause of impaired auditory location discrimination in humans.,16596970_11,-1,-1,-1,5997,-1,0.0067502563,0.9932498
5998,Nerve growth factor,0,3,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,5998,-1,0.97383773,0.026162269
6000,overactive bladder,12,14,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,6000,-1,0.0012113677,0.99878865
6001,NGF,2,3,9,12,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6001,-1,0.9943369,0.005663062
6002,PGs,4,5,17,20,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6002,-1,0.9890472,0.010952746
6003,NGF,5,6,35,38,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6003,-1,0.98532134,0.014678668
6004,PGs,7,8,43,46,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6004,-1,0.9290536,0.070946395
6005,OAB,11,12,61,64,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6005,-1,0.0125025045,0.98749757
6006,OAB,11,12,63,66,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6006,-1,0.0033935518,0.99660647
6007,bladder symptoms,15,17,82,98,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6007,-1,0.0013625193,0.9986375
6008,NGF,0,1,0,3,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6008,-1,0.9898747,0.010125267
6009,PGE2,2,3,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6009,-1,0.9939574,0.006042577
6010,PGF2alpha,4,5,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6010,-1,0.9917305,0.008269537
6011,PGI2,6,7,25,29,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6011,-1,0.9924971,0.007502925
6012,NGF,6,7,42,45,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6012,-1,0.9830329,0.016967135
6013,PG,8,9,50,52,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6013,-1,0.9536943,0.04630578
6014,OAB,16,17,97,100,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6014,-1,0.003102809,0.9968972
6015,NGF,3,4,17,20,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6015,-1,0.99060315,0.009396774
6016,PGE2,5,6,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6016,-1,0.9932868,0.006713221
6017,PGF2alpha,7,8,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6017,-1,0.991093,0.00890704
6018,OAB,14,15,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6018,-1,0.0036393602,0.9963606
6019,p,19,20,115,116,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6019,-1,0.1563204,0.84367967
6020,PGI2,3,4,17,21,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6020,-1,0.9808199,0.019180128
6021,OAB,12,13,75,78,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6021,-1,0.0037218784,0.9962781
6022,OAB,3,4,17,20,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6022,-1,0.006611577,0.9933884
6023,PGE2,5,6,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6023,-1,0.99266654,0.007333434
6024,p,20,21,126,127,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6024,-1,0.20455918,0.79544085
6025,NGF,1,2,8,11,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6025,-1,0.98859745,0.01140252
6026,PGF2alpha,3,4,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6026,-1,0.98940164,0.010598392
6027,PGI2,5,6,27,31,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6027,-1,0.9916734,0.008326575
6028,OAB,15,16,94,97,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6028,-1,0.0036377267,0.99636227
6029,NGF,2,3,13,16,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6029,-1,0.9932973,0.0067027747
6030,PGs,4,5,21,24,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6030,-1,0.98738134,0.012618667
6031,OAB,12,13,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6031,-1,0.0035499241,0.99645007
6032,OAB,12,13,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,-1,6032,-1,0.007452809,0.9925472
6034,infected with hepatitis C virus,7,12,48,79,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,-1,-1,6034,-1,0.004754442,0.9952455
6035,Chronic infection with hepatitis C virus,0,6,0,40,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,6035,-1,0.0056453845,0.9943546
6036,HCV,7,8,42,45,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,6036,-1,0.006628316,0.9933717
6040,HCV infection,5,7,31,44,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6040,-1,0.0026129235,0.9973871
6041,pegylated interferon,11,13,73,93,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6041,-1,0.99819857,0.0018014344
6046,HCV infection,20,22,138,151,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6046,-1,0.003029272,0.99697065
6047,renal,28,29,188,193,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6047,-1,0.0013927759,0.9986072
6048,cardiovascular disorders,30,32,197,221,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6048,-1,0.0011789269,0.9988211
6052,Viramidine,0,1,0,10,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6052,-1,0.9975956,0.002404353
6056,chronic hepatitis C.,28,31,181,201,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6056,-1,0.013482654,0.98651737
6060,fetal growth impairment,10,13,74,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,-1,-1,-1,6060,-1,0.0017926388,0.99820733
6066,reduced cerebellar growth,11,14,87,112,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6066,-1,0.0025320854,0.9974679
6067,decreased,17,18,124,133,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6067,-1,0.0061579305,0.993842
6068,to body growth,19,22,142,156,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6068,-1,0.008604645,0.9913954
6069,Amphetamine abuse,0,2,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,-1,-1,-1,6069,-1,0.655699,0.34430102
6071,amsacrine,5,6,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6071,-1,0.9979539,0.0020460996
6072,CI-921,7,8,41,47,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6072,-1,0.99635845,0.0036415586
6073,NSC 343499,9,11,49,59,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6073,-1,0.9395553,0.060444754
6074,lung cancer,15,17,79,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6074,-1,0.0015199049,0.99848014
6075,CI-921,0,1,0,6,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6075,-1,0.9583757,0.041624244
6076,NSC 343499,2,4,8,18,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6076,-1,0.5047402,0.49525982
6077,"9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide",5,9,20,110,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6077,-1,0.97157997,0.028419964
6078,lung cancer,14,16,84,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6078,-1,0.0012667967,0.9987332
6079,NSCLC,17,18,97,102,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6079,-1,0.0012396483,0.99876034
6080,squamous carcinoma,3,5,24,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6080,-1,0.0026214172,0.9973786
6081,adenocarcinoma,9,10,49,63,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6081,-1,0.0023669347,0.9976331
6083,large cell undifferentiated carcinoma,26,30,126,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6083,-1,0.0050985143,0.9949014
6086,grand mal seizures,21,24,105,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,-1,-1,6086,-1,0.0016299482,0.9983701
6087,nausea and vomiting,7,10,30,49,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,6087,-1,0.0011179631,0.998882
6088,phlebitis,16,17,78,87,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,6088,-1,0.0010037628,0.9989962
6089,squamous cell carcinoma,3,6,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,-1,6089,-1,0.001791472,0.9982085
6090,tumour,6,7,34,40,Further testing in this and other tumour types using multiple daily schedules is warranted.,1664218_8,-1,-1,-1,6090,-1,0.0027800312,0.9972199
6091,desipramine HCl,2,4,20,35,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6091,-1,0.9978423,0.0021576558
6092,cinacalcet HCl,7,9,59,73,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6092,-1,0.99800926,0.0019907334
6097,mg,31,32,191,193,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6097,-1,0.9206697,0.07933036
6099,mg,49,50,281,283,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6099,-1,0.8899802,0.11001976
6100,h,9,10,49,50,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,-1,6100,-1,0.07225521,0.9277448
6116,optic neuropathy,1,3,22,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,-1,-1,6116,-1,0.0012203988,0.9987796
6117,Ethambutol,2,3,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,-1,-1,6117,-1,0.9982571,0.0017428942
6120,hemianopia,8,9,50,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,-1,-1,-1,6120,-1,0.0009308871,0.99906915
6121,toxic optic neuropathy,7,10,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,-1,-1,6121,-1,0.0010220474,0.998978
6122,loss of,4,6,19,26,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6122,-1,0.003630101,0.99636996
6123,visual,7,8,35,41,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6123,-1,0.002522553,0.9974775
6124,", colour vision",9,12,48,63,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6124,-1,0.007101702,0.99289834
6125,Ishihara,13,14,65,73,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6125,-1,0.0035206536,0.99647933
6126,and visual field.,15,19,75,92,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6126,-1,0.012079633,0.9879204
6127,visual field loss,1,4,4,21,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,-1,-1,-1,6127,-1,0.0023442116,0.99765575
6128,ethambutol,4,5,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6128,-1,0.9985399,0.001460073
6129,visual,8,9,53,59,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6129,-1,0.004419362,0.9955806
6130,loss of visual function,8,12,43,66,OUTCOME: All 3 patients had some permanent loss of visual function.,16710500_9,-1,-1,-1,6130,-1,0.0020453627,0.9979546
6131,Ethambutol,2,3,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,-1,6131,-1,0.9983525,0.0016474418
6133,ethambutol,7,8,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6133,-1,0.9985683,0.0014316994
6134,chiasmopathy,9,10,61,73,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6134,-1,0.0011014378,0.9988985
6135,ethambutol,11,12,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6135,-1,0.9983809,0.0016191101
6136,neuroleptic malignant syndrome,1,4,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,-1,-1,-1,6136,-1,0.0018791337,0.99812084
6139,depressive symptoms,4,6,23,42,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6139,-1,0.0010059245,0.99899405
6141,insomnia,14,15,89,97,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6141,-1,0.001069047,0.998931
6142,loss of appetite,16,19,99,115,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6142,-1,0.002012858,0.99798715
6144,mg paroxetine,10,12,54,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6144,-1,0.99374807,0.0062518823
6145,mg alprazolam,14,16,76,89,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6145,-1,0.99361116,0.006388784
6148,psychomotor retardation,14,16,85,108,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6148,-1,0.0009667464,0.9990332
6149,disorientation,17,18,110,124,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6149,-1,0.0010659056,0.9989341
6150,muscle rigidity,21,23,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6150,-1,0.0013221304,0.9986778
6153,C,8,9,38,39,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6153,-1,0.028054679,0.9719453
6154,mg mm Hg,19,22,96,104,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6154,-1,0.01404584,0.9859541
6159,BUN,28,29,155,158,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,-1,-1,-1,6159,-1,0.9467458,0.053254236
6163,neuroleptic malignant syndrome,6,9,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6163,-1,0.04670796,0.9532921
6164,NMS,10,11,72,75,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6164,-1,0.0016637477,0.99833626
6167,adverse drug reaction,1,4,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6167,-1,0.0020325389,0.9979674
6168,adverse symptoms,25,27,151,167,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6168,-1,0.001368125,0.9986319
6169,NMS,4,5,25,28,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6169,-1,0.0012996051,0.9987004
6173,malnutrition,20,21,129,141,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6173,-1,0.001025506,0.99897456
6184,tricaine,6,7,47,55,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,-1,-1,-1,6184,-1,0.99870265,0.0012973252
6197,lidocaine convulsions,21,23,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,-1,6197,-1,0.045834694,0.9541653
6199,lidocaine seizures,3,5,37,55,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,-1,-1,-1,6199,-1,0.08809223,0.9119078
6204,plant extracts,16,18,100,114,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6204,-1,0.9767454,0.023254596
6205,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6205,-1,0.0019586745,0.9980413
6206,carbamylcholin,16,17,80,94,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,-1,-1,-1,6206,-1,0.99785846,0.0021415183
6209,mg,21,22,104,106,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,-1,-1,-1,6209,-1,0.88099474,0.11900526
6212,sweating,12,13,74,82,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,-1,6212,-1,0.0011756439,0.9988243
6220,hyperhidrosis,3,4,19,32,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6220,-1,0.0010874361,0.9989126
6221,hypersalivation,5,6,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6221,-1,0.0016054676,0.99839455
6222,bronchorrhoea,7,8,51,64,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6222,-1,0.0012016909,0.99879825
6223,miosis,11,12,77,83,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6223,-1,0.0011396017,0.99886036
6225,mg,8,9,33,35,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,-1,-1,-1,6225,-1,0.8559659,0.14403404
6228,dyspnoea,3,4,19,27,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6228,-1,0.00089912425,0.9991009
6229,bronchospasm,5,6,32,44,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6229,-1,0.0008708001,0.99912924
6230,Respiratory insufficiency,0,2,0,25,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6230,-1,0.0011098122,0.9988902
6231,Proteus mirabilis infection,6,9,50,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6231,-1,0.014287494,0.9857125
6232,bronchoconstriction,11,12,89,108,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6232,-1,0.0009044313,0.99909556
6233,heart failure,12,14,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,-1,-1,-1,6233,-1,0.0012747634,0.99872524
6237,cholinergics,11,12,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6237,-1,0.9933936,0.0066064214
6238,acute cardiovascular failure,17,20,105,133,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6238,-1,0.0010382413,0.9989618
6239,cognitive dysfunctions,12,14,81,103,Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.,16755009_0,-1,-1,-1,6239,-1,0.0012204197,0.9987796
6241,DCE,8,9,46,49,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6241,-1,0.95290226,0.047097787
6243,DCE,0,1,0,3,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,-1,-1,-1,6243,-1,0.995609,0.0043910253
6244,DCE,7,8,43,46,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,-1,-1,-1,6244,-1,0.9955499,0.00445012
6245,DCE,2,3,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,-1,-1,6245,-1,0.9948909,0.005109118
6250,DCE,10,11,68,71,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,-1,-1,-1,6250,-1,0.99691486,0.0030851616
6252,DCE,30,31,141,144,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,-1,-1,-1,6252,-1,0.99460703,0.0053930045
6253,DCE,2,3,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6253,-1,0.9928284,0.007171563
6254,cognitive dysfunctions,14,16,69,91,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6254,-1,0.0013334715,0.9986665
6256,Valproic acid,0,2,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,-1,6256,-1,0.9983398,0.0016602142
6257,Valproic acid,0,2,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6257,-1,0.9983285,0.0016714924
6258,VPA,3,4,15,18,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6258,-1,0.99697554,0.0030244126
6259,haemorrhagic pancreatitis,10,12,65,90,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,-1,-1,6259,-1,0.00090045185,0.9990996
6264,impaired consciousness,7,9,52,74,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,-1,-1,6264,-1,0.0015676604,0.99843234
6267,VPA,9,10,47,50,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,-1,-1,6267,-1,0.11372689,0.88627315
6270,Atorvastatin,0,1,0,12,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,-1,-1,6270,-1,0.9984664,0.0015336602
6272,atorvastatin,6,7,37,49,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6272,-1,0.9985079,0.0014921125
6273,atorva,8,9,51,57,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6273,-1,0.99767786,0.0023221404
6276,atorva,22,23,150,156,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6276,-1,0.9976769,0.0023230962
6280,P,36,37,152,153,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,-1,6280,-1,0.13584836,0.86415166
6281,atorva,8,9,37,43,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6281,-1,0.24864253,0.75135744
6283,P,37,38,169,170,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6283,-1,0.19027005,0.80972993
6284,Atorva,0,1,0,6,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6284,-1,0.9826681,0.017331883
6286,mmHg,9,10,54,58,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6286,-1,0.005862925,0.99413705
6287,mmHg P,16,18,76,82,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6287,-1,0.06233296,0.9376671
6290,atorva,37,38,160,166,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6290,-1,0.97460335,0.025396604
6292,P,41,42,174,175,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6292,-1,0.1519141,0.84808594
6293,P,29,30,154,155,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,-1,6293,-1,0.18009043,0.8199096
6294,Atorva,0,1,0,6,Atorva affected neither plasma NOx nor thymus weight.,16820346_6,-1,-1,-1,6294,-1,0.28059587,0.71940416
6295,atorvastatin,2,3,6,18,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,-1,-1,6295,-1,0.9984518,0.0015481071
6298,cytosine arabinoside,5,7,42,62,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6298,-1,0.9983481,0.0016519435
6299,acute myeloid leukemia,12,15,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6299,-1,0.0010577756,0.9989422
6300,central nervous system toxicity,1,5,4,35,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6300,-1,0.0012865798,0.9987134
6301,cytosine arabinoside,7,9,49,69,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6301,-1,0.9982358,0.0017641094
6303,cytosine arabinoside,17,19,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6303,-1,0.99812394,0.0018760685
6304,acute myeloid leukemia,7,10,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,-1,-1,-1,6304,-1,0.0011911017,0.99880886
6305,cytosine arabinoside,9,11,60,80,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,-1,6305,-1,0.99840134,0.0015986848
6306,cytosine arabinoside,5,7,30,50,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6306,-1,0.9981402,0.0018597833
6307,numbness,28,29,159,167,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6307,-1,0.0011791089,0.99882084
6312,cytosine arabinoside,11,13,78,98,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6312,-1,0.99805164,0.0019484266
6316,dopaminergic neurotoxicity,2,4,29,55,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,-1,6316,-1,0.0025710247,0.99742895
6317,reactive oxygen species,14,17,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6317,-1,0.37266245,0.6273375
6319,DFO,21,22,121,124,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6319,-1,0.99741864,0.0025813782
6322,MA,5,6,28,30,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6322,-1,0.99496245,0.0050375382
6323,h,12,13,50,51,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6323,-1,0.2869178,0.7130822
6324,DFO,21,22,114,117,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,-1,-1,-1,6324,-1,0.99737847,0.002621587
6326,DA,5,6,32,34,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6326,-1,0.99567986,0.0043200664
6328,DFO,25,26,158,161,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6328,-1,0.9971456,0.0028544462
6329,DFO,2,3,13,16,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,-1,-1,6329,-1,0.9965586,0.003441353
6331,reduced glutathione,9,11,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,-1,-1,-1,6331,-1,0.980772,0.019227982
6332,DFO,8,9,60,63,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,-1,-1,-1,6332,-1,0.99650407,0.003495892
6333,DFO,5,6,32,35,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,-1,-1,6333,-1,0.9968052,0.0031948574
6337,cerebral haemorrhages,12,14,84,105,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6337,-1,0.0011449422,0.9988551
6344,p,27,28,102,103,"Of the 59 cases, 26 (44%) had a fatal outcome, compared to 136 (25%) among the non-warfarin patients (p < 0.01).",16858720_6,-1,-1,-1,6344,-1,0.07531497,0.92468506
6345,haemorrhage,8,9,58,69,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,-1,6345,-1,0.0011487254,0.9988513
6348,cerebral haemorrhages,3,5,30,51,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,-1,6348,-1,0.0012059783,0.99879396
6349,cerebral haemorrhages,5,7,45,66,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,-1,-1,-1,6349,-1,0.00096465694,0.99903536
6351,thioperamide,3,4,30,42,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,-1,-1,-1,6351,-1,0.998588,0.0014119886
6359,RAMH,2,3,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6359,-1,0.9955426,0.0044573783
6360,thioperamide,11,12,55,67,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6360,-1,0.99854577,0.0014542289
6361,THP,13,14,69,72,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6361,-1,0.9972927,0.0027072704
6362,se,23,24,95,97,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6362,-1,0.70138144,0.2986186
6364,THP,2,3,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6364,-1,0.99748456,0.0025154639
6365,h,14,15,54,55,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6365,-1,0.4603934,0.5396066
6368,P,28,29,139,140,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6368,-1,0.15666516,0.84333485
6369,RAMH,4,5,27,31,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6369,-1,0.99595356,0.00404649
6370,THP,11,12,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6370,-1,0.99777263,0.002227315
6371,RAMH,0,1,0,4,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6371,-1,0.850137,0.14986296
6372,se,2,3,9,11,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6372,-1,0.9567712,0.043228883
6373,THP,16,17,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6373,-1,0.99747086,0.00252921
6374,se,24,25,124,126,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6374,-1,0.95279443,0.04720558
6376,THP,4,5,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6376,-1,0.9974106,0.0025894146
6377,P,23,24,129,130,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6377,-1,0.22854687,0.77145314
6378,RAMH,2,3,18,22,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6378,-1,0.9965295,0.0034704448
6379,THP,15,16,81,84,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6379,-1,0.99761486,0.002385207
6381,THP,11,12,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,-1,-1,-1,6381,-1,0.9974789,0.0025211354
6382,RAMH,11,12,53,57,"Such an effect was, however, reversed in presence of RAMH.",16867021_11,-1,-1,-1,6382,-1,0.9940599,0.0059400606
6383,THP,0,1,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,-1,6383,-1,0.9953703,0.004629604
6386,THP,3,4,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6386,-1,0.9963917,0.0036083164
6387,RAMH,7,8,37,41,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6387,-1,0.9963955,0.0036045278
6397,fluphenazine,4,5,23,35,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6397,-1,0.998831,0.0011690208
6398,SCH 23390,8,10,52,61,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6398,-1,0.99771607,0.0022839622
6401,fluphenazine,3,4,14,26,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,-1,6401,-1,0.99885845,0.0011415536
6403,SCH 23390,2,4,15,24,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,-1,-1,6403,-1,0.9974222,0.0025778103
6406,SKF 38393,4,6,15,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6406,-1,0.9965828,0.003417255
6407,quinpirole,9,10,40,50,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6407,-1,0.9988237,0.0011763346
6409,fluphenazine,15,16,86,98,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6409,-1,0.9988438,0.001156197
6410,SCH 23390,17,19,100,109,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6410,-1,0.99762374,0.0023762295
6412,SKF 38393,2,4,15,24,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6412,-1,0.99709773,0.0029023257
6413,quinpirole,5,6,30,40,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6413,-1,0.9988385,0.0011615732
6417,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,-1,-1,-1,6417,-1,0.0023621675,0.99763787
6419,radiculopathy,7,8,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,-1,6419,-1,0.0010881957,0.99891186
6421,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,-1,-1,-1,6421,-1,0.0027078574,0.9972921
6422,cauda equina syndrome,7,10,34,55,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6422,-1,0.0022267299,0.99777323
6423,triamcinolone,16,17,97,110,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6423,-1,0.9987282,0.0012718019
6425,low,7,8,44,47,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6425,-1,0.0026832025,0.9973168
6426,leg pain,11,13,63,71,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6426,-1,0.0016769808,0.998323
6428,contrast medium,3,5,14,29,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,-1,-1,-1,6428,-1,0.3535099,0.6464901
6431,perineal numbness,7,9,37,54,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6431,-1,0.0013022245,0.99869776
6432,lower extremity weakness,10,13,59,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6432,-1,0.0017137333,0.9982862
6433,loss of sensation,4,7,35,52,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,-1,-1,-1,6433,-1,0.0019373143,0.9980627
6435,neurologic deterioration,6,8,49,73,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,-1,-1,-1,6435,-1,0.00090985064,0.9990902
6439,androgen,8,9,46,54,OBJECTIVES: To study the long-term effects of androgen treatment on atherosclerosis in postmenopausal women.,16938416_1,-1,-1,-1,6439,-1,0.996349,0.0036509999
6446,n=11,14,15,79,83,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,-1,-1,6446,-1,0.02935951,0.9706405
6454,androgen,19,20,147,155,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,-1,-1,-1,6454,-1,0.9969228,0.0030771655
6455,hepatitis B,8,10,63,74,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,-1,-1,-1,6455,-1,0.0042967554,0.9957033
6458,Hepatitis B virus (HBV) infection,0,7,0,33,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6458,-1,0.005704179,0.9942958
6459,liver cirrhosis,10,12,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6459,-1,0.001358795,0.9986412
6463,hepatitis B,3,5,15,26,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6463,-1,0.007438456,0.9925615
6466,cibenzoline,6,7,45,56,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,-1,-1,6466,-1,0.9984786,0.0015213722
6468,ventricular arrhythmia,11,13,93,115,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,-1,-1,-1,6468,-1,0.0011580868,0.99884194
6469,Digitalis arrhythmia,0,2,0,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6469,-1,0.0033742802,0.9966258
6470,Na channel,7,9,45,55,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6470,-1,0.98161364,0.01838637
6472,Adrenaline arrhythmia,0,2,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6472,-1,0.47680554,0.52319443
6473,Ca,7,8,46,48,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6473,-1,0.9938221,0.0061779004
6474,blockers,9,10,57,65,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6474,-1,0.979047,0.020953007
6478,SD,29,30,184,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6478,-1,0.11001297,0.889987
6479,n,31,32,188,189,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6479,-1,0.3057224,0.69427764
6483,SD,29,30,185,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6483,-1,0.11552747,0.8844725
6484,n,31,32,189,190,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6484,-1,0.3113216,0.6886784
6485,Na,21,22,141,143,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6485,-1,0.9905151,0.009484853
6486,Ca,30,31,183,185,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6486,-1,0.98340285,0.016597131
6488,gliomas,7,8,42,49,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,-1,-1,-1,6488,-1,0.0012728573,0.99872714
6490,brain edema,8,10,42,53,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6490,-1,0.0010405049,0.99895954
6491,ICP,13,14,73,76,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6491,-1,0.0011326682,0.9988674
6492,brain tumor,15,17,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6492,-1,0.001999103,0.9980009
6495,brain tumor,22,24,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,-1,-1,6495,-1,0.0019697177,0.99803025
6497,malignant glioma,21,23,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6497,-1,0.0013424999,0.99865746
6498,brain metastases,25,27,114,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6498,-1,0.001489811,0.9985102
6499,meningioma,29,30,140,150,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6499,-1,0.0012111139,0.9987889
6500,edematous,8,9,46,55,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,-1,-1,-1,6500,-1,0.0037621025,0.9962379
6502,glioma,25,26,144,150,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,-1,-1,-1,6502,-1,0.0016990142,0.99830097
6504,meningioma,1,2,3,13,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6504,-1,0.0010584592,0.9989416
6505,metastases,3,4,18,28,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6505,-1,0.0015816673,0.99841833
6508,gliomas,23,24,122,129,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,-1,6508,-1,0.001642395,0.9983576
6511,atrial fibrillation,5,7,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,-1,-1,6511,-1,0.0013568694,0.9986431
6512,Atrial fibrillation,0,2,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,-1,-1,6512,-1,0.001727013,0.998273
6519,Ximelagatran,0,1,0,12,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6519,-1,0.9981938,0.0018061685
6520,direct thrombin inhibitor,4,7,22,47,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6520,-1,0.9621465,0.03785349
6521,vitamin K,15,17,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6521,-1,0.9975871,0.0024129408
6522,embolic events,23,25,129,143,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6522,-1,0.0009649493,0.9990351
6523,abnormal liver function tests,33,37,188,217,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6523,-1,0.0026516947,0.9973483
6524,Atrial Fibrillation Clopidogrel,3,6,14,45,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6524,-1,0.11879646,0.88120353
6525,Irbesartan,8,9,57,67,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6525,-1,0.9981111,0.0018888859
6526,Vascular Events,12,14,86,101,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6526,-1,0.0012092091,0.9987908
6530,af embolic events,33,36,217,234,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6530,-1,0.0015918692,0.99840814
6531,Idraparinux,0,1,0,11,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6531,-1,0.99504554,0.004954444
6532,Factor Xa,3,5,15,24,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6532,-1,0.88338554,0.11661442
6533,atrial fibrillation,13,15,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6533,-1,0.0012189606,0.998781
6534,enzyme inhibitors,1,3,23,40,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6534,-1,0.9792467,0.02075331
6535,angiotensin II,4,6,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6535,-1,0.99372864,0.0062714033
6536,atrial fibrillation,11,13,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6536,-1,0.001335804,0.99866414
6537,cardiac remodelling,14,16,128,147,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6537,-1,0.0013948082,0.9986052
6540,EPS,6,7,52,55,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6540,-1,0.0009428905,0.9990571
6541,quetiapine,9,10,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6541,-1,0.9986327,0.001367264
6542,bipolar mania,16,18,112,125,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6542,-1,0.00087008014,0.99912995
6544,EPS,7,8,49,52,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6544,-1,0.0012632165,0.9987368
6545,akathisia,11,12,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6545,-1,0.001269339,0.9987306
6546,quetiapine,14,15,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6546,-1,0.998678,0.0013219077
6547,bipolar mania,18,20,109,122,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6547,-1,0.0010570344,0.99894303
6548,quetiapine,3,4,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6548,-1,0.99874276,0.0012573245
6549,n,12,13,65,66,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6549,-1,0.2597643,0.7402356
6550,n,19,20,90,91,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6550,-1,0.27156,0.7284399
6553,quetiapine,3,4,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6553,-1,0.99867743,0.0013224895
6555,divalproex,19,20,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6555,-1,0.99847335,0.0015266117
6556,n,26,27,129,130,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6556,-1,0.27901688,0.7209831
6557,n,42,43,194,195,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6557,-1,0.25292826,0.74707174
6559,Akathisia,14,15,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,-1,-1,6559,-1,0.0019769056,0.99802315
6560,akathisia,10,11,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6560,-1,0.0016638363,0.99833614
6561,quetiapine,16,17,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6561,-1,0.9986564,0.001343641
6562,QTP,6,7,43,46,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6562,-1,0.011166463,0.98883355
6563,EPS,4,5,26,29,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6563,-1,0.0012213675,0.99877864
6565,n,15,16,86,87,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6565,-1,0.10800593,0.89199406
6567,n,30,31,155,156,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6567,-1,0.11992632,0.88007367
6568,EPS,40,41,213,216,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6568,-1,0.0013070165,0.99869305
6569,akathisia,3,4,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6569,-1,0.0011289837,0.998871
6570,quetiapine,9,10,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6570,-1,0.9986173,0.0013827448
6572,p,9,10,62,63,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6572,-1,0.22967051,0.77032954
6574,quetiapine,20,21,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6574,-1,0.9985964,0.0014036141
6580,p,7,8,54,55,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6580,-1,0.13405816,0.8659418
6581,akathisia,12,13,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6581,-1,0.0011476186,0.9988524
6583,extrapyramidal syndrome,31,33,131,154,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6583,-1,0.0010313728,0.9989686
6584,quetiapine,41,42,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6584,-1,0.99864346,0.0013565582
6585,quetiapine,6,7,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,-1,6585,-1,0.9985367,0.0014632953
6586,quetiapine,7,8,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,-1,-1,-1,6586,-1,0.99853337,0.0014666672
6587,bipolar mania,3,5,16,29,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6587,-1,0.0011329311,0.99886715
6588,EPS,9,10,48,51,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6588,-1,0.0010325516,0.9989674
6589,akathisia,12,13,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6589,-1,0.0016375327,0.9983625
6590,quetiapine,15,16,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6590,-1,0.99864846,0.0013515719
6591,atorvastatin,3,4,24,36,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,-1,6591,-1,0.9986854,0.0013145718
6595,dysfunction,7,8,73,84,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6595,-1,0.001300512,0.9986994
6596,nitric oxide,10,12,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6596,-1,0.99548364,0.004516333
6598,O2-,20,21,156,159,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6598,-1,0.97591954,0.024080524
6599,Atorvastatin,0,1,0,12,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6599,-1,0.99812704,0.0018730031
6600,Ato,2,3,14,17,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6600,-1,0.9955064,0.004493591
6601,O2-,22,23,157,160,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6601,-1,0.95575327,0.044246715
6603,Ato,16,17,70,73,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6603,-1,0.99003255,0.009967431
6604,O2-,30,31,154,157,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6604,-1,0.935021,0.06497908
6605,SD,34,35,177,179,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6605,-1,0.02089972,0.9791003
6606,SD,3,4,8,10,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6606,-1,0.008425688,0.99157435
6607,n,6,7,17,18,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6607,-1,0.14994435,0.8500557
6608,Ato,13,14,43,46,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6608,-1,0.9935423,0.0064577204
6609,water,21,22,77,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6609,-1,0.59648585,0.40351418
6612,P,30,31,119,120,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,-1,6612,-1,0.10061096,0.899389
6613,Ato,2,3,7,10,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6613,-1,0.048285715,0.95171434
6615,P,29,30,106,107,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6615,-1,0.1309825,0.8690174
6617,P,48,49,192,193,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6617,-1,0.14996813,0.85003185
6619,Ato,12,13,84,87,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6619,-1,0.67221546,0.32778457
6621,P,21,22,122,123,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6621,-1,0.13187106,0.8681289
6622,P,25,26,135,136,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6622,-1,0.15083838,0.8491616
6625,Ato,9,10,52,55,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6625,-1,0.20896596,0.79103404
6627,P,20,21,110,111,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6627,-1,0.15751188,0.8424881
6628,Ato,2,3,15,18,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6628,-1,0.9825815,0.017418457
6630,SD,15,16,111,113,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6630,-1,0.00546375,0.9945363
6632,hypothermic,6,7,38,49,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6632,-1,0.0015956995,0.9984043
6633,Chiari malformation,12,14,78,97,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6633,-1,0.0014389663,0.9985611
6634,hypothermic,9,10,67,78,"During anaesthesia and surgery, he inadvertently became moderately hypothermic.",17049862_1,-1,-1,-1,6634,-1,0.0019489978,0.99805105
6645,lead,9,10,63,67,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6645,-1,0.004472905,0.9955271
6646,cardiac,13,14,82,89,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6646,-1,0.001201651,0.9987984
6648,chorea,1,2,18,24,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6648,-1,0.0009170596,0.9990829
6650,nonketotic hyperglycinemia,6,8,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6650,-1,0.0012567259,0.99874336
6651,hyperglycinemia,1,2,11,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6651,-1,0.001468633,0.99853134
6652,disorder of amino acid metabolism,4,9,32,65,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6652,-1,0.01937988,0.98062015
6655,neonatal apnea,7,9,37,51,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6655,-1,0.0012067311,0.99879324
6657,hypotonia,14,15,79,88,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6657,-1,0.0009343352,0.9990657
6658,psychomotor retardation,19,21,114,137,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6658,-1,0.00092214503,0.9990778
6659,nonketotic hyperglycinemia,6,8,37,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6659,-1,0.001764588,0.99823534
6660,language delay,7,9,42,56,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6660,-1,0.0012937296,0.9987062
6661,mental retardation,10,12,61,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6661,-1,0.0010052397,0.99899477
6662,hyperglycinemia,19,20,114,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6662,-1,0.001218905,0.99878114
6664,chorea,27,28,187,193,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6664,-1,0.000994591,0.9990054
6665,valproate,32,33,222,231,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6665,-1,0.99867296,0.0013271114
6666,citrate toxicity,1,3,7,23,Severe citrate toxicity complicating volunteer apheresis platelet donation.,17111419_0,-1,-1,-1,6666,-1,0.078401245,0.9215988
6667,citrate toxicity,6,8,27,43,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,-1,6667,-1,0.15069635,0.84930366
6669,hyperlipidemia,8,9,54,68,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,-1,-1,6669,-1,0.0012203326,0.9987797
6671,bumetanide,3,4,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,-1,-1,-1,6671,-1,0.9985934,0.0014065981
6675,calcium gluconate,4,6,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6675,-1,0.9980757,0.0019242824
6676,muscle contractions,10,12,74,93,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6676,-1,0.0017643949,0.9982356
6680,bumetanide,9,10,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6680,-1,0.99839574,0.001604294
6681,loop diuretic,12,14,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6681,-1,0.0735911,0.92640895
6684,citrate toxicity,22,24,161,177,We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.,17111419_10,-1,-1,-1,6684,-1,0.15707558,0.8429245
6687,cerebral ischemia,6,8,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6687,-1,0.00089472614,0.9991053
6688,brain edema,11,13,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6688,-1,0.0011122111,0.99888784
6690,middle cerebral artery occlusion,11,15,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6690,-1,0.0033843236,0.9966157
6691,MCAO,16,17,108,112,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6691,-1,0.0020821989,0.99791783
6692,brain edema,19,21,117,128,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6692,-1,0.0013554842,0.99864453
6695,n,5,6,22,23,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6695,-1,0.110775985,0.88922405
6696,MAP,15,16,58,61,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6696,-1,0.0066563236,0.9933437
6698,n,5,6,27,28,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6698,-1,0.04295504,0.95704496
6699,MAP,11,12,39,42,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6699,-1,0.0039202366,0.99607974
6700,mm Hg,18,20,65,70,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6700,-1,0.011598751,0.9884013
6701,h,22,23,83,84,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6701,-1,0.030589115,0.9694109
6702,MCAO,24,25,91,95,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6702,-1,0.0041104974,0.9958895
6703,MCAO,3,4,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,-1,-1,-1,6703,-1,0.0037798113,0.9962202
6705,MCAO,14,15,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,-1,6705,-1,0.011784899,0.9882151
6706,ischemic,23,24,112,120,Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).,1711760_7,-1,-1,-1,6706,-1,0.0030986643,0.9969014
6707,neuronal injury,3,5,14,29,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6707,-1,0.0015577661,0.99844223
6708,"2,3,5-triphenyltetrazolium",8,9,48,74,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6708,-1,0.9950511,0.004948923
6709,ischemic,2,3,7,15,"In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.",1711760_9,-1,-1,-1,6709,-1,0.002673315,0.9973266
6710,ischemic,5,6,24,32,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6710,-1,0.0024828862,0.9975171
6713,P,34,35,162,163,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6713,-1,0.12876856,0.8712314
6715,P,36,37,154,155,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,-1,6715,-1,0.17428236,0.8257176
6717,h,8,9,71,72,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6717,-1,0.07337962,0.92662036
6718,MCAO,10,11,79,83,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6718,-1,0.0063200756,0.9936799
6720,ischemic,17,18,116,124,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6720,-1,0.0032311159,0.99676895
6722,ischemic,29,30,178,186,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6722,-1,0.003738676,0.9962613
6723,neuronal dysfunction,40,42,244,264,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6723,-1,0.0018334812,0.9981665
6728,chronic allograft nephropathy,15,18,106,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,-1,-1,6728,-1,0.0011257844,0.99887425
6730,autoimmunity,8,9,47,59,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6730,-1,0.0009419664,0.99905807
6731,cystic renal diseases,10,13,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6731,-1,0.0009895038,0.99901044
6732,renal cancer,14,16,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6732,-1,0.0010332174,0.9989668
6734,calcineurin inhibitors,12,14,82,104,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,-1,-1,-1,6734,-1,0.9914199,0.008580093
6737,acute renal dysfunction,17,20,111,134,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,-1,-1,6737,-1,0.0009552385,0.9990447
6738,chronic renal damage,10,13,60,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,-1,-1,6738,-1,0.0010039208,0.9989961
6740,calcineurin,19,20,143,154,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,-1,-1,-1,6740,-1,0.99538785,0.004612181
6742,acute renal dysfunction,1,4,4,27,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6742,-1,0.001133652,0.9988663
6744,delayed graft function,11,14,66,88,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6744,-1,0.0018621527,0.99813783
6748,angiotensin II,49,51,317,331,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,-1,6748,-1,0.9933535,0.0066464967
6754,SRL,2,3,11,14,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,-1,-1,-1,6754,-1,0.9952618,0.0047381516
6758,SRL,18,19,128,131,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,-1,-1,-1,6758,-1,0.9296757,0.07032432
6759,SRL,13,14,55,58,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6759,-1,0.9963946,0.0036054906
6760,chronic allograft nephropathy,20,23,89,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6760,-1,0.0019022948,0.9980977
6761,CAN,24,25,120,123,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6761,-1,0.0053143627,0.99468565
6762,n,27,28,126,127,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6762,-1,0.027757313,0.97224265
6763,neoplasia,31,32,134,143,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6763,-1,0.0017831636,0.9982168
6764,n,33,34,145,146,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6764,-1,0.019780582,0.9802194
6765,Kaposi's sarcoma,37,40,153,169,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6765,-1,0.0027405133,0.9972595
6766,skin cancers,42,44,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6766,-1,0.002014739,0.99798524
6767,intestinal tumors,46,48,194,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6767,-1,0.002268715,0.99773127
6768,renal cell carsinom,50,53,217,236,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6768,-1,0.003769052,0.9962309
6770,n,59,60,263,264,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6770,-1,0.022708263,0.9772917
6771,SRL,0,1,0,3,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,-1,-1,-1,6771,-1,0.016986765,0.9830132
6772,SRL,3,4,18,21,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,-1,6772,-1,0.9940567,0.0059433226
6774,P,23,24,108,109,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,-1,-1,6774,-1,0.10355745,0.89644253
6780,membranoproliferative glomerulopathy,11,13,75,111,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,-1,-1,6780,-1,0.0010611269,0.99893886
6783,SRL,3,4,17,20,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6783,-1,0.9965508,0.0034492002
6784,P,15,16,71,72,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6784,-1,0.15396748,0.84603256
6785,Kaposi's sarcoma,5,8,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,-1,-1,-1,6785,-1,0.0024216808,0.9975783
6786,P,29,30,131,132,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,-1,6786,-1,0.12869601,0.871304
6788,P,15,16,89,90,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,-1,-1,-1,6788,-1,0.1151283,0.8848717
6790,SRL,8,9,46,49,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,-1,-1,-1,6790,-1,0.99621034,0.0037896135
6792,SRL,8,9,54,57,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6792,-1,0.99102753,0.008972459
6796,AAS,17,18,101,104,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6796,-1,0.9937499,0.0062500043
6799,5-HT,26,27,157,161,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6799,-1,0.99485767,0.0051423036
6801,parachlorophenylalanine,9,10,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6801,-1,0.99840873,0.0015912584
6802,PCPA,11,12,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6802,-1,0.9956221,0.0043779514
6807,5-HT,3,4,16,20,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6807,-1,0.9937057,0.006294308
6808,5-hydroxyindoleacetic acid,8,10,41,67,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6808,-1,0.9951138,0.0048862495
6809,5-HIAA,11,12,69,75,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6809,-1,0.9941109,0.005889089
6810,PCPA,0,1,0,4,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6810,-1,0.99661547,0.0033845808
6811,5-HT,5,6,46,50,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6811,-1,0.9939626,0.00603737
6812,5-HIAA,7,8,55,61,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6812,-1,0.9921767,0.007823314
6813,T,1,2,8,9,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6813,-1,0.9953355,0.0046645207
6814,5-HT,5,6,44,48,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6814,-1,0.9927336,0.007266333
6815,5-HIAA,7,8,53,59,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6815,-1,0.99064696,0.009353017
6816,PCPA,20,21,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6816,-1,0.99501735,0.004982724
6817,PCPA,3,4,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,-1,6817,-1,0.9962597,0.0037402872
6822,5-HT,16,17,83,87,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,-1,-1,6822,-1,0.9949155,0.005084478
6824,ifosfamide renal toxicity,3,6,23,48,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6824,-1,0.5835585,0.41644153
6825,malignant mesenchymal tumors,10,13,73,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6825,-1,0.0017717894,0.99822825
6826,malignant mesenchymal tumors,7,10,39,67,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6826,-1,0.0022622999,0.99773765
6828,Malignant Mesenchymal Tumor,28,31,199,226,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6828,-1,0.0038811308,0.9961189
6832,dactinomycin,21,22,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6832,-1,0.9987238,0.0012761428
6833,IVA,23,24,120,123,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6833,-1,0.97339094,0.026609099
6836,glucosuria,11,12,78,88,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6836,-1,0.007816236,0.99218374
6838,aminoaciduria,15,16,103,116,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6838,-1,0.1468153,0.85318476
6841,renal abnormalities,19,21,81,100,"Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities.",1720453_7,-1,-1,-1,6841,-1,0.0014750395,0.99852496
6843,Fanconi's syndrome,30,33,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6843,-1,0.0031823944,0.9968176
6844,TDFS,34,35,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6844,-1,0.0018455603,0.99815446
6849,TDFS,8,9,28,32,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6849,-1,0.0052737035,0.99472624
6851,mesenchymal tumors,23,25,114,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6851,-1,0.0015671208,0.9984328
6855,contrast,1,2,3,11,"In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable.",17241657_2,-1,-1,-1,6855,-1,0.11502012,0.88497996
6856,1-(2-phenethyl)-4-(2-pyridyl)-piperazine,10,11,55,95,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6856,-1,0.9885203,0.011479652
6857,1-(2-phenethyl)-4-(2-pyridyl)-piperazine,10,11,55,95,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6857,-1,0.9885203,0.011479652
6858,3alpha-tropanyl-2-(4-chorophenoxy)butyrate,16,17,114,156,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6858,-1,0.9920373,0.007962696
6859,3alpha-tropanyl-2-(4-chorophenoxy)butyrate,16,17,114,156,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6859,-1,0.9920373,0.007962696
6860,UMB24,10,11,63,68,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,-1,-1,-1,6860,-1,0.995856,0.0041439645
6862,UMB24,18,19,115,120,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,-1,6862,-1,0.9968266,0.003173434
6868,hyperCKaemia,7,8,45,57,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,-1,-1,6868,-1,0.0014718166,0.9985281
6893,contrast,8,9,49,57,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6893,-1,0.08382965,0.91617036
6894,adenosine-5'-triphosphate,10,11,70,95,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,-1,6894,-1,0.9961479,0.0038520906
6896,4-DAMP,8,9,84,90,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6896,-1,0.99237376,0.007626264
6897,methoctramine,16,17,122,135,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6897,-1,0.9987685,0.0012314498
6898,pirenzepine,23,24,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6898,-1,0.99873954,0.0012604418
6899,4-DAMP,0,1,0,6,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6899,-1,0.9959124,0.004087633
6900,methoctramine,10,11,71,84,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6900,-1,0.9987947,0.0012053445
6901,pirenzepine,12,13,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6901,-1,0.9986387,0.0013612722
6902,pirenzepine,22,23,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6902,-1,0.99825364,0.0017463196
6903,4-DAMP,24,25,178,184,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6903,-1,0.9963432,0.003656812
6904,contrast,1,2,3,11,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6904,-1,0.12266317,0.87733686
6905,methoctramine,5,6,25,38,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6905,-1,0.99864787,0.001352119
6907,ATP,5,6,36,39,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,-1,6907,-1,0.9982126,0.0017874158
6911,cardiovascular disease,14,16,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6911,-1,0.0011013042,0.9988986
6913,coronary heart disease,20,23,147,169,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6913,-1,0.0014245904,0.99857545
6914,chronic heart failure,25,28,175,196,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6914,-1,0.0014409485,0.99855906
6921,bradycardic,2,3,10,21,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,-1,6921,-1,0.0011247295,0.9988752
6925,bradycardic,12,13,84,95,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,-1,6925,-1,0.0013144643,0.99868554
6928,cerebral palsy,6,8,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,-1,-1,6928,-1,0.0009745582,0.99902546
6932,cerebral palsy,9,11,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6932,-1,0.0009760634,0.9990239
6933,seizure disorder,12,14,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6933,-1,0.0009371767,0.99906284
6935,restlessness,18,19,106,118,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6935,-1,0.0010373811,0.99896264
6936,baclofen,26,27,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6936,-1,0.9985208,0.001479268
6938,anxiety,27,28,166,173,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,-1,6938,-1,0.0015518931,0.99844813
6944,mg,26,27,166,168,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,-1,-1,-1,6944,-1,0.9601204,0.039879687
6945,abdominal pain,15,17,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,-1,-1,6945,-1,0.0013344627,0.9986656
6951,ARB,13,14,89,92,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,-1,-1,-1,6951,-1,0.99328506,0.00671497
6953,Granulomatous hepatitis,0,2,0,23,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6953,-1,0.0011563193,0.99884367
6955,clavulanic acid,8,10,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6955,-1,0.9983999,0.0016001202
6957,granulomas,14,15,108,118,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,-1,-1,-1,6957,-1,0.0013371208,0.9986628
6959,cholestatic syndrome,21,23,119,139,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,-1,-1,6959,-1,0.0010472714,0.99895275
6960,granulomas,3,4,19,29,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,-1,-1,-1,6960,-1,0.0009987317,0.9990013
6965,clavulanic acid,26,28,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,-1,-1,-1,6965,-1,0.99823916,0.0017608309
6968,atrioventricular block,6,8,37,59,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,-1,-1,6968,-1,0.0013647967,0.99863523
6971,sinus tachycardias,4,6,28,46,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6971,-1,0.0011717471,0.99882823
6972,carbamazepine overdose,12,14,75,97,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6972,-1,0.6370531,0.36294687
6973,bradyarrhythmias,13,14,106,122,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6973,-1,0.00075565255,0.99924433
6974,atrioventricular conduction delay,15,18,126,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6974,-1,0.001444026,0.99855596
6982,cardiac damage,9,11,65,79,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,-1,6982,-1,0.0012082428,0.99879175
6991,mm,17,18,116,118,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6991,-1,0.0067012543,0.99329877
6992,mm,23,24,139,141,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6992,-1,0.008444956,0.99155504
6993,p,28,29,164,165,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6993,-1,0.07358122,0.9264188
6995,mm,22,23,157,159,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6995,-1,0.0074436576,0.9925564
6996,mm,28,29,180,182,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6996,-1,0.009043557,0.9909565
6997,p,33,34,205,206,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6997,-1,0.09599854,0.9040014
6999,iodine-125-metaiodobenzylguanidine,11,12,99,133,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,-1,-1,-1,6999,-1,0.9978872,0.0021127637
7000,metaiodobenzylguanidine,1,2,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7000,-1,0.9975313,0.0024686663
7001,MIBG,3,4,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7001,-1,0.99660766,0.0033923357
7003,NE,11,12,74,76,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7003,-1,0.99726343,0.0027365123
7005,adriamycin cardiomyopathy,25,27,180,205,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,-1,7005,-1,0.68330747,0.31669256
7006,degeneration of myocardial cells,4,8,23,55,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,-1,-1,-1,7006,-1,0.0023536044,0.9976464
7008,p,39,40,202,203,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,-1,-1,-1,7008,-1,0.1195832,0.8804168
7009,MIBG,5,6,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7009,-1,0.98843503,0.011564994
7010,p,27,28,127,128,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7010,-1,0.08144688,0.9185531
7011,MIBG,5,6,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7011,-1,0.9859767,0.014023273
7012,p,27,28,127,128,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7012,-1,0.08279924,0.91720074
7013,MIBG,2,3,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,-1,7013,-1,0.98475385,0.015246159
7015,myocardial impairment,13,15,88,109,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,7015,-1,0.0013957091,0.99860436
7022,hearing loss,22,24,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,-1,7022,-1,0.0016799641,0.99832004
7024,hearing impairment,12,14,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,-1,-1,-1,7024,-1,0.0014319147,0.99856806
7026,n=200,8,9,58,63,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7026,-1,0.036946427,0.9630536
7027,n=200,20,21,116,121,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7027,-1,0.039040867,0.96095914
7028,n=88,14,15,69,73,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7028,-1,0.11141559,0.8885844
7029,n=76,28,29,121,125,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7029,-1,0.06418525,0.93581474
7030,n=36,41,42,165,169,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7030,-1,0.10268079,0.8973192
7034,QT prolongation,2,4,12,27,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7034,-1,0.0013307031,0.99866927
7036,heroin dependence,10,12,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7036,-1,0.39978033,0.60021967
7038,heroin,6,7,39,45,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,-1,-1,-1,7038,-1,0.9965216,0.003478441
7039,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7039,-1,0.002771692,0.9972283
7040,torsade de pointes,11,14,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7040,-1,0.0037823769,0.99621767
7041,TdP,15,16,80,83,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7041,-1,0.0025709877,0.99742895
7043,heroin,1,2,3,9,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7043,-1,0.9966108,0.0033891874
7045,TdP,28,29,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7045,-1,0.002663583,0.99733645
7047,heroin,19,20,113,119,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7047,-1,0.9827518,0.017248267
7049,buprenorphine,25,26,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7049,-1,0.9986743,0.0013257116
7050,Drug,5,6,23,27,"Of the patients at the Drug Addiction Service in the municipal of Copenhagen, 450 (approximately 52%) were included.",17344330_5,-1,-1,-1,7050,-1,0.41747355,0.58252645
7055,p,14,15,79,80,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,-1,7055,-1,0.13343245,0.86656755
7056,buprenorphine,3,4,23,36,No association between buprenorphine and QTc was found.,17344330_10,-1,-1,-1,7056,-1,0.9985845,0.001415508
7058,prolonged QTc interval,15,18,69,91,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,-1,7058,-1,0.0039113224,0.99608874
7059,buprenorphine,6,7,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,-1,7059,-1,0.9986902,0.001309859
7060,mg,2,3,5,7,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,-1,7060,-1,0.879356,0.12064399
7064,QT prolongation,6,8,42,57,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7064,-1,0.0014097369,0.9985903
7066,heroin,17,18,109,115,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7066,-1,0.99374807,0.006251915
7067,leg compartment syndrome,2,5,30,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7067,-1,0.00097496575,0.999025
7068,myonecrosis,6,7,59,70,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7068,-1,0.0008424963,0.99915755
7073,compartment syndrome,12,14,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7073,-1,0.00091681763,0.99908316
7074,myonecrosis,15,16,118,129,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7074,-1,0.0008844103,0.9991155
7076,arteriopathic,24,25,131,144,It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients.,17344566_3,-1,-1,-1,7076,-1,0.0010704589,0.99892956
7077,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7077,-1,0.004678626,0.99532133
7078,ziprasidone,5,6,42,53,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7078,-1,0.99859244,0.0014074884
7079,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7079,-1,0.018719604,0.9812804
7080,NMS,4,5,32,35,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7080,-1,0.001623723,0.99837625
7081,movement disorders,15,17,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7081,-1,0.0011332051,0.9988668
7082,neuroleptic malignant syndrome,5,8,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7082,-1,0.010352399,0.98964757
7083,NMS,9,10,54,57,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7083,-1,0.0014701356,0.9985298
7084,ziprasidone,16,17,86,97,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7084,-1,0.99865144,0.0013485702
7085,neuroleptics,2,3,22,34,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7085,-1,0.98928636,0.010713682
7086,NMS,8,9,71,74,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7086,-1,0.002074629,0.9979254
7087,antipsychotic drugs,11,13,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7087,-1,0.9719648,0.028035207
7088,ziprasidone,14,15,110,121,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7088,-1,0.9985018,0.0014982612
7090,signs and symptoms,13,16,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7090,-1,0.0018698075,0.99813026
7091,NMS,17,18,102,105,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7091,-1,0.0016116275,0.9983884
7092,ziprasidone,30,31,179,190,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7092,-1,0.9984421,0.0015578691
7093,NMS,11,12,52,55,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7093,-1,0.0030121084,0.9969879
7094,ziprasidone,14,15,63,74,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7094,-1,0.99848455,0.0015154472
7095,Neuroinflammation,0,1,0,17,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7095,-1,0.0009669436,0.9990331
7096,behavioral abnormalities,2,4,22,46,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7096,-1,0.0011387174,0.9988613
7098,autism,13,14,110,116,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7098,-1,0.0014685652,0.99853146
7099,Autism,0,1,0,6,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7099,-1,0.0014483097,0.99855167
7100,neurodevelopmental disorder,3,5,12,39,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7100,-1,0.001220608,0.99877936
7101,deficits in communication and social skills,12,18,78,121,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7101,-1,0.0034163385,0.9965836
7102,repetitive behaviors,19,21,126,146,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7102,-1,0.0017892171,0.9982108
7103,autism,19,20,120,126,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,-1,7103,-1,0.0015639606,0.99843603
7105,preterm labor,8,10,57,70,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7105,-1,0.0011730907,0.9988269
7106,autism,18,19,123,129,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7106,-1,0.0011343651,0.9988656
7109,h,27,28,114,115,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,-1,7109,-1,0.10904618,0.8909538
7113,startle,37,38,210,217,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,-1,7113,-1,0.004838471,0.9951616
7114,behavioral abnormalities,21,23,181,205,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7114,-1,0.0017659022,0.99823403
7115,autism,29,30,237,243,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7115,-1,0.0017877391,0.9982122
7116,autism spectrum disorders,13,16,103,128,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,-1,-1,-1,7116,-1,0.0015702747,0.9984297
7120,tariquidar,14,15,108,118,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,-1,7120,-1,0.9985629,0.001437175
7121,injury to the brain,10,14,67,86,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,-1,-1,7121,-1,0.003311075,0.9966889
7123,xanthine oxidase,2,4,8,24,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,-1,7123,-1,0.9820462,0.01795383
7126,xanthine oxidase,7,9,26,42,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7126,-1,0.9896952,0.010304744
7127,reactive oxygen species,20,23,90,113,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7127,-1,0.4679683,0.5320317
7131,allopurinol,21,22,114,125,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7131,-1,0.9986129,0.0013870635
7132,allopurinol,26,27,143,154,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7132,-1,0.99853027,0.0014697369
7134,urate,13,14,73,78,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,-1,7134,-1,0.99629515,0.003704788
7136,P,15,16,45,46,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7136,-1,0.13710663,0.86289334
7137,decreased thymus,20,22,60,76,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7137,-1,0.02043174,0.97956824
7138,P,23,24,78,79,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7138,-1,0.18356167,0.8164383
7139,bodyweights,28,29,93,104,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7139,-1,0.011063695,0.98893636
7140,P,30,31,106,107,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7140,-1,0.23298328,0.7670167
7141,Allopurinol,0,1,0,11,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7141,-1,0.99820995,0.0017900545
7142,urate,3,4,28,33,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7142,-1,0.5875263,0.4124737
7143,P,16,17,72,73,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7143,-1,0.16068852,0.8393115
7144,P,37,38,151,152,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7144,-1,0.17192392,0.8280761
7145,Allopurinol,2,3,3,14,6. Allopurinol did not prevent dex-HT.,17439425_9,-1,-1,-1,7145,-1,0.9984199,0.001580159
7146,allopurinol,8,9,47,58,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,-1,-1,7146,-1,0.99821126,0.0017886976
7154,n,10,11,38,39,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7154,-1,0.111575454,0.8884246
7157,n,37,38,175,176,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7157,-1,0.122702844,0.8772971
7158,"nausea, vomiting",9,12,60,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,-1,-1,7158,-1,0.0013772584,0.9986228
7160,postoperative emetic symptoms,8,11,44,73,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,-1,7160,-1,0.0018068368,0.9981932
7167,iron dextran,1,3,11,23,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7167,-1,0.9909532,0.009046761
7168,degeneration of dopaminergic neurons,4,8,32,68,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7168,-1,0.0013451134,0.99865484
7170,Parkinson's disease,11,14,70,89,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,-1,-1,-1,7170,-1,0.0018235581,0.99817646
7171,iron overload,6,8,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7171,-1,0.15005317,0.8499468
7172,loss,11,12,89,93,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7172,-1,0.0017486222,0.9982514
7173,SN,17,18,119,121,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7173,-1,0.0052108825,0.9947891
7176,of dopaminergic,52,54,343,358,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7176,-1,0.013072224,0.9869278
7178,SN,61,62,401,403,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7178,-1,0.0069949855,0.993005
7179,iron dextran,63,65,407,419,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7179,-1,0.9711,0.02890008
7180,iron dextran,5,7,36,48,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7180,-1,0.99514776,0.0048522847
7182,SN,23,24,160,162,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7182,-1,0.005854028,0.994146
7184,iron dextran,5,7,38,50,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7184,-1,0.99212754,0.007872497
7186,SN,14,15,86,88,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7186,-1,0.0035671974,0.9964328
7188,degeneration of,21,23,122,137,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7188,-1,0.003226656,0.9967733
7189,neurons,24,25,151,158,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7189,-1,0.002438784,0.9975612
7190,iron overload,2,4,12,25,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7190,-1,0.14120345,0.85879654
7191,iron overload,14,16,89,102,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7191,-1,0.13292862,0.8670714
7203,myocardial ischemia,13,15,98,117,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,-1,7203,-1,0.0011982459,0.9988017
7204,myocardial ischemia,11,13,91,110,BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.,17491223_1,-1,-1,-1,7204,-1,0.0011774332,0.9988225
7205,myocardial ischemia,36,38,217,236,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,-1,7205,-1,0.0014201325,0.99857986
7210,myocardial ischemia,34,36,208,227,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,-1,7210,-1,0.0016161375,0.9983839
7211,myocardial infarction,1,3,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,-1,-1,7211,-1,0.0010305876,0.99896944
7216,atherosclerotic obstruction,6,8,40,67,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7216,-1,0.0011495607,0.99885046
7217,coronary occlusion,9,11,69,87,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7217,-1,0.0013040508,0.998696
7219,thrombus,17,18,109,117,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7219,-1,0.0014084298,0.9985916
7225,delusional parasitosis,5,7,26,48,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7225,-1,0.00082545343,0.99917454
7226,chronic hepatitis C,9,12,54,73,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7226,-1,0.0017314843,0.9982685
7227,pegylated interferon alpha-2b,14,17,89,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7227,-1,0.99674964,0.0032503263
7229,chronic hepatitis C,3,6,20,39,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7229,-1,0.0012820594,0.998718
7230,interferon,8,9,54,64,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7230,-1,0.997584,0.002415952
7233,psychosis,6,7,33,42,A minority of patients evolve to psychosis.,17511042_3,-1,-1,-1,7233,-1,0.0010354024,0.99896455
7234,psychogenic parasitosis,10,12,42,65,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7234,-1,0.00087207294,0.9991279
7235,interferon,14,15,83,93,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7235,-1,0.9974226,0.0025773959
7236,delusional parasitosis,8,10,47,69,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7236,-1,0.00087314966,0.99912685
7237,pegylated interferon alpha-2b,13,16,92,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7237,-1,0.9964594,0.003540575
7239,pegylated interferon alpha-2b,6,9,46,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,-1,-1,-1,7239,-1,0.9963553,0.0036447295
7242,LID,3,4,27,30,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7242,-1,0.001139591,0.9988605
7243,Parkinson's disease,13,16,79,98,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7243,-1,0.0015052462,0.99849474
7244,PD,17,18,100,102,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7244,-1,0.0013240763,0.9986759
7245,LID,14,15,73,76,"To this day, transcriptome analysis has been performed in a rat model of LID [Neurobiol. Dis., 17 (2004), 219] but information regarding the proteome is still lacking.",17532790_2,-1,-1,-1,7245,-1,0.0017231206,0.9982768
7246,PD,25,26,170,172,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7246,-1,0.0012372255,0.99876285
7248,LID,16,17,90,93,Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.,17532790_4,-1,-1,-1,7248,-1,0.0026269897,0.997373
7249,LID,6,7,26,29,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7249,-1,0.49001414,0.50998586
7250,guanidoacetate,20,21,127,141,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7250,-1,0.9974833,0.0025167346
7251,LID,14,15,86,89,"In conclusion, this study provides new insights into the protein changes occurring in LID.",17532790_8,-1,-1,-1,7251,-1,0.0045931484,0.99540687
7253,chronic kidney disease,21,24,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,-1,7253,-1,0.0011365949,0.99886346
7254,contrast medium iopamidol,13,16,88,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7254,-1,0.98756045,0.01243951
7255,contrast medium iodixanol,21,24,146,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7255,-1,0.9862599,0.013740065
7258,chronic kidney disease,22,25,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,-1,7258,-1,0.0013116853,0.9986883
7260,contrast,4,5,17,25,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7260,-1,0.09782222,0.9021778
7261,diabetes mellitus,9,11,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7261,-1,0.00091522397,0.99908483
7264,P=0.39,31,32,131,137,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7264,-1,0.064192355,0.93580765
7265,P=0.44,53,54,217,223,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7265,-1,0.07445917,0.92554086
7269,P=0.11,35,36,148,154,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7269,-1,0.08457665,0.91542333
7270,P=0.37,55,56,226,232,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7270,-1,0.07836477,0.92163527
7272,P=0.03,22,23,130,136,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,-1,7272,-1,0.08597628,0.9140237
7274,P=0.01,38,39,214,220,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,-1,7274,-1,0.121491894,0.87850815
7278,diabetes mellitus,33,35,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,-1,-1,7278,-1,0.0009942227,0.99900585
7279,Hepatonecrosis,0,1,0,14,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7279,-1,0.0009081496,0.99909186
7280,cholangitis,2,3,19,30,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7280,-1,0.0008676924,0.99913234
7283,PB,2,3,15,17,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7283,-1,0.99411064,0.0058893682
7284,chronic liver disease,31,34,193,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7284,-1,0.0010222899,0.9989778
7286,PB,15,16,82,84,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7286,-1,0.25560308,0.744397
7288,bronchopneumonia,31,32,161,177,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7288,-1,0.0009804425,0.9990195
7290,PB,4,5,29,31,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7290,-1,0.9442831,0.055716902
7291,chronic liver damage,9,12,55,75,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7291,-1,0.0015054998,0.9984945
7292,lead,15,16,87,91,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7292,-1,0.04753346,0.95246655
7293,chronic hepatic enzyme dysfunction,17,21,118,152,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,-1,-1,-1,7293,-1,0.001236726,0.9987633
7296,maltol,24,25,164,170,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,-1,-1,-1,7296,-1,0.9968125,0.0031875144
7297,cognitive decline,12,14,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,-1,-1,-1,7297,-1,0.0011641029,0.99883586
7301,H2O2,19,20,108,112,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7301,-1,0.9854525,0.0145475725
7303,reactive oxygen species,12,15,92,115,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7303,-1,0.42173275,0.5782673
7304,cytochrome c,16,18,117,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7304,-1,0.92487246,0.07512751
7305,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7305,-1,0.0014888388,0.99851114
7306,neuronal death,31,33,199,213,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7306,-1,0.0015514621,0.9984485
7307,decline of cognitive function,35,39,230,259,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7307,-1,0.0019818651,0.99801815
7310,dopaminergic terminal damage,11,14,85,113,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,-1,-1,-1,7310,-1,0.016641077,0.9833589
7312,dopamine neurotoxicity,23,25,170,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,-1,7312,-1,0.12759064,0.8724093
7317,"3,4-dihydroxyphenylacetic acid",9,11,99,129,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,-1,-1,-1,7317,-1,0.99331445,0.006685612
7321,"3,4-dihydroxyphenylacetic acid",30,32,190,220,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,-1,-1,-1,7321,-1,0.99295455,0.007045417
7325,"3,4-dihydroxyphenylacetic acid",15,17,125,155,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,-1,-1,-1,7325,-1,0.9932516,0.006748409
7329,dopamine neurotoxicity,17,19,160,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,-1,7329,-1,0.13278955,0.86721045
7343,psychosis,11,12,79,88,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,-1,7343,-1,0.0009615573,0.99903846
7346,acute renal failure,3,6,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7346,-1,0.0009942357,0.99900573
7349,atazanavir,16,17,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7349,-1,0.9982028,0.0017972001
7352,atazanavir,16,17,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7352,-1,0.99814475,0.0018552197
7354,acute renal failure,21,24,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7354,-1,0.0009522816,0.9990477
7355,human immunodeficiency virus,8,11,52,80,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7355,-1,0.04770571,0.9522943
7356,atrial fibrillation,12,14,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7356,-1,0.0014446534,0.99855536
7357,coronary artery disease,15,18,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7357,-1,0.0026459177,0.99735415
7358,hyperlipidemia,20,21,132,146,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7358,-1,0.001384339,0.9986156
7361,mg simvastatin,5,7,26,40,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7361,-1,0.9945799,0.005420135
7363,mg,22,23,109,111,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7363,-1,0.96138686,0.038613144
7364,mg,30,31,139,141,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7364,-1,0.9740105,0.025989456
7365,mg atazanavir,41,43,185,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7365,-1,0.99340785,0.0065922006
7366,creatine kinase,5,7,42,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,-1,-1,-1,7366,-1,0.9904937,0.009506327
7373,human immunodeficiency virus,8,11,43,71,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,-1,7373,-1,0.03373069,0.9662693
7374,creatine kinase,6,8,30,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,-1,7374,-1,0.9749791,0.025020903
7380,atazanavir,2,3,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,-1,-1,-1,7380,-1,0.9982565,0.0017434559
7384,fluvastatin,14,15,88,99,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7384,-1,0.9982083,0.0017917491
7385,rosuvastatin,17,18,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7385,-1,0.99840504,0.0015949635
7386,atorvastatin,26,27,162,174,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7386,-1,0.99823916,0.0017608057
7393,fluoroquinolone,3,4,16,31,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,-1,-1,-1,7393,-1,0.9979996,0.002000425
7405,cerebrovascular accident,6,8,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7405,-1,0.0009714878,0.99902856
7407,leukaemia,26,27,203,212,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7407,-1,0.000812126,0.9991879
7408,cerebrovascular accidents,2,4,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,-1,-1,-1,7408,-1,0.0011819899,0.998818
7412,carmofur,24,25,160,168,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,-1,7412,-1,0.99840766,0.0015923225
7414,white,17,18,118,123,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,-1,7414,-1,0.00720127,0.9927987
7415,white matter abnormalities,13,16,94,120,"However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent white matter abnormalities.",17682013_10,-1,-1,-1,7415,-1,0.0027944539,0.99720556
7417,oedema,9,10,56,62,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,-1,7417,-1,0.001450677,0.9985493
7424,pulmonary hypertension syndrome,12,15,104,135,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,-1,-1,-1,7424,-1,0.0009635377,0.99903643
7431,P,32,33,194,195,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7431,-1,0.09061565,0.90938437
7432,P,46,47,263,264,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7432,-1,0.10821992,0.8917801
7434,P,26,27,161,162,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,-1,7434,-1,0.15494166,0.8450584
7436,P,18,19,101,102,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7436,-1,0.107298076,0.892702
7437,P,30,31,167,168,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7437,-1,0.18167,0.81833
7439,P,29,30,179,180,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,-1,7439,-1,0.18227208,0.8177279
7440,contrast,3,4,16,24,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,-1,-1,7440,-1,0.032576174,0.9674238
7446,alcohol dependence,17,19,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,-1,-1,7446,-1,0.25373387,0.7462661
7447,loss of vision,8,11,51,65,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7447,-1,0.002107983,0.9978921
7448,headaches,16,17,97,106,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7448,-1,0.0013295955,0.99867046
7449,paraesthesia,4,5,22,34,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7449,-1,0.0011813968,0.9988186
7450,numbness,6,7,40,48,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7450,-1,0.0013091827,0.9986908
7451,scotomata,6,7,56,65,Visual field testing confirmed bilateral central-caecal scotomata.,17786501_7,-1,-1,-1,7451,-1,0.0010269266,0.99897313
7453,alcohol dependence,6,8,34,52,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,-1,-1,-1,7453,-1,0.11951962,0.8804804
7455,lead,2,3,27,31,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,-1,-1,-1,7455,-1,0.020813929,0.9791861
7457,hepatitis B virus,8,11,66,83,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7457,-1,0.0061503393,0.9938497
7458,HBV,12,13,85,88,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7458,-1,0.009400913,0.9905991
7459,infected,14,15,90,98,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7459,-1,0.0023882873,0.99761176
7460,hepatitis B,8,10,66,77,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7460,-1,0.005822308,0.9941777
7461,human immunodeficiency virus,25,28,158,186,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7461,-1,0.022239363,0.9777606
7462,HBV infected,4,6,30,42,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,-1,7462,-1,0.0037387542,0.9962612
7463,HBsAg,0,1,0,5,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,-1,7463,-1,0.008243088,0.99175686
7464,chronic hepatitis B,10,13,72,91,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,-1,7464,-1,0.0021602735,0.9978397
7465,Rabbit syndrome,0,2,0,15,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,-1,-1,-1,7465,-1,0.0023814905,0.9976185
7467,rabbit syndrome,1,3,4,19,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7467,-1,0.00261626,0.9973838
7468,neuroleptic,11,12,77,88,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7468,-1,0.9962618,0.0037381735
7469,imipramine,8,9,47,57,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,-1,-1,-1,7469,-1,0.9989477,0.0010523866
7471,movement disorder,12,14,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7471,-1,0.0017436402,0.9982564
7472,rabbit syndrome,25,27,166,181,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7472,-1,0.0022048256,0.9977952
7474,cholesteryl ester,2,4,18,35,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7474,-1,0.99055755,0.009442496
7476,protease inhibitors,14,16,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,-1,-1,-1,7476,-1,0.991879,0.008121083
7478,premature atherosclerosis,12,14,72,97,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,-1,-1,-1,7478,-1,0.0014701454,0.9985298
7480,atherosclerotic lesion,8,10,67,89,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,-1,7480,-1,0.0017641884,0.9982358
7481,cholesteryl ester,11,13,89,106,"Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation.",17879945_4,-1,-1,-1,7481,-1,0.99005824,0.009941811
7484,E2,27,28,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7484,-1,0.99622154,0.003778433
7488,E2,0,1,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7488,-1,0.9963852,0.0036148177
7489,cholesteryl esters,5,7,33,51,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7489,-1,0.96263784,0.03736217
7493,E2,2,3,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,-1,-1,-1,7493,-1,0.99506325,0.0049367794
7494,E2,0,1,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,-1,-1,-1,7494,-1,0.99414164,0.0058583636
7495,E2,4,5,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7495,-1,0.99006325,0.009936695
7496,cholesteryl ester,22,24,147,164,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7496,-1,0.9939365,0.0060635395
7498,Acute hepatitis attack,0,3,0,22,Acute hepatitis attack after exposure to telithromycin.,17919553_0,-1,-1,-1,7498,-1,0.0011891781,0.9988109
7502,adverse drug reactions,16,19,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7502,-1,0.002007154,0.9979929
7503,Emergency Department,24,26,127,147,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7503,-1,0.011398721,0.98860127
7505,malaise,39,40,201,208,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7505,-1,0.0011056345,0.9988944
7509,upper respiratory tract infection,11,15,61,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,-1,-1,7509,-1,0.001462802,0.9985372
7512,alkaline phosphatase,34,36,155,175,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,-1,7512,-1,0.94279385,0.057206187
7516,acute hepatitis,9,11,48,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,-1,-1,-1,7516,-1,0.00097079744,0.99902916
7519,hepatic dysfunction,10,12,69,88,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,-1,-1,-1,7519,-1,0.0010044824,0.9989955
7520,adverse drug reaction,9,12,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7520,-1,0.0066159787,0.99338406
7522,acute hepatitis,21,23,118,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7522,-1,0.0009800908,0.99901986
7523,toxic hepatitis,32,34,200,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7523,-1,0.0010114431,0.99898857
7526,acute hepatitis,8,10,37,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,-1,7526,-1,0.00096329185,0.9990368
7528,uveitis,5,6,38,45,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7528,-1,0.00094464066,0.9990553
7529,fluocinolone acetonide,8,10,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7529,-1,0.99850684,0.0014931614
7530,elevated intraocular pressure,9,12,53,82,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7530,-1,0.001674881,0.99832517
7531,IOP,13,14,84,87,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7531,-1,0.0019594808,0.9980405
7532,uveitis,18,19,106,113,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7532,-1,0.00095754204,0.99904245
7533,fluocinolone acetonide,22,24,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7533,-1,0.99857974,0.0014202569
7534,FA,25,26,155,157,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7534,-1,0.9947582,0.0052418127
7535,FA,28,29,166,168,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,-1,7535,-1,0.99081564,0.009184369
7536,mm Hg,18,20,88,93,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7536,-1,0.015984384,0.9840156
7537,mm Hg,41,43,172,177,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7537,-1,0.016163614,0.98383635
7538,mm Hg,47,49,190,195,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7538,-1,0.01932566,0.9806743
7539,mm Hg,54,56,212,217,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7539,-1,0.01725093,0.982749
7540,mm Hg,14,16,93,98,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,-1,-1,-1,7540,-1,0.007655431,0.99234456
7541,hypotony,3,4,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7541,-1,0.00092987565,0.9990701
7542,mm Hg,9,11,32,37,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7542,-1,0.00911105,0.99088895
7543,P,36,37,158,159,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7543,-1,0.10373475,0.89626527
7544,FA,10,11,64,66,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,-1,-1,-1,7544,-1,0.81991446,0.1800855
7573,DCM,5,6,36,39,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7573,-1,0.0010831899,0.99891686
7575,heart failure,18,20,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7575,-1,0.00095477357,0.9990452
7576,acquired immunodeficiency syndrome,14,17,98,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7576,-1,0.0012314727,0.9987685
7577,AIDS,18,19,134,138,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7577,-1,0.0011308171,0.9988691
7578,skeletal myopathies,30,32,188,207,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7578,-1,0.0010116382,0.99898833
7580,"3'-azido-2',3'-deoxythymidine",14,15,85,114,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7580,-1,0.99256563,0.007434412
7581,AZT,16,17,116,119,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7581,-1,0.99735117,0.0026488246
7582,DCM,32,33,222,225,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7582,-1,0.0016324269,0.9983676
7583,NTg,50,51,320,323,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7583,-1,0.04942269,0.9505773
7584,AZT,61,62,395,398,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7584,-1,0.9974011,0.002598879
7585,NTg,0,1,0,3,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7585,-1,0.25382546,0.7461746
7586,Tg,4,5,23,25,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7586,-1,0.0044810507,0.9955189
7587,contrast,1,2,3,11,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7587,-1,0.014349933,0.98565
7588,cardiac dilation,8,10,48,64,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7588,-1,0.001119701,0.9988803
7590,troponin I,9,11,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,-1,-1,-1,7590,-1,0.92036897,0.07963105
7592,cardiac dilation,33,35,221,237,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7592,-1,0.0012223556,0.9987777
7593,dysfunction,36,37,242,253,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7593,-1,0.001206669,0.99879324
7594,etoricoxib,3,4,33,43,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7594,-1,0.9982609,0.0017391094
7596,etoricoxib,12,13,93,103,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7596,-1,0.99811894,0.0018809768
7597,diclofenac sodium,14,16,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7597,-1,0.99804795,0.0019520888
7598,etoricoxib,41,42,307,317,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7598,-1,0.9983182,0.001681778
7601,RA,50,51,372,374,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7601,-1,0.0017683079,0.9982317
7602,RA,17,18,84,86,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7602,-1,0.002016381,0.9979836
7603,etoricoxib,22,23,114,124,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7603,-1,0.99844414,0.0015558945
7604,mg,24,25,128,130,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7604,-1,0.9632144,0.036785632
7605,n,27,28,138,139,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7605,-1,0.27239245,0.72760755
7607,mg,34,35,165,167,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7607,-1,0.9666417,0.033358235
7608,n,38,39,181,182,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7608,-1,0.26980934,0.73019063
7610,thrombotic cardiovascular event,8,11,56,87,"General safety was also assessed, including adjudicated thrombotic cardiovascular event data.",17965424_4,-1,-1,-1,7610,-1,0.0014402295,0.9985598
7611,SD,4,5,15,17,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7611,-1,0.07553823,0.9244618
7612,etoricoxib,28,29,108,118,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7612,-1,0.9982394,0.0017606214
7614,GI AEs,6,8,43,49,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7614,-1,0.0020479974,0.99795204
7615,etoricoxib,12,13,79,89,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7615,-1,0.9982187,0.0017812151
7617,p,38,39,201,202,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7617,-1,0.15936537,0.84063464
7618,etoricoxib,13,14,113,123,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7618,-1,0.99821556,0.0017844815
7620,p<0.001,33,34,207,214,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7620,-1,0.13122095,0.868779
7622,p<0.01,37,38,236,242,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7622,-1,0.08153765,0.9184624
7623,oedema,39,40,247,253,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7623,-1,0.0013804816,0.99861956
7624,Etoricoxib,0,1,0,10,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,-1,-1,-1,7624,-1,0.99814856,0.0018514319
7626,Etoricoxib,2,3,13,23,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7626,-1,0.9979582,0.0020417988
7627,mg,4,5,27,29,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7627,-1,0.85024583,0.14975412
7628,AEs,16,17,108,111,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7628,-1,0.0019148125,0.99808526
7630,mg,21,22,141,143,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7630,-1,0.8824379,0.117562175
7631,etoricoxib,18,19,127,137,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7631,-1,0.99765885,0.00234109
7633,norfloxacin,5,6,42,53,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,-1,-1,-1,7633,-1,0.9988047,0.0011952616
7634,fluoroquinolones,7,8,49,65,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7634,-1,0.9981713,0.0018286009
7636,norfloxacin,12,13,92,103,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7636,-1,0.9986029,0.0013970574
7637,anxious behaviour,11,13,86,103,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,-1,7637,-1,0.00161499,0.9983851
7639,norfloxacin,15,16,125,136,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,-1,-1,-1,7639,-1,0.998803,0.0011969934
7648,liver failure,16,18,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,-1,7648,-1,0.0010859299,0.9989141
7654,liver failure,14,16,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,-1,-1,7654,-1,0.0012428287,0.9987571
7659,remifentanil,9,10,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,-1,-1,7659,-1,0.99863976,0.0013601863
7664,remifentanil,11,12,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,-1,7664,-1,0.99872226,0.0012777105
7666,remifentanil,20,21,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7666,-1,0.99852777,0.001472254
7668,remifentanil,21,22,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7668,-1,0.9986166,0.0013833981
7669,Ce,25,26,147,149,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7669,-1,0.802197,0.19780305
7670,ng,28,29,155,157,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7670,-1,0.7593206,0.24067944
7671,ng,36,37,173,175,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7671,-1,0.77661353,0.22338651
7672,ng,45,46,194,196,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7672,-1,0.7929477,0.20705235
7674,remifentanil,6,7,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,-1,-1,7674,-1,0.99880934,0.0011906163
7679,P<0.001,32,33,159,166,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,-1,-1,-1,7679,-1,0.15300743,0.8469926
7681,P<0.001,17,18,76,83,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,-1,-1,7681,-1,0.13924156,0.8607585
7684,remifentanil,11,12,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7684,-1,0.99874073,0.0012592454
7687,remifentanil,29,30,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7687,-1,0.99872583,0.0012741322
7688,Ce,33,34,233,235,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7688,-1,0.871752,0.12824799
7689,ng,36,37,241,243,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7689,-1,0.68486893,0.3151311
7692,SD,10,11,47,49,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,-1,7692,-1,0.066185,0.93381506
7693,n,6,7,23,24,"Of these, nearly half (n = 78)",18020536_4,-1,-1,-1,7693,-1,0.36516082,0.63483924
7694,n,10,11,55,56,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,-1,7694,-1,0.08542037,0.9145796
7695,n,12,13,60,61,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,-1,7695,-1,0.14525586,0.8547442
7696,oxazepam,5,6,37,45,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7696,-1,0.9981501,0.0018499099
7697,temazepam,7,8,47,56,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7697,-1,0.9982476,0.0017524427
7698,zopiclone,9,10,61,70,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7698,-1,0.99849105,0.0015089242
7699,SD,6,7,22,24,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,-1,7699,-1,0.038442302,0.9615577
7700,n,13,14,64,65,Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20).,18020536_12,-1,-1,-1,7700,-1,0.067808874,0.93219113
7703,inability to sleep,10,13,56,74,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7703,-1,0.0064246985,0.9935753
7704,tiredness,18,19,102,111,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7704,-1,0.001228782,0.99877125
7705,depressive symptoms,31,33,181,200,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7705,-1,0.0013215138,0.9986785
7706,temazepam,6,7,41,50,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,-1,7706,-1,0.9982324,0.0017675455
7707,vocal fold palsy,1,4,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,-1,-1,-1,7707,-1,0.001528975,0.99847096
7710,disulfiram overdose,6,8,40,59,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7710,-1,0.56070125,0.43929875
7711,vocal fold palsy,20,23,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7711,-1,0.0025783107,0.99742174
7712,quadriparesis,10,11,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7712,-1,0.0011085237,0.99889153
7714,sensory loss,15,17,98,110,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7714,-1,0.0012600649,0.9987399
7715,paresthesia,19,20,116,127,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7715,-1,0.0010700546,0.9989299
7719,giddiness,21,22,104,113,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,-1,-1,7719,-1,0.0012939441,0.9987061
7721,and sensory dysfunction,7,10,54,77,She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state.,18023325_7,-1,-1,-1,7721,-1,0.0019724718,0.9980275
7722,axonal polyneuropathy,9,11,65,86,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,-1,-1,-1,7722,-1,0.0009914775,0.9990086
7724,palsy,6,7,25,30,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,-1,-1,7724,-1,0.0010707695,0.9989292
7729,valproate,6,7,49,58,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,-1,-1,-1,7729,-1,0.9988518,0.0011481653
7733,generalized seizures,10,12,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7733,-1,0.0009781573,0.9990219
7734,LEV,15,16,106,109,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7734,-1,0.99739635,0.002603678
7735,mg,18,19,116,118,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7735,-1,0.9134312,0.08656882
7736,valproate,22,23,129,138,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7736,-1,0.9987147,0.0012853611
7737,VPA,24,25,140,143,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7737,-1,0.9978194,0.0021805407
7738,mg,28,29,151,153,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7738,-1,0.8887077,0.111292325
7740,"impaired word fluency, psychomotor speed and working memory",3,12,34,93,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,-1,-1,-1,7740,-1,0.0035214014,0.9964786
7741,LEV,5,6,38,41,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,-1,-1,-1,7741,-1,0.95505935,0.044940647
7744,anxiety,11,12,105,112,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,-1,-1,-1,7744,-1,0.0013696899,0.9986303
7748,anxiety,29,30,184,191,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,-1,-1,-1,7748,-1,0.0015409779,0.998459
7751,NE,24,25,134,136,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7751,-1,0.9964301,0.0035699
7752,anxiety,44,45,245,252,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7752,-1,0.0018294064,0.9981706
7755,anxiety,1,2,16,23,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,-1,7755,-1,0.0012111445,0.9987889
7758,adrenergic antagonists,4,6,30,52,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,-1,7758,-1,0.97848696,0.021513
7762,anxiety,15,16,127,134,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,-1,-1,-1,7762,-1,0.00146677,0.99853325
7763,Dexmedetomidine,0,1,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,-1,7763,-1,0.9987392,0.0012608261
7764,dexmedetomidine,9,10,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,-1,-1,-1,7764,-1,0.9988431,0.0011568911
7765,dexmedetomidine,8,9,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,-1,7765,-1,0.9987645,0.0012354796
7766,Dexmedetomidine,0,1,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7766,-1,0.99860793,0.0013920671
7767,p,24,25,127,128,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7767,-1,0.09464304,0.9053569
7768,myocardial infarction,30,32,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7768,-1,0.0012850484,0.9987149
7769,p,43,44,198,199,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7769,-1,0.11726014,0.88273984
7770,myocardial ischaemia,49,51,213,233,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7770,-1,0.0013619692,0.998638
7771,p,62,63,262,263,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7771,-1,0.08874592,0.9112541
7773,p,16,17,60,61,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,-1,-1,7773,-1,0.1054838,0.89451617
7775,p,36,37,121,122,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,-1,-1,7775,-1,0.112164184,0.8878358
7777,p,10,11,64,65,An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).,18086064_8,-1,-1,-1,7777,-1,0.08747255,0.9125275
7778,dexmedetomidine,5,6,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,-1,7778,-1,0.99875665,0.0012433117
7779,Myocardial infarction,0,2,0,21,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7779,-1,0.0010938841,0.99890614
7780,clomiphene citrate,6,8,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7780,-1,0.9986148,0.0013852029
7781,Clomiphene citrate,2,4,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7781,-1,0.9982628,0.0017371541
7782,CC,5,6,32,34,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7782,-1,0.9885992,0.011400788
7783,Thromboembolism,0,1,0,15,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7783,-1,0.0011291009,0.9988709
7784,CC,15,16,114,116,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7784,-1,0.9803432,0.019656792
7785,coronary thrombosis,1,3,12,31,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7785,-1,0.0013525847,0.9986474
7786,thromboembolism,4,5,35,50,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7786,-1,0.0009996787,0.9990004
7787,myocardial infarction,20,22,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7787,-1,0.0010378392,0.99896216
7788,MI,23,24,156,158,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7788,-1,0.0012879464,0.99871206
7789,CC,12,13,72,74,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7789,-1,0.99384004,0.006160044
7790,chest pain,19,21,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7790,-1,0.0018360559,0.998164
7791,wall myocardial infarction,7,10,51,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,-1,-1,-1,7791,-1,0.0016955773,0.99830437
7792,troponin I,7,9,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,-1,-1,-1,7792,-1,0.3503035,0.64969647
7793,radiation injury,13,15,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,-1,7793,-1,0.0048012263,0.9951988
7794,CC,15,16,98,100,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7794,-1,0.0033109982,0.996689
7795,myocardial infarction,17,19,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7795,-1,0.0013005493,0.9986994
7797,CC,9,10,57,59,Thrombosis might be a rare but hazardous complication of CC.,18161408_11,-1,-1,-1,7797,-1,0.041882467,0.9581175
7798,messenger ribonucleic acid,3,6,32,58,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7798,-1,0.9338915,0.06610851
7799,hyperprolactinemic,12,13,92,110,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7799,-1,0.0025493067,0.99745065
7800,luteinizing hormone,16,18,135,154,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7800,-1,0.92319393,0.0768061
7818,left ventricular apical ballooning syndrome,3,8,20,63,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7818,-1,0.002673512,0.9973265
7819,Takotsubo cardiomyopathy,10,12,73,97,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7819,-1,0.001916793,0.99808323
7821,left ventricular apical ballooning syndrome,1,6,10,53,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7821,-1,0.0024362772,0.9975637
7822,Takotsubo cardiomyopathy,13,15,87,111,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7822,-1,0.0040656445,0.99593437
7823,akinesia,17,18,92,100,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7823,-1,0.0014277739,0.99857223
7824,apical ballooning,27,29,140,157,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7824,-1,0.003976764,0.9960232
7825,apical ballooning syndrome,21,24,109,135,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,-1,-1,-1,7825,-1,0.0028619664,0.997138
7830,ADHD,21,22,157,161,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,-1,-1,-1,7830,-1,0.0012913548,0.9987086
7831,ADHD,13,14,72,76,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7831,-1,0.0016447359,0.9983552
7833,n,20,21,114,115,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7833,-1,0.175718,0.82428205
7835,n,27,28,140,141,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7835,-1,0.14606674,0.8539332
7838,n,36,37,180,181,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7838,-1,0.18179917,0.8182008
7839,n,44,45,201,202,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7839,-1,0.19206092,0.80793905
7845,p,27,28,152,153,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,-1,-1,7845,-1,0.07762502,0.922375
7849,p,19,20,97,98,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,-1,7849,-1,0.096829385,0.9031706
7850,Drowsiness,0,1,0,10,"Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.",18182964_9,-1,-1,-1,7850,-1,0.0012317449,0.99876827
7854,ADHD,17,18,105,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,-1,7854,-1,0.0014547374,0.9985453
7857,drowsiness,16,17,121,131,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,-1,-1,-1,7857,-1,0.0008755908,0.99912447
7858,Renal Fanconi syndrome,0,3,0,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,-1,-1,7858,-1,0.0019054383,0.9980946
7860,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,-1,-1,7860,-1,0.0014080019,0.99859196
7862,MMF,2,3,12,15,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,-1,-1,-1,7862,-1,0.996612,0.0033879895
7865,hepatitis B infection,7,10,40,61,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,-1,-1,-1,7865,-1,0.0013138709,0.99868613
7866,renal Fanconi syndrome,6,9,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7866,-1,0.0012812257,0.99871886
7868,hypophosphatemia,14,15,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7868,-1,0.0012825546,0.9987174
7870,aminoaciduria,19,20,134,147,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7870,-1,0.011770597,0.9882294
7875,muscle weakness,1,3,9,24,Proximal muscle weakness has developed during her follow-up.,18186898_7,-1,-1,-1,7875,-1,0.0014053456,0.9985947
7876,Fanconi syndrome,0,2,0,16,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7876,-1,0.0027094432,0.99729055
7878,mitochondrial disorders,14,16,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7878,-1,0.00183752,0.99816245
7879,tubular dysfunction,6,8,30,49,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,-1,-1,7879,-1,0.0011547398,0.9988452
7884,telmisartan,28,29,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7884,-1,0.99863356,0.001366367
7885,amlodipine,30,31,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7885,-1,0.9986058,0.0013942517
7886,amlodipine,32,33,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7886,-1,0.99866104,0.0013389615
7888,telmisartan,23,24,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7888,-1,0.99860734,0.0013927395
7889,mg,25,26,135,137,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7889,-1,0.97418416,0.025815831
7890,amlodipine,27,28,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7890,-1,0.9985403,0.0014597484
7891,mg,29,30,153,155,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7891,-1,0.9657033,0.03429668
7892,amlodipine,35,36,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7892,-1,0.9985391,0.001460968
7895,FDC,5,6,32,35,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,-1,7895,-1,0.9913641,0.008635838
7896,mm Hg,36,38,197,202,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7896,-1,0.012041196,0.9879588
7897,P,50,51,198,199,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,-1,7897,-1,0.1353026,0.86469734
7898,P,23,24,87,88,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,-1,-1,-1,7898,-1,0.08529804,0.91470194
7899,Peripheral edema,0,2,0,16,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7899,-1,0.0013791478,0.99862087
7900,cough,28,29,121,126,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7900,-1,0.0011967529,0.99880326
7905,BP reductions,26,28,145,158,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,-1,-1,-1,7905,-1,0.005292624,0.99470735
7909,HIT,15,16,112,115,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,-1,7909,-1,0.002658536,0.99734145
7915,HIT,5,6,21,24,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,-1,-1,7915,-1,0.0015598331,0.9984402
7920,HIT,10,11,63,66,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,-1,-1,7920,-1,0.0016927425,0.9983072
7923,n,12,13,70,71,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7923,-1,0.08443686,0.9155631
7925,n,33,34,170,171,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7925,-1,0.06761216,0.9323879
7927,P,58,59,276,277,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7927,-1,0.15202317,0.84797686
7928,P,62,63,290,291,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7928,-1,0.13432014,0.8656798
7934,lymphomas,11,12,93,102,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7934,-1,0.0012729871,0.998727
7936,Leukemia,21,22,139,147,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7936,-1,0.0029050754,0.99709487
7937,B.Thalidomide,23,24,154,167,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7937,-1,0.95927584,0.040724143
7938,multiple myeloma,32,34,227,243,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7938,-1,0.0015965004,0.9984035
7939,mantle cell lymphoma,35,38,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7939,-1,0.0023853611,0.9976146
7940,lymphoplasmacytic lymphoma,39,41,270,296,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7940,-1,0.0019561714,0.9980438
7941,tumour,10,11,53,59,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,-1,7941,-1,0.0032574746,0.99674255
7942,lymphomas,12,13,80,89,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7942,-1,0.0012866958,0.9987134
7944,mg,16,17,115,117,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7944,-1,0.98024255,0.01975747
7945,mg,22,23,147,149,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7945,-1,0.9747059,0.025294185
7946,mg,38,39,209,211,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7946,-1,0.9591388,0.04086119
7950,dyspnea,16,17,104,111,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,-1,-1,7950,-1,0.001082243,0.9989178
7953,lymphomas,15,16,101,110,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7953,-1,0.0013496411,0.9986504
7954,contrast,17,18,115,123,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7954,-1,0.17568037,0.82431966
7955,lenalidomide,31,32,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7955,-1,0.9986772,0.0013227364
7956,NMDA,3,4,19,23,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7956,-1,0.99740404,0.0025958847
7961,acute pain,1,3,3,13,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7961,-1,0.0015886425,0.9984113
7962,NMDA,7,8,44,48,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7962,-1,0.99683434,0.0031656965
7968,acute pain,8,10,44,54,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,-1,-1,-1,7968,-1,0.0022411135,0.99775887
7969,NMDA,5,6,30,34,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7969,-1,0.9962476,0.003752452
7970,dextromethorphan,7,8,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7970,-1,0.9986173,0.0013826762
7973,dextromethorphan,5,6,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7973,-1,0.9985519,0.0014480478
7975,NMDA,7,8,68,72,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,7975,-1,0.9973781,0.0026219073
7979,mental slowing,1,3,10,24,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,-1,7979,-1,0.0010412907,0.9989587
7983,mg,4,5,30,32,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,7983,-1,0.87368584,0.12631416
7984,mg trihexyphenidyl,7,9,40,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,7984,-1,0.9913119,0.008688067
7986,mental slowness,14,16,91,106,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,-1,-1,-1,7986,-1,0.0014539866,0.998546
7987,mg trihexyphenidyl,9,11,60,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,7987,-1,0.99181116,0.008188874
7988,mental slowness,16,18,105,120,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,7988,-1,0.0018801965,0.9981198
7989,mental slowing,13,15,92,106,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,-1,7989,-1,0.0011427663,0.99885726
7992,lead,3,4,34,38,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,-1,-1,7992,-1,0.0045334455,0.9954666
7994,sirolmus,7,8,38,46,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7994,-1,0.997922,0.0020779616
7995,Srl,9,10,48,51,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7995,-1,0.97087777,0.029122297
7998,Srl,20,21,117,120,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7998,-1,0.12783286,0.8721671
8000,Srl,10,11,73,76,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,-1,8000,-1,0.0044906507,0.9955094
8002,mycophenolate mofetil,4,6,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,-1,-1,-1,8002,-1,0.9985877,0.0014123269
8005,p,29,30,136,137,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,-1,8005,-1,0.13523968,0.8647604
8007,p,24,25,114,115,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,-1,8007,-1,0.08867368,0.91132635
8008,ARB,6,7,49,52,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,8008,-1,0.9964982,0.0035017226
8011,increased renal function,4,7,33,57,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8011,-1,0.0019085456,0.9980914
8012,p,13,14,81,82,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8012,-1,0.061173785,0.93882626
8014,decreased renal function,25,28,153,177,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8014,-1,0.0024754405,0.99752456
8015,p,39,40,225,226,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8015,-1,0.09569578,0.9043042
8017,Srl,12,13,77,80,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,-1,-1,8017,-1,0.9950494,0.0049505145
8018,Srl,0,1,0,3,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,-1,-1,8018,-1,0.9935808,0.006419234
8021,Ginsenoside Rg1,0,2,0,15,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8021,-1,0.9887524,0.011247557
8022,impairment of learning,4,7,29,51,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8022,-1,0.0018919179,0.998108
8024,Rg1,0,1,0,3,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8024,-1,0.9842258,0.015774194
8025,ginsenoside,4,5,10,21,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8025,-1,0.9807311,0.019268876
8026,learning impairment,13,15,77,96,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8026,-1,0.0019347426,0.9980653
8027,Rg1,5,6,40,43,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,-1,-1,-1,8027,-1,0.99237823,0.0076217763
8029,Rg1,11,12,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8029,-1,0.9640737,0.03592632
8030,learning impairment,13,15,62,81,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8030,-1,0.0018079154,0.99819213
8033,Rg1,23,24,114,117,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,-1,8033,-1,0.99512225,0.0048776804
8035,Rg1,14,15,98,101,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,-1,8035,-1,0.9880143,0.011985692
8037,Rg1,7,8,56,59,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8037,-1,0.9959551,0.004044957
8039,NMDA,42,43,269,273,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8039,-1,0.9962572,0.0037428667
8040,MK801,46,47,295,300,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8040,-1,0.9970475,0.0029525484
8041,Rg1,3,4,17,20,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,-1,-1,-1,8041,-1,0.96674246,0.033257484
8043,NMDA,3,4,15,19,This effect is NMDA receptor dependent.,18308784_10,-1,-1,-1,8043,-1,0.98665655,0.013343448
8047,Parkinson's disease,41,44,187,206,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,-1,8047,-1,0.001480795,0.99851924
8055,increase,8,9,42,50,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,-1,8055,-1,0.00538094,0.994619
8057,mecamylamine,12,13,81,93,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,-1,-1,-1,8057,-1,0.9988784,0.0011215525
8060,SCH 23390,9,11,74,83,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8060,-1,0.99770504,0.002294986
8061,raclopride,16,17,113,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8061,-1,0.99865425,0.0013456821
8062,fluphenazine,21,22,149,161,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8062,-1,0.9987956,0.0012043093
8063,PHNO,5,6,33,37,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8063,-1,0.9964462,0.003553797
8065,SKF 38393,14,16,102,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8065,-1,0.99680257,0.0031973927
8070,Central retinal vein occlusion,0,4,0,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,-1,8070,-1,0.0015500817,0.9984499
8071,central retinal vein occlusion,7,11,31,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8071,-1,0.0014222302,0.9985777
8072,clomiphene citrate,13,15,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8072,-1,0.99860615,0.0013938334
8073,CC,16,17,98,100,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8073,-1,0.9894028,0.010597243
8074,infertility,8,9,50,61,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8074,-1,0.0033679262,0.99663204
8075,blurred vision,11,13,73,87,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8075,-1,0.0017819417,0.998218
8076,CC,5,6,46,48,INTERVENTION(S): Ophthalmic examination after CC therapy.,18343374_5,-1,-1,-1,8076,-1,0.98770314,0.012296878
8077,Central retinal vein occlusion,4,8,25,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8077,-1,0.002038725,0.9979613
8078,CC,12,13,87,89,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8078,-1,0.9767875,0.023212515
8079,central retinal vein occlusion,7,11,49,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8079,-1,0.0015458402,0.9984541
8080,CC,15,16,103,105,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8080,-1,0.38948038,0.61051965
8082,CC,10,11,66,68,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8082,-1,0.36309066,0.6369093
8083,visual disturbance,21,23,137,155,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8083,-1,0.0010008506,0.9989992
8084,CC,24,25,162,164,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8084,-1,0.9639716,0.036028374
8085,central retinal vein occlusion,9,13,50,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8085,-1,0.0018162488,0.99818367
8086,CC,16,17,102,104,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8086,-1,0.7415366,0.2584634
8087,infertility,6,7,39,50,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8087,-1,0.0012034483,0.9987966
8088,CC,9,10,65,67,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8088,-1,0.002893755,0.99710625
8089,ipratropium bromide,4,6,33,52,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8089,-1,0.99854374,0.001456271
8091,chronic obstructive pulmonary disease,9,13,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8091,-1,0.0010960507,0.998904
8092,ipratropium bromide,8,10,47,66,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8092,-1,0.9986305,0.0013694806
8094,chronic obstructive pulmonary disease,47,51,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8094,-1,0.0012845504,0.9987155
8095,ipratropium,42,43,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,-1,8095,-1,0.99864,0.001360051
8097,ipratropium,13,14,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,-1,8097,-1,0.9984925,0.0015075585
8099,ipratropium,9,10,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,-1,-1,-1,8099,-1,0.99854714,0.0014528809
8102,ipratropium,4,5,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8102,-1,0.99851185,0.0014881648
8104,airflow obstruction,17,19,116,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8104,-1,0.0014476796,0.99855226
8105,amikacin nephrotoxicity,3,5,17,40,An evaluation of amikacin nephrotoxicity in the hematology/oncology population.,18356633_0,-1,-1,-1,8105,-1,0.317598,0.6824021
8108,febrile neutropenia,13,15,100,119,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,-1,-1,8108,-1,0.00089764077,0.99910235
8117,P,22,23,129,130,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,-1,-1,8117,-1,0.11508776,0.88491225
8118,P,19,20,114,115,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,-1,8118,-1,0.065994844,0.9340052
8120,dexmedetomidine,2,3,10,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8120,-1,0.9986658,0.0013341932
8121,dexmedetomidine,20,21,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8121,-1,0.99869365,0.0013063505
8122,dexmedetomidine,19,20,110,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,-1,8122,-1,0.9987968,0.0012031926
8123,Dexmedetomidine,2,3,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,-1,-1,-1,8123,-1,0.99867815,0.0013218296
8124,dexmedetomidine,9,10,53,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,-1,-1,-1,8124,-1,0.99872464,0.0012752884
8125,dexmedetomidine,10,11,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,-1,-1,-1,8125,-1,0.99882895,0.0011710329
8126,dexmedetomidine,11,12,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,-1,-1,-1,8126,-1,0.9987696,0.0012304252
8127,dexmedetomidine,21,22,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8127,-1,0.99872965,0.0012703817
8128,P,30,31,177,178,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8128,-1,0.12911351,0.8708865
8130,dexmedetomidine,48,49,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8130,-1,0.9987552,0.0012447935
8131,P,60,61,349,350,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8131,-1,0.1753018,0.82469815
8132,dexmedetomidine,1,2,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,-1,8132,-1,0.99867165,0.0013283987
8135,Dexmedetomidine,2,3,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,-1,8135,-1,0.9986885,0.0013114379
8136,dexmedetomidine,5,6,23,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,-1,8136,-1,0.99874073,0.0012592707
8137,Dexmedetomidine,0,1,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,-1,-1,-1,8137,-1,0.9985519,0.0014480229
8140,inflammatory arthritis,5,7,48,70,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,-1,-1,8140,-1,0.0010961656,0.9989039
8141,adverse drug reactions,6,9,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8141,-1,0.00284083,0.9971591
8142,ADRs,10,11,70,74,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8142,-1,0.004448211,0.99555176
8143,adverse drug reactions,10,13,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8143,-1,0.0015335748,0.9984665
8144,liver failure,26,28,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8144,-1,0.0009463184,0.99905366
8145,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,-1,8145,-1,0.0060932236,0.9939068
8148,ADR,15,16,85,88,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,-1,-1,8148,-1,0.0019286292,0.9980714
8151,hepatic failure,7,9,41,56,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,-1,-1,-1,8151,-1,0.0011129698,0.998887
8152,skin rash,4,6,21,30,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,-1,-1,8152,-1,0.001088189,0.99891186
8162,METH,2,3,17,21,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8162,-1,0.9937727,0.0062272763
8164,DA,7,8,41,43,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8164,-1,0.9951304,0.004869603
8165,neurodegeneration,22,23,130,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8165,-1,0.0011048012,0.9988952
8166,DA,24,25,151,153,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8166,-1,0.021728342,0.97827166
8167,CNS damage,2,4,12,22,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8167,-1,0.0011334945,0.99886656
8168,METH,6,7,33,37,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8168,-1,0.9961243,0.0038756228
8169,MPTP,8,9,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8169,-1,0.99226415,0.007735812
8170,DA,14,15,75,77,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8170,-1,0.9566037,0.04339625
8173,METH,25,26,141,145,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,-1,8173,-1,0.993451,0.0065489495
8175,METH,0,1,0,4,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8175,-1,0.9948191,0.00518087
8176,DA,2,3,14,16,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8176,-1,0.9937079,0.0062921178
8177,METH,3,4,15,19,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,-1,8177,-1,0.9950783,0.004921694
8178,METH,9,10,83,87,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,-1,-1,-1,8178,-1,0.98665655,0.013343467
8179,METH,22,23,152,156,This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.,18410508_9,-1,-1,-1,8179,-1,0.9937296,0.0062704403
8180,METH neurotoxicity,11,13,71,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,-1,-1,8180,-1,0.17320155,0.8267985
8181,METH,9,10,68,72,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,-1,8181,-1,0.99523395,0.004766049
8182,nystagmus,1,2,17,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,-1,-1,-1,8182,-1,0.0010857282,0.99891424
8183,nystagmus,4,5,39,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8183,-1,0.0012415609,0.99875844
8184,NIN,6,7,50,53,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8184,-1,0.0063053803,0.9936946
8185,NIN,14,15,77,80,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,-1,-1,-1,8185,-1,0.3376406,0.66235936
8187,NIN,0,1,0,3,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,-1,-1,-1,8187,-1,0.022354167,0.9776458
8189,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8189,-1,0.99394304,0.0060569337
8190,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8190,-1,0.99394304,0.0060569337
8197,GABA,29,30,182,186,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8197,-1,0.9965205,0.003479467
8198,N-(2-propylpentanoyl)urea,32,33,191,216,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8198,-1,0.9927932,0.0072067743
8199,VPU,34,35,218,221,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8199,-1,0.9969451,0.0030549238
8200,valproic acid,43,45,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8200,-1,0.9981529,0.0018470207
8201,VPA,46,47,276,279,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8201,-1,0.9966192,0.0033807098
8202,VPU,0,1,0,3,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8202,-1,0.9968079,0.0031921067
8203,VPA,5,6,25,28,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8203,-1,0.99695635,0.0030436693
8205,VPA,30,31,179,182,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8205,-1,0.99681276,0.0031872566
8210,GABA,31,32,230,234,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,-1,-1,-1,8210,-1,0.99712354,0.0028763888
8211,VPU,3,4,25,28,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8211,-1,0.9981982,0.0018017765
8212,VPA,11,12,51,54,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8212,-1,0.9981845,0.0018155022
8215,GABA,14,15,85,89,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,-1,-1,-1,8215,-1,0.9971794,0.002820592
8219,VPU,5,6,26,29,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8219,-1,0.9976445,0.002355547
8220,VPA,7,8,34,37,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8220,-1,0.99782526,0.0021747798
8225,VPA,3,4,16,19,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8225,-1,0.9965353,0.003464739
8226,VPU,8,9,38,41,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8226,-1,0.996698,0.003301964
8230,atrioventricular block,1,3,9,31,Complete atrioventricular block secondary to lithium therapy.,18441470_0,-1,-1,-1,8230,-1,0.0013405043,0.9986595
8232,Sinus node dysfunction,0,3,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,-1,-1,-1,8232,-1,0.0019767182,0.9980233
8234,atrioventricular (AV) block,6,11,30,57,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8234,-1,0.0024195153,0.9975804
8235,syncopal attacks,12,14,63,79,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8235,-1,0.0011522307,0.9988477
8238,syncopal attacks,12,14,79,95,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,-1,8238,-1,0.0011035615,0.99889636
8241,gastric hemorrhagic ulcers,5,8,34,60,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,-1,-1,8241,-1,0.0010669723,0.998933
8243,gastric hemorrhage,5,7,40,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,-1,-1,8243,-1,0.001151647,0.9988483
8246,lipid peroxide,20,22,106,120,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8246,-1,0.98778915,0.01221079
8247,LPO,23,24,122,125,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8247,-1,0.8076731,0.19232695
8248,gastric hemorrhage,32,34,191,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8248,-1,0.0013694018,0.99863064
8251,vitamin D2,44,46,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8251,-1,0.9966349,0.0033651586
8255,corn oil,15,17,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8255,-1,0.9882825,0.011717512
8256,vitamin D2,18,20,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8256,-1,0.99647397,0.0035259773
8259,corn oil,3,5,22,30,Control rats received corn oil only.,18442015_5,-1,-1,-1,8259,-1,0.9887184,0.011281572
8260,h,10,11,57,58,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,-1,-1,-1,8260,-1,0.029210554,0.97078943
8261,LPO,5,6,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,-1,-1,8261,-1,0.2727784,0.7272216
8268,gastric ulcers,1,3,7,21,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8268,-1,0.0011430868,0.9988569
8270,LPO,17,18,128,131,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8270,-1,0.8422921,0.15770794
8272,gastric hemorrhage,8,10,49,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,-1,-1,8272,-1,0.001129875,0.9988701
8275,hemorrhagic ulcer,1,3,5,22,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,-1,-1,-1,8275,-1,0.0009535173,0.9990465
8278,hemorrhagic ulcer,4,6,38,55,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8278,-1,0.0010095123,0.9989905
8279,LPO,13,14,104,107,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8279,-1,0.7840381,0.21596186
8283,hepatitis B,5,7,33,44,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8283,-1,0.008343298,0.99165666
8285,Hepatitis B,0,2,0,11,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8285,-1,0.00931534,0.9906846
8286,chronic liver disease,13,16,54,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8286,-1,0.001321493,0.9986785
8288,hepatic complication,11,13,62,82,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,-1,8288,-1,0.0013405755,0.9986594
8290,hematological malignancies,10,12,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8290,-1,0.0011600418,0.99884003
8291,HBV infection,14,16,90,103,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8291,-1,0.004493958,0.99550605
8295,lamivudin,2,3,17,26,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,-1,-1,-1,8295,-1,0.99857104,0.0014289137
8298,n=,5,6,22,24,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,-1,8298,-1,0.118726924,0.88127303
8303,p,21,22,109,110,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,-1,-1,8303,-1,0.052951705,0.9470483
8306,p,28,29,176,177,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,-1,8306,-1,0.19327939,0.80672055
8309,nucleoside,9,10,61,71,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8309,-1,0.9973303,0.0026697284
8310,nucleotide,11,12,75,85,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8310,-1,0.9972065,0.002793436
8317,h,42,43,223,224,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,-1,8317,-1,0.03134169,0.9686583
8318,CYP,9,10,53,56,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8318,-1,0.985905,0.014094994
8319,h,13,14,71,72,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8319,-1,0.06153718,0.93846285
8320,CYP,20,21,99,102,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8320,-1,0.9811849,0.018815052
8321,h,24,25,117,118,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8321,-1,0.063062906,0.93693715
8322,CYP,37,38,169,172,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8322,-1,0.9885747,0.0114252735
8323,h,41,42,187,188,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8323,-1,0.048385277,0.9516147
8324,CYP,47,48,211,214,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8324,-1,0.9888974,0.01110261
8325,h,51,52,229,230,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8325,-1,0.045972522,0.9540275
8326,p,19,20,95,96,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,-1,-1,-1,8326,-1,0.34387127,0.6561287
8327,CYP,0,1,0,3,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8327,-1,0.99675804,0.0032420042
8328,p,4,5,29,30,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8328,-1,0.2705135,0.72948647
8329,CYP,34,35,173,176,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8329,-1,0.9962955,0.0037044818
8330,p,39,40,206,207,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8330,-1,0.24980913,0.75019085
8331,bladder inflammation,9,11,44,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8331,-1,0.0014156415,0.9985844
8332,bladder dysfunction,8,10,50,69,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8332,-1,0.0009980795,0.9990019
8333,bladder inflammation,15,17,92,112,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8333,-1,0.0011396223,0.99886036
8334,Debrisoquine,0,1,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,-1,-1,-1,8334,-1,0.99838066,0.0016193737
8340,hypokalemia,11,12,80,91,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,-1,8340,-1,0.0008018188,0.99919814
8343,mg,4,5,21,23,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8343,-1,0.9328887,0.06711129
8345,mg,30,31,136,138,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8345,-1,0.9386492,0.06135083
8348,mg,18,19,97,99,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,-1,-1,-1,8348,-1,0.9336427,0.06635733
8357,P,31,32,142,143,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8357,-1,0.12431997,0.87567997
8358,brachial neuritis,3,5,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,-1,-1,8358,-1,0.0009889416,0.99901104
8360,TAC,0,1,0,3,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,-1,-1,-1,8360,-1,0.99548906,0.0045108865
8363,headaches,6,7,39,48,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8363,-1,0.0011136831,0.9988863
8365,neurological deficits,11,13,63,84,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8365,-1,0.0012035272,0.99879646
8366,myelitis,17,18,113,121,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8366,-1,0.0010479954,0.99895203
8367,brachial plexitis,20,22,132,149,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8367,-1,0.0015400714,0.99845994
8368,TAC,6,7,44,47,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,-1,-1,-1,8368,-1,0.99530184,0.004698194
8370,TAC,8,9,61,64,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,-1,-1,-1,8370,-1,0.89069355,0.10930641
8379,blood loss,10,12,83,93,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,-1,-1,8379,-1,0.0022580181,0.99774206
8384,puromycin aminonucleoside nephrosis,5,8,38,73,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,-1,8384,-1,0.5305962,0.4694038
8385,coagulation factors,11,13,67,86,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8385,-1,0.04370605,0.956294
8387,nephrotic syndrome,28,30,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8387,-1,0.00089919235,0.9991008
8388,puromycin aminonucleoside,23,25,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,-1,-1,-1,8388,-1,0.9975447,0.0024552913
8389,hematological abnormalities,7,9,77,104,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,-1,-1,-1,8389,-1,0.0009483041,0.99905163
8391,hyperlipidemia,5,6,56,70,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,-1,-1,8391,-1,0.00086807116,0.999132
8393,nephrotic syndrome,15,17,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,-1,-1,-1,8393,-1,0.0009818741,0.9990181
8394,nephrotic syndrome,10,12,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,-1,-1,-1,8394,-1,0.0009869547,0.99901307
8396,nausea and vomiting,3,6,26,45,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,-1,-1,8396,-1,0.0011599136,0.99884015
8400,postoperative nausea and vomiting,15,19,107,140,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,-1,-1,-1,8400,-1,0.0013698818,0.99863017
8402,analgesia,17,18,97,106,"Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.",18544179_2,-1,-1,-1,8402,-1,0.0019132294,0.9980868
8403,postoperative nausea and vomiting,11,15,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8403,-1,0.0016432757,0.99835676
8405,h,21,22,131,132,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8405,-1,0.018174918,0.98182505
8411,postoperative nausea and vomiting,12,16,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8411,-1,0.001438173,0.9985618
8415,P,49,50,278,279,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8415,-1,0.1484538,0.8515462
8416,P,14,15,61,62,Antiemetic requirements were reduced from 24% and 31% to 7% (P = 0.0012).,18544179_6,-1,-1,-1,8416,-1,0.10260934,0.89739066
8418,postoperative nausea and vomiting,11,15,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,-1,-1,-1,8418,-1,0.0014146307,0.99858534
8420,postoperative nausea and vomiting,16,20,112,145,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8420,-1,0.0017412781,0.99825877
8422,P,38,39,209,210,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8422,-1,0.12500489,0.8749951
8423,P,42,43,223,224,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8423,-1,0.17443465,0.8255654
8425,h,55,56,278,279,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8425,-1,0.013510759,0.9864892
8426,P,65,66,311,312,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8426,-1,0.09971099,0.90028906
8430,respiratory depression,13,15,102,124,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,-1,-1,8430,-1,0.0014102471,0.9985897
8434,postoperative nausea and vomiting,5,9,36,69,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8434,-1,0.0018848949,0.99811506
8435,postoperative pain,13,15,96,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8435,-1,0.0019105297,0.9980895
8438,Parkinson's disease,6,9,40,59,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,-1,8438,-1,0.0011963675,0.9988036
8440,Valvular heart abnormalities,0,3,0,28,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8440,-1,0.0011104231,0.9988896
8441,Parkinson's disease,9,12,65,84,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8441,-1,0.0012083133,0.99879175
8442,PD,13,14,86,88,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8442,-1,0.0010783868,0.99892163
8444,valvular heart abnormality,9,12,54,80,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,-1,8444,-1,0.001197457,0.99880254
8445,PD,3,4,13,15,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,-1,8445,-1,0.0020727247,0.9979273
8447,PD,1,2,7,9,Thirty PD patients participated in the study.,18560792_6,-1,-1,-1,8447,-1,0.0026658133,0.99733424
8449,n=10,16,17,97,101,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,-1,8449,-1,0.08322096,0.91677904
8450,aortic regurgitation,6,8,31,51,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8450,-1,0.002093916,0.9979061
8452,PD,41,42,153,155,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8452,-1,0.0032389946,0.996761
8453,tricuspid,44,45,166,175,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8453,-1,0.010776633,0.98922336
8454,NS,46,47,177,179,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8454,-1,0.019149482,0.98085046
8455,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8455,-1,0.03504823,0.9649517
8456,n=2.8+/-1.09,15,16,81,93,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8456,-1,0.037786182,0.9622138
8457,p=0.008,20,21,108,115,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8457,-1,0.23607899,0.76392096
8458,p=0.006,22,23,120,127,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8458,-1,0.2597815,0.7402185
8461,valvular regurgitation,4,6,25,47,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8461,-1,0.0010700413,0.9989299
8463,heart failure,26,28,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8463,-1,0.0009859622,0.999014
8466,p=0.01,18,19,113,119,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8466,-1,0.060022675,0.93997735
8467,heart failure,30,32,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8467,-1,0.0010362723,0.9989637
8468,valve regurgitation,8,10,54,73,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8468,-1,0.0010685057,0.99893147
8469,PD,11,12,77,79,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8469,-1,0.0013802908,0.9986197
8471,dopamine agonists,31,33,209,226,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8471,-1,0.9971656,0.002834394
8473,Unfractionated heparin sodium,2,5,12,41,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8473,-1,0.9942093,0.005790768
8474,UFH,6,7,43,46,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8474,-1,0.9943591,0.0056409617
8476,LMWH,13,14,81,85,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8476,-1,0.9960134,0.0039866357
8479,HIT,3,4,34,37,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,-1,8479,-1,0.0012035691,0.99879646
8481,HIT,3,4,19,22,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8481,-1,0.0014986387,0.9985014
8482,HIT,13,14,100,103,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8482,-1,0.010470419,0.98952955
8483,LMWH,2,3,11,15,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8483,-1,0.9974832,0.002516828
8484,UFH,17,18,72,75,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8484,-1,0.99668545,0.0033145866
8485,UFH,3,4,12,15,The dose of UFH was changed according to the activated clotting time level.,18589141_6,-1,-1,-1,8485,-1,0.99541426,0.0045857555
8486,HIT,0,1,0,3,HIT antibody levels were measured the day before surgery and on POD 7 and 14.,18589141_7,-1,-1,-1,8486,-1,0.059207212,0.9407928
8488,HIT,17,18,100,103,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8488,-1,0.21581112,0.78418887
8490,HIT,3,4,18,21,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,-1,8490,-1,0.015776696,0.9842233
8491,HIT,6,7,52,55,None of the subjects/patients developed UFH-related HIT.,18589141_14,-1,-1,-1,8491,-1,0.0012234552,0.9987765
8492,HIT,9,10,46,49,"CONCLUSIONS: In our series, the occurrence of HIT after liver transplantation was uncommon.",18589141_15,-1,-1,-1,8492,-1,0.001722022,0.998278
8494,heart failure,13,15,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,-1,-1,8494,-1,0.0009355984,0.9990644
8495,heart failure,5,7,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,-1,-1,-1,8495,-1,0.0011081727,0.9988919
8497,heart failure,16,18,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8497,-1,0.0010733248,0.9989267
8499,heart failure,32,34,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8499,-1,0.0011366387,0.99886334
8501,3MA,4,5,26,29,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8501,-1,0.99507326,0.00492674
8502,heart failure,16,18,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8502,-1,0.001236136,0.9987639
8504,3MA,20,21,140,143,"Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group.",18619688_4,-1,-1,-1,8504,-1,0.976858,0.023141926
8505,3MA,2,3,9,12,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8505,-1,0.9820936,0.017906433
8506,mitochondrial injury,9,11,65,85,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8506,-1,0.0026190595,0.9973809
8508,3MA,11,12,74,77,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,-1,8508,-1,0.9914836,0.008516301
8510,heart failure,13,15,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,-1,-1,8510,-1,0.0009755558,0.9990244
8512,Mitochondrial injury,0,2,0,20,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8512,-1,0.0036318982,0.99636805
8513,heart failure,9,11,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8513,-1,0.0010462726,0.9989537
8517,anthracycline doxorubicin,4,6,20,45,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8517,-1,0.99694073,0.0030593215
8518,DOX,7,8,47,50,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8518,-1,0.9956958,0.004304122
8520,DOX cardiomyopathy,17,19,88,106,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8520,-1,0.018496227,0.9815037
8521,cardiac inflammation,31,33,165,185,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8521,-1,0.0015925295,0.99840754
8523,DOX,0,1,0,3,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,-1,8523,-1,0.98365605,0.016343923
8525,cardiac apoptosis,23,25,128,145,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,-1,8525,-1,0.0028726496,0.99712735
8526,DOX,1,2,3,6,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8526,-1,0.99314195,0.0068581114
8528,DOX,12,13,67,70,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8528,-1,0.9926726,0.0073274043
8529,DOX cardiomyopathy,8,10,50,68,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,-1,-1,8529,-1,0.007771956,0.992228
8530,DOX cardiomyopathy,16,18,114,132,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,-1,-1,-1,8530,-1,0.0047987523,0.99520123
8532,protein,2,3,16,23,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8532,-1,0.069617994,0.930382
8533,calcineurin inhibitors,10,12,74,96,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8533,-1,0.9954685,0.0045315176
8535,chronic allograft nephropathy,30,33,207,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8535,-1,0.00106824,0.9989317
8539,calcineurin inhibitors,11,13,66,88,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,-1,8539,-1,0.9964903,0.0035096216
8543,focal segmental glomerulosclerosis,3,6,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,-1,-1,-1,8543,-1,0.001202512,0.9987974
8545,epileptiform activity,6,8,57,78,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,-1,-1,8545,-1,0.0009888625,0.99901116
8548,epileptiform activity,14,16,92,113,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,-1,8548,-1,0.0011836671,0.9988164
8549,urethane,8,9,45,53,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,-1,8549,-1,0.99650013,0.0034998194
8552,epileptiform activity,8,10,57,78,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,-1,8552,-1,0.001738972,0.99826103
8553,epileptiform activity,20,22,111,132,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8553,-1,0.0017524225,0.9982476
8554,epileptiform activity,43,45,269,290,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8554,-1,0.0019805904,0.99801946
8555,epilepsies,39,40,246,256,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,-1,8555,-1,0.0011540762,0.99884593
8559,psychoses,7,8,46,55,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8559,-1,0.0010611659,0.99893886
8560,anxiety neurosis,9,11,57,73,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8560,-1,0.0010985929,0.99890137
8562,neuropsychiatric reactions,27,29,157,183,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,-1,-1,-1,8562,-1,0.0010410671,0.99895895
8564,malaria,5,6,35,42,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,-1,-1,-1,8564,-1,0.0027741152,0.9972258
8566,fat,1,2,5,8,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8566,-1,0.7041466,0.29585338
8567,obese,3,4,18,23,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8567,-1,0.0031773883,0.9968226
8573,triglycerides,10,11,79,92,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8573,-1,0.38887483,0.6111252
8574,ATP,17,18,137,140,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8574,-1,0.9857028,0.014297207
8575,high fat,15,17,90,98,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8575,-1,0.8850905,0.114909455
8576,obesity,24,25,125,132,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8576,-1,0.001141291,0.9988587
8578,mg,6,7,17,19,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8578,-1,0.7752269,0.22477311
8579,HFD,17,18,70,73,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8579,-1,0.12796526,0.8720347
8582,obese,37,38,186,191,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8582,-1,0.0039999797,0.99600005
8583,OB,39,40,193,195,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8583,-1,0.008797336,0.9912027
8584,renal,48,49,236,241,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8584,-1,0.0016951986,0.9983047
8585,hepatic toxicity,50,52,245,261,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8585,-1,0.001079685,0.9989203
8588,doxorubicinol,11,12,89,102,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8588,-1,0.9978465,0.0021534755
8589,OB,24,25,154,156,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8589,-1,0.029210694,0.9707893
8590,OB,4,5,34,36,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8590,-1,0.13728683,0.86271316
8591,ND,58,59,349,351,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8591,-1,0.21260633,0.7873937
8592,OB,64,65,392,394,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8592,-1,0.2954695,0.7045305
8593,ATP,85,86,480,483,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8593,-1,0.991375,0.008624937
8595,obese,4,5,27,32,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8595,-1,0.0025222518,0.9974777
8597,ATP,17,18,152,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8597,-1,0.9809291,0.019070895
8600,PD,7,8,44,46,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,-1,8600,-1,0.0027306944,0.99726933
8604,PD,11,12,93,95,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,-1,-1,8604,-1,0.0015485534,0.9984515
8605,PD,3,4,13,15,"In addition, PD female rats showed increased (3)H-MK-801 binding in the striatum and hippocampus, but not in the cortex.",18703024_6,-1,-1,-1,8605,-1,0.002546855,0.99745315
8606,PD,0,1,0,2,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,-1,-1,-1,8606,-1,0.002091596,0.9979085
8608,PD,12,13,83,85,No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex.,18703024_8,-1,-1,-1,8608,-1,0.0023293202,0.9976707
8609,nutritional deficiency,13,15,76,98,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,-1,-1,-1,8609,-1,0.12517695,0.87482303
8612,Papaverine hydrochloride,2,4,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,-1,-1,8612,-1,0.99833727,0.00166272
8614,cranial nerve dysfunction,1,4,10,35,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,-1,-1,-1,8614,-1,0.0011992473,0.99880075
8627,cranial nerve deficits,4,7,35,57,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,-1,-1,-1,8627,-1,0.0012766771,0.9987233
8629,hepatic failure,1,3,30,45,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,-1,-1,-1,8629,-1,0.0009963277,0.9990037
8630,coenzyme A,12,14,109,119,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,-1,-1,-1,8630,-1,0.99133223,0.008667768
8633,ezetimibe,10,11,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,-1,-1,8633,-1,0.9986481,0.0013518891
8639,Simvastatinezetimibe,0,1,0,20,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8639,-1,0.997729,0.0022710152
8640,escitalopram,2,3,25,37,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8640,-1,0.9986965,0.0013035666
8643,drug toxicity,17,19,130,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,-1,-1,8643,-1,0.013010297,0.9869897
8644,Ezetimibe,0,1,0,9,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8644,-1,0.9980229,0.0019770644
8645,uridine diphosphate,5,7,49,68,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8645,-1,0.99609995,0.0039000916
8649,liver failure,12,14,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,-1,-1,-1,8649,-1,0.0011756849,0.9988243
8652,ezetimibe,15,16,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,-1,-1,8652,-1,0.99849415,0.0015057885
8655,acute renal failure,3,6,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8655,-1,0.00094022555,0.99905974
8656,bisphosphonate,8,9,55,69,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8656,-1,0.9988072,0.0011927611
8657,alendronate,10,11,71,82,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8657,-1,0.99864405,0.0013558967
8658,focal segmental glomerulosclerosis,17,20,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8658,-1,0.0011125698,0.9988875
8659,nephrotic syndrome,5,7,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8659,-1,0.000926625,0.9990734
8660,focal segmental glomerulosclerosis,9,12,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8660,-1,0.0011740627,0.99882597
8662,bisphosphonate,18,19,93,107,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8662,-1,0.9985562,0.0014438275
8663,alendronate sodium,20,22,109,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8663,-1,0.99799263,0.0020074332
8664,acute renal failure,38,41,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8664,-1,0.0010194402,0.9989806
8665,alendronate,4,5,29,40,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,-1,-1,-1,8665,-1,0.9983424,0.0016576533
8667,bisphosphonates,11,12,66,81,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8667,-1,0.997416,0.0025839587
8669,acute renal failure,16,19,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8669,-1,0.00095845707,0.9990415
8670,nephrotic syndrome,7,9,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,-1,-1,8670,-1,0.0009754889,0.9990245
8673,volume retention,8,10,84,100,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,-1,-1,8673,-1,0.00497631,0.9950237
8675,renal fibrosis,20,22,146,160,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,-1,-1,-1,8675,-1,0.0012158216,0.99878424
8677,volume retention,13,15,69,85,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8677,-1,0.006035656,0.9939644
8679,nephrotic syndrome,18,20,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8679,-1,0.0010523443,0.9989477
8683,mg,9,10,58,60,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8683,-1,0.046721272,0.9532787
8684,nephrotic syndrome,27,29,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8684,-1,0.0008800035,0.99911994
8686,lipidemia,32,33,179,188,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8686,-1,0.0022758304,0.9977241
8687,hypoalbuminemia,35,36,194,209,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8687,-1,0.0010843988,0.9989157
8691,body weight gain,39,42,197,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,-1,8691,-1,0.00449342,0.9955065
8692,nephrotic syndrome,4,6,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8692,-1,0.0008905304,0.99910945
8694,uremia,24,25,150,156,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8694,-1,0.0008419232,0.999158
8695,volume,9,10,62,68,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8695,-1,0.13682319,0.8631768
8697,nephrotic syndrome,21,23,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8697,-1,0.0009139987,0.999086
8699,haemolytic anaemia,3,5,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,-1,8699,-1,0.00093059486,0.9990694
8702,abdominal pain,7,9,42,56,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8702,-1,0.0010137367,0.9989863
8705,urinary tract infection,21,24,136,159,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8705,-1,0.0013012803,0.9986987
8707,haemolysis,10,11,83,93,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,-1,-1,8707,-1,0.00087505614,0.99912494
8708,petechiae,4,5,36,45,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8708,-1,0.0012161447,0.9987839
8709,purpura,6,7,50,57,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8709,-1,0.0012619135,0.9987381
8710,petechial haemorrhages,8,10,54,76,An accurate autopsy revealed most organs with diffuse petechial haemorrhages.,18791946_6,-1,-1,-1,8710,-1,0.0012441191,0.99875593
8711,bone marrow depression,3,6,12,34,No signs of bone marrow depression were found.,18791946_7,-1,-1,-1,8711,-1,0.0017419985,0.99825805
8713,microangiopathies,5,6,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,-1,-1,8713,-1,0.0010854923,0.9989145
8716,haemolytic anaemia,11,13,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,-1,8716,-1,0.0008962636,0.9991037
8721,coronary hypotension,18,20,122,142,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8721,-1,0.0013918345,0.9986082
8722,myocardial hyperactivity,21,23,147,171,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8722,-1,0.0013305139,0.9986695
8727,ischaemic injury,5,7,26,42,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,-1,-1,-1,8727,-1,0.0016563304,0.9983437
8729,mitochondrial damage,3,5,27,47,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,-1,-1,8729,-1,0.0018765882,0.99812335
8733,mitochondrial damage,14,16,110,130,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8733,-1,0.007086195,0.9929137
8737,axonal damage,11,13,84,97,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8737,-1,0.0016720066,0.99832803
8738,apoptosis,14,15,102,111,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8738,-1,0.0014536531,0.99854636
8741,mitochondrial impairment,10,12,71,95,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,-1,8741,-1,0.0030902354,0.9969098
8743,mitochondrial toxicity,16,18,127,149,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,-1,-1,8743,-1,0.0021975855,0.99780244
8744,mitochondrial toxicity,2,4,14,36,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,-1,-1,-1,8744,-1,0.0020822056,0.99791783
8748,peripheral nerve toxicity,12,15,82,107,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,-1,-1,8748,-1,0.0011365262,0.99886346
8751,5-(l-hexyloxy)-6-methoxy-4-methylquinoline,10,11,110,152,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,-1,8751,-1,0.99267524,0.007324821
8752,cyanide,23,24,244,251,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,-1,8752,-1,0.9924263,0.0075737094
8754,CN poisoning,9,11,61,73,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,-1,8754,-1,0.1192786,0.8807214
8755,CN,27,28,151,153,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,-1,-1,8755,-1,0.976669,0.023330985
8757,WR242511,6,7,24,32,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8757,-1,0.9946397,0.0053603537
8758,WR242511,34,35,169,177,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8758,-1,0.99534494,0.0046550613
8759,WR242511,6,7,31,39,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8759,-1,0.9918641,0.008135952
8760,methemoglobinemia,11,12,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8760,-1,0.0012142938,0.9987857
8761,hemoglobinuria,3,4,23,37,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8761,-1,0.0010032171,0.9989968
8762,WR242511,11,12,90,98,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8762,-1,0.9903611,0.009638885
8763,Myoglobinuria,0,1,0,13,Myoglobinuria was also observed following the 7.0 mg/kg dose.,18821488_7,-1,-1,-1,8763,-1,0.00095146906,0.99904853
8766,WR242511,4,5,21,29,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8766,-1,0.9880961,0.011903884
8767,CN poisoning,13,15,74,86,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8767,-1,0.035025794,0.9649742
8769,liver tumors,6,8,41,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,-1,8769,-1,0.0014146604,0.99858534
8771,liver tumors,8,10,47,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8771,-1,0.0015020546,0.99849796
8772,oral contraceptive steroids,17,20,96,123,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8772,-1,0.99782026,0.0021797793
8773,Liver Tumors,3,5,17,29,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,-1,8773,-1,0.0020172815,0.99798274
8775,focal nodular hyperplasia,11,14,65,90,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8775,-1,0.0022783524,0.9977216
8776,adenoma,15,16,92,99,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8776,-1,0.0015610862,0.9984389
8777,hamartoma,17,18,101,110,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8777,-1,0.0017371238,0.99826294
8778,hepatoma,20,21,116,124,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8778,-1,0.001248251,0.99875176
8779,oral contraceptive steroids,9,12,83,110,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,-1,8779,-1,0.997703,0.0022969937
8781,liver rupture,3,5,17,30,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,-1,-1,8781,-1,0.0011795997,0.99882036
8783,Parkinson's disease,8,11,81,100,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,-1,-1,-1,8783,-1,0.0014263232,0.99857366
8785,Parkinson's disease,39,42,214,233,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8785,-1,0.0016029136,0.99839705
8786,PD,43,44,235,237,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8786,-1,0.0013909678,0.998609
8787,PD,3,4,18,20,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,-1,8787,-1,0.0010283877,0.9989716
8793,PD,14,15,77,79,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,-1,-1,8793,-1,0.0013296492,0.99867034
8795,PD,20,21,153,155,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,-1,8795,-1,0.0013102619,0.9986897
8814,priapism,8,9,63,71,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8814,-1,0.0017044847,0.9982955
8815,emergency department,11,13,79,99,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8815,-1,0.0034478207,0.9965522
8816,Priapism,0,1,0,8,Priapism is the prolonged erection of the penis in the absence of sexual arousal.,18996674_1,-1,-1,-1,8816,-1,0.0012334102,0.99876666
8818,Emergency Department,13,15,71,91,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8818,-1,0.006930218,0.9930697
8819,priapism,26,27,141,149,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8819,-1,0.0014019902,0.99859804
8828,ventricular ectopy,26,28,178,196,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,-1,-1,8828,-1,0.0011589228,0.9988411
8829,cardiac disease,9,11,50,65,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8829,-1,0.0009720182,0.99902797
8831,bigeminy,16,17,104,112,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8831,-1,0.0018110953,0.9981889
8837,rheumatologic disorders,9,11,74,97,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,-1,8837,-1,0.0008999963,0.99909997
8839,hepatitis B,20,22,138,149,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8839,-1,0.016971573,0.9830284
8840,HBs Ag,26,28,173,179,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8840,-1,0.023184147,0.9768158
8841,rheumatologic disease,32,34,204,225,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8841,-1,0.0009803711,0.9990196
8842,Ag,9,10,39,41,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8842,-1,0.021319741,0.97868025
8843,rheumatologic diseases,13,15,65,87,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8843,-1,0.0009696438,0.99903035
8845,hepatitis B,4,6,22,33,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,-1,-1,8845,-1,0.03731632,0.9626837
8847,abnormal liver function tests,15,19,100,129,Shortly after treatment their tests normalized and during follow-up period none of the patients had abnormal liver function tests.,19037603_7,-1,-1,-1,8847,-1,0.0025108506,0.9974891
8851,vitamin E,5,7,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8851,-1,0.99796605,0.0020340155
8853,myocardial infarction,11,13,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8853,-1,0.0009829876,0.999017
8855,vitamin E,14,16,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8855,-1,0.997338,0.002662
8856,weight,18,19,100,106,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8856,-1,0.0044381195,0.99556184
8857,body weight,20,22,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8857,-1,0.0049677957,0.9950322
8859,myocardial infarction,39,41,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8859,-1,0.0010564202,0.9989436
8860,ISO,7,8,37,40,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8860,-1,0.99484503,0.0051549063
8861,h,23,24,91,92,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8861,-1,0.046419054,0.953581
8862,P<0.05,28,29,115,121,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8862,-1,0.14170611,0.85829395
8863,heart weight,32,34,136,148,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8863,-1,0.007628842,0.9923712
8864,P<0.05,51,52,246,252,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8864,-1,0.15986198,0.84013796
8865,body weight,55,57,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8865,-1,0.011273236,0.98872674
8867,vitamin E,12,14,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8867,-1,0.99782676,0.0021732447
8868,ISO,29,30,139,142,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8868,-1,0.9923579,0.0076420866
8869,P<0.05,41,42,191,197,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8869,-1,0.20100097,0.7989991
8870,heart weight,45,47,211,223,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8870,-1,0.010400057,0.98959994
8871,body weight,63,65,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8871,-1,0.016670495,0.98332953
8872,ISO,77,78,400,403,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8872,-1,0.99126786,0.008732204
8874,vitamin E,84,86,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8874,-1,0.99742174,0.002578226
8876,vitamin E,11,13,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8876,-1,0.9978562,0.002143759
8877,ISO,14,15,92,95,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8877,-1,0.8264397,0.17356035
8878,myocardial infarction,16,18,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8878,-1,0.0010695908,0.9989304
8879,gastrointestinal haemorrhage,3,5,27,55,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8879,-1,0.0010125542,0.9989874
8881,haemorrhage,7,8,35,46,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,-1,-1,-1,8881,-1,0.0011638923,0.9988361
8883,flavonoids,8,9,54,64,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,-1,8883,-1,0.9961079,0.0038920892
8886,adverse drug reactions,16,19,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,-1,-1,-1,8886,-1,0.0015069628,0.9984931
8890,bupropion HCl,13,15,85,98,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,-1,-1,8890,-1,0.9983627,0.0016373066
8893,bupropion HCl,22,24,104,117,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,-1,-1,-1,8893,-1,0.99824995,0.0017500219
8894,Bupropion HCl,0,2,0,13,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,-1,-1,-1,8894,-1,0.99781716,0.0021828474
8897,bupropion HCl,9,11,54,67,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,-1,8897,-1,0.9981762,0.0018238324
8899,p,10,11,74,75,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8899,-1,0.2746301,0.72536993
8900,bupropion HCl,26,28,145,158,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8900,-1,0.99836975,0.0016302539
8908,sinusoidal obstruction syndrome,14,17,108,139,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8908,-1,0.0010200037,0.99898
8909,microangiopathy,18,19,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8909,-1,0.001057692,0.9989423
8910,calcineurin inhibitor,1,3,2,23,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8910,-1,0.9916289,0.008371111
8912,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8912,-1,0.0011345682,0.9988655
8917,myelodysplastic syndrome,21,23,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8917,-1,0.0011386366,0.99886143
8918,MDS,24,25,132,135,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8918,-1,0.0011943637,0.99880564
8919,n,26,27,137,138,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8919,-1,0.011910667,0.9880894
8920,acute myeloid leukemia,31,34,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8920,-1,0.0015077579,0.99849224
8921,AML,35,36,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8921,-1,0.0013681927,0.9986318
8922,n,37,38,177,178,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8922,-1,0.012610549,0.98738945
8923,n,50,51,249,250,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8923,-1,0.030288043,0.969712
8924,n,57,58,270,271,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8924,-1,0.027465729,0.9725343
8926,GVHD,10,11,48,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8926,-1,0.0010848588,0.9989152
8927,GVHD,25,26,120,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8927,-1,0.0010724278,0.99892753
8928,microangiopathy,1,2,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8928,-1,0.0009908391,0.99900913
8929,TMA,3,4,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8929,-1,0.002009338,0.9979907
8930,acute renal failure,18,21,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8930,-1,0.00092742295,0.99907255
8931,sinusoidal obstruction syndrome,15,18,86,117,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8931,-1,0.0013326374,0.99866736
8932,SOS,19,20,119,122,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8932,-1,0.0011970095,0.998803
8933,GVHD,14,15,90,94,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8933,-1,0.00090974924,0.9990903
8934,TMA,19,20,113,116,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8934,-1,0.0030604738,0.99693954
8935,SOS,21,22,121,124,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8935,-1,0.0015320882,0.99846786
8936,difluoromethylornithine,13,14,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8936,-1,0.99835384,0.0016462276
8938,colorectal adenomas,20,22,150,169,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8938,-1,0.0011341986,0.99886584
8939,adenomatous polyps,9,11,54,72,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8939,-1,0.0011226947,0.99887735
8940,difluoromethylornithine,17,18,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8940,-1,0.9983954,0.0016045535
8941,DFMO,19,20,133,137,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8941,-1,0.99779284,0.0022071188
8943,hearing loss,1,3,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8943,-1,0.0012766875,0.9987233
8945,DFMO,10,11,61,65,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8945,-1,0.9974382,0.0025617771
8946,DFMO,17,18,96,100,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8946,-1,0.997962,0.0020379801
8948,P,37,38,200,201,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8948,-1,0.17661525,0.82338476
8949,P,23,24,101,102,"In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected.",19139001_5,-1,-1,-1,8949,-1,0.1485077,0.85149235
8950,DFMO,11,12,35,39,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8950,-1,0.9979948,0.0020052963
8952,hearing reduction,33,35,132,149,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8952,-1,0.0042079645,0.99579203
8953,P,49,50,233,234,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8953,-1,0.06689296,0.933107
8954,P,29,30,158,159,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,-1,8954,-1,0.15727131,0.8427287
8955,DFMO,12,13,73,77,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8955,-1,0.9980836,0.0019163796
8957,hearing loss,20,22,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8957,-1,0.001370065,0.9986299
8959,P,26,27,123,124,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,-1,8959,-1,0.1207819,0.87921816
8960,DFMO,14,15,72,76,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,-1,-1,-1,8960,-1,0.99817085,0.0018291458
8964,RPN,4,5,26,29,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,-1,-1,8964,-1,0.0021272313,0.9978727
8967,RPN,27,28,183,186,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8967,-1,0.002671739,0.9973283
8970,ulcerative colitis,4,6,25,43,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8970,-1,0.0010436664,0.9989563
8971,red eyes,7,9,54,62,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8971,-1,0.0022409908,0.997759
8972,pleural effusion,10,12,64,80,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8972,-1,0.0013259283,0.99867415
8974,urinary abnormalities,15,17,99,120,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8974,-1,0.0016902738,0.99830973
8976,necrotizing glomerulonephritis,8,10,55,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,-1,-1,-1,8976,-1,0.0009369861,0.9990631
8977,pleural effusions,8,10,39,56,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,-1,-1,-1,8977,-1,0.0017311218,0.99826884
8980,red eyes,11,13,82,90,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8980,-1,0.0031245218,0.9968754
8981,chest pain,14,16,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8981,-1,0.0018957322,0.9981042
8982,pleural effusions,25,27,150,167,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8982,-1,0.0022084275,0.9977915
8984,pleural effusion,50,52,296,312,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8984,-1,0.0016248889,0.99837506
8986,pleural effusion,7,9,37,53,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,-1,-1,-1,8986,-1,0.001255838,0.99874413
8991,contrast,1,2,3,11,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,-1,8991,-1,0.110305406,0.8896946
8993,increases in BP,26,29,174,189,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,-1,8993,-1,0.002153494,0.9978465
9001,idiopathic Parkinson's disease,9,13,77,107,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,-1,-1,-1,9001,-1,0.0013797547,0.9986203
9002,idiopathic Parkinson's disease,20,24,145,175,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9002,-1,0.001547108,0.9984529
9003,PD,25,26,177,179,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9003,-1,0.0013444563,0.99865556
9006,Parkinson's Disease,8,11,52,71,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,9006,-1,0.002912314,0.99708766
9007,ADL,27,28,158,161,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,9007,-1,0.010396061,0.9896039
9010,ADL,10,11,50,53,"Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.",19234905_8,-1,-1,-1,9010,-1,0.0075398763,0.9924601
9011,hemianopsia,12,13,71,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9011,-1,0.00094321114,0.99905676
9012,Valproate,33,34,226,235,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9012,-1,0.998565,0.0014350627
9013,PD,22,23,137,139,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,-1,9013,-1,0.0012471956,0.99875283
9022,pains,4,5,29,34,Subjects also recalled their pains one week later.,19269743_5,-1,-1,-1,9022,-1,0.002449,0.997551
9024,p<0.001,8,9,61,68,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,-1,9024,-1,0.17374836,0.8262516
9028,p<0.001,15,16,101,108,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,-1,9028,-1,0.15570135,0.84429866
9030,p<0.01,11,12,61,67,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,-1,-1,9030,-1,0.1200061,0.8799939
9031,p<0.05,15,16,79,85,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,-1,-1,9031,-1,0.10514203,0.89485794
9034,myeloma,21,22,166,173,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,-1,9034,-1,0.0010983617,0.9989016
9036,bortezomib,15,16,104,114,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9036,-1,0.9985292,0.0014707567
9038,multiple myeloma,31,33,231,247,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9038,-1,0.001717405,0.9982827
9039,MM,34,35,249,251,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9039,-1,0.001454585,0.9985454
9040,bortezomib,9,10,57,67,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9040,-1,0.9984882,0.0015118145
9042,mg,26,27,126,128,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9042,-1,0.9868881,0.013111851
9043,bortezomib,31,32,143,153,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9043,-1,0.9984478,0.0015522003
9046,CR,8,9,46,48,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9046,-1,0.0034286266,0.9965714
9047,CR,29,30,121,123,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9047,-1,0.0033946598,0.9966054
9050,bortezomib,4,5,25,35,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9050,-1,0.9982628,0.0017372321
9053,MM,25,26,176,178,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9053,-1,0.0015743903,0.9984256
9056,captopril overdose,6,8,40,58,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,-1,-1,9056,-1,0.5589523,0.44104773
9058,inhibitors,9,10,77,87,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,-1,-1,-1,9058,-1,0.9859159,0.014084099
9062,captopril overdose,7,9,35,53,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,-1,-1,9062,-1,0.52349603,0.47650394
9070,chondroitin sulfate,13,15,93,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,-1,9070,-1,0.99130476,0.008695299
9073,critically ill,9,11,62,76,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,-1,-1,-1,9073,-1,0.0022624612,0.9977375
9075,chondroitin sulfate,18,20,109,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,-1,9075,-1,0.9932035,0.0067964694
9083,Pneumocystis pneumonia,10,12,81,103,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,-1,-1,-1,9083,-1,0.0015685204,0.9984315
9084,Pneumocystis pneumonia,0,2,0,22,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9084,-1,0.0019521214,0.9980478
9085,PCP,3,4,24,27,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9085,-1,0.0013262521,0.9986738
9086,opportunistic infection,8,10,39,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9086,-1,0.0012690763,0.99873096
9088,liver abscess,23,25,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9088,-1,0.0019784085,0.9980216
9089,PCP,34,35,243,246,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9089,-1,0.0015642853,0.9984357
9090,cm,9,10,44,46,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,-1,9090,-1,0.017122487,0.9828775
9091,apical ballooning syndrome,2,5,23,49,5 flourouracil-induced apical ballooning syndrome: a case report.,19300240_0,-1,-1,-1,9091,-1,0.0017282481,0.9982717
9092,apical ballooning syndrome,1,4,4,30,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9092,-1,0.003674022,0.9963259
9093,ABS,5,6,32,35,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9093,-1,0.0046849255,0.9953151
9094,acute cardiac syndrome,12,15,77,99,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9094,-1,0.0013437854,0.99865615
9095,hyperkinesis,26,27,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9095,-1,0.0015621843,0.9984378
9096,epicardial coronary disease,38,41,271,298,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9096,-1,0.0016186677,0.9983814
9098,ABS,7,8,33,36,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,-1,-1,-1,9098,-1,0.0023231448,0.9976769
9100,ischemic chest pain,6,9,43,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,-1,-1,-1,9100,-1,0.0011822338,0.99881774
9101,fluorouracil,5,6,39,51,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9101,-1,0.99832016,0.0016798322
9102,colorectal cancer,8,10,67,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9102,-1,0.0015117122,0.9984883
9104,coronary lesions,5,7,45,61,Coronary angiography revealed no obstructive coronary lesions.,19300240_8,-1,-1,-1,9104,-1,0.0017117896,0.9982882
9105,akinesis,12,13,82,90,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,-1,-1,-1,9105,-1,0.0011187488,0.9988813
9106,cardiac complications,3,5,27,48,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9106,-1,0.0011066523,0.9988933
9108,coronary vasospasm,11,13,100,118,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9108,-1,0.0012796937,0.9987203
9109,thrombus,18,19,154,162,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9109,-1,0.0020460743,0.9979539
9112,ABS,28,29,194,197,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,-1,-1,9112,-1,0.003688887,0.9963111
9114,nitric oxide,4,6,37,49,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9114,-1,0.99039125,0.009608717
9118,diabetic neuropathy,17,19,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9118,-1,0.0011339037,0.9988661
9120,HOE 140,68,70,385,392,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9120,-1,0.99513984,0.00486018
9121,des Arg10,76,78,412,421,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9121,-1,0.99566025,0.0043397006
9122,HOE 140,78,80,422,429,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9122,-1,0.99574834,0.0042516897
9127,diabetic hyperalgesia,24,26,155,176,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,-1,-1,-1,9127,-1,0.0011968001,0.99880314
9128,HOE 140,14,16,105,112,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9128,-1,0.9933303,0.0066696606
9129,des Arg10 HOE 140,17,21,117,134,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9129,-1,0.996051,0.0039489795
9133,HOE 140,12,14,80,87,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9133,-1,0.9967385,0.0032614558
9134,toxic neuropathy,18,20,111,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9134,-1,0.0009403622,0.9990596
9136,toxic neuropathy,23,25,143,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,-1,-1,9136,-1,0.0012209673,0.998779
9139,hyperalgesia bradykinin,17,19,148,171,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,-1,9139,-1,0.27856132,0.72143865
9143,adverse drug reaction,5,8,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9143,-1,0.0015845706,0.99841547
9144,valproic acid,9,11,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9144,-1,0.9984388,0.0015611857
9146,adverse drug reaction,5,8,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9146,-1,0.0018141856,0.9981858
9147,valproic acid,11,13,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9147,-1,0.9984244,0.001575651
9148,adverse drug reaction,13,16,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,-1,-1,-1,9148,-1,0.0019710013,0.99802893
9150,valproic acid,18,20,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,-1,9150,-1,0.99853396,0.001466027
9152,valproic acid,9,11,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,-1,-1,-1,9152,-1,0.99853635,0.001463615
9154,valproic acid,9,11,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,-1,-1,-1,9154,-1,0.99851686,0.0014831454
9155,ADR,4,5,23,26,The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.,19308880_8,-1,-1,-1,9155,-1,0.0024820794,0.99751794
9157,valproic acid,8,10,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9157,-1,0.9983903,0.0016097074
9158,adverse drug reaction,18,21,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9158,-1,0.0021916537,0.9978084
9160,intracerebral hemorrhage,13,15,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,-1,-1,9160,-1,0.0009746421,0.99902534
9161,intracerebral hemorrhage,1,3,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,-1,-1,9161,-1,0.0012552914,0.9987447
9163,prothrombin complex concentrate,15,18,89,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9163,-1,0.9565814,0.043418534
9164,PCC,19,20,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9164,-1,0.8831181,0.1168819
9167,h,12,13,59,60,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,-1,9167,-1,0.1038602,0.8961398
9168,PCC,10,11,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,-1,9168,-1,0.107064106,0.89293593
9170,PCC,10,11,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9170,-1,0.9952897,0.004710364
9171,n=12,20,21,96,100,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9171,-1,0.104300626,0.8956994
9175,P=0.015,22,23,139,146,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,-1,-1,9175,-1,0.1996426,0.80035746
9176,hematomas,12,13,53,62,"In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).",19319147_10,-1,-1,-1,9176,-1,0.0015437625,0.99845624
9177,contrast,1,2,3,11,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9177,-1,0.07017941,0.9298206
9178,PCC,11,12,60,63,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9178,-1,0.0054139155,0.9945861
9179,PCC,5,6,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,-1,9179,-1,0.94729,0.052710075
9181,inferior colliculus lesion,1,4,11,37,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,-1,9181,-1,0.003170872,0.9968291
9183,inferior colliculus lesions,7,10,41,68,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,-1,-1,9183,-1,0.0029879115,0.997012
9188,map,26,27,146,149,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,-1,9188,-1,0.08238594,0.91761404
9190,map,13,14,80,83,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9190,-1,0.031706914,0.96829313
9191,map,39,40,200,203,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9191,-1,0.04394822,0.9560518
9192,corpus callosal lesion,31,34,156,178,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,-1,-1,-1,9192,-1,0.004449157,0.9955509
9193,inferior colliculus lesions,3,6,24,51,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,-1,-1,9193,-1,0.004309402,0.99569064
9225,PA,16,17,111,113,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,-1,9225,-1,0.036889102,0.96311086
9226,memory impaired,9,11,60,75,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9226,-1,0.00310078,0.99689925
9229,deficit of associative memory,20,24,133,162,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9229,-1,0.0030154642,0.99698454
9230,PA,25,26,166,168,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9230,-1,0.10432662,0.89567333
9234,HT,5,6,29,31,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9234,-1,0.88415325,0.11584677
9235,menopausal symptoms,12,14,64,83,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9235,-1,0.0019106361,0.9980894
9236,cardiovascular disease,25,27,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9236,-1,0.0011503454,0.99884963
9239,HT,8,9,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,-1,-1,9239,-1,0.28713828,0.7128618
9243,Menstrual Disorders,17,19,103,122,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9243,-1,0.00308791,0.9969121
9244,Subfertility,20,21,127,139,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9244,-1,0.0023543157,0.9976457
9245,HT,7,8,54,56,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,-1,9245,-1,0.9889749,0.011025018
9246,HT,0,1,0,2,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9246,-1,0.015193101,0.9848069
9247,oestrogens,2,3,12,22,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9247,-1,0.99402034,0.005979718
9248,progestogens,7,8,40,52,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9248,-1,0.9899622,0.01003785
9249,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,-1,9249,-1,0.98160857,0.018391468
9253,HT,2,3,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,-1,-1,9253,-1,0.9181381,0.08186188
9257,HT,6,7,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9257,-1,0.9812858,0.018714258
9259,HT,17,18,108,110,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9259,-1,0.47984147,0.5201585
9260,colon cancer,19,21,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9260,-1,0.0014846008,0.9985154
9261,HT,22,23,128,130,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,-1,-1,9261,-1,0.9604014,0.03959856
9263,cardiovascular disease,3,5,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9263,-1,0.0010318398,0.9989681
9264,HT,11,12,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9264,-1,0.9515278,0.048472222
9265,HT,17,18,107,109,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9265,-1,0.9874264,0.012573648
9266,HT,22,23,141,143,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9266,-1,0.9626503,0.037349712
9267,HT,15,16,115,117,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,-1,-1,-1,9267,-1,0.965098,0.03490194
9268,HT,4,5,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9268,-1,0.1812565,0.8187435
9269,chronic disease,13,15,72,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9269,-1,0.0021015902,0.99789834
9270,HT,8,9,39,41,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,-1,-1,-1,9270,-1,0.9860968,0.013903177
9278,painful,19,20,125,132,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,-1,9278,-1,0.004914581,0.9950854
9282,mechanical pain,21,23,173,188,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,-1,-1,9282,-1,0.0030172637,0.99698275
9283,salvianolic acid A,3,6,27,45,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9283,-1,0.9931744,0.0068256455
9284,myocardial infarction,8,10,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9284,-1,0.0010272666,0.9989728
9285,salvianolic acid A,11,14,77,95,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9285,-1,0.9927942,0.0072058057
9286,myocardial infarction,16,18,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9286,-1,0.0010299968,0.99897003
9287,lactate,9,10,73,80,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9287,-1,0.99404377,0.005956282
9289,creatine kinase,15,17,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9289,-1,0.98868227,0.011317755
9291,superoxide dismutase,26,28,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9291,-1,0.98882526,0.011174722
9292,glutathione peroxidase,31,33,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9292,-1,0.9823417,0.017658273
9293,mitochondrial respiratory dysfunction,3,6,13,50,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,-1,9293,-1,0.0031576725,0.9968424
9294,salvianolic acid A,2,5,18,36,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,-1,-1,9294,-1,0.99308187,0.0069181593
9297,salvianolic acid A,4,7,23,41,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,-1,-1,9297,-1,0.99271846,0.0072815944
9299,salvianolic acid A,7,10,38,56,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9299,-1,0.9889178,0.011082147
9300,myocardial infarction,20,22,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9300,-1,0.0010718011,0.9989281
9302,peripheral neurotoxicity,7,9,62,86,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,-1,-1,-1,9302,-1,0.0010430132,0.9989569
9304,Toxic peripheral neuropathy,0,3,0,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9304,-1,0.0010329856,0.99896705
9306,PAC,14,15,101,104,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9306,-1,0.9939926,0.0060073473
9308,amino acid glutamine,23,26,150,170,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9308,-1,0.99138546,0.008614595
9309,PAC neurotoxicity,30,32,198,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9309,-1,0.09527106,0.90472895
9314,mg,37,38,226,228,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9314,-1,0.9529829,0.047017165
9317,P,44,45,291,292,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9317,-1,0.11248336,0.8875166
9318,P,21,22,118,119,Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%).,19473225_6,-1,-1,-1,9318,-1,0.060755588,0.93924445
9320,peripheral neurotoxicity,18,20,119,143,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9320,-1,0.0012217399,0.9987783
9321,PAC,21,22,147,150,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9321,-1,0.6860041,0.31399587
9322,ocular myasthenia,2,4,15,32,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9322,-1,0.00093109516,0.9990689
9323,pegylated interferon,5,7,40,60,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9323,-1,0.9983833,0.0016167624
9325,chronic hepatitis C.A,11,14,89,110,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9325,-1,0.008872488,0.99112755
9326,diplopia,18,19,147,155,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9326,-1,0.00087514654,0.9991248
9327,pegylated interferon,25,27,191,211,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9327,-1,0.997364,0.0026360005
9328,IFN) alpha-2b,28,31,213,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9328,-1,0.99410963,0.0058904323
9330,chronic hepatitis C,34,37,245,264,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9330,-1,0.0022631653,0.9977368
9331,CHC,38,39,266,269,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9331,-1,0.0017600264,0.99824
9332,ptosis on the,3,6,35,48,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9332,-1,0.004175216,0.9958248
9333,lid,8,9,61,64,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9333,-1,0.0030332808,0.9969668
9334,restricted right eye movement,10,14,69,98,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9334,-1,0.0022193517,0.9977806
9336,acetylcholinesterase inhibitors,8,10,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,-1,-1,-1,9336,-1,0.99358433,0.006415631
9337,pegylated IFN alpha-2b,12,15,90,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,-1,-1,-1,9337,-1,0.99623847,0.0037614913
9339,ocular myasthenia,1,3,4,21,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9339,-1,0.0009698471,0.9990301
9340,pegylated IFN alpha-2b,8,11,61,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9340,-1,0.99668044,0.0033195554
9342,CHC,14,15,102,105,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9342,-1,0.001557086,0.99844295
9343,IFN,35,36,213,216,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9343,-1,0.9970078,0.0029922812
9344,memory deficits,2,4,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,-1,-1,9344,-1,0.0023272266,0.99767274
9353,hypoactivity,10,11,82,94,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,-1,9353,-1,0.0012210035,0.998779
9358,hypoactivity,1,2,17,29,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,-1,-1,-1,9358,-1,0.0015028428,0.9984971
9364,Acute renal failure,0,3,0,19,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9364,-1,0.00091821456,0.99908173
9365,AIDS,6,7,37,41,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9365,-1,0.0010813732,0.99891865
9366,tenofovir,8,9,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9366,-1,0.9986375,0.0013625128
9368,osteomyelitis,15,16,103,116,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9368,-1,0.0008773629,0.9991227
9369,Renal failure,0,2,0,13,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9369,-1,0.0010486615,0.9989513
9371,tenofovir disoproxil fumarate,16,19,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9371,-1,0.9984785,0.0015215883
9372,Tenofovir,0,1,0,9,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9372,-1,0.99841,0.0015900341
9373,Fanconi syndrome,8,10,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9373,-1,0.0021496813,0.9978503
9374,renal insufficiency,11,13,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9374,-1,0.0010220045,0.998978
9375,Vancomycin nephrotoxicity,0,2,0,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,-1,9375,-1,0.056083657,0.9439163
9377,tenofovir,5,6,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9377,-1,0.9985897,0.0014102941
9378,renal failure,11,13,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9378,-1,0.00090143044,0.99909854
9380,hydrogen cyanamide,3,5,31,49,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,-1,9380,-1,0.9984578,0.0015421978
9381,Hydrogen cyanamide,0,2,0,18,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,-1,-1,-1,9381,-1,0.99798155,0.002018476
9382,aldehyde,14,15,91,99,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9382,-1,0.9939912,0.006008817
9383,acetaldehyde,19,20,129,141,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9383,-1,0.99652904,0.0034709112
9385,hydrogen cyanamide,18,20,117,135,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,-1,9385,-1,0.99840885,0.0015911305
9386,Dormex,9,10,51,57,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9386,-1,0.9833182,0.01668182
9387,hydrogen cyanamide,13,15,74,92,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9387,-1,0.9979771,0.0020229649
9390,malaise,13,14,65,72,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9390,-1,0.0010913174,0.99890864
9391,flushing,15,16,78,86,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9391,-1,0.0016890407,0.9983109
9393,dyspnea,23,24,117,124,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9393,-1,0.001322074,0.9986779
9394,Dormex,12,13,82,88,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,-1,9394,-1,0.8339092,0.16609076
9395,flushing,10,11,70,78,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9395,-1,0.0016367643,0.9983632
9397,arterial hypotension,15,17,97,117,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9397,-1,0.0011113855,0.9988887
9399,Dormex,17,18,112,118,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,-1,-1,-1,9399,-1,0.9515407,0.048459247
9400,dysosmia,1,2,10,18,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9400,-1,0.00087655487,0.9991234
9401,pyrazinamide,4,5,30,42,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9401,-1,0.99873275,0.0012672638
9402,Pyrazinamide,0,1,0,12,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9402,-1,0.998362,0.0016380209
9403,hepatic toxicity,7,9,46,62,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9403,-1,0.0009452191,0.99905473
9404,hyperuricemia,10,11,64,77,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9404,-1,0.0010025989,0.9989974
9405,digestive disorders,12,14,81,100,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9405,-1,0.0009838622,0.99901617
9406,pyrazinamide,14,15,78,90,"In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.",19674115_2,-1,-1,-1,9406,-1,0.99865144,0.00134856
9407,olfactory disorder,6,8,31,49,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9407,-1,0.0010880672,0.998912
9408,pyrazinamide,10,11,61,73,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9408,-1,0.9987463,0.0012536447
9409,Dysosmia,0,1,0,8,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9409,-1,0.0010220371,0.998978
9410,pyrazinamide,4,5,38,50,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9410,-1,0.9985983,0.0014017319
9411,tardive dystonia,1,3,18,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,-1,-1,9411,-1,0.0010838421,0.99891615
9414,tardive dyskinesia,12,14,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,-1,-1,9414,-1,0.00076942827,0.9992306
9418,tardive dystonia,9,11,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,-1,-1,9418,-1,0.0009874504,0.9990125
9421,prostaglandin,9,10,49,62,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9421,-1,0.9943604,0.0056395917
9422,PG,11,12,64,66,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9422,-1,0.9917965,0.00820348
9424,prostaglandin E,14,16,100,115,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,-1,-1,-1,9424,-1,0.991223,0.008777042
9425,LiCl,4,5,25,29,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,-1,9425,-1,0.99775726,0.002242804
9427,PGE(2),12,14,87,93,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,-1,9427,-1,0.96335685,0.036643147
9428,contrast,1,2,3,11,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9428,-1,0.029738152,0.9702618
9430,PGE(2),26,28,169,175,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9430,-1,0.9775329,0.022467058
9431,cAMP,29,30,180,184,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9431,-1,0.99572384,0.004276188
9433,contrast,1,2,3,11,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,-1,9433,-1,0.03332918,0.9666708
9434,PGE(2),4,6,33,39,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,-1,-1,-1,9434,-1,0.96638376,0.033616267
9437,fenoldopam,9,10,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,-1,-1,-1,9437,-1,0.9986093,0.0013906532
9439,Fenoldopam mesylate,0,2,0,19,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,-1,-1,-1,9439,-1,0.99826366,0.0017363342
9440,fenoldopam,3,4,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,-1,-1,9440,-1,0.9985247,0.0014752784
9442,fenoldopam,34,35,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,-1,9442,-1,0.9986754,0.0013246181
9445,fenoldopam,16,17,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9445,-1,0.9987355,0.0012645713
9447,NS,41,42,221,223,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9447,-1,0.0823331,0.9176669
9451,P,29,30,170,171,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,-1,-1,9451,-1,0.0909268,0.9090732
9454,Fenoldopam,0,1,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,-1,-1,9454,-1,0.99844104,0.0015589703
9465,Etodolac,0,1,0,8,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9465,-1,0.9972017,0.002798366
9466,E,2,3,10,11,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9466,-1,0.984306,0.015694004
9468,etodolac,8,9,56,64,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9468,-1,0.99262094,0.0073790685
9469,EAI,10,11,66,69,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9469,-1,0.8535775,0.1464225
9471,Etodolac,0,1,0,8,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,-1,9471,-1,0.984769,0.015231025
9472,etodolac,8,9,26,34,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,-1,9472,-1,0.9966022,0.0033978315
9473,acetic acid,8,10,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9473,-1,0.99341524,0.0065847985
9474,writhing,11,12,91,99,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9474,-1,0.00152608,0.99847394
9475,paw edema,19,21,141,150,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9475,-1,0.0016211831,0.99837875
9476,E,5,6,26,27,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9476,-1,0.9870902,0.012909878
9477,p,16,17,109,110,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9477,-1,0.1512091,0.8487909
9478,etodolac,25,26,193,201,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,-1,-1,-1,9478,-1,0.9970669,0.002933141
9485,fibrillation,20,21,142,154,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9485,-1,0.0011575383,0.99884254
9487,arrhythmic,32,33,217,227,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9487,-1,0.0012323059,0.99876773
9488,aconitine,5,6,32,41,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,-1,9488,-1,0.99808717,0.0019128257
9492,4-DAMP,9,10,68,74,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,-1,-1,-1,9492,-1,0.9953876,0.0046124063
9495,arrhythmic,9,10,71,81,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9495,-1,0.0012039917,0.998796
9496,aconitine,17,18,119,128,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9496,-1,0.9982161,0.0017838597
9503,P,11,12,74,75,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9503,-1,0.16129653,0.83870345
9504,P,37,38,209,210,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9504,-1,0.16804111,0.8319589
9505,chronic pain,13,15,77,89,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,-1,-1,-1,9505,-1,0.0011788663,0.9988211
9508,opioids,8,9,56,63,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,-1,-1,-1,9508,-1,0.99521834,0.0047816895
9510,SSR103800,4,5,36,45,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,-1,9510,-1,0.9971054,0.0028946083
9514,NMDA,11,12,81,85,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9514,-1,0.99600595,0.003994057
9515,NMDA,33,34,218,222,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9515,-1,0.994653,0.005346993
9516,antipsychotic,17,18,101,114,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9516,-1,0.5958712,0.4041288
9517,NMDA,32,33,204,208,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9517,-1,0.99438655,0.005613506
9519,SSR103800,11,12,64,73,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9519,-1,0.99764144,0.0023586159
9520,NMDA,16,17,100,104,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9520,-1,0.9950919,0.0049081016
9522,NMDA,28,29,171,175,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9522,-1,0.9943908,0.0056091794
9523,SSR103800,10,11,81,90,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9523,-1,0.9976993,0.0023006871
9526,MK-801,30,31,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9526,-1,0.99657696,0.003423018
9527,NMDA,38,39,229,233,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9527,-1,0.99469477,0.0053052707
9528,SSR103800,3,4,20,29,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9528,-1,0.9976306,0.002369336
9530,NMDA,18,19,102,106,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9530,-1,0.99503714,0.0049628597
9531,MK-801,22,23,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9531,-1,0.9963844,0.0036156164
9533,NMDA,29,30,187,191,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9533,-1,0.9953016,0.0046984414
9534,contrast,1,2,3,11,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9534,-1,0.19617143,0.8038286
9535,SSR103800,3,4,13,22,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9535,-1,0.9969897,0.003010256
9542,aripiprazole,14,15,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9542,-1,0.9987124,0.001287636
9543,antipsychotics,16,17,96,110,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9543,-1,0.9763333,0.023666732
9545,SSR103800,6,7,30,39,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,-1,-1,9545,-1,0.997062,0.002937928
9547,SSR103800,9,10,55,64,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,-1,9547,-1,0.99719405,0.0028058856
9548,orofacial dyskinesia,18,20,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9548,-1,0.0011943682,0.99880564
9552,superoxide dismutase,17,19,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9552,-1,0.98635,0.013650003
9553,glutathione reductase,28,30,182,203,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9553,-1,0.9914928,0.008507167
9554,GSH,31,32,205,208,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9554,-1,0.99306124,0.0069387467
9555,GSH,18,19,121,124,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,-1,-1,-1,9555,-1,0.9918541,0.008145929
9556,orofacial dyskinesia,17,19,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9556,-1,0.0011185325,0.9988815
9557,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9557,-1,0.9976318,0.0023682138
9558,pilocarpine status epilepticus,8,11,64,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9558,-1,0.30189988,0.6981001
9559,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9559,-1,0.9973998,0.0026001686
9560,PDTC,3,4,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9560,-1,0.9946464,0.005353575
9561,reactive oxygen species,4,7,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,-1,9561,-1,0.43288738,0.5671127
9563,PDTC,3,4,14,18,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,-1,-1,-1,9563,-1,0.99221826,0.007781792
9565,PDTC,4,5,25,29,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9565,-1,0.9916579,0.008342099
9566,status epilepticus,8,10,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9566,-1,0.0010845105,0.99891555
9567,PDTC,4,5,27,31,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9567,-1,0.993403,0.006597037
9568,status epilepticus,18,20,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9568,-1,0.0009197912,0.9990802
9569,status epilepticus,4,6,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,-1,9569,-1,0.0011316184,0.99886847
9571,PDTC,1,2,9,13,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9571,-1,0.99074394,0.009256058
9572,status epilepticus,19,21,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,-1,9572,-1,0.0011175993,0.99888235
9573,PDTC,8,9,55,59,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9573,-1,0.9956477,0.0043522827
9574,neuronal loss,20,22,123,136,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9574,-1,0.0015075196,0.9984925
9575,reactive oxygen species,8,11,49,72,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,-1,-1,9575,-1,0.47243348,0.52756655
9577,PDTC,14,15,100,104,"However, future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex.",19767176_11,-1,-1,-1,9577,-1,0.9962453,0.0037546968
9578,masseter spasm,4,6,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9578,-1,0.003028529,0.9969715
9579,myotonia congenita,13,15,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9579,-1,0.0016000896,0.9983999
9580,myotonia congenita,6,8,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9580,-1,0.0010935122,0.9989065
9581,masseter spasm,19,21,133,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9581,-1,0.0020369212,0.9979631
9584,human immunodeficiency virus infection,17,21,92,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,-1,-1,9584,-1,0.009356911,0.9906431
9585,heart block,6,8,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,-1,-1,9585,-1,0.00090152584,0.99909854
9588,right heart failure,8,11,71,90,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,-1,9588,-1,0.0016702056,0.9983298
9604,birth defects,8,10,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9604,-1,0.0016045193,0.9983955
9605,Birth Defects,12,14,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9605,-1,0.0032086403,0.9967913
9606,birth defects,11,13,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,-1,-1,-1,9606,-1,0.0014982669,0.9985018
9607,birth defects,27,29,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9607,-1,0.002940645,0.99705935
9608,birth defect,31,33,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9608,-1,0.004220912,0.99577904
9609,n,39,40,235,236,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9609,-1,0.20685817,0.7931419
9610,n,55,56,319,320,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9610,-1,0.22331023,0.7766897
9611,birth defects,17,19,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,-1,9611,-1,0.0016009902,0.99839896
9612,Sulfonamides,0,1,0,12,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9612,-1,0.99819857,0.0018015159
9614,hypoplastic left heart syndrome,27,31,112,143,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9614,-1,0.0019003446,0.9980996
9615,coarctation of the aorta,45,49,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9615,-1,0.0034522272,0.99654776
9616,choanal atresia,63,65,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9616,-1,0.0034757575,0.9965243
9617,transverse limb deficiency,79,82,276,302,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9617,-1,0.007444341,0.9925557
9618,diaphragmatic hernia,97,99,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9618,-1,0.0025741004,0.99742585
9619,Nitrofurantoins,0,1,0,15,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9619,-1,0.99687284,0.0031271947
9620,anophthalmia,4,5,37,49,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9620,-1,0.0010061369,0.9989938
9621,microphthalmos,6,7,53,67,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9621,-1,0.0014881138,0.99851185
9622,hypoplastic left heart syndrome,21,25,99,130,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9622,-1,0.0022355258,0.99776447
9623,atrial septal defects,39,42,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9623,-1,0.0052937577,0.9947062
9624,cleft lip,57,59,217,226,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9624,-1,0.0021134666,0.9978865
9625,cleft palate,60,62,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9625,-1,0.0019244162,0.9980756
9626,erythromycins,7,8,61,74,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9626,-1,0.997013,0.0029870393
9627,penicillins,13,14,88,99,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9627,-1,0.99715376,0.0028462654
9629,quinolones,26,27,143,153,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9629,-1,0.9976173,0.0023826258
9630,penicillins,4,5,27,38,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9630,-1,0.99539965,0.0046003116
9631,erythromycins,6,7,40,53,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9631,-1,0.99657506,0.0034248773
9633,birth defects,23,25,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9633,-1,0.0017583936,0.99824166
9634,Sulfonamides,0,1,0,12,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9634,-1,0.9980038,0.0019962445
9635,nitrofurantoins,2,3,17,32,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9635,-1,0.9978358,0.002164216
9636,birth defects,7,9,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9636,-1,0.0015759976,0.99842405
9637,hepatitis B,15,17,106,117,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9637,-1,0.0075229034,0.9924771
9638,e,18,19,124,125,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9638,-1,0.10559803,0.894402
9639,hepatitis B,5,7,30,41,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,-1,9639,-1,0.0092797065,0.9907203
9641,LAM,40,41,274,277,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9641,-1,0.9942597,0.005740296
9642,HBeAg,43,44,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9642,-1,0.041917276,0.9580827
9643,LAM,9,10,60,63,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,-1,9643,-1,0.99199015,0.008009807
9644,HBsAg,5,6,37,42,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9644,-1,0.49861792,0.50138205
9645,HBsAg,7,8,47,52,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,-1,9645,-1,0.43230402,0.567696
9646,HBeAg,6,7,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9646,-1,0.079389274,0.9206108
9647,LAM,16,17,78,81,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9647,-1,0.99420714,0.005792807
9648,LAM,8,9,46,49,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9648,-1,0.64964247,0.3503575
9649,nucleotide,13,14,76,86,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9649,-1,0.9949228,0.0050771968
9650,adefovir,15,16,97,105,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9650,-1,0.9985423,0.0014577335
9651,tenofovir,17,18,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9651,-1,0.9986084,0.0013916437
9652,acute renal failure,6,9,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,-1,-1,9652,-1,0.0011248003,0.9988752
9653,acute renal failure,7,10,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,-1,9653,-1,0.0011394129,0.9988606
9655,vitamin C,4,6,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,-1,9655,-1,0.99761343,0.0023866282
9659,Vitamin C,0,2,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,-1,9659,-1,0.99766785,0.0023321463
9660,vitamin C,37,39,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,-1,9660,-1,0.99754375,0.0024562203
9661,myocardial hypertrophy,1,3,11,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,-1,-1,-1,9661,-1,0.0010670536,0.9989329
9665,myocardial hypertrophy,4,6,29,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,-1,-1,-1,9665,-1,0.0010744398,0.9989255
9669,myocardial hypertrophy,18,20,120,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,-1,-1,9669,-1,0.0014623712,0.99853766
9672,Myocardial hypertrophy,0,2,0,22,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,-1,-1,-1,9672,-1,0.001386062,0.99861395
9675,myocardial hypertrophy,8,10,53,75,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,-1,-1,-1,9675,-1,0.0013741369,0.9986259
9681,cognitive dysfunction,18,20,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,-1,-1,9681,-1,0.0009743075,0.9990257
9683,NIMO,7,8,42,46,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,-1,9683,-1,0.9967974,0.0032026859
9686,PA,6,7,32,34,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,-1,-1,-1,9686,-1,0.120388485,0.87961155
9687,PA,1,2,4,6,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,-1,9687,-1,0.1979113,0.80208874
9689,h,4,5,27,28,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,-1,9689,-1,0.042708863,0.9572911
9690,NTG,29,30,103,106,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9690,-1,0.9941089,0.005891063
9691,NTG,36,37,138,141,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9691,-1,0.9930928,0.006907239
9692,h,38,39,144,145,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9692,-1,0.33718845,0.6628116
9693,NTG,44,45,165,168,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9693,-1,0.99556965,0.0044303276
9694,NIMO,46,47,173,177,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9694,-1,0.9971583,0.0028417055
9695,NIMO,55,56,198,202,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9695,-1,0.99752384,0.0024761185
9698,NTG,26,27,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9698,-1,0.99365413,0.0063459114
9699,NIMO,28,29,149,153,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9699,-1,0.9932795,0.006720509
9700,NTG,32,33,166,169,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9700,-1,0.9858393,0.014160712
9701,H,16,17,109,110,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9701,-1,0.28471446,0.71528554
9702,P,20,21,120,121,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9702,-1,0.19675528,0.80324477
9703,NTG,16,17,82,85,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9703,-1,0.99628985,0.0037101104
9704,n,18,19,87,88,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9704,-1,0.31575298,0.68424696
9705,NTG,23,24,98,101,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9705,-1,0.9957074,0.0042925715
9706,NIMO,25,26,104,108,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9706,-1,0.9878594,0.012140569
9707,n,27,28,110,111,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9707,-1,0.19712727,0.8028728
9708,mm Hg,43,45,183,188,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9708,-1,0.016380522,0.9836195
9709,mm Hg,51,53,209,214,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9709,-1,0.018969968,0.98103
9710,mm Hg,60,62,241,246,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9710,-1,0.016840696,0.9831593
9711,mm Hg,68,70,267,272,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9711,-1,0.01818723,0.9818127
9712,NIMO,8,9,50,54,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9712,-1,0.9942145,0.0057855677
9713,mm Hg,16,18,89,94,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9713,-1,0.005395506,0.9946045
9714,mm Hg,23,25,111,116,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9714,-1,0.005756687,0.9942433
9715,P,7,8,57,58,The intergroup difference was statistically significant (P < 0.05).,19923525_13,-1,-1,-1,9715,-1,0.11817342,0.8818266
9716,mm Hg,8,10,36,41,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9716,-1,0.05948914,0.9405108
9717,mm Hg,16,18,62,67,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9717,-1,0.0633709,0.9366292
9718,NTG,21,22,79,82,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9718,-1,0.9656366,0.03436337
9719,mm Hg,29,31,111,116,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9719,-1,0.05781116,0.94218886
9720,mm Hg,37,39,137,142,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9720,-1,0.07331556,0.92668444
9721,NTG,42,43,154,157,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9721,-1,0.9582265,0.041773535
9722,NIMO,44,45,160,164,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9722,-1,0.99012786,0.0098721
9723,PA,4,5,17,19,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9723,-1,0.8667332,0.13326675
9724,NTG,11,12,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9724,-1,0.9955936,0.0044064196
9726,NIMO,0,1,0,4,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9726,-1,0.9914893,0.008510674
9727,NTG,11,12,78,81,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9727,-1,0.9957683,0.0042317524
9729,NIMO,4,5,23,27,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,-1,-1,9729,-1,0.9948807,0.0051193265
9735,peptic ulcer disease,12,15,64,84,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9735,-1,0.0011341311,0.99886584
9736,reflux esophagitis,16,18,86,104,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9736,-1,0.0011078023,0.99889225
9741,lethargy,5,6,32,40,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9741,-1,0.0011033808,0.9988966
9742,shortness of breath,8,11,46,65,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9742,-1,0.0020730956,0.99792683
9749,Parkinson's disease,12,15,87,106,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,-1,-1,-1,9749,-1,0.0013734369,0.9986266
9751,Parkinson's disease,23,26,174,193,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9751,-1,0.0015889851,0.99841094
9752,PD,27,28,195,197,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9752,-1,0.0013650911,0.9986349
9753,PD,28,29,163,165,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,-1,-1,9753,-1,0.0010924648,0.99890757
9754,"N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride",3,7,15,66,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9754,-1,0.987015,0.012984935
9755,AMN082,8,9,68,74,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9755,-1,0.98665166,0.01334832
9756,PD,28,29,185,187,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9756,-1,0.0014078893,0.9985921
9757,AMN082,20,21,88,94,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,-1,-1,9757,-1,0.9932929,0.006707061
9759,AMN082,0,1,0,6,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,-1,-1,-1,9759,-1,0.99431,0.0056899735
9762,PD,13,14,76,78,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9762,-1,0.0013575016,0.9986425
9763,AMN082,18,19,97,103,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9763,-1,0.99637824,0.0036217475
9764,AMN082,3,4,13,19,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,-1,9764,-1,0.9957436,0.004256464
9766,AMN082,3,4,16,22,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9766,-1,0.9958955,0.0041044625
9767,PD,20,21,83,85,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9767,-1,0.0011943706,0.99880564
9768,motor dysfunction,10,12,74,91,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,-1,-1,-1,9768,-1,0.0011030455,0.99889696
9771,coronary artery spasm,6,9,53,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,-1,-1,9771,-1,0.00103902,0.998961
9772,renal cell carcinoma,5,8,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9772,-1,0.0014180742,0.9985819
9773,chest pain,13,15,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9773,-1,0.0015217548,0.99847823
9775,myocardial infarction,5,7,39,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,-1,-1,-1,9775,-1,0.00094007334,0.99906
9776,subendocardial infarction,7,9,54,79,Enhanced heart magnetic resonance imaging also showed subendocardial infarction.,19944333_4,-1,-1,-1,9776,-1,0.0014537992,0.99854624
9777,stenosis,5,6,22,30,"However, there was no stenosis in coronary arteries on angiography.",19944333_5,-1,-1,-1,9777,-1,0.0016511816,0.99834883
9778,Coronary artery spasm,0,3,0,21,Coronary artery spasm was induced by a provocative test.,19944333_6,-1,-1,-1,9778,-1,0.0014657025,0.9985343
9780,nitrates,9,10,68,76,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,-1,-1,-1,9780,-1,0.9960311,0.003968839
9782,nicorandil,3,4,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9782,-1,0.998713,0.0012869517
9783,angina,10,11,71,77,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9783,-1,0.0015023099,0.9984977
9784,coronary artery spasm,7,10,46,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,-1,-1,-1,9784,-1,0.001235548,0.9987645
9786,coronary artery spasm,16,19,85,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,-1,9786,-1,0.001399849,0.9986002
9788,Tacrine,0,1,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9788,-1,0.9985262,0.0014737773
9789,LiCl,4,5,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9789,-1,0.9978854,0.0021145318
9791,hippocampal damage,13,15,99,117,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9791,-1,0.0016533997,0.99834657
9792,tacrine,16,17,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,-1,9792,-1,0.9985493,0.0014507518
9794,tacrine,27,28,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9794,-1,0.9983418,0.0016581565
9804,mg,10,11,61,63,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9804,-1,0.93691665,0.06308343
9806,mg,18,19,90,92,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9806,-1,0.9089493,0.09105064
9808,mg,29,30,142,144,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9808,-1,0.9408198,0.059180185
9810,mg,39,40,188,190,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9810,-1,0.9303654,0.06963462
9811,MAP,48,49,230,233,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9811,-1,0.016012054,0.98398787
9812,MAP,6,7,17,20,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9812,-1,0.009251316,0.9907487
9814,CO,17,18,58,60,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9814,-1,0.101105876,0.8988942
9815,MAP,11,12,63,66,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9815,-1,0.025048815,0.9749512
9816,CO,18,19,80,82,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9816,-1,0.43902376,0.56097627
9818,MAP,5,6,39,42,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9818,-1,0.004382711,0.9956173
9819,P,19,20,83,84,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9819,-1,0.09107848,0.9089215
9820,SD,26,27,103,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9820,-1,0.05803239,0.9419676
9821,P,24,25,68,69,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9821,-1,0.17623185,0.82376814
9822,CO,33,34,105,107,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9822,-1,0.9446694,0.05533051
9824,MAP,10,11,61,64,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9824,-1,0.026015889,0.9739842
9825,mmHg,21,22,87,91,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9825,-1,0.012440939,0.987559
9826,P,23,24,93,94,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9826,-1,0.13095559,0.8690444
9827,CO,29,30,114,116,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9827,-1,0.9227202,0.07727975
9831,CO,31,32,214,216,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,-1,9831,-1,0.84754485,0.15245517
9832,tranexamic Acid,1,3,10,25,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,-1,-1,9832,-1,0.99867696,0.0013229612
9834,convulsive seizures,17,19,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,-1,-1,-1,9834,-1,0.00087775,0.9991222
9835,tranexamic acid,11,13,74,89,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9835,-1,0.99882525,0.0011747748
9836,TXA,14,15,91,94,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9836,-1,0.99743074,0.0025692643
9837,TXA,19,20,115,118,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,-1,-1,-1,9837,-1,0.99710923,0.0028908192
9840,cerebral ischemic injury,13,16,68,92,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9840,-1,0.0011377415,0.99886227
9842,ischemic brain injury,23,26,126,147,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9842,-1,0.0011098525,0.9988902
9844,permanent neurological abnormalities,7,10,40,76,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,-1,-1,9844,-1,0.0012389466,0.99876106
9846,TXA,9,10,53,56,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,-1,-1,9846,-1,0.9964644,0.0035355617
9847,ischemic,4,5,21,29,"No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.",19996135_10,-1,-1,-1,9847,-1,0.0014821035,0.99851793
9849,TXA,9,10,54,57,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,-1,-1,9849,-1,0.99707866,0.002921349
9854,Direct thrombin inhibitors,2,5,12,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9854,-1,0.96741027,0.032589667
9856,HIT,23,24,160,163,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9856,-1,0.001368952,0.99863106
9857,HIT,26,27,168,171,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9857,-1,0.0015479185,0.99845207
9859,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9859,-1,0.0025028943,0.99749714
9860,critically ill,7,9,39,53,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9860,-1,0.0026688755,0.99733114
9861,HITT,15,16,90,94,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9861,-1,0.0023808053,0.9976192
9863,Factor VIIa,35,37,195,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9863,-1,0.9807093,0.019290667
9864,postoperative bleeding,42,44,238,260,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9864,-1,0.0022996466,0.9977004
9868,hepatic impairment,54,56,265,283,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,-1,9868,-1,0.001388284,0.9986117
9875,psychotropic drugs,8,10,75,93,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,-1,-1,9875,-1,0.9866584,0.013341646
9876,psychotropic drugs,12,14,90,108,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9876,-1,0.9789488,0.021051278
9877,phenothiazines,16,17,117,131,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9877,-1,0.99834836,0.0016516203
9879,Mellaril,8,9,53,61,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9879,-1,0.9960259,0.003974121
9880,thioridazine,10,11,63,75,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9880,-1,0.9986809,0.0013190435
9882,Supraventricular tachycardia,0,2,0,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9882,-1,0.0012968212,0.9987031
9883,Thorazine,7,8,64,73,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9883,-1,0.9983688,0.0016311582
9885,Aventyl,0,1,0,7,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9885,-1,0.9981042,0.0018958199
9886,nortriptyline,2,3,9,22,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9886,-1,0.9986784,0.0013215502
9887,Elavil,5,6,28,34,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9887,-1,0.9985097,0.0014902835
9889,left bundle branch block,11,15,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9889,-1,0.0036639245,0.9963361
9892,electric shock,13,15,103,117,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,-1,-1,9892,-1,0.0014216008,0.9985784
9894,tachyarrhythmias,1,2,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,-1,-1,-1,9894,-1,0.0009225189,0.99907744
9895,heart disease,18,20,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,-1,-1,-1,9895,-1,0.0013226204,0.9986773
9897,heart disease,10,12,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9897,-1,0.0010580932,0.99894196
9898,psychotropic drugs,19,21,132,150,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9898,-1,0.98388886,0.016111149
9899,cardiac complications,11,13,66,87,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9899,-1,0.0011811751,0.9988188
9900,phenothiazines,16,17,110,124,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9900,-1,0.99835867,0.00164126
9903,immunodeficient,10,11,89,104,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,-1,-1,-1,9903,-1,0.0018039725,0.99819607
9904,anaemia,1,2,4,11,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9904,-1,0.0010800898,0.99891996
9905,3'-azido-3'dideoxythymidine,4,5,23,50,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9905,-1,0.9938969,0.006103055
9906,AZT,6,7,52,55,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9906,-1,0.9953277,0.0046722842
9907,AIDS,7,8,31,35,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9907,-1,0.0012913352,0.9987086
9909,leukaemia,17,18,89,98,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9909,-1,0.0020901284,0.99790984
9910,anaemia,27,28,141,148,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9910,-1,0.0010609946,0.998939
9911,AZT,11,12,58,61,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9911,-1,0.9967859,0.003214102
9912,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9912,-1,0.3775554,0.62244457
9913,AZT,0,1,0,3,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9913,-1,0.9962773,0.0037227273
9914,anaemia,2,3,13,20,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9914,-1,0.0009824797,0.9990175
9915,anaemia,2,3,12,19,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9915,-1,0.0010469283,0.9989531
9916,AZT,13,14,68,71,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9916,-1,0.99537647,0.004623517
9917,AZT,18,19,113,116,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,-1,-1,9917,-1,0.9972748,0.0027252224
9918,AZT,8,9,42,45,The mean plasma levels of EPO observed in AZT treated mice,2004015_8,-1,-1,-1,9918,-1,0.9926116,0.007388403
9919,anaemia,6,7,35,42,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9919,-1,0.0010105632,0.9989894
9920,phenylhydrazine,11,12,71,86,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9920,-1,0.9984397,0.001560231
9921,PHZ,13,14,88,91,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9921,-1,0.99534297,0.004657102
9922,AZT,15,16,97,100,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9922,-1,0.995269,0.004730944
9923,PHZ,17,18,105,108,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9923,-1,0.9918841,0.00811593
9924,anaemia,24,25,146,153,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9924,-1,0.00096919783,0.9990308
9925,reticulocytosis,2,3,9,24,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9925,-1,0.001078846,0.99892116
9926,anaemia,9,10,61,68,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9926,-1,0.00095106015,0.9990489
9927,AZT,12,13,81,84,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9927,-1,0.9959197,0.004080222
9928,peripheral anaemia,1,3,12,30,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,-1,-1,-1,9928,-1,0.0011525464,0.9988475
9929,postoperative delirium,9,11,63,85,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9929,-1,0.0011637715,0.9988362
9930,hip fracture,15,17,117,129,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9930,-1,0.0026452772,0.99735475
9931,hip fracture,13,15,100,112,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9931,-1,0.002426,0.99757403
9932,postoperative delirium,24,26,171,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9932,-1,0.0016025756,0.9983974
9935,hip fracture,33,35,207,219,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,-1,9935,-1,0.0037260216,0.996274
9937,Postoperative delirium,0,2,0,22,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9937,-1,0.002178985,0.997821
9938,Mental Disorders,12,14,87,103,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9938,-1,0.008170109,0.99182993
9940,postoperative delirium,3,5,18,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9940,-1,0.0016100754,0.99838996
9941,P=.02,31,32,149,154,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9941,-1,0.072052725,0.9279473
9943,SD,4,5,13,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9943,-1,0.047712136,0.9522879
9945,P=.01,32,33,171,176,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9945,-1,0.12692986,0.8730701
9947,postoperative delirium,12,14,75,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,-1,-1,-1,9947,-1,0.0014433285,0.9985567
9948,postoperative delirium,18,20,118,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,-1,-1,-1,9948,-1,0.0013320436,0.99866796
9954,SD,20,21,123,125,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9954,-1,0.0020508547,0.9979492
9956,SSRI,30,31,180,184,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9956,-1,0.995145,0.0048549795
9957,SD,34,35,190,192,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9957,-1,0.0017688164,0.99823123
9958,SSRIs,40,41,220,225,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9958,-1,0.9911965,0.008803478
9959,SSRI,18,19,106,110,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,-1,9959,-1,0.9944865,0.005513445
9961,mg,10,11,52,54,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,-1,-1,-1,9961,-1,0.94870025,0.051299725
9962,Erectile Dysfunction,37,39,212,232,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,-1,9962,-1,0.0037245124,0.99627554
9963,sd,11,12,48,50,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9963,-1,0.058777932,0.9412221
9965,P=,47,48,193,195,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9965,-1,0.2521613,0.74783874
9967,P=,20,21,94,96,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,-1,9967,-1,0.176063,0.823937
9969,P=,29,30,133,135,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,-1,9969,-1,0.21213716,0.78786284
9971,P=,21,22,91,93,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,-1,-1,-1,9971,-1,0.17891838,0.8210816
9972,P=,9,10,49,51,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,-1,9972,-1,0.19505683,0.80494314
9973,SD,15,16,97,99,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,9973,-1,0.001650215,0.9983498
9974,SSRI,19,20,109,113,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,9974,-1,0.99343514,0.006564849
9976,SD,9,10,58,60,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,9976,-1,0.0015100676,0.99848986
9977,SSRIs,12,13,72,77,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,9977,-1,0.9919594,0.008040562
9983,status epilepticus,19,21,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,9983,-1,0.0012218574,0.99877816
9984,SE,22,23,146,148,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,9984,-1,0.0013777307,0.9986223
9985,Spontaneous recurrent seizures,0,3,0,30,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,9985,-1,0.0016815908,0.99831843
9986,SRS,4,5,32,35,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,9986,-1,0.0017002927,0.9982998
9989,SRS,11,12,72,75,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,-1,9989,-1,0.0015856646,0.9984143
10001,daytime sleepiness,19,21,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,-1,-1,-1,10001,-1,0.0012614436,0.9987386
10004,mg,13,14,95,97,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10004,-1,0.9730698,0.026930181
10005,N=10,15,16,99,103,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10005,-1,0.27909833,0.72090167
10006,N=10,21,22,118,122,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10006,-1,0.34028643,0.65971357
10012,daytime sleepiness,25,27,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,-1,10012,-1,0.0012173037,0.9987827
10014,daytime sleepiness,14,16,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,-1,-1,10014,-1,0.0013679815,0.998632
10016,cocaine dependence,9,11,50,68,These effects may be relevant in the treatment of cocaine dependence.,20080983_12,-1,-1,-1,10016,-1,0.15370521,0.8462948
10017,Midazolan,13,14,69,78,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10017,-1,0.9986731,0.0013269824
10018,MZ,15,16,80,82,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10018,-1,0.9972427,0.0027573102
10019,Flumazenil,18,19,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10019,-1,0.9986247,0.0013753506
10020,FL,20,21,100,102,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10020,-1,0.99613035,0.0038696576
10021,MZ,11,12,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,-1,10021,-1,0.9732806,0.02671942
10022,MZ,14,15,90,92,"We analyzed the following events: complications related with the topical anesthesia, with MZ use and with the procedure.",20084309_4,-1,-1,-1,10022,-1,0.9960139,0.003986141
10024,myocardiopathy,21,22,108,122,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10024,-1,0.0010519144,0.99894816
10025,MP,23,24,124,126,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10025,-1,0.0016909754,0.998309
10027,MR,34,35,173,175,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10027,-1,0.0015361207,0.99846387
10028,MZ,38,39,185,187,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10028,-1,0.9899447,0.010055378
10029,MZ,4,5,18,20,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10029,-1,0.7792997,0.2207003
10030,FL,6,7,25,27,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10030,-1,0.5855872,0.41441283
10031,mg,9,10,43,45,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10031,-1,0.55577976,0.4442203
10032,mg,12,13,61,63,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10032,-1,0.60933334,0.39066666
10035,upper airway obstruction,27,30,115,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10035,-1,0.001519431,0.9984806
10037,MZ,44,45,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10037,-1,0.992029,0.007971062
10039,MR,6,7,45,47,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10039,-1,0.0012612358,0.9987388
10040,MP,8,9,49,51,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10040,-1,0.0014373534,0.99856263
10041,MZ,17,18,79,81,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10041,-1,0.9953885,0.004611472
10042,mg,21,22,85,87,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10042,-1,0.9303557,0.069644265
10043,p<0.001,28,29,118,125,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10043,-1,0.11501744,0.8849825
10044,MP,10,11,34,36,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10044,-1,0.0017842487,0.9982158
10045,MR,19,20,70,72,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10045,-1,0.0013821771,0.99861777
10046,methylergonovine,6,7,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,-1,10046,-1,0.99878615,0.0012138515
10048,methylergonovine,6,7,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10048,-1,0.9987306,0.0012693825
10050,chest pain,20,22,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10050,-1,0.0010210907,0.998979
10051,angina pectoris,26,28,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10051,-1,0.0009067009,0.9990933
10052,Methylergonovine,0,1,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,-1,-1,-1,10052,-1,0.9985745,0.0014255363
10055,SD,25,26,114,116,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,-1,-1,10055,-1,0.05101644,0.9489835
10056,ischemic,5,6,29,37,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,-1,10056,-1,0.002240931,0.997759
10059,methylergonovine,19,20,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,-1,10059,-1,0.998599,0.0014010193
10064,cardiac dysrhythmias,23,25,155,175,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10064,-1,0.0010564897,0.9989435
10067,violent behavior,31,33,211,227,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10067,-1,0.0018062948,0.9981937
10069,xerostomia,11,12,76,86,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10069,-1,0.0010454999,0.99895453
10070,caries,14,15,96,102,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10070,-1,0.0013299128,0.9986701
10072,tooth wear,24,26,133,143,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10072,-1,0.001940326,0.9980597
10075,bad breath,12,14,76,86,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,-1,-1,10075,-1,0.003366323,0.9966337
10076,carious lesions,16,18,119,134,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,-1,-1,-1,10076,-1,0.0018577228,0.99814224
10078,carious episodes,15,17,89,105,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,-1,-1,-1,10078,-1,0.0013884222,0.99861157
10079,lead,15,16,98,102,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,-1,10079,-1,0.059225477,0.9407745
10082,methamphetamines,26,27,176,192,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,10082,-1,0.8769627,0.12303725
10085,renal failure,11,13,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10085,-1,0.0011273543,0.9988726
10086,reactive oxygen species,21,24,119,142,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10086,-1,0.49797884,0.5020212
10093,DNA damage,16,18,100,110,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,-1,-1,10093,-1,0.0024707725,0.9975292
10099,Metformin,0,1,0,9,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,-1,-1,10099,-1,0.9978288,0.002171192
10101,metformin,3,4,22,31,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10101,-1,0.9974031,0.0025969334
10102,vascular dysfunction,16,18,116,136,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10102,-1,0.0010238541,0.9989761
10103,gentamicin toxicity,14,16,68,87,Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.,20164825_2,-1,-1,-1,10103,-1,0.2261001,0.77389985
10104,reactive oxygen species,8,11,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10104,-1,0.48512152,0.51487845
10105,c,17,18,122,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10105,-1,0.95090616,0.049093798
10107,Metformin,0,1,0,9,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10107,-1,0.99789244,0.0021075988
10108,acute renal failure,5,8,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10108,-1,0.0009856994,0.99901426
10109,Metformin,0,1,0,9,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,-1,-1,-1,10109,-1,0.99800307,0.001996876
10111,kidney dysfunction,5,7,25,43,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10111,-1,0.001281089,0.998719
10112,metformin,11,12,68,77,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10112,-1,0.99803275,0.001967303
10114,cytochrome c,9,11,68,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,10114,-1,0.9764789,0.02352112
10115,NADH,12,13,82,86,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,10115,-1,0.9932672,0.0067328196
10116,reactive oxygen species,9,12,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10116,-1,0.37539718,0.6246028
10117,metformin,22,23,135,144,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10117,-1,0.9980184,0.001981578
10118,metformin,9,10,53,62,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10118,-1,0.9981499,0.00185019
10119,gentamicin nephrotoxicity,12,14,74,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10119,-1,0.05403697,0.945963
10121,contrast media,7,9,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,-1,-1,10121,-1,0.57909065,0.42090935
10122,contrast,5,6,39,47,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10122,-1,0.95351756,0.046482455
10124,CIN,9,10,75,78,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10124,-1,0.0016901426,0.99830985
10125,CIN,7,8,51,54,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10125,-1,0.0018055076,0.9981945
10126,contrast media,11,13,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10126,-1,0.7859099,0.21409014
10127,CM,14,15,88,90,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10127,-1,0.279122,0.720878
10128,iopromide,17,18,93,102,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10128,-1,0.998621,0.0013790039
10129,iohexol,19,20,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10129,-1,0.99872583,0.0012741236
10130,CM,43,44,239,241,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10130,-1,0.059763286,0.94023675
10131,cyanosis,48,49,262,270,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10131,-1,0.0010837818,0.99891627
10132,iopromide,9,10,59,68,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10132,-1,0.9987338,0.001266144
10133,n,14,15,79,80,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10133,-1,0.14447229,0.8555277
10134,iohexol,19,20,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10134,-1,0.9987784,0.0012215904
10135,n,24,25,108,109,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10135,-1,0.14427383,0.8557261
10137,Na,3,4,14,16,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10137,-1,0.992784,0.0072159646
10139,K,8,9,30,31,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10139,-1,0.9928646,0.0071353465
10141,Cr,14,15,50,52,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10141,-1,0.98055536,0.019444661
10142,h,19,20,71,72,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10142,-1,0.18564758,0.81435245
10143,CM,38,39,170,172,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10143,-1,0.9865089,0.013491084
10144,Na,3,4,18,20,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10144,-1,0.9689242,0.031075733
10145,Cr,5,6,25,27,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10145,-1,0.9452516,0.054748356
10146,renal failure,2,4,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10146,-1,0.0011784036,0.99882156
10147,Injury to the kidney,5,9,23,43,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10147,-1,0.0026811948,0.9973188
10148,Failure of kidney function,10,14,45,71,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10148,-1,0.0029710382,0.997029
10149,Loss of kidney function,15,19,73,96,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10149,-1,0.003327408,0.9966725
10151,CIN,32,33,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10151,-1,0.0017479504,0.998252
10152,CIN,5,6,26,29,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,-1,10152,-1,0.0023030161,0.99769694
10155,CIN,7,8,35,38,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10155,-1,0.001487094,0.9985129
10156,CM,17,18,90,92,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10156,-1,0.9927717,0.007228269
10157,CIN,40,41,217,220,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10157,-1,0.0014113287,0.9985886
10158,CM,47,48,257,259,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10158,-1,0.99191874,0.008081321
10159,p,49,50,261,262,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10159,-1,0.13496046,0.8650396
10160,CIN,5,6,27,30,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10160,-1,0.0015367761,0.9984633
10161,congenital heart diseases,10,13,47,72,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10161,-1,0.0011210644,0.9988789
10162,p,28,29,161,162,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10162,-1,0.082965046,0.9170349
10163,CIN,4,5,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,-1,-1,-1,10163,-1,0.0014858992,0.9985141
10164,CM,13,14,73,75,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10164,-1,0.060332272,0.9396677
10165,cyanosis,20,21,100,108,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10165,-1,0.0011027855,0.9988972
10166,CIN,24,25,123,126,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10166,-1,0.0025042694,0.9974957
10167,Antituberculosis,0,1,0,16,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,-1,-1,-1,10167,-1,0.3149754,0.68502456
10169,Antituberculosis,0,1,0,16,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10169,-1,0.027722705,0.9722773
10171,ALF,13,14,102,105,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10171,-1,0.0011687345,0.9988312
10172,ALF,9,10,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,-1,-1,-1,10172,-1,0.0015739431,0.9984261
10173,hepatitis virus infection,10,13,43,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,-1,-1,10173,-1,0.0012726076,0.9987274
10175,icterus encephalopathy,7,9,45,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,-1,-1,-1,10175,-1,0.0015550607,0.998445
10176,ALF,6,7,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,-1,-1,-1,10176,-1,0.0016252323,0.9983747
10178,cerebral edema,6,8,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,-1,-1,10178,-1,0.0009931121,0.9990069
10179,Gastrointestinal bleed,0,2,0,22,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10179,-1,0.0011672577,0.99883276
10182,acute renal failure,8,11,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10182,-1,0.0011909498,0.9988091
10183,hepatitis E,2,4,14,25,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10183,-1,0.022111446,0.9778886
10184,ALF,11,12,62,65,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10184,-1,0.001395491,0.9986045
10185,n,13,14,64,65,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,-1,10185,-1,0.09362199,0.906378
10188,ALF,7,8,40,43,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,-1,-1,-1,10188,-1,0.0014743711,0.9985257
10191,PAH,21,22,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,-1,10191,-1,0.8100343,0.18996577
10193,nitrous oxide,6,8,41,54,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,-1,-1,-1,10193,-1,0.9972294,0.002770553
10203,congestive heart failure,20,23,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,-1,10203,-1,0.00093713374,0.99906284
10205,ACE,8,9,57,60,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10205,-1,0.99272174,0.007278192
10206,congestive heart failure,18,21,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10206,-1,0.00079445937,0.9992055
10210,mg enalapril,4,6,25,37,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,-1,10210,-1,0.99550533,0.0044946703
10217,Brainstem dysgenesis,0,2,0,20,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,-1,-1,-1,10217,-1,0.0015862312,0.9984138
10220,fetal anomalies,15,17,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,-1,-1,-1,10220,-1,0.0017649074,0.9982351
10221,brainstem dysgenesis,11,13,79,99,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,-1,-1,10221,-1,0.001052771,0.9989472
10223,selective serotonin reuptake inhibitors,9,13,62,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,-1,-1,-1,10223,-1,0.9968426,0.003157338
10227,n,12,13,59,60,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,-1,-1,10227,-1,0.06578193,0.93421805
10231,P,29,30,181,182,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,-1,10231,-1,0.18816616,0.81183386
10232,serotonin reuptake inhibitors,11,14,76,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10232,-1,0.9955051,0.0044948515
10233,SSRIs,15,16,107,112,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10233,-1,0.99357057,0.0064294212
10234,P,28,29,172,173,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10234,-1,0.15315571,0.8468443
10235,P,41,42,218,219,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10235,-1,0.18118952,0.8188104
10238,SSRIs,10,11,61,66,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,-1,-1,10238,-1,0.9905448,0.00945518
10241,SSRI,12,13,88,92,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,-1,-1,10241,-1,0.99782085,0.0021791935
10242,fracture,20,21,135,143,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,-1,-1,-1,10242,-1,0.0017478017,0.9982522
10243,startle,1,2,17,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10243,-1,0.0027701892,0.99722975
10244,startle,6,7,49,56,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10244,-1,0.00265087,0.99734914
10245,startle,6,7,45,52,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10245,-1,0.007377276,0.99262273
10246,anxiety,15,16,90,97,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10246,-1,0.0016779534,0.99832207
10247,contrast,1,2,3,11,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10247,-1,0.03848766,0.9615124
10248,startle,5,6,34,41,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10248,-1,0.0023384488,0.9976616
10250,mCPP,26,27,168,172,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10250,-1,0.9967514,0.0032485703
10251,pentylenetetrazole,39,40,228,246,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10251,-1,0.9987368,0.0012632653
10252,PTZ,41,42,248,251,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10252,-1,0.99644107,0.0035589393
10253,mCPP,10,11,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,-1,-1,-1,10253,-1,0.996566,0.0034340168
10256,startle,5,6,42,49,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10256,-1,0.0032392007,0.9967608
10257,mCPP,12,13,78,82,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10257,-1,0.99727935,0.002720641
10258,startle,15,16,103,110,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10258,-1,0.0024962234,0.9975038
10259,PTZ,23,24,139,142,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10259,-1,0.99396086,0.00603919
10260,startle,26,27,163,170,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10260,-1,0.0024723432,0.99752766
10261,contrast,3,4,16,24,"CONCLUSIONS: In contrast to findings in the FPS paradigm, none of the drugs were able to exacerbate the LES response.",20394767_8,-1,-1,-1,10261,-1,0.113183185,0.88681686
10264,dermatitis eruptions,8,10,57,77,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10264,-1,0.00121247,0.9987876
10266,facial dermatitis,20,22,128,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10266,-1,0.0015608342,0.99843913
10267,telangiectasia,4,5,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,-1,-1,10267,-1,0.0012846274,0.9987154
10269,pimecrolimus,9,10,65,77,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,-1,10269,-1,0.9987562,0.0012438585
10271,Central nervous system complications,0,4,0,36,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,-1,-1,10271,-1,0.001233415,0.99876666
10273,Central nervous system (CNS) complications,0,7,0,42,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10273,-1,0.0016932301,0.99830675
10275,ALL,15,16,103,106,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10275,-1,0.0020601999,0.99793977
10276,neurological complications,6,8,37,63,"This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution, focusing on clinical, radiological, and electrophysiological findings.",20470218_3,-1,-1,-1,10276,-1,0.0010352269,0.9989648
10277,leukemic infiltration,4,6,32,53,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10277,-1,0.0009663164,0.9990337
10280,neurocognitive defects,18,20,147,169,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10280,-1,0.0009711749,0.9990288
10281,leukoencephalopathy syndrome,5,7,48,76,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10281,-1,0.0010491547,0.99895084
10282,n,8,9,78,79,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10282,-1,0.017158888,0.98284113
10284,n,15,16,95,96,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10284,-1,0.012122008,0.98787796
10286,n,24,25,127,128,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10286,-1,0.013146134,0.98685384
10287,methotrexate toxicity,30,32,145,166,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10287,-1,0.22927037,0.77072966
10288,n,33,34,168,169,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10288,-1,0.014886931,0.985113
10289,syndrome of inappropriate antidiuretic hormone secretion,38,44,176,232,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10289,-1,0.007549616,0.99245036
10290,n,45,46,234,235,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10290,-1,0.016216734,0.9837833
10291,n,55,56,273,274,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10291,-1,0.023090577,0.97690946
10292,CNS complications,3,5,15,32,"In conclusion, CNS complications are frequent events during ALL therapy, and require rapid detection and prompt treatment to limit permanent damage.",20470218_7,-1,-1,-1,10292,-1,0.0014921599,0.9985078
10294,topiramate,22,23,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,-1,-1,-1,10294,-1,0.9985757,0.0014242688
10295,cocaine toxicity,6,8,45,61,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,-1,10295,-1,0.18514718,0.8148528
10297,drug toxicity,23,25,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,-1,-1,10297,-1,0.028252691,0.97174734
10298,nitric oxide synthase,8,11,56,77,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10298,-1,0.96485204,0.03514792
10299,topiramate,26,27,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10299,-1,0.99868757,0.0013124238
10300,cocaine addiction,33,35,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10300,-1,0.20727974,0.79272026
10303,GSH,16,17,90,93,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10303,-1,0.9965145,0.003485577
10304,glutathione peroxidase,19,21,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10304,-1,0.9750528,0.024947297
10306,contrast,1,2,3,11,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10306,-1,0.07554476,0.9244553
10307,glutathione peroxidase,21,23,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10307,-1,0.959499,0.040500972
10309,Topiramate,0,1,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,-1,-1,-1,10309,-1,0.99845123,0.0015487936
10310,Coenzyme Q10,0,2,0,12,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10310,-1,0.9971392,0.0028608567
10311,cisplatin nephrotoxicity,5,7,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10311,-1,0.011517863,0.9884821
10312,coenzyme Q10,4,6,31,43,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10312,-1,0.997297,0.0027030178
10313,acute renal injury,11,14,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10313,-1,0.0011336526,0.9988663
10315,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,-1,-1,-1,10315,-1,0.997129,0.002871033
10317,Coenzyme Q10,0,2,0,12,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,-1,-1,-1,10317,-1,0.9969536,0.0030463748
10321,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10321,-1,0.99670273,0.0032972656
10322,reduced glutathione,11,13,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10322,-1,0.9328831,0.067116894
10323,superoxide dismutase,15,17,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10323,-1,0.984974,0.015026037
10325,nitric oxide,32,34,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10325,-1,0.99482155,0.0051784455
10326,platinum,35,36,254,262,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10326,-1,0.9968941,0.0031058681
10327,selenium,44,45,315,323,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10327,-1,0.9973496,0.0026503962
10328,zinc,46,47,328,332,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10328,-1,0.99708766,0.002912314
10330,renal tissue damage,3,6,24,43,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10330,-1,0.0011833498,0.9988167
10332,coenzyme Q10,12,14,85,97,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10332,-1,0.9972771,0.0027229604
10333,coenzyme Q10,4,6,43,55,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10333,-1,0.99711573,0.0028843074
10334,nitric oxide synthase,13,16,130,151,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10334,-1,0.9264651,0.0735349
10335,coenzyme Q10,4,6,22,34,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10335,-1,0.995915,0.0040849824
10336,cisplatin nephrotoxicity,15,17,102,126,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10336,-1,0.016008675,0.9839914
10338,bile duct injury,3,6,28,44,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,-1,-1,10338,-1,0.0022457254,0.9977543
10340,primary polymyositis,5,7,28,48,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,-1,-1,10340,-1,0.001057361,0.9989427
10347,bile duct injury,19,22,140,156,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,-1,-1,10347,-1,0.0027841744,0.99721575
10353,bipolar I disorder,24,27,152,170,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10353,-1,0.0017769462,0.998223
10354,psychotic features,30,32,187,205,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10354,-1,0.0011356118,0.9988644
10357,mg,21,22,137,139,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10357,-1,0.9630131,0.036986876
10359,mg,31,32,175,177,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10359,-1,0.9562932,0.043706782
10361,mg,40,41,212,214,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10361,-1,0.94701976,0.05298027
10363,mg,29,30,185,187,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10363,-1,0.9672095,0.03279052
10365,P,45,46,250,251,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10365,-1,0.17451435,0.82548565
10367,mg,73,74,381,383,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10367,-1,0.9500608,0.049939256
10369,P,93,94,469,470,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10369,-1,0.20294546,0.79705447
10370,Syndrome,5,6,29,37,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10370,-1,0.0021585105,0.9978415
10372,mg,24,25,138,140,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10372,-1,0.94196796,0.058032084
10373,general psychopathology,39,41,215,238,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10373,-1,0.0028826538,0.9971174
10375,mg,27,28,106,108,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,-1,-1,-1,10375,-1,0.9440915,0.05590853
10379,mg,26,27,107,109,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,-1,-1,10379,-1,0.94944817,0.05055185
10381,weight change,14,16,74,87,"Across all groups, no more than 5% of patients had clinically significant weight change.",20520283_7,-1,-1,-1,10381,-1,0.0032407437,0.99675924
10388,leukaemia,14,15,120,129,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10388,-1,0.0009262569,0.99907374
10389,lymphoma,16,17,134,142,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10389,-1,0.0010402015,0.9989598
10391,AraG,8,9,36,40,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10391,-1,0.9953916,0.004608378
10393,VP,16,17,65,67,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10393,-1,0.9972875,0.0027124546
10395,CPM,21,22,91,94,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10395,-1,0.9952122,0.004787805
10396,leukaemia,40,41,219,228,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10396,-1,0.0008906157,0.9991093
10397,lymphoma,42,43,232,240,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10397,-1,0.0010284034,0.9989716
10398,AraG,8,9,49,53,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10398,-1,0.82692975,0.17307019
10399,sensory and motor neuropathy,14,18,77,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10399,-1,0.0012141735,0.9987858
10400,musculoskeletal pain,19,21,110,130,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10400,-1,0.0011257662,0.99887425
10401,Haematological toxicity,0,2,0,23,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10401,-1,0.001154357,0.9988456
10402,AraG,8,9,61,65,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10402,-1,0.9964083,0.0035916632
10403,AraG,7,8,45,49,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10403,-1,0.99699163,0.0030082988
10406,neurological toxicity,19,21,128,149,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10406,-1,0.0011878547,0.9988122
10410,DA,7,8,37,39,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10410,-1,0.9972248,0.002775213
10413,DA,23,24,155,157,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10413,-1,0.99624145,0.0037586032
10415,DA,32,33,223,225,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10415,-1,0.99582505,0.0041749743
10417,DA,13,14,78,80,"However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.",20533999_2,-1,-1,-1,10417,-1,0.9934029,0.0065970486
10418,DA neurotoxicity,19,21,155,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,-1,10418,-1,0.11111711,0.8888829
10419,DA,13,14,75,77,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10419,-1,0.6498322,0.3501678
10420,METH neurotoxicity,15,17,86,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10420,-1,0.10226391,0.89773613
10421,METH,25,26,140,144,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10421,-1,0.99082434,0.009175721
10422,DA deficits,13,15,86,97,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10422,-1,0.09247448,0.90752554
10423,dopaminergic deficits,17,19,119,140,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10423,-1,0.01309614,0.9869039
10424,DA,7,8,48,50,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10424,-1,0.9964508,0.0035492429
10425,dopaminergic neurotoxicity,16,18,104,130,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10425,-1,0.010725424,0.98927456
10426,DA,24,25,174,176,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10426,-1,0.9962446,0.0037553385
10437,kidney injury,21,23,127,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,-1,-1,10437,-1,0.0013989893,0.998601
10439,renal lesions,27,29,159,172,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,-1,-1,-1,10439,-1,0.0018440832,0.9981559
10442,atrial tachyarrhythmia,1,3,19,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,-1,10442,-1,0.0011489945,0.99885094
10444,atrial tachyarrhythmia,5,7,34,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,-1,-1,-1,10444,-1,0.0010384074,0.99896157
10446,atenolol,6,7,43,51,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,-1,-1,10446,-1,0.9982496,0.0017503635
10448,atenolol,11,12,59,67,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,-1,-1,10448,-1,0.99812096,0.0018789942
10450,atrial tachyarrhythmia,3,5,31,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10450,-1,0.0014426,0.9985574
10451,SIAT,6,7,55,59,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10451,-1,0.016634438,0.9833656
10452,SIAT,5,6,23,27,Fewer than 50 cases of SIAT have been described in the literature.,20552622_7,-1,-1,-1,10452,-1,0.011401047,0.98859894
10453,SIAT,19,20,122,126,"This article summarizes all the cases published, creating a comprehensive review of the current knowledge and approach to SIAT.",20552622_8,-1,-1,-1,10453,-1,0.028903263,0.9710967
10455,SIAT,14,15,102,106,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,-1,-1,10455,-1,0.3098909,0.69010913
10457,SIAT,11,12,67,71,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,-1,-1,-1,10457,-1,0.044570655,0.9554294
10460,atenolol,47,48,272,280,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,-1,-1,-1,10460,-1,0.9983625,0.0016375289
10461,diabetes mellitus.1,18,20,128,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,-1,10461,-1,0.012188506,0.9878115
10463,body weight,11,13,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,-1,10463,-1,0.010139922,0.9898601
10465,ATP,22,23,139,142,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10465,-1,0.9973363,0.002663649
10466,bethanechol,25,26,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10466,-1,0.9980259,0.0019741498
10468,body weight,10,12,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,-1,10468,-1,0.014144219,0.98585576
10470,ATP,19,20,130,133,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10470,-1,0.9975067,0.0024934004
10471,bethanechol,22,23,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10471,-1,0.99801433,0.0019856317
10473,NMDA,4,5,44,48,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,-1,10473,-1,0.99642545,0.0035745916
10480,glutamate NMDA,9,11,91,105,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10480,-1,0.99370724,0.0062927515
10481,MK-801,14,15,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10481,-1,0.9975158,0.0024842091
10482,AP7,23,24,166,169,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10482,-1,0.9979607,0.0020393645
10483,NMDA,35,36,208,212,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10483,-1,0.99341136,0.0065885945
10484,NMDA,40,41,252,256,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10484,-1,0.9964121,0.0035878874
10485,MK-801,7,8,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10485,-1,0.99673295,0.003267019
10486,AP7,9,10,69,72,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10486,-1,0.9966864,0.0033135654
10489,NMDA,5,6,47,51,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,-1,10489,-1,0.99666995,0.0033300472
10491,puromycin aminonucleoside nephrosis,16,19,109,144,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,-1,10491,-1,0.5604788,0.43952122
10493,puromycin aminonucleoside nephrosis,1,4,6,41,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10493,-1,0.6130165,0.38698348
10494,PAN,5,6,43,46,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10494,-1,0.0041023972,0.99589765
10497,PAN,2,3,13,16,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,-1,-1,10497,-1,0.00805645,0.9919436
10499,PAN,13,14,78,81,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,-1,-1,-1,10499,-1,0.037790783,0.96220917
10500,OCD,9,10,68,71,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10500,-1,0.0015268523,0.9984731
10501,anxiety,25,26,177,184,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10501,-1,0.0012979562,0.99870205
10502,antidepressant clomipramine,9,11,55,82,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,-1,10502,-1,0.99769515,0.0023048269
10504,anxiety,16,17,126,133,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10504,-1,0.0016449537,0.998355
10505,behavioral inflexibility,26,28,175,199,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10505,-1,0.0020549812,0.997945
10506,perseveration,29,30,201,214,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10506,-1,0.0023197853,0.9976802
10507,working memory impairment,41,44,284,309,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10507,-1,0.009128773,0.99087125
10508,hoarding,51,52,338,346,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10508,-1,0.0051302887,0.9948697
10509,corticostriatal dysfunction,54,56,352,379,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10509,-1,0.0055082683,0.9944917
10513,OCD,17,18,119,122,"Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD.",20619828_7,-1,-1,-1,10513,-1,0.0015526133,0.99844736
10514,OCD,4,5,20,23,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10514,-1,0.0013274994,0.9986725
10515,psychiatric disorders,33,35,223,244,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10515,-1,0.0016765434,0.9983235
10516,thoracic aortic aneurysm,15,18,103,127,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,-1,-1,-1,10516,-1,0.0014044344,0.99859554
10517,thoracic aortic aneurysm,12,15,61,85,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10517,-1,0.002533308,0.9974667
10518,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10518,-1,0.0033992396,0.9966008
10519,calcium chloride,19,21,95,111,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10519,-1,0.99725014,0.0027498547
10520,arterial injury,23,25,130,145,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10520,-1,0.0018133717,0.99818665
10521,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10521,-1,0.0046842364,0.9953158
10522,CaCl(2),13,15,72,79,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10522,-1,0.9875608,0.012439257
10523,NaCl,19,20,98,102,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10523,-1,0.99012226,0.0098777665
10524,n=12,12,13,80,84,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10524,-1,0.047228564,0.95277137
10525,n=12,19,20,120,124,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10525,-1,0.0692685,0.9307314
10526,n=6,17,18,136,139,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10526,-1,0.0554766,0.9445234
10527,n=12,39,40,259,263,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10527,-1,0.056883257,0.9431168
10528,p<0.01,16,17,94,100,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,-1,10528,-1,0.17960615,0.8203939
10529,p<0.01,15,16,109,115,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,-1,-1,-1,10529,-1,0.152292,0.847708
10530,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10530,-1,0.0032700917,0.99672985
10531,CaCl(2),10,12,63,70,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10531,-1,0.98612577,0.013874292
10532,vascular remodeling,35,37,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10532,-1,0.0015768567,0.9984231
10537,organophosphorus,13,14,105,121,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10537,-1,0.95832527,0.04167476
10538,OP) poisons,15,18,123,134,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10538,-1,0.07672263,0.9232773
10541,OP compound,13,15,85,96,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,-1,-1,-1,10541,-1,0.9787467,0.021253271
10542,congestive heart failure,1,4,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,-1,-1,10542,-1,0.0010217275,0.99897826
10547,congestive heart failure,17,20,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10547,-1,0.00089138193,0.9991086
10548,CHF,21,22,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10548,-1,0.00097112777,0.9990289
10553,T4,8,9,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10553,-1,0.99204576,0.007954205
10554,T3,14,15,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10554,-1,0.9929946,0.0070054107
10555,CHF,2,3,14,17,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,-1,10555,-1,0.0009644769,0.9990356
10559,CHF,15,16,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,-1,-1,-1,10559,-1,0.0014517632,0.9985482
10561,CHF,22,23,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,-1,-1,10561,-1,0.0017837748,0.9982162
10565,cognitive dysfunction,2,4,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,-1,-1,-1,10565,-1,0.0010285156,0.99897146
10570,cognitive impairment,12,14,82,102,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10570,-1,0.0009922959,0.99900776
10571,cognitive impairment,16,18,98,118,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,-1,-1,-1,10571,-1,0.0009804345,0.9990195
10574,cognitive impairment,20,22,151,171,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,-1,-1,-1,10574,-1,0.0010861399,0.9989139
10581,reduced glutathione,16,18,100,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,-1,-1,-1,10581,-1,0.9854283,0.01457175
10584,impairment,11,12,87,97,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,-1,-1,-1,10584,-1,0.002007628,0.9979924
10586,cognitive impairment,5,7,50,70,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,-1,-1,-1,10586,-1,0.00086590677,0.9991341
10591,deterioration of cognitive functions,11,15,73,109,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,-1,-1,-1,10591,-1,0.0015263364,0.9984737
10597,cognitive impairment,22,24,154,174,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,-1,10597,-1,0.0010271226,0.9989729
10598,crocin,9,10,53,59,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10598,-1,0.9956845,0.0043154787
10599,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10599,-1,0.0012649965,0.998735
10600,carotenoids,6,7,45,56,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10600,-1,0.99259275,0.0074072233
10601,crocins,8,9,58,65,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10601,-1,0.98909163,0.010908308
10602,crocins,8,9,36,43,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10602,-1,0.9940772,0.0059228432
10603,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10603,-1,0.0011841056,0.9988159
10604,streptozocin,20,21,117,129,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10604,-1,0.9979917,0.0020083054
10605,STZ,22,23,131,134,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10605,-1,0.9712017,0.02879832
10606,n,7,8,33,34,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10606,-1,0.25430107,0.745699
10607,crocins,27,28,94,101,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10607,-1,0.99766076,0.0023392276
10608,STZ,37,38,124,127,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10608,-1,0.97963583,0.020364173
10609,STZ,43,44,138,141,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10609,-1,0.98218346,0.017816586
10610,crocins,45,46,144,151,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10610,-1,0.9973749,0.002625109
10611,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,-1,10611,-1,0.0019799003,0.99802005
10612,STZ,1,2,3,6,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10612,-1,0.13281775,0.86718225
10613,crocin,3,4,9,15,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10613,-1,0.9964294,0.0035706144
10614,crocin,7,8,31,37,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10614,-1,0.9966703,0.0033297068
10615,crocin,2,3,16,22,Prescription of crocin in each dose was repeated once for two days.,20683499_6,-1,-1,-1,10615,-1,0.99608755,0.0039124927
10616,crocin,7,8,31,37,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,-1,10616,-1,0.9975547,0.0024453448
10617,crocin,3,4,13,19,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,-1,-1,10617,-1,0.997408,0.0025920544
10619,crocin,10,11,70,76,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10619,-1,0.9972704,0.0027295488
10621,neurodegenerative diseases,32,34,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10621,-1,0.0009766419,0.9990233
10622,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10622,-1,0.0014458651,0.99855417
10624,hemolytic anemia?BACKGROUND/AIMS,10,12,67,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10624,-1,0.006463676,0.9935363
10626,sunitinib,29,30,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10626,-1,0.99784493,0.0021550911
10630,chronically infected with hepatitis C virus,4,10,27,70,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10630,-1,0.0026880072,0.99731207
10631,pegylated interferon alpha 2a,13,17,87,116,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10631,-1,0.99633896,0.0036610218
10633,contrast,1,2,3,11,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10633,-1,0.14343938,0.8565606
10634,pegylated interferon,16,18,102,122,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10634,-1,0.99812394,0.0018760633
10638,hepatitis C,24,26,158,169,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,-1,-1,-1,10638,-1,0.0017923077,0.9982077
10652,P,28,29,140,141,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,-1,10652,-1,0.11039433,0.8896057
10656,psychosis,8,9,69,78,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,-1,10656,-1,0.0010738913,0.9989261
10657,psychotic disorders,14,16,103,122,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,-1,-1,10657,-1,0.0014481512,0.9985518
10660,antipsychotics,14,15,90,104,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,-1,-1,10660,-1,0.9918281,0.008171929
10664,phencyclidine,11,12,75,88,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,-1,10664,-1,0.99885654,0.0011434271
10666,psychotic disorders,28,30,187,206,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,-1,-1,10666,-1,0.0012296952,0.9987703
10668,psychosis,5,6,47,56,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10668,-1,0.0010421327,0.9989579
10669,paranoid type schizophrenia,11,14,81,108,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10669,-1,0.001508453,0.9984915
10670,5-HT6,11,12,62,67,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10670,-1,0.9861944,0.013805606
10671,psychosis,18,19,98,107,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10671,-1,0.0010613905,0.9989386
10672,psychosis,30,31,178,187,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,-1,10672,-1,0.0014411479,0.9985588
10673,methamphetamine dependence,15,17,73,99,The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients.,20705401_8,-1,-1,-1,10673,-1,0.3840214,0.6159786
10674,psychosis,7,8,52,61,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,-1,10674,-1,0.0013022976,0.99869764
10675,psychosis,31,32,185,194,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,-1,10675,-1,0.0013633047,0.99863666
10676,psychosis,13,14,83,92,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,-1,10676,-1,0.001053858,0.99894613
10682,h,12,13,31,32,"Before and 0.5, 1, 2, 3, and 6 h after injection the subjects were given attention and mnemonic tests.",2071257_4,-1,-1,-1,10682,-1,0.30990496,0.69009507
10683,impairment of attention and memory,13,18,72,106,The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.,2071257_5,-1,-1,-1,10683,-1,0.0023506952,0.99764925
10686,Fluoropyrimidines,5,6,25,42,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10686,-1,0.9962991,0.0037009001
10688,5-FU,11,12,74,78,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10688,-1,0.99695694,0.003043124
10690,head and neck cancers,30,34,176,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10690,-1,0.0028570383,0.997143
10693,renal,27,28,154,159,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10693,-1,0.0017001219,0.9982999
10694,kidney disease,29,31,164,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10694,-1,0.0015035326,0.9984964
10697,5-FU,10,11,54,58,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,-1,-1,-1,10697,-1,0.99622226,0.0037776737
10698,head and neck cancers,25,29,157,178,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,-1,-1,10698,-1,0.0027340853,0.99726593
10705,renal dysfunctions,19,21,118,136,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,-1,-1,-1,10705,-1,0.0012318264,0.99876815
10706,psychosis,5,6,40,49,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,-1,-1,-1,10706,-1,0.0010640733,0.9989359
10707,NMDA,4,5,40,44,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,-1,-1,10707,-1,0.9949727,0.0050272904
10709,NMDA,11,12,80,84,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10709,-1,0.99541855,0.004581419
10711,psychopathological,17,18,123,141,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10711,-1,0.0010974078,0.99890256
10712,psychopathological,17,18,123,141,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10712,-1,0.0010974078,0.99890256
10716,glutamatergic dysfunction,18,20,114,139,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,-1,-1,10716,-1,0.11287005,0.8871299
10717,psychopathological,1,2,17,35,Ketamine-induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS).,20727411_6,-1,-1,-1,10717,-1,0.0012567797,0.99874324
10719,psychosis,2,3,18,27,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10719,-1,0.0012817492,0.99871826
10720,psychopathology,4,5,33,48,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10720,-1,0.0012616359,0.99873835
10725,NMDA,10,11,61,65,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10725,-1,0.9918168,0.008183179
10730,acute liver injury,10,13,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,-1,10730,-1,0.0011857941,0.9988142
10738,substance abuse,17,19,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,-1,-1,10738,-1,0.047752254,0.9522478
10741,liver failure,10,12,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10741,-1,0.0014440515,0.99855596
10742,liver failure,17,19,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10742,-1,0.001428141,0.9985719
10744,Parkinson's disease,5,8,46,65,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,-1,-1,10744,-1,0.0016513389,0.9983487
10746,Parkinson's disease,10,13,57,76,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,-1,-1,-1,10746,-1,0.0015107997,0.99848914
10750,Parkinson's disease,9,12,48,67,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10750,-1,0.0011159973,0.998884
10751,dyskinetic movements,31,33,218,238,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10751,-1,0.0010945242,0.9989054
10756,parkinsonian catalepsy,6,8,55,77,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,-1,10756,-1,0.0008812597,0.99911875
10759,parkinsonian symptoms,13,15,98,119,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,-1,-1,10759,-1,0.0008703139,0.9991297
10761,parkinsonian catalepsy,12,14,98,120,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,-1,-1,-1,10761,-1,0.0008756583,0.99912435
10765,SR48692,5,6,43,50,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,-1,-1,-1,10765,-1,0.9975303,0.0024697727
10768,organic mental disorders,1,4,17,41,Carmofur-induced organic mental disorders.,2096243_0,-1,-1,-1,10768,-1,0.0013922912,0.9986077
10769,Organic mental disorder,0,3,0,23,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,-1,-1,10769,-1,0.0009944576,0.9990056
10771,organic personality syndrome,17,20,106,134,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10771,-1,0.00208803,0.997912
10772,frontal lobe syndrome,34,37,210,231,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10772,-1,0.0024797441,0.99752027
10774,organic personality syndrome,8,11,76,104,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,-1,-1,10774,-1,0.0013612165,0.9986388
10775,structural damage to the frontal lobe,6,12,28,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,-1,-1,-1,10775,-1,0.0038690493,0.99613094
10777,Parkinson's disease,14,17,92,111,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,-1,-1,-1,10777,-1,0.0012435025,0.9987565
10779,Parkinson's disease,17,20,108,127,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10779,-1,0.0011422683,0.99885774
10780,Parkinson's disease,44,47,198,217,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10780,-1,0.001179656,0.99882036
10782,akinesia,60,61,316,324,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10782,-1,0.0011070225,0.99889296
10784,6-OHDA,65,66,349,355,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10784,-1,0.99405056,0.00594945
10785,rotation,71,72,386,394,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10785,-1,0.0020331892,0.9979668
10800,n=10,3,4,12,16,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10800,-1,0.054015275,0.9459848
10801,n=10,14,15,62,66,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10801,-1,0.05084993,0.94915
10802,penicillin G,37,39,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10802,-1,0.99731714,0.0026828696
10804,lead,8,9,52,56,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,-1,10804,-1,0.030273661,0.9697263
10808,CCNU,0,1,0,4,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10808,-1,0.9963574,0.0036425758
10809,lomustine,2,3,6,15,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10809,-1,0.9982868,0.0017131771
10811,gastrointestinal toxicities,26,28,142,169,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10811,-1,0.0012737099,0.9987263
10812,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,32,33,203,247,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10812,-1,0.9927893,0.007210686
10813,CCNU,34,35,249,253,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10813,-1,0.9965411,0.0034589334
10814,CCNU,12,13,63,67,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,-1,10814,-1,0.9939678,0.006032233
10815,CCNU,8,9,38,42,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,-1,10815,-1,0.99645907,0.003540945
10817,CCNU,0,1,0,4,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10817,-1,0.9955135,0.0044864463
10818,lymphoma,9,10,48,56,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10818,-1,0.0012378779,0.99876213
10819,mast cell tumour,11,14,58,74,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10819,-1,0.002259458,0.9977405
10820,brain tumour,15,17,76,88,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10820,-1,0.0015821054,0.99841785
10821,histiocytic tumours,18,20,90,109,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10821,-1,0.0019017473,0.9980983
10822,epitheliotropic lymphoma,21,23,114,138,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10822,-1,0.0023651621,0.9976349
10824,anaemia,13,14,79,86,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,-1,-1,10824,-1,0.0010952412,0.9989047
10826,Gastrointestinal toxicosis,0,2,0,26,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,-1,-1,-1,10826,-1,0.0009611402,0.99903893
10830,hepatic failure,3,5,17,32,The incidence of hepatic failure was 1.2%.,21418164_7,-1,-1,-1,10830,-1,0.0010994012,0.99890053
10836,angina pectoris,35,37,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,-1,-1,10836,-1,0.0008794018,0.99912065
10837,demyelinating disorder,22,24,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,-1,-1,-1,10837,-1,0.0009279321,0.9990721
10839,Central vein thrombosis,0,3,0,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10839,-1,0.0018124182,0.9981876
10840,dipivalyl epinephrine,5,7,36,57,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10840,-1,0.9983192,0.0016807328
10841,central vein thrombosis,10,13,56,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10841,-1,0.0015679,0.9984321
10842,dipivalyl epinephrine,25,27,151,172,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10842,-1,0.9984168,0.0015832117
10846,Pirarubicin,12,13,76,87,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,-1,-1,10846,-1,0.9981357,0.0018642605
10848,hepatic dysfunction,25,27,119,138,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,-1,10848,-1,0.001270976,0.99872905
10849,granulocytopenia,7,8,59,75,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,-1,-1,-1,10849,-1,0.0008227002,0.9991773
10853,alopecia,12,13,76,84,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10853,-1,0.0011391108,0.99886096
10854,phlebitis,14,15,86,95,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10854,-1,0.0011934551,0.9988066
10857,hepatic dysfunction,6,8,43,62,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,-1,-1,10857,-1,0.0009979095,0.99900216
10858,Pirarubicin,6,7,49,60,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10858,-1,0.9981704,0.0018296386
10859,SE,14,15,85,87,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10859,-1,0.36065787,0.63934207
10860,Adriamycinol,0,1,0,12,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10860,-1,0.9982925,0.0017075415
10862,adriamycinone,4,5,27,40,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10862,-1,0.99777126,0.0022287099
10863,tetrahydropyranyladriamycinol,7,8,46,75,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10863,-1,0.9971445,0.0028554217
10865,Pirarubicin,3,4,21,32,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,2224762_13,-1,-1,-1,10865,-1,0.9985599,0.0014400759
10866,mesothelioma,4,5,22,34,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10866,-1,0.0015410968,0.99845886
10867,leiomyosarcoma,6,7,36,50,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10867,-1,0.001802612,0.9981974
10868,basal cell carcinoma,9,12,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10868,-1,0.0025431302,0.99745685
10869,auditory toxicity,2,4,11,28,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,-1,-1,-1,10869,-1,0.0011584212,0.9988416
10872,audiovisual toxicity,29,31,169,189,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,-1,10872,-1,0.0013663878,0.99863356
10873,visual or auditory toxicity,6,10,42,69,6 patients presented clinical symptoms of visual or auditory toxicity.,2234245_2,-1,-1,-1,10873,-1,0.0013904088,0.99860954
10874,Visual toxicity,0,2,0,15,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10874,-1,0.0012872595,0.9987128
10875,dyschromatopsy,12,13,77,91,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10875,-1,0.00092243776,0.99907756
10876,loss of visual acuity,18,22,121,142,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10876,-1,0.0018138455,0.9981862
10877,pigmentary retinal deposits,23,26,147,174,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10877,-1,0.0014162774,0.9985838
10878,Auditory toxicity,0,2,0,17,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10878,-1,0.001760531,0.9982395
10879,neurosensorial hearing loss,9,12,64,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10879,-1,0.0011838198,0.99881625
10881,hearing loss,24,26,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,-1,-1,-1,10881,-1,0.0014905999,0.99850935
10884,aluminium,19,20,132,141,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,-1,-1,10884,-1,0.9907369,0.009263054
10885,audiovisual toxicity,4,6,23,43,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,-1,-1,-1,10885,-1,0.0010803794,0.9989196
10887,Benzylacyclouridine,0,1,0,19,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10887,-1,0.998547,0.0014529
10888,marrow suppression,3,5,52,70,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10888,-1,0.0017248753,0.99827516
10889,immunodeficiency,9,10,104,120,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10889,-1,0.0026694362,0.99733055
10890,uridine,4,5,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10890,-1,0.9983267,0.001673279
10891,Urd,6,7,51,54,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10891,-1,0.99610966,0.003890352
10893,immunodeficiency,30,31,221,237,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10893,-1,0.004132963,0.995867
10895,Urd,8,9,59,62,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10895,-1,0.9672213,0.03277868
10896,benzylacyclouridine,14,15,94,113,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10896,-1,0.9984596,0.0015403748
10897,BAU,16,17,115,118,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10897,-1,0.99565625,0.004343699
10900,Urd,3,4,20,23,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10900,-1,0.9940562,0.005943751
10901,Urd,15,16,87,90,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10901,-1,0.99446636,0.0055336137
10903,anemic,3,4,17,23,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10903,-1,0.0010900727,0.99890995
10904,leukopenic,5,6,28,38,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10904,-1,0.0010034178,0.99899656
10905,AZT,10,11,64,67,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10905,-1,0.9979589,0.0020411306
10906,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10906,-1,0.8247859,0.1752141
10907,AZT,26,27,143,146,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10907,-1,0.99777335,0.0022265965
10908,BAU,29,30,158,161,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10908,-1,0.99623424,0.0037657372
10911,P,43,44,236,237,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10911,-1,0.095097706,0.9049023
10912,P,57,58,299,300,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10912,-1,0.08433447,0.91566557
10913,megaloblastosis,71,72,367,382,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10913,-1,0.0011545802,0.99884534
10914,AZT,3,4,25,28,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10914,-1,0.9977792,0.002220805
10915,BAU,11,12,68,71,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10915,-1,0.99390393,0.0060961
10916,marrow toxicity,14,16,92,107,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10916,-1,0.0013771894,0.9986228
10917,BAU,10,11,45,48,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10917,-1,0.99462897,0.0053710784
10918,AZT,23,24,121,124,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10918,-1,0.996014,0.00398606
10921,hallucinosis,43,44,259,271,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,-1,-1,10921,-1,0.0014377272,0.9985623
10923,vitamin B6,19,21,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,-1,-1,-1,10923,-1,0.99697876,0.0030212856
10925,Duchenne dystrophy,7,9,46,64,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,-1,10925,-1,0.0016076341,0.9983923
10926,growth hormone,4,6,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10926,-1,0.9959351,0.0040648393
10928,Duchenne dystrophy,15,17,87,105,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10928,-1,0.002197047,0.9978029
10930,growth hormone,11,13,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10930,-1,0.98522514,0.01477489
10931,Duchenne dystrophy,20,22,117,135,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10931,-1,0.0019270702,0.99807286
10932,contractures,3,4,17,29,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10932,-1,0.0011522642,0.9988477
10933,pulmonary function,8,10,54,72,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10933,-1,0.0019380335,0.99806195
10936,P,28,29,138,139,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,-1,-1,10936,-1,0.3279093,0.6720907
10939,decreased appetite,6,8,47,65,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10939,-1,0.002497393,0.9975026
10941,gastrointestinal symptoms,28,30,119,144,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10941,-1,0.0013700259,0.99863005
10944,GH,5,6,26,28,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,-1,-1,-1,10944,-1,0.729424,0.27057594
10948,Duchenne dystrophy,9,11,55,73,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,-1,-1,10948,-1,0.0015127186,0.99848723
10966,nalozone,29,30,184,192,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,-1,-1,10966,-1,0.998539,0.0014609963
10978,halogenated hydroxyquinolines,2,4,17,46,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,-1,-1,10978,-1,0.95777565,0.042224355
10980,halogenated hydroxyquinolines,12,14,74,103,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,-1,-1,10980,-1,0.98285174,0.017148267
10981,clioquinol,19,20,122,132,In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded.,230316_2,-1,-1,-1,10981,-1,0.9982135,0.0017864632
10982,clioquinol,7,8,36,46,"Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases.",230316_3,-1,-1,-1,10982,-1,0.99810153,0.0018985504
10983,neurological disturbance,7,9,33,57,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,10983,-1,0.0009105674,0.9990895
10985,clioquinol,25,26,157,167,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,10985,-1,0.99816704,0.0018329648
10986,optic atrophy,13,15,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,-1,-1,-1,10986,-1,0.0016143812,0.99838567
10987,clioquinol,13,14,70,80,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,10987,-1,0.99843186,0.001568174
10988,acrodermatitis enteropathica,17,19,98,126,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,10988,-1,0.0012384263,0.99876153
10989,myelopathy,8,9,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,10989,-1,0.0008670891,0.99913293
10990,visual disturbance,10,12,53,71,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,10990,-1,0.0011387613,0.9988612
10992,myelopathy,1,2,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,-1,-1,10992,-1,0.00086689746,0.99913317
10994,toxic encephalopathy,7,9,40,60,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,-1,-1,-1,10994,-1,0.0011560732,0.9988439
11006,Myocardial infarction,0,2,0,21,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11006,-1,0.0010780421,0.998922
11007,isosorbide dinitrate,6,8,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11007,-1,0.99850035,0.0014996807
11008,septal necrosis,4,6,26,41,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11008,-1,0.0015540335,0.99844605
11009,myocardial infarction,9,11,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11009,-1,0.0011205886,0.9988794
11010,isosorbide dinitrate,19,21,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11010,-1,0.99827564,0.0017243909
11011,mg,22,23,161,163,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11011,-1,0.961458,0.038541958
11013,myocardial ischemia,17,19,113,132,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11013,-1,0.0010680509,0.99893194
11014,coronary arterial stenosis,23,26,169,195,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11014,-1,0.0015465711,0.9984534
11015,acute coronary insufficiency,30,33,222,250,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11015,-1,0.0011976692,0.9988023
11019,impaired renal function,14,17,96,119,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,-1,-1,11019,-1,0.0015305687,0.9984694
11022,renal failure,17,19,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,-1,-1,11022,-1,0.00090934837,0.9990907
11025,Postrenal failure,0,2,0,17,Postrenal failure was excluded by echography.,2320800_2,-1,-1,-1,11025,-1,0.0016510196,0.99834895
11026,renal failure,7,9,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11026,-1,0.0009080263,0.999092
11028,ascitis,19,20,118,125,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11028,-1,0.0015150605,0.9984849
11032,tubulopathies,8,9,57,70,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,-1,-1,11032,-1,0.00087183487,0.99912816
11039,prostaglandin D2,7,9,61,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11039,-1,0.9973385,0.002661501
11040,E2,10,11,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11040,-1,0.99468404,0.0053160014
11041,F2,13,14,86,88,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11041,-1,0.9933523,0.0066476334
11044,acetic acid writhing,20,23,134,154,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,-1,11044,-1,0.12275212,0.87724787
11045,Prostaglandin D2,0,2,0,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11045,-1,0.9974437,0.002556317
11046,hyperalgesic,10,11,40,52,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11046,-1,0.0016671829,0.9983328
11047,Prostaglandin E2,0,2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11047,-1,0.9964508,0.0035492561
11048,hyperalgesic,4,5,26,38,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11048,-1,0.0013643107,0.9986357
11049,pg,10,11,60,62,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11049,-1,0.9361966,0.06380341
11050,prostaglandin D2,29,31,133,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11050,-1,0.996509,0.0034909337
11051,acetic acid writhing,5,8,33,53,Similar results were obtained by acetic acid writhing tests.,2322844_4,-1,-1,-1,11051,-1,0.20628217,0.79371786
11052,hyperalgesic,1,2,4,16,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11052,-1,0.0014776102,0.99852246
11053,prostaglandin D2,4,6,27,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11053,-1,0.99703085,0.0029691348
11054,substance P,13,15,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11054,-1,0.9955545,0.004445458
11055,ng,23,24,140,142,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11055,-1,0.9003888,0.09961121
11056,AH6809,28,29,155,161,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11056,-1,0.99678457,0.0032154801
11057,prostaglandin,2,3,12,25,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11057,-1,0.9971295,0.00287055
11059,AH6809,8,9,65,71,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11059,-1,0.99747604,0.0025239198
11060,ng,16,17,102,104,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11060,-1,0.89882386,0.10117609
11061,substance P,22,24,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11061,-1,0.9955913,0.0044087465
11062,Prostaglandin F2 alpha,0,3,0,22,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,-1,-1,-1,11062,-1,0.99617577,0.0038242075
11064,prostaglandin D2,5,7,36,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11064,-1,0.9961605,0.0038394711
11065,prostaglandin E2,8,10,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11065,-1,0.9956409,0.0043591256
11067,localized scleroderma,5,7,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,-1,-1,-1,11067,-1,0.0011945524,0.9988054
11068,Localized scleroderma,0,2,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11068,-1,0.0014489229,0.9985511
11069,localized scleroderma,8,10,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,-1,-1,-1,11069,-1,0.0013684429,0.99863154
11070,localized scleroderma,9,11,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,-1,-1,11070,-1,0.0010018847,0.9989981
11071,cutaneous,13,14,76,85,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,-1,-1,-1,11071,-1,0.0024845516,0.99751544
11072,contractures,3,4,20,32,Joint stiffness and contractures also improved.,2334179_6,-1,-1,-1,11072,-1,0.001182593,0.9988174
11073,nephrotic syndrome,2,4,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11073,-1,0.0008592756,0.99914074
11075,renal insufficiency,18,20,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11075,-1,0.0009353083,0.99906474
11076,localized scleroderma,12,14,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,-1,-1,-1,11076,-1,0.0010919892,0.99890804
11078,analgesia,5,6,35,44,infusions of morphine and regional analgesia by extradural block.,2334618_1,-1,-1,-1,11078,-1,0.0017144073,0.9982856
11079,postoperative respiratory apnoea,3,6,17,49,The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.,2334618_2,-1,-1,-1,11079,-1,0.0013247259,0.9986753
11081,mg,6,7,32,34,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11081,-1,0.7285354,0.2714646
11083,mg,23,24,128,130,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11083,-1,0.7437646,0.25623548
11084,carbon dioxide,7,9,47,61,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,-1,-1,-1,11084,-1,0.9921291,0.007870903
11085,P,3,4,18,19,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11085,-1,0.050453793,0.94954616
11087,P,12,13,56,57,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11087,-1,0.046978187,0.9530219
11089,tachyarrhythmias,7,8,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11089,-1,0.00090539345,0.9990946
11090,P,9,10,55,56,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11090,-1,0.05294856,0.9470514
11091,ventricular ectopic beats,15,18,77,102,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11091,-1,0.0012346655,0.99876535
11092,P,19,20,104,105,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11092,-1,0.049619187,0.95038074
11094,Cerebral sinus thrombosis,0,3,0,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11094,-1,0.0010973696,0.99890256
11095,menorrhagia,11,12,81,92,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11095,-1,0.001979062,0.998021
11097,menorrhagia,21,22,165,176,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,-1,11097,-1,0.0015033337,0.99849665
11098,menorrhagia,9,10,56,67,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,11098,-1,0.0012412736,0.9987588
11099,blood loss,15,17,99,109,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,11099,-1,0.0014304148,0.9985696
11100,thromboembolic disease,4,6,27,49,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,11100,-1,0.0008409033,0.9991591
11101,cerebral sinus thrombosis,15,18,117,142,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,11101,-1,0.0009221996,0.9990778
11103,imipenem,3,4,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,-1,-1,11103,-1,0.99862075,0.0013792989
11104,cerebral vascular accident,8,11,46,72,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11104,-1,0.0010550815,0.99894494
11105,CVA,12,13,74,77,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11105,-1,0.0013187365,0.99868125
11106,head trauma,15,17,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11106,-1,0.0011983904,0.9988016
11107,renal disease,21,23,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11107,-1,0.0011011097,0.99889886
11114,ventricular fibrillation,8,10,57,81,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11114,-1,0.0009809625,0.999019
11115,respiratory failure,11,13,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11115,-1,0.0012268008,0.99877316
11117,respiratory failure,9,11,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,-1,-1,11117,-1,0.0010972333,0.9989028
11118,cardiac disturbances,9,11,68,88,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11118,-1,0.00091476575,0.9990852
11119,respiratory failure,14,16,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11119,-1,0.0009787881,0.9990212
11121,ventricular fibrillation,6,8,36,60,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11121,-1,0.0010192216,0.9989807
11122,respiratory failure,15,17,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11122,-1,0.0010535558,0.9989465
11123,ventricular fibrillation,1,3,4,28,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,-1,-1,-1,11123,-1,0.0013738528,0.9986261
11125,ventricular fibrillation,7,9,42,66,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11125,-1,0.0010743184,0.9989256
11127,PO2,28,29,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11127,-1,0.9707135,0.029286511
11128,carbon dioxide,31,33,174,188,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11128,-1,0.9943693,0.005630703
11129,CO2,34,35,190,193,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11129,-1,0.97043276,0.029567285
11130,respiratory failure,1,3,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11130,-1,0.0012529518,0.998747
11131,hypoventilation,6,7,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11131,-1,0.0011981649,0.9988018
11132,mm Hg,17,19,90,95,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11132,-1,0.11336858,0.8866314
11133,mm Hg,24,26,110,115,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11133,-1,0.113601685,0.8863983
11135,ventricular fibrillation,38,40,184,208,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11135,-1,0.0014261743,0.9985738
11137,respiratory failure,17,19,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,-1,-1,11137,-1,0.0011629392,0.99883705
11140,Trental,2,3,16,23,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,-1,-1,11140,-1,0.99752647,0.0024735243
11142,peripheral vascular disease,12,15,95,122,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,-1,11142,-1,0.0012327437,0.99876726
11144,Trental,8,9,50,57,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11144,-1,0.99687636,0.0031236338
11145,methylxanthine,12,13,62,76,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11145,-1,0.99846315,0.001536872
11146,intermittent claudication,17,19,106,131,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11146,-1,0.0010194178,0.9989806
11148,coronary hyperemia,4,6,53,71,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,11148,-1,0.0011656111,0.99883443
11149,methylxanthines,8,9,83,98,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,11149,-1,0.997326,0.002674026
11151,hyperemic,5,6,26,35,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,-1,-1,-1,11151,-1,0.0011385406,0.99886143
11157,p,2,3,16,17,pentoxifylline (p less than 0.002).,2348231_7,-1,-1,-1,11157,-1,0.2876723,0.7123277
11161,p,21,22,166,167,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,-1,11161,-1,0.14779802,0.852202
11162,pentoxyifylline,3,4,17,32,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,11162,-1,0.99872285,0.0012770941
11163,coronary hyperemia,8,10,71,89,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,11163,-1,0.0010483154,0.9989517
11165,Parkinson's disease,6,9,35,54,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,11165,-1,0.0016086594,0.99839133
11169,Parkinson's disease,17,20,113,132,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,11169,-1,0.0014169754,0.9985831
11171,pneumonia,6,7,33,42,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11171,-1,0.0011631675,0.9988368
11172,bronchitis,8,9,47,57,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11172,-1,0.001263205,0.9987368
11173,malignant neoplasms,14,16,67,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11173,-1,0.0017233538,0.9982767
11174,heart diseases,21,23,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11174,-1,0.0017263422,0.9982736
11175,cerebral infarction,28,30,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11175,-1,0.0014049145,0.99859506
11176,septicaemia,35,36,150,161,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11176,-1,0.0011797819,0.99882025
11183,Parkinson's disease,14,17,79,98,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,-1,-1,11183,-1,0.0012222357,0.9987778
11189,cardiorespiratory arrest,3,5,44,68,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,-1,-1,11189,-1,0.00092829193,0.9990717
11191,Midazolam hydrochloride,0,2,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,-1,-1,-1,11191,-1,0.99823076,0.0017692669
11192,cardiovascular depression,16,18,123,148,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,-1,-1,-1,11192,-1,0.0011932272,0.99880683
11193,cardiorespiratory arrest,8,10,50,74,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,-1,-1,11193,-1,0.00093501515,0.999065
11197,Myasthenia gravis,0,2,0,17,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,-1,-1,11197,-1,0.0014053014,0.9985947
11200,neuromuscular disease,9,11,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11200,-1,0.00090810977,0.99909186
11201,quadriplegic,14,15,89,101,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11201,-1,0.0015274893,0.9984725
11203,preeclampsia,20,21,148,160,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11203,-1,0.0009334752,0.99906653
11206,neuromuscular blockade,23,25,160,182,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,-1,-1,-1,11206,-1,0.0023407782,0.9976592
11210,myasthenia gravis,12,14,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,-1,-1,11210,-1,0.0010538608,0.99894613
11212,disorder of neuromuscular transmission,18,22,123,161,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,-1,-1,-1,11212,-1,0.001848558,0.99815136
11216,hepatocellular carcinomas,5,7,36,61,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,-1,-1,11216,-1,0.0014120626,0.9985879
11219,hepatocellular carcinomas,7,9,46,71,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,-1,-1,-1,11219,-1,0.0012049135,0.99879503
11221,neoplastic lesions,1,3,9,27,"Sporadic neoplastic lesions were observed in organs other than the liver of some of the animals, irrespective of the diet fed.",2396046_6,-1,-1,-1,11221,-1,0.0012742875,0.9987257
11233,mm Hg,32,34,192,197,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11233,-1,0.010146284,0.9898537
11234,h,41,42,221,222,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11234,-1,0.09179116,0.9082088
11236,"5,7-dihydroxytryptamine",51,52,290,313,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11236,-1,0.9960573,0.003942728
11237,"5,7-DHT",53,54,315,322,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11237,-1,0.9931324,0.006867552
11238,"5,7-DHT",5,6,34,41,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,-1,-1,11238,-1,0.9955647,0.004435323
11241,"5,7-DHT",2,3,9,16,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11241,-1,0.9938232,0.00617677
11244,fall,30,31,170,174,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11244,-1,0.0030231432,0.99697685
11245,blood pressure,32,34,178,192,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11245,-1,0.0039717397,0.9960283
11246,serotonin methyldopa,39,41,222,242,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11246,-1,0.99649125,0.003508768
11252,Liver enlargement,0,2,0,17,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11252,-1,0.0014431077,0.9985569
11253,muscle wastage,3,5,22,36,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11253,-1,0.0014245795,0.99857545
11256,cibenzoline,4,5,40,51,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,-1,-1,11256,-1,0.9986644,0.0013356024
11259,cibenzoline,16,17,129,140,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,-1,11259,-1,0.9986859,0.001314085
11261,Cibenzoline,0,1,0,11,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11261,-1,0.99849796,0.0015020737
11264,digitalis,24,25,167,176,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11264,-1,0.009177628,0.9908223
11266,n,86,87,368,369,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11266,-1,0.28756765,0.7124324
11270,tocainide,10,11,67,76,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,-1,-1,-1,11270,-1,0.9988292,0.0011708473
11271,cibenzoline,1,2,8,19,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,-1,-1,11271,-1,0.99845445,0.0015455952
11278,pentylenetrazol,21,22,139,154,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11278,-1,0.99864906,0.0013510154
11279,PTZ,23,24,156,159,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11279,-1,0.99689305,0.0031069296
11280,h,26,27,163,164,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11280,-1,0.12065056,0.87934947
11282,h,39,40,254,255,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11282,-1,0.10711038,0.8928896
11283,h,19,20,101,102,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,-1,-1,-1,11283,-1,0.03463278,0.96536726
11284,h,23,24,143,144,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,-1,-1,-1,11284,-1,0.1264455,0.8735545
11286,PTZ,4,5,24,27,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11286,-1,0.99511695,0.0048830276
11288,PTX,8,9,44,47,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11288,-1,0.9904102,0.009589804
11290,3-mercaptopropionic acid,20,22,111,135,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11290,-1,0.9965371,0.0034629463
11291,MPA,23,24,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11291,-1,0.99722385,0.002776207
11293,BCC,28,29,156,159,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11293,-1,0.9958716,0.0041283634
11294,DMCM,34,35,218,222,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11294,-1,0.99425596,0.0057441024
11295,strychnine,38,39,228,238,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11295,-1,0.99846625,0.0015337602
11296,STR,40,41,240,243,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11296,-1,0.9945867,0.0054132477
11297,pentylenetetrazol,5,6,21,38,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,-1,11297,-1,0.9987394,0.00126058
11299,MPA,0,1,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11299,-1,0.99477094,0.005229063
11300,DMCM,4,5,10,14,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11300,-1,0.9913987,0.008601317
11301,STR,7,8,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11301,-1,0.9884986,0.011501371
11303,PTZ,14,15,99,102,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11303,-1,0.9973149,0.0026850596
11304,PTX,16,17,107,110,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11304,-1,0.99774444,0.0022555743
11305,h,18,19,114,115,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11305,-1,0.14246339,0.85753655
11307,h,16,17,92,93,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11307,-1,0.032416806,0.96758324
11308,chloride,24,25,144,152,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11308,-1,0.97326964,0.026730414
11310,Argentine hemorrhagic fever,9,12,61,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,-1,-1,-1,11310,-1,0.0074009052,0.9925991
11312,Argentine hemorrhagic fever,12,15,75,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11312,-1,0.0047725765,0.99522746
11313,AHF,16,17,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11313,-1,0.0013613001,0.9986387
11315,viremia,8,9,60,67,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11315,-1,0.00090849574,0.9990915
11316,interferon,14,15,93,103,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11316,-1,0.9815151,0.018484944
11320,AHF,16,17,92,95,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,-1,-1,-1,11320,-1,0.0010355578,0.9989644
11323,AHF,11,12,71,74,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,-1,-1,-1,11323,-1,0.001595458,0.99840456
11324,fluorouracil,5,6,44,56,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,-1,11324,-1,0.9986229,0.0013771548
11326,fluorouracil,11,12,79,91,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11326,-1,0.99856347,0.0014365949
11327,5-FU,13,14,93,97,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11327,-1,0.9976247,0.0023752823
11328,5-FU,11,12,90,94,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11328,-1,0.99800473,0.0019953072
11330,ischemic,25,26,170,178,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11330,-1,0.0021182944,0.9978817
11331,5-FU,10,11,50,54,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11331,-1,0.99736565,0.002634395
11332,5-FU,20,21,91,95,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11332,-1,0.99718505,0.002814933
11333,Anginal episodes,0,2,0,16,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11333,-1,0.0011032673,0.9988967
11334,angina,9,10,49,55,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11334,-1,0.0010138844,0.99898607
11335,5-FU,12,13,64,68,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11335,-1,0.99772125,0.0022787668
11336,mm,12,13,61,63,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11336,-1,0.008658033,0.991342
11337,5-FU,31,32,138,142,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11337,-1,0.9978179,0.0021820706
11338,5-FU,40,41,170,174,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11338,-1,0.9976803,0.0023197168
11339,P,43,44,185,186,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11339,-1,0.06587527,0.9341247
11340,ischemic,3,4,17,25,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,-1,-1,-1,11340,-1,0.0015598914,0.9984401
11341,5-FU,3,4,14,18,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11341,-1,0.9978948,0.0021052365
11342,5-FU,11,12,51,55,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11342,-1,0.99778193,0.0022181326
11343,P,14,15,66,67,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11343,-1,0.13835733,0.86164266
11344,5-FU,36,37,165,169,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11344,-1,0.99725914,0.002740886
11345,5-FU,48,49,220,224,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11345,-1,0.9974502,0.0025498609
11346,P,50,51,226,227,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11346,-1,0.10187135,0.8981287
11347,coronary artery disease,9,12,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,-1,-1,-1,11347,-1,0.0011314432,0.9988686
11348,sudden death,5,7,24,36,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,-1,-1,-1,11348,-1,0.0011032315,0.9988967
11349,5-FU,3,4,17,21,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11349,-1,0.99774927,0.0022506884
11351,coronary artery disease,24,27,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11351,-1,0.0013322321,0.99866784
11352,scabies,4,5,20,27,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11352,-1,0.0019587495,0.9980413
11353,scabies,7,8,52,59,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11353,-1,0.0017036662,0.9982963
11355,gamma benzene hexachloride,19,22,130,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11355,-1,0.9941877,0.005812297
11358,toxic to the central nervous system,7,13,45,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11358,-1,0.0024256515,0.9975744
11359,aplastic anaemia,18,20,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11359,-1,0.0008284628,0.9991716
11363,biogenic amines,9,11,66,81,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,-1,-1,-1,11363,-1,0.9447762,0.05522389
11364,amantadine hydrochloride,3,5,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11364,-1,0.998437,0.0015630443
11365,biogenic amines,29,31,154,169,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11365,-1,0.96969867,0.030301394
11367,amantadine depressed,4,6,20,40,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,-1,11367,-1,0.8833527,0.116647325
11371,suppression of motility,26,29,173,196,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,-1,11371,-1,0.0024016427,0.99759835
11374,"3,4-dihydroxyphenylacetic acid",15,17,97,127,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,-1,-1,-1,11374,-1,0.9905427,0.009457334
11375,normetanephrine,3,4,18,33,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,-1,-1,-1,11375,-1,0.98931307,0.01068699
11379,biogenic amines,5,7,33,48,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11379,-1,0.975471,0.024528928
11381,monoamine,22,23,152,161,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11381,-1,0.9965899,0.0034101477
11383,behavioral depression,37,39,254,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11383,-1,0.0012445872,0.99875546
11385,Chloroacetaldehyde,0,1,0,18,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,-1,-1,-1,11385,-1,0.99149466,0.008505342
11388,chloroacetaldehyde,7,8,40,58,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11388,-1,0.996176,0.0038240333
11389,CAA,9,10,60,63,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11389,-1,0.98697644,0.013023554
11390,oxazaphosphorine,16,17,95,111,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11390,-1,0.9982229,0.0017770765
11391,CAA,32,33,197,200,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11391,-1,0.96478766,0.035212334
11392,hemorrhagic cystitis,37,39,223,243,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11392,-1,0.0009538025,0.99904615
11393,CAA,4,5,26,29,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11393,-1,0.9788043,0.02119578
11394,bladder damage,13,15,79,93,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11394,-1,0.00148312,0.99851686
11395,CAA,7,8,42,45,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,-1,-1,-1,11395,-1,0.94998735,0.050012596
11401,migraine attacks,2,4,12,28,Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.,2515254_1,-1,-1,-1,11401,-1,0.0009195914,0.9990804
11412,leukemoid reaction,6,8,52,70,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11412,-1,0.0011557682,0.99884415
11414,erythroderma,11,12,86,98,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11414,-1,0.0009221749,0.9990778
11415,renal failure,14,16,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11415,-1,0.0009843338,0.9990157
11418,erythroderma,12,13,89,101,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11418,-1,0.0009436669,0.9990563
11419,leukemoid reaction,16,18,112,130,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11419,-1,0.0012408752,0.99875915
11422,renal failure,24,26,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11422,-1,0.0010036529,0.9989963
11425,HIV disease,30,32,161,172,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,-1,11425,-1,0.0032346346,0.9967654
11430,megaloblastosis,8,9,56,71,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,-1,-1,-1,11430,-1,0.0010907385,0.99890924
11432,hepatitis B virus,9,12,68,85,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11432,-1,0.031252228,0.9687478
11434,hepatitis B,26,28,175,186,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11434,-1,0.08282262,0.9171774
11435,hepatitis B surface,18,21,116,135,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11435,-1,0.06573805,0.9342619
11436,HBsAg,23,24,145,150,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11436,-1,0.14584003,0.85416
11437,hepatitis B e,26,29,156,169,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11437,-1,0.09848458,0.9015154
11438,HBeAg,31,32,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11438,-1,0.19360153,0.80639845
11439,hepatitis B,8,10,49,60,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11439,-1,0.039351974,0.960648
11440,hepatitis B vaccine,23,26,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11440,-1,0.09012099,0.909879
11441,HBsAg,11,12,55,60,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,-1,-1,-1,11441,-1,0.09779299,0.902207
11442,HBeAg,1,2,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11442,-1,0.02603735,0.97396266
11443,HBsAg,5,6,27,32,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11443,-1,0.14120646,0.85879356
11444,HBsAg,1,2,4,9,The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively.,2533791_6,-1,-1,-1,11444,-1,0.30978814,0.69021183
11445,akathisia,1,2,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,-1,-1,-1,11445,-1,0.0013150576,0.99868494
11447,obsessive compulsive disorder,8,11,56,85,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11447,-1,0.0009367727,0.9990632
11449,akathisia,15,16,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11449,-1,0.0009144316,0.99908555
11450,restlessness,5,6,43,55,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11450,-1,0.0012997332,0.99870026
11451,anxiety,20,21,129,136,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11451,-1,0.0015971967,0.9984028
11452,akathisia,27,28,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11452,-1,0.0011612024,0.99883884
11453,akathisia,6,7,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11453,-1,0.001283405,0.9987166
11454,akathisia,16,17,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11454,-1,0.0012835133,0.9987165
11455,Akathisia,0,1,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,-1,-1,11455,-1,0.0014539673,0.998546
11458,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11458,-1,0.0045353607,0.9954646
11459,akathisia,22,23,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11459,-1,0.00502125,0.9949787
11460,jitteriness,27,28,241,252,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11460,-1,0.00097151037,0.99902844
11461,analgesia,7,8,52,61,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,-1,-1,-1,11461,-1,0.0015206677,0.9984793
11463,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11463,-1,0.98258084,0.017419161
11464,cyclohexyl]benzeneactemide,17,18,147,173,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11464,-1,0.9938089,0.006191089
11465,prostaglandin,18,19,116,129,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,-1,-1,11465,-1,0.99627435,0.0037256835
11469,pertussis toxin,17,19,126,141,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,-1,-1,-1,11469,-1,0.9947978,0.0052021923
11472,8-bromo cyclic adenosine monophosphate,11,15,61,99,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,-1,-1,11472,-1,0.9970106,0.002989392
11473,cyclic adenosine monophosphate,36,39,221,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,-1,11473,-1,0.9952048,0.004795208
11476,adriamycin nephrosis,18,20,114,134,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,-1,11476,-1,0.39846498,0.601535
11481,mm Hg,20,22,104,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11481,-1,0.009030882,0.9909691
11482,P,28,29,126,127,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11482,-1,0.13358355,0.86641645
11483,mm Hg,47,49,201,206,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11483,-1,0.0091120275,0.990888
11484,P,50,51,208,209,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11484,-1,0.108262636,0.89173734
11488,adriamycin nephrosis,24,26,122,142,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,-1,11488,-1,0.41688243,0.58311754
11492,P,33,34,150,151,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,-1,11492,-1,0.15845968,0.8415403
11494,muscular rigidity,9,11,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,-1,-1,-1,11494,-1,0.0009726877,0.9990274
11495,muscular rigidity,1,3,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,-1,11495,-1,0.001342496,0.99865746
11498,CO2,10,11,68,71,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,-1,-1,-1,11498,-1,0.7357211,0.26427892
11500,muscular rigidity,3,5,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,-1,11500,-1,0.0010968053,0.99890316
11503,muscular rigidity,7,9,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,-1,11503,-1,0.001064489,0.9989355
11505,Dexmedetomidine,0,1,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11505,-1,0.99859315,0.0014068191
11506,muscle rigidity,10,12,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11506,-1,0.0010203619,0.9989796
11507,dexmedetomidine,5,6,48,63,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11507,-1,0.99873537,0.0012646025
11508,muscle flaccidity,13,15,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11508,-1,0.0010190964,0.9989808
11509,muscle rigidity,2,4,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,-1,-1,11509,-1,0.001093144,0.99890685
11511,muscle rigidity,14,16,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,-1,-1,-1,11511,-1,0.0011205333,0.9988795
11513,n,2,3,9,10,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11513,-1,0.15479344,0.8452065
11514,medetomidine,25,26,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11514,-1,0.9984035,0.0015965087
11515,idazoxan,58,59,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11515,-1,0.99840707,0.0015929283
11516,DG-5128,76,77,377,384,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11516,-1,0.997246,0.0027540056
11518,ALF,8,9,44,47,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,-1,-1,-1,11518,-1,0.9884539,0.011546134
11519,ALF,0,1,0,3,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,-1,11519,-1,0.5060192,0.49398085
11520,contrast,1,2,3,11,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11520,-1,0.049685657,0.95031434
11521,muscle rigidity,6,8,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11521,-1,0.001156239,0.9988438
11523,startle,12,13,65,72,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,-1,-1,11523,-1,0.0022309315,0.9977691
11524,acute hepatitis,1,3,20,35,Clotiazepam-induced acute hepatitis.,2572625_0,-1,-1,-1,11524,-1,0.00107817,0.9989219
11525,acute hepatitis,9,11,46,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11525,-1,0.00094386924,0.99905616
11526,hepatocellular necrosis,13,15,77,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11526,-1,0.0010259887,0.9989741
11527,clotiazepam,24,25,148,159,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11527,-1,0.9983992,0.0016007677
11528,thienodiazepine,27,28,163,178,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11528,-1,0.9979736,0.0020263493
11529,Clotiazepam,0,1,0,11,Clotiazepam withdrawal was followed by prompt recovery.,2572625_2,-1,-1,-1,11529,-1,0.99775106,0.0022489394
11531,clotiazepam,9,10,69,80,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,-1,-1,11531,-1,0.9985519,0.0014481113
11533,clotiazepam,4,5,28,39,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11533,-1,0.9986326,0.0013673505
11534,acute hepatitis,7,9,51,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11534,-1,0.0008628326,0.9991372
11536,clotiazepam,18,19,126,137,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11536,-1,0.99856085,0.0014392211
11538,fluvoxamine,7,8,48,59,Some central effects of repeated treatment with fluvoxamine.,2576810_0,-1,-1,-1,11538,-1,0.9988464,0.0011536228
11539,fluvoxamine,8,9,54,65,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11539,-1,0.9988294,0.0011705953
11541,methoxamine,22,23,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11541,-1,0.9989318,0.0010681644
11542,fluvoxamine,4,5,26,37,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,-1,-1,-1,11542,-1,0.9988657,0.0011343008
11545,nomifensine,4,5,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11545,-1,0.99878126,0.0012186911
11546,fluvoxamine,10,11,72,83,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11546,-1,0.9988632,0.001136773
11547,methoxamine,8,9,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11547,-1,0.9989126,0.0010873957
11548,fluvoxamine,16,17,136,147,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11548,-1,0.9987698,0.0012301755
11549,fluvoxamine,3,4,18,29,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,-1,11549,-1,0.9987232,0.0012767524
11550,fluvoxamine,4,5,26,37,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,-1,-1,-1,11550,-1,0.9987997,0.0012003251
11555,carcinogens,5,6,48,59,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,-1,-1,-1,11555,-1,0.041184198,0.95881575
11556,carcinogenic,19,20,112,124,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11556,-1,0.0031778715,0.9968221
11558,5-AzC,24,25,149,154,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11558,-1,0.9969704,0.0030295977
11559,carcinogens,51,52,277,288,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11559,-1,0.15766415,0.8423359
11560,benzo[a]-pyrene,53,54,290,305,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11560,-1,0.9967385,0.0032615522
11562,"1,2-DMH",67,68,380,387,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11562,-1,0.9879038,0.012096243
11564,CCl4,34,35,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,-1,11564,-1,0.99246573,0.007534305
11565,5-AzC,12,13,81,86,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11565,-1,0.9976235,0.0023765394
11566,5-AzC,30,31,191,196,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11566,-1,0.9969478,0.0030521455
11567,"1,2-DMH",9,10,81,88,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11567,-1,0.9904447,0.009555337
11568,cytosine,17,18,124,132,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11568,-1,0.98875123,0.011248804
11569,5-AzC,31,32,216,221,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11569,-1,0.99391854,0.006081452
11570,5-AzC,7,8,34,39,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,-1,11570,-1,0.997003,0.0029969364
11571,se,8,9,52,54,The results suggest that hypomethylation of DNA per se may not be sufficient for initiation.,2578334_6,-1,-1,-1,11571,-1,0.05486126,0.9451387
11572,BN 52021,9,11,71,79,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11572,-1,0.9963787,0.0036213035
11573,cardiovascular impairments,14,16,104,130,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11573,-1,0.0011938058,0.99880624
11576,BN 52021,11,13,82,90,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,-1,-1,-1,11576,-1,0.99771047,0.002289505
11578,contrast,1,2,3,11,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11578,-1,0.26446718,0.73553276
11579,BN 52021,7,9,30,38,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11579,-1,0.99670285,0.0032971355
11581,BN 52021,1,3,5,13,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,-1,11581,-1,0.9973834,0.002616551
11583,BN 52021,15,17,107,115,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,-1,11583,-1,0.99651885,0.003481091
11584,BN 52021,4,6,28,36,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11584,-1,0.9973948,0.0026052275
11585,BN 52021,34,36,173,181,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11585,-1,0.99727964,0.0027202812
11586,cardiovascular toxicity,45,47,241,264,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11586,-1,0.0013021779,0.99869776
11587,cardiovascular alterations,17,19,102,128,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,-1,11587,-1,0.0012883561,0.9987117
11588,flank pain,5,7,30,40,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11588,-1,0.00116328,0.9988367
11589,suprofen,9,10,55,63,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11589,-1,0.9979563,0.0020436903
11590,Suprofen,0,1,0,8,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,-1,-1,-1,11590,-1,0.9977843,0.0022156907
11591,flank pain,7,9,50,60,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,-1,11591,-1,0.001335631,0.9986644
11592,hay fever,26,28,107,116,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11592,-1,0.0016757165,0.9983242
11593,asthma,29,30,121,127,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11593,-1,0.0015170457,0.998483
11594,p,75,76,316,317,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11594,-1,0.13525242,0.86474764
11597,renal disease,19,21,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11597,-1,0.0010768407,0.9989231
11598,kidney stones,25,27,147,160,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11598,-1,0.0010719064,0.9989281
11599,gout,31,32,175,179,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11599,-1,0.0010314619,0.9989686
11600,uric acid,17,19,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,-1,11600,-1,0.9859432,0.01405682
11601,Antihypertensive drugs,0,2,0,22,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,-1,-1,11601,-1,0.9365836,0.0634164
11609,depressions,9,10,50,61,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11609,-1,0.0010639841,0.998936
11612,Chronic active hepatitis,0,3,0,24,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11612,-1,0.0013695771,0.9986304
11613,diclofenac sodium,5,7,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11613,-1,0.99874985,0.001250181
11614,Diclofenac sodium,0,2,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11614,-1,0.99856704,0.001433021
11615,Voltarol,3,4,19,27,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11615,-1,0.9976587,0.002341246
11617,abnormalities of liver function,5,9,48,79,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,-1,-1,-1,11617,-1,0.0015994757,0.9984005
11620,chronic active hepatitis,4,7,32,56,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11620,-1,0.0009793554,0.9990207
11621,diclofenac sodium,12,14,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11621,-1,0.9987458,0.0012541201
11622,Arterial hypertension,0,2,0,21,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,-1,-1,-1,11622,-1,0.0012067104,0.99879324
11624,Cushing's syndrome,5,8,24,42,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,-1,-1,-1,11624,-1,0.0009961278,0.99900395
11630,deoxycorticosterone,7,8,31,50,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,-1,11630,-1,0.9975198,0.0024801784
11632,deoxycorticosterone,11,12,49,68,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,-1,-1,-1,11632,-1,0.9980172,0.0019827639
11639,renal insufficiency,14,16,86,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11639,-1,0.0010258,0.9989742
11640,intravascular coagulation,18,20,113,138,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11640,-1,0.0009979345,0.99900204
11641,intravascular coagulation,2,4,13,38,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11641,-1,0.0011064362,0.99889356
11642,tranexamic acid,13,15,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11642,-1,0.9985915,0.0014085197
11643,AMCA,16,17,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11643,-1,0.9960747,0.0039253808
11644,renal insufficiency,26,28,161,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11644,-1,0.0011038001,0.9988961
11645,trauma,32,33,213,219,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11645,-1,0.0015216817,0.99847835
11649,renal insufficiency,22,24,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,-1,-1,-1,11649,-1,0.0009863897,0.99901354
11653,weight,13,14,69,75,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,-1,-1,-1,11653,-1,0.0037627013,0.9962373
11655,AMCA,18,19,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,-1,-1,-1,11655,-1,0.9960918,0.0039082603
11657,Angiotension,27,28,151,163,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11657,-1,0.29855248,0.7014475
11658,prostacyclin,33,34,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11658,-1,0.99720734,0.0027926262
11661,kidney damage,48,50,276,289,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,-1,-1,-1,11661,-1,0.0018485034,0.9981515
11666,SD,9,10,38,40,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,-1,11666,-1,0.086585365,0.9134146
11669,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11669,-1,0.0011549181,0.9988451
11670,arteriovenous malformations,3,5,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11670,-1,0.001141352,0.9988587
11671,cerebral vasculitis,18,20,128,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11671,-1,0.0009890689,0.9990109
11672,Cerebral infarction,0,2,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11672,-1,0.0011313127,0.99886864
11673,intracerebral hemorrhage,11,13,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11673,-1,0.0012983109,0.9987017
11674,subarachnoid hemorrhage,21,23,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11674,-1,0.0013784782,0.9986216
11682,intracranial aneurysms,53,55,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11682,-1,0.0015480829,0.99845195
11683,arteriovenous malformations,56,58,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11683,-1,0.0019386155,0.99806136
11685,intracranial hemorrhage,70,72,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11685,-1,0.001112041,0.99888796
11686,cerebral infarction,75,77,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11686,-1,0.0012703794,0.99872965
11692,reductions in mean arterial blood pressure,12,18,88,130,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11692,-1,0.0043282597,0.99567175
11693,BP,19,20,132,134,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11693,-1,0.0043759085,0.9956241
11695,p,8,9,58,59,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11695,-1,0.08777989,0.91222006
11696,cardiac,18,19,103,110,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11696,-1,0.005061158,0.99493885
11700,PO2,1,2,9,12,Arterial PO2 decreased in both groups.,2696505_5,-1,-1,-1,11700,-1,0.14233166,0.85766834
11704,gentamicin nephrotoxicity,5,7,46,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,-1,-1,11704,-1,0.056205377,0.9437946
11705,diabetes mellitus,4,6,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11705,-1,0.00095196045,0.99904805
11706,DM,7,8,60,62,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11706,-1,0.0014052605,0.9985947
11708,acute renal failure,38,41,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11708,-1,0.00092914514,0.9990709
11709,ARF,42,43,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11709,-1,0.0009916249,0.99900836
11710,gentamicin nephrotoxicity,3,5,20,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11710,-1,0.054977812,0.9450222
11712,phlorizin,22,23,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11712,-1,0.9985329,0.0014670813
11713,P,24,25,176,177,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11713,-1,0.99433255,0.0056675
11714,DM,0,1,0,2,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11714,-1,0.0032158468,0.9967841
11716,P,13,14,63,64,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11716,-1,0.97765213,0.022347936
11717,P,3,4,9,10,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11717,-1,0.9715062,0.028493792
11718,P,7,8,27,28,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11718,-1,0.99431676,0.005683255
11719,P,19,20,65,66,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11719,-1,0.98310155,0.016898435
11722,DM,35,36,130,132,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11722,-1,0.012276821,0.98772323
11726,P,4,5,12,13,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11726,-1,0.96544325,0.03455678
11728,SE,18,19,75,77,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11728,-1,0.04507959,0.9549204
11731,P,4,5,13,14,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11731,-1,0.94412786,0.055872194
11732,P,19,20,85,86,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11732,-1,0.18950506,0.81049496
11734,P,18,19,86,87,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,-1,11734,-1,0.09450226,0.9054977
11741,analgesia,9,10,70,79,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,-1,-1,11741,-1,0.0011889696,0.998811
11747,cataleptic,22,23,169,179,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,-1,-1,-1,11747,-1,0.0018393594,0.99816066
11759,cataleptic,4,5,31,41,Naloxone inhibited the induced cataleptic effects.,2716967_6,-1,-1,-1,11759,-1,0.0015574049,0.9984426
11771,mm Hg,15,17,104,109,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11771,-1,0.00947306,0.9905269
11772,p,23,24,124,125,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11772,-1,0.079924144,0.9200759
11773,increased cardiac output,32,35,162,186,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11773,-1,0.0059011444,0.9940989
11774,p,46,47,219,220,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11774,-1,0.11145875,0.8885413
11775,mm,9,10,60,62,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11775,-1,0.026070958,0.9739291
11776,p,17,18,87,88,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11776,-1,0.17403197,0.825968
11777,mm,26,27,166,168,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11777,-1,0.07613974,0.9238603
11778,p,47,48,259,260,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11778,-1,0.13014615,0.86985385
11782,p,53,54,288,289,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,-1,11782,-1,0.16926597,0.8307341
11786,rise in resting blood pressure,1,6,4,34,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11786,-1,0.003293405,0.99670666
11788,increased cardiac output,12,15,77,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11788,-1,0.0042595356,0.99574053
11789,increased blood volume).(ABSTRACT,19,22,121,154,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11789,-1,0.054873403,0.9451266
11790,Neuromuscular blockade,0,2,0,22,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11790,-1,0.0014770299,0.99852294
11791,magnesium sulfate,3,5,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11791,-1,0.9982497,0.0017502516
11794,neuromuscular blockade,8,10,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11794,-1,0.0009082707,0.99909174
11795,mg,12,13,92,94,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11795,-1,0.86208594,0.13791414
11796,magnesium sulfate,14,16,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11796,-1,0.997926,0.0020739331
11805,CBZ,5,6,30,33,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11805,-1,0.9975756,0.0024243882
11807,CBZ,28,29,186,189,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11807,-1,0.9974291,0.0025709635
11808,CBZ,2,3,13,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,-1,-1,11808,-1,0.99745375,0.00254619
11811,CBZ,1,2,8,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,-1,11811,-1,0.99316144,0.0068385187
11812,CBZ,1,2,6,9,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,-1,11812,-1,0.93896246,0.061037533
11814,CBZ,2,3,13,16,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,-1,-1,-1,11814,-1,0.9976895,0.0023104828
11816,CBZ,4,5,28,31,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,-1,-1,11816,-1,0.99772924,0.002270757
11819,CBZ,11,12,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,-1,11819,-1,0.9972945,0.0027054893
11820,CBZ,5,6,32,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,-1,-1,11820,-1,0.99665195,0.003348082
11823,amphotericin B nephrotoxicity,4,7,33,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,-1,-1,-1,11823,-1,0.3197048,0.6802952
11825,amphotericin B,4,6,29,43,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,-1,-1,11825,-1,0.9980513,0.0019486952
11826,amphotericin B,4,6,23,37,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,-1,-1,-1,11826,-1,0.99786025,0.0021397541
11828,contrast,1,2,3,11,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,-1,-1,-1,11828,-1,0.03779927,0.9622007
11831,amphotericin B,2,4,18,32,Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study.,2802551_5,-1,-1,-1,11831,-1,0.9976941,0.0023058753
11832,amphotericin B,9,11,32,46,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,-1,11832,-1,0.9976295,0.0023704183
11834,amphotericin B,9,11,60,74,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11834,-1,0.99814487,0.001855134
11835,amphotericin B,14,16,102,116,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11835,-1,0.99817,0.0018299504
11838,venous thrombosis,5,7,39,56,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,-1,11838,-1,0.0011863686,0.9988136
11839,deep venous thrombosis,7,10,51,73,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,-1,11839,-1,0.0014244615,0.99857557
11840,oral contraceptive pills,9,12,42,66,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,-1,-1,-1,11840,-1,0.98411924,0.01588072
11841,hypokalemia,1,2,29,40,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11841,-1,0.00081351586,0.99918646
11842,oxprenolol,6,7,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11842,-1,0.9984378,0.0015621486
11843,hypokalemia,8,9,77,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,-1,11843,-1,0.0009259917,0.999074
11844,oxprenolol,6,7,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11844,-1,0.99841106,0.0015888716
11845,hypokalemia,10,11,77,88,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11845,-1,0.00095431064,0.99904567
11846,mg,7,8,38,40,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11846,-1,0.8989516,0.101048365
11848,mg oxprenolol,29,31,158,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11848,-1,0.99273247,0.007267586
11853,Oxprenolol,0,1,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,-1,-1,-1,11853,-1,0.99821544,0.0017845323
11856,oxprenolol,7,8,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11856,-1,0.99845934,0.0015407198
11857,hypokalemia,11,12,81,92,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11857,-1,0.0009380464,0.999062
11858,movement disorder,1,3,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11858,-1,0.0013369547,0.99866307
11859,idiopathic dystonia,14,16,91,110,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11859,-1,0.0012161955,0.99878377
11860,ACTH,20,21,90,94,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11860,-1,0.993985,0.00601508
11861,NE,36,37,170,172,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11861,-1,0.9953258,0.0046742028
11863,movement disorder,75,77,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11863,-1,0.0016841631,0.9983158
11866,ACC-9089,2,3,11,19,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,-1,-1,-1,11866,-1,0.98625827,0.013741661
11874,contrast,1,2,3,11,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,-1,-1,-1,11874,-1,0.14687105,0.85312897
11876,supraventricular tachyarrhythmia,8,10,58,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,-1,-1,-1,11876,-1,0.000977331,0.9990227
11877,unstable angina,3,5,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11877,-1,0.0009720029,0.99902797
11879,chest pain,17,19,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11879,-1,0.0010350631,0.9989649
11884,h,14,15,92,93,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,-1,11884,-1,0.7260572,0.27394283
11897,Phentolamine,0,1,0,12,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,-1,11897,-1,0.99886,0.0011400307
11899,phentolamine,5,6,32,44,"Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.",2886572_11,-1,-1,-1,11899,-1,0.99886787,0.0011321428
11901,prolactinomas,10,11,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,-1,11901,-1,0.0011163577,0.99888366
11906,h,26,27,194,195,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11906,-1,0.07782508,0.9221749
11907,h,29,30,202,203,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11907,-1,0.07498534,0.9250146
11909,body weight,38,40,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11909,-1,0.07027789,0.9297221
11910,h,1,2,4,5,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,-1,11910,-1,0.049860053,0.95013994
11913,h,2,3,5,6,"At 6 h after injection, serum prolactin levels were still considerably lower than in controls.",2887062_6,-1,-1,-1,11913,-1,0.055677623,0.94432235
11916,h,13,14,87,88,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11916,-1,0.099170126,0.90082985
11918,adenoma,19,20,126,133,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11918,-1,0.003447768,0.9965522
11920,GABA,0,1,0,4,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11920,-1,0.99712855,0.002871475
11922,respiratory paralysis,7,9,49,70,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11922,-1,0.0010345482,0.9989655
11923,thiopental,11,12,83,93,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11923,-1,0.9987627,0.0012372932
11924,respiratory paralysis,7,9,37,58,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11924,-1,0.0012107015,0.99878937
11925,CNS depressants,11,13,71,86,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11925,-1,0.04768454,0.95231545
11927,respiratory paralysis,5,7,32,53,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11927,-1,0.0011590918,0.998841
11928,thiopental,9,10,65,75,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11928,-1,0.9985721,0.0014278159
11929,thiopental,5,6,15,25,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11929,-1,0.99850273,0.0014973277
11930,GABA,14,15,91,95,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11930,-1,0.9972262,0.0027737576
11934,thiosemicarbazide,4,5,26,43,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11934,-1,0.998221,0.0017789875
11935,thiopental,20,21,139,149,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11935,-1,0.998569,0.0014309325
11936,thiopental,5,6,15,25,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11936,-1,0.99848074,0.0015192748
11937,respiratory arrest,7,9,35,53,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11937,-1,0.0017135801,0.9982864
11938,GABA,13,14,79,83,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11938,-1,0.9970298,0.0029702024
11940,amino acids,29,31,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11940,-1,0.93732053,0.06267944
11942,respiratory paralysis,9,11,36,57,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11942,-1,0.0015567822,0.9984432
11944,GABA,14,15,73,77,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11944,-1,0.99701047,0.0029894926
11946,respiratory paralysis,5,7,37,58,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11946,-1,0.0012640101,0.99873596
11947,thiopental,9,10,71,81,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11947,-1,0.9987225,0.0012774568
11948,GABA,12,13,95,99,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11948,-1,0.99776447,0.0022354757
11953,mg,8,9,45,47,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,-1,11953,-1,0.75555843,0.24444158
11961,chloride,25,26,171,179,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,-1,11961,-1,0.99697673,0.0030232987
11964,lupus erythematosus,1,3,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,-1,-1,11964,-1,0.0014295453,0.99857044
11965,Pneumonitis,0,1,0,11,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11965,-1,0.0009114801,0.9990885
11966,pleural effusions,3,5,23,40,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11966,-1,0.0012169094,0.99878305
11967,cardiac tamponade,9,11,72,89,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11967,-1,0.001731379,0.9982686
11969,ulcerative colitis,29,31,213,231,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11969,-1,0.0010080499,0.9989919
11972,lupus,8,9,59,64,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11972,-1,0.0009744044,0.9990256
11973,serositis,13,14,88,97,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11973,-1,0.0010400797,0.9989599
11974,pulmonary,15,16,102,111,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11974,-1,0.0020252492,0.9979747
11975,involvement,17,18,124,135,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11975,-1,0.00125351,0.9987465
11976,joint symptoms,22,24,154,168,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11976,-1,0.001264876,0.99873513
11978,inflammatory bowel disease,8,11,56,82,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,11978,-1,0.0010586001,0.99894136
11979,lupus syndrome,19,21,137,151,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,11979,-1,0.0009780686,0.9990219
11981,hypokalaemia,4,5,27,39,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11981,-1,0.00083479425,0.9991652
11982,chlorthalidone,6,7,47,61,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11982,-1,0.99873406,0.001265904
11983,essential hypertension,11,13,94,116,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11983,-1,0.0012960087,0.99870396
11986,hypokalaemia,9,10,61,73,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11986,-1,0.0010493887,0.9989506
11987,diuretic,16,17,111,119,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11987,-1,0.9968419,0.0031580688
11988,essential hypertension,27,29,183,205,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11988,-1,0.0012464386,0.99875355
11989,hypokalaemia,32,33,220,232,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11989,-1,0.0011584029,0.9988416
11990,diuretic,36,37,250,258,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11990,-1,0.99742776,0.0025722696
11991,Chlorthalidone,0,1,0,14,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,11991,-1,0.9985158,0.0014841838
11992,mg,3,4,19,21,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,11992,-1,0.8996685,0.10033149
11994,K,11,12,58,59,All patients had a normal initial total body potassium (40K).,28952_4,-1,-1,-1,11994,-1,0.8098611,0.19013886
11995,bromide,6,7,34,41,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,-1,11995,-1,0.73687327,0.2631267
12007,buspirone,5,6,27,36,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,-1,-1,12007,-1,0.998818,0.0011819527
12010,buspirone,6,7,41,50,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12010,-1,0.9986706,0.0013293821
12011,5-hydroxytryptaminergic agonists,9,11,61,93,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12011,-1,0.9681483,0.031851683
12015,5-HT,5,6,30,34,Drugs with affinity for other 5-HT receptors or weak affinity were ineffective.,2907585_4,-1,-1,-1,12015,-1,0.9910102,0.008989846
12016,5-HT,5,6,36,40,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,-1,-1,12016,-1,0.9945444,0.005455641
12018,Glycopyrronium,0,1,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12018,-1,0.99653876,0.0034612932
12019,edrophonium,10,11,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12019,-1,0.9962871,0.00371293
12020,glycopyrronium,13,14,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12020,-1,0.9980129,0.0019870754
12021,edrophonium,28,29,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12021,-1,0.99795294,0.0020470934
12022,mg,30,31,184,186,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12022,-1,0.94355565,0.05644429
12023,P,9,10,63,64,Significant differences between the four groups were detected (P less than 0.001).,2917114_2,-1,-1,-1,12023,-1,0.10801237,0.8919877
12024,glycopyrronium,2,3,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12024,-1,0.99807477,0.0019252443
12025,edrophonium,17,18,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12025,-1,0.96970046,0.03029957
12026,bradycardias,26,27,177,189,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12026,-1,0.00096163515,0.99903834
12027,glycopyrronium,4,5,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,-1,-1,-1,12027,-1,0.99727315,0.0027268506
12030,folate,17,18,96,102,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,-1,-1,-1,12030,-1,0.99725014,0.002749902
12031,Folate,0,1,0,6,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,-1,-1,-1,12031,-1,0.9949616,0.0050383457
12033,CBZ,2,3,15,18,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,-1,-1,-1,12033,-1,0.9971986,0.0028013904
12034,CBZ,11,12,60,63,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12034,-1,0.9978599,0.0021401248
12035,folate,14,15,77,83,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12035,-1,0.9973258,0.0026741948
12036,propylene glycol,12,14,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12036,-1,0.9985629,0.0014371133
12038,weight gain,32,34,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12038,-1,0.0025175824,0.9974825
12040,hexafluorodiethyl ether,3,5,20,43,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12040,-1,0.99309194,0.0069080107
12041,HFDE,6,7,45,49,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12041,-1,0.98289317,0.017106766
12042,CBZ,20,21,115,118,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12042,-1,0.99731284,0.002687069
12044,CBZ,3,4,23,26,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12044,-1,0.9967572,0.0032427807
12045,h,10,11,60,61,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12045,-1,0.17701237,0.8229877
12047,weight gain,30,32,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12047,-1,0.0045094076,0.9954906
12048,CBZ,1,2,4,7,"The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective.",2924746_7,-1,-1,-1,12048,-1,0.9955586,0.004441298
12049,CBZ,3,4,20,23,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12049,-1,0.9977488,0.0022512346
12050,folate,10,11,58,64,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12050,-1,0.99723876,0.0027612033
12051,folate,21,22,109,115,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12051,-1,0.9969537,0.0030462663
12052,myocardial ischemia,1,3,21,40,Dipyridamole-induced myocardial ischemia.,2950248_0,-1,-1,-1,12052,-1,0.0012636839,0.9987363
12053,Angina,0,1,0,6,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12053,-1,0.0008914796,0.9991085
12054,ischemic,2,3,11,19,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12054,-1,0.001287593,0.9987124
12057,myocardial ischemia,21,23,141,160,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12057,-1,0.0011219057,0.99887806
12058,coronary artery disease,33,36,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12058,-1,0.0012913345,0.9987086
12060,atrial natriuretic factor,5,8,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,-1,12060,-1,0.9861837,0.013816257
12064,p,37,38,155,156,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12064,-1,0.158852,0.8411481
12065,p,48,49,184,185,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12065,-1,0.17708157,0.8229184
12066,p,61,62,217,218,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12066,-1,0.14247638,0.8575236
12069,contrast,92,93,381,389,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12069,-1,0.114423014,0.885577
12071,hydralazine,98,99,427,438,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12071,-1,0.99866056,0.0013393863
12074,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12074,-1,0.98508817,0.014911827
12075,p,34,35,170,171,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12075,-1,0.22065574,0.7793443
12076,p,53,54,252,253,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12076,-1,0.46017087,0.53982913
12077,atrial natriuretic factor,6,9,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12077,-1,0.92458487,0.07541513
12078,n,16,17,95,96,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12078,-1,0.20068283,0.7993171
12079,n,31,32,151,152,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12079,-1,0.19744638,0.8025536
12080,n,42,43,182,183,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12080,-1,0.1856673,0.81433266
12081,iopentol,3,4,23,31,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12081,-1,0.99858165,0.0014183092
12082,iohexol,5,6,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12082,-1,0.99875736,0.0012426778
12083,metrizoate,7,8,45,55,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12083,-1,0.9985488,0.0014511234
12084,ventricular fibrillation,2,4,13,37,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,-1,-1,-1,12084,-1,0.0010315271,0.9989685
12085,iopentol,14,15,88,96,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12085,-1,0.99863905,0.0013609916
12086,iohexol,16,17,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12086,-1,0.9987997,0.0012002495
12087,metrizoate,18,19,110,120,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12087,-1,0.9985292,0.001470843
12088,iopentol,1,2,11,19,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12088,-1,0.99824584,0.0017541384
12089,iohexol,5,6,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12089,-1,0.99868995,0.0013100149
12090,metrizoate,9,10,61,71,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12090,-1,0.99842167,0.0015782973
12091,ventricular fibrillation,2,4,15,39,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12091,-1,0.0011991207,0.9988009
12092,p,8,9,66,67,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12092,-1,0.17033143,0.8296686
12093,iopentol,14,15,90,98,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12093,-1,0.9986706,0.0013294239
12094,iohexol,20,21,108,115,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12094,-1,0.9988224,0.0011775575
12095,metrizoate,27,28,132,142,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12095,-1,0.9986498,0.0013501876
12096,Iopentol,0,1,0,8,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12096,-1,0.99843484,0.001565189
12097,iohexol,2,3,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12097,-1,0.99873024,0.0012697186
12098,metrizoate,13,14,93,103,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12098,-1,0.9984421,0.0015578587
12100,nephrogenic diabetes insipidus,16,19,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,-1,-1,12100,-1,0.0010373496,0.99896264
12107,euthyroid,6,7,32,41,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,-1,-1,12107,-1,0.0030392117,0.9969608
12111,isoniazid neuropathy,6,8,47,67,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,-1,-1,12111,-1,0.5862491,0.41375086
12115,ACTH,3,4,41,45,Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.,3015567_1,-1,-1,-1,12115,-1,0.98569876,0.014301267
12116,arginine vasopressin,5,7,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,-1,-1,-1,12116,-1,0.9975141,0.0024858438
12119,arginine vasopressin,34,36,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,-1,12119,-1,0.9977399,0.0022600407
12127,delta 9-tetrahydrocannabinol,6,8,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,-1,-1,-1,12127,-1,0.9964695,0.0035305594
12128,delta 9-tetrahydrocannabinol,15,17,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12128,-1,0.9976363,0.0023636715
12129,THC,18,19,125,128,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12129,-1,0.99774724,0.0022526786
12131,6-OHDA,28,29,182,188,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12131,-1,0.9965496,0.003450364
12133,6-OHDA,34,35,214,220,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12133,-1,0.99733377,0.0026662785
12134,THC,4,5,29,32,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12134,-1,0.9975358,0.0024641778
12135,6-OHDA,12,13,80,86,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12135,-1,0.9971765,0.0028234788
12137,6-OHDA,30,31,180,186,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12137,-1,0.9975684,0.0024314944
12140,6-OHDA,18,19,121,127,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12140,-1,0.9977883,0.00221168
12141,6-OHDA,25,26,157,163,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12141,-1,0.9978563,0.0021436634
12143,THC,17,18,118,121,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,-1,-1,12143,-1,0.99808747,0.001912521
12146,azelastine,12,13,87,97,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12146,-1,0.9987104,0.0012895511
12147,chlorpheniramine,14,15,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12147,-1,0.99885,0.0011499812
12148,spring allergic rhinitis,22,25,149,173,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12148,-1,0.001985627,0.99801433
12149,Azelastine,0,1,0,10,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12149,-1,0.9982681,0.001731814
12150,chlorpheniramine maleate,10,12,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12150,-1,0.99838877,0.0016112216
12151,spring allergic rhinitis,22,25,144,168,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12151,-1,0.0023818053,0.99761814
12152,spring allergic rhinitis,19,22,87,111,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,-1,12152,-1,0.0013521572,0.99864787
12153,azelastine,8,9,45,55,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12153,-1,0.99843043,0.0015694951
12154,mg,17,18,89,91,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12154,-1,0.97568876,0.024311198
12155,chlorpheniramine,33,34,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12155,-1,0.99875057,0.0012494536
12156,mg,37,38,205,207,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12156,-1,0.96984863,0.030151358
12157,body weights,3,5,13,25,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,-1,12157,-1,0.011038337,0.98896164
12158,azelastine,10,11,68,78,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12158,-1,0.9986027,0.0013973581
12159,mg,13,14,84,86,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12159,-1,0.9007406,0.09925936
12160,azelastine,3,4,15,25,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,-1,-1,-1,12160,-1,0.9985954,0.0014045803
12161,contrast,1,2,3,11,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12161,-1,0.041196413,0.9588036
12162,chlorpheniramine,5,6,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12162,-1,0.9988305,0.0011695325
12163,Drowsiness,0,1,0,10,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12163,-1,0.0010935861,0.9989064
12164,altered taste perception,2,5,15,39,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12164,-1,0.0017610873,0.9982389
12165,azelastine,14,15,104,114,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12165,-1,0.9985337,0.0014663201
12166,Azelastine,0,1,0,10,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12166,-1,0.998181,0.0018190555
12167,seasonal allergic rhinitis,10,13,60,86,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12167,-1,0.0014013923,0.99859864
12168,renal insufficiency,3,5,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12168,-1,0.0008085034,0.99919146
12169,renovascular hypertension,13,15,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12169,-1,0.0009277553,0.9990722
12171,solitary kidney,14,16,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12171,-1,0.0024593289,0.9975407
12172,sudden deterioration of renal function,19,24,106,144,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12172,-1,0.0013574613,0.9986425
12174,renal function,1,3,4,18,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,-1,-1,-1,12174,-1,0.0015495296,0.9984504
12176,renal failure,5,7,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,-1,-1,12176,-1,0.0008049914,0.99919504
12177,HMG CoA,0,2,0,7,HMG CoA reductase inhibitors.,3076126_0,-1,-1,-1,12177,-1,0.9923813,0.007618704
12184,creatine kinase,3,5,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,-1,-1,-1,12184,-1,0.99416465,0.0058353944
12186,myoglobinuria,7,8,40,53,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12186,-1,0.00088602304,0.999114
12187,renal failure,15,17,85,98,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12187,-1,0.00088991545,0.99911004
12189,cyclosporin,31,32,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12189,-1,0.998312,0.0016880593
12190,gemfibrozil,33,34,205,216,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12190,-1,0.9985983,0.0014017486
12191,niacin,35,36,220,226,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12191,-1,0.9985864,0.0014136544
12195,hypercholesterolaemia,18,19,112,133,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,-1,-1,-1,12195,-1,0.0015858113,0.99841416
12199,RA,6,7,48,50,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,12199,-1,0.0010854179,0.9989146
12202,nephritis,7,8,44,53,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12202,-1,0.0010128974,0.99898714
12204,Tiopronin,12,13,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12204,-1,0.99854517,0.0014548093
12206,gold thiosulphate,30,32,180,197,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12206,-1,0.99683267,0.0031672856
12207,RA,13,14,81,83,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12207,-1,0.0011667723,0.99883324
12208,Tiopronin,17,18,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12208,-1,0.998264,0.0017360483
12209,nephritis,19,20,117,126,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12209,-1,0.00090196356,0.99909806
12210,contralateral rotation,1,3,10,32,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12210,-1,0.0017777347,0.9982223
12211,substantia nigra lesion,5,8,54,77,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12211,-1,0.003728366,0.9962716
12213,6-OHDA,2,3,21,27,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12213,-1,0.9951428,0.00485715
12214,SN lesion,4,6,36,45,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12214,-1,0.0029216087,0.9970784
12215,contralateral rotation,11,13,69,91,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12215,-1,0.002423596,0.9975764
12216,ipsilateral circling,20,22,137,157,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12216,-1,0.0036994726,0.99630046
12217,contralateral rotation,9,11,47,69,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12217,-1,0.002624083,0.99737597
12218,rotational behavior,27,29,169,188,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12218,-1,0.0014737817,0.9985262
12219,contralateral rotation,1,3,5,27,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12219,-1,0.0036961825,0.9963038
12220,DA,11,12,89,91,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12220,-1,0.9949414,0.005058537
12221,DA,18,19,128,130,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12221,-1,0.9939089,0.006091098
12223,contralateral rotation,29,31,191,213,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,-1,12223,-1,0.0035950474,0.996405
12225,rotation,26,27,161,169,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,-1,12225,-1,0.0023317914,0.9976682
12228,DA,12,13,86,88,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12228,-1,0.99546427,0.0045357696
12229,contralateral rotation,16,18,110,132,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12229,-1,0.0033058613,0.9966941
12237,hepatocellular injury,8,10,52,73,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,-1,-1,-1,12237,-1,0.0011258272,0.9988741
12238,contrast,1,2,3,11,"In contrast, the results of histological examination of the liver often showed evidence of cholestasis.",3101906_9,-1,-1,-1,12238,-1,0.05453334,0.9454667
12240,Allergic,0,1,0,8,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,-1,-1,12240,-1,0.0018318031,0.99816823
12253,sulfonylureas,12,13,87,100,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,-1,-1,12253,-1,0.9979925,0.0020074674
12254,glyburide,1,2,4,13,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12254,-1,0.998741,0.0012590514
12255,sulfonylurea,5,6,35,47,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12255,-1,0.99811065,0.0018893157
12257,type II diabetes mellitus,3,7,18,43,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12257,-1,0.0011206123,0.9988794
12258,glyburide,16,17,112,121,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12258,-1,0.9987876,0.001212433
12259,viral infection,6,8,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,-1,12259,-1,0.0018239885,0.998176
12261,glyburide,6,7,47,56,Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow-up period of 1 year.,3107448_5,-1,-1,-1,12261,-1,0.9988211,0.0011789078
12262,Glyburide,0,1,0,9,Glyburide can produce an acute hepatitis-like illness in some persons.,3107448_6,-1,-1,-1,12262,-1,0.99866366,0.0013363933
12263,Mitomycin C,0,2,0,11,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,-1,-1,-1,12263,-1,0.9981634,0.0018366432
12265,Mitomycin C,0,2,0,11,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12265,-1,0.9980902,0.0019097569
12267,HUS,7,8,50,53,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12267,-1,0.0010718865,0.9989281
12268,microangiopathic hemolytic anemia,3,6,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12268,-1,0.00089097006,0.99910897
12270,progressive renal failure,9,12,71,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12270,-1,0.0010584511,0.9989416
12271,mitomycin C,14,16,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12271,-1,0.9984249,0.0015750718
12272,renal failure,1,3,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12272,-1,0.0009865306,0.9990134
12273,mitomycin C,13,15,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12273,-1,0.99849653,0.0015034813
12274,renal failure,24,26,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12274,-1,0.00097314554,0.9990269
12275,pulmonary edema,27,29,148,163,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12275,-1,0.0009795974,0.99902034
12276,Renal lesions,0,2,0,13,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12276,-1,0.0014654812,0.99853456
12277,HUS,9,10,54,57,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12277,-1,0.0011758192,0.9988242
12278,fibrin thrombi,13,15,81,95,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12278,-1,0.00786634,0.9921336
12279,ischemic,24,25,158,166,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12279,-1,0.0034563802,0.9965436
12280,gastric adenocarcinoma,14,16,82,104,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12280,-1,0.0019133806,0.9980867
12281,renal failure,18,20,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12281,-1,0.0010259515,0.9989741
12283,mitomycin C,26,28,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12283,-1,0.9981871,0.0018129023
12284,pulmonary edema,31,33,202,217,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12284,-1,0.0010846669,0.9989153
12285,Ketanserin,0,1,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12285,-1,0.9988452,0.0011547866
12286,muscle rigidity,4,6,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12286,-1,0.0011109102,0.99888915
12287,ketanserin,3,4,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12287,-1,0.9988286,0.0011714045
12289,muscle rigidity,16,18,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12289,-1,0.0011639711,0.9988361
12292,ketanserin,1,2,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,-1,-1,-1,12292,-1,0.9988242,0.0011757989
12293,Chlordiazepoxide,0,1,0,16,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,-1,-1,-1,12293,-1,0.99799204,0.0020079345
12297,ketanserin,9,10,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,-1,-1,12297,-1,0.9988158,0.0011842326
12300,ketanserin,3,4,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12300,-1,0.9988343,0.0011656854
12302,ketanserin,25,26,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12302,-1,0.9988175,0.001182526
12303,muscle rigidity,11,13,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,-1,-1,12303,-1,0.0013124064,0.99868757
12304,serotonin antagonists,3,5,25,46,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12304,-1,0.99683666,0.0031633286
12306,respiratory depression,32,34,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12306,-1,0.001859717,0.9981402
12307,Ro15-1788,6,9,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,-1,-1,-1,12307,-1,0.99690837,0.003091658
12308,Ro15-1788,11,14,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12308,-1,0.99799407,0.0020060046
12309,Ro15-1788,37,40,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12309,-1,0.9982058,0.0017942514
12311,Ro15-1788,5,8,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,-1,12311,-1,0.9968443,0.0031556813
12314,Ro15-1788,1,4,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,-1,-1,-1,12314,-1,0.9958664,0.004133538
12315,Chorea,0,1,0,6,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12315,-1,0.0013815549,0.9986185
12316,oral contraception,3,5,23,41,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12316,-1,0.98804945,0.011950537
12317,chorea,3,4,25,31,Three patients developed chorea while receiving oral contraceptives.,3123611_1,-1,-1,-1,12317,-1,0.0010156807,0.9989843
12319,chorea,5,6,30,36,Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued.,3123611_2,-1,-1,-1,12319,-1,0.0010883082,0.99891174
12320,chorea,6,7,48,54,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12320,-1,0.0011450503,0.998855
12321,oral contraception,9,11,71,89,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12321,-1,0.98557043,0.0144295115
12322,sex hormones,4,6,35,47,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12322,-1,0.98231214,0.017687792
12323,chorea,11,12,71,77,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12323,-1,0.0009051882,0.99909484
12324,chorea,19,20,115,121,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12324,-1,0.0009879395,0.999012
12325,rheumatic fever,21,23,125,140,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12325,-1,0.0008086934,0.99919134
12329,normocarbia,7,8,52,63,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12329,-1,0.0029559543,0.997044
12330,PCO2,9,10,65,69,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12330,-1,0.11879582,0.8812041
12331,SE,20,21,96,98,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12331,-1,0.1083447,0.8916554
12335,somatic rigidity,6,8,32,48,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,-1,12335,-1,0.0012594375,0.9987406
12337,metocurine,10,11,70,80,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,-1,-1,-1,12337,-1,0.9988255,0.0011745235
12341,retinyl acetate,3,5,26,41,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12341,-1,0.9981092,0.0018908288
12342,forestomach carcinogenesis,6,8,45,71,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12342,-1,0.0028232546,0.99717677
12343,butylated hydroxyanisole,14,16,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12343,-1,0.9977124,0.0022876824
12344,retinyl acetate,5,7,34,49,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12344,-1,0.9978935,0.0021064698
12345,RA,8,9,51,53,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12345,-1,0.9961403,0.0038596767
12346,butylated hydroxyanisole,11,13,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12346,-1,0.9978563,0.0021436561
12347,forestomach tumorigenesis,15,17,101,126,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12347,-1,0.0033152194,0.99668473
12348,BHA,19,20,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12348,-1,0.9939121,0.006087909
12349,RA,29,30,145,147,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12349,-1,0.9964619,0.0035380623
12350,BHA,5,6,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12350,-1,0.9910424,0.0089575965
12351,RA,25,26,148,150,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12351,-1,0.9970144,0.002985648
12352,P,28,29,166,167,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12352,-1,0.22790034,0.7720997
12353,forestomach tumors,37,39,211,229,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12353,-1,0.002033841,0.9979662
12354,squamous cell papilloma,40,43,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12354,-1,0.00206536,0.9979347
12358,BHA,5,6,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12358,-1,0.9925523,0.007447695
12359,RA,7,8,22,24,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12359,-1,0.9962339,0.00376609
12360,epithelial hyperplasia,32,34,157,179,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12360,-1,0.0024967173,0.99750334
12362,papillomas,3,4,12,22,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12362,-1,0.0013424194,0.9986576
12363,RA,17,18,64,66,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12363,-1,0.9967231,0.0032769346
12364,RA,29,30,99,101,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12364,-1,0.99669075,0.0033092725
12365,RA,0,1,0,2,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,-1,-1,-1,12365,-1,0.99419373,0.0058062794
12366,RA,4,5,29,31,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12366,-1,0.9941281,0.0058718813
12367,BHA forestomach carcinogenesis,11,14,64,94,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12367,-1,0.012968019,0.98703194
12369,mitomycin C.Since,11,13,72,89,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12369,-1,0.9605731,0.03942686
12370,mitomycin C,14,16,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12370,-1,0.9981335,0.001866562
12371,MMC,17,18,108,111,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12371,-1,0.99265623,0.007343852
12374,cardiac failure,5,7,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12374,-1,0.0009998498,0.99900013
12375,mg,9,10,55,57,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12375,-1,0.7344456,0.26555446
12376,MMC,11,12,62,65,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12376,-1,0.99049383,0.009506156
12377,mg,15,16,79,81,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12377,-1,0.65703595,0.34296408
12379,cardiac failure,1,3,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,-1,12379,-1,0.00094910996,0.9990509
12382,mg,29,30,174,176,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,-1,12382,-1,0.8497373,0.15026271
12385,myocardial infarction,7,9,44,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,-1,-1,12385,-1,0.00084382354,0.99915624
12389,myocardial infarction,6,8,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,-1,12389,-1,0.0009316129,0.99906844
12398,cerebral lesions,1,3,11,27,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12398,-1,0.0013954539,0.9986046
12399,tiazofurin,5,6,44,54,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12399,-1,0.9984628,0.0015371814
12400,MR,8,9,62,64,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12400,-1,0.018887104,0.98111284
12401,Tiazofurin,0,1,0,10,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,-1,-1,-1,12401,-1,0.99786854,0.0021314786
12402,MR,8,9,47,49,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12402,-1,0.009374421,0.9906255
12403,cerebral abnormalities,13,15,79,101,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12403,-1,0.0012780348,0.9987219
12404,MR,3,4,21,23,The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.,3183120_3,-1,-1,-1,12404,-1,0.023459654,0.9765404
12405,MR,3,4,15,17,The utility of MR in the evaluation of patients receiving this new agent is illustrated.,3183120_4,-1,-1,-1,12405,-1,0.0031952325,0.99680483
12407,head and neck carcinoma,5,9,36,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12407,-1,0.0015588062,0.99844116
12408,esophageal carcinoma,10,12,64,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12408,-1,0.0013755878,0.99862444
12409,5-FU,13,14,55,59,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,-1,-1,-1,12409,-1,0.99747425,0.0025257429
12410,cardiovascular disease,7,9,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,-1,-1,12410,-1,0.0010442706,0.9989557
12412,cardiovascular disease,12,14,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,-1,-1,12412,-1,0.0009661305,0.9990339
12414,chest pain,7,9,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12414,-1,0.0013105496,0.9986895
12415,atrial fibrillation,14,16,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12415,-1,0.0013129128,0.9986871
12416,ventricular fibrillation,4,6,21,45,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12416,-1,0.0010796855,0.9989203
12417,sudden death,10,12,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12417,-1,0.0012321819,0.99876785
12418,5-FU,6,7,33,37,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12418,-1,0.99709785,0.0029021157
12419,chest pain,21,23,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12419,-1,0.0010947546,0.9989052
12420,tachyarrhythmia,24,25,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12420,-1,0.00086859736,0.9991314
12422,gestational trophoblastic disease,4,7,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,-1,-1,12422,-1,0.0016276048,0.9983724
12423,choriocarcinoma,16,17,113,128,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,-1,-1,-1,12423,-1,0.0018239592,0.9981761
12431,pulmonary obstruction,16,18,103,124,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,-1,-1,-1,12431,-1,0.0010666857,0.99893326
12432,tumor necrosis,9,11,55,69,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,-1,12432,-1,0.001944272,0.9980557
12436,massive embolism,17,19,95,111,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,-1,-1,12436,-1,0.0015090232,0.9984909
12446,DA,41,42,255,257,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,-1,12446,-1,0.9956346,0.0043654093
12448,DA,27,28,180,182,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,-1,-1,-1,12448,-1,0.9954275,0.0045724837
12451,DA,26,27,187,189,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12451,-1,0.9976814,0.0023185804
12452,DA,32,33,226,228,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12452,-1,0.99715626,0.0028437006
12456,cm H2O,5,7,33,39,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12456,-1,0.89246356,0.10753643
12457,P,10,11,60,61,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12457,-1,0.30315828,0.6968417
12458,cm H2O,1,3,4,10,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12458,-1,0.87204397,0.12795603
12460,decrease in,10,12,65,76,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12460,-1,0.009921597,0.99007845
12461,blood pressure,13,15,86,100,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12461,-1,0.004181156,0.9958189
12462,decreased cardiac output,21,24,144,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12462,-1,0.0053011663,0.9946989
12464,cm H2O,1,3,5,11,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,-1,12464,-1,0.6426441,0.35735586
12466,cm H2O,3,5,12,18,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,-1,12466,-1,0.8417012,0.15829878
12469,cm H2O,21,23,124,130,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12469,-1,0.8555391,0.14446092
12470,decreases in arterial blood pressure and cardiac output,31,39,172,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12470,-1,0.004648132,0.9953519
12471,hypokalemia,3,4,39,50,Amelioration of bendrofluazide-induced hypokalemia by timolol.,326460_0,-1,-1,-1,12471,-1,0.0008181725,0.9991818
12474,hypokalemia,12,13,66,77,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12474,-1,0.000935303,0.99906474
12475,bendrofluazide,15,16,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12475,-1,0.9985952,0.0014047835
12479,bendrofluazide,13,14,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,-1,12479,-1,0.9984932,0.001506805
12482,methysergide,20,21,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,-1,-1,12482,-1,0.99847645,0.0015235832
12483,ergot,6,7,31,36,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12483,-1,0.99741215,0.0025878733
12484,gangrene,15,16,87,95,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12484,-1,0.0010977985,0.9989022
12485,migraine headache,33,35,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12485,-1,0.0010276356,0.9989724
12486,calcium channel blockers,4,7,22,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12486,-1,0.9925377,0.0074623246
12487,ergot,11,12,80,85,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12487,-1,0.99785393,0.00214607
12503,mm Hg,7,9,43,48,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12503,-1,0.009084913,0.9909151
12505,HEM,16,17,86,89,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12505,-1,0.0023429755,0.99765706
12506,n,18,19,91,92,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12506,-1,0.045317695,0.9546823
12508,SNP,30,31,149,152,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12508,-1,0.99609333,0.0039067217
12509,n,32,33,154,155,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12509,-1,0.06550584,0.93449414
12511,SNP,19,20,140,143,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,-1,-1,12511,-1,0.9899367,0.010063303
12513,mm Hg,9,11,44,49,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12513,-1,0.004151622,0.9958483
12514,HEM,13,14,57,60,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12514,-1,0.011560492,0.98843944
12515,mm Hg,22,24,94,99,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12515,-1,0.00490902,0.99509096
12516,SNP,26,27,107,110,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12516,-1,0.6177271,0.38227293
12517,P,29,30,118,119,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12517,-1,0.05990234,0.9400977
12518,mm Hg,27,29,117,122,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12518,-1,0.013469157,0.98653084
12519,HEM,31,32,130,133,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12519,-1,0.7441496,0.2558504
12520,SNP,33,34,138,141,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12520,-1,0.8842667,0.1157334
12522,P,41,42,184,185,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12522,-1,0.07838817,0.92161185
12524,hypovolemia,7,8,45,56,They are thus more important during absolute hypovolemia than during deliberate hypotension.,3341566_9,-1,-1,-1,12524,-1,0.000898481,0.9991015
12526,Ventricular tachyarrhythmias,0,2,0,28,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12526,-1,0.0011126631,0.99888736
12527,ritodrine,6,7,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12527,-1,0.99894017,0.0010598085
12528,ritodrine,6,7,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12528,-1,0.99902356,0.0009764132
12529,preterm labor,8,10,60,73,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12529,-1,0.0011983044,0.9988017
12530,ritodrine,19,20,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12530,-1,0.9989938,0.0010061541
12531,cardiovascular complications,6,8,40,68,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12531,-1,0.0011386079,0.99886143
12532,ritodrine,15,16,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12532,-1,0.99896896,0.0010309935
12538,carbamazepine neurotoxicity,1,3,18,45,Verapamil-induced carbamazepine neurotoxicity.,3371379_0,-1,-1,-1,12538,-1,0.7339206,0.2660794
12539,carbamazepine neurotoxicity,5,7,27,54,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,-1,-1,-1,12539,-1,0.71466655,0.28533345
12546,Ethopropazine,0,1,0,13,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12546,-1,0.99871504,0.0012849731
12547,benztropine,2,3,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12547,-1,0.9987257,0.0012742401
12549,ethopropazine,5,6,30,43,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12549,-1,0.9986517,0.0013483868
12550,benztropine,9,10,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12550,-1,0.9986229,0.0013771199
12554,Ethopropazine,0,1,0,13,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12554,-1,0.9986506,0.0013494568
12555,benztropine,2,3,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12555,-1,0.99869543,0.0013045396
12556,parkinsonian symptoms,11,13,80,101,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12556,-1,0.0009407297,0.99905926
12557,procyclidine,18,19,129,141,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12557,-1,0.99878496,0.0012150598
12558,benztropine,2,3,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12558,-1,0.99868363,0.001316408
12559,tardive dyskinesia,10,12,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12559,-1,0.00082561193,0.9991744
12560,procyclindine,17,18,122,135,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12560,-1,0.9987148,0.0012852579
12561,anxiety,23,24,170,177,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12561,-1,0.0012872975,0.99871266
12563,ethopropazine,27,28,198,211,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12563,-1,0.9987956,0.0012043081
12564,benztropine,3,4,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12564,-1,0.99877304,0.0012269913
12565,parkinsonian symptoms,16,18,113,134,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12565,-1,0.0008210048,0.99917895
12568,renal,6,7,49,54,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12568,-1,0.0013018232,0.9986981
12569,hepatic failure,8,10,59,74,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12569,-1,0.0009794887,0.99902046
12571,acute renal failure,6,9,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12571,-1,0.0010446974,0.99895525
12572,hepatic failure,10,12,54,69,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12572,-1,0.0009552271,0.9990447
12579,osteoarthritis,16,17,116,130,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12579,-1,0.0010340863,0.99896586
12580,spondyloarthropathy,18,19,135,154,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12580,-1,0.0009066832,0.9990933
12582,Sexual dysfunctions,0,2,0,19,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12582,-1,0.0016575734,0.9983424
12583,dysfunctions,21,22,123,135,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12583,-1,0.0018658797,0.9981342
12584,Impotence,0,1,0,9,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,-1,-1,12584,-1,0.0010520011,0.99894804
12586,Depressed mood,0,2,0,14,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12586,-1,0.001406978,0.99859303
12587,sexual difficulties,12,14,78,97,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12587,-1,0.001417568,0.9985825
12588,impotence,18,19,112,121,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12588,-1,0.0012811755,0.99871886
12591,Quinidine,0,1,0,9,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12591,-1,0.9980811,0.0019189507
12592,fulminant hepatitis,2,4,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12592,-1,0.0012122298,0.9987878
12593,fulminant hepatitis,11,13,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12593,-1,0.0009500822,0.99904996
12594,quinidine phenylethylbarbiturate,25,27,162,194,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12594,-1,0.99728537,0.0027146395
12595,Quinidine,0,1,0,9,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12595,-1,0.99849105,0.0015089386
12596,phenylethylbarbiturate,3,4,20,42,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12596,-1,0.9981078,0.0018921844
12597,fulminant hepatitis,8,10,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12597,-1,0.0011248821,0.9988751
12599,urothelial cancer,3,5,23,40,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12599,-1,0.0013498854,0.99865013
12600,renal papillary necrosis?The,6,9,44,72,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12600,-1,0.007414719,0.99258524
12608,ureteric cancer,31,33,181,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,-1,-1,12608,-1,0.0015417758,0.99845827
12609,contrast,1,2,3,11,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12609,-1,0.0422123,0.9577877
12611,papillary necrosis,16,18,101,119,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12611,-1,0.0012952338,0.9987048
12614,the ureter,34,36,209,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12614,-1,0.0036338295,0.99636614
12615,myocardial ischemia,2,4,14,33,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,-1,-1,12615,-1,0.0013293276,0.9986707
12619,myocardial ischemia,6,8,37,56,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12619,-1,0.00094968936,0.9990503
12620,coronary artery disease,13,16,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12620,-1,0.0011757923,0.9988242
12625,myocardial ischemia,5,7,39,58,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12625,-1,0.0010741442,0.99892586
12627,angina,14,15,101,107,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12627,-1,0.0010057841,0.9989942
12628,myocardial ischemia,5,7,27,46,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,-1,-1,-1,12628,-1,0.0012513042,0.99874866
12630,myocardial ischemia,1,3,17,36,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,-1,12630,-1,0.0013252156,0.99867487
12635,E,11,12,84,85,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,-1,-1,12635,-1,0.03727238,0.96272767
12636,E,5,6,34,35,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12636,-1,0.043490518,0.9565095
12637,leprosy,11,12,51,58,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12637,-1,0.0011333823,0.9988667
12641,reduced glutathione,15,17,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12641,-1,0.9950794,0.0049206004
12642,GSH,18,19,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12642,-1,0.99572134,0.004278594
12643,GSH,23,24,124,127,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12643,-1,0.9947685,0.0052315835
12644,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,-1,-1,-1,12644,-1,0.9788967,0.021103373
12646,GSH,18,19,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12646,-1,0.992393,0.007606989
12647,GSH,21,22,125,128,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12647,-1,0.9916672,0.008332792
12648,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,-1,-1,-1,12648,-1,0.9776754,0.022324666
12652,thymidylate,7,8,49,60,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12652,-1,0.9958631,0.0041368785
12653,"N10-propargyl-5,8-dideazafolic acid",10,12,80,115,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12653,-1,0.99128485,0.008715166
12654,"N10-propargyl-5,8-dideazafolic acid",17,19,135,170,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12654,-1,0.98778814,0.012211906
12655,thymidylate,25,26,204,215,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12655,-1,0.9953685,0.004631525
12656,TS,28,29,226,228,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12656,-1,0.7351762,0.26482382
12657,cytotoxicity,31,32,236,248,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12657,-1,0.001738645,0.9982614
12658,CB 3717,10,12,74,81,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,-1,12658,-1,0.9792646,0.020735322
12659,CB,7,8,36,38,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12659,-1,0.98542964,0.014570354
12660,CB,27,28,130,132,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12660,-1,0.99095047,0.009049464
12661,CB,44,45,220,222,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12661,-1,0.99100035,0.008999664
12662,cytotoxicity,46,47,228,240,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12662,-1,0.0029795293,0.9970204
12663,CB 3717,5,7,31,38,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12663,-1,0.9934576,0.006542432
12666,hepatoma,19,20,97,105,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12666,-1,0.0009994146,0.9990006
12667,mesothelioma,22,23,111,123,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12667,-1,0.0011241009,0.9988759
12670,malaise,4,5,36,43,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,-1,-1,12670,-1,0.0010180703,0.9989819
12672,CB 3717,23,25,124,131,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,-1,12672,-1,0.9892833,0.01071672
12673,CB 3717,12,14,60,67,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,-1,12673,-1,0.99517846,0.004821577
12677,malaise,2,3,19,26,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,-1,-1,12677,-1,0.0010266586,0.99897337
12678,CB 3717,10,12,80,87,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,-1,12678,-1,0.9954591,0.004540914
12679,Type B hepatitis,0,3,0,16,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12679,-1,0.0027897935,0.9972102
12680,hepatitis B,9,11,62,73,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12680,-1,0.026551396,0.97344863
12681,Hepatitis B,0,2,0,11,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12681,-1,0.015489862,0.9845101
12682,type B hepatitis,29,32,167,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12682,-1,0.002481271,0.9975188
12683,hepatitis B,36,38,215,226,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12683,-1,0.048687734,0.9513123
12685,P,16,17,76,77,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12685,-1,0.054549184,0.94545084
12686,P,37,38,167,168,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12686,-1,0.050171487,0.9498285
12687,e,12,13,65,66,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12687,-1,0.570612,0.42938796
12688,HBeAg,17,18,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12688,-1,0.02843125,0.97156876
12689,HBeAg,3,4,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,-1,12689,-1,0.0933405,0.90665954
12690,Hepatitis B,0,2,0,11,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12690,-1,0.004679579,0.9953204
12691,type B hepatitis,11,14,81,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12691,-1,0.0020262576,0.99797374
12692,type B hepatitis,6,9,34,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,-1,-1,-1,12692,-1,0.0016986463,0.99830127
12694,propafenone,17,18,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,-1,-1,-1,12694,-1,0.9989491,0.0010509384
12697,coronary artery disease,5,8,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,-1,12697,-1,0.00210856,0.9978915
12699,AV block,0,2,0,8,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12699,-1,0.0013386096,0.9986614
12701,impairment of ventricular function,7,11,34,68,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12701,-1,0.0016403219,0.9983596
12703,mg,14,15,77,79,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12703,-1,0.94936746,0.050632514
12704,mg,20,21,100,102,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12704,-1,0.9260877,0.073912285
12706,mg,7,8,40,42,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,-1,-1,-1,12706,-1,0.896831,0.103169054
12711,propafenone,16,17,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,-1,-1,-1,12711,-1,0.9990055,0.0009945589
12713,adverse drug reactions,26,29,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,-1,12713,-1,0.0020189637,0.997981
12716,prostate adenocarcinomas,15,17,75,99,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12716,-1,0.0017993314,0.99820065
12717,PAs,18,19,101,104,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12717,-1,0.004173077,0.9958269
12718,testosterone propionate,34,36,175,198,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12718,-1,0.9977501,0.0022498963
12719,TP,38,39,201,203,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12719,-1,0.99335915,0.0066408613
12720,PA,12,13,67,69,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12720,-1,0.0031524221,0.99684757
12721,TP,17,18,93,95,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12721,-1,0.9953387,0.004661299
12722,TP,4,5,13,15,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,-1,12722,-1,0.99491644,0.005083557
12725,bromperidol,8,9,43,54,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12725,-1,0.9986922,0.0013077796
12727,mg,17,18,82,84,The open study lasted for four weeks; the drug was administrated in the form of 1 mg tablets.,347884_2,-1,-1,-1,12727,-1,0.86534226,0.13465777
12728,mg,8,9,32,34,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12728,-1,0.42872098,0.571279
12729,mg,20,21,76,78,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12729,-1,0.41783145,0.5821686
12730,extrapyramidal concomitant symptoms,6,9,41,76,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,-1,-1,12730,-1,0.0010441428,0.99895585
12732,psychotic syndromes,20,22,114,133,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12732,-1,0.0011394662,0.9988606
12734,bromperidol,17,18,90,101,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,-1,12734,-1,0.99860436,0.0013956066
12736,acute hepatitis,4,6,51,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,-1,-1,12736,-1,0.00092114485,0.99907887
12740,troleandomycin,5,6,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12740,-1,0.9977597,0.0022402445
12741,hypereosinophilia,13,14,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12741,-1,0.0009549746,0.99904495
12745,alkaline phosphatase,19,21,127,147,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,-1,-1,12745,-1,0.9741853,0.025814693
12749,acute hepatitis,9,11,91,106,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,-1,-1,12749,-1,0.0008908059,0.9991092
12750,auditory neurotoxicity,3,5,18,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,-1,-1,12750,-1,0.0013090806,0.9986909
12756,abnormal audiograms,7,9,46,65,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12756,-1,0.0018715326,0.9981285
12757,"deficits mostly in the high frequency range of 4,000",10,19,71,123,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12757,-1,0.03698923,0.9630108
12758,"4,000 to",18,20,118,126,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12758,-1,0.2631639,0.73683614
12759,"8,000 Hz",20,22,127,135,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12759,-1,0.21983182,0.7801681
12761,hearing aids,10,12,73,85,Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability.,3503576_4,-1,-1,-1,12761,-1,0.0020702053,0.9979298
12762,permanent disability,14,16,97,117,Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability.,3503576_4,-1,-1,-1,12762,-1,0.0015005206,0.9984995
12764,auditory abnormality,41,43,230,250,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,-1,-1,-1,12764,-1,0.001909188,0.9980908
12772,hearing loss,5,7,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,-1,-1,-1,12772,-1,0.0013299672,0.9986701
12773,auditory dysfunction,27,29,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,-1,-1,12773,-1,0.0015445682,0.9984554
12775,netilmicin,5,6,34,44,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,-1,-1,12775,-1,0.99837095,0.0016290885
12777,netilmicin sulfate,8,10,53,71,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12777,-1,0.9981065,0.0018935502
12778,tobramycin sulfate,11,13,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12778,-1,0.9978759,0.0021240492
12779,piperacillin sodium,16,18,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12779,-1,0.99868494,0.0013150753
12782,netilmicin,10,11,73,83,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,-1,-1,12782,-1,0.99841905,0.00158094
12785,netilmicin,10,11,42,52,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12785,-1,0.9984328,0.0015672187
12786,piperacillin,12,13,57,69,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12786,-1,0.9986683,0.0013317227
12788,netilmicin,10,11,62,72,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,-1,12788,-1,0.9984478,0.0015521442
12790,netilmicin,34,35,194,204,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,-1,12790,-1,0.9984326,0.0015673812
12793,netilmicin,13,14,102,112,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,-1,-1,12793,-1,0.9983941,0.0016058557
12795,cardiac asystole,1,3,18,34,Lidocaine-induced cardiac asystole.,354896_0,-1,-1,-1,12795,-1,0.0009376487,0.99906236
12798,bradyarrhythmias,16,17,105,121,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,-1,-1,-1,12798,-1,0.0008388757,0.9991611
12800,Flurbiprofen,0,1,0,12,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12800,-1,0.9983911,0.0016089092
12801,juvenile rheumatoid arthritis,5,8,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12801,-1,0.0012885304,0.99871147
12802,juvenile rheumatoid arthritis,3,6,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12802,-1,0.0011371142,0.99886286
12803,flurbiprofen,11,12,79,91,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12803,-1,0.9985312,0.001468742
12805,tender joints,7,9,40,53,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12805,-1,0.0018193385,0.9981806
12806,swelling,13,14,71,79,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12806,-1,0.0013372295,0.9986627
12807,tenderness,15,16,84,94,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12807,-1,0.001291829,0.9987081
12808,morning stiffness,27,29,138,155,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12808,-1,0.0014861526,0.9985139
12809,fecal occult blood,7,10,45,63,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12809,-1,0.003214858,0.99678516
12810,gastrointestinal (GI) bleeding,25,30,123,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12810,-1,0.001240607,0.9987594
12812,abdominal pain,12,14,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,-1,-1,12812,-1,0.0009774273,0.9990226
12816,NSAID,13,14,101,106,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12816,-1,0.9952899,0.0047100824
12819,prostacyclin,20,21,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,-1,-1,-1,12819,-1,0.9960614,0.003938578
12828,NSAID,19,20,123,128,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,-1,12828,-1,0.99492884,0.005071144
12831,sodium pentothal,9,11,59,75,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12831,-1,0.9981287,0.0018713422
12832,cerebral ischaemia,16,18,114,132,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12832,-1,0.0010890191,0.998911
12834,gangrene,4,5,34,42,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,-1,-1,12834,-1,0.0009710926,0.9990289
12847,cephalosporin hematotoxicity,15,17,85,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,-1,12847,-1,0.33913192,0.6608681
12848,Cephalosporin,0,1,0,13,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12848,-1,0.9975407,0.0024593382
12849,hematologic disturbances,6,8,45,69,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12849,-1,0.001037149,0.9989629
12850,blood dyscrasias,12,14,63,79,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,-1,-1,-1,12850,-1,0.0022445892,0.99775547
12858,cytopenias,9,10,58,68,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,-1,-1,-1,12858,-1,0.000982576,0.99901736
12861,cytopenias,2,3,10,20,All three cytopenias were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days).,3629586_5,-1,-1,-1,12861,-1,0.0009982755,0.9990017
12862,cephalosporin,4,5,29,42,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12862,-1,0.99837375,0.0016262719
12863,hematologic syndrome,7,9,48,68,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12863,-1,0.0009936208,0.99900645
12865,hemolytic,22,23,117,126,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12865,-1,0.0011446249,0.99885535
12866,cytopenia,38,39,241,250,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12866,-1,0.0009117846,0.99908817
12869,hematotoxicity,16,17,96,110,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12869,-1,0.00089077395,0.9991092
12870,blood dyscrasias,21,23,148,164,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12870,-1,0.0014848107,0.9985152
12871,injury,8,9,54,60,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12871,-1,0.0019946669,0.99800533
12873,hexachloro-1:3-butadiene,24,25,147,171,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12873,-1,0.994558,0.005442088
12874,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12874,-1,0.990395,0.009605044
12875,puromycin aminonucleoside,29,31,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12875,-1,0.9971929,0.0028070842
12876,PAN,32,33,207,210,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12876,-1,0.9941195,0.0058805337
12877,2-bromoethylamine,36,37,217,234,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12877,-1,0.9963858,0.0036141875
12878,BEA,38,39,236,239,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12878,-1,0.9901383,0.009861741
12880,alkaline phosphatase,8,10,58,78,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12880,-1,0.8811708,0.118829176
12881,protein,18,19,142,149,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12881,-1,0.56985503,0.43014494
12882,Tubular damage,0,2,0,14,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12882,-1,0.0017410873,0.9982589
12883,HCBD,4,5,27,31,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12883,-1,0.8192329,0.18076709
12884,BEA,6,7,35,38,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12884,-1,0.61746746,0.38253257
12885,glomerular damage,14,16,100,117,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12885,-1,0.0018211771,0.99817884
12886,PAN,18,19,130,133,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12886,-1,0.31650186,0.6834982
12887,protein,9,10,57,64,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12887,-1,0.7933168,0.20668325
12888,Da,20,21,138,140,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12888,-1,0.45573422,0.5442658
12889,contrast,1,2,3,11,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12889,-1,0.03661054,0.9633895
12890,protein,3,4,13,20,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12890,-1,0.77678883,0.22321115
12891,tubular damage,6,8,34,48,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12891,-1,0.0015040267,0.99849594
12892,Proximal tubular damage,0,3,0,23,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12892,-1,0.0016749877,0.99832505
12893,HCBD,5,6,34,38,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12893,-1,0.0052794404,0.9947206
12894,papillary damage,7,9,43,59,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12894,-1,0.0016385955,0.9983614
12895,BEA,11,12,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12895,-1,0.009610492,0.9903895
12896,Alkaline phosphatase,0,2,0,20,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12896,-1,0.93627924,0.06372077
12898,proximal tubular damage,10,13,75,98,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12898,-1,0.002014781,0.99798524
12899,papillary damage,20,22,165,181,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12899,-1,0.001940931,0.9980591
12901,Reye,4,5,15,19,A catch in the Reye.,3670965_0,-1,-1,-1,12901,-1,0.077251785,0.9227482
12902,Reye syndrome,3,5,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,-1,-1,12902,-1,0.002534998,0.997465
12903,Reye syndrome,20,22,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,-1,-1,12903,-1,0.004718708,0.9952813
12905,salicylate,2,3,11,21,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,-1,-1,-1,12905,-1,0.9984937,0.0015063746
12908,Reye syndrome,6,8,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,-1,-1,-1,12908,-1,0.0034566463,0.99654335
12909,Reye syndrome,3,5,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,-1,12909,-1,0.0023937481,0.9976063
12910,Reye syndrome,4,6,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,-1,12910,-1,0.0016615363,0.99833846
12914,Reye syndrome,0,2,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12914,-1,0.002366212,0.9976338
12915,salicylates,14,15,90,101,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12915,-1,0.9981658,0.0018341925
12918,cerebral aneurysms,14,16,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,-1,-1,12918,-1,0.0011076217,0.99889237
12921,cerebral aneurysm,24,26,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,-1,-1,12921,-1,0.0012798193,0.99872017
12922,subarachnoid haemorrhage,11,13,54,78,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,-1,-1,12922,-1,0.0014347731,0.99856526
12924,nitrous oxide,15,17,88,101,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,-1,12924,-1,0.99692553,0.00307449
12927,MAP,5,6,37,40,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12927,-1,0.0024622115,0.99753773
12928,mm Hg,10,12,50,55,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12928,-1,0.0057056234,0.99429435
12933,psychosis,1,2,11,20,Postpartum psychosis induced by bromocriptine.,3686155_0,-1,-1,-1,12933,-1,0.0011654889,0.99883455
12936,psychosis,12,13,86,95,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12936,-1,0.0009796601,0.99902034
12938,inhibition of lactation,18,21,131,154,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12938,-1,0.008082239,0.9919178
12940,psychosis,9,10,59,68,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12940,-1,0.00097424706,0.9990257
12941,Parkinson's disease,16,19,104,123,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12941,-1,0.0012932183,0.9987068
12943,psychosis,7,8,53,62,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,-1,-1,-1,12943,-1,0.00097544055,0.9990245
12944,secondary mania,4,6,36,51,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,-1,-1,12944,-1,0.0010396235,0.9989604
12946,triazolam,3,4,15,24,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12946,-1,0.9986572,0.0013427768
12947,mania,9,10,62,67,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12947,-1,0.0010368121,0.99896324
12949,organic mental disorder,2,5,12,35,Features of organic mental disorder (delirium) were not present.,3693336_2,-1,-1,-1,12949,-1,0.0012201959,0.99877983
12952,triazolam,10,11,63,72,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,-1,-1,12952,-1,0.9986249,0.0013750481
12953,triazolo,5,6,33,41,The possible contribution of the triazolo group to changes in affective status is discussed.,3693336_4,-1,-1,-1,12953,-1,0.99410856,0.005891417
12954,Hyperglycemic,0,1,0,13,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,-1,-1,12954,-1,0.0016307211,0.9983693
12958,lethargy,10,11,65,73,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12958,-1,0.00090260024,0.99909747
12961,polyphagia,17,18,110,120,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12961,-1,0.0013558954,0.99864405
12965,hyperglycemia,13,14,77,90,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,-1,-1,12965,-1,0.0010823765,0.9989177
12967,lactic acidosis,1,3,11,26,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12967,-1,0.0010218755,0.99897814
12968,ketosis,8,9,50,57,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12968,-1,0.0011032772,0.9988967
12969,lactate,13,14,80,87,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12969,-1,0.98082757,0.019172397
12970,Respiratory failure,0,2,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,-1,-1,-1,12970,-1,0.0012032302,0.9987967
12971,cyclosporine nephrotoxicity,1,3,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,-1,-1,-1,12971,-1,0.14971024,0.8502898
12973,CSA,5,6,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,-1,-1,12973,-1,0.99694115,0.0030588505
12975,CSA,4,5,31,34,Administration of 20 mg/kg/day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man.,3708922_2,-1,-1,-1,12975,-1,0.9968989,0.0031010997
12976,CSA,4,5,31,34,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12976,-1,0.99725026,0.002749674
12979,amphothericin B,23,25,143,158,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12979,-1,0.9974049,0.002595066
12981,CSA,40,41,255,258,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12981,-1,0.9937733,0.006226746
12984,CSA nephrotoxicity,8,10,46,64,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,-1,-1,-1,12984,-1,0.017684322,0.9823157
12986,CSA,6,7,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,-1,12986,-1,0.9967996,0.0032004032
12988,neuropathic damage,8,10,75,93,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,-1,-1,12988,-1,0.0010193519,0.9989806
12989,neuropathic damage,3,5,24,42,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12989,-1,0.0010968435,0.99890316
12992,Mipafox,24,25,155,162,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12992,-1,0.99814725,0.0018528213
12993,"N, N'-diisopropylphosphorodiamidofluoridate",26,29,164,207,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12993,-1,0.9880904,0.01190964
12994,neurotoxic organophosphate,32,34,212,238,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12994,-1,0.19234312,0.8076569
12995,Mipafox,19,20,116,123,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,-1,12995,-1,0.9980567,0.0019432072
12996,cervical cord damage,7,10,54,74,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,-1,-1,-1,12996,-1,0.0012938373,0.9987061
12997,contrast,1,2,3,11,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12997,-1,0.071332574,0.92866737
12998,Mipafox,5,6,24,31,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12998,-1,0.99809736,0.0019027053
12999,cord damage,43,45,199,210,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12999,-1,0.0016742815,0.99832577
13000,Mipafox,18,19,112,119,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13000,-1,0.99819857,0.0018014301
13001,neuropathic damage,22,24,141,159,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13001,-1,0.0010715694,0.99892837
13005,angioneurotic edema,5,7,35,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13005,-1,0.0009167211,0.9990833
13007,carcinoma of the,18,21,140,156,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13007,-1,0.0028177479,0.99718225
13009,impaired renal function,28,31,203,226,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13009,-1,0.0016706294,0.99832934
13010,diphenhydramine,1,2,5,20,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,-1,-1,13010,-1,0.9985341,0.0014659544
13013,disease progression,13,15,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,-1,-1,-1,13013,-1,0.0010408598,0.9989592
13016,hypertensive coronary disease,6,9,40,69,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,13016,-1,0.0011155719,0.9988844
13019,coronary artery disease,7,10,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,-1,-1,-1,13019,-1,0.001810049,0.99819
13020,essential hypertension,11,13,76,98,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13020,-1,0.00105111,0.9989489
13021,coronary artery disease,15,18,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13021,-1,0.001169352,0.9988306
13022,diuretic,26,27,188,196,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13022,-1,0.9929999,0.0070000384
13024,diuretic,37,38,252,260,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13024,-1,0.98872465,0.011275308
13025,chlorthalidone,39,40,262,276,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13025,-1,0.998585,0.0014149911
13027,chlorthalidone,11,12,74,88,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,-1,-1,-1,13027,-1,0.9988702,0.0011298277
13032,chlorthalidone,6,7,37,51,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13032,-1,0.9986947,0.0013052959
13033,ventricular ectopic beats,15,18,104,129,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13033,-1,0.002279224,0.9977208
13034,diuretic,7,8,57,65,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13034,-1,0.9972435,0.0027565002
13035,ischaemic heart disease,17,20,139,162,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13035,-1,0.0011059954,0.99889404
13037,Myasthenia gravis,0,2,0,17,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,-1,-1,13037,-1,0.0012558834,0.99874413
13041,myasthenia gravis,11,13,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,-1,-1,13041,-1,0.0008949967,0.9991049
13046,Wernicke's encephalopathy,4,7,48,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,-1,-1,13046,-1,0.0022431584,0.9977569
13048,Wernicke's encephalopathy,16,19,108,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13048,-1,0.0025931688,0.9974068
13049,tolazamide,22,23,152,162,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13049,-1,0.99862444,0.0013755391
13050,thiamine pyrophosphate,39,41,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13050,-1,0.9977034,0.0022966485
13051,TPP,42,43,274,277,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13051,-1,0.99190205,0.008097992
13053,Wernicke's encephalopathy,19,22,109,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,-1,-1,13053,-1,0.0023100597,0.99768996
13055,Wernicke's encephalopathy,16,19,94,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13055,-1,0.0025197244,0.99748033
13056,TPP,28,29,175,178,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13056,-1,0.99054295,0.009457119
13057,Wernicke's encephalopathy,14,17,122,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,-1,13057,-1,0.0027617011,0.9972383
13059,trihexyphenidyl hydrochloride,3,5,19,48,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,-1,-1,-1,13059,-1,0.9979265,0.0020734633
13061,trihexyphenidyl hydrochloride,11,13,74,103,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,-1,13061,-1,0.9980646,0.0019354379
13068,respiratory failure,7,9,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,-1,-1,13068,-1,0.001053621,0.99894637
13072,diethylnitrosamine,7,8,68,86,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,-1,-1,-1,13072,-1,0.9982766,0.0017234687
13074,PB,15,16,85,87,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13074,-1,0.99126256,0.008737468
13075,mg,18,19,92,94,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13075,-1,0.5409273,0.4590727
13077,diethylnitrosamine,33,34,183,201,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13077,-1,0.9981286,0.0018714678
13078,DEN,35,36,203,206,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13078,-1,0.9926433,0.0073567354
13079,DEN,9,10,36,39,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13079,-1,0.9908597,0.009140322
13080,DEN,13,14,52,55,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13080,-1,0.9902271,0.009772887
13081,PB,15,16,58,60,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13081,-1,0.99210817,0.007891775
13082,hepatocarcinogenesis,28,29,115,135,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13082,-1,0.0010007551,0.9989993
13083,PAS,14,15,67,70,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13083,-1,0.89723665,0.102763325
13084,preneoplastic foci,16,18,80,98,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13084,-1,0.0022605525,0.99773943
13085,PB,22,23,130,132,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13085,-1,0.9913823,0.008617752
13086,DEN,27,28,163,166,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13086,-1,0.96562964,0.034370333
13087,micronuclei,7,8,45,56,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13087,-1,0.0019098467,0.9980901
13088,DEN,14,15,104,107,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13088,-1,0.94163597,0.0583641
13089,DEN,22,23,158,161,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13089,-1,0.86803097,0.13196906
13090,PB,24,25,164,166,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13090,-1,0.98402077,0.01597922
13091,PB,11,12,54,56,"When the treatment last only 2 weeks, the presence of PB did not change significantly the last parameters.",3780814_5,-1,-1,-1,13091,-1,0.81772906,0.1822709
13092,DEN,1,2,3,6,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13092,-1,0.98828226,0.01171775
13093,PB,3,4,9,11,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13093,-1,0.9845633,0.0154367825
13095,DEN,23,24,128,131,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13095,-1,0.9907575,0.009242461
13096,PB,4,5,21,23,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13096,-1,0.9918636,0.008136391
13098,DEN,13,14,83,86,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13098,-1,0.98913735,0.010862642
13099,DEN,24,25,159,162,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13099,-1,0.98887616,0.011123828
13100,precancerous lesions,17,19,88,108,This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.,3780814_8,-1,-1,-1,13100,-1,0.001652572,0.9983474
13101,PB,14,15,95,97,Biochemical investigations are in progress to obtain more information about this 'paradoxical' PB effect.,3780814_9,-1,-1,-1,13101,-1,0.9625636,0.037436366
13102,muscular rigidity,10,12,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,-1,-1,-1,13102,-1,0.0010891643,0.9989108
13104,muscular rigidity,6,8,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,-1,-1,-1,13104,-1,0.0009826444,0.99901736
13109,h,13,14,63,64,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,-1,-1,13109,-1,0.040615298,0.9593846
13115,hyperkinetic,26,27,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13115,-1,0.0016298813,0.9983701
13116,K,28,29,158,159,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13116,-1,0.022515131,0.9774849
13126,molindone,6,7,43,52,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,-1,-1,13126,-1,0.99865854,0.0013414411
13129,signs and symptoms,2,5,13,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,-1,-1,13129,-1,0.0027031654,0.99729687
13133,acute renal failure,14,17,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13133,-1,0.00093046494,0.9990695
13134,molindone,18,19,130,139,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13134,-1,0.99863654,0.0013634423
13135,molindone,3,4,25,34,Physicians who prescribe molindone should be aware of this reaction.,3782049_4,-1,-1,-1,13135,-1,0.9984384,0.0015615909
13136,Compression neuropathy,0,2,0,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13136,-1,0.0012742863,0.9987257
13137,fibrous myopathy,9,11,70,86,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13137,-1,0.0011325933,0.9988674
13138,Fibrous myopathy,0,2,0,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,-1,-1,13138,-1,0.0011732789,0.9988267
13140,compression neuropathy,2,4,9,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,-1,-1,13140,-1,0.0012292864,0.99877065
13142,fibrous myopathy,7,9,59,75,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13142,-1,0.0013956599,0.99860436
13143,fibrous myopathy,49,51,314,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13143,-1,0.001311999,0.99868804
13144,acute renal failure,2,5,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13144,-1,0.0009871671,0.9990128
13145,amphotericin,6,7,46,58,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13145,-1,0.99849725,0.0015027054
13147,sporotrichosis,7,8,54,68,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13147,-1,0.0011922291,0.9988078
13148,acute renal failure,9,12,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13148,-1,0.0009013927,0.99909866
13149,amphotericin B,17,19,143,157,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13149,-1,0.99801934,0.001980628
13150,renal failure,4,6,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,-1,-1,13150,-1,0.0010838091,0.99891615
13152,amphotericin,3,4,16,28,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13152,-1,0.9982381,0.0017619528
13153,acute renal failure,22,25,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13153,-1,0.0009773988,0.9990226
13154,Cerebral infarction,0,2,0,19,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13154,-1,0.0011468742,0.9988531
13155,phenylpropanolamine,8,9,47,66,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13155,-1,0.99864715,0.0013529042
13156,Phenylpropanolamine,0,1,0,19,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13156,-1,0.99843174,0.0015682097
13157,PPA,2,3,21,24,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13157,-1,0.9959193,0.0040806932
13160,intracerebral hemorrhage,11,13,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13160,-1,0.0010337614,0.9989662
13161,neuropsychiatric symptoms,14,16,90,115,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13161,-1,0.00104795,0.99895203
13162,cerebral infarction,19,21,136,155,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13162,-1,0.0009668589,0.9990332
13163,cerebral infarction,11,13,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13163,-1,0.0009685506,0.9990314
13164,PPA,20,21,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13164,-1,0.9923787,0.0076212417
13165,optic neuropathy,1,3,10,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13165,-1,0.0013669617,0.99863297
13166,ethambutol,6,7,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13166,-1,0.99871147,0.0012885549
13168,ethambutol,17,18,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,-1,-1,-1,13168,-1,0.99847907,0.0015209813
13170,retrobulbar neuropathy,2,4,12,34,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13170,-1,0.0015360629,0.998464
13171,scotoma,10,11,81,88,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13171,-1,0.0009940293,0.999006
13172,Ethambutol,0,1,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,-1,-1,-1,13172,-1,0.9980392,0.0019608298
13174,optic nerve toxicity,3,6,15,35,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13174,-1,0.0012404037,0.9987596
13175,ethambutol,8,9,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13175,-1,0.9985637,0.0014362637
13176,ethambutol,9,10,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,-1,-1,-1,13176,-1,0.9985877,0.001412325
13178,meningeal leukemia,3,5,23,41,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,-1,-1,-1,13178,-1,0.0010472724,0.99895275
13181,meningeal disease,8,10,64,81,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,-1,13181,-1,0.0009924797,0.9990075
13185,Leucovorin,0,1,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,-1,13185,-1,0.998278,0.0017219366
13193,transient hemiparesis,6,8,35,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,-1,-1,13193,-1,0.0011737668,0.9988262
13196,cyclosporin A,2,4,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,13196,-1,0.99789387,0.0021061632
13198,cyclosporin A,6,8,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13198,-1,0.9972723,0.0027276208
13199,leukemia,16,17,103,111,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13199,-1,0.0009851444,0.99901485
13201,cyclosporin A,6,8,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13201,-1,0.997519,0.0024809663
13202,leukemic infiltration,14,16,109,130,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13202,-1,0.0010459073,0.99895406
13204,hyperbilirubinemia,10,11,65,83,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,13204,-1,0.0008096688,0.9991904
13206,cyclosporin A,12,14,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,-1,-1,-1,13206,-1,0.9981446,0.0018554088
13212,thrombophlebitis,2,3,19,35,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,-1,-1,13212,-1,0.0008827397,0.9991173
13217,Thrombophlebitis,0,1,0,16,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,-1,-1,13217,-1,0.00083752116,0.99916244
13230,P,16,17,108,109,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,-1,-1,13230,-1,0.12305477,0.8769452
13232,contrast,1,2,3,11,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13232,-1,0.17088392,0.82911605
13233,P,14,15,92,93,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13233,-1,0.21433263,0.78566736
13235,P,25,26,120,121,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,-1,13235,-1,0.1628389,0.8371611
13236,contrast,1,2,3,11,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,-1,13236,-1,0.17865975,0.8213402
13239,angina,6,7,32,38,Report of a case of spontaneous angina.,3952818_1,-1,-1,-1,13239,-1,0.0012442963,0.9987557
13240,colon carcinoma,8,10,35,50,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13240,-1,0.0014936101,0.99850637
13241,liver metastasis,11,13,55,71,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13241,-1,0.0013235443,0.9986765
13242,chest pain,15,17,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13242,-1,0.0013392905,0.9986607
13244,5-FU,20,21,119,123,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13244,-1,0.9974618,0.0025381758
13245,Prinzmetal's angina,9,12,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13245,-1,0.11289104,0.887109
13246,chest pain,14,16,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13246,-1,0.0014785258,0.9985215
13250,5-FU,14,15,81,85,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13250,-1,0.99747074,0.002529345
13252,5-FU cardiotoxicity,30,32,171,190,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13252,-1,0.24066436,0.75933564
13254,delayed neuropathy,10,12,98,116,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,-1,-1,-1,13254,-1,0.0011810118,0.99881893
13255,Tri-ortho-tolyl phosphate,0,2,0,25,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13255,-1,0.99548763,0.004512358
13256,TOTP,3,4,27,31,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13256,-1,0.9951508,0.0048491633
13257,"0,0'-diisopropyl phosphorofluoridate",12,14,53,89,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13257,-1,0.9916658,0.008334186
13258,DFP,15,16,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13258,-1,0.99534553,0.0046544913
13263,TOTP,35,36,213,217,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13263,-1,0.99538356,0.004616421
13264,DFP,37,38,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13264,-1,0.9962022,0.0037978783
13266,TOTP,6,7,43,47,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13266,-1,0.9933175,0.006682499
13267,DFP,8,9,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13267,-1,0.99474454,0.00525547
13268,organophosphorous compounds,21,23,115,142,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13268,-1,0.25640956,0.7435905
13270,TOTP,6,7,46,50,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13270,-1,0.9941012,0.005898764
13271,DFP,8,9,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13271,-1,0.9957288,0.0042712023
13272,Degenerating myelinated fibers,0,3,0,30,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13272,-1,0.0018499275,0.9981501
13273,TOTP,16,17,109,113,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13273,-1,0.98548603,0.014513929
13274,DFP,18,19,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13274,-1,0.9871869,0.012813093
13278,cardiac tachyarrhythmias,11,13,77,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,-1,-1,-1,13278,-1,0.0008882813,0.9991117
13280,cholestatic hepatitis,3,5,15,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,-1,-1,13280,-1,0.0008985791,0.9991014
13286,steatosis,16,17,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13286,-1,0.0010405862,0.9989594
13287,alcoholic hepatitis,20,22,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13287,-1,0.0012132556,0.99878675
13288,cholestatic hepatitis,23,25,155,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13288,-1,0.0014431729,0.9985568
13289,cirrhosis of the liver,27,31,194,216,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13289,-1,0.002112742,0.9978873
13291,cholestatic injury,8,10,51,69,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,-1,-1,13291,-1,0.0010642903,0.99893576
13294,fat,6,7,48,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13294,-1,0.9881152,0.011884773
13295,prostate carcinogenesis,8,10,55,78,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13295,-1,0.0013447785,0.9986552
13296,prostate adenocarcinomas,19,21,87,111,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,-1,-1,-1,13296,-1,0.0017496161,0.9982503
13301,corn oil,18,20,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13301,-1,0.9905325,0.0094674425
13302,fat,24,25,139,142,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13302,-1,0.7905802,0.20941973
13304,SD,4,5,24,26,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,-1,-1,13304,-1,0.025998306,0.9740017
13306,SD,1,2,13,15,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13306,-1,0.0063808314,0.99361914
13308,prostatitis,12,13,81,92,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13308,-1,0.0009825283,0.9990175
13310,neoplasms,2,3,13,22,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,-1,-1,13310,-1,0.0011681597,0.9988318
13314,chlorambucil,7,8,49,61,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13314,-1,0.99882656,0.001173379
13315,alkylating agents,9,11,63,80,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13315,-1,0.9266604,0.07333959
13317,purine,15,16,97,103,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13317,-1,0.9979594,0.002040682
13319,folic acid,22,24,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13319,-1,0.9980763,0.0019236157
13320,synovitis,10,11,67,76,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,-1,-1,-1,13320,-1,0.0011082604,0.9988918
13321,alkylating agents,3,5,22,39,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13321,-1,0.99618715,0.0038128998
13322,acute nonlymphocytic leukemia,12,15,81,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13322,-1,0.0010315498,0.9989685
13323,alkylating agents,18,20,121,138,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13323,-1,0.99685365,0.003146368
13325,lymphoma,30,31,209,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13325,-1,0.001033591,0.99896646
13334,alkylating agents,30,32,194,211,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13334,-1,0.99317837,0.0068216673
13336,disease,47,48,310,317,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13336,-1,0.001179439,0.9988205
13337,hypaque 76.Sequential,8,10,47,68,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13337,-1,0.7076307,0.29236937
13338,hypaque 76,34,36,208,218,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13338,-1,0.97674745,0.023252508
13339,QTC prolongation,1,3,12,28,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13339,-1,0.0017213286,0.99827874
13341,elevation of,16,18,109,121,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13341,-1,0.0044402694,0.9955597
13342,output,19,20,130,136,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13342,-1,0.0016284016,0.99837166
13344,femoral nerve palsy,5,8,54,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,-1,-1,13344,-1,0.0017754448,0.99822456
13346,muscle tear,16,18,91,102,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13346,-1,0.0021036975,0.9978963
13348,flexure contracture,24,26,139,158,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13348,-1,0.0017617454,0.9982382
13350,femoral nerve entrapment,7,10,56,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13350,-1,0.002592032,0.997408
13351,femoral nerve palsy,14,17,97,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13351,-1,0.002499356,0.9975006
13352,partial loss of quadriceps functions,18,23,121,157,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13352,-1,0.0042180554,0.995782
13353,femoral nerve palsy,1,4,22,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13353,-1,0.0015059952,0.998494
13356,motor and sensory impairment,28,32,195,223,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13356,-1,0.0016676331,0.99833244
13357,flexure contracture,34,36,229,248,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13357,-1,0.0016189113,0.99838114
13358,Pneumonitis,0,1,0,11,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13358,-1,0.00091116194,0.9990889
13359,pericardial effusion,4,6,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13359,-1,0.0013988562,0.99860114
13362,sinuatrial disease,3,5,15,33,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13362,-1,0.002438594,0.99756145
13364,mg,16,17,105,107,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13364,-1,0.95711136,0.04288866
13365,mg,21,22,130,132,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13365,-1,0.9409117,0.05908825
13366,supraventricular tachyarrhythmias,31,33,170,203,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13366,-1,0.001386124,0.99861383
13367,pneumonitis,2,3,13,24,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13367,-1,0.0010044556,0.9989956
13368,pericardial effusions,6,8,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13368,-1,0.0019233009,0.9980767
13369,proximal motor neuropathy,12,15,81,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13369,-1,0.0014418146,0.9985582
13372,amiodarone pneumonitis,14,16,87,109,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,-1,-1,-1,13372,-1,0.44358635,0.55641365
13375,sinoatrial block,1,3,19,35,Amiodarone-induced sinoatrial block.,4008111_0,-1,-1,-1,13375,-1,0.006683724,0.99331635
13376,sinoatrial block,2,4,12,28,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13376,-1,0.0026117594,0.9973883
13378,primary cardiomyopathy,14,16,95,117,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13378,-1,0.0011843735,0.99881566
13379,supraventricular tachycardia,20,22,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13379,-1,0.0013915497,0.9986085
13381,sinoatrial block,12,14,75,91,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,-1,-1,13381,-1,0.0036230518,0.99637693
13388,bupivacaine hydrochloride,12,14,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13388,-1,0.9982449,0.0017550938
13389,mepivacaine hydrochloride,17,19,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13389,-1,0.9983234,0.0016766102
13390,lidocaine hydrochloride,23,25,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13390,-1,0.997612,0.002388034
13392,Muscle degeneration,0,2,0,19,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,-1,-1,-1,13392,-1,0.001541913,0.99845815
13393,muscle damage,3,5,15,28,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13393,-1,0.0015047804,0.9984952
13394,mepivacaine,19,20,108,119,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13394,-1,0.9988778,0.001122205
13397,diplopia,12,13,67,75,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13397,-1,0.00092140475,0.99907863
13398,Gentamicin nephropathy,0,2,0,22,Gentamicin nephropathy in a neonate.,4069770_0,-1,-1,-1,13398,-1,0.1896404,0.81035966
13399,acute renal failure,12,15,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,-1,-1,-1,13399,-1,0.0009131269,0.99908686
13404,PAS,5,6,31,34,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,-1,13404,-1,0.9807078,0.019292193
13406,renal insufficiency,1,3,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,-1,-1,13406,-1,0.00092059554,0.99907935
13407,renal failure,8,10,42,55,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13407,-1,0.00093299506,0.999067
13411,cor pulmonale,21,23,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13411,-1,0.001294394,0.9987056
13414,oliguria,22,23,152,160,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,-1,13414,-1,0.00084253756,0.9991574
13416,acute renal failure,12,15,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,-1,13416,-1,0.0009666654,0.99903333
13418,tumours,7,8,46,53,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,-1,-1,-1,13418,-1,0.0014084198,0.9985916
13420,Papillomas,0,1,0,10,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13420,-1,0.0012129425,0.9987871
13421,bladder carcinomas,18,20,122,140,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13421,-1,0.0015205743,0.9984794
13422,bladder tumours,5,7,31,46,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,-1,-1,-1,13422,-1,0.001195618,0.99880433
13423,hyperplasia,10,11,62,73,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13423,-1,0.0013142889,0.99868566
13424,bladder calculi,24,26,147,162,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13424,-1,0.0013586851,0.9986413
13425,tumours,4,5,15,22,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,-1,-1,-1,13425,-1,0.0016564218,0.9983436
13427,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,-1,13427,-1,0.0021903382,0.9978097
13433,tender hepatomegaly,2,4,14,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13433,-1,0.0013903256,0.99860966
13434,malaise,10,11,67,74,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13434,-1,0.0010606524,0.99893934
13435,anorexia,12,13,76,84,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13435,-1,0.0009709649,0.99902904
13436,nausea and vomiting,14,17,86,105,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13436,-1,0.0012754174,0.9987245
13437,upper abdominal pain,21,24,127,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13437,-1,0.0012032052,0.9987968
13438,hepatocellular necrosis,5,7,43,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13438,-1,0.0010062102,0.9989938
13440,fatty change,22,24,167,179,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13440,-1,0.0022718722,0.99772817
13441,hepatocellular necrosis,26,28,190,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13441,-1,0.0012360235,0.99876404
13442,massive hepatic necrosis,29,32,217,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13442,-1,0.0015916002,0.9984084
13443,acute hepatitis,6,8,40,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13443,-1,0.00094907876,0.9990509
13444,chronic active hepatitis,9,12,59,83,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13444,-1,0.0011160239,0.998884
13446,hepatic failure,7,9,38,53,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,-1,-1,-1,13446,-1,0.0010270596,0.998973
13448,fulminant hepatitis,7,9,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,-1,13448,-1,0.00096815266,0.9990319
13451,hepatic dysfunction,16,18,88,107,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,-1,-1,13451,-1,0.0008724599,0.99912757
13453,Transient hemiparesis,0,2,0,21,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13453,-1,0.0010154552,0.9989845
13454,diphenylhydantoin toxicity,7,9,47,73,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13454,-1,0.63890946,0.36109048
13455,diphenylhydantoin,6,7,33,50,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13455,-1,0.9980019,0.0019981214
13456,DPH,8,9,52,55,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13456,-1,0.97858274,0.021417243
13458,cerebellar dysfunction,21,23,131,153,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13458,-1,0.0011201309,0.99887985
13459,hemiparesis,7,8,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13459,-1,0.00075989874,0.99924016
13460,DPH overdose,10,12,71,83,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13460,-1,0.02039422,0.97960573
13461,DPH,5,6,30,33,Both had brain surgery before DPH treatment.,430165_5,-1,-1,-1,13461,-1,0.99314404,0.006855968
13462,cerebral damage,7,9,38,53,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13462,-1,0.0011748374,0.99882513
13463,DPH toxicity,13,15,77,89,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13463,-1,0.011541861,0.9884581
13465,fasciculations,5,6,41,55,Suxamethonium infusion rate and observed fasciculations.,435349_0,-1,-1,-1,13465,-1,0.0015652456,0.9984347
13466,Suxamethonium chloride,0,2,0,22,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13466,-1,0.9980762,0.0019237631
13467,Sch,3,4,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13467,-1,0.9924899,0.0075100623
13468,mg,18,19,88,90,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13468,-1,0.8202025,0.17979749
13469,mg,22,23,101,103,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13469,-1,0.725566,0.27443394
13470,tetanic,12,13,76,83,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13470,-1,0.002404249,0.9975957
13471,Sch,20,21,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13471,-1,0.96944517,0.030554848
13472,mg,22,23,131,133,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13472,-1,0.64559567,0.35440433
13473,Fasciculations,0,1,0,14,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,-1,-1,13473,-1,0.0017921228,0.9982079
13476,twitch,6,7,34,40,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13476,-1,0.001635427,0.9983646
13477,tetanus,9,10,57,64,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13477,-1,0.0017163539,0.9982836
13478,Fasciculations,0,1,0,14,Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion.,435349_8,-1,-1,-1,13478,-1,0.0020191253,0.9979809
13481,Tiapride,0,1,0,8,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13481,-1,0.9984205,0.0015795438
13482,involuntary movements,3,5,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13482,-1,0.0011298191,0.9988702
13483,Tiapride,0,1,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13483,-1,0.99864894,0.001351108
13484,benzamide,4,5,24,33,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13484,-1,0.9985128,0.0014871873
13486,involuntary movements,15,17,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13486,-1,0.0012400091,0.99876
13487,idiopathic Parkinson's disease,21,25,157,187,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13487,-1,0.0015399321,0.99846005
13488,disability,6,7,37,47,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13488,-1,0.0009933179,0.9990067
13490,akinesia,13,14,98,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13490,-1,0.0008941205,0.9991059
13491,Tiapride,0,1,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,-1,13491,-1,0.99866843,0.0013315565
13503,Quinidine hepatitis,0,2,0,19,Quinidine hepatitis.,48362_0,-1,-1,-1,13503,-1,0.62956107,0.37043887
13504,quinidine,3,4,28,37,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13504,-1,0.9985067,0.0014932004
13505,lactic acid,15,17,112,123,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13505,-1,0.89181554,0.108184494
13506,alkaline phosphatase,20,22,143,163,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13506,-1,0.6989943,0.3010057
13507,active hepatitis,3,5,20,36,Liver biopsy showed active hepatitis.,48362_2,-1,-1,-1,13507,-1,0.0014516485,0.9985483
13508,quinidine,2,3,18,27,Discontinuance of quinidine therapy led to normalization of liver function tests.,48362_3,-1,-1,-1,13508,-1,0.9985771,0.0014228495
13509,quinidine,4,5,20,29,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13509,-1,0.99835914,0.0016408039
13510,alkaline phosphatase,14,16,85,105,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13510,-1,0.6690607,0.33093935
13511,lactic acid,18,20,111,122,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13511,-1,0.93720573,0.062794276
13512,quinidine hepatotoxicity,6,8,35,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,-1,-1,13512,-1,0.285354,0.71464604
13513,hepatic toxicity,12,14,73,89,"This report also suggests that, even after long-term administration, the hepatic toxicity is reversible.",48362_6,-1,-1,-1,13513,-1,0.0011673421,0.99883264
13514,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,-1,-1,-1,13514,-1,0.001272992,0.998727
13516,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13516,-1,0.001080921,0.9989191
13517,adenocarcinoma,16,17,103,117,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13517,-1,0.0015469977,0.998453
13519,Angiosarcoma,0,1,0,12,Angiosarcoma was also present within pulmonary and renal arteries.,567256_2,-1,-1,-1,13519,-1,0.0010424197,0.9989575
13520,intraarterial lesions,4,6,25,46,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,-1,-1,13520,-1,0.003730116,0.9962698
13522,thromboembolism,1,2,9,24,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,-1,13522,-1,0.00084373215,0.99915624
13525,thromboembolism,1,2,9,24,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,-1,-1,-1,13525,-1,0.0009742968,0.9990257
13527,arterial occlusion,5,7,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13527,-1,0.0014480163,0.998552
13529,distal ischemia,11,13,83,98,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13529,-1,0.0013642918,0.9986357
13532,ischemic,16,17,117,125,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13532,-1,0.0030453207,0.9969547
13534,thromboembolism,4,5,27,42,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,-1,-1,13534,-1,0.00079971814,0.9992003
13538,sodium warfarin,11,13,87,102,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,-1,-1,-1,13538,-1,0.9975011,0.0024988996
13539,Galanthamine hydrobromide,0,2,0,25,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13539,-1,0.99732935,0.0026706478
13541,(Hyoscine).Galanthamine,18,19,123,146,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13541,-1,0.9899985,0.010001458
13542,(Hyoscine).Galanthamine hydrobromide,18,20,123,159,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13542,-1,0.98823243,0.011767609
13544,hyoscine,42,43,304,312,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13544,-1,0.99777704,0.0022228917
13545,overdosage,44,45,314,324,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13545,-1,0.0028179998,0.997182
13546,physostigmine,5,6,25,38,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,-1,-1,13546,-1,0.998374,0.0016259745
13548,flunitrazepam,2,3,18,31,administration of flunitrazepam in volunteers.,6103707_1,-1,-1,-1,13548,-1,0.99780697,0.002193025
13549,Flunitrazepam,0,1,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13549,-1,0.997741,0.0022590605
13550,mg,6,7,30,32,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13550,-1,0.9108774,0.08912264
13551,mg,13,14,71,73,"The most striking effect was sedation which increased with the dose, 2 mg producing deep sleep although the subjects could still be aroused.",6103707_5,-1,-1,-1,13551,-1,0.8864953,0.11350466
13554,flunitrazepam,2,3,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,-1,-1,-1,13554,-1,0.9978531,0.0021469155
13555,h,10,11,61,62,The drug was still present in measurable quantities after 24 h even with the smallest dose.,6103707_11,-1,-1,-1,13555,-1,0.032877684,0.9671223
13556,GYKI-41 099,2,4,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13556,-1,0.98773193,0.012268005
13557,chlorpropanol,5,6,29,42,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13557,-1,0.99816835,0.0018316427
13558,Tobanum,7,8,44,51,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13558,-1,0.99696094,0.0030390832
13559,GYKI-41 099,2,4,13,24,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,-1,13559,-1,0.9881435,0.011856507
13562,pindolol,8,9,67,75,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13562,-1,0.99844164,0.0015584197
13563,ouabain arrhythmia,11,13,91,109,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13563,-1,0.5781634,0.42183667
13564,GYKI-41 900,0,2,0,11,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,-1,-1,-1,13564,-1,0.96459097,0.03540899
13565,14C-41 099,12,14,78,88,There was a prolonged elimination of the radioactivity after the injection of 14C-41 099 to rats and dogs.,6111982_5,-1,-1,-1,13565,-1,0.9819755,0.01802452
13566,bendrofluazide,3,4,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,-1,-1,13566,-1,0.9985903,0.0014096979
13571,bendrofluazide,21,22,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,-1,13571,-1,0.9986028,0.0013971679
13573,bendrofluazide,6,7,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13573,-1,0.99868864,0.0013114187
13574,impotence,9,10,69,78,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13574,-1,0.0011067495,0.9988933
13575,impotence,12,13,84,93,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13575,-1,0.0011462005,0.9988538
13577,impaired glucose tolerance,9,12,71,97,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13577,-1,0.0020175674,0.9979824
13578,gout,17,18,119,123,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13578,-1,0.0009964777,0.9990036
13579,bendrofluazide,23,24,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13579,-1,0.9986268,0.0013731838
13580,Raynaud's phenomenon,27,30,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13580,-1,0.003546633,0.9964534
13581,dyspnoea,31,32,203,211,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13581,-1,0.0008694743,0.99913055
13583,corneal disease,1,3,3,18,No corneal disease is known to have occurred in the propranolol group.,6115999_7,-1,-1,-1,13583,-1,0.0012847425,0.9987153
13587,uric acid,9,11,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13587,-1,0.987503,0.01249693
13588,bendrofluazide,19,20,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13588,-1,0.9985368,0.0014631246
13591,uric acid,8,10,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,-1,-1,-1,13591,-1,0.994759,0.005240972
13594,baclofen,5,6,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,-1,-1,13594,-1,0.99861836,0.0013816252
13596,muscimol,5,6,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,-1,-1,13596,-1,0.99813193,0.0018681278
13600,muscimol,29,30,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,-1,-1,-1,13600,-1,0.9979929,0.0020071666
13602,MK-212,12,13,55,61,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13602,-1,0.9981761,0.0018239043
13603,muscimol,21,22,114,122,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13603,-1,0.9986778,0.0013222321
13605,clonazepam,4,5,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,-1,-1,13605,-1,0.99845195,0.0015479908
13608,muscimol,15,16,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,-1,-1,-1,13608,-1,0.9985489,0.001450997
13609,5-HTP,4,5,26,31,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,-1,13609,-1,0.9956542,0.0043457597
13613,MK-212,8,9,50,56,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,-1,-1,-1,13613,-1,0.99804795,0.0019520293
13615,ischaemic heart disease,3,6,20,43,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13615,-1,0.0009184089,0.9990816
13616,cardiac failure,8,10,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13616,-1,0.0007887652,0.9992112
13621,teratogenicity,1,2,9,23,Possible teratogenicity of sulphasalazine.,6133211_0,-1,-1,-1,13621,-1,0.0014708708,0.9985291
13623,inflammatory bowel disease,8,11,40,66,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13623,-1,0.0011050438,0.998895
13625,congenital anomalies,24,26,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13625,-1,0.0011196261,0.9988803
13626,ulcerative colitis,8,10,43,61,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13626,-1,0.0011866575,0.9988134
13627,coarctation of the aorta,19,23,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13627,-1,0.0021448438,0.9978551
13628,ventricular septal defect,25,28,122,147,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13628,-1,0.0032593159,0.99674064
13629,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,-1,-1,13629,-1,0.0015402752,0.9984597
13630,Potter's facies,11,14,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13630,-1,0.007312838,0.9926872
13631,hypoplastic lungs,15,17,63,80,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13631,-1,0.0025175775,0.9974825
13632,absent kidneys and ureters,18,22,82,108,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13632,-1,0.0032957552,0.9967043
13633,talipes equinovarus,24,26,114,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13633,-1,0.0027523823,0.99724764
13635,teratogenic,13,14,76,87,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,-1,-1,-1,13635,-1,0.0020372113,0.99796283
13640,systemic mastocytosis,9,11,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,-1,-1,13640,-1,0.0012991342,0.99870086
13647,impotence,9,10,55,64,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,-1,-1,-1,13647,-1,0.0010379268,0.99896204
13653,hematologic toxicity,36,38,165,185,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13653,-1,0.0012085411,0.9987915
13654,gastrin,42,43,210,217,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13654,-1,0.9861551,0.013844951
13670,epileptic foci,16,18,77,91,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,-1,-1,-1,13670,-1,0.0011662308,0.99883384
13672,renal failure,3,5,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13672,-1,0.0009568936,0.99904305
13675,renal insufficiency,10,12,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13675,-1,0.0011043672,0.99889565
13676,microangiopathic hemolytic anemia,13,16,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13676,-1,0.0009680967,0.9990319
13679,bleomycin,26,27,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13679,-1,0.9981865,0.0018134535
13680,vinca alkaloid,30,32,219,233,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13680,-1,0.99292105,0.0070789857
13681,thrombotic thrombocytopenic purpura,3,6,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,-1,-1,13681,-1,0.0010390488,0.998961
13682,intravascular coagulation,9,11,62,87,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,-1,-1,-1,13682,-1,0.0013739766,0.998626
13685,renal failure,24,26,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13685,-1,0.0009198687,0.99908006
13686,cisplatin nephrotoxicity,30,32,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13686,-1,0.043606248,0.9563938
13693,ISO,19,20,137,140,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13693,-1,0.9958085,0.0041914806
13694,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13694,-1,0.08542436,0.9145757
13695,hydroxyproline,20,21,93,107,"A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.",6203632_2,-1,-1,-1,13695,-1,0.9969175,0.0030824756
13696,h,9,10,50,51,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,-1,13696,-1,0.0794379,0.9205621
13697,hydroxyproline,4,5,21,35,The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.,6203632_6,-1,-1,-1,13697,-1,0.99592376,0.0040763007
13698,hypertrophic growth,16,18,75,94,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,-1,13698,-1,0.0013807642,0.9986192
13700,P,12,13,73,74,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,-1,13700,-1,0.18512508,0.81487495
13701,ISO,8,9,50,53,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13701,-1,0.3956954,0.6043047
13702,hypertrophic,12,13,69,81,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13702,-1,0.001702566,0.9982974
13704,hyperplasia,21,22,119,130,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,-1,-1,13704,-1,0.0016005567,0.99839944
13708,myocardial infarction,26,28,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,-1,13708,-1,0.0009492623,0.9990507
13714,gastrointestinal problems,8,10,60,85,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,-1,-1,13714,-1,0.0010265544,0.9989735
13718,Skin rashes,0,2,0,11,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13718,-1,0.0012308928,0.9987691
13720,systemic lupus erythematosus,5,8,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13720,-1,0.0010650307,0.9989349
13721,polymyositis,9,10,56,68,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13721,-1,0.001125438,0.9988746
13722,myasthenia gravis,11,13,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13722,-1,0.0011722394,0.99882776
13725,skin lesion,1,3,4,15,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13725,-1,0.0016533069,0.9983467
13726,elastosis perforans serpiginosa,4,7,26,57,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13726,-1,0.0026250393,0.997375
13727,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13727,-1,0.0014136132,0.9985864
13731,myocardial infarction,9,11,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,-1,-1,-1,13731,-1,0.0009609035,0.9990392
13733,myocardial infarction,10,12,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,-1,13733,-1,0.0009710296,0.9990289
13735,contrast,15,16,100,108,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,-1,13735,-1,0.04886835,0.95113164
13737,cardiomegaly,3,4,17,29,"In patients with cardiomegaly, the increase in heart size was similar in both groups.",6229975_6,-1,-1,-1,13737,-1,0.0008267956,0.9991732
13739,hypercalcaemia,4,5,18,32,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13739,-1,0.00083278975,0.9991672
13742,carbon-ate-sodium bicarbonate,22,24,147,176,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13742,-1,0.9952029,0.0047970903
13743,Vitamin D3 toxicity,0,3,0,19,Vitamin D3 toxicity in dairy cows.,6286738_0,-1,-1,-1,13743,-1,0.61960477,0.3803952
13744,vitamin D3,4,6,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13744,-1,0.997288,0.002711994
13745,vitamin D3,14,16,60,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13745,-1,0.9967257,0.003274313
13747,hyperphosphatemia,23,24,118,135,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13747,-1,0.0009797137,0.99902034
13748,vitamin D3,29,31,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13748,-1,0.9969747,0.003025248
13750,vitamin D3,11,13,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,-1,13750,-1,0.9976635,0.0023365295
13751,vitamin D3,6,8,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,-1,13751,-1,0.9976782,0.0023218123
13754,vitamin D3 toxicity,2,5,9,28,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13754,-1,0.5214374,0.4785626
13755,vitamin D3 toxicity,22,25,139,158,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13755,-1,0.523128,0.476872
13758,vitamin D3,6,8,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13758,-1,0.99817264,0.0018273757
13759,vitamin D3,21,23,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13759,-1,0.9980065,0.0019935302
13762,vitamin D3,37,39,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13762,-1,0.9981552,0.0018448507
13764,Diseases of peripheral nerves,0,4,0,29,Diseases of peripheral nerves as seen in the Nigerian African.,6287825_0,-1,-1,-1,13764,-1,0.0027309253,0.9972691
13765,peripheral nerve disease,6,9,45,69,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,-1,-1,-1,13765,-1,0.0018821786,0.9981178
13767,motor neuropathy,20,22,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,-1,-1,13767,-1,0.0010267401,0.99897325
13769,nutritional deficiency,4,6,29,51,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13769,-1,0.0045952206,0.99540484
13770,thiamine,7,8,55,63,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13770,-1,0.99844295,0.0015570215
13771,riboflavin,9,10,68,78,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13771,-1,0.9986393,0.0013607505
13773,Diabetes mellitus,0,2,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,-1,-1,13773,-1,0.0011271064,0.9988728
13778,cranial neuropathy,11,13,44,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,-1,-1,13778,-1,0.0010044192,0.9989956
13781,connective tissue disorders,2,5,19,46,Heredofamilial and connective tissue disorders were rare.,6287825_10,-1,-1,-1,13781,-1,0.0016442317,0.9983557
13782,neuropathies,13,14,81,93,Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed.,6287825_11,-1,-1,-1,13782,-1,0.001238451,0.99876153
13783,Doxorubicin cardiomyopathy,0,2,0,26,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13783,-1,0.099705726,0.90029424
13784,Wilms tumor,6,8,55,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13784,-1,0.0016717878,0.99832827
13785,Wilms tumor,3,5,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13785,-1,0.0011243032,0.9988757
13786,anthracycline cardiomyopathy,11,13,68,96,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13786,-1,0.28207636,0.7179237
13790,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,-1,13790,-1,0.002694788,0.99730515
13793,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,-1,13793,-1,0.0015849672,0.998415
13800,DA,15,16,100,102,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13800,-1,0.9970931,0.0029069174
13801,DOPAC,17,18,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13801,-1,0.99764425,0.0023557644
13803,caffeine toxicity,2,4,13,30,Reduction in caffeine toxicity by acetaminophen.,6308277_0,-1,-1,-1,13803,-1,0.23256756,0.7674325
13805,sodium acetylsalicylate,12,14,89,112,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,-1,-1,-1,13805,-1,0.99812716,0.0018728606
13809,salicylates,1,2,8,19,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,-1,-1,-1,13809,-1,0.9972875,0.0027124612
13826,pentylenetetrezol,30,31,161,178,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,-1,13826,-1,0.9986045,0.0013955015
13829,ATP,16,17,103,106,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,-1,-1,-1,13829,-1,0.9954839,0.004516151
13832,Naloxazone,0,1,0,10,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,-1,13832,-1,0.9986779,0.0013220866
13835,naloxazone,18,19,121,131,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,-1,13835,-1,0.99855715,0.0014428921
13836,naloxazone,2,3,18,28,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13836,-1,0.9984687,0.0015313043
13837,morphine analgesia,5,7,51,69,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13837,-1,0.29867744,0.70132256
13840,naloxazone,2,3,10,20,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13840,-1,0.9983486,0.001651475
13842,respiratory depression,9,11,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13842,-1,0.0011221204,0.9988778
13847,NH4Ac,5,6,36,41,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13847,-1,0.99659085,0.0034091969
13848,incoordination,28,29,172,186,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13848,-1,0.0010870033,0.99891305
13850,NH4Ac,33,34,204,209,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13850,-1,0.9966794,0.0033205776
13855,mM NH4Ac,21,23,140,148,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13855,-1,0.99115014,0.008849915
13856,mM NH4Ac,35,37,222,230,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13856,-1,0.9903646,0.00963544
13860,acetaldehyde,16,17,117,129,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13860,-1,0.9973545,0.0026454518
13861,NH4Ac,21,22,149,154,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13861,-1,0.99621755,0.0037824954
13862,ammonia,4,5,29,36,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13862,-1,0.9974496,0.0025504201
13864,NH4Ac,5,6,28,33,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,-1,-1,-1,13864,-1,0.9959657,0.0040342766
13868,NH4Ac,9,10,35,40,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13868,-1,0.99804175,0.0019581767
13870,muscular incoordination,16,18,104,127,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13870,-1,0.0012300103,0.99876994
13872,NH4Ac,28,29,206,211,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13872,-1,0.9980444,0.0019556112
13873,metrazol,34,35,246,254,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13873,-1,0.9987685,0.0012314199
13876,central nervous system depressants,16,20,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,-1,13876,-1,0.027596617,0.9724034
13880,dystonic,17,18,108,116,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,-1,13880,-1,0.0014178603,0.9985821
13882,thalamic lesions,5,7,43,59,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,-1,-1,13882,-1,0.0015120152,0.99848795
13884,dothiepin hydrochloride,9,11,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13884,-1,0.99832124,0.0016788002
13885,major depressive disorder,15,18,95,120,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13885,-1,0.0011603179,0.9988397
13886,dothiepin,8,9,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,-1,13886,-1,0.99848515,0.0015148773
13889,Dothiepin,0,1,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13889,-1,0.9981766,0.0018234748
13891,depressive illness,11,13,82,100,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13891,-1,0.0008980583,0.999102
13892,blurred vision,12,14,72,86,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13892,-1,0.0016453704,0.9983546
13894,drowsiness,19,20,103,113,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13894,-1,0.0011051829,0.9988949
13895,dothiepin,24,25,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13895,-1,0.99832135,0.0016785652
13897,Dothiepin,0,1,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,-1,-1,-1,13897,-1,0.9977646,0.0022354259
13898,Dothiepin,0,1,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,-1,-1,13898,-1,0.99843615,0.0015638527
13904,panic disorder,9,11,64,78,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,-1,-1,-1,13904,-1,0.0009567118,0.9990433
13907,mg,12,13,57,59,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13907,-1,0.96844965,0.031550404
13909,mg,31,32,139,141,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13909,-1,0.9638591,0.036140956
13910,panic disorders,49,51,233,248,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13910,-1,0.0012911439,0.99870884
13912,impaired immediate free recall,2,6,11,41,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,-1,-1,-1,13912,-1,0.0059483107,0.99405164
13915,Delayed free recall,0,3,0,19,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13915,-1,0.005449397,0.99455065
13916,impaired,5,6,29,37,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13916,-1,0.0025904889,0.9974095
13921,h,11,12,48,49,"After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance.",6387529_5,-1,-1,-1,13921,-1,0.18401965,0.8159803
13922,behavioral impairment,8,10,53,74,Accumulation of drugs was not reflected in prolonged behavioral impairment.,6387529_7,-1,-1,-1,13922,-1,0.001137799,0.99886227
13923,urothelial toxicity,3,5,32,51,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13923,-1,0.0010115602,0.99898845
13924,sodium 2-mercaptoethane sulphonate,9,12,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13924,-1,0.99770135,0.002298673
13926,lung cancer,19,21,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13926,-1,0.0010342124,0.99896574
13927,thiol,8,9,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13927,-1,0.9880695,0.011930492
13928,sodium 2-mercaptoethane sulphonate,10,13,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13928,-1,0.99724066,0.0027593644
13930,urothelial toxicity,17,19,118,137,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13930,-1,0.0011183956,0.99888164
13932,lung cancer,35,37,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13932,-1,0.0010559976,0.998944
13934,haematuria,17,18,99,109,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13934,-1,0.000912635,0.99908733
13935,haematuria,23,24,135,145,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13935,-1,0.00089068833,0.9991093
13937,haematuria,24,25,121,131,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13937,-1,0.0009098111,0.9990902
13938,bladder irritation,28,30,151,169,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13938,-1,0.0011207061,0.99887925
13940,pollakisuria,33,34,184,196,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13940,-1,0.002005849,0.9979942
13945,absence seizures,5,7,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,-1,-1,13945,-1,0.0014134767,0.99858654
13954,ceroid lipofuscinosis,12,14,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,-1,-1,13954,-1,0.009513862,0.9904861
13955,prostaglandin,2,3,10,23,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,-1,-1,-1,13955,-1,0.992638,0.007362047
13958,PGs,7,8,51,54,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13958,-1,0.94898874,0.051011227
13960,PG,17,18,97,99,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13960,-1,0.9814409,0.018559137
13962,flurothyl,24,25,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13962,-1,0.99872714,0.0012728804
13964,pentetrazol,28,29,171,182,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13964,-1,0.9986663,0.0013337752
13965,PTZ,30,31,184,187,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13965,-1,0.9963665,0.003633488
13969,mefenamic acid,4,6,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13969,-1,0.99838233,0.0016177109
13970,meclofenamic acid,10,12,50,67,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13970,-1,0.99867874,0.0013212475
13971,flurothyl,17,18,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13971,-1,0.99818975,0.0018102524
13972,PTZ,19,20,123,126,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13972,-1,0.8928672,0.10713282
13975,PGs,4,5,27,30,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,-1,13975,-1,0.9094475,0.09055249
13978,ammonia,4,5,23,30,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,13978,-1,0.0065482357,0.9934517
13979,valproic acid,11,13,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,13979,-1,0.9986241,0.0013758956
13980,Valproic acid,0,2,0,13,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,13980,-1,0.9983885,0.0016115301
13981,VPA,3,4,15,18,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,13981,-1,0.9970897,0.0029103428
13983,VPA,5,6,31,34,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,-1,-1,-1,13983,-1,0.99750525,0.0024948083
13984,Ammonia,0,1,0,7,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13984,-1,0.9806793,0.019320702
13985,NH3,2,3,9,12,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13985,-1,0.933994,0.06600602
13986,drowsiness,16,17,83,93,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13986,-1,0.00095449074,0.99904555
13987,VPA,33,34,167,170,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13987,-1,0.995376,0.004624018
13988,NH3,6,7,42,45,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,13988,-1,0.9747971,0.025202835
13989,VPA,22,23,130,133,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,13989,-1,0.99772185,0.0022780944
13996,renal abnormality,6,8,40,57,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,-1,13996,-1,0.0013727002,0.9986273
14002,puromycin aminonucleoside,15,17,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,-1,14002,-1,0.9984621,0.0015378894
14007,body weight,24,26,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,-1,-1,-1,14007,-1,0.0189562,0.98104376
14008,ketone bodies,2,4,9,22,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,-1,14008,-1,0.095566615,0.90443337
14027,heart block,1,3,9,20,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14027,-1,0.0013243298,0.99867564
14028,trazodone,8,9,48,57,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14028,-1,0.99851364,0.0014863961
14029,trazodone,9,10,56,65,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14029,-1,0.9986082,0.0013918318
14030,heart block,15,17,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14030,-1,0.0010807244,0.99891925
14031,trazodone,12,13,67,76,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,14031,-1,0.9982502,0.0017497544
14032,delay,27,28,160,165,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,14032,-1,0.0013605291,0.9986395
14034,dacarbazine,4,5,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14034,-1,0.99870205,0.0012979376
14035,DTIC,7,8,56,60,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14035,-1,0.24377191,0.7562281
14036,melanoma,10,11,66,74,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14036,-1,0.001714151,0.99828583
14037,dacarbazine,12,13,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14037,-1,0.9986951,0.001304944
14038,DTIC,14,15,84,88,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14038,-1,0.9952425,0.004757543
14039,melanoma,18,19,102,110,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14039,-1,0.0012328249,0.99876726
14041,venous congestion,11,13,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,-1,-1,-1,14041,-1,0.0018623177,0.9981377
14043,Eosinophilic,0,1,0,12,Eosinophilic infiltrations were found around the vessels.,6503301_5,-1,-1,-1,14043,-1,0.0055428897,0.9944571
14045,neurologic impairment,5,7,30,51,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,-1,-1,14045,-1,0.00083492,0.99916506
14049,movement disorders,3,5,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,-1,-1,-1,14049,-1,0.001056071,0.998944
14053,movement disorders,13,15,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,-1,-1,-1,14053,-1,0.0011396836,0.99886036
14055,Ebstein's anomaly,4,7,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,-1,-1,-1,14055,-1,0.0033315448,0.9966685
14057,Ebstein's anomaly,4,7,15,32,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,-1,-1,-1,14057,-1,0.007008924,0.9929911
14058,Ebstein's anomaly,14,17,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,-1,-1,-1,14058,-1,0.008054925,0.9919451
14060,cardiac malformations,24,26,190,211,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,-1,14060,-1,0.0013036336,0.9986964
14061,myocardial infarction,8,10,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,-1,-1,14061,-1,0.00086987874,0.9991302
14062,myocardial infarction,9,11,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,-1,14062,-1,0.0009414371,0.99905854
14063,infarcts,3,4,18,26,The occurrence of infarcts were confirmed by histological methods.,6534871_3,-1,-1,-1,14063,-1,0.0015272727,0.99847275
14064,myocardial infarction,3,5,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,-1,-1,-1,14064,-1,0.0012901741,0.9987098
14066,adriamycin toxicity,6,8,37,56,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,-1,-1,-1,14066,-1,0.6294861,0.37051392
14068,PEG,13,14,70,73,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14068,-1,0.9934115,0.0065884856
14070,ADR,30,31,150,153,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14070,-1,0.07202719,0.92797285
14071,PEG 400,0,2,0,7,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,-1,14071,-1,0.9960193,0.0039807386
14072,cardiac morphological alterations,9,12,79,112,Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.,6538499_3,-1,-1,-1,14072,-1,0.0016389709,0.99836105
14073,ADR,6,7,36,39,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14073,-1,0.8941828,0.10581714
14074,L1210 leukemia,10,12,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14074,-1,0.0070405593,0.9929595
14075,Ehrlich ascites tumor,14,17,84,105,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14075,-1,0.0015369569,0.99846303
14076,amine,2,3,11,16,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14076,-1,0.9977397,0.0022603138
14077,ketamine catatonia,5,7,33,51,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14077,-1,0.045124106,0.95487595
14079,catatonia,16,17,114,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,-1,-1,-1,14079,-1,0.00091638014,0.99908364
14081,catatonia,12,13,83,92,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,14081,-1,0.0010107283,0.9989893
14082,DOC,14,15,94,97,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,14082,-1,0.009688779,0.99031115
14088,melatonin,22,23,121,130,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,-1,-1,14088,-1,0.997364,0.0026360054
14091,melatonin,22,23,132,141,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,-1,-1,-1,14091,-1,0.9974292,0.0025708303
14094,amines,13,14,78,84,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,-1,14094,-1,0.98961204,0.010387957
14096,melatonin,20,21,111,120,"In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.",6540303_7,-1,-1,-1,14096,-1,0.9981184,0.0018816082
14098,ketamine catatonia,15,17,93,111,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,-1,-1,-1,14098,-1,0.055521093,0.9444789
14115,Ventricular fibrillation,0,2,0,24,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14115,-1,0.00134659,0.9986534
14116,diatrizoate,3,4,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14116,-1,0.9975223,0.0024776761
14117,chelating agents,7,9,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14117,-1,0.98981196,0.010188054
14119,Renografin,3,4,16,26,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14119,-1,0.9858505,0.0141494945
14120,Hypaque,11,12,57,64,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14120,-1,0.0138415005,0.98615843
14121,Renografin,0,1,0,10,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14121,-1,0.9677481,0.032251853
14122,chelating agents sodium citrate,3,7,24,55,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14122,-1,0.9781739,0.021826115
14123,disodium edetate,8,10,60,76,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14123,-1,0.9978809,0.002119107
14124,Hypaque,12,13,84,91,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14124,-1,0.8837613,0.116238736
14125,calcium disodium edetate,14,17,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14125,-1,0.99741215,0.002587898
14127,Ventricular fibrillation,0,2,0,24,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14127,-1,0.0010411752,0.9989588
14128,Renografin,7,8,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14128,-1,0.99486464,0.0051353434
14129,chelating agents,11,13,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14129,-1,0.7664155,0.23358457
14131,quaternary ammonium,4,6,29,48,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14131,-1,0.99433124,0.005668763
14132,ventricular tachycardias,28,30,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14132,-1,0.0011570366,0.99884295
14133,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,14133,-1,0.9744878,0.025512252
14138,ventricular fibrillation,12,14,95,119,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,-1,-1,14138,-1,0.0009690422,0.99903095
14141,VT,14,15,100,102,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14141,-1,0.0010354981,0.99896455
14142,n,17,18,105,106,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14142,-1,0.02127389,0.97872615
14144,n,26,27,135,136,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14144,-1,0.009797046,0.9902029
14146,VT,14,15,104,106,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14146,-1,0.0010620833,0.9989379
14147,ventricular fibrillation,16,18,110,134,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14147,-1,0.0011307424,0.99886924
14148,VF,19,20,136,138,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14148,-1,0.0010601262,0.99893993
14149,VT,10,11,57,59,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,-1,-1,-1,14149,-1,0.0010296891,0.99897027
14151,adverse drug reactions,3,6,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,-1,-1,-1,14151,-1,0.0016959768,0.998304
14157,anorexia,17,18,86,94,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14157,-1,0.0011334264,0.99886656
14158,visual halos,23,25,101,113,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14158,-1,0.002098225,0.9979018
14159,blurring,26,27,117,125,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14159,-1,0.0016805242,0.99831945
14160,thyroid function abnormalities,32,35,132,162,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14160,-1,0.008961059,0.99103886
14161,pulmonary interstitial infiltrates,40,43,172,206,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14161,-1,0.0017444845,0.99825555
14163,VT,11,12,81,83,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14163,-1,0.00090687507,0.9990932
14164,VF,13,14,87,89,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14164,-1,0.0009760634,0.9990239
14166,VT,23,24,122,124,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14166,-1,0.001040616,0.9989594
14167,VF,25,26,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14167,-1,0.0010359115,0.9989641
14170,bladder carcinoma,5,7,41,58,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,-1,-1,-1,14170,-1,0.0017175438,0.99828243
14171,transitional cell carcinoma,10,13,67,94,A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder.,6640832_1,-1,-1,-1,14171,-1,0.0022139193,0.99778605
14173,h,11,12,67,68,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14173,-1,0.028193017,0.971807
14174,bladder tumors,20,22,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14174,-1,0.0016590774,0.99834096
14178,angiopathy,1,2,24,34,D-penicillamine-induced angiopathy in rats.,6666578_0,-1,-1,-1,14178,-1,0.000906958,0.99909306
14179,hyaluronate,43,44,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,-1,14179,-1,0.99612856,0.0038713652
14180,EACA,5,6,35,39,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,-1,-1,-1,14180,-1,0.060533028,0.939467
14183,EACA,12,13,73,77,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14183,-1,0.98807526,0.01192467
14184,subarachnoid haemorrhage,21,23,119,143,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14184,-1,0.001222447,0.99877757
14185,SAH,24,25,145,148,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14185,-1,0.0009750364,0.999025
14188,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14188,-1,0.99209154,0.007908459
14189,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14189,-1,0.99209154,0.007908459
14190,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14190,-1,0.99209154,0.007908459
14191,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14191,-1,0.99209154,0.007908459
14192,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14192,-1,0.99209154,0.007908459
14193,FANFT,7,8,85,90,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14193,-1,0.9955922,0.0044077835
14194,bladder carcinomas,18,20,149,167,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14194,-1,0.0013574059,0.9986426
14195,forestomach tumors,25,27,199,217,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14195,-1,0.0069109104,0.99308914
14196,FANFT,12,13,79,84,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14196,-1,0.9955397,0.0044602994
14199,FANFT,40,41,219,224,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14199,-1,0.99415153,0.0058484077
14202,FANFT carcinogenesis,16,18,124,144,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14202,-1,0.050607976,0.9493921
14204,FANFT,30,31,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14204,-1,0.22450845,0.77549154
14206,Cerebral hemorrhage,0,2,0,19,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14206,-1,0.0011040652,0.9988959
14207,phenylpropanolamine,4,5,36,55,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14207,-1,0.9986364,0.0013635266
14209,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14209,-1,0.99833846,0.0016615647
14210,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14210,-1,0.99264693,0.0073530627
14213,lead,7,8,42,46,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,-1,-1,14213,-1,0.0052241734,0.9947758
14216,cerebral hemorrhage,2,4,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,-1,-1,14216,-1,0.0009546707,0.9990453
14218,lead,8,9,49,53,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,-1,-1,14218,-1,0.016171578,0.9838284
14221,lead,6,7,44,48,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14221,-1,0.0047996184,0.9952004
14222,cerebral hemorrhage,8,10,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14222,-1,0.0009134293,0.9990866
14224,elevation in blood pressure,2,6,9,36,An acute elevation in blood pressure may be a contributing factor.,6695415_7,-1,-1,-1,14224,-1,0.0021079397,0.9978921
14226,naproxen,5,6,32,40,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,14226,-1,0.9988273,0.0011726565
14229,fenoprofen calcium,15,17,92,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14229,-1,0.99875665,0.0012434125
14230,salicylates,20,21,122,133,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14230,-1,0.998231,0.0017689839
14231,gold salts,22,24,138,148,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14231,-1,0.99550027,0.004499676
14233,RPN,30,31,186,189,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14233,-1,0.0018386549,0.9981614
14234,naproxen,37,38,221,229,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14234,-1,0.99886703,0.0011329537
14235,RPN,5,6,32,35,No other factor predisposing to RPN could be discovered.,6699841_2,-1,-1,-1,14235,-1,0.002831618,0.99716836
14237,naproxen,4,5,29,37,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,-1,-1,-1,14237,-1,0.99872464,0.0012753366
14238,RPN,5,6,35,38,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,-1,-1,14238,-1,0.0032253559,0.9967746
14241,tardive dyskinesia,3,5,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,-1,-1,-1,14241,-1,0.0008261017,0.9991738
14243,Abnormal involuntary movements,0,3,0,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14243,-1,0.0016122183,0.9983878
14245,gastrointestinal disorder,23,25,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14245,-1,0.00107021,0.9989298
14246,mg,30,31,187,189,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14246,-1,0.9629898,0.037010152
14248,abnormal movements,8,10,61,79,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,-1,-1,-1,14248,-1,0.0018989859,0.99810106
14249,tardive dyskinesia,7,9,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,-1,-1,-1,14249,-1,0.00076824724,0.9992318
14252,protein,7,8,57,64,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,-1,-1,-1,14252,-1,0.82329524,0.17670472
14255,netilmicin,9,10,53,63,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,14255,-1,0.9980642,0.0019357705
14256,protein,12,13,73,80,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,14256,-1,0.60797775,0.39202228
14261,netilmicin,2,3,14,24,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,-1,-1,-1,14261,-1,0.9979103,0.002089629
14267,netilmicin,4,5,37,47,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,-1,14267,-1,0.9967146,0.003285405
14271,nephrotoxicants,6,7,33,48,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14271,-1,0.002503732,0.9974962
14272,obstructive sleep apnea syndrome,3,7,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14272,-1,0.0010820029,0.99891806
14273,androgen,12,13,74,82,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14273,-1,0.9968311,0.0031688984
14274,syndrome of obstructive sleep apnea,25,30,167,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14274,-1,0.0015243362,0.9984756
14275,androgens,34,35,238,247,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14275,-1,0.9952225,0.0047775437
14276,androgens,2,3,9,18,"When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.",6732043_2,-1,-1,-1,14276,-1,0.9872121,0.012787877
14277,androgen,3,4,19,27,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14277,-1,0.9959215,0.0040785354
14278,obstructive sleep apnea,7,10,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14278,-1,0.0010500047,0.99895006
14279,androgens,7,8,40,49,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14279,-1,0.99458474,0.0054152296
14280,sleep apnea,12,14,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14280,-1,0.0015610808,0.9984389
14281,androgens,6,7,53,62,Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.,6732043_6,-1,-1,-1,14281,-1,0.99390346,0.0060965074
14282,obstructive sleep apnea syndrome,3,7,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14282,-1,0.0010752588,0.9989247
14283,androgen,15,16,97,105,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14283,-1,0.9967527,0.0032473493
14284,BCNU,1,2,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14284,-1,0.99402654,0.0059734657
14285,malignant gliomas,6,8,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14285,-1,0.0011596229,0.9988404
14286,BCNU,7,8,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14286,-1,0.99667513,0.003324816
14288,malignant gliomas,26,28,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14288,-1,0.0011888552,0.9988111
14289,BCNU,5,6,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,-1,-1,14289,-1,0.9952419,0.004758135
14290,astrocytomas,7,8,37,49,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,-1,-1,14290,-1,0.0010955235,0.99890447
14294,astrocytomas,8,9,50,62,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14294,-1,0.0011697527,0.99883026
14295,BCNU,25,26,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14295,-1,0.9928005,0.0071995524
14296,BCNU,14,15,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,-1,-1,-1,14296,-1,0.9950304,0.0049695685
14297,loss of vision,9,12,60,74,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14297,-1,0.0014284648,0.9985715
14298,retinal vasculitis,15,17,90,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14298,-1,0.0011744502,0.9988255
14304,congestive heart failure,6,9,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,-1,-1,-1,14304,-1,0.0009215328,0.9990784
14306,myocardial lesions,3,5,20,38,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,-1,-1,-1,14306,-1,0.001589978,0.99841
14308,acute myeloblastic leukemia,6,9,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,-1,-1,-1,14308,-1,0.00088137394,0.9991186
14311,leukemia,18,19,98,106,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,-1,-1,-1,14311,-1,0.001064348,0.99893564
14312,postural hypotension,2,4,15,35,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14312,-1,0.0009986598,0.9990013
14314,diabetic autonomic neuropathy?The,7,10,56,89,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14314,-1,0.0067035197,0.99329644
14325,vasodilator drugs,11,13,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,-1,-1,14325,-1,0.975089,0.024910932
14328,Tricuspid valve regurgitation,0,3,0,29,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14328,-1,0.0021783952,0.99782157
14329,lithium carbonate toxicity,4,7,34,60,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14329,-1,0.4911722,0.5088278
14330,tricuspid regurgitation,4,6,23,46,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14330,-1,0.0014995221,0.99850047
14331,atrial flutter,7,9,48,62,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14331,-1,0.0013243272,0.99867564
14332,congestive heart failure,10,13,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14332,-1,0.0009926301,0.9990074
14334,tricuspid regurgitation,8,10,48,71,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14334,-1,0.0017739446,0.9982261
14335,atrial flutter,11,13,76,90,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14335,-1,0.0016452231,0.99835473
14336,cardiac disease,20,22,128,143,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14336,-1,0.0011026552,0.9988973
14338,Lithium carbonate,0,2,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14338,-1,0.9980895,0.0019104632
14339,congenital heart disease,11,14,65,89,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14339,-1,0.0010828896,0.9989171
14340,neurologic depression,3,5,15,36,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14340,-1,0.001029954,0.99897003
14341,cyanosis,6,7,38,46,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14341,-1,0.0009356832,0.9990644
14342,cardiac arrhythmia,9,11,52,70,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14342,-1,0.0010023438,0.9989976
14343,aniracetam,5,6,30,40,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14343,-1,0.9981785,0.001821516
14344,Ro 13-5057,7,11,42,52,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14344,-1,0.978626,0.02137402
14345,aniracetam,3,4,14,24,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14345,-1,0.9983316,0.0016683843
14346,Ro 13-5057,5,9,26,36,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14346,-1,0.98922324,0.010776808
14347,1-anisoyl-2-pyrrolidinone,10,11,38,63,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14347,-1,0.9931323,0.006867702
14348,impaired cognitive functions,19,22,112,140,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14348,-1,0.0027085892,0.9972914
14349,hypercapnia,55,56,324,335,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14349,-1,0.002582278,0.9974177
14353,chloramphenicol,130,131,781,796,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14353,-1,0.99844766,0.0015522956
14355,h,149,150,903,904,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14355,-1,0.24143754,0.75856245
14357,hypercapnia,197,198,1178,1189,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14357,-1,0.004995094,0.99500495
14358,h,205,206,1239,1240,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14358,-1,0.13810271,0.86189723
14359,impaired cognitive functions,5,8,40,68,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14359,-1,0.0014877802,0.9985122
14360,aniracetam,12,13,87,97,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14360,-1,0.99832565,0.0016743203
14361,aniracetam,6,7,42,52,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,-1,14361,-1,0.9981623,0.0018376993
14362,Piracetam,0,1,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14362,-1,0.998626,0.0013740009
14363,pyrrolidinone,3,4,19,32,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14363,-1,0.9956338,0.0043662484
14364,aniracetam,16,17,79,89,It was active only in six of nine tests and had about one-tenth the potency of aniracetam.,6817363_6,-1,-1,-1,14364,-1,0.99807394,0.0019260608
14365,aniracetam,4,5,26,36,The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.,6817363_7,-1,-1,-1,14365,-1,0.9980813,0.0019186657
14367,Sodium chloride,0,2,0,15,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,-1,-1,-1,14367,-1,0.9980592,0.0019408248
14378,adenohypophyseal tumors,3,5,37,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,-1,-1,-1,14378,-1,0.0013328837,0.9986671
14379,Pituitary tumors,0,2,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14379,-1,0.0014293425,0.9985707
14381,DES,14,15,96,99,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14381,-1,0.994935,0.0050650807
14382,mg,19,20,106,108,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14382,-1,0.6533166,0.3466834
14383,DES,9,10,30,33,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,-1,14383,-1,0.9963612,0.0036388643
14384,prolactin,15,16,109,118,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14384,-1,0.99427795,0.005721988
14385,PRL,17,18,120,123,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14385,-1,0.98892385,0.011076166
14386,PRL,28,29,195,198,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14386,-1,0.98419154,0.015808439
14387,acriflavine,51,52,340,351,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14387,-1,0.99768627,0.0023137499
14388,PRL,1,2,14,17,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14388,-1,0.9853897,0.014610316
14389,PRL,13,14,75,78,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14389,-1,0.9844705,0.0155294705
14390,DES,31,32,178,181,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14390,-1,0.99524695,0.0047530793
14391,DES,4,5,17,20,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,-1,14391,-1,0.9946003,0.005399699
14392,PRL,5,6,34,37,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14392,-1,0.94405144,0.05594859
14393,PRL,14,15,85,88,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14393,-1,0.7643063,0.23569366
14394,DES,4,5,21,24,All these effects of DES were more pronounced among previously ovariectomized animals.,6888657_8,-1,-1,-1,14394,-1,0.9962406,0.0037594268
14396,PRL,20,21,120,123,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,-1,-1,14396,-1,0.96105796,0.038942013
14397,calcium chloride,2,4,10,26,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14397,-1,0.9979122,0.00208771
14399,eserine,12,13,82,89,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14399,-1,0.99857175,0.0014282812
14400,calcium chloride,3,5,14,30,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14400,-1,0.9979486,0.0020513944
14401,mydriasis,41,42,233,242,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14401,-1,0.0020317093,0.99796826
14405,eserine,51,52,306,313,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14405,-1,0.99831235,0.0016876785
14406,Calcium chloride depressed,0,3,0,26,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14406,-1,0.87353927,0.12646069
14408,eserine,15,16,109,116,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14408,-1,0.99849594,0.0015040102
14409,mydriasis,5,6,19,28,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14409,-1,0.0011485404,0.9988514
14413,eserine,15,16,90,97,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14413,-1,0.99841475,0.0015852549
14414,calcium chloride,21,23,132,148,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14414,-1,0.9979506,0.0020494305
14415,calcium chloride,4,6,20,36,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14415,-1,0.9978551,0.0021448438
14416,mydriasis,20,21,123,132,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14416,-1,0.0014686105,0.99853134
14420,eserine,30,31,194,201,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14420,-1,0.99836355,0.0016363903
14421,Calcium chloride,0,2,0,16,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14421,-1,0.9977295,0.0022704795
14423,eserine,11,12,83,90,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14423,-1,0.9984976,0.0015023907
14425,Thiazide,0,1,0,8,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14425,-1,0.9979546,0.0020454244
14426,hypokalemia,3,4,20,31,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14426,-1,0.00088433234,0.99911565
14428,Thiazide,0,1,0,8,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,-1,-1,-1,14428,-1,0.9980343,0.001965711
14429,Hypokalemia,0,1,0,11,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14429,-1,0.0010564036,0.9989436
14430,thiazide,9,10,71,79,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14430,-1,0.99873513,0.00126487
14431,diastolic hypertension,15,17,69,91,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14431,-1,0.0010711419,0.99892884
14432,hydrochlorothiazide,18,19,97,116,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14432,-1,0.99875915,0.001240887
14433,HCTC,20,21,118,122,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14433,-1,0.98163164,0.018368322
14434,mg,4,5,20,22,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14434,-1,0.91983,0.080169916
14435,mg,15,16,78,80,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14435,-1,0.92558116,0.074418865
14436,mg,18,19,86,88,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14436,-1,0.93072814,0.069271855
14437,mg,21,22,97,99,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14437,-1,0.9434783,0.056521736
14438,K,2,3,10,11,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14438,-1,0.96572536,0.03427469
14439,an,13,14,60,62,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14439,-1,0.65735537,0.34264466
14440,mg HCTZ,22,24,87,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14440,-1,0.98981655,0.0101834815
14441,K,5,6,37,38,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,-1,14441,-1,0.8425957,0.15740426
14442,HCTZ,8,9,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14442,-1,0.9970259,0.0029740653
14443,mg,12,13,60,62,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14443,-1,0.95066875,0.04933118
14444,PVC,19,20,91,94,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14444,-1,0.0021288006,0.99787116
14445,PVC,8,9,37,40,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,-1,14445,-1,0.012385563,0.9876144
14446,HCTZ,3,4,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14446,-1,0.99530834,0.004691708
14447,mg,6,7,46,48,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14447,-1,0.9503201,0.049679887
14448,PVC,3,4,18,21,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14448,-1,0.0028109818,0.997189
14449,p,18,19,94,95,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14449,-1,0.18297705,0.8170229
14450,thiazide,5,6,28,36,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14450,-1,0.9982052,0.0017947475
14451,hypokalemia,8,9,53,64,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14451,-1,0.0011525211,0.9988475
14453,hypokalemia,3,4,18,29,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14453,-1,0.0010247704,0.9989753
14454,PVC,13,14,80,83,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14454,-1,0.0034877108,0.99651235
14455,acute hepatic necrosis,4,7,34,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,-1,-1,-1,14455,-1,0.0011237529,0.9988763
14456,acid phosphatase,14,16,96,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,-1,-1,14456,-1,0.8341059,0.16589406
14459,paracetamol overdose,26,28,160,180,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14459,-1,0.56822395,0.4317761
14461,viral hepatitis,42,44,274,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14461,-1,0.001283253,0.9987167
14462,D,18,19,113,114,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,-1,14462,-1,0.90864444,0.091355555
14478,kidney disease,34,36,164,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,-1,-1,14478,-1,0.001317087,0.9986829
14482,6-thioguanine,5,6,41,54,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,-1,-1,-1,14482,-1,0.99784267,0.0021573522
14483,acute lymphocytic leukemia,13,16,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14483,-1,0.0009898815,0.9990101
14484,6-thioguanine,23,24,165,178,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14484,-1,0.9976255,0.0023744227
14486,6-thioguanine,31,32,205,218,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,-1,-1,-1,14486,-1,0.99753666,0.0024633915
14487,optic neuropathy,1,3,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,-1,-1,14487,-1,0.0013483649,0.9986517
14489,chlorpropamide,8,9,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14489,-1,0.9987765,0.0012235013
14490,Diabenese,10,11,75,84,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14490,-1,0.2874373,0.7125627
14491,toxic optic neuropathy,14,17,92,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14491,-1,0.0010851083,0.99891496
14492,chlorpropamide,22,23,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14492,-1,0.99867517,0.0013247876
14494,diabetics,4,5,22,31,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,-1,-1,14494,-1,0.001702583,0.9982974
14495,optic neuropathy,5,7,34,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14495,-1,0.0009992374,0.9990007
14497,diabetics,18,19,120,129,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14497,-1,0.0015413339,0.9984586
14498,nephrotic syndrome,10,12,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14498,-1,0.0008813184,0.9991186
14499,puromycin aminonucleoside,17,19,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14499,-1,0.9979455,0.0020545668
14500,nephrotic syndrome,14,16,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14500,-1,0.0010858224,0.99891424
14501,puromycin aminonucleoside,18,20,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14501,-1,0.99800867,0.0019913903
14502,nephrotic syndrome,23,25,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14502,-1,0.0010254179,0.99897456
14503,se,26,27,186,188,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14503,-1,0.010131478,0.9898685
14504,aminonucleoside,37,38,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14504,-1,0.99755174,0.0024482452
14505,puromycin aminonucleoside,20,22,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14505,-1,0.99788123,0.002118776
14506,nephrotic syndrome,34,36,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14506,-1,0.00083452795,0.99916553
14509,fatty acids,7,9,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14509,-1,0.9807077,0.019292237
14510,triacylglycerol,10,11,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14510,-1,0.986979,0.013021043
14511,cholesteryl esters,19,21,119,137,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14511,-1,0.97669786,0.023302125
14514,puromycin aminonucleoside,4,6,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,-1,14514,-1,0.997422,0.002578031
14517,chloramphenicol,8,9,69,84,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,-1,-1,14517,-1,0.99871457,0.0012854353
14520,chloramphenicol,20,21,137,152,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,-1,-1,14520,-1,0.99861777,0.0013822339
14521,pancytopenia,4,5,19,31,The first signs of pancytopenia began within one month of the surgery.,7072798_2,-1,-1,-1,14521,-1,0.0008956242,0.9991043
14523,chloramphenicol,13,14,84,99,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,-1,-1,14523,-1,0.9987245,0.0012754762
14525,chloramphenicol,13,14,81,96,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14525,-1,0.9986551,0.0013449431
14526,bone marrow hypoplasia,23,26,153,175,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14526,-1,0.0013119171,0.99868804
14527,ocular toxicity,5,7,29,44,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14527,-1,0.0010566959,0.99894327
14528,chloramphenicol,11,12,79,94,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14528,-1,0.9985905,0.0014094878
14530,block,8,9,49,54,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14530,-1,0.0012660832,0.99873394
14532,atrial tachycardia,14,16,96,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14532,-1,0.0011518043,0.9988482
14533,intraventricular conduction abnormalities,21,24,142,183,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14533,-1,0.0016477564,0.9983523
14534,atrial tachycardia,5,7,32,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,-1,-1,14534,-1,0.0018286757,0.9981713
14536,atrial flutter,10,12,77,91,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,-1,-1,-1,14536,-1,0.0026665526,0.9973335
14538,conduction defects,17,19,120,138,Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.,7083920_4,-1,-1,-1,14538,-1,0.0010643703,0.99893564
14539,clear cell adenocarcinoma,2,5,15,40,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,-1,-1,-1,14539,-1,0.0016003471,0.9983997
14540,clear cell adenocarcinoma,3,6,13,38,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,-1,-1,-1,14540,-1,0.0018732189,0.9981268
14548,mg nitrazepam,10,12,57,70,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,-1,-1,-1,14548,-1,0.9931258,0.0068741576
14562,Akathisia,0,1,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14562,-1,0.0010486421,0.9989513
14563,benzodiazepine lorazepam,5,7,32,56,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14563,-1,0.99738175,0.00261821
14564,EPS,16,17,102,105,The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.,7161250_6,-1,-1,-1,14564,-1,0.0013079253,0.9986921
14571,chloroprocaine,28,29,142,156,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,-1,14571,-1,0.9988306,0.0011693967
14574,chloroprocaine,20,21,117,131,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,-1,-1,-1,14574,-1,0.9987318,0.0012682551
14577,cardiopulmonary arrest,8,10,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,-1,-1,14577,-1,0.0011127553,0.99888724
14580,chloroprocaine,29,30,133,147,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,-1,-1,14580,-1,0.9987784,0.0012216032
14583,REM sleep deprivation,0,3,0,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,-1,-1,14583,-1,0.010252704,0.9897473
14584,REM sleep deprivation,3,6,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14584,-1,0.006326862,0.9936732
14585,REMD,7,8,38,42,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14585,-1,0.0051688636,0.99483114
14587,head twitches,14,16,104,117,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14587,-1,0.0015815024,0.99841845
14588,REMD,3,4,18,22,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14588,-1,0.0038212528,0.99617875
14590,REMD,15,16,114,118,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14590,-1,0.004692705,0.99530727
14591,REMD,25,26,160,164,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14591,-1,0.0055436515,0.9944563
14592,head twitches,28,30,184,197,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14592,-1,0.0021972437,0.9978028
14596,N,22,23,109,110,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14596,-1,0.25179362,0.7482063
14597,N,29,30,139,140,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14597,-1,0.26376137,0.73623866
14598,N,43,44,179,180,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14598,-1,0.24620983,0.75379014
14599,N,52,53,206,207,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14599,-1,0.25574464,0.74425536
14603,subpial necrosis,14,16,83,99,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,-1,-1,-1,14603,-1,0.0017360977,0.9982639
14608,mg,15,16,111,113,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,-1,-1,14608,-1,0.9186861,0.08131391
14612,premature ventricular contractions,14,17,95,129,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14612,-1,0.001086427,0.9989135
14613,atrial flutter,18,20,133,147,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14613,-1,0.0018385026,0.9981615
14619,ventricular fibrillation,9,11,62,86,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,-1,-1,14619,-1,0.0010087212,0.9989913
14624,enlargement of the liver,1,5,23,47,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14624,-1,0.0019758022,0.9980242
14625,carbon,12,13,80,86,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14625,-1,0.99732447,0.0026754835
14627,cirrhosis of the liver,4,8,20,42,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14627,-1,0.0023053938,0.99769455
14629,splenomegaly,33,34,179,191,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14629,-1,0.0014479388,0.998552
14630,testicular atrophy,41,43,214,232,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14630,-1,0.002613898,0.99738616
14631,carbon tetrachloride,52,54,285,305,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14631,-1,0.9981875,0.0018125476
14632,carbon tetrachloride,77,79,436,456,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14632,-1,0.9981823,0.0018177103
14633,enlargement of the liver,85,89,499,523,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14633,-1,0.0025516124,0.99744844
14635,body weight,36,38,186,197,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,-1,-1,-1,14635,-1,0.02312586,0.9768742
14636,carbon tetrachloride,8,10,41,61,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,-1,-1,-1,14636,-1,0.99793017,0.0020698023
14642,allopurinol,14,15,74,85,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,-1,-1,14642,-1,0.9984308,0.0015692405
14647,Triamterene nephrolithiasis,0,2,0,27,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14647,-1,0.24164055,0.75835943
14648,dyazide,3,4,41,48,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14648,-1,0.9983138,0.0016862168
14649,triamterene nephrolithiasis,3,5,10,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,-1,-1,14649,-1,0.4256399,0.57436013
14651,triamterene,10,11,58,69,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14651,-1,0.9982223,0.0017777467
14652,uric acid salts,14,17,94,109,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14652,-1,0.8872884,0.11271158
14653,triamterene nephrolithiasis,2,4,18,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,-1,-1,14653,-1,0.38067427,0.6193257
14654,hemorrhagic cystitis,1,3,17,37,Busulfan-induced hemorrhagic cystitis.,7269015_0,-1,-1,-1,14654,-1,0.0010731881,0.9989268
14655,hemorrhage cystitis,5,7,29,48,A case of a busulfan-induced hemorrhage cystitis is reported.,7269015_1,-1,-1,-1,14655,-1,0.0011216818,0.9988783
14656,busulfan cystitis,7,9,53,70,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,-1,-1,14656,-1,0.46212712,0.5378729
14660,doxorubicin cardiomyopathy,5,7,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,-1,14660,-1,0.12424278,0.8757572
14662,CM,3,4,20,22,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14662,-1,0.002037916,0.9979621
14664,DXR,12,13,69,72,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14664,-1,0.9966813,0.0033187475
14666,myocardial disease,30,32,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14666,-1,0.0011917067,0.99880826
14667,DXR,26,27,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,-1,-1,-1,14667,-1,0.99457115,0.0054288898
14668,DXR,11,12,77,80,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,-1,-1,-1,14668,-1,0.99520385,0.0047962097
14670,DXR,13,14,79,82,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,-1,14670,-1,0.9855698,0.014430223
14672,desipramine toxicity,4,6,35,55,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,-1,-1,14672,-1,0.67169213,0.32830784
14674,desipramine toxicity,10,12,63,83,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,-1,-1,14674,-1,0.711656,0.288344
14678,Massive cerebral edema,0,3,0,22,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14678,-1,0.0011322459,0.99886775
14680,acetaminophen overdose,9,11,68,90,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14680,-1,0.48688662,0.5131134
14681,Cerebral edema,0,2,0,14,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,-1,-1,14681,-1,0.0011084102,0.99889165
14684,signs and symptoms,12,15,86,104,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14684,-1,0.002329732,0.99767023
14685,cerebral edema,16,18,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14685,-1,0.0010025502,0.9989975
14693,SNP,15,16,77,80,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,-1,-1,-1,14693,-1,0.9974331,0.0025669388
14695,angiotensin II,23,25,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,-1,-1,-1,14695,-1,0.99233997,0.007660088
14696,SNP,4,5,15,18,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14696,-1,0.99640536,0.0035946134
14697,in blood pressure,11,14,60,77,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14697,-1,0.004226756,0.99577326
14698,SNP,2,3,11,14,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14698,-1,0.99659014,0.0034098593
14699,increase in blood pressure,10,14,71,97,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14699,-1,0.0026265115,0.99737346
14700,SNP,3,4,29,32,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,-1,14700,-1,0.99668497,0.0033150036
14702,SNP,16,17,106,109,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,-1,-1,-1,14702,-1,0.99773103,0.0022690413
14706,SNP,19,20,135,138,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,-1,-1,14706,-1,0.9974241,0.002575929
14708,digoxin,11,12,87,94,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,-1,-1,14708,-1,0.99841774,0.0015822365
14709,digoxin,9,10,58,65,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14709,-1,0.9983872,0.0016128479
14712,luteinizing hormone,27,29,174,193,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14712,-1,0.982294,0.017705996
14713,digoxin,13,14,91,98,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14713,-1,0.99864084,0.0013591679
14714,digoxin,23,24,146,153,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14714,-1,0.99842936,0.0015706052
14717,digoxin,10,11,53,60,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14717,-1,0.9982778,0.0017222408
14718,rheumatic heart disease,32,35,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14718,-1,0.0014330265,0.99856704
14719,digoxin,6,7,44,51,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,-1,-1,-1,14719,-1,0.99847704,0.0015230154
14726,Gentamicin sulfate,0,2,0,18,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14726,-1,0.9968604,0.0031396004
14727,tobramycin sulfate,3,5,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14727,-1,0.996813,0.0031870247
14730,renal,10,11,57,62,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14730,-1,0.0020823702,0.9979176
14731,gentamicin sulfate,20,22,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14731,-1,0.99768627,0.002313697
14732,tobramycin sulfate,23,25,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14732,-1,0.99772173,0.002278306
14733,renal failure,40,42,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14733,-1,0.0008916805,0.99910825
14734,reduction in renal function,49,53,302,329,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14734,-1,0.0030879504,0.996912
14735,renal failure,9,11,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,-1,-1,-1,14735,-1,0.0009189532,0.999081
14736,renal failure,24,26,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,-1,14736,-1,0.00096080865,0.9990392
14738,renal failure,6,8,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,-1,-1,14738,-1,0.00097107363,0.9990289
14740,Endometrial carcinoma,0,2,0,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14740,-1,0.0020471262,0.9979528
14741,Hodgkin disease,3,5,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14741,-1,0.003138408,0.9968616
14742,endometrial carcinoma,5,7,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14742,-1,0.0013312078,0.9986688
14743,Hodgkin disease,8,10,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14743,-1,0.0040211757,0.99597883
14744,ovarian failure,2,4,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14744,-1,0.0009421114,0.99905795
14745,Hodgkin disease,10,12,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14745,-1,0.0020948173,0.99790525
14746,estrogens,16,17,113,122,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14746,-1,0.9972077,0.002792242
14748,estrogens,4,5,27,36,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14748,-1,0.9965503,0.0034496724
14749,ovarian failure,6,8,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14749,-1,0.0009533992,0.9990466
14751,endometrial carcinoma,17,19,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14751,-1,0.0011117121,0.9988883
14752,adriamycin cardiotoxicity,3,5,25,50,Metabolic involvement in adriamycin cardiotoxicity.,7423039_0,-1,-1,-1,14752,-1,0.33084098,0.669159
14756,phosphorylcreatine,19,20,120,138,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,-1,14756,-1,0.99643505,0.0035649505
14757,phophorylcreatine,13,14,79,96,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,-1,14757,-1,0.9884644,0.011535552
14759,mM adenosine,4,6,18,30,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14759,-1,0.99328136,0.006718593
14760,ATP,14,15,86,89,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14760,-1,0.99597365,0.0040263827
14761,ATP,24,25,164,167,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14761,-1,0.99407417,0.005925797
14773,Abnormal movements,0,2,0,18,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14773,-1,0.0016161791,0.9983839
14774,deafness,3,4,23,31,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14774,-1,0.0011220949,0.99887794
14777,doxorubicin cardiotoxicity,3,5,11,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,-1,-1,-1,14777,-1,0.051202714,0.9487973
14788,LiCl,35,36,209,213,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,-1,14788,-1,0.9981013,0.0018987266
14790,h,16,17,77,78,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,-1,-1,-1,14790,-1,0.03789753,0.9621025
14791,h,1,2,2,3,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,-1,-1,-1,14791,-1,0.08829307,0.9117069
14794,h,2,3,6,7,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,-1,-1,-1,14794,-1,0.062984854,0.9370152
14805,Cardiovascular complications,0,2,0,28,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14805,-1,0.0015541451,0.9984459
14807,preterm labor,7,9,71,84,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14807,-1,0.0012855515,0.99871445
14808,cardiovascular complications,1,3,7,35,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14808,-1,0.0010208436,0.9989792
14810,preterm labor,13,15,99,112,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14810,-1,0.0010904132,0.9989096
14811,corticosteroid,1,2,11,25,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,-1,-1,-1,14811,-1,0.99715674,0.0028432258
14812,Toxic hepatitis,0,2,0,15,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14812,-1,0.0010258391,0.9989742
14813,antithyroid drugs,4,6,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14813,-1,0.2008969,0.7991031
14815,benzylthiouracil,16,17,117,133,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14815,-1,0.99866545,0.0013345769
14816,adverse,12,13,72,79,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14816,-1,0.0014752473,0.9985247
14817,antithyroid drugs,16,18,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14817,-1,0.3888751,0.6111249
14819,toxic hepatitis,11,13,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14819,-1,0.00092565035,0.99907434
14820,antithyroid agent,22,24,118,135,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14820,-1,0.3096375,0.6903625
14821,cholestatic hepatitis,4,6,19,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14821,-1,0.0009348562,0.9990652
14823,cholestatic,6,7,24,35,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,-1,-1,-1,14823,-1,0.001419585,0.99858046
14827,Benzylthiouracil,14,15,94,110,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14827,-1,0.9985636,0.0014363854
14831,Toxic hepatitis,2,4,12,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14831,-1,0.0011518515,0.9988481
14832,antithyroid drugs,10,12,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14832,-1,0.58187366,0.41812634
14833,haematological disturbances,17,19,102,129,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14833,-1,0.0010572809,0.9989427
14835,antithyroid agents,11,13,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,-1,-1,14835,-1,0.0589032,0.9410967
14836,Na,8,9,59,61,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14836,-1,0.99549156,0.0045084376
14837,Ca,10,11,66,68,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14837,-1,0.99531674,0.004683229
14839,mM Na,5,7,39,44,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14839,-1,0.973462,0.026537983
14840,mM Ca,9,11,54,59,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14840,-1,0.96372086,0.036279093
14841,N,12,13,61,62,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14841,-1,0.83355516,0.1664449
14842,mM,13,14,50,52,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14842,-1,0.6680302,0.3319698
14843,mM,29,30,109,111,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14843,-1,0.64234644,0.3576536
14844,mM,34,35,131,133,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14844,-1,0.7659758,0.23402427
14845,mM,49,50,182,184,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14845,-1,0.6551088,0.3448912
14846,mM,55,56,214,216,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14846,-1,0.6974804,0.30251962
14847,mM,7,8,33,35,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14847,-1,0.5405301,0.4594699
14848,mM,13,14,54,56,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14848,-1,0.38540652,0.61459345
14849,mM,29,30,118,120,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14849,-1,0.4794124,0.5205876
14852,Na,6,7,40,42,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14852,-1,0.9965964,0.0034035712
14853,Ca,8,9,47,49,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14853,-1,0.99637634,0.0036236544
14856,cyclosporin A,2,4,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14856,-1,0.9982457,0.001754344
14857,FK506,5,6,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14857,-1,0.9986811,0.0013188545
14858,Cyclosporin A,0,2,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14858,-1,0.9979809,0.0020191695
14859,CsA,3,4,15,18,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14859,-1,0.99754673,0.0024532673
14860,Fujimycine,9,10,34,44,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14860,-1,0.9985196,0.0014804023
14861,FK506,11,12,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14861,-1,0.9982609,0.0017391243
14862,macrolide,21,22,83,92,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14862,-1,0.9900547,0.009945218
14864,CsA,4,5,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14864,-1,0.9975962,0.0024038318
14865,FK506 toxicity,6,8,36,50,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14865,-1,0.6026576,0.3973424
14866,Cyclophilin A,0,2,0,13,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14866,-1,0.96725947,0.03274054
14867,CsA,11,12,81,84,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14867,-1,0.99789727,0.0021027185
14868,FK506,13,14,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14868,-1,0.99857056,0.0014294575
14869,CsA,20,21,140,143,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14869,-1,0.99811137,0.001888627
14870,FK506,22,23,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14870,-1,0.99853456,0.0014654485
14872,CsA,11,12,89,92,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14872,-1,0.99820673,0.0017932942
14873,FK506,13,14,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14873,-1,0.99862146,0.0013784833
14876,CsA,8,9,54,57,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14876,-1,0.9983115,0.0016884997
14877,FK506,10,11,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14877,-1,0.99869907,0.0013008551
14878,Acute renal failure,0,3,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,-1,-1,-1,14878,-1,0.0010546474,0.9989454
14881,acute renal failure,6,9,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,-1,-1,-1,14881,-1,0.000877235,0.9991228
14883,embryonal rhabdomyosarcoma,15,17,104,130,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,-1,-1,-1,14883,-1,0.0012586784,0.9987413
14884,Acute renal failure,0,3,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,-1,-1,-1,14884,-1,0.0010301131,0.9989699
14887,Triniol,7,8,52,59,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,-1,14887,-1,0.9962921,0.0037079682
14890,conjunctivitis,19,20,97,111,"A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1).",7582165_2,-1,-1,-1,14890,-1,0.0011653446,0.99883467
14893,Triniol,5,6,41,48,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,-1,-1,-1,14893,-1,0.9976909,0.0023090632
14898,hypersensitivity reactions,6,8,59,85,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,-1,-1,-1,14898,-1,0.0011764265,0.9988236
14900,prostacyclin,7,8,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14900,-1,0.9979054,0.0020945878
14901,beraprost,9,10,77,86,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14901,-1,0.998406,0.0015940671
14902,cilostazol,13,14,119,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14902,-1,0.99863017,0.0013698936
14903,prostacyclin,10,11,59,71,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14903,-1,0.9978217,0.0021783062
14904,beraprost,12,13,81,90,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14904,-1,0.9983517,0.0016483323
14905,BPT,14,15,92,95,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14905,-1,0.9920493,0.007950733
14906,cilostazol,21,22,138,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14906,-1,0.99855906,0.0014409181
14907,CLZ,23,24,150,153,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14907,-1,0.9955094,0.004490618
14908,cAMP,38,39,250,254,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14908,-1,0.9960524,0.0039475285
14909,"cyclic adenosine 3',5'-monophosphate",40,43,256,292,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14909,-1,0.98930025,0.010699742
14910,BPT,13,14,83,86,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14910,-1,0.99486476,0.0051353127
14911,CLZ,31,32,155,158,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14911,-1,0.9955942,0.004405821
14912,mg,34,35,164,166,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14912,-1,0.97072744,0.029272538
14914,cAMP,19,20,137,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,-1,14914,-1,0.96810585,0.031894114
14916,facial flush,12,14,79,91,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14916,-1,0.0015951685,0.9984048
14918,CLZ,25,26,148,151,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14918,-1,0.9947496,0.0052503445
14919,cAMP,1,2,14,18,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,-1,14919,-1,0.992986,0.00701393
14923,coenzyme,18,19,123,131,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14923,-1,0.9820063,0.01799375
14924,coenzyme A,18,20,123,133,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14924,-1,0.98812205,0.011877871
14925,diabetes mellitus,10,12,69,86,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,-1,-1,14925,-1,0.00094722415,0.9990528
14932,chronic autoimmune thyroiditis,8,11,53,83,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,-1,-1,-1,14932,-1,0.0011140534,0.9988859
14937,ammonia coma,2,4,12,24,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,-1,-1,14937,-1,0.0038939975,0.99610597
14938,Ammonia coma,0,2,0,12,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14938,-1,0.005023319,0.9949767
14939,NH4CL,17,18,101,106,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14939,-1,0.9902445,0.009755492
14941,ammonium salt,16,18,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,-1,-1,14941,-1,0.9970804,0.002919598
14942,ammonia,13,14,71,78,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14942,-1,0.95528287,0.044717163
14944,ammonia,28,29,149,156,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14944,-1,0.9862926,0.013707401
14948,ammonia coma,18,20,116,128,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14948,-1,0.014304696,0.9856953
14949,ammonia,26,27,160,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14949,-1,0.9624779,0.037522044
14950,ammonia,12,13,84,91,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14950,-1,0.10102178,0.8989782
14951,ammonia coma,15,17,100,112,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14951,-1,0.0037774064,0.9962226
14952,ammonia,8,9,39,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14952,-1,0.69853514,0.30146483
14953,ammonia coma,13,15,69,81,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14953,-1,0.012399214,0.9876008
14955,encephalopathic,13,14,91,106,These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.,761833_7,-1,-1,-1,14955,-1,0.0008926721,0.9991073
14956,myocardial infarction,1,3,18,39,Etoposide-related myocardial infarction.,7619765_0,-1,-1,-1,14956,-1,0.0011053702,0.99889463
14957,myocardial infarction,4,6,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14957,-1,0.000931242,0.9990688
14959,coronary heart disease,21,24,129,151,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14959,-1,0.0011452493,0.99885476
14960,vitamin B12,5,7,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,14960,-1,0.99756646,0.002433595
14962,hematologic toxicity,13,15,80,100,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,14962,-1,0.0008795987,0.9991204
14964,vitamin B12,12,14,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,-1,-1,14964,-1,0.9977443,0.0022557375
14968,human immunodeficiency,1,3,13,35,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14968,-1,0.008471926,0.99152803
14969,ZDV,18,19,132,135,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14969,-1,0.996302,0.00369796
14970,mg,21,22,141,143,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14970,-1,0.9729129,0.027087104
14971,n,29,30,167,168,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14971,-1,0.12779638,0.8722036
14973,mg,41,42,215,217,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14973,-1,0.9745803,0.025419772
14974,vitamin B12,46,48,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14974,-1,0.9972065,0.002793512
14975,n,57,58,292,293,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14975,-1,0.12388202,0.876118
14977,vitamin B12,4,6,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,14977,-1,0.9966719,0.0033280698
14978,folate,7,8,34,40,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,14978,-1,0.9971181,0.0028818976
14979,hematologic toxicity,1,3,7,27,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,-1,-1,14979,-1,0.0009785644,0.9990214
14980,vitamin B12,5,7,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,14980,-1,0.9969332,0.0030667183
14981,folate,8,9,48,54,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,14981,-1,0.9973706,0.0026294235
14983,Vitamin B12,0,2,0,11,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14983,-1,0.997658,0.0023419834
14985,ZDV,7,8,48,51,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14985,-1,0.99646026,0.0035397576
14986,myelotoxicity,18,19,119,132,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14986,-1,0.0008103935,0.99918956
14991,Halothane hepatitis,0,2,0,19,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,-1,-1,-1,14991,-1,0.6264825,0.37351748
14992,trifluoroacetyl,9,10,67,82,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,14992,-1,0.9965828,0.003417253
14993,halothane hepatitis,16,18,112,131,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,14993,-1,0.5915433,0.40845665
15006,Cholinergic toxicity,0,2,0,20,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,15006,-1,0.004601305,0.9953987
15007,echothiophate iodide,7,9,59,79,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,15007,-1,0.97712255,0.022877483
15008,syndrome,6,7,41,49,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15008,-1,0.0011092447,0.9988908
15009,echothiophate iodide,11,13,66,86,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15009,-1,0.9885211,0.01147884
15010,muscle weakness,19,21,129,144,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15010,-1,0.0011355488,0.9988644
15011,myasthenia gravis,28,30,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15011,-1,0.0015323295,0.9984676
15014,flumazenil,2,3,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,-1,-1,15014,-1,0.9986235,0.0013765272
15015,Flumazenil,0,1,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15015,-1,0.9986039,0.0013961444
15017,respiratory depression,11,13,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15017,-1,0.0009874629,0.9990125
15023,flumazenil,7,8,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,-1,-1,-1,15023,-1,0.9985513,0.0014486891
15025,flumazenil,17,18,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,-1,-1,15025,-1,0.9986388,0.0013611796
15026,neuroblastoma,9,10,55,68,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,-1,-1,15026,-1,0.0011311786,0.99886876
15027,neuroblastoma,4,5,22,35,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,-1,-1,-1,15027,-1,0.0023115627,0.9976884
15028,neuroblastoma,7,8,52,65,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,-1,15028,-1,0.0011734718,0.99882656
15030,neuroblastoma,29,30,182,195,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,-1,15030,-1,0.0011697989,0.99883026
15034,n,13,14,88,89,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15034,-1,0.007275729,0.99272424
15036,n,20,21,102,103,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15036,-1,0.0087889945,0.991211
15037,n,28,29,151,152,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15037,-1,0.015747033,0.984253
15039,marrow metastases,6,8,42,59,Three complete responses were observed in marrow metastases.,7707116_10,-1,-1,-1,15039,-1,0.0024886562,0.9975114
15040,neuroblastoma,7,8,43,56,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,-1,15040,-1,0.0011301511,0.99886984
15044,oxypurines,6,7,43,53,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15044,-1,0.9973098,0.0026902477
15045,nucleosides,9,10,59,70,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15045,-1,0.9967687,0.0032313094
15046,cerebral ischemia,12,14,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15046,-1,0.0010856506,0.99891436
15047,cerebral ischemia,1,3,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,-1,-1,15047,-1,0.0010544183,0.99894565
15051,oxypurines,19,20,148,158,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15051,-1,0.9940421,0.0059578368
15052,nucleosides,22,23,164,175,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15052,-1,0.9701277,0.029872283
15054,oxypurines,8,9,53,63,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15054,-1,0.9968574,0.0031426256
15055,nucleosides,10,11,68,79,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15055,-1,0.9953157,0.004684289
15057,SD,17,18,100,102,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15057,-1,0.09069875,0.9093013
15059,SD,44,45,240,242,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15059,-1,0.08335312,0.9166469
15061,acetylsalicylate,29,30,184,200,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,-1,15061,-1,0.99833053,0.0016694822
15068,oxypurines,10,11,69,79,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15068,-1,0.9965617,0.0034383014
15069,nucleosides,13,14,85,96,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15069,-1,0.9945911,0.005408921
15070,ischemic,30,31,195,203,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15070,-1,0.0036121001,0.99638796
15071,Acute renal toxicity,0,3,0,20,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,15071,-1,0.0012102346,0.99878985
15073,cyanoacrylate,6,7,56,69,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,15073,-1,0.9952121,0.0047879065
15077,DX,10,11,49,51,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,-1,15077,-1,0.9962812,0.0037188353
15080,p,16,17,85,86,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,15080,-1,0.18205914,0.8179409
15082,contrast,17,18,94,102,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,15082,-1,0.028613668,0.9713864
15084,p,15,16,68,69,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,-1,15084,-1,0.13474481,0.86525524
15088,Prostaglandin,0,1,0,13,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15088,-1,0.997265,0.0027350453
15089,bladder hyperactivity,2,4,25,46,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15089,-1,0.0011360277,0.99886394
15090,tachykinins?In,12,13,89,103,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15090,-1,0.35656965,0.64343035
15091,prostaglandin,23,24,190,203,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15091,-1,0.99704,0.0029600582
15092,PG) E2,25,28,205,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15092,-1,0.99562305,0.004376964
15093,"RP 67,580",11,13,72,81,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15093,-1,0.9964084,0.0035915542
15094,"SR 48,968",19,21,124,133,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15094,-1,0.99617696,0.003823074
15095,PGE2,2,3,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15095,-1,0.99729496,0.0027050313
15096,PG,19,20,137,139,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15096,-1,0.99223655,0.007763419
15097,PGE2,4,5,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15097,-1,0.9968913,0.0031086523
15098,"RP 67,580",11,13,73,82,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15098,-1,0.99531823,0.0046816887
15099,"SR 48,968",14,16,86,95,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15099,-1,0.9947812,0.0052187666
15100,PGE2,28,29,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15100,-1,0.9971962,0.0028037971
15101,PG,40,41,251,253,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15101,-1,0.9935055,0.006494513
15102,PGE2,7,8,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,-1,-1,-1,15102,-1,0.9973562,0.002643803
15103,PGE2,6,7,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15103,-1,0.9972639,0.0027360804
15104,tachykinins,12,13,80,91,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15104,-1,0.7850355,0.21496448
15105,tachykinins,1,2,6,17,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,-1,-1,-1,15105,-1,0.9049669,0.09503304
15106,Prostanoids,0,1,0,11,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15106,-1,0.9913796,0.008620412
15107,tachykinins,6,7,32,43,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15107,-1,0.88064057,0.11935945
15108,bladder hyperactivity,13,15,73,94,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15108,-1,0.0010766264,0.99892336
15109,cardiogenic shock,1,3,11,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15109,-1,0.00083488465,0.9991652
15110,heart block,5,7,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15110,-1,0.0009692887,0.9990307
15113,heart block,6,8,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,-1,15113,-1,0.0009581517,0.99904186
15118,heart block,8,10,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,-1,-1,15118,-1,0.001048357,0.9989517
15122,calcium chloride,8,10,46,62,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15122,-1,0.9981704,0.001829643
15124,heart block,16,18,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15124,-1,0.0011298852,0.9988701
15125,misoprostol,3,4,21,32,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,-1,-1,15125,-1,0.9987534,0.0012466245
15128,misoprostol,9,10,58,69,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,-1,-1,-1,15128,-1,0.99878544,0.0012145309
15130,NSAID,20,21,130,135,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15130,-1,0.99152136,0.008478627
15133,misoprostol,42,43,246,257,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15133,-1,0.9986305,0.0013694623
15136,BUN,13,14,79,82,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,-1,-1,-1,15136,-1,0.9162756,0.08372435
15138,BUN,17,18,82,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15138,-1,0.8112402,0.18875979
15140,p,52,53,237,238,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15140,-1,0.085639976,0.91436005
15142,K,2,3,11,12,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15142,-1,0.9932294,0.006770552
15143,p,29,30,114,115,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15143,-1,0.098602235,0.9013978
15144,BUN,4,5,23,26,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15144,-1,0.51123565,0.48876432
15146,K,9,10,44,45,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15146,-1,0.9726625,0.027337536
15149,misoprostol,2,3,12,23,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15149,-1,0.9985978,0.001402252
15150,renal impairment,6,8,42,58,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15150,-1,0.0010107899,0.99898916
15154,panic disorder,5,7,37,51,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,-1,-1,15154,-1,0.001120601,0.9988794
15157,panic disorder,7,9,42,56,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,-1,-1,15157,-1,0.0009227435,0.9990772
15159,panic disorder,13,15,72,86,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,-1,15159,-1,0.0012882997,0.9987117
15163,mg,7,8,36,38,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,-1,-1,-1,15163,-1,0.8632179,0.13678218
15166,enuresis,21,22,112,120,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15166,-1,0.0010944814,0.99890554
15167,disinhibition,23,24,122,135,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15167,-1,0.0012035617,0.99879646
15170,impaired memory,36,38,212,227,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15170,-1,0.0018369228,0.99816304
15171,weight loss,39,41,229,240,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15171,-1,0.0016723282,0.9983277
15174,Cognitive deterioration,0,2,0,23,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15174,-1,0.0011796099,0.99882036
15175,dextromethorphan,6,7,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15175,-1,0.9976749,0.0023251064
15176,Dextromethorphan,0,1,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15176,-1,0.99838734,0.0016127235
15177,DM,2,3,18,20,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15177,-1,0.9927209,0.0072790887
15179,restlessness,17,18,82,94,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15179,-1,0.0011214602,0.99887854
15180,insomnia,19,20,96,104,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15180,-1,0.0010790649,0.9989209
15182,slurred speech,23,25,114,128,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15182,-1,0.0019962671,0.9980038
15183,nystagmus,26,27,133,142,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15183,-1,0.0011878636,0.9988122
15184,inattention,34,35,184,195,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15184,-1,0.0012220955,0.9987779
15185,disorientation,36,37,197,211,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15185,-1,0.0010659882,0.998934
15187,DM overdoses,8,10,50,62,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,-1,-1,-1,15187,-1,0.009245631,0.99075437
15188,cognitive deterioration,6,8,32,55,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15188,-1,0.000951227,0.99904877
15189,DM,13,14,88,90,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15189,-1,0.014275022,0.9857249
15192,coronary artery disease,13,16,83,106,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,-1,-1,-1,15192,-1,0.0011961552,0.99880385
15193,heart failure,11,13,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,-1,-1,-1,15193,-1,0.0010715042,0.9989285
15194,digitalis glycosides,3,5,15,35,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15194,-1,0.9924751,0.007524933
15196,coronary artery disease,20,23,133,156,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15196,-1,0.0011860547,0.998814
15198,body weight,9,11,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15198,-1,0.15431036,0.84568965
15199,coronary artery disease,26,29,149,172,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15199,-1,0.0010118879,0.9989881
15200,congestive heart failure,31,34,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15200,-1,0.0007946739,0.9992053
15203,mean+/-SE,8,9,62,71,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15203,-1,0.22328481,0.7767152
15204,mm Hg,12,14,86,91,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15204,-1,0.015351136,0.9846489
15205,P,15,16,93,94,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15205,-1,0.14392371,0.8560763
15206,P,32,33,191,192,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15206,-1,0.127101,0.872899
15207,h,38,39,211,212,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15207,-1,0.13629846,0.8637015
15209,P,15,16,120,121,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,-1,15209,-1,0.20890816,0.7910918
15213,chronic coronary artery disease,6,10,34,65,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15213,-1,0.001335575,0.9986644
15214,congestive heart failure,15,18,90,114,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15214,-1,0.0010611868,0.99893886
15218,deterioration,6,7,48,61,"Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.",783197_12,-1,-1,-1,15218,-1,0.0018084352,0.99819154
15221,pulmonary tuberculosis,9,11,91,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,-1,15221,-1,0.0012327584,0.99876726
15226,pulmonary tuberculosis,11,13,72,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15226,-1,0.0009822695,0.9990177
15227,renal failure,22,24,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15227,-1,0.0008253378,0.99917465
15233,ocular hypertension,1,3,22,41,Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.,7843916_0,-1,-1,-1,15233,-1,0.001026769,0.99897325
15234,lead,5,6,43,47,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15234,-1,0.0098996805,0.9901003
15235,ocular hypertension,10,12,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15235,-1,0.0010080485,0.9989919
15236,corticosteroid glaucoma,13,15,94,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15236,-1,0.18944386,0.8105562
15239,mm Hg,30,32,170,175,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,-1,15239,-1,0.00934464,0.99065536
15242,contrast,1,2,3,11,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15242,-1,0.026385551,0.9736145
15243,hypertensive eyes,5,7,39,56,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15243,-1,0.0024089678,0.997591
15245,ocular hypertension,15,17,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,-1,15245,-1,0.0009738991,0.99902606
15247,corticosteroid glaucoma,15,17,107,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15247,-1,0.23604883,0.7639512
15248,open angle glaucoma,18,21,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15248,-1,0.0012647008,0.99873525
15249,steroid glaucoma,16,18,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15249,-1,0.059428938,0.94057107
15250,primary open angle glaucoma,19,23,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15250,-1,0.0015812276,0.9984188
15254,cisplatinum,9,10,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15254,-1,0.99715626,0.0028437655
15258,gastric adenocarcinoma,26,28,181,203,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15258,-1,0.0016193328,0.99838066
15260,disorientation,9,10,60,74,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,-1,-1,15260,-1,0.0010723538,0.99892765
15270,5-fluorouracil neurotoxicity,3,5,20,48,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15270,-1,0.59258014,0.40741992
15271,fluoroacetate,14,15,89,102,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15271,-1,0.9984932,0.0015067834
15272,fluorocitrate,16,17,107,120,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15272,-1,0.9985299,0.0014700742
15273,thiamine,18,19,122,130,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15273,-1,0.99815,0.0018500473
15274,dihydrouracil,22,23,146,159,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15274,-1,0.99808854,0.0019113899
15277,oxcarbazepine,5,6,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15277,-1,0.9986841,0.0013158997
15278,neuroleptics,11,12,75,87,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15278,-1,0.9806887,0.019311309
15280,10-keto,5,6,34,41,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15280,-1,0.941161,0.05883908
15281,oxcarbazepine,7,8,51,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15281,-1,0.9985598,0.0014402398
15283,organic psychotic,13,15,111,128,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15283,-1,0.0019965349,0.9980034
15287,neuroleptics,21,22,92,104,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,-1,-1,15287,-1,0.9803878,0.019612167
15289,contrast,11,12,57,65,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15289,-1,0.47639722,0.5236028
15290,carbamazepine oxcarbazepine,13,15,71,98,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15290,-1,0.99851984,0.0014802135
15291,antipsychotic drugs,27,29,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15291,-1,0.991608,0.008391952
15292,Auditory disturbance,0,2,0,20,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,-1,-1,-1,15292,-1,0.0019860344,0.998014
15296,h,23,24,104,105,"Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.",7880714_3,-1,-1,-1,15296,-1,0.11944146,0.8805585
15297,hearing impairment,3,5,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,-1,-1,-1,15297,-1,0.0014371949,0.9985629
15299,auditory dysfunction,4,6,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,-1,-1,-1,15299,-1,0.0011888332,0.9988111
15301,Reactive oxygen species,0,3,0,23,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15301,-1,0.19024153,0.8097585
15302,puromycin aminonucleoside,11,13,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15302,-1,0.9979596,0.0020404311
15306,puromycin aminonucleoside,9,11,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15306,-1,0.9977851,0.0022149256
15307,PAN,13,14,76,79,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15307,-1,0.98764986,0.012350186
15308,N,32,33,178,179,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15308,-1,0.19844466,0.8015553
15309,TRIS,9,10,48,52,"The kidneys were removed, flushed with ice cold TRIS buffer.",7881871_4,-1,-1,-1,15309,-1,0.9786234,0.021376647
15310,thiobarbituric acid reactive substances,17,21,109,148,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,-1,15310,-1,0.6599557,0.34004438
15312,proteinuric injury,11,13,68,86,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15312,-1,0.0022020051,0.99779797
15313,PAN nephropathy,14,16,90,105,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15313,-1,0.0024394896,0.9975605
15314,gall bladder stones,2,5,15,34,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15314,-1,0.0017091745,0.99829084
15316,ursodeoxycholic acid,12,14,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15316,-1,0.9983852,0.0016148053
15318,acromegaly,6,7,39,49,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15318,-1,0.0010546684,0.9989453
15319,gall bladder stones,9,12,59,78,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15319,-1,0.001497322,0.99850273
15321,acromegalic,30,31,192,203,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15321,-1,0.0020448286,0.9979552
15322,gall stones,33,35,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15322,-1,0.0047635664,0.99523646
15323,gall stones,3,5,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,-1,-1,-1,15323,-1,0.0026558507,0.9973442
15329,ursodeoxycholic acid,7,9,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15329,-1,0.9984042,0.0015957655
15330,UDCA,10,11,61,65,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15330,-1,0.9972965,0.002703506
15331,UDCA,25,26,132,136,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15331,-1,0.99702173,0.002978235
15332,n,16,17,88,89,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15332,-1,0.024081463,0.9759185
15333,n,23,24,108,109,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15333,-1,0.032692693,0.9673073
15334,gall stone,27,29,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15334,-1,0.009655377,0.9903446
15336,gall stone,14,16,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,-1,-1,-1,15336,-1,0.010474482,0.98952556
15338,gall stones,5,7,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15338,-1,0.0032788722,0.9967211
15340,gall stone disease,22,25,135,153,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15340,-1,0.0027922038,0.9972078
15341,gall stones,38,40,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15341,-1,0.0051494264,0.9948506
15343,SC-48334,8,9,65,73,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15343,-1,0.9962429,0.003757141
15345,HIV-1 infection,15,17,107,122,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15345,-1,0.0053227474,0.9946773
15346,SC-48334,43,44,294,302,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15346,-1,0.995628,0.00437194
15350,SC-48334,19,20,106,114,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15350,-1,0.99755836,0.0024415953
15351,mg,22,23,121,123,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15351,-1,0.9072373,0.09276267
15352,h,25,26,132,133,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15352,-1,0.49114966,0.50885034
15354,mg,31,32,155,157,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15354,-1,0.90017325,0.09982682
15355,h,34,35,166,167,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15355,-1,0.47935808,0.52064186
15359,p,25,26,120,121,"Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15).",7905523_3,-1,-1,-1,15359,-1,0.07099752,0.92900246
15360,SC-48334,2,3,9,17,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15360,-1,0.99036413,0.009635915
15361,human immunodeficiency virus,21,24,126,154,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15361,-1,0.008290124,0.9917099
15363,p,24,25,136,137,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,-1,-1,-1,15363,-1,0.12184199,0.87815803
15367,p,32,33,143,144,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15367,-1,0.082835115,0.91716486
15368,p,52,53,194,195,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15368,-1,0.080750406,0.91924965
15370,flatulence,2,3,10,20,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15370,-1,0.001244644,0.99875534
15371,abdominal pain,4,6,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15371,-1,0.0013237882,0.99867624
15372,weight loss,8,10,42,53,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15372,-1,0.001976404,0.9980236
15374,nondepolarizing neuromuscular blocking agents,4,8,27,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,-1,-1,15374,-1,0.28782654,0.7121734
15376,nondepolarizing neuromuscular blocking agents,4,8,21,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15376,-1,0.5063385,0.49366155
15377,muscle weakness,20,22,130,145,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15377,-1,0.0010533871,0.9989466
15378,respiratory insufficiency,13,15,50,75,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,-1,-1,15378,-1,0.0010148736,0.9989851
15381,impaired,8,9,51,59,"Renal function was normal but hepatic function was impaired in all patients, and all had acidosis.",7910951_4,-1,-1,-1,15381,-1,0.0020398353,0.9979602
15383,fibrillations,15,16,112,125,"Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations.",7910951_5,-1,-1,-1,15383,-1,0.0017053704,0.99829465
15384,vecuronium,2,3,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,-1,-1,-1,15384,-1,0.99834824,0.0016518129
15386,pathology at,8,10,41,53,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15386,-1,0.004156024,0.99584395
15387,the neuromuscular junction,11,14,59,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15387,-1,0.006974286,0.9930258
15389,Hepatic dysfunction,0,2,0,19,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,-1,-1,15389,-1,0.0012198932,0.9987801
15391,Erythema multiforme,0,2,0,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15391,-1,0.0016416586,0.9983583
15392,hypersensitivity myocarditis,3,5,24,52,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15392,-1,0.0010831888,0.99891686
15394,erythema multiforme,7,9,31,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15394,-1,0.0015070087,0.99849296
15395,hypersensitivity myocarditis,10,12,55,83,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15395,-1,0.0010288792,0.9989711
15399,septicemia,15,16,96,106,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,-1,-1,-1,15399,-1,0.0008529486,0.99914706
15400,erythema multiforme,4,6,35,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15400,-1,0.0013272264,0.99867284
15401,congestive heart failure,7,10,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15401,-1,0.0009655696,0.9990344
15406,erythema multiforme,6,8,42,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,-1,-1,15406,-1,0.0014424778,0.9985575
15411,Hypersensitivity myocarditis,2,4,13,41,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15411,-1,0.0010912301,0.99890876
15412,allergy,11,12,83,90,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15412,-1,0.0017343896,0.9982657
15413,penicillins,13,14,94,105,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15413,-1,0.9960724,0.0039275405
15414,sleep disturbance,1,3,21,38,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,-1,-1,-1,15414,-1,0.001490918,0.9985091
15415,sleep disturbance,10,12,56,73,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15415,-1,0.0022159733,0.9977841
15417,PRL,25,26,151,154,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15417,-1,0.9543292,0.045670785
15418,n,19,20,117,118,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15418,-1,0.07068881,0.9293112
15419,n,32,33,162,163,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15419,-1,0.07716292,0.92283714
15420,mg,6,7,34,36,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,-1,15420,-1,0.891582,0.10841803
15422,PRL,1,2,7,10,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,-1,15422,-1,0.9903162,0.0096837515
15423,PRL,11,12,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,-1,15423,-1,0.94897956,0.051020514
15425,PRL,5,6,28,31,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15425,-1,0.93282,0.06717992
15426,sleep disturbance,46,48,214,231,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15426,-1,0.0023395547,0.9976604
15427,se,56,57,275,277,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15427,-1,0.12997064,0.87002933
15429,indocyanine green,4,6,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,-1,-1,-1,15429,-1,0.9960526,0.0039473935
15430,indocyanine green,7,9,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,-1,-1,-1,15430,-1,0.9973865,0.002613469
15431,indocyanine green,9,11,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15431,-1,0.9978308,0.0021691457
15432,indocyanine green,35,37,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15432,-1,0.99692744,0.0030726243
15433,indocyanine green,13,15,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,-1,-1,-1,15433,-1,0.9922863,0.007713719
15434,indocyanine green,6,8,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,-1,-1,-1,15434,-1,0.9947844,0.0052155717
15435,indocyanine green,3,5,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15435,-1,0.9968629,0.0031371478
15436,mg,13,14,74,76,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15436,-1,0.7413617,0.25863832
15438,exanthema,22,23,99,108,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15438,-1,0.0012359216,0.99876416
15439,urtication,24,25,110,120,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15439,-1,0.0011545705,0.99884546
15440,itchiness,26,27,122,131,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15440,-1,0.0025525484,0.9974475
15445,indocyanine green,10,12,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15445,-1,0.9978877,0.0021122885
15446,fluorescein sodium,21,23,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15446,-1,0.9979259,0.002074101
15447,indocyanine green,25,27,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15447,-1,0.9976283,0.0023717561
15451,pulmonary edema,12,14,62,77,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15451,-1,0.0010930018,0.99890697
15452,chest pain,17,19,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15452,-1,0.0012032087,0.9987968
15453,coronary artery disease,4,7,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15453,-1,0.0017142792,0.9982857
15454,myocardial infarctions,9,11,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15454,-1,0.0012492965,0.9987507
15456,diabetes mellitus,15,17,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15456,-1,0.0012817027,0.99871826
15458,lisinopril,6,7,37,47,A history of angioedema secondary to lisinopril therapy was elicited.,7988234_3,-1,-1,-1,15458,-1,0.9983833,0.0016167454
15459,angiotensin-converting enzyme inhibitors,5,8,36,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,-1,-1,-1,15459,-1,0.9908455,0.009154462
15464,diphenhydramine hydrochloride,9,11,68,97,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,-1,-1,15464,-1,0.9983912,0.0016087329
15465,arterial thrombosis,8,10,54,73,Failure of ancrod in the treatment of heparin-induced arterial thrombosis.,8012887_0,-1,-1,-1,15465,-1,0.0010670922,0.9989329
15471,thrombosis syndrome,34,36,230,249,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,-1,-1,15471,-1,0.0010830959,0.99891686
15473,Water,0,1,0,5,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15473,-1,0.9546843,0.04531564
15475,abortion,8,9,81,89,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15475,-1,0.0010368027,0.99896324
15476,water,3,4,14,19,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15476,-1,0.9162706,0.08372935
15478,abortions,12,13,98,107,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15478,-1,0.0010027093,0.9989973
15479,water,3,4,17,22,The mechanism of water intoxication is discussed in regard to these cases.,803783_2,-1,-1,-1,15479,-1,0.77571726,0.22428274
15481,abortions,4,5,52,61,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15481,-1,0.0011472125,0.9988527
15482,water,28,29,184,189,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15482,-1,0.9705522,0.029447801
15483,asthenia,45,46,287,295,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15483,-1,0.0010650276,0.9989349
15484,muscular irritability,47,49,297,318,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15484,-1,0.001512754,0.99848723
15485,headaches,51,52,323,332,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15485,-1,0.0012581474,0.9987419
15487,lactate,8,9,45,52,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15487,-1,0.9873279,0.012672174
15488,lactate,15,16,81,88,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15488,-1,0.98882526,0.011174786
15489,dextrose,21,22,106,114,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15489,-1,0.9950787,0.0049212873
15500,tuberculous,8,9,35,46,as well as of those of seven other tuberculous patients.,804391_4,-1,-1,-1,15500,-1,0.0018106126,0.9981894
15502,KF17837,0,1,0,7,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,-1,-1,-1,15502,-1,0.9834432,0.016556777
15504,KF17837,0,1,0,7,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,-1,-1,-1,15504,-1,0.9930167,0.0069832876
15506,KF17837,3,4,23,30,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15506,-1,0.9963182,0.0036818099
15507,cataleptic,15,16,88,98,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15507,-1,0.001516569,0.9984835
15509,CGS 21680,28,30,197,206,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15509,-1,0.996191,0.0038089862
15510,KF17837,0,1,0,7,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,-1,-1,-1,15510,-1,0.99396604,0.0060340143
15514,KF17837,2,3,10,17,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15514,-1,0.99227,0.0077299876
15515,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15515,-1,0.995698,0.0043020467
15516,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15516,-1,0.995698,0.0043020467
15517,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15517,-1,0.995698,0.0043020467
15518,benserazide,28,29,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15518,-1,0.9985905,0.0014094429
15519,KF17837,4,5,29,36,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15519,-1,0.9966311,0.0033689637
15522,KF17837,2,3,13,20,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,-1,-1,15522,-1,0.99488705,0.00511295
15526,teratogenic,17,18,82,93,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,-1,-1,-1,15526,-1,0.0019241303,0.99807584
15527,arthrogryposis,5,6,33,47,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15527,-1,0.0008887605,0.99911124
15529,arthrogryposis,7,8,39,53,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15529,-1,0.00097068364,0.9990293
15530,teratogenic,16,17,89,100,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15530,-1,0.0013512425,0.9986488
15535,deformations,3,4,22,34,Both compounds caused deformations and lethality in a dose-dependent manner.,8073369_6,-1,-1,-1,15535,-1,0.001345765,0.99865425
15536,nicotine sulfate,3,5,22,38,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,-1,-1,-1,15536,-1,0.99616206,0.0038379177
15538,deformations,1,2,4,16,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15538,-1,0.0017067449,0.9982932
15541,excessive flexion or extension of one or more toes,10,19,66,116,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15541,-1,0.0031119785,0.996888
15542,cranial hemorrhage,25,27,146,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,-1,-1,15542,-1,0.0012466612,0.9987533
15544,P,6,7,39,40,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,-1,15544,-1,0.16796279,0.83203715
15548,arthrogryposis,16,17,105,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,-1,-1,-1,15548,-1,0.0010416354,0.99895835
15552,allergic,27,28,159,167,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15552,-1,0.004039516,0.99596053
15553,allergic,34,35,219,227,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15553,-1,0.0028177584,0.99718225
15555,AX,39,40,254,256,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15555,-1,0.9657727,0.03422732
15557,benzylpenicilloate,10,11,74,92,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15557,-1,0.9976884,0.0023115627
15558,benzylpenicillin,12,13,94,110,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15558,-1,0.9981029,0.0018970843
15559,PG,14,15,112,114,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15559,-1,0.995596,0.004403964
15561,AMP,19,20,129,132,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15561,-1,0.9943836,0.005616427
15562,AX,23,24,139,141,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15562,-1,0.9858802,0.014119791
15563,BPO,7,8,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15563,-1,0.007551074,0.9924489
15564,PG,22,23,134,136,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15564,-1,0.61762154,0.38237846
15565,AX,26,27,155,157,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15565,-1,0.73261684,0.26738316
15566,allergic,8,9,42,50,A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.,8092427_6,-1,-1,-1,15566,-1,0.002201971,0.9977981
15567,AX allergy,11,13,46,56,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15567,-1,0.004001612,0.9959984
15568,PG,17,18,80,82,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15568,-1,0.3026164,0.6973836
15572,BPO,8,9,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15572,-1,0.030690659,0.9693094
15573,MDM,21,22,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15573,-1,0.9318848,0.06811515
15574,PG,32,33,113,115,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15574,-1,0.8678282,0.13217174
15575,AX,3,4,16,18,Skin tests with AX were positive in 34 (63%) patients.,8092427_10,-1,-1,-1,15575,-1,0.098202795,0.90179724
15576,AX,4,5,22,24,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15576,-1,0.0039709173,0.99602914
15577,BPO,14,15,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15577,-1,0.0039256345,0.99607444
15578,AX,8,9,40,42,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15578,-1,0.024862295,0.97513765
15579,BPO,12,13,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15579,-1,0.1335531,0.8664469
15580,AX,3,4,21,23,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15580,-1,0.22790515,0.77209485
15582,AX,22,23,121,123,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15582,-1,0.44822028,0.55177975
15583,AX,38,39,175,177,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15583,-1,0.09852595,0.90147406
15584,PG,0,1,0,2,PG was well tolerated by all 54 patients.,8092427_14,-1,-1,-1,15584,-1,0.81543833,0.18456173
15585,PG,11,12,73,75,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,-1,-1,-1,15585,-1,0.93396693,0.066033065
15594,myocardial infarctions,5,7,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15594,-1,0.0011124563,0.9988876
15596,mm Hg,27,29,165,170,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15596,-1,0.01047201,0.989528
15597,P,30,31,172,173,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15597,-1,0.13051347,0.8694866
15598,mm Hg,15,17,70,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15598,-1,0.0069423188,0.9930576
15599,P,18,19,77,78,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15599,-1,0.090012655,0.90998733
15600,P,14,15,77,78,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,-1,-1,-1,15600,-1,0.14911161,0.8508884
15603,mm Hg,17,19,108,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15603,-1,0.021718068,0.9782819
15604,P,20,21,115,116,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15604,-1,0.1694026,0.83059746
15605,mm Hg,39,41,206,211,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15605,-1,0.016311605,0.98368835
15606,P,42,43,213,214,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15606,-1,0.16430627,0.8356937
15607,P,53,54,273,274,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15607,-1,0.22050247,0.77949756
15613,MPTP,11,12,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,-1,-1,15613,-1,0.98610723,0.013892779
15616,dyskinetic movements,22,24,135,155,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,-1,-1,-1,15616,-1,0.0010423332,0.99895763
15618,physostigmine,6,7,36,49,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15618,-1,0.99861586,0.0013841663
15619,methysergide,8,9,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15619,-1,0.99855787,0.0014421303
15620,5-MDOT,10,11,65,71,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15620,-1,0.9970868,0.0029132045
15622,MK-801,15,16,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15622,-1,0.99721223,0.0027878417
15623,dyskinetic movements,20,22,119,139,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15623,-1,0.0010600575,0.99893993
15626,meperidine,4,5,23,33,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15626,-1,0.99883527,0.0011647908
15627,dyskinetic movements,8,10,60,80,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15627,-1,0.0010258225,0.9989742
15628,Baclofen,0,1,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15628,-1,0.9985399,0.0014600778
15629,dystonic,10,11,54,62,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15629,-1,0.0011628608,0.9988372
15632,dystonic movements,3,5,23,41,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15632,-1,0.0010825405,0.99891746
15633,chorea,6,7,47,53,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15633,-1,0.0010991875,0.9989008
15648,hallucinatory,22,23,148,161,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,-1,-1,15648,-1,0.0014465573,0.99855345
15650,neuroleptics,6,7,42,54,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,-1,-1,-1,15650,-1,0.9899048,0.010095117
15653,neuromuscular disorders,7,9,69,92,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,-1,-1,15653,-1,0.00097034714,0.99902964
15654,Carbonic anhydrase,0,2,0,18,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,-1,-1,-1,15654,-1,0.9657331,0.03426684
15656,periodic paralysis,11,13,86,104,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15656,-1,0.0009629876,0.999037
15657,myotonia,14,15,109,117,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15657,-1,0.0008075367,0.9991924
15658,acetazolamide,3,4,18,31,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15658,-1,0.9988405,0.00115955
15659,renal calculi,9,11,48,61,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15659,-1,0.0011290158,0.9988709
15660,calculus,6,7,56,64,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15660,-1,0.0016256348,0.99837434
15661,calculus,15,16,111,119,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15661,-1,0.0021549403,0.99784505
15663,acetazolamide,5,6,37,50,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,-1,-1,-1,15663,-1,0.9988625,0.0011375237
15664,calcium channel blockers,2,5,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,-1,15664,-1,0.99500644,0.0049934727
15666,calcium channel blockers,11,14,62,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,-1,-1,15666,-1,0.9947856,0.005214439
15668,calcium channel blockers,6,9,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15668,-1,0.990239,0.009761018
15672,n,45,46,222,223,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15672,-1,0.19554485,0.80445516
15674,calcium channel blockers,11,14,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,-1,-1,-1,15674,-1,0.99256766,0.007432393
15676,calcium channel blockers,10,13,74,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,-1,-1,-1,15676,-1,0.99121547,0.008784542
15679,facial telangiectasia,2,4,36,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,-1,-1,-1,15679,-1,0.0011281655,0.99887186
15681,Adalat,6,7,39,45,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15681,-1,0.996223,0.0037770132
15682,telangiectasia,14,15,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15682,-1,0.0009936005,0.99900645
15683,flushing,6,7,50,58,Neither patient complained of photosensitivity or flushing.,8251368_2,-1,-1,-1,15683,-1,0.0014469918,0.998553
15684,amlodipine,6,7,39,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15684,-1,0.99865735,0.0013426938
15685,telangiectasia,14,15,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15685,-1,0.0010955981,0.99890435
15686,telangiectasia,4,5,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,-1,15686,-1,0.0009862309,0.9990138
15691,RPGN,11,12,96,100,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,-1,-1,15691,-1,0.0013212583,0.99867874
15695,antiplatelet,12,13,81,93,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,-1,15695,-1,0.9865915,0.013408414
15696,RPGN,4,5,17,21,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,-1,-1,15696,-1,0.0010925074,0.99890745
15698,polymyositis,3,4,10,22,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15698,-1,0.00091812364,0.99908185
15699,primary biliary cirrhosis,8,11,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15699,-1,0.0012516965,0.9987483
15700,rheumatologic diseases,7,9,48,70,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,-1,-1,-1,15700,-1,0.0008571045,0.9991429
15702,primary biliary cirrhosis,5,8,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15702,-1,0.0012567545,0.99874324
15703,polymyositis,11,12,66,78,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15703,-1,0.00096546515,0.9990345
15704,autoimmune,12,13,95,105,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,-1,-1,-1,15704,-1,0.0012860426,0.99871397
15713,hyperesthesia,6,7,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,-1,-1,15713,-1,0.0009961237,0.99900395
15715,neuralgia,5,6,29,38,In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.,8278214_4,-1,-1,-1,15715,-1,0.0008651002,0.99913496
15719,prostaglandin E1,4,6,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15719,-1,0.9977245,0.00227551
15720,trimethaphan,7,8,47,59,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15720,-1,0.99862397,0.0013761001
15722,prostaglandin E1,5,7,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15722,-1,0.99701154,0.0029884141
15723,PGE1,8,9,44,48,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15723,-1,0.9961824,0.0038175571
15724,trimethaphan,11,12,53,65,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15724,-1,0.9986148,0.0013851849
15725,TMP,13,14,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15725,-1,0.99549496,0.004505094
15728,PGE1,7,8,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15728,-1,0.9978823,0.0021176182
15729,TMP,17,18,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15729,-1,0.9970716,0.0029283674
15730,MAP,42,43,243,246,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15730,-1,0.015263767,0.98473626
15732,PGE1,2,3,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15732,-1,0.99773455,0.0022653951
15733,TMP,4,5,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15733,-1,0.9539095,0.046090476
15734,MAP,6,7,28,31,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15734,-1,0.008901207,0.9910988
15735,P,21,22,122,123,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15735,-1,0.117324844,0.88267523
15737,PGE1,33,34,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15737,-1,0.99737763,0.0026223513
15738,PGE1,5,6,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15738,-1,0.99763405,0.00236589
15739,TMP,10,11,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15739,-1,0.9941121,0.005887891
15740,TMP,25,26,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15740,-1,0.9925027,0.0074972706
15741,P,10,11,35,36,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,-1,15741,-1,0.14680617,0.8531939
15742,P,10,11,33,34,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,-1,-1,-1,15742,-1,0.11019269,0.88980734
15743,PGE1,4,5,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15743,-1,0.99716896,0.002831062
15744,TMP,9,10,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15744,-1,0.99631315,0.0036869107
15746,TMP,17,18,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15746,-1,0.99167174,0.008328246
15748,Kaposi's sarcoma,4,7,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,-1,15748,-1,0.0017044798,0.9982955
15750,DaunoXome,18,19,112,121,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15750,-1,0.9983329,0.0016670901
15751,AIDS,24,25,143,147,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15751,-1,0.0037429144,0.99625707
15752,Kaposi's sarcoma,26,29,156,172,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15752,-1,0.0017555818,0.9982444
15753,Kaposi's sarcoma,5,8,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,-1,-1,-1,15753,-1,0.0025175633,0.9974825
15754,oedema,7,8,39,45,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,-1,15754,-1,0.0018562381,0.9981438
15756,Kaposi's sarcoma,2,5,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,-1,-1,-1,15756,-1,0.0019806884,0.99801934
15758,haematological toxicity,5,7,33,56,"The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).",8305357_9,-1,-1,-1,15758,-1,0.001065502,0.99893445
15762,Kaposi's sarcoma,19,22,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,-1,15762,-1,0.0018502843,0.99814975
15763,Dup 753,0,2,0,7,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,-1,-1,-1,15763,-1,0.9920151,0.007984806
15765,nephrotic syndromes,3,5,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15765,-1,0.0009033909,0.99909663
15767,hypoalbuminemia,9,10,59,74,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15767,-1,0.000995459,0.99900454
15769,increase in blood nitrogen urea,13,18,101,132,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15769,-1,0.10885854,0.8911415
15770,puromycin aminonucleoside,25,27,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15770,-1,0.99724257,0.0027574361
15771,Dup 753,34,36,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15771,-1,0.9974049,0.0025950684
15774,hearing loss,9,11,72,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,-1,-1,-1,15774,-1,0.0016942596,0.9983057
15775,hearing loss,17,19,110,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,-1,-1,-1,15775,-1,0.0020370453,0.99796295
15778,hearing loss,16,18,100,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,-1,-1,-1,15778,-1,0.0017778559,0.9982222
15780,Lymphoma,5,6,34,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15780,-1,0.0012201641,0.99877983
15782,mg,17,18,110,112,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15782,-1,0.9161956,0.08380439
15784,neuropathic symptoms,7,9,47,67,The patients were interviewed with emphasis on neuropathic symptoms.,8384253_2,-1,-1,-1,15784,-1,0.001410427,0.9985896
15786,neuropathic symptoms,3,5,31,51,Twenty-seven patients reported neuropathic symptoms.,8384253_4,-1,-1,-1,15786,-1,0.0011713197,0.9988287
15787,signs and symptoms,4,7,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,-1,-1,-1,15787,-1,0.0017216023,0.9982784
15788,Neuropathic,0,1,0,11,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,-1,-1,15788,-1,0.0018356486,0.99816436
15790,signs and symptoms,11,14,72,90,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15790,-1,0.0030114027,0.9969886
15791,vincristine neuropathy,15,17,94,116,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15791,-1,0.67084205,0.32915798
15792,Sodium bicarbonate,0,2,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15792,-1,0.99808097,0.0019190952
15794,erectile dysfunction,10,12,83,103,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15794,-1,0.0009649328,0.9990351
15797,sodium bicarbonate,42,44,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,-1,15797,-1,0.9976706,0.0023293374
15798,impotence,12,13,68,77,A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml.,8386779_2,-1,-1,-1,15798,-1,0.0019002615,0.99809974
15799,mg,8,9,31,33,of a combination of 3 drugs: 6 mg.,8386779_3,-1,-1,-1,15799,-1,0.6711337,0.3288663
15801,phentolamine,0,1,0,12,phentolamine and 10 micrograms.,8386779_5,-1,-1,-1,15801,-1,0.99808323,0.0019167709
15802,prostaglandin E1,0,2,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15802,-1,0.9937332,0.006266727
15803,sodium bicarbonate,16,18,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15803,-1,0.9969175,0.003082527
15804,sodium bicarbonate,5,7,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15804,-1,0.99799925,0.0020007265
15806,sodium bicarbonate,38,40,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15806,-1,0.99826616,0.0017338133
15811,ddI,7,8,36,39,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15811,-1,0.99363375,0.0063662427
15813,(AZT)One,16,17,103,111,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15813,-1,0.653841,0.34615895
15815,AZT,25,26,169,172,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15815,-1,0.99650854,0.0034913898
15817,ddI,30,31,195,198,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15817,-1,0.9922029,0.007797078
15818,opportunistic infections,4,6,33,57,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15818,-1,0.0012210349,0.998779
15819,AIDS,14,15,96,100,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15819,-1,0.0017668011,0.9982332
15820,AIDS,12,13,68,72,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,-1,15820,-1,0.0017627556,0.99823725
15822,diarrhoea,5,6,32,41,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,-1,-1,-1,15822,-1,0.0010450816,0.9989549
15824,pancreatitis,7,8,50,62,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,-1,-1,15824,-1,0.0011128014,0.99888724
15825,abdominal pain,8,10,59,73,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,-1,-1,-1,15825,-1,0.0010727042,0.9989273
15829,adenomas,1,2,8,16,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15829,-1,0.0012832321,0.99871683
15830,nodular hyperplasia,4,6,27,46,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15830,-1,0.0014580103,0.99854195
15832,adenoma,4,5,21,28,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15832,-1,0.0012285853,0.99877137
15833,focal nodular hyperplasia,8,11,40,65,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15833,-1,0.0016975066,0.99830246
15835,adenoma,7,8,65,72,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15835,-1,0.0013707295,0.99862933
15836,focal nodular hyperplasia,9,12,77,102,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15836,-1,0.0022681628,0.99773186
15837,neurofilament,5,6,47,60,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15837,-1,0.64127386,0.35872614
15838,proteins,6,7,61,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15838,-1,0.14795683,0.8520432
15839,axonal damage,8,10,73,86,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15839,-1,0.0014157642,0.9985843
15840,axonal injury,26,28,160,173,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15840,-1,0.0017496519,0.9982503
15841,lactate,10,11,55,62,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15841,-1,0.9963457,0.0036543005
15842,Infarcts,0,1,0,8,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15842,-1,0.0014828078,0.9985172
15843,status epilepticus,11,13,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15843,-1,0.0011062382,0.9988938
15844,axonal damage,11,13,67,80,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15844,-1,0.0013997983,0.9986002
15845,traumatic,16,17,105,114,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15845,-1,0.0017497486,0.9982502
15846,ischemic lesions,18,20,118,134,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15846,-1,0.0013048061,0.9986952
15849,glutamic acid,9,11,56,69,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,-1,-1,15849,-1,0.9944174,0.0055826143
15854,neuronal degeneration,9,11,71,92,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15854,-1,0.0020191032,0.9979809
15855,glial fibrillary acidic protein,17,21,136,167,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15855,-1,0.4199218,0.58007824
15856,neuronal loss,36,38,257,270,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15856,-1,0.0018462227,0.99815375
15857,GABA,12,13,89,93,Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons.,8410199_9,-1,-1,-1,15857,-1,0.9735368,0.026463227
15858,confusion.15,9,10,83,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,-1,15858,-1,0.0066089067,0.99339116
15861,liver dysfunction,7,9,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15861,-1,0.0012528964,0.9987471
15862,P,10,11,55,56,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15862,-1,0.037420794,0.9625792
15864,P,27,28,150,151,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15864,-1,0.07226653,0.9277335
15869,hepatic dysfunction,17,19,116,135,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,-1,-1,-1,15869,-1,0.0010158429,0.99898416
15872,gallstone,16,17,107,116,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15872,-1,0.0016434963,0.9983565
15873,acromegalic,20,21,138,149,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15873,-1,0.0011897786,0.9988103
15874,acromegaly,17,18,120,130,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,-1,15874,-1,0.0011746885,0.99882525
15877,gallstones,12,13,71,81,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15877,-1,0.0013815305,0.9986185
15878,cholecystitis,18,19,105,118,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15878,-1,0.000963663,0.9990363
15881,gallstones,8,9,54,64,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,-1,-1,-1,15881,-1,0.0011448789,0.9988551
15882,gallstones,9,10,48,58,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,-1,-1,-1,15882,-1,0.0012681693,0.9987318
15884,gallstones,20,21,127,137,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15884,-1,0.0020070625,0.997993
15885,cholecystitis,23,24,143,156,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15885,-1,0.0010590431,0.998941
15887,acromegalic,29,30,194,205,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15887,-1,0.0016660555,0.998334
15889,acromegalic,17,18,116,127,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,-1,-1,-1,15889,-1,0.0013967475,0.9986033
15890,Parkinson disability,2,4,12,32,Increase of Parkinson disability after fluoxetine medication.,8423889_0,-1,-1,-1,15890,-1,0.0009783604,0.99902165
15893,Parkinson's disease,7,10,42,61,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,-1,-1,15893,-1,0.0017178186,0.9982822
15895,idiopathic Parkinson's disease,12,16,73,103,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15895,-1,0.0010964349,0.9989035
15896,antidepressant fluoxetine,20,22,126,151,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15896,-1,0.99767226,0.002327769
15898,Parkinson's disease,11,14,89,108,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,-1,-1,-1,15898,-1,0.0017393072,0.9982607
15911,anxiety,37,38,214,221,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,-1,15911,-1,0.008022942,0.99197704
15916,Sinus arrest,0,2,0,12,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,-1,-1,15916,-1,0.0012689445,0.9987311
15919,bradyarrhythmias,15,16,122,138,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,-1,15919,-1,0.0007902286,0.99920976
15920,leukemia,4,5,23,31,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15920,-1,0.00094120926,0.9990588
15921,cardiac disease,9,11,50,65,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15921,-1,0.0011443947,0.9988556
15922,sinus arrest,18,20,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15922,-1,0.0011007404,0.9988992
15927,sinus arrest,7,9,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,-1,15927,-1,0.0012170001,0.99878305
15930,erosive rheumatoid arthritis,12,15,78,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15930,-1,0.000946916,0.99905306
15931,RA,16,17,108,110,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15931,-1,0.0012022628,0.9987978
15933,gold,12,13,65,69,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,-1,-1,15933,-1,0.9967206,0.0032793477
15934,RA,26,27,140,142,"In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.",8441146_3,-1,-1,-1,15934,-1,0.001605129,0.9983949
15935,RA,6,7,40,42,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,-1,-1,-1,15935,-1,0.0012544381,0.99874556
15936,synovitis,20,21,129,138,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,-1,-1,-1,15936,-1,0.001024463,0.9989755
15939,fluvoxamine,6,7,36,47,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15939,-1,0.99884427,0.0011556855
15940,phenothiazines,8,9,53,67,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15940,-1,0.99835545,0.0016445011
15941,pentamidine,3,4,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,-1,-1,15941,-1,0.99862504,0.0013750318
15943,Pentamidine isethionate,0,2,0,23,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15943,-1,0.99800307,0.0019969866
15944,ventricular tachyarrhythmias,6,8,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15944,-1,0.0009723479,0.9990276
15945,torsade de pointes,10,13,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15945,-1,0.0018736807,0.9981263
15946,torsade de pointes,1,4,20,38,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15946,-1,0.0016685303,0.9983315
15948,hypomagnesemia,12,13,84,98,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15948,-1,0.0011877483,0.9988123
15949,torsade.,16,18,126,134,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15949,-1,0.008358893,0.99164104
15950,Torsade de pointes,0,3,0,18,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15950,-1,0.0015415518,0.9984585
15951,pentamidine,13,14,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15951,-1,0.9987734,0.001226539
15952,pentamidine,10,11,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,-1,-1,-1,15952,-1,0.9987748,0.0012251252
15953,Torsade de pointes,0,3,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15953,-1,0.0018725415,0.9981275
15954,pentamidine,14,15,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15954,-1,0.9987814,0.0012185889
15955,QTc interval prolongation,1,4,5,30,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,-1,-1,-1,15955,-1,0.003276215,0.99672383
15963,mg,40,41,234,236,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,15963,-1,0.9706646,0.029335372
15964,mg,48,49,261,263,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,15964,-1,0.97577274,0.02422725
15965,n,4,5,17,18,PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers.,8480959_4,-1,-1,-1,15965,-1,0.10461117,0.89538884
15967,triglycerides,20,21,111,124,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,-1,-1,-1,15967,-1,0.9284166,0.07158344
15969,P,23,24,108,109,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,15969,-1,0.1252811,0.87471884
15971,triglycerides,39,40,166,179,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,15971,-1,0.5438675,0.45613247
15976,creatine kinase,7,9,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,15976,-1,0.9763474,0.023652565
15978,mg,34,35,200,202,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,15978,-1,0.93147516,0.0685249
15986,hypokalemia,3,4,21,32,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,15986,-1,0.00096398534,0.9990361
15988,hypomagnesemia,7,8,51,65,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,15988,-1,0.0010472933,0.9989526
15989,hypokalemia,2,3,13,24,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15989,-1,0.0010416713,0.99895835
15990,muscle weakness,5,7,35,50,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15990,-1,0.0010561524,0.99894387
15991,hypomagnesemia,9,10,59,73,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15991,-1,0.0010597939,0.99894017
15992,muscle spasms,13,15,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15992,-1,0.0010657909,0.9989342
15996,diuretic,1,2,14,22,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15996,-1,0.948225,0.051775016
15997,obese,16,17,101,106,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15997,-1,0.0025499128,0.99745005
15998,edematous,18,19,110,119,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15998,-1,0.0013919121,0.9986082
15999,hypokalemia,1,2,12,23,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,-1,15999,-1,0.00089194946,0.999108
16007,acute renal failure,6,9,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,-1,-1,16007,-1,0.000972753,0.99902725
16010,Allergic interstitial nephritis,0,3,0,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,-1,-1,16010,-1,0.0012473607,0.9987526
16011,acute renal failure,19,22,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,-1,-1,16011,-1,0.00086359296,0.9991364
16012,Venous complications,0,2,0,20,Venous complications of midazolam versus diazepam.,8514073_0,-1,-1,-1,16012,-1,0.0020593647,0.9979406
16015,venous complications,6,8,43,63,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,-1,-1,-1,16015,-1,0.0018880499,0.99811196
16018,venous complications,6,8,44,64,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,-1,-1,-1,16018,-1,0.0014691507,0.99853086
16021,venous complications,2,4,9,29,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,16021,-1,0.0014131516,0.9985869
16024,p,25,26,123,124,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,16024,-1,0.07774,0.92226005
16027,p,36,37,148,149,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,-1,-1,-1,16027,-1,0.08138945,0.9186105
16031,p,35,36,148,149,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,-1,-1,16031,-1,0.05786594,0.942134
16032,Swelling,0,1,0,8,Swelling and warmth at the injection site were not significantly different between the two groups.,8514073_6,-1,-1,-1,16032,-1,0.001422569,0.9985775
16036,venous complications,32,34,180,200,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,-1,-1,16036,-1,0.00182963,0.9981704
16041,uremia,14,15,83,89,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16041,-1,0.0009669445,0.9990331
16042,se,16,17,94,96,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16042,-1,0.0046330327,0.99536693
16044,macrolide,13,14,92,101,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16044,-1,0.99498796,0.005012082
16045,clarithromycin,16,17,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16045,-1,0.9987907,0.00120936
16046,renal disease,10,12,52,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16046,-1,0.000982087,0.99901795
16047,ESRD,13,14,67,71,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16047,-1,0.0010779358,0.9989221
16048,clarithromycin,8,9,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16048,-1,0.99874336,0.0012566947
16050,aluminum,23,24,145,153,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16050,-1,0.96332264,0.036677342
16053,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,-1,16053,-1,0.0012380653,0.9987619
16054,hepatoma,7,8,50,58,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,16054,-1,0.0009048096,0.9990952
16055,hepatomas,2,3,15,24,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16055,-1,0.0010852369,0.9989147
16056,liver lesions,6,8,56,69,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16056,-1,0.0012658553,0.9987342
16057,hepatomas,4,5,21,30,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,-1,-1,16057,-1,0.0014586631,0.99854136
16060,hepatomas,17,18,96,105,"These cells proliferated further, replacing the most part of the nodules, and with this process hepatomas appeared to have been formed.",85485_6,-1,-1,-1,16060,-1,0.0015790504,0.99842095
16062,squamous cell esophageal carcinoma,7,11,44,78,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,-1,-1,16062,-1,0.0014974145,0.9985026
16066,VNB,27,28,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16066,-1,0.9932231,0.006776982
16067,squamous cell esophageal carcinoma,36,40,230,264,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16067,-1,0.0021556055,0.99784434
16069,VNB,0,1,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,-1,-1,-1,16069,-1,0.98102784,0.018972134
16070,CR,16,17,73,75,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,-1,16070,-1,0.0019202479,0.9980798
16071,DI,4,5,27,29,The median dose-intensity (DI) was 20 mg/m2/wk.,8558192_8,-1,-1,-1,16071,-1,0.018620502,0.98137945
16072,VNB,0,1,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,-1,-1,16072,-1,0.8953895,0.104610525
16074,granulocytopenia,9,10,37,53,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,-1,-1,-1,16074,-1,0.0008998609,0.9991002
16077,peripheral neurotoxicity,7,9,34,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,-1,-1,16077,-1,0.0012676006,0.9987324
16078,VNB,6,7,37,40,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16078,-1,0.9927401,0.007259918
16079,esophageal squamous cell carcinoma,13,17,74,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16079,-1,0.0019062473,0.9980938
16081,VNB,12,13,78,81,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,-1,-1,-1,16081,-1,0.9886312,0.011368781
16085,sodium chloride,30,32,202,217,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,-1,16085,-1,0.9980287,0.0019713223
16087,sodium chloride,25,27,131,146,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16087,-1,0.9975764,0.0024235952
16088,sodium chloride,33,35,171,186,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16088,-1,0.996617,0.0033829971
16092,MAP,13,14,92,95,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16092,-1,0.005643939,0.994356
16094,MAP,22,23,160,163,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16094,-1,0.0043052034,0.99569476
16096,MAP,17,18,124,127,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16096,-1,0.005715657,0.99428433
16097,sodium chloride,34,36,199,214,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16097,-1,0.9978022,0.0021978314
16098,sodium chloride,22,24,141,156,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,-1,16098,-1,0.99724543,0.0027545528
16099,aponidine hydrochloride,5,7,35,58,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,-1,-1,-1,16099,-1,0.99852884,0.0014711749
16100,apraclonidine,7,8,52,65,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16100,-1,0.9986817,0.0013182139
16101,apraclonidine,20,21,124,137,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16101,-1,0.99862397,0.0013760758
16102,ocular hypotensive,1,3,4,22,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16102,-1,0.001203337,0.9987967
16103,apraclonidine,29,30,224,237,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16103,-1,0.9986131,0.0013869164
16104,Decreases in systolic blood pressure,0,5,0,36,"Decreases in systolic blood pressure were statistically, but not clinically, significant.",8590259_4,-1,-1,-1,16104,-1,0.0025434617,0.9974565
16105,Conjunctival blanching,0,2,0,22,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16105,-1,0.0020753704,0.99792457
16106,mydriasis,3,4,27,36,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16106,-1,0.0015437913,0.99845624
16107,mm,16,17,83,85,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16107,-1,0.008212575,0.9917874
16108,entropion,31,32,174,183,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16108,-1,0.0011176117,0.99888235
16109,corneal abrasion,34,36,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16109,-1,0.0016780844,0.99832195
16117,mg,21,22,81,83,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16117,-1,0.93033093,0.06966903
16119,mg,34,35,124,126,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16119,-1,0.8953751,0.10462491
16121,Loss of consciousness,0,3,0,21,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16121,-1,0.0015439447,0.998456
16122,SD,16,17,78,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16122,-1,0.05130295,0.94869703
16123,C,42,43,170,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16123,-1,0.3781306,0.6218694
16124,P,50,51,187,188,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16124,-1,0.16807847,0.8319216
16125,P,14,15,64,65,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,16125,-1,0.12373086,0.87626916
16127,P,24,25,121,122,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,-1,16127,-1,0.17105527,0.82894474
16128,C,7,8,44,45,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,-1,16128,-1,0.18275766,0.8172424
16135,droperidol,3,4,27,37,Angioedema associated with droperidol administration.,8599504_0,-1,-1,-1,16135,-1,0.9980338,0.0019661917
16137,angioneurotic edema,5,7,26,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16137,-1,0.001298152,0.9987018
16138,Quincke's disease,8,11,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16138,-1,0.022217581,0.9777825
16140,drug allergies,13,15,73,87,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16140,-1,0.012761123,0.9872388
16142,tongue swelling,20,22,124,139,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16142,-1,0.0013082667,0.99869174
16143,droperidol,37,38,228,238,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16143,-1,0.99804986,0.0019501706
16145,malignant bone tumor,6,9,42,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,-1,-1,16145,-1,0.0012799895,0.99872005
16146,bone tumors,9,11,66,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16146,-1,0.0011464187,0.99885356
16147,Rosen's T5,16,19,108,118,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16147,-1,0.79115605,0.20884396
16148,T10,20,21,122,125,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16148,-1,0.7374511,0.2625489
16153,left ventricular dilation,30,33,167,192,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,-1,-1,16153,-1,0.001992997,0.998007
16154,cardiac abnormalities,3,5,17,38,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16154,-1,0.0013044942,0.99869555
16155,P,11,12,75,76,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16155,-1,0.1635342,0.83646584
16160,systemic hypertension,10,12,69,90,Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.,8607407_0,-1,-1,-1,16160,-1,0.0008778262,0.9991222
16165,n,4,5,29,30,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16165,-1,0.041741833,0.95825815
16166,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16166,-1,0.010079694,0.98992026
16167,mm Hg,30,32,144,149,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16167,-1,0.009260363,0.9907396
16168,n,3,4,19,20,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16168,-1,0.09316827,0.90683174
16170,mm Hg,19,21,102,107,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16170,-1,0.0052619507,0.99473804
16172,mm Hg,23,25,120,125,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16172,-1,0.00906721,0.9909328
16173,p,26,27,127,128,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16173,-1,0.111214384,0.8887856
16174,p,52,53,269,270,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16174,-1,0.1122794,0.8877206
16179,hypertensives,34,35,219,232,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,-1,16179,-1,0.0015542287,0.9984458
16181,disease progression,22,24,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,-1,-1,-1,16181,-1,0.0013327922,0.99866724
16183,cognitive impairment,9,11,63,83,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,-1,-1,-1,16183,-1,0.0010084646,0.99899155
16189,mg,12,13,65,67,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,-1,16189,-1,0.97285795,0.027142063
16192,Impairment of cognitive function,2,6,9,41,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,-1,-1,-1,16192,-1,0.0012910203,0.99870896
16200,cognitive impairment,8,10,52,72,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,-1,-1,-1,16200,-1,0.0010156257,0.9989844
16203,atracurium,6,7,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,-1,-1,16203,-1,0.99851054,0.0014894436
16205,Neuromuscular blocking agents,0,3,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,16205,-1,0.80344266,0.19655736
16207,vecuronium bromide,18,20,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,-1,-1,-1,16207,-1,0.99859136,0.001408643
16209,Atracurium besylate,0,2,0,19,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16209,-1,0.9980538,0.0019461882
16210,benzylisoquinolinium,5,6,36,56,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16210,-1,0.99580824,0.0041916976
16215,internal carotid artery thrombosis,6,10,41,75,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,-1,16215,-1,0.0023281942,0.9976718
16216,sex,13,14,102,105,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,-1,16216,-1,0.99030685,0.0096931765
16218,nausea and vomiting,8,11,61,80,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,16218,-1,0.0011901446,0.9988098
16219,hemiparesis,13,14,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,16219,-1,0.0008724636,0.99912757
16223,Diabetes mellitus,0,2,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16223,-1,0.0011420469,0.998858
16224,DM,3,4,19,21,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16224,-1,0.0014783992,0.9985216
16225,hemorrhagic infarct,4,6,29,48,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,-1,-1,16225,-1,0.0014213584,0.99857867
16226,venous sinus thrombosis,15,18,91,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,-1,-1,-1,16226,-1,0.0018485263,0.9981515
16227,occlusion,9,10,56,65,Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.,8638876_7,-1,-1,-1,16227,-1,0.0012838551,0.9987161
16230,DM,17,18,98,100,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,-1,-1,16230,-1,0.0068688276,0.9931312
16232,lung cancer,6,8,51,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,-1,-1,16232,-1,0.0013328228,0.99866724
16235,Taxol,2,3,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,16235,-1,0.9977264,0.0022736466
16239,lung cancer,18,20,120,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16239,-1,0.0013061464,0.9986939
16240,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16240,-1,0.0012527609,0.9987472
16245,NSCLC,24,25,139,144,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,-1,16245,-1,0.0014205262,0.9985795
16246,NSCLC,9,10,35,40,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,-1,16246,-1,0.0016341265,0.99836594
16248,disease progression,28,30,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,-1,-1,-1,16248,-1,0.0015746932,0.99842536
16249,Hematologic toxicities,0,2,0,22,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,-1,-1,16249,-1,0.0013879291,0.99861205
16253,Nausea and vomiting,0,3,0,19,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,-1,-1,16253,-1,0.0013972915,0.9986027
16257,NSCLC,12,13,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,-1,16257,-1,0.0018496731,0.99815035
16261,head and neck cancers,12,16,74,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,-1,-1,16261,-1,0.0019120142,0.99808794
16262,head and neck carcinomas,5,9,38,62,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,-1,-1,-1,16262,-1,0.0016042925,0.99839574
16264,Taxol,13,14,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16264,-1,0.99791175,0.0020881859
16265,head and neck cancer,32,36,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16265,-1,0.0017338778,0.99826616
16270,head and neck carcinoma,32,36,243,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,-1,-1,16270,-1,0.0016365352,0.99836344
16278,Alopecia,0,1,0,8,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16278,-1,0.0010913345,0.99890864
16279,paresthesias,2,3,10,22,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16279,-1,0.0011328165,0.99886715
16281,hematologic toxicity,2,4,17,37,No dose-limiting hematologic toxicity has been seen.,8643971_17,-1,-1,-1,16281,-1,0.0011202579,0.99887973
16282,head and neck cancer,9,13,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,-1,-1,16282,-1,0.0015704924,0.9984295
16288,Taxol,14,15,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,-1,16288,-1,0.99805754,0.0019424639
16298,granulocytopenia,11,12,80,96,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,-1,-1,16298,-1,0.0011026037,0.9988973
16301,disease progression,3,5,15,34,No patient had disease progression.,8643973_8,-1,-1,-1,16301,-1,0.001369469,0.9986305
16308,Parkinson's disease,7,10,61,80,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,-1,-1,-1,16308,-1,0.0011618392,0.9988381
16309,Parkinson's disease,4,7,30,49,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16309,-1,0.0012615001,0.99873847
16310,PD,8,9,51,53,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16310,-1,0.0011779165,0.99882203
16314,parkinsonian motor disability,14,17,84,113,There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability.,8649546_2,-1,-1,-1,16314,-1,0.00083887414,0.9991611
16318,PD,18,19,135,137,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,-1,-1,16318,-1,0.0012059025,0.9987941
16324,triamcinolone,24,25,116,129,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16324,-1,0.99873215,0.0012678638
16325,reduction of food,45,48,225,242,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16325,-1,0.05342658,0.9465735
16326,loss in body weight,6,10,35,54,This was associated with a similar loss in body weight.,8665051_4,-1,-1,-1,16326,-1,0.0035846108,0.9964154
16328,twitches,1,2,8,16,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16328,-1,0.0017176796,0.9982823
16329,C,9,10,52,53,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16329,-1,0.52706665,0.47293335
16330,p,32,33,124,125,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16330,-1,0.116507135,0.8834928
16331,NS,48,49,172,174,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16331,-1,0.060513396,0.93948656
16333,tetanic,20,21,111,118,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,-1,16333,-1,0.004309594,0.9956904
16335,p,22,23,130,131,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,-1,16335,-1,0.1626833,0.8373167
16340,muscle atrophy,24,26,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16340,-1,0.0013619135,0.9986381
16345,muscle necrosis,50,52,294,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,-1,16345,-1,0.0017203334,0.9982797
16347,nutritional deprivation,64,66,356,379,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,-1,16347,-1,0.12809877,0.8719012
16353,renal disease,26,28,173,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16353,-1,0.0010696942,0.9989303
16354,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16354,-1,0.0010758799,0.9989241
16358,ESRD,36,37,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,-1,16358,-1,0.0010315838,0.9989685
16361,ESRD,14,15,93,97,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,-1,-1,-1,16361,-1,0.0010044695,0.9989955
16367,ESRD,12,13,79,83,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,-1,-1,-1,16367,-1,0.0010088984,0.9989911
16369,hemorrhagic cystitis,8,10,78,98,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,-1,16369,-1,0.0008553137,0.9991447
16370,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,-1,-1,-1,16370,-1,0.0009178386,0.9990822
16378,emesis,34,35,223,229,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,-1,16378,-1,0.0009304296,0.99906963
16384,cardiovascular toxicities,6,8,43,68,The potential for acetaminophen to produce cardiovascular toxicities is very low.,8682684_2,-1,-1,-1,16384,-1,0.0011557797,0.99884415
16388,critically ill,4,6,27,41,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,-1,-1,16388,-1,0.0014174829,0.9985825
16395,Leg and back pain,0,4,0,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,-1,-1,-1,16395,-1,0.0014186349,0.9985814
16400,p,6,7,36,37,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16400,-1,0.1514784,0.84852153
16401,p,20,21,93,94,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16401,-1,0.13842662,0.86157334
16406,Leg and/or back pain,0,4,0,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,-1,16406,-1,0.0015731031,0.9984269
16411,cuprolinic blue,33,35,223,238,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,-1,16411,-1,0.99763536,0.0023646906
16412,heparan sulphate,1,3,4,20,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16412,-1,0.9898605,0.010139495
16413,cuprolinic blue,6,8,40,55,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16413,-1,0.9954094,0.0045905067
16415,p<0.001,33,34,202,209,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,-1,16415,-1,0.24655363,0.75344634
16419,h,13,14,82,83,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16419,-1,0.066744186,0.9332558
16420,contrast,18,19,102,110,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16420,-1,0.049538616,0.9504614
16421,h,31,32,155,156,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16421,-1,0.07536301,0.92463696
16422,p<0.002,33,34,158,165,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16422,-1,0.09350281,0.9064972
16423,heparan sulphate,8,10,32,48,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16423,-1,0.9954389,0.0045611816
16424,p<0.021,45,46,235,242,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16424,-1,0.2044022,0.7955978
16425,p<0.02,52,53,256,262,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16425,-1,0.14137802,0.858622
16426,heparan sulphate,15,17,104,120,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,-1,16426,-1,0.99270225,0.00729774
16429,MK-486,18,19,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,-1,16429,-1,0.99711156,0.0028884204
16433,FLA-63,0,1,0,6,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,-1,-1,16433,-1,0.9936041,0.0063959104
16436,Pimozide,0,1,0,8,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,-1,-1,-1,16436,-1,0.99862635,0.0013736673
16440,5-HTP,0,1,0,5,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,-1,-1,16440,-1,0.9967307,0.003269279
16446,Microangiopathic hemolytic anemia,0,3,0,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16446,-1,0.0010764848,0.9989235
16447,FK506,4,5,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16447,-1,0.99850273,0.001497322
16449,microangiopathic hemolytic anemia,5,8,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16449,-1,0.00095330103,0.99904674
16450,MAHA,9,10,61,65,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16450,-1,0.0012512738,0.99874866
16451,FK506,17,18,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16451,-1,0.99858165,0.0014183796
16453,FK506,6,7,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16453,-1,0.9986841,0.0013158633
16457,MAHA,28,29,173,177,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16457,-1,0.002643563,0.9973564
16458,FK506,6,7,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16458,-1,0.9984176,0.0015823398
16459,MAHA,12,13,67,71,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16459,-1,0.0020064781,0.9979936
16460,MAHA,1,2,17,21,FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.,8701950_4,-1,-1,-1,16460,-1,0.0014236491,0.9985764
16461,FK506,9,10,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16461,-1,0.9985973,0.001402636
16462,cyclosporin A,16,18,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16462,-1,0.99795616,0.0020437732
16463,CyA,19,20,106,109,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16463,-1,0.9943243,0.0056757205
16464,MAHA,29,30,163,167,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16464,-1,0.0029591122,0.9970408
16465,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,-1,-1,-1,16465,-1,0.40078592,0.5992141
16469,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,-1,-1,-1,16469,-1,0.37100813,0.6289919
16470,deoxycholic acid,6,8,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,-1,16470,-1,0.99665487,0.0033451288
16472,Deoxycholic acid,0,2,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,-1,16472,-1,0.9965976,0.0034024736
16473,deoxycholic acid,11,13,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16473,-1,0.9976209,0.0023790968
16474,taurodeoxycholic acid,14,16,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16474,-1,0.99768996,0.0023100192
16475,ethinyl estradiol,22,24,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16475,-1,0.99804354,0.001956434
16476,bile acid,8,10,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16476,-1,0.9609909,0.03900912
16477,taurocholic acid,8,10,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16477,-1,0.9964342,0.0035657382
16478,taurodeoxycholic acid,22,24,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16478,-1,0.99614644,0.00385354
16479,Ethinyl estradiol,0,2,0,17,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16479,-1,0.9978727,0.002127296
16480,deoxycholic acid,8,10,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16480,-1,0.99604815,0.0039518806
16481,taurodeoxycholic acid,20,22,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16481,-1,0.99647826,0.003521706
16482,P,32,33,182,183,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16482,-1,0.15166868,0.84833133
16483,deoxycholic acid,15,17,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,-1,16483,-1,0.99778134,0.0022186888
16484,deoxycholic acid,5,7,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16484,-1,0.9973436,0.0026564659
16485,taurocholic acid,13,15,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16485,-1,0.99733645,0.0026635397
16486,ethinyl estradiol,6,8,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16486,-1,0.9983652,0.0016347864
16487,bile acid,23,25,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16487,-1,0.7471965,0.25280344
16490,nitrogranulogen,8,9,51,66,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16490,-1,0.99651223,0.0034877271
16491,NG,10,11,68,70,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16491,-1,0.9955722,0.0044277203
16493,MTX,15,16,87,90,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16493,-1,0.99786264,0.0021373853
16495,5-FU,20,21,109,113,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16495,-1,0.9974794,0.0025206401
16497,CY,25,26,137,139,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16497,-1,0.99716264,0.002837346
16498,MTX,33,34,179,182,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16498,-1,0.99718744,0.0028125325
16499,5-FU,35,36,185,189,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16499,-1,0.99707854,0.002921439
16500,CY,37,38,192,194,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16500,-1,0.9964348,0.0035652253
16503,MTX,1,2,6,9,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16503,-1,0.9971275,0.0028724882
16504,p,7,8,49,50,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16504,-1,0.17556116,0.8244388
16506,p,20,21,119,120,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16506,-1,0.19514325,0.8048567
16508,NG,4,5,28,30,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16508,-1,0.9962788,0.0037212246
16509,5-FU,6,7,32,36,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16509,-1,0.99711156,0.0028883817
16510,CY,8,9,41,43,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16510,-1,0.99659926,0.0034007553
16513,CMF,5,6,39,42,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16513,-1,0.9706284,0.029371634
16514,p,13,14,90,91,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16514,-1,0.19286,0.80714005
16517,CY,0,1,0,2,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16517,-1,0.008596532,0.9914035
16518,hemorrhagic cystitis,2,4,10,30,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16518,-1,0.0009311958,0.9990688
16519,5-FU,20,21,105,109,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16519,-1,0.9975343,0.0024657303
16520,MTX,22,23,114,117,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16520,-1,0.9977616,0.0022383865
16521,MTX,10,11,69,72,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16521,-1,0.9978434,0.0021566288
16522,CY,12,13,74,76,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16522,-1,0.9971451,0.0028548476
16523,NG,14,15,81,83,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16523,-1,0.99620914,0.0037908128
16524,5-FU,23,24,125,129,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16524,-1,0.9975883,0.002411761
16525,MTX,28,29,158,161,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16525,-1,0.9974739,0.0025261322
16526,5-FU,30,31,164,168,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16526,-1,0.9974111,0.0025889422
16527,CY,32,33,171,173,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16527,-1,0.99661773,0.003382288
16529,MTX,6,7,44,47,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16529,-1,0.99704725,0.0029527715
16530,5-FU,8,9,50,54,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16530,-1,0.9973224,0.002677642
16531,CY,10,11,57,59,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16531,-1,0.9967514,0.0032486492
16533,kainic acid,5,7,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,-1,-1,-1,16533,-1,0.9984805,0.0015194758
16534,p,8,9,61,62,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16534,-1,0.33308256,0.66691744
16535,locomotor hypoactivity,21,23,110,132,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16535,-1,0.0015295022,0.9984705
16537,mg,28,29,157,159,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16537,-1,0.944126,0.055873983
16540,p,15,16,120,121,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,-1,16540,-1,0.26458988,0.73541015
16543,acetaminophen hepatotoxicity,7,9,44,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,-1,16543,-1,0.42056006,0.57943994
16544,nicotinic acid amide,8,11,58,78,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,-1,-1,16544,-1,0.99721885,0.0027811313
16547,NAD,13,14,75,78,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16547,-1,0.9969477,0.0030522675
16548,AAP hepatitis,27,29,139,152,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16548,-1,0.008803207,0.99119675
16550,Liver injuries,0,2,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,-1,16550,-1,0.0016619331,0.998338
16551,AAP,1,2,6,9,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16551,-1,0.9849296,0.015070407
16553,nicotinic acid amide,28,31,179,199,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16553,-1,0.9969928,0.0030072182
16554,NAA,32,33,201,204,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16554,-1,0.9965611,0.0034388618
16555,NAD,48,49,278,281,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16555,-1,0.9961618,0.0038381438
16556,AAP,17,18,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,-1,16556,-1,0.9920433,0.007956754
16561,NAA,11,12,56,59,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,-1,-1,-1,16561,-1,0.9971137,0.0028863102
16564,NAA,23,24,151,154,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16564,-1,0.99662846,0.0033715698
16565,NAD,33,34,205,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16565,-1,0.99571073,0.0042892178
16566,NAA,6,7,31,34,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,-1,-1,16566,-1,0.99647754,0.0035224543
16569,cognitive and functional deficits,1,5,19,52,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16569,-1,0.0013422852,0.9986577
16570,divalproex sodium,10,12,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16570,-1,0.99861324,0.0013867763
16572,bipolar disorder,14,16,94,110,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,-1,-1,-1,16572,-1,0.0017731738,0.9982268
16578,loss of creativity,33,36,189,207,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16578,-1,0.005303039,0.994697
16579,functional impairments,38,40,213,235,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16579,-1,0.0024609307,0.99753904
16582,divalproex sodium,12,14,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16582,-1,0.99865973,0.0013402067
16583,cognitive and functional impairments,17,21,120,156,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16583,-1,0.0012861836,0.99871385
16585,divalproex sodium,17,19,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16585,-1,0.9985917,0.0014082273
16586,"cognitive, motivational,",25,29,150,174,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16586,-1,0.03725891,0.96274114
16587,creative deficits,30,32,178,195,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16587,-1,0.0036323508,0.9963677
16590,divalproex sodium,7,9,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16590,-1,0.99851686,0.001483161
16594,loss of creativity,22,25,149,167,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16594,-1,0.0021357446,0.9978643
16595,functional impairments,27,29,173,195,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16595,-1,0.002017245,0.99798274
16597,tramadol,7,8,56,64,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,-1,-1,16597,-1,0.99878234,0.0012176869
16599,Tramadol,0,1,0,8,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16599,-1,0.99872607,0.0012739106
16600,cancer pain,17,19,110,121,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16600,-1,0.0017437612,0.99825627
16603,dosulepine hydrochloride,9,11,59,83,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16603,-1,0.99850684,0.0014931451
16604,tetraparetic,13,14,89,101,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16604,-1,0.0017130212,0.9982869
16605,chronic pain,16,18,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16605,-1,0.0012377842,0.99876225
16607,tramadol,21,22,152,160,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,-1,-1,16607,-1,0.9986985,0.00130146
16611,calcium chloride,2,4,10,26,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16611,-1,0.99785054,0.0021494422
16612,4-aminopyridine,5,6,31,46,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16612,-1,0.99800533,0.001994687
16613,desipramine toxicity,8,10,58,78,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16613,-1,0.66898173,0.33101827
16615,antidepressant overdose,11,13,73,96,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,-1,-1,-1,16615,-1,0.11638168,0.88361835
16622,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16622,-1,0.99492764,0.0050723646
16623,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16623,-1,0.9972156,0.0027843679
16624,antidepressant desipramine,5,7,41,67,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,-1,-1,16624,-1,0.9975286,0.0024713743
16627,CaCl2,6,7,36,41,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16627,-1,0.99621695,0.0037830449
16628,NaHCO3,8,9,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16628,-1,0.995023,0.0049769683
16629,antidepressant desipramine,8,10,48,74,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16629,-1,0.99769187,0.0023081847
16630,4-aminopyridine,16,17,100,115,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16630,-1,0.99799746,0.0020025345
16631,NaHCO3,2,3,9,15,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,-1,16631,-1,0.9967438,0.0032562115
16633,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16633,-1,0.9969849,0.003015139
16634,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16634,-1,0.99779093,0.0022091118
16636,p,6,7,42,43,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16636,-1,0.040343262,0.9596567
16638,p,13,14,67,68,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16638,-1,0.032106668,0.96789336
16639,CaCl2,19,20,84,89,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16639,-1,0.99593145,0.004068619
16640,CaCl2,5,6,34,39,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16640,-1,0.9972007,0.0027992746
16641,4-aminopyridine,7,8,43,58,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16641,-1,0.9978672,0.0021326907
16643,CaCl2,0,1,0,5,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16643,-1,0.9975591,0.0024409173
16644,central nervous system toxicity,8,12,58,89,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16644,-1,0.0011335398,0.99886644
16662,cerebral hypoxia,9,11,58,74,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,-1,-1,-1,16662,-1,0.0009616293,0.99903846
16663,comatose,5,6,32,40,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16663,-1,0.001375399,0.99862456
16664,stuporous,7,8,44,53,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16664,-1,0.0016528174,0.99834716
16665,hypoxic,16,17,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16665,-1,0.0016112408,0.99838877
16666,chlormethiazole,6,7,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16666,-1,0.9988306,0.0011693821
16667,alcohol withdrawal symptoms,8,11,58,85,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16667,-1,0.06668304,0.93331695
16669,nitrazepam,19,20,123,133,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16669,-1,0.9985599,0.0014400881
16670,nitrazepam overdose,3,5,17,36,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16670,-1,0.29944503,0.7005549
16671,chlormethiazole,10,11,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16671,-1,0.9986155,0.0013845415
16673,chlormethiazole,7,8,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,-1,-1,-1,16673,-1,0.9987373,0.0012626997
16674,neurological sequelae,5,7,38,59,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,-1,-1,-1,16674,-1,0.0010653301,0.9989347
16677,hypoxaemia,21,22,139,149,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,-1,-1,-1,16677,-1,0.0010056295,0.9989944
16678,Valsartan,0,1,0,9,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16678,-1,0.99865794,0.0013420896
16680,essential hypertension,11,13,64,86,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16680,-1,0.0012338333,0.9987662
16681,amlodipine,23,24,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16681,-1,0.9984377,0.0015622892
16682,valsartan,14,15,88,97,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16682,-1,0.9987669,0.0012330906
16683,amlodipine,21,22,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16683,-1,0.99865,0.001350039
16685,mg valsartan,24,26,165,177,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16685,-1,0.9931764,0.0068236445
16686,mg amlodipine,28,30,183,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16686,-1,0.99314296,0.0068569803
16687,mg amlodipine,15,17,84,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,-1,-1,-1,16687,-1,0.99241626,0.0075836726
16688,valsartan,3,4,14,23,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16688,-1,0.99862087,0.0013791044
16689,amlodipine,5,6,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16689,-1,0.99856746,0.001432478
16690,mm Hg,8,10,48,53,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16690,-1,0.014263083,0.98573685
16691,valsartan,13,14,66,75,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16691,-1,0.9983188,0.0016812675
16692,p,15,16,77,78,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16692,-1,0.11306126,0.88693875
16693,valsartan,9,10,42,51,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16693,-1,0.9987066,0.00129339
16694,amlodipine,14,15,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16694,-1,0.99860734,0.0013927427
16695,p,16,17,78,79,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16695,-1,0.08596135,0.91403866
16697,amlodipine,11,12,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16697,-1,0.9987117,0.0012882972
16698,mg,20,21,120,122,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16698,-1,0.92420655,0.07579348
16699,mg valsartan,28,30,144,156,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16699,-1,0.9932203,0.006779669
16700,mg amlodipine,35,37,169,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16700,-1,0.9916819,0.008318147
16701,valsartan,41,42,191,200,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16701,-1,0.99873644,0.0012635937
16702,mg amlodipine,44,46,208,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16702,-1,0.9913367,0.0086632855
16703,mg amlodipine,51,53,236,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16703,-1,0.99106663,0.008933374
16704,valsartan,6,7,32,41,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16704,-1,0.9987307,0.001269232
16705,amlodipine,13,14,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16705,-1,0.998638,0.0013619964
16707,valsartan,4,5,22,31,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16707,-1,0.9985655,0.001434534
16708,dihydropyridine calcium,25,27,150,173,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16708,-1,0.99778855,0.0022114832
16709,pupillary oscillation,3,5,13,34,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16709,-1,0.001694997,0.99830496
16710,paranoia,10,11,66,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16710,-1,0.0012500915,0.99874985
16711,paranoia,1,2,16,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16711,-1,0.0012003959,0.99879956
16712,CIP,3,4,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16712,-1,0.0020861041,0.9979139
16713,paranoia,12,13,85,93,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16713,-1,0.0010719876,0.998928
16714,pupillary oscillation,2,4,12,33,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16714,-1,0.003375024,0.99662495
16715,crack cocaine,13,15,94,107,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16715,-1,0.9913049,0.008695118
16716,CIP,18,19,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16716,-1,0.0025296165,0.9974704
16717,n,20,21,136,137,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16717,-1,0.0538248,0.9461752
16718,crack,28,29,166,171,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16718,-1,0.9894224,0.010577562
16719,CIP,33,34,196,199,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16719,-1,0.0026461615,0.9973538
16720,n,35,36,201,202,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16720,-1,0.04872631,0.9512737
16722,phenytoin overdosages,10,12,75,96,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,-1,-1,16722,-1,0.6112301,0.3887699
16724,cerebellar atrophy,14,16,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,-1,-1,16724,-1,0.0008977918,0.99910223
16728,phenytoin overdosage,3,5,17,37,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16728,-1,0.5144223,0.48557773
16729,cerebellar atrophy,10,12,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16729,-1,0.0009919918,0.999008
16731,cerebellar atrophy,24,26,155,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16731,-1,0.0009786435,0.9990213
16732,cerebellar disorders,13,15,103,123,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,-1,-1,-1,16732,-1,0.0011761722,0.9988238
16733,Serotonin syndrome,0,2,0,18,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,-1,-1,-1,16733,-1,0.0060271397,0.99397284
16736,muscle rigidity,17,19,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16736,-1,0.0012169123,0.99878305
16740,monoamine oxidase,12,14,67,84,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,-1,-1,-1,16740,-1,0.99533373,0.0046662963
16746,serotonin syndrome,9,11,62,80,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16746,-1,0.013511376,0.98648864
16747,tranylcypromine,18,19,115,130,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16747,-1,0.9985049,0.0014951975
16750,h,2,3,9,10,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,-1,-1,-1,16750,-1,0.014403299,0.9855967
16753,agitated,13,14,63,71,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16753,-1,0.0013084599,0.9986915
16756,salivation,24,25,128,138,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16756,-1,0.0012962302,0.9987037
16757,diaphoresis,26,27,143,154,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16757,-1,0.0011969352,0.998803
16758,mm,4,5,18,20,His pupils were 7 mm and sluggishly reactive to light.,8888541_8,-1,-1,-1,16758,-1,0.009070526,0.9909294
16759,mm Hg,7,9,40,45,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16759,-1,0.0137947295,0.9862053
16760,mg,24,25,124,126,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16760,-1,0.7672755,0.23272452
16762,muscle rigidity,33,35,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16762,-1,0.0020209353,0.9979791
16763,hypoventilation,9,10,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16763,-1,0.0010206797,0.9989793
16764,paralyzed,13,14,79,88,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16764,-1,0.0023901204,0.99760985
16765,muscle rigidity,16,18,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16765,-1,0.001447486,0.9985525
16768,neuromuscular paralysis,11,13,74,97,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,-1,-1,-1,16768,-1,0.00088986044,0.99911016
16771,HUS,10,11,53,56,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,-1,-1,16771,-1,0.0010111438,0.9989888
16776,HUS,6,7,42,45,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16776,-1,0.0008889994,0.999111
16777,oliguria,18,19,115,123,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16777,-1,0.0009394134,0.9990606
16778,HUS,7,8,41,44,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16778,-1,0.000908173,0.99909186
16780,microangiopathic hemolytic anemia,27,30,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16780,-1,0.00093911955,0.9990609
16784,urothelial cancer,15,17,102,119,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,-1,-1,-1,16784,-1,0.001610707,0.99838936
16788,transitional cell carcinoma,9,12,38,65,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,-1,-1,16788,-1,0.003442266,0.99655765
16791,bladder tumor,4,6,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,-1,-1,16791,-1,0.001506234,0.9984938
16792,bladder tumors,12,14,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,-1,-1,16792,-1,0.0018571243,0.99814284
16794,valproate,11,12,96,105,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,-1,16794,-1,0.99873275,0.0012673059
16795,sodium valproate,7,9,61,77,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16795,-1,0.9983883,0.0016117886
16796,neurological disorders,40,42,193,215,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16796,-1,0.001107339,0.9988927
16797,cerebellum damage,43,45,227,244,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16797,-1,0.0015488083,0.99845123
16798,valproate encephalopathy,47,49,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16798,-1,0.65176517,0.34823483
16802,valproate encephalopathy,15,17,93,117,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,-1,-1,16802,-1,0.6670711,0.33292887
16803,intracranial bleeding,1,3,6,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,-1,-1,-1,16803,-1,0.0012252139,0.9987748
16806,pulmonary edema,23,25,126,141,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16806,-1,0.00090381835,0.99909616
16807,wheezing,26,27,147,155,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16807,-1,0.0009726334,0.9990274
16808,respiratory distress,4,6,20,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,-1,-1,16808,-1,0.0013571719,0.99864286
16812,subarachnoid hemorrhage,7,9,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,-1,-1,16812,-1,0.0012223206,0.9987777
16824,Hoe-140,24,25,192,199,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,-1,16824,-1,0.99763036,0.0023695908
16829,antipurine,7,8,32,42,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16829,-1,0.958821,0.04117899
16830,lometrexol,9,10,54,64,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16830,-1,0.9984914,0.0015085938
16831,DDATHF,11,12,66,72,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16831,-1,0.9973036,0.0026963262
16832,folic acid,16,18,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16832,-1,0.9983041,0.0016958541
16833,Lometrexol,0,1,0,10,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16833,-1,0.9984787,0.0015212694
16835,purine,19,20,129,135,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16835,-1,0.9936102,0.0063897492
16836,lometrexol,9,10,65,75,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16836,-1,0.9986513,0.0013486485
16837,tumours,13,14,97,104,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16837,-1,0.001847712,0.9981523
16839,lometrexol,7,8,45,55,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,-1,-1,-1,16839,-1,0.99849665,0.0015033444
16842,lometrexol,8,9,61,71,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16842,-1,0.99865,0.0013500456
16843,folic acid,15,17,101,111,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16843,-1,0.99844605,0.0015539993
16844,lometrexol,9,10,54,64,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16844,-1,0.998486,0.0015140467
16845,folic acid,12,14,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16845,-1,0.99842715,0.0015729145
16847,lometrexol,22,23,144,154,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16847,-1,0.9985257,0.0014743528
16848,folic acid,28,30,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16848,-1,0.998293,0.0017070473
16853,folate,13,14,83,89,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,-1,-1,16853,-1,0.997051,0.0029489864
16854,lometrexol,4,5,37,47,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16854,-1,0.99846447,0.0015355307
16855,folic acid,11,13,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16855,-1,0.9985298,0.0014701945
16857,lometrexol,24,25,194,204,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16857,-1,0.9984509,0.0015491225
16861,cocaine toxicity,15,17,108,124,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,-1,-1,16861,-1,0.18564063,0.8143593
16864,EDDs,11,12,73,77,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,-1,-1,16864,-1,0.00243821,0.9975618
16866,EDDs,19,20,90,94,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16866,-1,0.0024232909,0.9975768
16867,cocaine overdose,27,29,140,156,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16867,-1,0.073289506,0.92671055
16869,EDDs,4,5,24,28,"Compared with controls, EDDs were more frequently black, male, and younger.",8988571_3,-1,-1,-1,16869,-1,0.0019186382,0.9980813
16872,EDDs,0,1,0,4,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,-1,-1,-1,16872,-1,0.0021809891,0.99781907
16880,sudden death,37,39,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,-1,16880,-1,0.0013344041,0.9986656
16882,preterm infants,7,9,46,61,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,-1,-1,16882,-1,0.002365488,0.99763453
16883,preterm infants,2,4,10,25,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,-1,-1,16883,-1,0.0027255332,0.99727446
16885,hearing loss,6,8,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16885,-1,0.0012496178,0.9987503
16886,birth weight,20,22,125,137,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16886,-1,0.004632349,0.99536765
16887,perinatal complications,24,26,146,169,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16887,-1,0.0013347283,0.99866533
16888,hearing loss,6,8,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,-1,-1,-1,16888,-1,0.0013257811,0.9986743
16890,ototoxic,13,14,92,100,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,-1,-1,16890,-1,0.0014257494,0.99857426
16893,hearing loss,17,19,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,-1,-1,-1,16893,-1,0.0018033184,0.99819666
16894,Pemoline,0,1,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16894,-1,0.99731785,0.0026821715
16895,choreoathetosis,3,4,23,38,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16895,-1,0.0012130424,0.998787
16896,Pemoline,2,3,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16896,-1,0.99852365,0.0014764
16897,oxazolidine,5,6,27,38,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16897,-1,0.9983505,0.0016495208
16898,amphetamines,12,13,86,98,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16898,-1,0.99763274,0.0023672455
16899,attention deficit disorder,19,22,128,154,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16899,-1,0.0017899941,0.9982101
16900,Pemoline,0,1,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16900,-1,0.9981596,0.0018404041
16901,movement disorders,14,16,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16901,-1,0.0010091763,0.99899083
16902,pemoline,9,10,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16902,-1,0.9976599,0.0023401016
16903,choreoathetosis,13,14,98,113,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16903,-1,0.0012152721,0.9987847
16904,emergency department,14,16,76,96,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16904,-1,0.009852373,0.99014765
16905,pemoline,25,26,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16905,-1,0.9976223,0.0023776987
16906,attention deficit disorder,8,11,51,77,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,-1,-1,-1,16906,-1,0.001816631,0.9981833
16908,pemoline,6,7,28,36,This was their first day of pemoline therapy.,9022662_6,-1,-1,-1,16908,-1,0.9980691,0.0019309086
16909,choreoathetoid movements,1,3,4,28,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16909,-1,0.0017450076,0.99825495
16910,h,8,9,47,48,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16910,-1,0.03784059,0.9621594
16911,movement disorders,7,9,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16911,-1,0.0010516876,0.9989484
16912,movement disorders,16,18,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16912,-1,0.001051088,0.998949
16914,choreoathetoid movements,17,19,130,154,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,-1,-1,-1,16914,-1,0.0018939683,0.998106
16915,choreoathetosis,8,9,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,-1,-1,-1,16915,-1,0.0013121782,0.9986878
16916,Pemoline,2,3,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16916,-1,0.9976255,0.0023745198
16917,movement disorder,4,6,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16917,-1,0.0011352489,0.99886477
16918,choreoathetoid movements,3,5,19,43,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16918,-1,0.0013751254,0.9986249
16919,pemoline overdose,12,14,94,111,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16919,-1,0.2784534,0.72154665
16921,venlafaxine overdose,4,6,25,45,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,-1,-1,16921,-1,0.66068107,0.33931893
16922,venlafaxine overdose,7,9,31,51,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,-1,-1,-1,16922,-1,0.6666114,0.33338866
16926,suicide,17,18,103,110,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,-1,-1,-1,16926,-1,0.0022782735,0.99772173
16930,venlafaxine overdose,13,15,65,85,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,-1,-1,16930,-1,0.6694348,0.33056515
16933,venlafaxine overdose,3,5,17,37,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16933,-1,0.6336762,0.36632386
16935,elevated intraocular pressure,12,15,65,94,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16935,-1,0.0016186214,0.9983814
16936,IOP,16,17,96,99,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16936,-1,0.0018321744,0.99816775
16937,corticosteroid,21,22,121,135,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16937,-1,0.9974477,0.0025522776
16938,rise,4,5,34,38,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16938,-1,0.002628332,0.9973717
16939,functional impairment,10,12,61,82,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16939,-1,0.0017801599,0.9982198
16941,hydrogen peroxide,3,5,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,-1,-1,16941,-1,0.99627507,0.003724974
16944,hydrogen peroxide,4,6,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16944,-1,0.9974138,0.0025862318
16945,bacterial infections,15,17,98,118,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16945,-1,0.0016591634,0.99834085
16947,ALF,24,25,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16947,-1,0.0009889228,0.99901104
16949,ALF,11,12,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16949,-1,0.0017364029,0.99826366
16950,paracetamol overdose,14,16,76,96,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16950,-1,0.5712499,0.4287501
16951,ALF,3,4,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16951,-1,0.0031815108,0.9968184
16952,ALF,15,16,107,110,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16952,-1,0.012453647,0.9875464
16954,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16954,-1,0.9946209,0.0053790207
16955,ALF,6,7,47,50,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16955,-1,0.019814312,0.98018575
16956,ALF,13,14,102,105,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16956,-1,0.20662124,0.7933788
16957,P,24,25,174,175,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16957,-1,0.19014785,0.8098521
16958,P,12,13,72,73,This defect persisted when zymosan opsonized by control serum was used (P < 0.05).,9061311_5,-1,-1,-1,16958,-1,0.15513462,0.84486544
16960,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16960,-1,0.99502605,0.004973953
16961,fMLP,11,12,114,118,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16961,-1,0.99447674,0.005523316
16962,ALF,17,18,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16962,-1,0.0023615023,0.99763846
16963,ALF,8,9,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,16963,-1,0.0017947525,0.9982052
16964,P,15,16,102,103,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,16964,-1,0.14738746,0.8526125
16965,ALF,7,8,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,16965,-1,0.0013254245,0.99867463
16966,paracetamol overdose,10,12,60,80,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,16966,-1,0.5937949,0.40620512
16967,Cholesteryl hemisuccinate,0,2,0,25,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16967,-1,0.99235815,0.0076418663
16970,carbon tetrachloride,14,16,106,126,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16970,-1,0.99781454,0.0021854672
16971,chloroform,17,18,128,138,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16971,-1,0.9975067,0.002493315
16972,galactosamine,19,20,143,156,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16972,-1,0.99765956,0.0023403838
16973,cholesteryl hemisuccinate,11,13,64,89,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16973,-1,0.99557436,0.004425667
16974,tris salt,14,16,91,100,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16974,-1,0.9890665,0.010933569
16975,CS,17,18,102,104,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16975,-1,0.99426395,0.005736085
16977,carbon tetrachloride,32,34,189,209,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16977,-1,0.9974323,0.0025677301
16978,CCl4,35,36,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16978,-1,0.9905414,0.009458625
16979,CS,8,9,49,51,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16979,-1,0.99092144,0.009078571
16980,CS,21,22,125,127,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16980,-1,0.99479735,0.0052026757
16981,ether,25,26,153,158,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16981,-1,0.8739571,0.12604289
16982,CS,28,29,167,169,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16982,-1,0.9923677,0.007632351
16983,tris salt,33,35,205,214,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16983,-1,0.97747326,0.022526786
16984,CSE,36,37,216,219,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16984,-1,0.96979654,0.030203452
16985,carbon,43,44,258,264,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16985,-1,0.9967914,0.003208509
16987,CS,13,14,64,66,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16987,-1,0.9951074,0.004892569
16989,CCl4,30,31,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16989,-1,0.99345016,0.0065498524
16990,CHCl3,32,33,161,166,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16990,-1,0.9967691,0.00323091
16992,galactosamine,36,37,186,199,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16992,-1,0.9978623,0.0021376954
16995,h,10,11,82,83,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,-1,16995,-1,0.15452582,0.8454742
16996,CS,4,5,24,26,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,-1,16996,-1,0.95167696,0.048323065
16998,CS,3,4,17,19,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,16998,-1,0.9614215,0.03857848
16999,galactosamine hepatotoxicity,30,32,185,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,16999,-1,0.21853556,0.7814644
17000,CS,15,16,78,80,"However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.",9067481_8,-1,-1,-1,17000,-1,0.9942999,0.0057001426
17001,CS,16,17,101,103,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17001,-1,0.9897232,0.01027681
17002,CSE,20,21,131,134,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17002,-1,0.9584624,0.04153753
17003,CS,25,26,156,158,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17003,-1,0.98852134,0.011478619
17004,prostaglandin,4,5,30,43,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,-1,-1,17004,-1,0.99609804,0.0039019664
17007,prostaglandin E1,4,6,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,-1,-1,17007,-1,0.99619055,0.0038094637
17010,n,16,17,79,80,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17010,-1,0.05645594,0.9435441
17012,n,32,33,153,154,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17012,-1,0.04827605,0.95172393
17014,n,45,46,206,207,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17014,-1,0.056160904,0.94383913
17020,PGE1,10,11,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,17020,-1,0.9976283,0.002371781
17021,ketone body,3,5,31,42,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,-1,-1,-1,17021,-1,0.3732102,0.62678987
17026,impairment of hepatic function,20,24,137,167,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,-1,-1,17026,-1,0.0014925167,0.99850744
17027,adenomyosis,4,5,18,29,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17027,-1,0.0010236143,0.99897647
17029,fluoxetine hydrochloride,12,14,76,100,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17029,-1,0.99867177,0.0013282374
17031,adenomyosis,22,23,147,158,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17031,-1,0.0012029726,0.99879706
17034,adenomyosis,26,27,170,181,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,-1,17034,-1,0.001106584,0.99889344
17039,adenomyosis,6,7,42,53,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,-1,17039,-1,0.0011048348,0.9988952
17042,adenomyosis,5,6,39,50,This invasion eventually progresses to adenomyosis.,9098464_10,-1,-1,-1,17042,-1,0.0013406314,0.9986594
17043,Cardiovascular alterations,0,2,0,26,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17043,-1,0.0015671918,0.9984328
17044,calcium channel blockers,7,10,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17044,-1,0.99403894,0.00596108
17046,Ro 40-5967,11,15,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17046,-1,0.9918799,0.0081201065
17047,cardiovascular alterations,17,19,104,130,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17047,-1,0.0012481596,0.9987519
17048,calcium channel blockers,10,13,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17048,-1,0.9919178,0.008082273
17049,cardiovascular malformations,16,18,109,137,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17049,-1,0.001190284,0.9988097
17050,calcium channel blockers,3,6,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,-1,-1,-1,17050,-1,0.97824544,0.021754595
17054,calcium channel blockers,7,10,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17054,-1,0.99259865,0.0074014026
17055,cardiovascular malformations,26,28,167,195,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17055,-1,0.0012264649,0.9987735
17056,cardiovascular malformations,4,6,19,47,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17056,-1,0.0011162637,0.9988838
17057,calcium channel blockers,15,18,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17057,-1,0.99519736,0.004802664
17060,Ro 40-5967,16,20,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,-1,-1,-1,17060,-1,0.99553764,0.0044623557
17062,ventricular septal defect,1,4,15,40,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,-1,17062,-1,0.0020843884,0.99791557
17064,ventricular septal rupture,4,7,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,-1,-1,17064,-1,0.0015113926,0.99848855
17067,septal rupture,9,11,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,-1,-1,-1,17067,-1,0.0019142885,0.99808574
17070,status epilepticus,11,13,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,-1,-1,17070,-1,0.0010735529,0.99892646
17072,deoxycorticosterone,12,13,96,115,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,-1,-1,-1,17072,-1,0.99784863,0.0021514068
17075,5-H,9,10,60,63,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,17075,-1,0.95910656,0.0408934
17078,status epilepticus,31,33,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,17078,-1,0.0011418636,0.9988581
17080,benzodiazepine clonazepam,10,12,73,98,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17080,-1,0.9977755,0.0022244428
17081,pilocarpine seizures,15,17,121,141,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17081,-1,0.50473773,0.4952623
17083,motor impairment,34,36,250,266,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17083,-1,0.0012728003,0.99872714
17085,clonazepam,44,45,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17085,-1,0.9982492,0.00175088
17090,kainic acid,23,25,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,-1,17090,-1,0.9982901,0.0017098889
17094,status epilepticus,27,29,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,-1,-1,17094,-1,0.0011043146,0.99889565
17096,NMDA,8,9,51,55,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17096,-1,0.9925458,0.0074541485
17097,NMDA seizures,22,24,132,145,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17097,-1,0.084770985,0.91522896
17100,status epilepticus,17,19,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17100,-1,0.0009437767,0.9990563
17101,status epilepticus,34,36,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17101,-1,0.0009077438,0.9990922
17102,nephrotic syndrome,10,12,76,94,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,-1,17102,-1,0.0009425536,0.9990575
17103,nephrotic syndrome,15,17,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17103,-1,0.0011898329,0.9988102
17104,NS,18,19,127,129,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17104,-1,0.0034488984,0.99655104
17105,ribonucleic acid,5,7,27,43,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,-1,17105,-1,0.68730986,0.3126901
17107,NS,0,1,0,2,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17107,-1,0.004996971,0.99500304
17108,PAN,11,12,68,71,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17108,-1,0.9947437,0.005256328
17109,PAN,17,18,100,103,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17109,-1,0.9879871,0.012012964
17110,NS,21,22,120,122,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17110,-1,0.100937456,0.8990626
17111,PAN,36,37,155,158,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,-1,17111,-1,0.982633,0.017367013
17112,NS,19,20,118,120,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17112,-1,0.0041737254,0.9958263
17113,PAN,22,23,132,135,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17113,-1,0.8700948,0.1299052
17114,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome with risperidone.,9165568_0,-1,-1,-1,17114,-1,0.0034544833,0.9965455
17116,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,-1,-1,17116,-1,0.0042897477,0.99571025
17119,benzisoxazole,3,4,15,28,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17119,-1,0.9985461,0.0014539541
17120,serotonin 5-HT2,9,11,64,79,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17120,-1,0.9879886,0.012011441
17124,neuroleptic malignant syndrome,14,17,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,-1,-1,17124,-1,0.006705927,0.9932941
17125,neuroleptic malignant syndrome,4,7,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,-1,-1,17125,-1,0.003764691,0.9962353
17128,dantrolene,10,11,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,-1,-1,-1,17128,-1,0.99864644,0.0013536091
17131,neuroleptic malignant syndrome,17,20,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,-1,-1,-1,17131,-1,0.0066279513,0.9933721
17133,Atypical sensations,0,2,0,19,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,-1,-1,-1,17133,-1,0.0020192433,0.9979808
17135,tingling,5,6,32,40,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17135,-1,0.0016191031,0.9983809
17136,burning sensations,7,9,44,62,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17136,-1,0.0016580976,0.9983419
17137,sunburn,16,17,100,107,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17137,-1,0.003233459,0.99676657
17141,endophthalmitis,11,12,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,-1,-1,17141,-1,0.001247489,0.9987525
17143,amikacin retinal toxicity,8,11,39,64,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17143,-1,0.48766539,0.5123346
17146,streptococcal endophthalmitis,19,21,135,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17146,-1,0.001212357,0.9987877
17147,Endophthalmitis,2,3,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,-1,-1,-1,17147,-1,0.0011849186,0.99881506
17149,telangiectasis,8,9,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,-1,-1,17149,-1,0.0012539972,0.99874604
17150,retinal toxicity,9,11,75,91,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17150,-1,0.0013603773,0.99863964
17151,ischaemia,13,14,104,113,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17151,-1,0.0010534283,0.9989466
17152,retinal toxicity,5,7,39,55,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,-1,-1,17152,-1,0.0011575383,0.99884254
17153,carteolol hydrochloride,4,6,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,-1,-1,-1,17153,-1,0.99829,0.0017099343
17155,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17155,-1,0.0015482213,0.9984517
17156,neuroleptic,23,24,149,160,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17156,-1,0.9952362,0.0047637513
17158,akathisia,20,21,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17158,-1,0.001085538,0.9989145
17160,akathisia,35,36,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17160,-1,0.0010394091,0.9989606
17161,carteolol,5,6,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17161,-1,0.9985172,0.0014827364
17164,biperiden,26,27,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17164,-1,0.99777454,0.0022254952
17165,Carteolol,0,1,0,9,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17165,-1,0.99847525,0.0015247036
17167,biperiden,7,8,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17167,-1,0.9980045,0.0019955349
17169,carteolol,4,5,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17169,-1,0.9983883,0.0016116872
17171,biperiden,19,20,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17171,-1,0.9894521,0.010547898
17172,Carteolol,0,1,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,17172,-1,0.99816173,0.0018383154
17174,Carteolol,0,1,0,9,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,-1,-1,-1,17174,-1,0.998223,0.0017769801
17176,carteolol,3,4,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17176,-1,0.99813867,0.0018613632
17177,head twitch,24,26,177,188,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17177,-1,0.0019658932,0.99803406
17178,carteolol,2,3,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,-1,17178,-1,0.99817,0.0018299059
17179,carteolol,5,6,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17179,-1,0.99839836,0.00160162
17181,akathisia,24,25,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17181,-1,0.0037141244,0.9962859
17182,antipsychotic,28,29,235,248,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17182,-1,0.98635757,0.013642468
17184,Granulosa cell tumor of the ovary,0,6,0,33,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,-1,17184,-1,0.0029579308,0.997042
17192,aspartate transaminase,1,3,4,26,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,-1,-1,-1,17192,-1,0.81297094,0.18702911
17193,alanine transaminase,4,6,31,51,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,-1,-1,-1,17193,-1,0.7035705,0.29642954
17195,granulosa cell tumor of the ovary,19,25,104,137,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,-1,-1,-1,17195,-1,0.0038054828,0.9961945
17196,liver dysfunction,5,7,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17196,-1,0.0011023555,0.9988977
17197,granulosa cell tumors,13,16,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17197,-1,0.0023754758,0.9976246
17200,AZT,7,8,48,51,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17200,-1,0.9948679,0.0051321248
17201,myelodysplasia,10,11,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17201,-1,0.00084094587,0.9991591
17202,AZT,0,1,0,3,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17202,-1,0.9972837,0.0027162614
17203,macrocytic anemia,4,6,18,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17203,-1,0.00092539546,0.9990746
17204,AIDS,7,8,39,43,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17204,-1,0.0013120128,0.99868804
17205,AZT,12,13,66,69,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17205,-1,0.997511,0.0024889838
17206,AZT,13,14,75,78,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17206,-1,0.996588,0.0034119533
17207,thymidine,20,21,106,115,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17207,-1,0.99763954,0.0023604734
17209,AZT,5,6,28,31,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17209,-1,0.99679595,0.0032040714
17210,H2O,8,9,43,46,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17210,-1,0.9868406,0.0131593915
17211,H2O,27,28,126,129,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17211,-1,0.9861351,0.013864788
17212,AZT,36,37,170,173,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17212,-1,0.99597794,0.004022146
17213,mg,47,48,224,226,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17213,-1,0.984329,0.015670987
17214,mg,9,10,39,41,At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).,9209318_4,-1,-1,-1,17214,-1,0.94711286,0.05288711
17216,myelodysplastic syndrome,14,16,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17216,-1,0.0011843375,0.99881566
17217,MDS,17,18,125,128,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17217,-1,0.0010093921,0.9989906
17218,hypocellular myelodysplasia,5,7,24,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17218,-1,0.0014262315,0.9985738
17219,myelodysplastic granulocytosis,12,14,81,111,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17219,-1,0.0013680063,0.998632
17220,hypercellular marrow,18,20,126,146,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17220,-1,0.003231185,0.99676883
17221,megakaryocytic myelosis,30,32,209,232,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17221,-1,0.0015599931,0.99843997
17222,hyperplastic marrow,35,37,251,270,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17222,-1,0.0034857122,0.99651426
17223,dysmyelopoiesis,38,39,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17223,-1,0.0014078752,0.9985921
17224,hypocellular marrow,41,43,294,313,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17224,-1,0.003203546,0.9967964
17225,myelodysplasia,47,48,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17225,-1,0.0012355796,0.9987644
17226,dyserythropoiesis,49,50,351,368,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17226,-1,0.0016105659,0.9983895
17227,hemosiderosis,51,52,370,383,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17227,-1,0.0012811432,0.99871886
17228,hypocellular marrow,54,56,390,409,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17228,-1,0.0034606364,0.99653935
17229,AZT,2,3,16,19,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17229,-1,0.9967783,0.003221743
17230,myelodysplastic syndrome,26,28,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17230,-1,0.0009905281,0.9990095
17234,mg,10,11,56,58,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,-1,17234,-1,0.86667275,0.13332726
17239,pituitary tumors,16,18,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,-1,17239,-1,0.0015187525,0.9984812
17241,Estrogens,0,1,0,9,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,-1,-1,17241,-1,0.99489623,0.005103785
17245,estrogen carcinogenesis,9,11,64,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,-1,17245,-1,0.22883417,0.77116585
17248,VIII,28,29,162,166,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,-1,17248,-1,0.942981,0.057019006
17249,E2,6,7,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,-1,-1,-1,17249,-1,0.9947389,0.005261177
17251,E2,15,16,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,-1,17251,-1,0.965977,0.03402302
17252,E2,4,5,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,-1,17252,-1,0.99091256,0.009087485
17253,E2,26,27,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,-1,17253,-1,0.99260616,0.0073938044
17256,nephrogenic diabetes insipidus,1,4,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,-1,-1,17256,-1,0.0010712602,0.9989287
17259,head injury,14,16,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,-1,-1,17259,-1,0.0016352276,0.99836475
17260,nephrogenic diabetes insipidus,10,13,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,-1,17260,-1,0.0009828612,0.9990171
17262,polyuric,4,5,24,32,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17262,-1,0.0013372768,0.9986627
17265,nephrogenic diabetes insipidus,28,31,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17265,-1,0.0012113862,0.99878865
17267,nephrogenic diabetes insipidus,2,5,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,-1,-1,17267,-1,0.0009309634,0.99906904
17270,nephrogenic diabetes insipidus,15,18,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,-1,-1,-1,17270,-1,0.0010010938,0.99899894
17271,NIK-247,2,3,11,18,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,-1,-1,17271,-1,0.9959428,0.004057235
17273,NIK-247,3,4,15,22,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17273,-1,0.99658245,0.0034175222
17275,cholinesterase,21,22,151,165,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17275,-1,0.98813266,0.0118673835
17276,tacrine,23,24,177,184,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17276,-1,0.9986603,0.0013396388
17277,E-2020,25,26,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17277,-1,0.99707615,0.0029238767
17278,NIK-247,0,1,0,7,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17278,-1,0.99625564,0.003744355
17279,tacrine,2,3,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17279,-1,0.9983891,0.0016108634
17280,E-2020,4,5,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17280,-1,0.99516463,0.004835331
17281,NIK-247,3,4,13,20,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17281,-1,0.99723756,0.0027624075
17282,tacrine,5,6,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17282,-1,0.9985505,0.0014494923
17283,E-2020,9,10,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17283,-1,0.9962057,0.0037942498
17284,NIK-247,6,7,35,42,"Moreover, the inhibitory effect of NIK-247 on AChE was reversible.",9228650_5,-1,-1,-1,17284,-1,0.9956014,0.004398603
17287,NIK-247,4,5,28,35,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,-1,-1,-1,17287,-1,0.99635965,0.0036403737
17289,NIK-247,4,5,26,33,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17289,-1,0.9950322,0.004967805
17290,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17290,-1,0.0017917773,0.9982083
17292,cardiovascular disease,6,8,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,-1,-1,-1,17292,-1,0.0011592783,0.99884075
17294,cardiovascular disease,13,15,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,-1,-1,17294,-1,0.0015801395,0.9984199
17299,carbon monoxide,39,41,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,-1,17299,-1,0.9975898,0.0024102104
17306,atrioventricular reentrant tachycardia,3,6,35,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17306,-1,0.001536011,0.998464
17308,idiopathic dilated cardiomyopathy,18,21,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17308,-1,0.0011075928,0.9988925
17309,WPW syndrome,4,6,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17309,-1,0.001433892,0.9985661
17310,idiopathic dilated cardiomyopathy,7,10,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17310,-1,0.0010709622,0.99892896
17311,atrioventricular reentrant tachycardia,12,15,82,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17311,-1,0.0019116028,0.9980884
17312,AVRT,16,17,122,126,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17312,-1,0.002725229,0.9972748
17314,AVRT,24,25,178,182,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,-1,17314,-1,0.013683466,0.9863165
17316,A-86929,11,12,73,80,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,-1,17316,-1,0.9945247,0.0054752566
17319,DA,6,7,34,36,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17319,-1,0.9964323,0.0035676954
17320,Parkinson's disease,15,18,79,98,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17320,-1,0.0013950332,0.99860495
17321,PD,19,20,100,102,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17321,-1,0.0012573411,0.99874264
17322,DA,5,6,33,35,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17322,-1,0.9872613,0.012738764
17323,SKF-82958,11,12,65,74,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17323,-1,0.99670666,0.0032933534
17324,"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide",13,16,76,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17324,-1,0.9805062,0.019493798
17325,A-77636,18,19,171,178,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17325,-1,0.9948184,0.0051815906
17326,"[1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride",20,28,180,275,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17326,-1,0.968501,0.031499077
17327,SKF-82958,43,44,351,360,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17327,-1,0.9965976,0.0034024203
17328,A-77636,53,54,387,394,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17328,-1,0.99619234,0.0038076292
17329,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",10,11,69,113,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17329,-1,0.99314886,0.006851109
17331,dyskinetic,24,25,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17331,-1,0.001317442,0.99868256
17332,A-86929,39,40,301,308,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17332,-1,0.9908082,0.009191796
17333,"[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+",41,42,310,369,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17333,-1,0.8895471,0.11045288
17334,DA,54,55,439,441,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17334,-1,0.979262,0.020738015
17336,DA,3,4,17,19,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17336,-1,0.9943089,0.0056911064
17337,LY-171555,8,9,46,55,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17337,-1,0.9959038,0.004096241
17338,4-quinoline,13,14,122,133,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17338,-1,0.9851089,0.014891108
17339,hydrochloride,14,15,134,147,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17339,-1,0.9864673,0.013532695
17340,A-86929,3,4,24,31,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17340,-1,0.99573636,0.004263586
17343,LY-171555,14,15,108,117,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17343,-1,0.9976082,0.0023917845
17345,LY-171555,31,32,219,228,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17345,-1,0.997584,0.0024159707
17347,DA,4,5,29,31,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17347,-1,0.9972203,0.0027797034
17349,DA,37,38,230,232,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17349,-1,0.9970283,0.002971726
17350,DA,1,2,7,9,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17350,-1,0.98429585,0.015704205
17351,A-86929,13,14,79,86,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17351,-1,0.99383414,0.006165862
17352,PD,28,29,166,168,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17352,-1,0.0017906518,0.99820936
17354,hydrochlorofluorocarbons,6,7,36,60,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17354,-1,0.9983779,0.0016220292
17355,chlorofluorocarbons,12,13,98,117,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17355,-1,0.9983364,0.0016636892
17356,Hydrochlorofluorocarbons,2,3,12,36,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17356,-1,0.9977272,0.0022727358
17357,HCFCs,4,5,38,43,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17357,-1,0.9925932,0.0074067814
17358,chlorofluorocarbons,15,16,114,133,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17358,-1,0.9968886,0.0031114197
17359,CFCs,17,18,135,139,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17359,-1,0.9876494,0.012350552
17363,HCFC 123,23,25,165,173,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17363,-1,0.99297136,0.0070286887
17365,HCFC 124,29,31,215,223,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17365,-1,0.99222344,0.0077765468
17368,trifluoroacetyl halide,16,18,118,140,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,-1,-1,17368,-1,0.9804034,0.019596556
17371,HCFCs,5,6,25,30,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,-1,-1,17371,-1,0.9583363,0.041663654
17373,trifluoroacetyl,16,17,109,124,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,-1,-1,-1,17373,-1,0.99730515,0.0026948624
17374,hepatocellular necrosis,7,9,41,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,-1,-1,17374,-1,0.0018459905,0.998154
17376,halothane hepatitis,10,12,67,86,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,-1,17376,-1,0.62465245,0.37534755
17377,HCFCs,8,9,53,58,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,-1,17377,-1,0.987975,0.012024978
17380,hamartoma,2,3,10,19,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,-1,-1,-1,17380,-1,0.0014990667,0.99850094
17382,hamartoma,7,8,30,39,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,-1,-1,-1,17382,-1,0.0014630563,0.99853694
17387,TLE,23,24,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,-1,17387,-1,0.0018931293,0.99810684
17389,PILO,3,4,17,21,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17389,-1,0.04873176,0.95126826
17391,status epilepticus,15,17,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17391,-1,0.0010728064,0.9989272
17394,PILO,3,4,13,17,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,-1,-1,-1,17394,-1,0.83734506,0.16265495
17395,PILO,30,31,174,178,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17395,-1,0.047620673,0.95237935
17396,TLE,33,34,188,191,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17396,-1,0.0027565132,0.9972435
17397,Parkinson's disease,5,8,46,65,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,-1,-1,-1,17397,-1,0.0015397943,0.9984602
17398,Parkinson's disease,13,16,112,131,"BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up.",9321531_1,-1,-1,-1,17398,-1,0.0014012507,0.99859875
17399,Parkinson's disease,5,8,29,48,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,-1,17399,-1,0.0013208154,0.9986792
17404,bradykinesia,13,14,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,-1,-1,17404,-1,0.0007533812,0.9992466
17407,Parkinson's disease,4,7,27,46,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17407,-1,0.0011558513,0.99884415
17409,disability,15,16,126,136,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17409,-1,0.0012576872,0.9987423
17411,Clarithromycin,0,1,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17411,-1,0.99857855,0.0014214442
17412,macrolide,5,6,35,44,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17412,-1,0.9934111,0.0065888227
17413,erythromycin,3,4,16,28,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17413,-1,0.99740857,0.0025914686
17414,erythromycin,5,6,36,48,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17414,-1,0.9981865,0.0018135081
17415,gastroenteritis,10,11,75,90,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17415,-1,0.00090109726,0.9990989
17416,macrolides,27,28,205,215,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17416,-1,0.9961617,0.0038383116
17418,erythromycin,11,12,87,99,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17418,-1,0.998216,0.0017840007
17419,macrolides,20,21,143,153,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17419,-1,0.99598616,0.004013801
17420,ventricular dysrhythmias,5,7,20,44,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17420,-1,0.0009313395,0.9990687
17421,clarithromycin,14,15,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17421,-1,0.99871373,0.0012862595
17422,dysrhythmias,1,2,4,16,The dysrhythmias resolved after discontinuation of the drug.,9326871_6,-1,-1,-1,17422,-1,0.00085737405,0.99914265
17423,erectile dysfunction,6,8,38,58,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,-1,17423,-1,0.0009455083,0.9990545
17425,erectile dysfunction,18,20,121,141,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,-1,17425,-1,0.00092519185,0.9990748
17429,gynecomastia,20,21,115,127,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,-1,-1,17429,-1,0.0008698513,0.9991302
17431,erectile dysfunction,15,17,96,116,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,-1,17431,-1,0.0009063446,0.99909365
17433,small testes,14,16,100,112,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17433,-1,0.0019942115,0.9980058
17434,gynecomastia,17,18,117,129,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17434,-1,0.00090798084,0.999092
17435,testosterone heptylate,4,6,31,53,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17435,-1,0.9981912,0.0018088804
17436,human chorionic gonadotropin,7,10,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17436,-1,0.812546,0.18745403
17437,hypogonadism,11,12,90,102,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17437,-1,0.0009923186,0.99900776
17442,pituitary tumors,1,3,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,-1,-1,17442,-1,0.0015306459,0.9984693
17445,hypothalamic dysfunction,12,14,75,99,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17445,-1,0.0011166215,0.9988834
17446,luteinizing hormone,18,20,124,143,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17446,-1,0.9877643,0.012235731
17447,erectile dysfunction,30,32,191,211,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17447,-1,0.00085112423,0.99914885
17448,androgen,45,46,263,271,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17448,-1,0.9970476,0.0029523782
17452,androgen,33,34,199,207,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,-1,-1,-1,17452,-1,0.99694306,0.003056901
17454,prolactinomas,7,8,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,-1,-1,-1,17454,-1,0.0013564528,0.9986436
17458,erectile dysfunction,13,15,83,103,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,-1,17458,-1,0.0010394467,0.9989605
17459,pituitary tumors,21,23,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,-1,-1,17459,-1,0.0014073269,0.9985927
17463,gynecomastia,12,13,67,79,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,-1,-1,17463,-1,0.0008777852,0.9991222
17469,serotonin 5-HT2,12,14,75,90,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17469,-1,0.9835473,0.016452681
17472,neuroleptics,33,34,241,253,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,-1,-1,17472,-1,0.64211535,0.35788465
17475,n,40,41,254,255,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17475,-1,0.20901155,0.79098845
17477,n,47,48,278,279,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17477,-1,0.15403818,0.8459618
17488,5-FU,15,16,118,122,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17488,-1,0.9979048,0.0020952078
17489,leucovorin,17,18,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17489,-1,0.99843985,0.0015601976
17490,MFL,19,20,139,142,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17490,-1,0.8592527,0.14074732
17495,5-FU,8,9,70,74,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17495,-1,0.9972644,0.0027356148
17496,leucovorin,11,12,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17496,-1,0.9986105,0.0013895194
17497,MFL,13,14,92,95,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17497,-1,0.95206505,0.047934987
17500,5-FU,30,31,184,188,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17500,-1,0.99789137,0.0021086622
17501,leucovorin,37,38,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17501,-1,0.9982521,0.0017478365
17502,h,44,45,246,247,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17502,-1,0.19861108,0.8013889
17503,lung metastasis,12,14,64,79,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,-1,-1,-1,17503,-1,0.0020564876,0.99794346
17505,MFL,5,6,28,31,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,-1,17505,-1,0.019181645,0.9808184
17511,MFL,1,2,4,7,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,-1,-1,17511,-1,0.93302315,0.06697684
17514,impaired heart function,17,20,110,133,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,-1,-1,17514,-1,0.002086831,0.9979132
17517,Agranulocytosis,0,1,0,15,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,-1,-1,-1,17517,-1,0.0009457475,0.99905425
17521,calcium channel blockers,11,14,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,-1,-1,-1,17521,-1,0.9963372,0.0036628314
17523,diabetes insipidus,16,18,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,-1,-1,17523,-1,0.0011982997,0.9988017
17524,arginine vasopressin,3,5,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17524,-1,0.9937921,0.006207893
17525,AVP,6,7,40,43,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17525,-1,0.97676784,0.023232223
17528,LiCl,9,10,53,57,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,-1,-1,17528,-1,0.9974668,0.0025331657
17530,hypotonic,8,9,47,56,The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations.,9406968_3,-1,-1,-1,17530,-1,0.0016933968,0.99830663
17532,AVP,3,4,24,27,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17532,-1,0.9917129,0.0082870545
17533,AVP,7,8,47,50,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17533,-1,0.98383385,0.016166162
17535,AVP,19,20,131,134,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17535,-1,0.9958331,0.0041669426
17536,AVP,24,25,159,162,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17536,-1,0.9943287,0.0056713764
17537,diabetes insipidus,36,38,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17537,-1,0.0014088054,0.9985911
17538,glyceryl trinitrate,2,4,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,-1,-1,17538,-1,0.9980221,0.0019779587
17540,glyceryl trinitrate,8,10,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17540,-1,0.9978751,0.002124959
17544,mg prostigmine,13,15,88,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17544,-1,0.99480116,0.0051988247
17545,mg morphine,18,20,126,137,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17545,-1,0.99264973,0.0073502366
17546,glyceryl trinitrate,6,8,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17546,-1,0.99849164,0.0015083008
17547,Nitrolingual,10,11,71,83,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17547,-1,0.9972548,0.002745227
17549,Glyceryl trinitrate,0,2,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17549,-1,0.99830365,0.0016963272
17550,glyceryl trinitrate,79,81,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17550,-1,0.998389,0.001611066
17551,glyceryl trinitrate,12,14,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,-1,-1,17551,-1,0.9982487,0.0017513285
17553,glyceryl trinitrate,1,3,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17553,-1,0.998312,0.0016880682
17556,mg,23,24,182,184,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17556,-1,0.8381084,0.16189155
17557,mg,31,32,202,204,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17557,-1,0.81777406,0.18222588
17558,mg,39,40,222,224,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17558,-1,0.80661213,0.19338785
17560,pirenzepine,17,18,137,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17560,-1,0.99859923,0.0014007477
17561,dicyclomine,19,20,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17561,-1,0.99870276,0.0012972777
17563,hemicholinium-3,24,25,196,211,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17563,-1,0.99721354,0.0027865176
17565,quinpirole,49,50,403,413,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17565,-1,0.99850035,0.0014997007
17567,2-methoxy-4-amino-5-chlorobenzoic,54,55,451,484,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17567,-1,0.98808587,0.011914067
17568,2-methoxy-4-amino-5-chlorobenzoic acid,54,56,451,489,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17568,-1,0.99192315,0.008076804
17569,2-(diethylamino)ethyl,56,57,490,511,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17569,-1,0.9896135,0.010386561
17570,2-(diethylamino)ethyl ester hydrochloride,56,59,490,531,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17570,-1,0.9898183,0.010181678
17571,5-hydroxytryptamin1A,61,62,537,557,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17571,-1,0.9761559,0.023844091
17578,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide,63,65,569,638,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17578,-1,0.98961186,0.010388193
17579,polyamines,67,68,647,657,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17579,-1,0.9767429,0.023257073
17581,mg,5,6,18,20,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17581,-1,0.84374946,0.15625052
17584,mg,20,21,86,88,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17584,-1,0.88457584,0.11542419
17585,dicyclomine,26,27,104,115,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17585,-1,0.99881506,0.0011850067
17586,mg,29,30,119,121,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17586,-1,0.90084577,0.099154264
17588,glomerular disease,3,5,41,59,Immunopathology of penicillamine-induced glomerular disease.,950631_0,-1,-1,-1,17588,-1,0.0010385469,0.99896145
17591,membranous glomerulonephritis,8,10,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,-1,-1,17591,-1,0.0009773189,0.9990227
17594,migraine without aura,15,18,79,100,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,-1,-1,-1,17594,-1,0.0014994893,0.99850047
17602,painful sensation,16,18,101,118,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,-1,-1,-1,17602,-1,0.0015739888,0.9984261
17608,cluster headache,42,44,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,-1,-1,17608,-1,0.001724601,0.9982754
17609,hearing loss,7,9,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,-1,-1,-1,17609,-1,0.0014573927,0.99854267
17610,hearing loss,3,5,13,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,-1,-1,-1,17610,-1,0.0014879919,0.99851197
17612,hearing loss,9,11,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17612,-1,0.0018017886,0.9981982
17613,hearing loss,20,22,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17613,-1,0.0018641098,0.9981359
17617,hearing loss,8,10,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17617,-1,0.0015420546,0.9984579
17619,P,27,28,126,127,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17619,-1,0.10315061,0.8968494
17620,hearing loss,2,4,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,-1,-1,-1,17620,-1,0.0021537696,0.99784625
17623,hearing loss,7,9,46,58,None of the patients complained of subjective hearing loss.,9522143_7,-1,-1,-1,17623,-1,0.0013188475,0.9986811
17624,neurological deficit,2,4,12,32,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,-1,-1,-1,17624,-1,0.00095553894,0.9990445
17626,neurological deficit,6,8,32,52,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17626,-1,0.0009335019,0.99906653
17627,mg,16,17,110,112,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17627,-1,0.77112097,0.22887899
17629,hypoaesthesia,19,20,103,116,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17629,-1,0.0012201756,0.99877983
17630,reduction,38,39,214,223,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17630,-1,0.00280745,0.99719256
17631,strength,41,42,236,244,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17631,-1,0.0022200847,0.9977799
17632,lead,49,50,304,308,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17632,-1,0.017479666,0.9825203
17633,neurological deficit,53,55,324,344,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17633,-1,0.0011547667,0.9988452
17634,Transient neurologic symptoms,0,3,0,29,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,-1,-1,-1,17634,-1,0.0012019916,0.998798
17638,transient neurologic symptoms,6,9,42,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17638,-1,0.0016951994,0.9983047
17639,TNSs,10,11,73,77,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17639,-1,0.0023417785,0.99765825
17648,TNSs,24,25,164,168,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,-1,17648,-1,0.0022145144,0.99778545
17655,TNSs,12,13,67,71,"In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure.",9523805_8,-1,-1,-1,17655,-1,0.003181753,0.9968182
17657,TNSs,9,10,61,65,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17657,-1,0.0035071129,0.9964929
17659,P,18,19,106,107,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17659,-1,0.18751565,0.8124844
17661,TNSs,33,34,176,180,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17661,-1,0.003501518,0.99649847
17665,P,37,38,190,191,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,-1,-1,-1,17665,-1,0.12751766,0.87248236
17668,TNSs,25,26,154,158,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,-1,17668,-1,0.0019787306,0.99802125
17670,iron dextran,16,18,120,132,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17670,-1,0.9957545,0.004245595
17671,iron dextran,12,14,56,68,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,-1,-1,-1,17671,-1,0.99663335,0.003366617
17673,MP,23,24,148,150,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,-1,17673,-1,0.99432266,0.0056774
17674,mg,29,30,129,131,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,-1,-1,-1,17674,-1,0.9767751,0.023224883
17675,MP,0,1,0,2,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17675,-1,0.9930341,0.00696587
17676,mg,13,14,49,51,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17676,-1,0.96558416,0.034415867
17677,MP,0,1,0,2,MP before and after TDI (group 3).,9523850_6,-1,-1,-1,17677,-1,0.924646,0.07535394
17678,MP,6,7,46,48,These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.,9523850_11,-1,-1,-1,17678,-1,0.9947621,0.0052378555
17679,mg,4,5,21,23,We conclude that 125 mg i.v.,9523850_12,-1,-1,-1,17679,-1,0.9580121,0.041987877
17680,MP,0,1,0,2,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17680,-1,0.018773904,0.9812261
17681,iron dextran,10,12,53,65,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17681,-1,0.9965738,0.0034262286
17682,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,-1,-1,-1,17682,-1,0.0028747946,0.9971252
17684,gastrointestinal motility disorders,18,21,95,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,-1,-1,-1,17684,-1,0.0012125665,0.99878746
17685,Prolongation of QT interval,0,4,0,27,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17685,-1,0.0030431482,0.9969568
17686,torsades de pointes,5,8,29,48,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17686,-1,0.0017259588,0.9982741
17687,sudden cardiac death,10,13,54,74,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17687,-1,0.0012296529,0.9987703
17688,erythromycin,20,21,132,144,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17688,-1,0.9984107,0.0015893151
17689,azole antifungal agents,22,25,148,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17689,-1,0.99725974,0.0027402565
17691,gastroesophageal reflux disorder,14,17,89,121,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,-1,-1,17691,-1,0.0011658131,0.9988342
17695,QT-interval,8,9,40,51,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,-1,-1,17695,-1,0.012023677,0.9879764
17696,prolongation,9,10,52,64,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,-1,-1,17696,-1,0.0015158966,0.9984841
17704,n,47,48,288,289,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17704,-1,0.036503624,0.9634964
17706,n,59,60,346,347,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17706,-1,0.03415714,0.96584284
17707,dyskinetic parkinsonian,1,3,4,27,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,-1,17707,-1,0.0013161866,0.99868375
17709,hyperkinetic abnormal involuntary movement,9,13,57,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,-1,-1,17709,-1,0.001156609,0.9988433
17712,sinusitis,10,11,75,84,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,-1,-1,-1,17712,-1,0.00082159834,0.99917835
17714,mg,12,13,66,68,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17714,-1,0.9555677,0.044432282
17715,sinusitis,29,30,157,166,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17715,-1,0.0008356101,0.99916446
17716,signs and symptoms,8,11,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,-1,-1,-1,17716,-1,0.002489691,0.9975103
17719,flatulence,9,10,59,69,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,-1,-1,17719,-1,0.0012112206,0.9987888
17722,mg,11,12,69,71,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17722,-1,0.9652977,0.034702312
17723,sinusitis,23,24,138,147,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17723,-1,0.0009979331,0.99900204
17724,endometrial carcinoma,3,5,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,-1,17724,-1,0.0012260089,0.998774
17735,n,9,10,59,60,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,-1,-1,17735,-1,0.054995522,0.94500446
17739,p,26,27,152,153,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,-1,-1,17739,-1,0.109014414,0.8909856
17740,p,15,16,94,95,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17740,-1,0.21636079,0.78363925
17742,p,27,28,152,153,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17742,-1,0.22493169,0.77506834
17743,p,18,19,95,96,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,-1,17743,-1,0.12432317,0.8756768
17745,p,14,15,82,83,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17745,-1,0.102478534,0.89752144
17746,p,27,28,132,133,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17746,-1,0.08739217,0.9126078
17747,p,35,36,167,168,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17747,-1,0.0856541,0.9143459
17755,Endometrial cancers,0,2,0,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,-1,-1,17755,-1,0.0015710703,0.9984289
17765,hyperkalaemia,16,17,90,103,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,-1,-1,17765,-1,0.0010089673,0.9989911
17772,hyperkalaemia,30,31,167,180,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,-1,-1,-1,17772,-1,0.00097586913,0.99902415
17777,Acute hepatitis,0,2,0,15,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17777,-1,0.001153158,0.99884677
17779,erythroblastocytopenia,8,9,50,72,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17779,-1,0.0010166866,0.9989833
17781,acute hepatitis,4,6,27,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,-1,-1,-1,17781,-1,0.0009833908,0.99901664
17785,erythroblastocytopenia,35,36,240,262,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17785,-1,0.0008925437,0.9991074
17787,beta lactam,20,22,122,133,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,-1,-1,-1,17787,-1,0.99588674,0.00411329
17789,NMDA,6,7,36,40,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,-1,17789,-1,0.9966857,0.0033143056
17791,NMDA,16,17,83,87,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,-1,-1,-1,17791,-1,0.99686205,0.0031379892
17792,Muscle rigidity,0,2,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,-1,-1,-1,17792,-1,0.0014926097,0.9985073
17795,"5,7-DCKA",3,4,28,36,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17795,-1,0.99172044,0.008279569
17797,muscle rigidity,35,37,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17797,-1,0.0014950325,0.998505
17798,"5,7-DCKA",0,1,0,8,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,-1,-1,17798,-1,0.9906528,0.009347201
17801,NMDA,11,12,65,69,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,-1,-1,-1,17801,-1,0.99684274,0.0031572268
17804,CBDCA,10,11,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17804,-1,0.9914392,0.008560742
17806,CDDP,15,16,82,86,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17806,-1,0.99584585,0.0041541224
17808,CBDCA,5,6,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17808,-1,0.9949333,0.0050666644
17809,neurotoxic drugs,13,15,84,100,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17809,-1,0.005260133,0.99473983
17810,peripheral nervous system damage,27,31,177,209,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17810,-1,0.0015588201,0.99844116
17811,CBDCA,8,9,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,-1,-1,-1,17811,-1,0.99635565,0.0036443311
17813,CBDCA,2,3,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17813,-1,0.99553275,0.0044671735
17814,peripheral neurotoxicity,6,8,53,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17814,-1,0.0011374842,0.9988625
17816,CDDP,23,24,125,129,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,-1,17816,-1,0.99250317,0.007496795
17817,platinum,5,6,33,41,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17817,-1,0.9892456,0.01075433
17818,CBDCA,16,17,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17818,-1,0.99307114,0.006928887
17819,CBDCA,2,3,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17819,-1,0.9874664,0.012533656
17821,CDDP,25,26,137,141,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17821,-1,0.9932882,0.0067118024
17823,CBDCA,17,18,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,-1,-1,-1,17823,-1,0.99622524,0.0037747156
17825,thyrotoxicosis,7,8,36,50,Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.,9653867_0,-1,-1,-1,17825,-1,0.0023670876,0.99763286
17826,Eating disorders,0,2,0,16,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,-1,-1,17826,-1,0.0014331084,0.9985669
17828,eating disorders,14,16,81,97,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17828,-1,0.0015330265,0.9984669
17829,metabolic disturbances,23,25,146,168,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17829,-1,0.0015867054,0.9984133
17830,diuretic,26,27,173,181,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17830,-1,0.9870386,0.012961392
17831,eating disorders,14,16,94,110,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17831,-1,0.0014631621,0.9985368
17832,thyrotoxicosis,24,25,148,162,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17832,-1,0.0027322916,0.9972677
17834,trimipramine,1,2,9,21,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,-1,17834,-1,0.99876034,0.001239679
17836,Trimipramine,0,1,0,12,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17836,-1,0.99879825,0.0012017642
17837,TRI,2,3,14,17,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17837,-1,0.99520254,0.004797496
17839,imipramine,16,17,93,103,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17839,-1,0.9988023,0.0011976776
17843,TRI,11,12,53,56,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,-1,-1,-1,17843,-1,0.9926287,0.0073712734
17845,TRI,0,1,0,3,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,-1,-1,-1,17845,-1,0.9905003,0.00949981
17846,TRI,4,5,24,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17846,-1,0.97724724,0.022752762
17847,reserpine hypothermia,14,16,65,86,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17847,-1,0.5750817,0.4249183
17848,5-hydroxytryptophan head twitches,23,26,123,156,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17848,-1,0.41071692,0.58928305
17849,TRI,0,1,0,3,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17849,-1,0.9938305,0.0061694975
17851,quinpirole,13,14,93,103,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17851,-1,0.99876785,0.0012322308
17854,TRI,11,12,80,83,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17854,-1,0.99564654,0.0043534916
17859,TRI,13,14,83,86,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,-1,-1,-1,17859,-1,0.99487704,0.0051229317
17864,irritable bowel syndrome,13,16,91,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,-1,17864,-1,0.0011061539,0.9988939
17865,Irritable bowel syndrome,2,5,12,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17865,-1,0.0011869927,0.99881303
17866,abdominal pain,10,12,58,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17866,-1,0.0010254761,0.99897456
17867,disordered gastrointestinal motility,19,22,110,146,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17867,-1,0.0014009232,0.9985991
17869,irritable bowel syndrome,25,28,146,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17869,-1,0.0015246667,0.9984754
17870,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17870,-1,0.0013679438,0.998632
17871,IBS,5,6,36,39,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17871,-1,0.0013275373,0.9986725
17872,n,9,10,67,68,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17872,-1,0.0146048665,0.9853952
17873,n,15,16,98,99,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17873,-1,0.011846577,0.9881534
17875,mg,35,36,201,203,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17875,-1,0.9652063,0.0347937
17876,n,40,41,223,224,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17876,-1,0.09633922,0.9036608
17877,n,47,48,243,244,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17877,-1,0.089173265,0.91082674
17879,mm Hg,20,22,128,133,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17879,-1,0.019510303,0.9804897
17881,P,27,28,161,162,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17881,-1,0.18473977,0.81526023
17882,mm Hg,38,40,200,205,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17882,-1,0.024339883,0.97566015
17884,P,63,64,308,309,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17884,-1,0.18979709,0.81020296
17886,P,99,100,462,463,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17886,-1,0.17921682,0.8207832
17887,IBS,11,12,90,93,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,-1,17887,-1,0.0012622487,0.99873775
17889,IBS,13,14,113,116,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17889,-1,0.0011936824,0.99880636
17890,mm,27,28,160,162,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17890,-1,0.007036683,0.9929634
17892,P,33,34,190,191,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17892,-1,0.06635535,0.9336447
17893,mm,44,45,225,227,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17893,-1,0.008976788,0.9910232
17894,IBS,1,2,22,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17894,-1,0.0012796676,0.9987204
17897,mm,23,24,118,120,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17897,-1,0.006904498,0.99309546
17899,P,29,30,148,149,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17899,-1,0.05502026,0.9449798
17900,mm,40,41,183,185,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17900,-1,0.0075106276,0.99248946
17902,IBS,11,12,87,90,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,-1,-1,-1,17902,-1,0.0016328527,0.99836713
17913,mg,7,8,46,48,"Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years.",9672273_5,-1,-1,-1,17913,-1,0.9786305,0.021369547
17924,vascular events,13,15,77,92,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17924,-1,0.0009984762,0.99900156
17925,hypertriglyceridaemia,16,17,97,118,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17925,-1,0.0008528015,0.9991472
17935,postoperative pain,9,11,77,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,-1,-1,17935,-1,0.0025943527,0.9974056
17937,analgesia,13,14,102,111,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17937,-1,0.011071712,0.9889283
17938,postoperative pain,21,23,141,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17938,-1,0.0023670741,0.99763286
17939,h,1,2,13,14,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,-1,-1,-1,17939,-1,0.03940178,0.9605982
17942,norpethidine,4,5,26,38,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,-1,-1,17942,-1,0.9983425,0.0016574961
17943,CNS toxicity,5,7,26,38,No other risk factors for CNS toxicity were identified.,9672936_4,-1,-1,-1,17943,-1,0.0012082045,0.9987919
17946,norpethidine,17,18,118,130,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,-1,17946,-1,0.99840456,0.0015954662
17948,postoperative analgesia,11,13,54,77,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,-1,-1,-1,17948,-1,0.002356125,0.9976439
17949,mepivacaine,8,9,47,58,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,-1,-1,-1,17949,-1,0.99869066,0.0013093163
17951,increase in blood pressure,1,5,3,29,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17951,-1,0.004909162,0.99509084
17952,atrial fibrillation,8,10,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17952,-1,0.0011244917,0.99887544
17954,loss of consciousness,16,19,106,127,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17954,-1,0.0024151502,0.9975848
17955,mepivacaine,43,44,267,278,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17955,-1,0.99880064,0.0011993187
17956,mg,45,46,283,285,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17956,-1,0.9705664,0.029433688
17958,mg,49,50,314,316,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17958,-1,0.96755666,0.03244338
17959,Dupuytren's contracture,54,57,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17959,-1,0.010201272,0.9897988
17963,atrial fibrillation,12,14,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,-1,-1,-1,17963,-1,0.0011858401,0.9988142
17964,mepivacaine,18,19,115,126,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,-1,17964,-1,0.99866295,0.001337045
17966,vanishing bile duct,2,5,28,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,-1,-1,17966,-1,0.0029362289,0.9970638
17967,vanishing bile duct syndrome,1,5,6,34,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,-1,-1,-1,17967,-1,0.0020037822,0.9979962
17969,hypersensitivity reaction,7,9,70,95,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,-1,17969,-1,0.0017709663,0.9982291
17970,vanishing bile duct syndrome,12,16,76,104,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,-1,17970,-1,0.0027177525,0.99728227
17972,ursodeoxycholic acid,3,5,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,17972,-1,0.998287,0.0017129864
17975,cholestatic disease,13,15,80,99,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,17975,-1,0.0011460301,0.9988539
17977,vanishing bile duct syndrome,5,9,39,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,17977,-1,0.0019390169,0.998061
17978,vanishing bile duct syndrome,27,31,190,218,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,17978,-1,0.002498883,0.9975011
17982,appetite suppressant,20,22,122,142,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,-1,17982,-1,0.9405026,0.05949734
17986,fenfluramines,11,12,80,93,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,17986,-1,0.99859005,0.0014098871
17987,p<0.0001,27,28,150,158,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,17987,-1,0.17979498,0.820205
17993,lead,9,10,67,71,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,-1,-1,17993,-1,0.018173238,0.9818268
17998,absence seizures,8,10,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,-1,-1,17998,-1,0.0011709973,0.99882895
18001,absence seizures,7,9,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,-1,-1,18001,-1,0.0012199235,0.9987801
18008,sodium valproate,8,10,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18008,-1,0.9986199,0.0013800833
18009,lamotrigine,11,12,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18009,-1,0.99882025,0.0011796958
18010,ethosuximide,14,15,84,96,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18010,-1,0.99877256,0.0012274056
18011,Choreoathetoid movements,0,2,0,24,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,-1,-1,-1,18011,-1,0.0017198658,0.99828017
18013,hyperkinesias,1,2,13,26,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18013,-1,0.0009463599,0.99905366
18014,movement abnormalities,7,9,54,76,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18014,-1,0.0012842531,0.99871576
18016,euphoria,6,7,25,33,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18016,-1,0.0012929277,0.99870706
18017,choreoathetoid movements,8,10,38,62,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18017,-1,0.0020999548,0.9979
18019,heroine,28,29,197,204,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18019,-1,0.99810827,0.0018916946
18021,folic acid,3,5,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18021,-1,0.9982851,0.0017148971
18022,SLE,8,9,56,59,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18022,-1,0.0021450857,0.9978549
18023,folic acid,10,12,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18023,-1,0.9973973,0.0026027285
18024,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18024,-1,0.005180728,0.99481934
18026,structural birth defects,38,41,251,275,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18026,-1,0.001753509,0.99824655
18028,folic acid,8,10,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,-1,-1,18028,-1,0.99826187,0.001738151
18030,cleft lip and palate,7,11,45,65,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,-1,-1,-1,18030,-1,0.0013453875,0.9986546
18034,folic acid,11,13,81,91,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,-1,-1,-1,18034,-1,0.9981371,0.0018628493
18035,status epilepticus,2,4,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18035,-1,0.0011917697,0.99880826
18036,systemic lupus erythematodes,8,11,55,83,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18036,-1,0.0014337936,0.9985662
18037,stillbirth,4,5,25,35,Her pregnancy ended with stillbirth.,9758264_7,-1,-1,-1,18037,-1,0.0016469675,0.998353
18039,autoimmune disease,7,9,46,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18039,-1,0.0011466361,0.9988533
18040,lupus,12,13,88,93,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18040,-1,0.0010888075,0.99891114
18041,mg,29,30,173,175,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18041,-1,0.885126,0.11487399
18042,folic acid,32,34,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18042,-1,0.9980584,0.0019416127
18044,mg,5,6,23,25,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18044,-1,0.8217521,0.17824788
18045,folic acid,8,10,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18045,-1,0.99763024,0.0023696935
18047,autoimmune disease,21,23,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18047,-1,0.0010463528,0.9989536
18048,epileptic seizures,30,32,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18048,-1,0.0008596686,0.99914026
18049,antipsychotics,5,6,32,46,Adverse effects of the atypical antipsychotics.,9766615_0,-1,-1,-1,18049,-1,0.96333283,0.03666715
18050,antipsychotics,3,4,19,33,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18050,-1,0.98277617,0.017223783
18051,lead,5,6,40,44,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18051,-1,0.019619651,0.98038036
18052,antipsychotics,7,8,41,55,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18052,-1,0.96165526,0.038344756
18053,neuroleptics,16,17,109,121,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18053,-1,0.9892553,0.010744727
18055,EPS,15,16,116,119,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18055,-1,0.00126605,0.99873394
18056,tardive dyskinesia,18,20,122,140,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18056,-1,0.0009981998,0.9990018
18059,weight gain,51,53,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18059,-1,0.0044682506,0.9955317
18060,EPS,9,10,47,50,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18060,-1,0.00093767466,0.99906236
18061,weight gain,26,28,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18061,-1,0.001959149,0.99804085
18065,agranulocytosis,44,45,257,272,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18065,-1,0.0011225835,0.99887747
18067,lead,27,28,175,179,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18067,-1,0.022521973,0.977478
18068,antipsychotic,38,39,253,266,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18068,-1,0.94856995,0.05143012
18080,emergency department,25,27,143,163,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,-1,18080,-1,0.017779425,0.9822206
18091,psychosis,9,10,74,83,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18091,-1,0.0009183848,0.9990816
18092,disruptive behaviors,11,13,88,108,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18092,-1,0.0011859654,0.9988141
18093,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18093,-1,0.0014941231,0.99850595
18095,psychosis,26,27,139,148,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18095,-1,0.00090026396,0.99909973
18096,disruptive behaviors,28,30,153,173,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18096,-1,0.0011773226,0.9988226
18097,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18097,-1,0.0016012372,0.9983987
18100,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,-1,18100,-1,0.0026548859,0.99734515
18106,psychosis,31,32,197,206,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18106,-1,0.0015164887,0.9984835
18107,psychomotor agitation,35,37,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18107,-1,0.0010638817,0.9989361
18108,extrapyramidal signs,17,19,84,104,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,-1,-1,-1,18108,-1,0.0010259368,0.9989741
18111,extrapyramidal signs,26,28,156,176,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,-1,-1,-1,18111,-1,0.00096115976,0.9990388
18113,neuroleptics,12,13,80,92,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18113,-1,0.996311,0.0036889568
18114,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18114,-1,0.0017922387,0.9982078
18115,psychosis,20,21,135,144,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18115,-1,0.00089743774,0.9991026
18116,disruptive behaviors,22,24,149,169,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18116,-1,0.0012114575,0.99878854
18117,Acute renal failure,0,3,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18117,-1,0.0010610218,0.998939
18118,rifampicin,8,9,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18118,-1,0.9984003,0.0015997485
18119,acute renal failure,16,19,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,-1,-1,-1,18119,-1,0.0008769016,0.99912316
18120,renal failure,5,7,37,50,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18120,-1,0.0008438046,0.99915624
18121,rifampicin,12,13,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18121,-1,0.99844664,0.0015533771
18122,renal lesions,6,8,32,45,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,-1,-1,-1,18122,-1,0.0014221843,0.99857783
18131,radiocalcium,15,16,79,91,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,-1,18131,-1,0.98950386,0.01049612
18133,mg.per,11,12,80,86,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,-1,18133,-1,0.4198106,0.5801894
18134,calcium chloride,2,4,13,29,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,-1,-1,-1,18134,-1,0.9973732,0.0026268128
18137,radiocalcium,1,2,14,26,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,-1,18137,-1,0.96087897,0.039121035
18143,mg,13,14,74,76,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,18143,-1,0.57757306,0.42242694
18148,SM-5887,9,10,63,70,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,-1,-1,18148,-1,0.99647266,0.0035272741
18151,SM-5887,11,12,76,83,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18151,-1,0.9980075,0.0019925372
18152,SM-5887,18,19,123,130,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18152,-1,0.9978854,0.002114537
18156,SM-5887,29,30,149,156,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,-1,-1,-1,18156,-1,0.99735886,0.0026411656
18159,SM-5887,33,34,238,245,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,18159,-1,0.99731535,0.0026846267
18161,SM-5887,8,9,58,65,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,-1,-1,18161,-1,0.9971591,0.0028409087
18165,SM-5887,18,19,98,105,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,-1,-1,-1,18165,-1,0.9976593,0.0023407103
18168,SM-5887,5,6,21,28,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,-1,-1,-1,18168,-1,0.9962022,0.0037978168
18170,SM-5887,3,4,15,22,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,-1,-1,18170,-1,0.996995,0.0030050485
18174,FK506,11,12,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,-1,-1,-1,18174,-1,0.9984163,0.0015836383
18176,FK506,19,20,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,-1,-1,-1,18176,-1,0.9984394,0.0015606098
18177,n,16,17,80,81,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18177,-1,0.02918506,0.97081494
18178,n=5,26,27,111,114,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18178,-1,0.02448636,0.9755137
18179,n,31,32,124,125,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18179,-1,0.021841155,0.97815883
18180,IgA nephropathy,37,39,141,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18180,-1,0.0039181425,0.9960819
18181,n,40,41,158,159,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18181,-1,0.022583306,0.97741663
18182,n,48,49,182,183,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18182,-1,0.033504933,0.9664951
18183,FK506 nephropathy,55,57,210,227,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18183,-1,0.4550189,0.54498106
18184,n,58,59,229,230,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18184,-1,0.019434208,0.9805658
18185,FK506 nephropathy,65,67,251,268,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18185,-1,0.43002003,0.56997997
18186,n,68,69,270,271,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18186,-1,0.024634248,0.97536576
18187,FK506 nephropathy,14,16,87,104,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,-1,18187,-1,0.494748,0.505252
18188,FK506 nephropathy,1,3,8,25,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18188,-1,0.52901083,0.47098923
18189,focal segmental glomerulosclerosis,27,30,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18189,-1,0.0015088482,0.99849117
18190,interstitial fibrosis,39,41,235,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18190,-1,0.0014230215,0.998577
18192,FK506 nephropathy,10,12,65,82,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18192,-1,0.5677094,0.4322906
18193,P,32,33,215,216,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18193,-1,0.1328011,0.8671989
18194,FK506 nephropathy,7,9,50,67,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18194,-1,0.572873,0.427127
18195,FK506 nephropathy,27,29,202,219,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18195,-1,0.5304897,0.46951032
18196,lead,34,35,245,249,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18196,-1,0.021718359,0.9782817
18197,of,37,38,267,269,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18197,-1,0.009365216,0.99063474
18201,ethinyl estradiol,8,10,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18201,-1,0.9984297,0.0015703123
18202,EE,11,12,69,71,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18202,-1,0.9969447,0.0030552987
18204,contrast,1,2,3,11,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,-1,18204,-1,0.070946775,0.9290532
18205,EE,1,2,6,8,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,-1,18205,-1,0.9859634,0.014036671
18207,fenfluramine,8,9,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18207,-1,0.99882644,0.0011735355
18208,dexfenfluramine,10,11,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18208,-1,0.99875736,0.0012425942
18209,fenfluramine,18,19,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18209,-1,0.99882466,0.0011753881
18210,dexfenfluramine,20,21,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18210,-1,0.99866855,0.0013314653
18211,valvular disease,22,24,140,156,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18211,-1,0.0014960627,0.9985039
18212,valvular abnormalities,10,12,54,76,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18212,-1,0.0015750988,0.9984249
18213,fenfluramine,15,16,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18213,-1,0.99880767,0.0011923744
18214,dexfenfluramine,17,18,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18214,-1,0.998747,0.0012529511
18215,fenfluramine,6,7,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18215,-1,0.9988172,0.0011827732
18216,dexfenfluramine,8,9,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18216,-1,0.9987521,0.0012479194
18217,valvulopathy,7,8,41,53,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18217,-1,0.0013912594,0.99860877
18219,aortic regurgitation,39,41,233,253,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18219,-1,0.0016309601,0.99836904
18222,bicuspid aortic valve,3,6,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18222,-1,0.0013883237,0.9986117
18223,aortic regurgitation,8,10,48,68,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18223,-1,0.0012799925,0.99872005
18224,aortic insufficiency,6,8,42,62,The second patient developed new moderate aortic insufficiency.,9867728_10,-1,-1,-1,18224,-1,0.001223947,0.998776
18226,nerve growth factor,6,9,50,69,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18226,-1,0.9803947,0.01960529
18229,nerve growth factor,31,34,232,251,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18229,-1,0.98205155,0.017948432
18230,NGF,35,36,253,256,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18230,-1,0.9894986,0.010501397
18231,PG-9,6,7,37,41,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18231,-1,0.9955707,0.0044293455
18234,S-(-)-ET-126,40,41,228,240,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18234,-1,0.9952697,0.0047302796
18235,PG-9,6,7,37,41,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,-1,18235,-1,0.9948791,0.005120828
18237,PG-9,6,7,32,36,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,-1,-1,-1,18237,-1,0.9944951,0.0055049025
18238,PG-9,0,1,0,4,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18238,-1,0.99352056,0.0064794784
18239,NGF,9,10,45,48,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18239,-1,0.9874264,0.012573583
18240,NGF,2,3,12,15,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18240,-1,0.9734259,0.02657402
18241,PG-9,6,7,37,41,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18241,-1,0.98959386,0.010406174
18242,PG-9,12,13,83,87,"During culture, no morphological changes were found at effective concentrations of PG-9.",9869257_6,-1,-1,-1,18242,-1,0.9917753,0.008224753
18243,PG-9,7,8,42,46,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18243,-1,0.9954594,0.004540636
18244,NGF,19,20,125,128,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18244,-1,0.9937691,0.0062308605
18245,PG-9,2,3,11,15,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,18245,-1,0.9897489,0.010251059
18246,impaired cognitive processes,15,18,88,116,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,18246,-1,0.0018271715,0.9981729
18248,tobramicyn,15,16,84,94,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,-1,18248,-1,0.9952543,0.0047457
18251,n,3,4,10,11,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18251,-1,0.14604792,0.8539521
18253,n,17,18,73,74,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18253,-1,0.16679445,0.8332056
18255,body weight,14,16,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,18255,-1,0.0067670103,0.99323297
18256,renal function,17,19,82,96,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,18256,-1,0.0021130152,0.99788696
18257,TD,19,20,81,83,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18257,-1,0.19053505,0.80946493
18258,P,22,23,91,92,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18258,-1,0.09126942,0.90873057
18259,TD,15,16,108,110,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18259,-1,0.46225742,0.5377426
18260,P,17,18,112,113,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18260,-1,0.13786618,0.86213386
18261,TD,14,15,84,86,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18261,-1,0.35208544,0.6479145
18262,h,21,22,108,109,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18262,-1,0.0707515,0.9292485
18263,h,26,27,132,133,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18263,-1,0.0689272,0.9310728
18264,TD,28,29,137,139,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18264,-1,0.23859394,0.761406
18265,Vd,31,32,142,144,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18265,-1,0.3895738,0.6104261
18266,TD,41,42,193,195,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18266,-1,0.71424186,0.28575814
18267,Cl,44,45,198,200,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18267,-1,0.16030419,0.8396958
18268,TD,54,55,259,261,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18268,-1,0.60840625,0.39159375
18270,TD,18,19,91,93,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,-1,-1,18270,-1,0.0031752808,0.99682474
18272,TD,1,2,3,5,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18272,-1,0.003919613,0.99608046
18273,decreased auditory function,7,10,38,65,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18273,-1,0.002498568,0.99750143
18274,auditory loss,17,19,98,111,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18274,-1,0.002657396,0.99734265
18275,decreased auditory function,32,35,174,201,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18275,-1,0.0026738718,0.99732614
18283,GABA,29,30,215,219,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,18283,-1,0.9968514,0.0031486275
18289,pindolol,7,8,65,73,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18289,-1,0.9985677,0.0014322317
18291,atenolol,11,12,89,97,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18291,-1,0.9984888,0.0015112379
18295,methylatropine,8,9,53,67,Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.,9915601_4,-1,-1,-1,18295,-1,0.99880016,0.0011998232
18298,FK 506,9,11,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,-1,18298,-1,0.9976023,0.0023977757
18299,FK 506,4,6,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,-1,-1,18299,-1,0.9977447,0.0022553762
18303,FK 506,15,17,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18303,-1,0.9982132,0.0017868835
18304,nitric oxide,41,43,231,243,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18304,-1,0.987219,0.01278101
18305,FR 139317,13,15,78,87,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,-1,-1,18305,-1,0.99707735,0.0029226714
18307,FK,0,1,0,2,"FK 506, 5 mg.",9931093_4,-1,-1,-1,18307,-1,0.9973621,0.0026378864
18308,mg,4,5,10,12,"FK 506, 5 mg.",9931093_4,-1,-1,-1,18308,-1,0.87978333,0.12021672
18309,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,-1,18309,-1,0.008422609,0.9915774
18310,FK 506,0,2,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,-1,-1,-1,18310,-1,0.99770904,0.0022909727
18311,FR 139317,3,5,22,31,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,18311,-1,0.9942847,0.005715248
18312,mg,7,8,36,38,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,18312,-1,0.7213327,0.2786672
18314,FK 506,4,6,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,-1,-1,-1,18314,-1,0.99767905,0.0023209255
18315,Structural and functional impairment of mitochondria,0,6,0,52,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18315,-1,0.0059876414,0.9940123
18317,c,15,16,125,126,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18317,-1,0.9652242,0.0347758
18319,ADR,5,6,23,26,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18319,-1,0.985052,0.014948034
18321,cardiovascular toxicity,17,19,90,113,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18321,-1,0.0014120652,0.9985879
18322,ADR,3,4,26,29,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18322,-1,0.9816127,0.01838729
18323,c,8,9,70,71,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18323,-1,0.95832765,0.041672338
18324,ADR,22,23,143,146,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18324,-1,0.99026275,0.009737235
18325,ADR,40,41,256,259,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18325,-1,0.9935867,0.0064133275
18326,heart tissue damage,17,20,121,140,"At various times during treatment, the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy.",9952311_3,-1,-1,-1,18326,-1,0.0024549696,0.99754506
18327,ADR,10,11,53,56,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18327,-1,0.003123031,0.99687696
18328,cardiovascular arrhythmias,12,14,64,90,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18328,-1,0.0011380705,0.9988619
18330,body weight,39,41,229,240,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18330,-1,0.4288309,0.57116914
18331,ADR,31,32,172,175,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,-1,18331,-1,0.9956115,0.0043885326
18332,ADR,21,22,126,129,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18332,-1,0.0055537084,0.9944463
18333,mitochondrial structural and functional impairment,26,31,165,215,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18333,-1,0.007400205,0.99259984
4505,Estrogen,0,1,0,8,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0,-1,0,4505,-1,0.9969394,0.0030605623
14716,testosterone,30,31,185,197,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,0,-1,0,14716,-1,0.9972838,0.0027161825
14645,indomethacin,6,7,47,59,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,0,-1,0,14645,-1,0.9986059,0.0013941163
3866,prazosin,13,14,82,90,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,0,-1,0,3866,-1,0.9985195,0.0014805334
4893,adriamycin,10,11,53,63,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,0,-1,0,4893,-1,0.99858874,0.001411229
8240,verapamil,3,4,21,30,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,0,-1,0,8240,-1,0.99861944,0.0013805421
460,olanzapine,26,27,159,169,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,0,-1,0,460,-1,0.9985532,0.0014467838
11037,ifosfamide,5,6,28,38,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,0,-1,0,11037,-1,0.9986755,0.0013244369
3384,clopidogrel,21,22,130,141,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0,3384,-1,0.99821764,0.0017822861
3027,cisplatin,11,12,64,73,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,3027,-1,0.99778396,0.002216083
9347,ecstasy,7,8,42,49,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,0,-1,0,9347,-1,0.99762386,0.002376095
2722,Ribavirin,0,1,0,9,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,0,-1,0,2722,-1,0.9984793,0.0015207032
11951,diazepam,3,4,15,23,The effects of diazepam on cardiovascular function were assessed in conscious rats.,2894433_1,0,-1,0,11951,-1,0.9985201,0.0014799541
2896,cocaine,28,29,139,146,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,0,-1,0,2896,-1,0.9972811,0.0027189509
5558,pentobarbital,7,8,41,54,Learning of rats under amnesia caused by pentobarbital.,1616457_0,0,-1,0,5558,-1,0.9983937,0.0016062219
16656,creatinine,13,14,98,108,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0,-1,0,16656,-1,0.9926554,0.007344581
9432,lithium,30,31,159,166,"Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.",19692487_10,0,-1,0,9432,-1,0.9977452,0.0022546998
2641,risperidone,21,22,130,141,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,0,-1,0,2641,-1,0.99848026,0.0015197957
15220,rifampin,6,7,70,78,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,0,-1,0,15220,-1,0.998212,0.0017879868
4333,atropine,14,15,94,102,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0,-1,0,4333,-1,0.9987589,0.0012411543
15979,lovastatin,15,16,100,110,Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.,8480959_10,0,-1,0,15979,-1,0.9985815,0.0014185342
405,diltiazem,16,17,108,117,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,0,-1,0,405,-1,0.9984465,0.0015535408
622,bromocriptine,5,6,29,42,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,0,-1,0,622,-1,0.9987606,0.0012394353
8191,amino acid,6,8,58,68,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,0,-1,0,8191,-1,0.9880453,0.011954721
2006,timolol,13,14,65,72,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0,2006,-1,0.99870026,0.0012997048
17023,bilirubin,68,69,307,316,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0,-1,0,17023,-1,0.961175,0.038824927
16065,vinorelbine,25,26,167,178,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0,-1,0,16065,-1,0.9985972,0.0014028344
7392,Levofloxacin,0,1,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0,-1,0,7392,-1,0.9987036,0.001296397
202,lithium,14,15,99,106,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,0,-1,0,202,-1,0.9980829,0.0019170876
3349,docetaxel,7,8,55,64,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,3349,-1,0.99788934,0.0021106456
6185,desipramine,8,9,61,72,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0,-1,0,6185,-1,0.9988728,0.001127174
2841,carbachol,5,6,36,45,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0,-1,0,2841,-1,0.9988009,0.0011990868
1198,venlafaxine,35,36,224,235,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0,1198,-1,0.9987581,0.0012419358
6571,Lithium,0,1,0,7,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0,-1,0,6571,-1,0.99833626,0.0016637277
4654,lidocaine,9,10,52,61,"However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg.",15278670_6,0,-1,0,4654,-1,0.9964109,0.0035891286
4249,superoxide,15,16,77,87,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,0,-1,0,4249,-1,0.96997255,0.030027436
17346,levodopa,36,37,256,264,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0,-1,0,17346,-1,0.99864894,0.0013510197
3146,creatinine,5,6,23,33,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,3146,-1,0.9923195,0.0076804487
1727,lithium,12,13,72,79,"It is suggested that these changes represent a specific toxic effect of lithium, reported here for the first time in man.",1141447_3,0,-1,0,1727,-1,0.99796534,0.0020347107
16221,progesterone,22,23,144,156,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,0,-1,0,16221,-1,0.99788934,0.0021106417
15959,lovastatin,9,10,50,60,OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.,8480959_1,0,-1,0,15959,-1,0.9986099,0.0013900918
11945,naloxone,3,4,19,27,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,0,-1,0,11945,-1,0.9987668,0.0012331958
3103,heparin,8,9,53,60,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,0,-1,0,3103,-1,0.9978295,0.00217046
9079,heparin,9,10,52,59,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,0,-1,0,9079,-1,0.99343646,0.006563549
14620,procainamide,16,17,100,112,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0,-1,0,14620,-1,0.9987257,0.0012742378
8500,3-methyladenine,2,3,9,24,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0,-1,0,8500,-1,0.9978192,0.0021808334
6980,Doxorubicin,0,1,0,11,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,0,-1,0,6980,-1,0.9978568,0.0021432196
6251,cholesterol,7,8,42,53,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,0,-1,0,6251,-1,0.9789227,0.021077324
9785,Sorafenib,0,1,0,9,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0,-1,0,9785,-1,0.9977296,0.0022703812
15593,phenylephrine,12,13,78,91,Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy.,809711_2,0,-1,0,15593,-1,0.99869835,0.0013016248
537,Warfarin,32,33,191,199,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0,537,-1,0.9979639,0.0020361326
15492,oxytocin,9,10,43,51,If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.,803783_7,0,-1,0,15492,-1,0.99757904,0.0024209747
15356,zidovudine,37,38,172,182,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,0,-1,0,15356,-1,0.998735,0.001265005
9071,heparin,16,17,116,123,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,0,-1,0,9071,-1,0.9913169,0.008683034
15814,zidovudine,23,24,157,167,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,0,-1,0,15814,-1,0.998528,0.0014720095
600,sodium,2,3,11,17,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0,-1,0,600,-1,0.9969585,0.0030415694
4155,calcitonin,13,14,70,80,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0,4155,-1,0.99129194,0.008708012
5715,pilocarpine,12,13,92,103,Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.,16337777_0,0,-1,0,5715,-1,0.9988959,0.0011040994
15002,isoflurane,13,14,86,96,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0,15002,-1,0.99817705,0.0018229889
2898,cocaine,4,5,27,34,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0,-1,0,2898,-1,0.9960538,0.0039462205
8563,mefloquine,30,31,190,200,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,0,-1,0,8563,-1,0.998798,0.0012019187
9081,heparin,9,10,45,52,This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives.,19289093_6,0,-1,0,9081,-1,0.99229807,0.0077019855
3389,salt,6,7,38,42,The molecular mechanism(s) leading to salt retention has not been completely elucidated.,12653683_2,0,-1,0,3389,-1,0.9732953,0.026704695
4993,testosterone,8,9,44,56,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,0,-1,0,4993,-1,0.9962608,0.0037391307
2153,Adenosine,2,3,9,18,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,0,-1,0,2153,-1,0.9979997,0.0020002124
11638,Captopril,9,10,58,67,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,0,-1,0,11638,-1,0.9985373,0.0014626837
4494,estrogen,8,9,54,62,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0,-1,0,4494,-1,0.99732363,0.0026762837
15970,cholesterol,30,31,137,148,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0,-1,0,15970,-1,0.53826785,0.46173218
2112,amifostine,16,17,107,117,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2112,-1,0.99880815,0.0011918424
14084,norepinephrine,22,23,137,151,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,0,-1,0,14084,-1,0.9979196,0.0020803576
12003,potassium,9,10,75,84,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,0,-1,0,12003,-1,0.99513596,0.004864033
2138,adenosine,11,12,87,96,Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans.,11752998_0,0,-1,0,2138,-1,0.9979728,0.0020271547
2089,Amifostine,0,1,0,10,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0,2089,-1,0.998628,0.0013720106
7882,tacrolimus,20,21,134,144,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0,-1,0,7882,-1,0.9987872,0.001212776
14535,amiodarone,3,4,18,28,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,0,-1,0,14535,-1,0.99865377,0.0013462438
8224,aspartate,38,39,256,265,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0,8224,-1,0.997157,0.002843026
10718,Ketamine,0,1,0,8,Ketamine elicited psychosis like psychopathology.,20727411_7,0,-1,0,10718,-1,0.99540764,0.004592388
12540,verapamil,11,12,85,94,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,0,-1,0,12540,-1,0.99881846,0.0011814676
10883,desferrioxamine,10,11,65,80,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,0,-1,0,10883,-1,0.9986733,0.0013266974
11113,aminophylline,2,3,11,24,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,0,-1,0,11113,-1,0.99856526,0.001434762
9657,creatinine,21,22,139,149,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0,9657,-1,0.99357176,0.006428249
10211,prazosin,8,9,45,53,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,0,-1,0,10211,-1,0.9986228,0.0013772578
13045,acetylcholine,1,2,9,22,"Although acetylcholine receptor antibodies were not detectable, the time course was consistent with an autoimmune process.",3750012_2,0,-1,0,13045,-1,0.9967715,0.0032284448
2009,timolol,34,35,174,181,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0,2009,-1,0.99803704,0.0019630203
12073,epinephrine,4,5,20,31,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0,-1,0,12073,-1,0.9968219,0.0031780829
8371,everolimus,16,17,122,132,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0,-1,0,8371,-1,0.9980909,0.0019090035
18136,calcium,5,6,29,36,per liter failed to increase calcium influx into the myocardial cell.,983936_5,0,-1,0,18136,-1,0.9927233,0.0072767497
1983,paracetamol,8,9,59,70,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0,-1,0,1983,-1,0.9987962,0.0012037554
17082,steroids,18,19,143,151,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0,17082,-1,0.9838113,0.016188703
373,vinorelbine,8,9,55,66,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0,373,-1,0.99862516,0.0013748569
14466,cimetidine,28,29,156,166,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0,14466,-1,0.9986766,0.0013233961
18279,isoniazid,3,4,14,23,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,0,-1,0,18279,-1,0.9979723,0.0020276844
2333,glutamate,14,15,75,84,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,0,-1,0,2333,-1,0.997759,0.0022409672
14475,cimetidine,20,21,129,139,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,0,-1,0,14475,-1,0.9987425,0.0012574693
5156,dexamethasone,13,14,86,99,Further long-term follow-up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development.,15814210_13,0,-1,0,5156,-1,0.99759775,0.002402302
14639,indomethacin,1,2,9,21,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,0,-1,0,14639,-1,0.99863714,0.0013628801
12318,oral contraceptives,6,8,48,67,Three patients developed chorea while receiving oral contraceptives.,3123611_1,0,-1,0,12318,-1,0.99743646,0.002563515
5063,morphine,5,6,28,36,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0,-1,0,5063,-1,0.99648726,0.0035127953
18276,tobramycin,12,13,74,84,CONCLUSION: This small study suggests that a once-daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice-daily regimen.,9875685_14,0,-1,0,18276,-1,0.9981415,0.0018584861
1292,acetylcholine,5,6,30,43,In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.,11208990_10,0,-1,0,1292,-1,0.9980363,0.001963633
18109,haloperidol,1,2,9,20,Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects.,9812111_7,0,-1,0,18109,-1,0.99835736,0.0016426406
18144,Acetylsalicylic acid,0,2,0,20,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0,18144,-1,0.9981394,0.0018605997
17683,Cisapride,0,1,0,9,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0,-1,0,17683,-1,0.99874914,0.001250855
8498,adriamycin,20,21,119,129,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,0,-1,0,8498,-1,0.9983864,0.001613638
8398,sevoflurane,12,13,78,89,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0,-1,0,8398,-1,0.99867487,0.0013252104
3385,sodium,1,2,11,17,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0,-1,0,3385,-1,0.9926802,0.0073198853
9301,glutamate,1,2,10,19,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0,-1,0,9301,-1,0.9971372,0.0028628432
13810,caffeine,11,12,77,85,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0,-1,0,13810,-1,0.9981982,0.0018018453
7864,Lamivudine,0,1,0,10,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,0,-1,0,7864,-1,0.9983247,0.001675309
7263,iodixanol,29,30,120,129,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0,-1,0,7263,-1,0.9983772,0.0016227337
16810,epinephrine,26,27,143,154,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,0,-1,0,16810,-1,0.99668306,0.003316898
9507,oxycodone,18,19,116,125,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,0,-1,0,9507,-1,0.9987047,0.001295309
9946,propofol,6,7,29,37,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,0,-1,0,9946,-1,0.99652666,0.0034733054
184,magnesium,8,9,50,59,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0,-1,0,184,-1,0.99761605,0.0023840105
545,dopamine,4,5,28,36,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0,-1,0,545,-1,0.99647707,0.0035229768
17040,fluoxetine,14,15,99,109,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,0,-1,0,17040,-1,0.99867475,0.0013252812
9828,phenylephrine,5,6,32,45,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,0,-1,0,9828,-1,0.9987582,0.0012418341
12298,alfentanil,20,21,109,119,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,12298,-1,0.998582,0.0014180527
1400,prednisone,14,15,85,95,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,0,-1,0,1400,-1,0.99837744,0.0016225978
14228,sulindac,13,14,82,90,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0,-1,0,14228,-1,0.99883443,0.0011655216
7351,amiodarone,13,14,73,83,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,0,-1,0,7351,-1,0.9987723,0.0012276892
4184,nitroglycerin,9,10,66,79,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,0,-1,0,4184,-1,0.9985605,0.0014394925
9891,lidocaine,8,9,71,80,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0,-1,0,9891,-1,0.9982749,0.0017250706
16507,creatinine,26,27,143,153,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,16507,-1,0.9941049,0.005895077
8551,potassium,18,19,119,128,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,0,-1,0,8551,-1,0.9975707,0.0024292364
4924,ribavirin,3,4,19,28,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,0,-1,0,4924,-1,0.99827445,0.0017255931
8631,statin,17,18,141,147,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,0,-1,0,8631,-1,0.9972989,0.0027010848
3792,steroids,4,5,35,43,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,0,-1,0,3792,-1,0.9947239,0.005276156
9130,bradykinin,19,20,109,119,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0,9130,-1,0.99551374,0.0044862246
15327,cholesterol,31,32,145,156,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,0,-1,0,15327,-1,0.9910103,0.008989658
17874,cisapride,32,33,188,197,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,0,-1,0,17874,-1,0.99867743,0.001322598
16501,creatinine,4,5,27,37,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0,16501,-1,0.9956018,0.004398227
7650,paracetamol,1,2,2,13,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,0,-1,0,7650,-1,0.9982299,0.0017700688
14009,captopril,17,18,117,126,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,0,-1,0,14009,-1,0.9984427,0.0015573092
2956,succinylcholine,4,5,21,36,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,0,-1,0,2956,-1,0.99859744,0.0014025525
5648,Chloroquine,0,1,0,11,Chloroquine related complete heart block with blindness: case report.,1628552_0,0,-1,0,5648,-1,0.99859875,0.001401248
16618,calcium,7,8,43,50,This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.,8800187_3,0,-1,0,16618,-1,0.9967524,0.0032476455
811,nimodipine,2,3,13,23,"For low-dose nimodipine, the results were not conclusive.",10835440_11,0,-1,0,811,-1,0.99874437,0.0012556466
11596,ibuprofen,15,16,95,104,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,0,-1,0,11596,-1,0.9987062,0.0012937912
2135,oral contraceptives,26,28,180,199,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0,2135,-1,0.9914289,0.008571064
4105,dexamethasone,16,17,78,91,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0,-1,0,4105,-1,0.9982982,0.0017017452
9057,captopril,4,5,27,36,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,0,-1,0,9057,-1,0.9987478,0.0012521
7556,heparin,14,15,79,86,METHOD: The sample for the study consisted of 50 patients to whom subcutaneous heparin was administered.,17931375_4,0,-1,0,7556,-1,0.9962852,0.0037147931
1023,methylprednisolone,1,2,10,28,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,0,-1,0,1023,-1,0.99876547,0.0012345327
8906,everolimus,4,5,43,53,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0,8906,-1,0.998307,0.0016930391
4079,amphetamine,30,31,180,191,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0,-1,0,4079,-1,0.9984434,0.0015566444
7829,methylphenidate,14,15,82,97,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,0,-1,0,7829,-1,0.99875,0.0012499773
7433,oxygen,10,11,75,81,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,0,-1,0,7433,-1,0.98152,0.01847992
9596,lithium,9,10,58,65,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0,-1,0,9596,-1,0.99749446,0.0025055814
11480,enalapril,5,6,37,46,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,-1,0,11480,-1,0.99827516,0.0017248589
1114,metoprolol,3,4,22,32,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,0,-1,0,1114,-1,0.9989145,0.0010855709
12467,nitroprusside,4,5,25,38,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,0,-1,0,12467,-1,0.99844813,0.0015517812
2966,ergotamine,18,19,117,127,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0,-1,0,2966,-1,0.99873286,0.0012671963
1987,paracetamol,17,18,102,113,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0,-1,0,1987,-1,0.99870944,0.001290515
3669,acetylsalicylic acid,2,4,9,29,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0,-1,0,3669,-1,0.9980959,0.0019040337
8616,papaverine,20,21,150,160,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,0,-1,0,8616,-1,0.99866414,0.0013358141
1214,amphetamine,20,21,120,131,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,0,-1,0,1214,-1,0.99875116,0.0012488468
12606,phenacetin,13,14,84,94,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,0,-1,0,12606,-1,0.9986326,0.0013673629
160,sirolimus,14,15,101,110,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,0,-1,0,160,-1,0.99825424,0.0017457055
15164,alprazolam,5,6,32,42,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,0,-1,0,15164,-1,0.998485,0.0015150165
12378,doxorubicin,17,18,86,97,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,0,-1,0,12378,-1,0.99769753,0.0023024795
17727,tamoxifen,14,15,76,85,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,0,-1,0,17727,-1,0.9978528,0.0021471912
14721,testosterone,12,13,80,92,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,0,-1,0,14721,-1,0.99609405,0.0039059883
1889,fentanyl,5,6,33,41,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,0,-1,0,1889,-1,0.99864036,0.0013595828
10723,Ketamine,0,1,0,8,"Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.",20727411_10,0,-1,0,10723,-1,0.9975546,0.0024453853
16364,acetaminophen,2,3,6,19,"Thus, acetaminophen has been used both as a single agent and in combination with other analgesics, whereas phenacetin was available only in combinations.",8669433_7,0,-1,0,16364,-1,0.9987172,0.0012828056
547,dopamine,28,29,169,177,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0,-1,0,547,-1,0.9962768,0.003723228
14398,carbachol,10,11,68,77,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0,-1,0,14398,-1,0.99879503,0.001204925
12978,gentamicin,16,17,108,118,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0,-1,0,12978,-1,0.9981394,0.0018605625
18292,clonidine,17,18,116,125,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,18292,-1,0.998706,0.001293992
5829,methylphenidate,3,4,17,32,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,0,-1,0,5829,-1,0.9988199,0.0011800481
11042,prostaglandins,6,7,45,59,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,0,-1,0,11042,-1,0.99647623,0.0035238187
17898,cisapride,25,26,122,131,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0,17898,-1,0.99875295,0.0012469866
11956,diazepam,6,7,42,50,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,0,-1,0,11956,-1,0.9985222,0.0014778508
14419,carbachol,28,29,180,189,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0,-1,0,14419,-1,0.99873513,0.0012648724
15761,daunorubicin,7,8,40,52,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0,-1,0,15761,-1,0.99817014,0.0018298425
8217,glutamate,24,25,139,148,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0,8217,-1,0.9967822,0.0032178531
5424,dexamethasone,2,3,17,30,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0,5424,-1,0.9982755,0.0017245321
7369,aspartate,20,21,120,129,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,7369,-1,0.99538714,0.0046128505
9061,captopril,15,16,93,102,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,0,-1,0,9061,-1,0.99873275,0.0012672233
8053,nicotine,31,32,214,222,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0,-1,0,8053,-1,0.9978186,0.002181456
4074,amphetamine,15,16,84,95,Nine days later locomotor activity was measured in response to a single low dose of amphetamine (0.5 mg/kg).,14596845_6,0,-1,0,4074,-1,0.9987399,0.0012600763
9370,vancomycin,8,9,52,62,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,0,-1,0,9370,-1,0.9979231,0.002076973
8271,histamine,6,7,36,45,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,0,-1,0,8271,-1,0.9963586,0.0036414582
14604,bupivacaine,8,9,46,57,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0,-1,0,14604,-1,0.9987012,0.0012987872
15710,morphine,16,17,99,107,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,0,-1,0,15710,-1,0.9974051,0.0025948812
3621,lindane,3,4,23,30,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0,-1,0,3621,-1,0.9982645,0.0017355508
1471,anthracycline,4,5,35,48,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,0,-1,0,1471,-1,0.9979213,0.002078727
15961,Lovastatin,7,8,44,54,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,0,-1,0,15961,-1,0.998381,0.0016189296
15197,ouabain,5,6,27,34,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,0,-1,0,15197,-1,0.9985821,0.0014179244
17032,fluoxetine,11,12,60,70,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,0,-1,0,17032,-1,0.9986564,0.0013435885
5468,calcium,7,8,37,44,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,0,-1,0,5468,-1,0.99597836,0.004021586
13402,gentamicin,2,3,10,20,The serum gentamicin concentration had reached toxic levels when anuria developed.,4069770_2,0,-1,0,13402,-1,0.9969825,0.0030175264
13387,antidepressants,3,4,23,38,Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly.,4027862_3,0,-1,0,13387,-1,0.99489766,0.0051023304
4098,mesna,7,8,27,32,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,4098,-1,0.998175,0.0018249368
13173,Isoniazid,0,1,0,9,"Isoniazid was discontinued later, followed by a dramatic improvement in the visual acuity.",384871_4,0,-1,0,13173,-1,0.99753976,0.0024602767
3095,carbimazole,38,39,244,255,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,3095,-1,0.9986759,0.001324087
17460,testosterone,8,9,41,53,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,0,-1,0,17460,-1,0.73115325,0.26884678
16005,ciprofloxacin,3,4,31,44,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,0,-1,0,16005,-1,0.99751735,0.0024826922
5065,glutamate,15,16,100,109,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0,-1,0,5065,-1,0.9963966,0.0036034784
13197,etoposide,4,5,24,33,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0,-1,0,13197,-1,0.99875176,0.0012482284
18085,cocaine,15,16,95,102,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,0,-1,0,18085,-1,0.99811614,0.0018838259
15501,rifampin,15,16,87,95,This last finding may be related to time of testing and/or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte.,804391_5,0,-1,0,15501,-1,0.99800795,0.0019921164
18015,cocaine,12,13,103,110,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,0,-1,0,18015,-1,0.9974783,0.002521687
13650,ranitidine,25,26,164,174,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,0,-1,0,13650,-1,0.99890304,0.0010969935
8607,dopamine,10,11,76,84,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,0,-1,0,8607,-1,0.99664503,0.0033549643
10263,tacrolimus,5,6,47,57,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0,-1,0,10263,-1,0.99868554,0.0013145137
3089,bupropion,3,4,20,29,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,0,-1,0,3089,-1,0.99834037,0.0016595693
13429,methyldopa,6,7,38,48,Patterns of hepatic injury induced by methyldopa.,424937_0,0,-1,0,13429,-1,0.99834216,0.001657773
11635,ketoconazole,10,11,62,74,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,0,-1,0,11635,-1,0.99883455,0.00116548
17642,lidocaine,11,12,77,86,"However, identification of a short-acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal.",9523805_2,0,-1,0,17642,-1,0.99734867,0.0026513417
1421,furosemide,22,23,122,132,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0,-1,0,1421,-1,0.9986259,0.0013741658
7129,dexamethasone,16,17,93,106,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0,-1,0,7129,-1,0.99821186,0.0017881487
16233,paclitaxel,9,10,68,78,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,0,-1,0,16233,-1,0.9972722,0.0027278024
8068,nicotine,8,9,45,53,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0,-1,0,8068,-1,0.99758065,0.0024193749
6795,steroid,15,16,92,99,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0,-1,0,6795,-1,0.9919493,0.008050636
17641,bupivacaine,21,22,149,160,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0,-1,0,17641,-1,0.99875784,0.0012421506
17991,appetite suppressants,7,9,37,58,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,0,-1,0,17991,-1,0.9899686,0.010031379
7508,telithromycin,4,5,23,36,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,0,-1,0,7508,-1,0.9985336,0.001466432
10685,capecitabine,2,3,10,22,Safety of capecitabine: a review.,20722491_0,0,-1,0,10685,-1,0.99797994,0.0020200748
5058,morphine,2,3,9,17,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,0,-1,0,5058,-1,0.99725574,0.0027442977
8987,sulphasalazine,4,5,24,38,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0,-1,0,8987,-1,0.9987841,0.0012159409
9491,acetylcholine,3,4,26,39,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0,-1,0,9491,-1,0.99613225,0.003867798
6931,Clonidine,0,1,0,9,Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.,17263743_1,0,-1,0,6931,-1,0.9984388,0.0015612387
10870,desferrioxamine,8,9,64,79,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,0,-1,0,10870,-1,0.9986247,0.0013753218
2704,glycopyrrolate,5,6,35,49,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0,2704,-1,0.99866223,0.001337734
2351,scopolamine,12,13,57,68,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,0,-1,0,2351,-1,0.99869305,0.001306995
9955,serotonin,26,27,150,159,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0,-1,0,9955,-1,0.9972082,0.0027917763
11396,mesna,21,22,122,127,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,0,-1,0,11396,-1,0.99742067,0.00257938
15224,rifampin,7,8,45,53,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,0,-1,0,15224,-1,0.9981767,0.0018232715
1805,epinephrine,6,7,27,38,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,0,-1,0,1805,-1,0.99798524,0.0020147082
17643,Prilocaine,0,1,0,10,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0,17643,-1,0.99847513,0.0015248109
2874,glutamate,22,23,120,129,"The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors.",12231232_0,0,-1,0,2874,-1,0.9939492,0.006050788
17117,dopamine,10,11,60,68,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,0,-1,0,17117,-1,0.99753404,0.0024659613
1502,Verapamil,2,3,9,18,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,0,-1,0,1502,-1,0.9985109,0.0014890543
16875,cocaine,11,12,80,87,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,0,-1,0,16875,-1,0.9972594,0.0027406462
16838,methotrexate,22,23,150,162,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,0,-1,0,16838,-1,0.99815184,0.0018480811
6635,phenytoin,1,2,12,21,Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.,17049862_2,0,-1,0,6635,-1,0.9987815,0.0012184462
1105,dobutamine,5,6,35,45,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0,-1,0,1105,-1,0.9989448,0.001055177
8193,amino acid,19,21,118,128,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0,8193,-1,0.97581714,0.024182841
11411,carbamazepine,2,3,20,33,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,0,-1,0,11411,-1,0.99870634,0.001293631
9670,tacrolimus,2,3,10,20,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0,9670,-1,0.99832004,0.0016798738
13831,caffeine,10,11,69,77,Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown.,6308277_7,0,-1,0,13831,-1,0.99838173,0.0016182254
11504,fentanyl,10,11,60,68,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,0,-1,0,11504,-1,0.9986456,0.001354432
8048,dopamine,8,9,41,49,Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.,1833784_0,0,-1,0,8048,-1,0.997247,0.0027530733
11610,methyl dopa,12,14,75,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,0,-1,0,11610,-1,0.9982736,0.0017264163
14692,halothane,3,4,22,31,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,0,-1,0,14692,-1,0.9981152,0.0018847882
16873,cocaine,4,5,27,34,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,0,-1,0,16873,-1,0.99777216,0.0022277716
6750,sirolimus,8,9,60,69,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0,-1,0,6750,-1,0.9984944,0.0015056003
9389,alcohol,9,10,43,50,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,0,-1,0,9389,-1,0.9951563,0.0048436965
14114,heparin,5,6,36,43,"Management consists of cessation of heparin, platelet anti-aggregating agents, and alternate forms of anticoagulation when indicated.",6615052_8,0,-1,0,14114,-1,0.99630165,0.0036983623
17440,Testosterone,2,3,9,21,RESULTS: Testosterone was less than 3 ng./ml.,9334596_8,0,-1,0,17440,-1,0.99276686,0.007233092
13622,sulphasalazine,3,4,27,41,Possible teratogenicity of sulphasalazine.,6133211_0,0,-1,0,13622,-1,0.9988035,0.0011965033
7300,glutamate,17,18,95,104,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0,-1,0,7300,-1,0.995893,0.0041069654
1108,dobutamine,4,5,29,39,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,0,-1,0,1108,-1,0.9989618,0.0010382324
15973,Cholesterol,17,18,89,100,"Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).",8480959_7,0,-1,0,15973,-1,0.9583857,0.041614316
11380,catecholamine,16,17,103,116,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0,11380,-1,0.9975139,0.0024861714
1523,verapamil,1,2,8,17,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,0,-1,0,1523,-1,0.99874324,0.0012567545
855,isoniazid,19,20,136,145,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,0,-1,0,855,-1,0.99822253,0.0017774691
7021,smoking,16,17,101,108,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,0,-1,0,7021,-1,0.9968131,0.0031869325
13830,acetaminophen,5,6,28,41,Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown.,6308277_7,0,-1,0,13830,-1,0.9986539,0.0013460309
13222,vancomycin,3,4,17,27,"We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.",3934126_6,0,-1,0,13222,-1,0.9977227,0.0022773012
2080,cisplatin,8,9,55,64,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0,2080,-1,0.99734616,0.0026538419
16741,serotonin,21,22,117,126,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0,-1,0,16741,-1,0.99724954,0.002750485
2467,isoproterenol,18,19,119,132,The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol.,11897407_2,0,-1,0,2467,-1,0.9985605,0.0014395041
8266,cholesterol,10,11,66,77,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0,-1,0,8266,-1,0.99101955,0.0089804875
10073,methamphetamine,5,6,38,53,Oral rehabilitation of patients using methamphetamine can be challenging.,20098969_4,0,-1,0,10073,-1,0.9972391,0.0027609079
960,scopolamine,9,10,41,52,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,0,-1,0,960,-1,0.9987093,0.001290726
13651,cimetidine,5,6,29,39,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0,13651,-1,0.99892056,0.0010794784
7513,bilirubin,69,70,279,288,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0,7513,-1,0.9182849,0.08171512
17305,nicotine,18,19,104,112,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,0,-1,0,17305,-1,0.9970548,0.0029452424
16321,corticosteroids,17,18,107,122,Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.,8665051_1,0,-1,0,16321,-1,0.99737406,0.0026259192
14205,aspirin,16,17,80,87,"Also, there appears to be an adaptation by the rats to the chronic ingestion of aspirin.",6692345_6,0,-1,0,14205,-1,0.9976997,0.0023003793
3062,vigabatrin,15,16,107,117,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0,3062,-1,0.99894625,0.00105376
16567,acetaminophen,16,17,98,111,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,0,-1,0,16567,-1,0.9984309,0.0015690672
15521,adenosine,25,26,175,184,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0,15521,-1,0.99735355,0.0026464674
4516,epinephrine,13,14,79,90,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,0,-1,0,4516,-1,0.99712604,0.0028739036
18020,cocaine,30,31,209,216,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,0,-1,0,18020,-1,0.9977379,0.002262077
6388,histamine,12,13,72,81,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,0,-1,0,6388,-1,0.9976012,0.0023987475
12000,aldosterone,13,14,80,91,The normal-sodium group showed an immediate but temporary rise of the renin and aldosterone levels; in the low-sodium group renin and aldosterone increased more slowly but remained elevated.,28952_8,0,-1,0,12000,-1,0.9822711,0.017728884
16009,creatinine,5,6,30,40,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,0,-1,0,16009,-1,0.9941824,0.005817537
2019,Timolol,0,1,0,7,"Timolol gellan showed a numerically but not significantly smaller reduction in 24-hour heart rate, compared with timolol solution.",11704023_7,0,-1,0,2019,-1,0.99834716,0.001652859
7871,tacrolimus,1,2,9,19,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0,7871,-1,0.99853194,0.0014679967
2289,bilirubin,15,16,92,101,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0,-1,0,2289,-1,0.94575155,0.054248434
15266,folinic acid,13,15,84,96,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0,15266,-1,0.99814284,0.0018571633
14710,estrogen,19,20,117,125,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,0,-1,0,14710,-1,0.99634737,0.003652648
943,levodopa,26,27,193,201,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0,-1,0,943,-1,0.9988262,0.0011738295
7485,progesterone,32,33,163,175,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0,-1,0,7485,-1,0.9976974,0.0023025824
11902,bromocriptine,12,13,111,124,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,0,-1,0,11902,-1,0.99877995,0.001220106
17625,bupivacaine,11,12,82,93,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0,-1,0,17625,-1,0.9986859,0.0013141362
3440,tacrolimus,27,28,180,190,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0,-1,0,3440,-1,0.9986481,0.0013518538
143,lignocaine,6,7,26,36,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,0,-1,0,143,-1,0.9976173,0.0023826996
9499,oxycodone,16,17,116,125,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0,-1,0,9499,-1,0.99876994,0.0012299826
16130,lidocaine,3,4,17,26,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0,16130,-1,0.99811137,0.0018886297
11185,levodopa,23,24,137,145,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,0,-1,0,11185,-1,0.9989133,0.00108676
6643,phenytoin,2,3,18,27,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,0,-1,0,6643,-1,0.9988397,0.0011603826
9067,naloxone,7,8,47,55,Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.,1928887_5,0,-1,0,9067,-1,0.9989002,0.0010998218
7662,propofol,3,4,21,29,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0,7662,-1,0.9971877,0.0028123131
465,dopamine,30,31,153,161,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0,-1,0,465,-1,0.9932454,0.006754603
16327,steroid,10,11,77,84,Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment.,8665051_6,0,-1,0,16327,-1,0.99732214,0.0026779184
12649,dapsone,21,22,105,112,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,0,-1,0,12649,-1,0.9983487,0.0016513224
14145,amiodarone,7,8,56,66,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,0,-1,0,14145,-1,0.9986656,0.00133446
11625,ketoconazole,14,15,77,89,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,0,-1,0,11625,-1,0.998752,0.0012480239
5363,propofol,20,21,127,135,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0,-1,0,5363,-1,0.9972389,0.0027611102
18135,calcium,8,9,56,63,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,0,-1,0,18135,-1,0.9959055,0.0040943976
11319,ribavirin,7,8,37,46,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,0,-1,0,11319,-1,0.99862015,0.0013798323
11933,glycine,26,27,152,159,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0,11933,-1,0.99744105,0.0025588812
11093,morphine,26,27,129,137,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,0,-1,0,11093,-1,0.9970879,0.0029121758
15962,lovastatin,33,34,202,212,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,0,-1,0,15962,-1,0.99840975,0.0015901717
4640,lidocaine,19,20,71,80,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,-1,0,4640,-1,0.99804354,0.001956434
17616,prilocaine,2,3,15,25,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0,17616,-1,0.9987357,0.0012642973
16591,lithium,14,15,88,95,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,0,-1,0,16591,-1,0.9984289,0.0015710344
14793,lithium,14,15,75,82,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0,14793,-1,0.99681586,0.0031841525
12249,ketoconazole,18,19,126,138,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,0,-1,0,12249,-1,0.9986835,0.0013164331
1091,Dobutamine,0,1,0,10,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,0,-1,0,1091,-1,0.99856204,0.0014379909
7753,cocaine,5,6,23,30,"RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.",18083142_4,0,-1,0,7753,-1,0.99694175,0.0030582265
7135,Dex,0,1,0,3,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0,-1,0,7135,-1,0.9931544,0.006845667
15905,isoflurane,14,15,117,127,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,0,-1,0,15905,-1,0.99759406,0.0024059056
5403,steroid,4,5,30,37,Dose reduction or concomitant steroid therapy may have a role in selected patients.,1595783_6,0,-1,0,5403,-1,0.99734575,0.002654233
17293,Nicotine,0,1,0,8,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,0,-1,0,17293,-1,0.99772507,0.002274917
17618,bupivacaine,19,20,99,110,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0,17618,-1,0.99879384,0.0012060852
5563,pentobarbital,10,11,65,78,Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed.,1616457_6,0,-1,0,5563,-1,0.99855167,0.0014482595
14601,bupivacaine,6,7,34,45,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0,-1,0,14601,-1,0.998711,0.0012889697
10696,Capecitabine,4,5,19,31,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0,-1,0,10696,-1,0.99821186,0.0017881964
13221,vancomycin,20,21,164,174,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0,-1,0,13221,-1,0.9978351,0.0021648647
11997,potassium,4,5,17,26,"In both groups a potassium deficit developed, with proportionally larger losses from the extracellular than from the intracellular compartment.",28952_6,0,-1,0,11997,-1,0.99174386,0.008256142
15826,glucose,3,4,25,32,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,0,-1,0,15826,-1,0.20209083,0.79790914
4093,mesna,15,16,90,95,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0,-1,0,4093,-1,0.9982796,0.0017204324
14694,saralasin,17,18,89,98,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0,-1,0,14694,-1,0.99847144,0.0015285837
15923,cimetidine,23,24,163,173,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,0,-1,0,15923,-1,0.99873966,0.0012603543
12695,diltiazem,19,20,123,132,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,12695,-1,0.9984262,0.0015738719
11623,ketoconazole,7,8,53,65,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,0,-1,0,11623,-1,0.99867815,0.0013218296
12001,aldosterone,22,23,134,145,The normal-sodium group showed an immediate but temporary rise of the renin and aldosterone levels; in the low-sodium group renin and aldosterone increased more slowly but remained elevated.,28952_8,0,-1,0,12001,-1,0.92059296,0.07940703
1040,rapamycin,2,3,14,23,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,0,-1,0,1040,-1,0.9972652,0.0027347903
11681,cocaine,47,48,240,247,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0,11681,-1,0.9969585,0.0030415244
17860,dopamine,21,22,142,150,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0,-1,0,17860,-1,0.99670094,0.0032989914
11226,serotonin,18,19,124,133,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,0,-1,0,11226,-1,0.99676776,0.0032322805
2734,ribavirin,8,9,53,62,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,0,-1,0,2734,-1,0.99870706,0.0012929129
6104,desipramine,6,7,17,28,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0,-1,0,6104,-1,0.99888235,0.0011176484
921,tacrolimus,6,7,26,36,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0,-1,0,921,-1,0.9987112,0.0012888312
1399,Propylthiouracil,0,1,0,16,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,0,-1,0,1399,-1,0.9984401,0.0015598715
13813,caffeine,36,37,221,229,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0,-1,0,13813,-1,0.99797994,0.002020126
4053,levodopa,20,21,117,125,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,0,-1,0,4053,-1,0.9987747,0.0012252243
10955,naloxone,33,34,211,219,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0,10955,-1,0.99883705,0.0011629415
13515,diethylstilbestrol,6,7,42,60,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,0,-1,0,13515,-1,0.9983789,0.0016211469
7209,dobutamine,7,8,44,54,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0,-1,0,7209,-1,0.99897975,0.0010202125
2509,levodopa,18,19,113,121,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,0,-1,0,2509,-1,0.99887854,0.0011214644
16948,oxygen,5,6,22,28,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0,-1,0,16948,-1,0.9863397,0.013660299
7259,creatinine,1,2,6,16,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0,-1,0,7259,-1,0.9918167,0.008183272
7579,zidovudine,12,13,73,83,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,0,-1,0,7579,-1,0.9986633,0.0013366592
12222,amphetamine,10,11,72,83,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,0,-1,0,12222,-1,0.99878603,0.0012139295
11837,sodium,25,26,182,188,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0,-1,0,11837,-1,0.9969242,0.0030757675
13229,creatinine,14,15,79,89,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0,13229,-1,0.99347407,0.0065259114
7629,diclofenac,19,20,126,136,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0,-1,0,7629,-1,0.99861836,0.0013816383
7338,clozapine,8,9,52,61,The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting.,17612891_5,0,-1,0,7338,-1,0.99889755,0.0011023785
541,Warfarin,20,21,113,121,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,0,-1,0,541,-1,0.9979881,0.0020119185
583,oxygen,7,8,41,47,This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.,10704919_7,0,-1,0,583,-1,0.9942059,0.0057941866
7401,levofloxacin,13,14,90,102,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0,-1,0,7401,-1,0.99868196,0.0013180646
8565,mefloquine,10,11,74,84,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,0,-1,0,8565,-1,0.9988507,0.0011492639
3403,aldosterone,20,21,123,134,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,0,-1,0,3403,-1,0.9969422,0.0030578126
9774,sorafenib,6,7,32,41,"Two weeks before his admission, sorafenib had been started.",19944333_2,0,-1,0,9774,-1,0.9951669,0.004833101
3724,morphine,44,45,216,224,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0,3724,-1,0.99822,0.0017799804
6394,dopamine,12,13,79,87,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,0,-1,0,6394,-1,0.99644876,0.003551179
1367,carboplatin,8,9,42,53,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,0,-1,0,1367,-1,0.9983563,0.0016436449
3026,carboplatin,2,3,11,22,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,3026,-1,0.9983841,0.0016159368
553,Dopamine,0,1,0,8,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0,-1,0,553,-1,0.9951681,0.0048318766
8114,creatinine,11,12,66,76,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0,-1,0,8114,-1,0.9771115,0.02288853
15335,cholesterol,36,37,173,184,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,0,-1,0,15335,-1,0.9935515,0.006448438
15403,methylprednisolone,5,6,29,47,The patient was treated with methylprednisolone and gradually improved.,7919560_4,0,-1,0,15403,-1,0.99866986,0.0013301312
4336,acetylcholine,12,13,63,76,The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges.,15009014_9,0,-1,0,4336,-1,0.9976355,0.0023645184
3829,creatinine,23,24,125,135,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0,3829,-1,0.9693133,0.030686634
3119,creatinine,9,10,57,67,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,0,-1,0,3119,-1,0.993341,0.006658941
1192,venlafaxine,10,11,72,83,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,0,-1,0,1192,-1,0.99868983,0.0013101739
8569,doxorubicin,4,5,23,34,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,0,-1,0,8569,-1,0.99822193,0.0017780088
5040,morphine,17,18,132,140,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,0,-1,0,5040,-1,0.99748886,0.0025111206
944,apomorphine,29,30,211,222,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0,-1,0,944,-1,0.99887234,0.0011276713
15424,clomipramine,3,4,17,29,During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness.,7930386_6,0,-1,0,15424,-1,0.9987851,0.0012149243
3462,cortisol,75,76,434,442,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,3462,-1,0.99705124,0.002948765
12290,alfentanil,27,28,203,213,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0,-1,0,12290,-1,0.998667,0.0013330335
1782,propylthiouracil,29,30,183,199,"This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.",1147734_1,0,-1,0,1782,-1,0.99852544,0.001474593
3080,propranolol,18,19,112,123,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0,-1,0,3080,-1,0.998847,0.0011529657
17749,tamoxifen,8,9,50,59,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,0,-1,0,17749,-1,0.99773395,0.0022660831
6673,paroxetine,8,9,59,69,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0,-1,0,6673,-1,0.9986193,0.0013806314
15531,coniine,13,14,69,76,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,0,-1,0,15531,-1,0.99749607,0.0025039539
8052,dopamine,24,25,161,169,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0,-1,0,8052,-1,0.9967656,0.0032343408
18033,carbamazepine,8,9,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0,-1,0,18033,-1,0.99871373,0.0012862331
3628,phenobarbital,35,36,224,237,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0,3628,-1,0.998061,0.0019389468
12099,lithium,6,7,56,63,Thyroid function and urine-concentrating ability during lithium treatment.,3001299_0,0,-1,0,12099,-1,0.9978751,0.002124961
7111,terbutaline,8,9,48,59,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,0,-1,0,7111,-1,0.99884343,0.0011565407
14197,aspirin,20,21,111,118,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0,-1,0,14197,-1,0.9983346,0.0016654935
10358,asenapine,28,29,159,168,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0,10358,-1,0.9986337,0.0013663111
9033,cyclophosphamide,8,9,47,63,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,0,-1,0,9033,-1,0.9988066,0.0011933879
16804,epinephrine,8,9,63,74,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,0,-1,0,16804,-1,0.99708575,0.0029142308
9512,dopamine,8,9,64,72,Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.,19759529_1,0,-1,0,9512,-1,0.99612916,0.0038708618
2875,Haloperidol,0,1,0,11,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,0,-1,0,2875,-1,0.9985537,0.0014463388
5512,Cocaine,0,1,0,7,Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates.,1610717_9,0,-1,0,5512,-1,0.99723107,0.002768977
6249,cholesterol,19,20,111,122,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,0,-1,0,6249,-1,0.9933403,0.006659695
8342,metoprolol,28,29,188,198,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0,-1,0,8342,-1,0.9984863,0.00151364
3324,creatinine,13,14,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0,3324,-1,0.99208367,0.007916364
17559,atropine,12,13,98,106,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,17559,-1,0.9987446,0.0012553524
2368,anthracycline,21,22,124,137,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0,-1,0,2368,-1,0.99618524,0.0038147585
13497,Azathioprine,0,1,0,12,Azathioprine treatment benefited 19 (66%) out of 29 patients suffering from severe psoriasis.,4812392_1,0,-1,0,13497,-1,0.99879503,0.001204991
16312,propranolol,16,17,108,119,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,0,-1,0,16312,-1,0.9987595,0.00124051
18288,propranolol,5,6,52,63,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,18288,-1,0.99870896,0.0012910364
5333,creatine,1,2,10,18,Exogenous creatine is used by athletes to theoretically improve exercise performance.,15899738_10,0,-1,0,5333,-1,0.9974312,0.0025687756
15267,folinic acid,1,3,8,20,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0,15267,-1,0.9982066,0.0017933719
6915,clonidine,16,17,123,132,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0,-1,0,6915,-1,0.9984445,0.0015555078
11530,benzodiazepines,4,5,30,45,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,0,-1,0,11530,-1,0.99695146,0.0030484768
2851,carbachol,11,12,74,83,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0,-1,0,2851,-1,0.9987502,0.0012497725
14755,Adriamycin,0,1,0,10,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,0,-1,0,14755,-1,0.99808526,0.0019147999
10314,cisplatin,2,3,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0,-1,0,10314,-1,0.9972113,0.0027887088
7828,clonidine,9,10,53,62,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,0,-1,0,7828,-1,0.9986639,0.0013361005
4055,levodopa,31,32,187,195,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,0,-1,0,4055,-1,0.99882776,0.0011722876
14376,noradrenaline,8,9,65,78,These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.,6861444_4,0,-1,0,14376,-1,0.99872714,0.0012728033
10362,asenapine,26,27,170,179,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0,10362,-1,0.99874985,0.0012501534
9072,Heparin,0,1,0,7,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,0,-1,0,9072,-1,0.9970625,0.0029375178
897,acetylcholine,26,27,162,175,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,0,-1,0,897,-1,0.99702376,0.002976184
17794,"5,7-dichlorokynurenic acid",0,2,0,26,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0,-1,0,17794,-1,0.9942878,0.005712247
8774,Oral Contraceptives,7,9,46,65,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0,-1,0,8774,-1,0.99605006,0.0039499025
12125,corticosterone,16,17,115,129,Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.,3015567_5,0,-1,0,12125,-1,0.9969873,0.003012684
5218,piroxicam,10,11,45,54,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,0,-1,0,5218,-1,0.9986727,0.0013273554
16651,tacrolimus,5,6,33,43,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0,16651,-1,0.99849916,0.0015009008
14212,caffeine,5,6,26,34,"It is often combined with caffeine in diet preparations and ""look-alike"" pills.",6695415_2,0,-1,0,14212,-1,0.99772114,0.0022788923
706,tacrolimus,6,7,37,47,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0,706,-1,0.99852604,0.0014740512
7550,heparin,26,27,161,168,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,0,-1,0,7550,-1,0.99688244,0.0031175907
8304,alanine,10,11,69,76,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,0,-1,0,8304,-1,0.9912054,0.0087946495
12629,epinephrine,9,10,58,69,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,0,-1,0,12629,-1,0.9977354,0.0022646517
17554,morphine,12,13,73,81,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,0,-1,0,17554,-1,0.99803776,0.001962318
7002,norepinephrine,9,10,58,72,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0,-1,0,7002,-1,0.99827814,0.0017219268
917,cyclosporine,7,8,57,69,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0,-1,0,917,-1,0.9984668,0.0015332119
6794,serotonin,13,14,90,99,Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.,17194457_0,0,-1,0,6794,-1,0.99702966,0.002970339
1999,paracetamol,12,13,76,87,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0,-1,0,1999,-1,0.9986941,0.0013058858
4983,creatinine,14,15,100,110,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0,-1,0,4983,-1,0.97270036,0.027299568
927,tacrolimus,18,19,122,132,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,927,-1,0.9987178,0.0012822034
7491,Ritonavir,0,1,0,9,"Ritonavir increased the expression of the scavenger receptor, CD36 mRNA, responsible for the uptake of LDL.",17879945_10,0,-1,0,7491,-1,0.9984982,0.0015017963
17601,capsaicin,4,5,18,27,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,0,-1,0,17601,-1,0.9983871,0.0016129554
12715,testosterone,13,14,112,124,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,0,-1,0,12715,-1,0.9979972,0.0020026946
13833,morphine,11,12,91,99,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,0,-1,0,13833,-1,0.99797386,0.0020260871
16828,bradykinin,19,20,135,145,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0,-1,0,16828,-1,0.99773765,0.0022623828
7808,Sulpiride,0,1,0,9,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0,-1,0,7808,-1,0.9982778,0.0017221833
6146,paroxetine,5,6,19,29,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0,-1,0,6146,-1,0.9985399,0.0014600848
15617,clonidine,4,5,25,34,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0,15617,-1,0.9986986,0.0013013601
10767,neurotensin,5,6,35,46,CONCLUSION: Activation of pallidal neurotensin receptors may be involved in neurotensin-induced antiparkinsonian effects.,20882060_8,0,-1,0,10767,-1,0.99729496,0.0027049796
16229,progesterone,13,14,66,78,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,0,-1,0,16229,-1,0.99812907,0.0018709548
47,methylprednisolone,9,10,67,85,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0,-1,0,47,-1,0.99885046,0.0011495338
16238,paclitaxel,6,7,31,41,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,0,-1,0,16238,-1,0.99706155,0.0029384424
14472,creatinine,6,7,37,47,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0,14472,-1,0.9947984,0.005201607
10962,Naloxone,0,1,0,8,Naloxone reverses the antihypertensive effect of clonidine.,227508_0,0,-1,0,10962,-1,0.99867874,0.0013212494
6840,phosphate,25,26,164,173,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0,6840,-1,0.9923934,0.007606592
17079,steroids,3,4,25,33,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0,17079,-1,0.97444326,0.02555672
8372,oxytocin,3,4,20,28,The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases.,18513945_0,0,-1,0,8372,-1,0.9979565,0.002043532
13585,potassium,2,3,11,20,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0,13585,-1,0.9972024,0.0027976008
8661,steroid,17,18,126,133,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,0,-1,0,8661,-1,0.9973151,0.0026848323
15977,lovastatin,31,32,185,195,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,0,-1,0,15977,-1,0.9983302,0.0016698064
10864,doxorubicin,18,19,134,145,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,0,-1,0,10864,-1,0.9969926,0.0030074469
11540,serotonin,12,13,79,88,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0,-1,0,11540,-1,0.99772984,0.0022701316
17936,pethidine,9,10,67,76,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,0,-1,0,17936,-1,0.99869615,0.0013039006
18293,hexamethonium,22,23,141,154,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,18293,-1,0.9988053,0.0011946788
8990,salt,7,8,28,32,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,0,-1,0,8990,-1,0.95261157,0.047388468
1224,cocaine,24,25,160,167,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,0,-1,0,1224,-1,0.99757975,0.0024202503
15050,malondialdehyde,17,18,131,146,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0,-1,0,15050,-1,0.99149406,0.008505921
5790,Ketoconazole,0,1,0,12,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,0,-1,0,5790,-1,0.99842936,0.0015706023
2113,cisplatin,18,19,121,130,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2113,-1,0.9970196,0.0029804236
7151,gentamicin,17,18,121,131,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0,-1,0,7151,-1,0.99829024,0.0017097554
14891,corticosteroids,11,12,78,93,"Clinical examinations and skin, oral and parenteral challenges with different corticosteroids and ELISA tests were performed.",7582165_4,0,-1,0,14891,-1,0.99673283,0.0032672088
3926,lithium,41,42,258,265,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,0,-1,0,3926,-1,0.9974598,0.0025401732
4258,superoxide,25,26,187,197,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,0,-1,0,4258,-1,0.69293827,0.3070618
11517,alfentanil,6,7,32,42,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0,-1,0,11517,-1,0.99838984,0.0016102379
5596,cocaine,33,34,240,247,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,0,-1,0,5596,-1,0.99676216,0.00323776
2670,morphine,4,5,23,31,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,0,-1,0,2670,-1,0.99741495,0.002585081
516,Warfarin,13,14,82,90,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,0,-1,0,516,-1,0.99791914,0.0020808727
2889,cocaine,1,2,9,16,Systemic cocaine (10 mg/kg) significantly increased the locomotor activity of rats.,12369736_4,0,-1,0,2889,-1,0.9974107,0.0025893066
12542,verapamil,2,3,7,16,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0,12542,-1,0.9987458,0.0012541966
13657,cimetidine,60,61,337,347,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0,13657,-1,0.99889755,0.0011023878
15800,papaverine,0,1,0,10,"papaverine, 100 micrograms.",8386779_4,0,-1,0,15800,-1,0.99834657,0.0016534517
17909,tamoxifen,9,10,53,62,Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.,9672273_3,0,-1,0,17909,-1,0.9973586,0.0026413589
13604,benzodiazepines,2,3,7,22,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0,-1,0,13604,-1,0.9950499,0.0049500735
8725,isoproterenol,10,11,58,71,We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.,18808529_4,0,-1,0,8725,-1,0.9984787,0.0015213493
6839,creatinine,22,23,142,152,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0,6839,-1,0.99373937,0.006260607
17786,steroids,4,5,28,36,These responded to systemic steroids and immunoglobulins.,9625142_3,0,-1,0,17786,-1,0.973665,0.026334953
12393,catecholamines,15,16,126,140,Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed.,3173179_4,0,-1,0,12393,-1,0.9973653,0.0026346769
16360,acetaminophen,7,8,47,60,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,0,-1,0,16360,-1,0.9987721,0.0012279103
17190,estrogen,13,14,81,89,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,0,-1,0,17190,-1,0.9947918,0.00520817
3398,sodium,4,5,24,30,The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously.,12653683_7,0,-1,0,3398,-1,0.99502665,0.004973333
11679,cocaine,39,40,199,206,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0,11679,-1,0.9968785,0.003121553
3345,prostate cancer,18,20,122,137,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,1,1,3345,-1,0.0012315777,0.9987684
8516,inflammation,2,3,35,47,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,-1,1,1,8516,-1,0.0010288468,0.9989712
14780,Cardiomyopathy,0,1,0,14,Cardiomyopathy is frequent when the total dose exceeds 600 mg/m2 and occurs within one to six months after cessation of therapy.,7449470_2,-1,1,1,14780,-1,0.0009806197,0.9990194
13119,rigidity,34,35,176,184,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,-1,1,1,13119,-1,0.0015738689,0.9984262
3454,hypertension,6,7,53,65,L-arginine transport in humans with cortisol-induced hypertension.,12707296_0,-1,1,1,3454,-1,0.0010886677,0.9989114
17508,cardiotoxicity,3,4,22,36,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,-1,1,1,17508,-1,0.0010204565,0.9989795
15369,Diarrhea,0,1,0,8,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,1,1,15369,-1,0.0012671944,0.99873286
10279,encephalopathy,14,15,118,132,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,1,1,10279,-1,0.0010205441,0.9989794
4839,diabetes,36,37,235,243,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1,4839,-1,0.0029216283,0.9970784
5273,myelosuppression,3,4,29,45,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,1,1,5273,-1,0.0012603062,0.99873966
15635,neurotoxicity,3,4,38,51,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,-1,1,1,15635,-1,0.0010200609,0.99897987
2220,convulsive,8,9,45,55,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,1,1,2220,-1,0.0012357951,0.9987643
17694,syncope,5,6,24,31,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,1,1,17694,-1,0.00089117134,0.99910885
2165,neuropathic pain,15,17,105,121,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,1,1,2165,-1,0.0008960855,0.99910384
6670,depression,11,12,74,84,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,1,1,6670,-1,0.0011180595,0.998882
10150,renal damage,22,24,112,124,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,1,1,10150,-1,0.001184448,0.99881554
2322,neurotoxicity,8,9,47,60,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1,2322,-1,0.0010603566,0.9989397
9311,peripheral neuropathy,14,16,100,121,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,1,1,9311,-1,0.0008757739,0.9991242
12434,tumor,39,40,210,215,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,1,1,12434,-1,0.008116075,0.9918839
10057,spasm,10,11,62,67,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,1,1,10057,-1,0.001054126,0.9989459
10432,tumor,6,7,39,44,Antitumor activity was studied using a tumor growth delay assay.,2054792_2,-1,1,1,10432,-1,0.0051494897,0.99485046
876,pain,30,31,150,154,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,1,1,876,-1,0.0019900736,0.99801
9747,hemolytic anemia,9,11,55,71,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,-1,1,1,9747,-1,0.00082042837,0.99917954
17385,temporal lobe epilepsy,7,10,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,1,1,17385,-1,0.0015425723,0.99845743
6594,hypertension,2,3,28,40,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,1,1,6594,-1,0.0011482628,0.9988518
5185,necrosis,25,26,149,157,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,1,1,5185,-1,0.001315862,0.9986841
17121,extrapyramidal symptoms,11,13,58,81,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,-1,1,1,17121,-1,0.0009941382,0.99900585
8731,neuropathy,10,11,95,105,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,1,1,8731,-1,0.0010279219,0.99897206
15706,myoclonus,2,3,17,26,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,1,1,15706,-1,0.00094896567,0.99905103
3611,anemia,4,5,26,32,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,1,1,3611,-1,0.00090810104,0.99909186
4276,breast cancer,25,27,132,145,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,1,1,4276,-1,0.0014078618,0.9985921
5012,hyperemia,25,26,126,135,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,1,1,5012,-1,0.0008329382,0.9991671
2543,dyskinesias,11,12,69,80,A close relationship was seen between the overshooting of forces and dyskinesias in the ON-drug condition.,11912119_12,-1,1,1,2543,-1,0.0008548582,0.99914515
1973,headache,21,22,120,128,The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%).,11679859_12,-1,1,1,1973,-1,0.0014705608,0.99852943
2920,Somnolence,0,1,0,10,Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.,12448656_7,-1,1,1,2920,-1,0.001165198,0.9988348
15495,tuberculosis,12,13,89,101,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,-1,1,1,15495,-1,0.0013259264,0.99867415
10803,epileptic,11,12,89,98,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,-1,1,1,10803,-1,0.0013129703,0.9986871
8064,hyperactivity,8,9,64,77,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,1,1,8064,-1,0.0011589355,0.9988411
15667,toxicity,17,18,116,124,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,1,1,15667,-1,0.0010519449,0.99894804
4609,tinnitus,5,6,20,28,"In one patient, the tinnitus was almost completely abolished, but in all the nine patients the decompensated tinnitus changed to a compensated one.",1527456_4,-1,1,1,4609,-1,0.0011525112,0.9988475
13841,hypotension,7,8,67,78,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1,13841,-1,0.0009501464,0.99904984
6751,Proteinuria,0,1,0,11,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,-1,1,1,6751,-1,0.0011400273,0.99886
10732,acute liver failure,21,24,130,149,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1,10732,-1,0.0011561266,0.9988438
11727,glycosuria,10,11,44,54,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1,11727,-1,0.0017201506,0.9982798
4934,hemolysis,18,19,121,130,In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.,15580403_2,-1,1,1,4934,-1,0.00076657214,0.9992335
8427,Pain,0,1,0,4,Pain severity and analgesic requirements were unaffected by the omission of fentanyl.,18544179_9,-1,1,1,8427,-1,0.001840292,0.9981597
14156,nausea,15,16,75,81,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1,14156,-1,0.0013685002,0.9986314
15379,weakness,18,19,100,108,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,1,1,15379,-1,0.0010180474,0.9989819
8364,seizures,8,9,50,58,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,1,1,8364,-1,0.0011072546,0.9988927
7718,ataxia,19,20,93,99,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,1,1,7718,-1,0.00109086,0.9989091
2521,dyskinesia,13,14,67,77,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,1,1,2521,-1,0.0009932446,0.9990068
11801,seizures,8,9,67,75,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,-1,1,1,11801,-1,0.0010449522,0.998955
5083,pseudolithiasis,13,14,83,98,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,-1,1,1,5083,-1,0.0014360435,0.99856395
2235,thrombocytopenia,2,3,30,46,Delayed-onset heparin-induced thrombocytopenia.,11827497_0,-1,1,1,2235,-1,0.00092128443,0.99907875
16399,pain,5,6,39,43,Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.,8686832_2,-1,1,1,16399,-1,0.0013957435,0.99860424
1152,parkinsonian,48,49,324,336,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1,1152,-1,0.0014277045,0.99857223
6867,myopathy,5,6,32,40,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,1,1,6867,-1,0.00091526314,0.9990847
16416,diabetic,37,38,225,233,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,1,1,16416,-1,0.006015143,0.9939849
2188,renal dysfunction,12,14,57,74,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,1,1,2188,-1,0.0009438161,0.99905616
17725,breast cancer,8,10,62,75,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1,17725,-1,0.0015245571,0.9984755
4958,hyperkalemia,21,22,137,149,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,1,1,4958,-1,0.00081418635,0.99918586
18057,orthostatic hypotension,37,39,232,255,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,18057,-1,0.0011693643,0.9988306
11872,tachycardia,7,8,73,84,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,-1,1,1,11872,-1,0.00084902643,0.999151
18306,hypertension,18,19,106,118,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,1,1,18306,-1,0.0009736348,0.9990264
12735,cholestasis,1,2,10,21,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,1,1,12735,-1,0.0009470184,0.99905294
9873,coagulopathy,17,18,103,115,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,-1,1,1,9873,-1,0.000869848,0.9991302
9273,pain,1,2,10,14,Perceived pain intensity is modulated by attention.,19387625_1,-1,1,1,9273,-1,0.002809632,0.9971904
7887,hypertension,40,41,260,272,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,1,1,7887,-1,0.001162163,0.9988379
7403,leukoencephalopathy,1,2,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,-1,1,1,7403,-1,0.00084636325,0.9991536
5789,hypertensive,38,39,187,199,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,1,1,5789,-1,0.003990864,0.9960091
13757,toxicity,4,5,23,31,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13757,-1,0.001553313,0.99844676
16082,hypertensive,12,13,111,123,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,-1,1,1,16082,-1,0.0017407399,0.99825925
10970,hypertensive,5,6,38,50,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,1,1,10970,-1,0.0023418486,0.99765813
5769,albuminuria,23,24,155,166,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,1,1,5769,-1,0.0015013445,0.9984987
8308,cancer,17,18,131,137,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,-1,1,1,8308,-1,0.0014838723,0.99851614
17720,nausea,12,13,75,81,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,1,1,17720,-1,0.0013500995,0.9986499
14671,ventricular tachycardia,1,3,8,31,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,1,1,14671,-1,0.0010432315,0.9989568
1902,nephrotoxicity,21,22,145,159,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,-1,1,1,1902,-1,0.0008155358,0.9991844
11742,catalepsy,11,12,84,93,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,1,1,11742,-1,0.001008212,0.9989918
16349,chronic renal failure,9,12,51,72,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,-1,1,1,16349,-1,0.0009216462,0.9990784
18329,bradycardia,16,17,108,119,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,1,1,18329,-1,0.0009584982,0.9990415
4918,hypoxia,3,4,14,21,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,1,1,4918,-1,0.0011344337,0.9988656
2257,hyperprolactinemia,3,4,33,51,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,1,1,2257,-1,0.00096377684,0.9990362
3807,seizures,1,2,8,16,Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.,12921865_5,-1,1,1,3807,-1,0.0011632661,0.9988367
9839,seizures,15,16,96,104,METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative seizures.,19996135_4,-1,1,1,9839,-1,0.0012276812,0.9987723
15731,hypotensive,1,2,4,15,The hypotensive drug was discontinued at the completion of the operative procedure.,8302922_3,-1,1,1,15731,-1,0.0012931229,0.9987068
8653,hepatotoxicity,6,7,40,54,Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.,18752389_13,-1,1,1,8653,-1,0.0010159013,0.99898404
12142,catalepsy,14,15,97,106,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,1,1,12142,-1,0.0010900877,0.99890995
17693,hypertension,30,31,188,200,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,1,1,17693,-1,0.0010041667,0.99899584
5786,hypertensive,30,31,154,166,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,1,1,5786,-1,0.0031110737,0.99688894
1467,cardiotoxicity,8,9,66,80,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,-1,1,1,1467,-1,0.00072848564,0.9992716
7285,epilepsy,12,13,60,68,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,1,1,7285,-1,0.0009534859,0.9990465
3055,visual hallucinations,3,5,19,40,"During monitoring, visual hallucinations did not correlate with EEG readings, nor did video recording capture any of the described events.",12523465_4,-1,1,1,3055,-1,0.0013845658,0.9986154
2085,neurotoxicity,24,25,161,174,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2085,-1,0.0011839429,0.99881613
13457,overdose,10,11,57,65,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,1,1,13457,-1,0.0012994164,0.9987006
11407,pain,17,18,113,117,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,-1,1,1,11407,-1,0.0012610101,0.99873906
1191,incontinence,7,8,46,58,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,-1,1,1,1191,-1,0.001069268,0.99893075
504,artery calcification,9,11,65,85,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,1,1,504,-1,0.0018418676,0.99815816
12241,rash,4,5,32,36,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,1,1,12241,-1,0.0012253679,0.9987746
10098,diabetic nephropathy,37,39,221,241,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1,10098,-1,0.0012249117,0.99877506
16852,toxicity,7,8,49,57,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,1,1,16852,-1,0.0010021715,0.99899787
16546,liver injury,36,38,239,251,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,1,1,16546,-1,0.0012883107,0.9987117
13789,cardiomyopathy,1,2,4,18,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,1,1,13789,-1,0.0010596919,0.9989403
14402,tremor,43,44,244,250,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,1,1,14402,-1,0.0010916169,0.9989084
8316,cystitis,33,34,193,201,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,1,1,8316,-1,0.00093706016,0.99906296
850,tuberculosis,14,15,87,99,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,1,1,850,-1,0.0011161217,0.9988839
9142,Confusion,0,1,0,9,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,1,1,9142,-1,0.0014196741,0.99858034
11605,hypertensive,19,20,108,120,"The results showed a high prevalence of depression in both groups of patients, with no preponderance in the hypertensive group.",26094_2,-1,1,1,11605,-1,0.0021066524,0.9978934
5104,psychotic symptoms,15,17,98,116,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,1,1,5104,-1,0.0010987812,0.99890125
12256,hepatotoxicity,12,13,75,89,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,1,1,12256,-1,0.00090899714,0.999091
569,breast cancer,15,17,87,100,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1,569,-1,0.0017166382,0.9982834
3788,Hemolytic anemia,0,2,0,16,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,-1,1,1,3788,-1,0.00089518144,0.9991048
9219,proteinuria,7,8,58,69,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,-1,1,1,9219,-1,0.0009949304,0.99900514
538,calcification,42,43,249,262,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,1,1,538,-1,0.004506542,0.9954934
3101,inflammation,13,14,90,102,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,1,1,3101,-1,0.0011818819,0.9988181
14781,cardiomyopathy,7,8,48,62,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,-1,1,1,14781,-1,0.0009907004,0.99900925
394,neutropenia,11,12,54,65,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,1,1,394,-1,0.001149794,0.9988502
18199,cholestasis,6,7,40,51,"Although hepatocyte TJs are impaired in cholestasis, attempts to localize the precise site of hepatocyte TJ damage by freeze-fracture electron microscopy have produced limited information.",9862868_2,-1,1,1,18199,-1,0.0014481966,0.9985518
2945,fasciculation,12,13,70,83,"Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.",12452237_5,-1,1,1,2945,-1,0.0016824628,0.9983176
11190,death,6,7,73,78,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,1,1,11190,-1,0.0011809759,0.99881905
2478,catalepsy,4,5,42,51,Nicotine potentiation of morphine-induced catalepsy in mice.,11900788_0,-1,1,1,2478,-1,0.0010026625,0.9989974
4280,breast cancer,20,22,135,148,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,-1,1,1,4280,-1,0.0014701412,0.9985298
11260,arrhythmia,27,28,211,221,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,1,1,11260,-1,0.0013478544,0.99865216
13728,rheumatoid arthritis,28,30,164,184,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,1,1,13728,-1,0.0010168784,0.9989831
12631,ischemia,23,24,189,197,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,1,1,12631,-1,0.0013087591,0.99869126
12621,ischemia,3,4,19,27,Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.,3413271_2,-1,1,1,12621,-1,0.0011915177,0.9988085
3565,myalgia,22,23,140,147,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1,3565,-1,0.0010184306,0.99898154
526,artery calcification,13,15,67,87,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,1,1,526,-1,0.0017285807,0.99827147
16739,hyperthermia,26,27,171,183,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,1,1,16739,-1,0.0008082981,0.9991917
6352,schizophrenia,16,17,107,120,Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia.,16867021_1,-1,1,1,6352,-1,0.0010907811,0.99890924
2870,pain,27,28,176,180,"Short-latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before, during, and after the pain.",12202650_4,-1,1,1,2870,-1,0.0017005589,0.9982994
11608,depression,10,11,76,86,Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients.,26094_3,-1,1,1,11608,-1,0.00093266985,0.99906737
17296,atherosclerosis,14,15,96,111,"Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.",9245658_2,-1,1,1,17296,-1,0.0013898343,0.99861014
17607,headache,37,38,206,214,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,1,1,17607,-1,0.001210012,0.99878997
12982,toxicity,42,43,267,275,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,1,1,12982,-1,0.001056773,0.99894327
17410,ventricular tachycardia,1,3,23,46,Clarithromycin-induced ventricular tachycardia.,9326871_0,-1,1,1,17410,-1,0.0010958638,0.9989041
4889,renal damage,13,15,106,118,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,-1,1,1,4889,-1,0.0009890066,0.9990109
7935,Cancer,19,20,128,134,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,1,1,7935,-1,0.005610935,0.994389
2470,acute myocardial infarction,21,24,130,157,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,1,1,2470,-1,0.0010117182,0.9989882
16818,hypertension,15,16,100,112,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,-1,1,1,16818,-1,0.0009626716,0.9990374
4631,bleeding,5,6,41,49,"The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.",15276120_1,-1,1,1,4631,-1,0.0012603843,0.99873966
1361,tumors,10,11,93,99,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,1,1,1361,-1,0.0014889586,0.998511
310,hypertension,9,10,63,75,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,1,1,310,-1,0.0010716399,0.99892837
13952,seizures,35,36,182,190,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,-1,1,1,13952,-1,0.0016405323,0.9983595
5974,hypertension,28,29,220,232,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,1,1,5974,-1,0.0010720127,0.998928
16652,hypertensive,18,19,104,116,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,-1,1,1,16652,-1,0.0023433676,0.9976566
13881,dyskinesias,3,4,28,39,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,1,1,13881,-1,0.00075428135,0.99924576
6721,edema,23,24,148,153,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,1,1,6721,-1,0.0013024613,0.9986975
13343,hemorrhage,2,3,27,37,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,1,1,13343,-1,0.0011135568,0.9988864
12668,Toxicities,0,1,0,10,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,1,1,12668,-1,0.0013296013,0.99867046
3617,prostate cancer,15,17,96,111,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,1,1,3617,-1,0.0019510896,0.9980489
9016,pain,7,8,40,44,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,-1,1,1,9016,-1,0.0028533712,0.99714667
5411,hiccups,2,3,33,40,Possible azithromycin-associated hiccups.,15985056_0,-1,1,1,5411,-1,0.0014248582,0.9985751
5684,hypertension,18,19,99,111,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,1,1,5684,-1,0.001300706,0.9986993
11272,hypotensive,5,6,34,45,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,1,1,11272,-1,0.0010845497,0.99891543
634,tachycardia,11,12,57,68,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,-1,1,1,634,-1,0.0010329891,0.99896705
18105,Psychiatric,28,29,172,183,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,1,1,18105,-1,0.018181141,0.9818188
95,orthostatic hypotension,18,20,125,148,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,-1,1,1,95,-1,0.00086960645,0.9991304
4704,Tremor,0,1,0,6,Tremor was measured simultaneously by two independent observers.,15338796_11,-1,1,1,4704,-1,0.0012836147,0.99871635
13531,thrombocytopenia,28,29,191,207,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,1,1,13531,-1,0.0007834635,0.99921656
12605,renal papillary necrosis,3,6,12,36,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,1,1,12605,-1,0.0011459329,0.99885404
3090,hepatotoxicity,5,6,38,52,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,-1,1,1,3090,-1,0.0009544461,0.99904555
497,artery calcification,14,16,83,103,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,-1,1,1,497,-1,0.0020377785,0.99796224
8598,schizophrenia,12,13,98,111,Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia.,18703024_1,-1,1,1,8598,-1,0.0011317154,0.99886835
5815,vasculitis,15,16,111,121,"Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports.",16418614_5,-1,1,1,5815,-1,0.0008367327,0.99916327
8802,hematuria,5,6,46,55,"Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d.",1899352_5,-1,1,1,8802,-1,0.0010128794,0.99898714
6445,atherosclerosis,7,8,37,52,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,1,1,6445,-1,0.0011672499,0.99883276
10646,pain,9,10,55,59,Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.,2070391_3,-1,1,1,10646,-1,0.0014142992,0.9985857
17922,breast cancer,38,40,238,251,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1,17922,-1,0.0011355977,0.9988644
3733,Delirium,0,1,0,8,Delirium during clozapine treatment: incidence and associated risk factors.,12905102_0,-1,1,1,3733,-1,0.0012838299,0.99871624
11813,seizures,22,23,116,124,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,1,1,11813,-1,0.0010472145,0.99895275
4271,breast cancer,7,9,42,55,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,-1,1,1,4271,-1,0.0017871794,0.9982128
372,toxicity,27,28,158,166,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,1,1,372,-1,0.0019252581,0.99807477
8765,toxicity,9,10,72,80,CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity.,18821488_9,-1,1,1,8765,-1,0.0014276066,0.99857235
14936,myopathy,12,13,98,106,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,-1,1,1,14936,-1,0.00088497647,0.99911505
2554,overdose,11,12,52,60,"In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre.",11928786_3,-1,1,1,2554,-1,0.001973716,0.9980263
9174,hemorrhagic,2,3,9,20,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,1,1,9174,-1,0.0019822668,0.9980178
6297,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,1,1,6297,-1,0.000984799,0.9990152
16255,toxicity,34,35,217,225,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,-1,1,1,16255,-1,0.001083262,0.99891675
8989,hypertension,1,2,23,35,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,-1,1,1,8989,-1,0.001179365,0.9988206
3006,nausea,32,33,154,160,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,-1,1,1,3006,-1,0.0012835592,0.9987165
8905,convulsions,26,27,154,165,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,-1,1,1,8905,-1,0.00088734826,0.99911267
5112,aneurysm,20,21,137,145,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,1,1,5112,-1,0.0035825248,0.9964175
15808,penile pain,7,9,37,48,"From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication, which can be overcome by elevating the pH to a neutral level.",8386779_8,-1,1,1,15808,-1,0.0012758566,0.99872416
1150,dyskinesias,27,28,174,185,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1,1150,-1,0.0010281618,0.9989718
8537,proteinuria,1,2,8,19,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,1,1,8537,-1,0.0010248579,0.99897516
6321,neurotoxicity,31,32,163,176,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,1,1,6321,-1,0.0010958909,0.9989041
2782,asystole,24,25,149,157,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,1,1,2782,-1,0.0017011864,0.9982988
17162,catalepsy,13,14,92,101,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,1,1,17162,-1,0.0010019782,0.998998
13333,rheumatoid arthritis,9,11,53,73,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,13333,-1,0.0009343179,0.9990657
13292,hepatomegaly,11,12,73,85,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,1,1,13292,-1,0.00077203196,0.999228
13818,seizures,59,60,314,322,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,-1,1,1,13818,-1,0.0010282246,0.9989718
13275,Hepatotoxicity,0,1,0,14,Hepatotoxicity of amiodarone.,3962737_0,-1,1,1,13275,-1,0.0012014402,0.9987985
4160,headache,32,33,203,211,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,1,1,4160,-1,0.0012530074,0.998747
2440,exencephaly,9,10,58,69,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1,2440,-1,0.0017011266,0.99829894
1368,anemia,8,9,38,44,"In a second group, the development of anemia was prevented by rHuEPO (1000 IU/kg) administered s.c.",11245434_3,-1,1,1,1368,-1,0.0008703836,0.9991296
3165,renal injury,20,22,132,144,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,1,1,3165,-1,0.0009837179,0.9990163
2328,neurotoxicity,22,23,129,142,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,1,1,2328,-1,0.0011625134,0.99883753
17491,toxicity,27,28,195,203,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1,17491,-1,0.0013954525,0.9986046
5782,glomerulosclerosis,9,10,55,73,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,-1,1,1,5782,-1,0.0009234041,0.9990766
14154,tremor,7,8,51,57,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1,14154,-1,0.0011389755,0.9988611
11208,paralysis,1,2,9,18,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,1,1,11208,-1,0.0010165428,0.99898344
11302,seizure,10,11,71,78,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,1,1,11302,-1,0.0010885663,0.9989114
13552,Dizziness,0,1,0,9,"Dizziness was less marked than sedation, but increased with the dose.",6103707_7,-1,1,1,13552,-1,0.001201331,0.9987986
6302,toxicity,15,16,98,106,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,1,1,6302,-1,0.0011599114,0.99884015
6309,neuropathy,1,2,5,15,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,-1,1,1,6309,-1,0.0011798268,0.9988201
8901,convulsions,39,40,211,222,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,1,1,8901,-1,0.00096323993,0.9990368
1148,parkinsonian,11,12,80,92,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1,1148,-1,0.0014130014,0.998587
6977,psychiatric,12,13,77,88,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,-1,1,1,6977,-1,0.0014545926,0.9985454
9241,gallbladder disease,17,19,96,115,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,1,1,9241,-1,0.0018520613,0.99814796
16658,nephrotoxicity,9,10,59,73,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,-1,1,1,16658,-1,0.0007914003,0.9992086
1270,seizures,22,23,181,189,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,1,1,1270,-1,0.001164352,0.9988356
453,Diabetes,0,1,0,8,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,1,1,453,-1,0.0009762341,0.9990238
17024,hypotension,14,15,86,97,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,1,1,17024,-1,0.0009663362,0.9990337
16621,overdose,19,20,127,135,METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.,8800187_4,-1,1,1,16621,-1,0.0016085485,0.99839145
16850,mucositis,2,3,21,30,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1,16850,-1,0.0012343869,0.9987656
10649,pain,2,3,9,13,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,1,1,10649,-1,0.0026487932,0.99735117
2696,anemia,10,11,88,94,Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.,12090760_0,-1,1,1,2696,-1,0.0009639211,0.9990361
15636,Hallucinations,2,3,12,26,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1,15636,-1,0.0009835407,0.9990164
8632,hepatotoxic,2,3,9,20,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,1,1,8632,-1,0.0011445442,0.9988555
530,artery calcification,36,38,197,217,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,1,1,530,-1,0.0017267615,0.99827325
17767,meningitis,9,10,45,55,"Five days after the onset of the symptoms of meningitis, the patient aspirated stomach contents and needed endotracheal intubation.",9587734_2,-1,1,1,17767,-1,0.0010431544,0.9989568
2450,exencephalic,7,8,46,58,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1,2450,-1,0.0052565723,0.99474347
16141,angioedema,17,18,96,106,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,1,1,16141,-1,0.0008222661,0.99917775
15063,hypotensive,44,45,294,305,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1,15063,-1,0.0020754212,0.99792457
1208,seizure,15,16,94,101,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,-1,1,1,1208,-1,0.0013985218,0.9986015
399,toxicity,8,9,61,69,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,1,1,399,-1,0.0014954311,0.99850464
4472,bladder cancer,18,20,126,140,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,1,1,4472,-1,0.0015218187,0.99847823
4460,seizure,17,18,132,139,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,-1,1,1,4460,-1,0.0012132684,0.99878675
5609,aggressiveness,16,17,92,106,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,1,1,5609,-1,0.0015198144,0.99848014
8896,convulsions,17,18,87,98,"The number, time of onset, duration and the intensity of the convulsions or absence of convulsions were recorded.",19105845_6,-1,1,1,8896,-1,0.0010108396,0.99898916
12650,hemolytic anemia,25,27,128,144,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,-1,1,1,12650,-1,0.0007718333,0.9992281
2801,hemorrhage,36,37,134,144,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,1,1,2801,-1,0.0016694885,0.99833053
7218,spasm,15,16,102,107,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,1,1,7218,-1,0.0010640273,0.998936
398,myelosuppression,8,9,40,56,This age group had an increased risk of myelosuppression.,10526274_19,-1,1,1,398,-1,0.0010101661,0.9989899
17406,dyskinesias,4,5,31,42,"The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.",9321531_6,-1,1,1,17406,-1,0.0008173049,0.99918264
550,hypothermia,15,16,108,119,"Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.",10683478_5,-1,1,1,550,-1,0.0010510605,0.998949
17807,neurotoxic,23,24,120,130,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,1,1,17807,-1,0.0013840686,0.99861586
12813,Hyperkalemia,0,1,0,12,Hyperkalemia associated with sulindac therapy.,3560096_0,-1,1,1,12813,-1,0.0009818733,0.9990181
14683,fulminant hepatic failure,7,10,54,79,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,1,1,14683,-1,0.0010265313,0.9989735
7053,syncope,14,15,80,87,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,-1,1,1,7053,-1,0.0008395203,0.9991605
8315,cystitis,22,23,148,156,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,-1,1,1,8315,-1,0.0010609233,0.9989391
18320,cancer,8,9,31,37,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,1,1,18320,-1,0.002901393,0.9970987
18162,cardiomyopathy,11,12,77,91,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,1,1,18162,-1,0.00082149624,0.99917847
7842,bradycardia,7,8,38,49,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,1,1,7842,-1,0.0008553255,0.9991447
16403,pain,10,11,35,39,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,-1,1,1,16403,-1,0.0013052959,0.9986947
819,cystitis,28,29,158,166,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,1,1,819,-1,0.0008327858,0.9991672
11262,arrhythmias,4,5,31,42,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,1,1,11262,-1,0.0012263171,0.99877363
307,tachycardia,6,7,24,35,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,1,1,307,-1,0.0010738258,0.9989261
16849,Thrombocytopenia,0,1,0,16,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1,16849,-1,0.0009794693,0.9990206
15689,rheumatoid arthritis,4,6,25,45,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,1,1,15689,-1,0.001036896,0.9989631
13125,rhabdomyolysis,4,5,18,32,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,1,1,13125,-1,0.00077729125,0.99922276
1145,dyskinesias,19,20,108,119,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,-1,1,1,1145,-1,0.0008497702,0.9991503
14818,hyperthyroidism,11,12,70,85,METHODS: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department (in- or out-patients) from 1986 to 1992.,7504976_2,-1,1,1,14818,-1,0.0010678006,0.9989322
342,headache,21,22,106,114,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,1,1,342,-1,0.0012451261,0.99875486
8432,bradycardia,18,19,142,153,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,1,1,8432,-1,0.0008821351,0.9991179
100,cystitis,12,13,101,109,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,-1,1,1,100,-1,0.00089861505,0.9991014
8113,nephrotoxicity,3,4,18,32,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,-1,1,1,8113,-1,0.000823749,0.9991762
10847,tumors,25,26,156,162,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,1,1,10847,-1,0.0015344394,0.99846554
5482,myocardial injury,3,5,33,50,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,-1,1,1,5482,-1,0.00094647723,0.99905354
1404,Pericarditis,2,3,12,24,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,-1,1,1,1404,-1,0.0011613972,0.9988386
9316,pain,41,42,275,279,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,1,1,9316,-1,0.00210438,0.9978956
16290,ovarian cancer,41,43,235,249,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,1,1,16290,-1,0.0013700807,0.9986299
16343,atrophy,32,33,183,190,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1,16343,-1,0.0014616247,0.9985384
10090,diabetic nephropathy,27,29,192,212,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,10090,-1,0.0012432337,0.99875677
9220,Proteinuria,0,1,0,11,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,-1,1,1,9220,-1,0.0012949932,0.998705
16389,hypotension,12,13,81,92,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,1,1,16389,-1,0.00090432697,0.9990957
5414,hiccups,9,10,58,65,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,1,1,5414,-1,0.0013781034,0.99862194
14176,tumors,7,8,33,39,"Of these recurrences, 27 were T1 tumors while five progressed to more highly invasive lesions.",6640832_10,-1,1,1,14176,-1,0.0020651505,0.9979348
17087,toxicity,55,56,390,398,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,1,1,17087,-1,0.001810025,0.99819
5991,seizures,19,20,122,130,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,1,1,5991,-1,0.0011691633,0.99883085
1420,anuria,14,15,71,77,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,1,1,1420,-1,0.0009189169,0.999081
4898,nephrotic,7,8,45,54,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1,4898,-1,0.0013198721,0.99868006
15469,platelet aggregation,16,18,117,137,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,1,1,15469,-1,0.0016384482,0.9983615
2617,catalepsy,30,31,177,186,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,1,1,2617,-1,0.00095652806,0.9990434
16299,thrombocytopenia,14,15,102,118,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1,16299,-1,0.0009716914,0.9990283
2559,convulsions,9,10,69,80,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,1,1,2559,-1,0.0010570986,0.9989429
13062,sinus bradycardia,6,8,38,55,"The patient developed, paradoxically, sinus bradycardia.",3769769_2,-1,1,1,13062,-1,0.0010971627,0.9989028
10088,diabetic nephropathy,13,15,76,96,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,10088,-1,0.0011837251,0.99881625
572,hemolytic anemia,20,22,135,151,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,1,1,572,-1,0.0007824112,0.9992176
12043,seizures,22,23,124,132,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,1,1,12043,-1,0.0015613352,0.99843866
2611,catalepsy,8,9,49,58,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,1,1,2611,-1,0.00093751913,0.9990625
1359,convulsions,12,13,83,94,These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.,11243580_7,-1,1,1,1359,-1,0.0010135057,0.9989864
6140,psychiatric,10,11,61,72,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,1,1,6140,-1,0.004027004,0.99597293
14614,syncope,7,8,50,57,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,-1,1,1,14614,-1,0.00081495434,0.999185
5008,hyperemia,2,3,28,37,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,1,1,5008,-1,0.00087058806,0.9991295
14512,nephrotic,4,5,20,29,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,-1,1,1,14512,-1,0.0011866695,0.9988134
2332,seizures,10,11,50,58,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,-1,1,1,2332,-1,0.0011731052,0.9988269
260,platelet aggregation,1,3,8,28,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,1,1,260,-1,0.001732787,0.9982672
44,Hypotension,0,1,0,11,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,-1,1,1,44,-1,0.0010373683,0.99896264
14646,aplastic anemia,19,21,134,149,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,1,1,14646,-1,0.0007338089,0.9992662
7906,thrombosis,8,9,52,62,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,1,1,7906,-1,0.00088773895,0.9991122
2951,myalgia,7,8,26,33,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,1,1,2951,-1,0.00084224454,0.9991578
15909,hypotension,33,34,126,137,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,1,1,15909,-1,0.0014077264,0.9985922
15906,hypotensive,16,17,129,140,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,-1,1,1,15906,-1,0.0011163811,0.99888366
12260,hepatitis,21,22,135,144,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,1,1,12260,-1,0.0009698471,0.9990301
4054,dyskinesia,23,24,144,154,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,1,1,4054,-1,0.0008348142,0.9991652
6870,myopathy,13,14,69,77,"What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.",17241784_2,-1,1,1,6870,-1,0.00095045054,0.9990495
16064,Cancer,10,11,82,88,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,1,1,16064,-1,0.0025519817,0.9974481
13776,neuropathy,8,9,54,64,Isoniazid was the most frequent agent in drug-induced neuropathy.,6287825_7,-1,1,1,13776,-1,0.00096280593,0.99903727
13607,myoclonic jerks,30,32,136,151,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,1,1,13607,-1,0.0014850788,0.99851495
18089,stroke,12,13,66,72,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,-1,1,1,18089,-1,0.0015223128,0.99847764
4395,liver injury,11,13,76,88,PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.,1504402_2,-1,1,1,4395,-1,0.0012114922,0.99878854
16357,chronic renal failure,32,35,176,197,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,1,1,16357,-1,0.0009565791,0.9990434
11428,fatigue,19,20,89,96,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1,11428,-1,0.001099155,0.9989008
3820,nephropathy,22,23,138,149,The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.,1300436_1,-1,1,1,3820,-1,0.0011543395,0.9988457
13684,thrombotic microangiopathy,19,21,97,123,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1,13684,-1,0.00090599235,0.999094
1020,pain,7,8,53,57,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,1,1,1020,-1,0.0013457976,0.9986541
13335,rheumatoid arthritis,37,39,233,253,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,13335,-1,0.00091032195,0.9990897
18297,hypertension,4,5,29,41,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,1,1,18297,-1,0.0009899097,0.9990101
15062,ischemia,33,34,234,242,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1,15062,-1,0.0031373715,0.99686265
11108,seizures,24,25,137,145,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,1,1,11108,-1,0.0009025752,0.99909747
9182,encephalopathy,6,7,63,77,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,1,1,9182,-1,0.001059802,0.99894017
4976,hyperkalemia,3,4,23,35,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,1,1,4976,-1,0.0010480997,0.9989519
4338,convulsions,1,2,24,35,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,1,1,4338,-1,0.0009751186,0.99902487
12737,hepatitis,10,11,63,72,We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.,3496378_1,-1,1,1,12737,-1,0.00086619233,0.9991339
2371,cardiac dysfunction,32,34,200,219,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,1,1,2371,-1,0.0012077063,0.9987923
12932,hypotension,12,13,79,90,These changes might offer protection to brain tissue during periods of induced hypotension.,3676049_8,-1,1,1,12932,-1,0.00094589306,0.99905413
17541,spasm,16,17,113,118,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,1,1,17541,-1,0.00091542973,0.9990846
323,hypertension,4,5,38,50,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,1,1,323,-1,0.0010701637,0.9989298
15003,hypersensitivity,17,18,113,129,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,-1,1,1,15003,-1,0.0012894769,0.9987105
5178,hepatotoxicity,13,14,83,97,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1,5178,-1,0.00087236305,0.9991277
11646,sepsis,34,35,223,229,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,1,1,11646,-1,0.0011371408,0.99886286
10855,mucositis,17,18,101,110,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1,10855,-1,0.0010681072,0.9989318
13820,seizures,4,5,31,39,The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.,6308277_4,-1,1,1,13820,-1,0.001078119,0.9989219
10337,cholestasis,1,2,11,22,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,1,1,10337,-1,0.0010286822,0.99897134
7213,acute myocardial infarction,17,20,116,143,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,-1,1,1,7213,-1,0.0011628408,0.9988372
3113,nephrotoxic,15,16,95,106,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,1,1,3113,-1,0.0012092942,0.9987907
5748,amnesia,14,15,103,110,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,1,1,5748,-1,0.0010768858,0.9989231
17778,autoimmune hemolytic anemia,3,6,17,44,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,1,1,17778,-1,0.001000998,0.99899906
18203,cholestasis,16,17,100,111,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1,18203,-1,0.0010896034,0.9989104
16589,bipolar,37,38,225,232,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,1,1,16589,-1,0.0060146665,0.99398535
16766,thrombocytopenia,7,8,52,68,His subsequent course was remarkable for non-immune thrombocytopenia which resolved.,8888541_11,-1,1,1,16766,-1,0.00082132564,0.9991787
8624,sensorineural hearing loss,12,15,69,95,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,-1,1,1,8624,-1,0.0011166502,0.9988833
12205,dermatitis,27,28,162,172,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,1,1,12205,-1,0.0012482106,0.99875176
16316,dystonia,9,10,68,76,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,-1,1,1,16316,-1,0.0008457594,0.9991542
9274,pain,8,9,34,38,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,-1,1,1,9274,-1,0.0026369384,0.99736303
14370,hypertension,5,6,44,56,Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.,6861444_2,-1,1,1,14370,-1,0.00096617005,0.9990338
7214,acute myocardial infarction,10,13,73,100,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,1,1,7214,-1,0.0010854355,0.9989146
18043,seizures,38,39,214,222,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,1,1,18043,-1,0.00092461286,0.9990754
378,toxicity,7,8,38,46,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,1,1,378,-1,0.0016397835,0.9983602
12836,vasospasm,24,25,161,170,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,-1,1,1,12836,-1,0.00092809653,0.99907184
15993,tetany,16,17,111,117,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,1,1,15993,-1,0.00088315277,0.99911684
13761,milk fever,31,33,173,183,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13761,-1,0.0013620028,0.998638
7240,dyskinesia,11,12,75,85,Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.,17532790_0,-1,1,1,7240,-1,0.00073009694,0.9992699
6805,aggression,13,14,91,101,"Behavioral measures included locomotion, irritability, copulation, partner preference, and aggression.",17194457_4,-1,1,1,6805,-1,0.0014444299,0.9985556
13492,dystonia,13,14,83,91,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,1,1,13492,-1,0.00085194584,0.999148
15437,nausea,20,21,91,97,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,1,1,15437,-1,0.0012740691,0.99872595
1969,nausea,5,6,30,36,The intensity of headache and nausea was measured with a 100-mm visual analog scale.,11679859_7,-1,1,1,1969,-1,0.0012155824,0.9987845
16297,leukopenia,9,10,68,78,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1,16297,-1,0.0010501897,0.9989498
9014,pain,8,9,84,88,Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.,19269743_0,-1,1,1,9014,-1,0.0014181229,0.9985819
16404,pain,22,23,83,87,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,-1,1,1,16404,-1,0.0013165021,0.9986835
17008,hypotension,7,8,62,73,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,1,1,17008,-1,0.00091954716,0.9990804
9198,nephrotoxicity,17,18,105,119,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,1,1,9198,-1,0.0009350357,0.999065
437,diabetes,18,19,100,108,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,1,1,437,-1,0.0013677848,0.99863213
13064,psychiatric,8,9,52,63,This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect.,3769769_4,-1,1,1,13064,-1,0.0019639856,0.99803597
14485,fibrosis,9,10,65,73,"Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted.",7053705_3,-1,1,1,14485,-1,0.0013609222,0.99863905
7118,seizures,12,13,85,93,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,1,1,7118,-1,0.0010923076,0.9989077
17931,breast cancer,5,7,26,39,There were no deaths from breast cancer recorded in women in the study.,9672273_18,-1,1,1,17931,-1,0.0011903192,0.9988097
15035,rash,18,19,96,100,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,1,1,15035,-1,0.0011833509,0.9988167
17191,breast carcinoma,15,17,108,124,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,-1,1,1,17191,-1,0.0014094737,0.9985905
11911,prolactinoma,20,21,148,160,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,1,1,11911,-1,0.0022307215,0.99776936
9123,diabetic,90,91,472,480,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,1,1,9123,-1,0.0029031525,0.9970969
5453,death,4,5,31,36,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,1,1,5453,-1,0.0012945061,0.9987055
888,fractures,20,21,133,142,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,1,1,888,-1,0.0016182145,0.99838173
1710,thrombotic microangiopathy,8,10,51,77,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,1,1,1710,-1,0.0009343054,0.9990657
10701,nausea,11,12,71,77,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,1,1,10701,-1,0.0012299212,0.99877006
975,pain,21,22,127,131,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1,975,-1,0.0017900936,0.99820995
7164,nausea,24,25,162,168,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,1,1,7164,-1,0.001124256,0.9988757
4060,dyskinesia,31,32,191,201,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,1,1,4060,-1,0.000909799,0.9990902
14215,hypertensive,13,14,80,92,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,1,1,14215,-1,0.0014474811,0.9985525
4700,tremor,12,13,79,85,"In another series of measurements, reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions, at 9 a.m., 4 p.m. and 9 a.m., respectively, 1 week later.",15338796_8,-1,1,1,4700,-1,0.0011434839,0.99885654
697,pain,15,16,79,83,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,-1,1,1,697,-1,0.001381685,0.99861836
5353,death,16,17,106,111,"Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.",1592014_7,-1,1,1,5353,-1,0.0017998378,0.9982002
7874,acidosis,19,20,120,128,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,-1,1,1,7874,-1,0.0010438447,0.9989561
10492,proteinuria,12,13,73,84,BACKGROUND/AIMS: It is still unclear what happens in the glomerulus when proteinuria starts.,20588063_1,-1,1,1,10492,-1,0.0014886934,0.99851125
11136,ventricular arrhythmias,14,16,98,121,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,1,1,11136,-1,0.0010112202,0.9989888
8944,toxicity,6,7,34,42,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,1,1,8944,-1,0.0016503124,0.99834967
5622,schizophrenic,7,8,55,68,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,1,1,5622,-1,0.0013915667,0.9986084
10979,neurotoxic,9,10,50,60,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,1,1,10979,-1,0.0012548706,0.9987451
14561,parkinsonism,16,17,95,107,"However, these medications were more effective in both young and old patients when given after parkinsonism developed.",7161250_4,-1,1,1,14561,-1,0.0009324353,0.9990676
17369,hepatotoxicity,26,27,190,204,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,1,1,17369,-1,0.0011510245,0.9988489
11603,hypertensive,3,4,25,37,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,1,1,11603,-1,0.0027280152,0.99727196
712,nephrotoxicity,22,23,108,122,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,712,-1,0.0011868831,0.99881315
3730,pain,17,18,111,115,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1,3730,-1,0.001235085,0.998765
10843,glaucoma,29,30,186,194,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,1,1,10843,-1,0.0010835439,0.9989165
10973,hypertensive,6,7,46,58,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,-1,1,1,10973,-1,0.0020621715,0.99793786
2230,convulsive,33,34,188,198,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,1,1,2230,-1,0.0012148827,0.9987851
11285,Seizure,0,1,0,7,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,1,1,11285,-1,0.0013216936,0.99867827
388,Toxicity,17,18,82,90,The median time to progression was 16 weeks and the 1-year survival rate was 33%. Toxicity was mild.,10526274_14,-1,1,1,388,-1,0.0012907069,0.9987093
